Page last updated: 2024-11-01

nevirapine and HIV Infections

nevirapine has been researched along with HIV Infections in 1992 studies

Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.

HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).

Research Excerpts

ExcerptRelevanceReference
" We hypothesize that Nevirapine is a cheaper alternative that possesses equal efficacy as Efavirenz in HIV-Tuberculosis (TB) co-infected patients."9.24Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study. ( Dhooria, S; Gupta, K; Pandey, RM; Ranjan, S; Sinha, S; Tripathy, S, 2017)
"This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique."9.19Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ( Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM, 2014)
" However, there was a high risk of recurrent parasitemia following AL treatment, which was significantly lower in children taking LPV/r-based ART compared with nevirapine-based ART."9.19Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. ( Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW, 2014)
"In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs."9.17Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. ( Bastos, R; Baudin, E; Bhatt, N; Bonnet, M; Calmy, A; Ciaffi, L; Jani, I; Michon, C; Nunes, E; Rouzioux, C; Silva, C; Sobry, A; Taburet, AM, 2013)
"HIV-infected, Zambian children were randomized to initiate antiretroviral therapy (ART) with full-dose twice-daily nevirapine versus 2-week nevirapine dose-escalation."9.17Is nevirapine dose-escalation appropriate in young, African, HIV-infected children? ( Burger, DM; Chintu, C; Cook, A; Fillekes, Q; Gibb, DM; Kabamba, D; Kankasa, C; Mulenga, V; Thomason, MJ; Walker, AS, 2013)
"To confirm whether 7 days of phenytoin, an enzyme inducer, would decrease the elimination half-life of single-dose nevirapine and to investigate its effect on the development of nevirapine resistance in pregnant, HIV-infected women."9.17Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. ( Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013)
"To describe the longitudinal changes in hepatic function among HIV-infected tuberculosis (TB) patients receiving once-daily nevirapine (NVP)- or efavirenz (EFV)-based antiretroviral treatment (ART) along with rifampin-containing anti-TB treatment."9.17Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy. ( Bhavani, PK; Chandrasekar, C; Hannah, E; Kumar, H; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Ramesh, C; Swaminathan, S; Tang, A; Wanke, C, 2013)
"Administration of rifampicin along with nevirapine reduces the plasma concentration of nevirapine in human immunodeficiency virus positive individuals with concomitant tuberculosis (HIV-TB patients)."9.17Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study. ( Ahmad, H; Chandrashekhar, R; Dhooria, S; Ekka, M; Khan, NH; Kumar, S; Pandey, RM; Raghunandan, P; Ranjan, S; Rewari, BB; Samantaray, JC; Sharma, SK; Sinha, S; Velpandian, T; Venkatesh, S, 2013)
"Pharmacokinetic data for lopinavir in late pregnancy and in breastfeeding are limited, and no data for abacavir in breast milk are available."9.17Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. ( Capparelli, E; Essex, M; Leidner, J; Lockman, S; Makhema, J; Moffat, C; Moss, M; Moyo, S; Ogwu, A; Rossi, S; Shapiro, RL, 2013)
"Nevirapine (NVP) resistance emerges in up to 70% of women exposed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency virus (HIV)."9.17Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. ( Bonhomme, J; Chan, ES; Halvas, EK; Hitti, J; Hong, F; Hughes, MD; Kabanda, J; Klingman, KL; Kumarasamy, N; McMahon, DK; Mellors, JW; Taulo, F; Wallis, CL; Zheng, L, 2013)
"Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy."9.16A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. ( Achalapong, J; Beck, IA; Britto, P; Chotivanich, N; Cressey, TR; Frenkel, L; Jourdain, G; Maupin, R; Mirochnick, M; Ngo-Giang-Huong, N; Prommas, S; Puthanakit, T; Rasri, W; Roongpisuthipong, A; Shapiro, DE; Van Dyke, RB; Yuthavisuthi, P, 2012)
"eighteen HIV-1/tuberculosis co-infected adults receiving rifampicin daily as part of anti-tuberculosis therapy were evenly randomized to nevirapine initiation by dose escalation (NVP200) or nevirapine initiation at 200 mg twice daily (NVP400)."9.15Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. ( Back, D; Boffito, M; Byakika-Kibwika, P; Coakley, P; Colebunders, R; Kalemeera, F; Khoo, S; Lamorde, M; Merry, C; Namakula, R; Okaba-Kayom, V; Ryan, M, 2011)
"Nevirapine (NVP) can be safely and effectively administered once-daily but has not been assessed in human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB)."9.15Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. ( Bhavani, PK; Dilip, M; Iliayas, S; Menon, PA; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Pooranagangadevi, NP; Ramachandran, R; Ramesh Kumar, S; Selvaraju, S; Swaminathan, S; Venkatesan, P, 2011)
"Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV-HBV coinfected patients from endemic settings where tenofovir is not readily available."9.15HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya. ( Cent, A; Chung, MH; Cook, L; Jerome, KR; John-Stewart, G; Kim, HN; Lule, G; Morrow, RA; Richardson, B; Scott, J; Tapia, K, 2011)
" We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP; 30/15/28 mg) in HIV-infected children."9.15Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ( Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R, 2011)
"The aim was to develop a model to describe the population pharmacokinetics of nevirapine in South African human immunodeficiency virus (HIV)-infected patients who were taking nevirapine-based antiretroviral therapy concomitantly or in the absence of rifampicin-based tuberculosis therapy."9.14Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. ( Cohen, K; Elsherbiny, D; Jansson, B; McIlleron, H; Simonsson, US; Smith, P, 2009)
"Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission."9.14Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. ( Balasubramaniam, U; Bharadwaj, R; Bhore, AV; Bhosale, R; Bollinger, R; Gupta, A; Gupte, N; Kagal, A; Kulkarni, S; Kulkarni, V; Moorthy, A; Patil, S; Persaud, D; Sastry, J; Suryavanshi, N; Thakar, M; Tripathy, S; Venkataramani, V; Ziemniak, C, 2009)
"The aim of this study was to evaluate the pharmacokinetics of lamivudine (3TC), stavudine (d4T) and nevirapine (NVP) in HIV-infected Malawian children receiving quartered tablet multiples of Triomune 40 (generic tablet [GT]) compared with individual generic liquid (GL) and trade liquid (TL)."9.14Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. ( Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Kazembe, P; Mkupani, P; Mwansambo, C; Nyirenda, J; Rezk, NL; Sichali, D; Tien, H; Weigel, R, 2010)
"We aim here to determine the appropriate dose of nevirapine (NVP) in Thai HIV-tuberculosis (TB)-coinfected patients receiving rifampicin."9.13Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. ( Avihingsanon, A; Burger, D; Chuchotaworn, C; Cooper, DA; Gorowara, M; Ishikawa, N; Kantipong, P; Manosuthi, W; Mitarai, S; Moolphate, S; Phanuphak, P; Ruxrungtham, K; Sakornjun, W; Yamada, N; Yanai, H, 2008)
"Nevirapine has been widely used in pregnancy for its efficacy, low pill burden, bioavailability and rapid transplacental transfer."9.12Safety of nevirapine in pregnancy. ( Anderson, J; de Ruiter, A; Edwards, SG; Hay, P; McDonald, C; Natarajan, U; Pym, A; Taylor, GP; Velisetty, P; Welch, J, 2007)
"To examine the effect of 2 weeks of treatment with prednisone on the incidence of nevirapine-associated rash in HIV-1-infected patients receiving combination antiretroviral therapy."9.10Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. ( Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003)
"To assess the virologic, immunologic, and clinical benefit of switching the PI to nevirapine in patients with HIV-associated lipodystrophy and sustained viral suppression before entry in the study."9.09Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. ( Balagué, M; Bonjoch, A; Clotet, B; Domingo, P; Francia, E; Fumaz, CR; Gel, S; Johnston, S; Lange, J; Negredo, E; Paredes, R; Romeu, J; Ruiz, L, 2001)
" We aimed to establish whether pregnancy rates differ between HIV-positive women who use various contraceptive methods and either efavirenz-based or nevirapine-based antiretroviral therapy (ART) regimens."8.91Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study. ( Blat, C; Bukusi, EA; Cohen, CR; Gandhi, M; Hagey, J; Newmann, SJ; Onono, M; Patel, RC; Shade, SB; Vittinghoff, E, 2015)
" Standard ART includes either nevirapine or efavirenz, however the efficacy of these drugs is limited in patients receiving rifampin treatment for tuberculosis (TB)."8.90Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. ( Chen, HJ; Deng, M; Jiang, HY; Ruan, B; Yang, Y; Zhang, MN, 2014)
" Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance."8.85Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009)
"Artemisinin-based combination therapies (ACTs) are the primary treatment for malaria."8.31Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. ( Aweeka, F; Ehrlich, H; Freeman, T; French, J; Goodwin, J; Huang, L; Kajubi, R; Kay, K; Li, F; Mwebaza, N; Ou, J; Parikh, S; Riggs, M; Ruiz-Garcia, A; Wade, M; Wang, K, 2023)
"Nevirapine has an exceptional record for long-term tolerability with few side effects in human immunodeficiency virus (HIV) combined antiretroviral therapy (cART)."7.91Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management? ( Bregenzer, A; Kahlert, CR; Notter, J; Vernazza, P, 2019)
"Nevirapine is used in developing countries for the treatment of HIV infection, but its use is associated with rare serious adverse reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)."7.88A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine. ( Borgiani, P; Ciccacci, C; Ciccacci, F; Lucaroni, F; Mancinelli, S; Marazzi, MC; Novelli, G; Palombi, L; Politi, C, 2018)
" No baseline differences in depression or suicidal ideation were found between patients ever exposed to efavirenz and those never exposed to efavirenz and receiving nevirapine (P > 0."7.88Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study. ( Bangsberg, DR; Boum, Y; Bwana, M; Chang, JL; Haberer, JE; Hunt, PW; Martin, JN; Musinguzi, N; Muzoora, C; Siedner, MJ; Tsai, AC, 2018)
"Clinical trials demonstrated intermittent preventive treatment in pregnancy with mefloquine (MQ) reduced malaria rates among pregnant women, yet an unexpected higher risk of mother-to-child transmission (MTCT) of HIV among HIV-positive women receiving MQ has also been observed."7.88Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy. ( Desai, M; Dinh, C; Gonzalez, R; Haaland, RE; Heneine, W; Katana, A; Martin, A; Menendez, C; Otieno, K; Slutsker, L; Williamson, J, 2018)
" Patients were allocated to 2groups according to exposure to nevirapine during pregnancy."7.83[Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy]. ( Figueras-Nadal, C; Fortuny-Guasch, C; Iveli, P; Martín-Nalda, A; Noguera-Julian, A; Rovira-Girabal, N; Soler-Palacín, P, 2016)
"We investigated the influence of efavirenz (EFV)- or nevirapine (NVP)-based antiretroviral therapy (ART) on lumefantrine plasma exposure in HIV-malaria-coinfected patients and implication of pharmacogenetic variations."7.83CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2016)
"We describe nevirapine and efavirenz exposure on and off tuberculosis treatment and consequences for virological efficacy and tolerance in patients included in the ANRS 12146/12214-CARINEMO trial."7.81Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship. ( Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; da Silva, C; Furlan, V; Grinsztejn, B; Meggi, B; Taburet, AM, 2015)
"HIV-malaria co-infected patients in most parts of sub-Saharan Africa are treated with both artemether-lumefantrine (AL) and efavirenz (EFV) or nevirapine (NVP)-based antiretroviral therapy (ART)."7.81The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)
"The objective of this study was to determine the prevalence of drug resistance mutations among HIV-positive women in Malawi 18 months after discontinuing nevirapine-based ART for the prevention of mother-to-child transmission."7.81Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. ( Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Vella, S, 2015)
"An exit interview was conducted one year post-partum for 85 HIV-infected women who participated in a study of HIV-1 transmission rates among NVP-experienced compared with NVP-naïve women in "The Nevirapine Repeat Pregnancy (NVP-RP) Study" at the Makerere University-Johns Hopkins University Research Collaboration, Kampala-Uganda, between June 2004 and June 2006."7.81A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study". ( Bakaki, PM; Fowler, MG; Kiweewa, FM; Kusasira, F; McConnell, MS; Mubiru, MC; Musisi, M; Musoke, P; Nakayiwa, F; Nakintu, D; Namirembe, C, 2015)
"Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited."7.81Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015)
"We report a case in which an HIV-positive man developed general malaise, skin rash and biochemical hepatitis within days of starting a nevirapine-based antiretroviral treatment regimen."7.80Rash and hepatitis within days of starting a new antiretroviral regimen: nevirapine hypersensitivity, secondary syphilis or both? ( Helbert, MR; Higgins, SP; Komolafe, AJ; Saxon, CJ, 2014)
"To determine whether residual plasma viremia in HIV(+) patients on nevirapine-including antiretroviral therapy (ART) is related to anti-HIV cellular immune responses, a case-control study was conducted comparing residual viremia in patients with detectable and undetectable Gag-specific T-cell responses."7.80Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response. ( Allavena, C; Billaud, E; Ferré, V; McIlroy, D; Raffi, F; Rodallec, A, 2014)
"Data from a prospective multisite cohort study were used to examine the effect of HIV exposure, untreated HIV infection, and single-dose nevirapine on infant growth velocity."7.80HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants. ( Chhagan, M; Doherty, T; Fadnes, LT; Goga, AE; Jackson, DJ; Lombard, C; Ramokolo, V; Van den Broeck, J, 2014)
"We modeled nevirapine (NVP) pharmacokinetics in HIV-infected Malawian patients to assess the relationship between drug exposure and patient characteristics, genetic polymorphisms, and development of hypersensitivity reaction (HSR)."7.80Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. ( Carr, DF; Chaponda, M; Dickinson, L; Heyderman, RS; Khoo, SH; Kumwenda, J; Lalloo, DG; Pirmohamed, M; van Oosterhout, JJ, 2014)
"We assessed the pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children while they were receiving nevirapine-containing fixed-dose combination tablets with rifampicin-based tuberculosis treatment and after discontinuation."7.78Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation. ( Capparelli, E; Chokephaibulkit, K; Cressey, TR; Lapphra, K; Prasitsuebsai, W; Vanprapar, N, 2012)
" We compared the pregnancy outcomes of women exposed to EFV and to nevirapine (NVP) during the first trimester."7.77Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire. ( Amani-Bosse, C; Anglaret, X; Coffie, PA; Dabis, F; Danel, C; Eholié, SP; Ekouevi, DK; Messou, E; Moh, R; Ouattara, E; Sissoko, M, 2011)
"The objective of this cross-sectional observational ('real-world') study was to investigate the effect of three HAART regimens plus stable nevirapine therapy on morphological and metabolic components of lipodystrophy in HIV-infected patients."7.77Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study. ( Adorni, F; Bagni, P; Carli, F; Garlassi, E; Guaraldi, G; Luzi, K; Menozzi, M; Orlando, G; Stentarelli, C; Zona, S, 2011)
"Coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) in HIV-infected patients receiving a commonly used nevirapine-based antiretroviral therapy is a major concern for African clinicians owing to its high prevalence, the infrequent testing and treatment of viral hepatitis, and the impact of liver disease on the tolerability and effectiveness of anti-HIV treatment."7.76Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. ( Bourgeois, A; Calmy, A; Ciaffi, L; Delaporte, E; Ducos, J; Gwet, H; Kouanfack, C; Koulla-Shiro, S; Laurent, C; Mbougua, JB; Molinari, N; Mpoudi-Ngolé, E, 2010)
"The concurrent use of nevirapine-based antiretroviral therapy (ART) and rifampin-containing anti-tuberculosis regimens for the treatment of HIV and tuberculosis (TB) is common in resource-limited countries."7.76Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. ( Chimsuntorn, S; Eampokarap, B; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Tantanathip, P; Thongyen, S, 2010)
"This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment."7.76Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. ( Biwolé-Sida, M; Bork, K; Coudray, M; Cournil, A; Delaporte, E; Essomba, CN; Kouanfack, C; Laurent, C; Tonfack, CA, 2010)
"Use of single dose nevirapine (sdNVP) to prevent HIV mother-to-child transmission is associated with the emergence of NVP resistance in many infants who are HIV infected despite prophylaxis."7.75In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. ( Bagenda, D; Bakaki, P; Church, JD; Donnell, D; Eshleman, SH; Eure, C; Fowler, MG; Guay, LA; Jackson, JB; Matovu, F; McConnell, M; Musoke, P; Mwatha, A; Nakabiito, C; Omer, SB; Thigpen, MC, 2009)
"Nevirapine (NVP) plasma levels are reduced in patients receiving rifampicin (RFM) for tuberculosis (TB) treatment."7.75Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. ( Bonkoungou, V; Carosi, G; Carvalho, AC; Dembele, M; Kouanda, S; Matteelli, A; Monno, L; Regazzi, M; Saleri, N; Sanou, MJ; Simporé, J; Villani, P, 2009)
"To determine the relationship between nutritional status and nevirapine exposure by comparing the pharmacokinetics of nevirapine in HIV-infected children of different ages with and without malnutrition receiving divided tablets of Triomune 30 (stavudine + lamivudine + nevirapine) in accordance with Malawi National Guidelines."7.75Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. ( Back, D; Else, L; Fraser, W; Khoo, S; Molyneux, E; Moons, P; Poerksen, G; Pollock, L; Walker, S, 2009)
"Single-dose nevirapine (SD NVP) at birth plus NVP prophylaxis for the infant up to 6 weeks of age is superior to SD NVP alone for prevention of vertical transmission of human immunodeficiency virus (HIV) through breastfeeding."7.74Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. ( Church, JD; Eshleman, SH; Guay, LA; Huang, W; Jackson, JB; Lidstrom, J; Mmiro, F; Musoke, P; Omer, SB, 2008)
"Single-dose nevirapine (SDNVP) for the prevention of mother-to-child HIV transmission (PMTCT) results in the selection of resistance mutants among HIV-infected mothers."7.74Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study. ( Aldrovandi, GM; Kankasa, C; Kuhn, L; Semrau, K; Sinkala, M; Thea, DM; Walter, J, 2008)
"Seventy patients with human immunodeficiency virus (HIV) and tuberculosis coinfection who initiated nevirapine-based antiretroviral therapy and had trough nevirapine levels determined while receiving rifampicin were enrolled in a study."7.74Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. ( Inthong, Y; Likanonsakul, S; Manosuthi, W; Phoorisri, T; Prasithsirikul, W; Ruxrungtham, K; Sungkanuparph, S, 2007)
"We prospectively followed 27 HIV-infected adult Malawians after starting Triomune (a generic fixed drug combination of stavudine, lamivudine and nevirapine) in the second week of tuberculosis treatment."7.74Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. ( Beadsworth, M; Burger, DM; Kumwenda, JJ; Longwe, T; Mateyu, G; van Oosterhout, JJ; Zijlstra, EE, 2007)
"Drug rash with eosinophilia and systemic symptoms (DRESS Syndrome) associated with nevirapine treatment has not been previously reported in children."7.74Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection. ( Barton, T; Ramilo, O; Santos, RP, 2007)
"Single-dose nevirapine (SDNVP) is widely used to prevent mother-to-child HIV transmission in resource-limited settings."7.74Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. ( Bagenda, D; Bakaki, P; Downing, R; Eure, C; Fowler, MG; Greenberg, AE; Matovu, F; McConnell, M; Mubiru, M; Thigpen, MC, 2007)
"To determine the impact of pregnancy on the pharmacokinetics (PK) of nevirapine (NVP) during chronic dosing in HIV-infected women and appropriate NVP dosing in this population."7.74Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. ( Aweeka, F; Best, B; Burchett, SK; Capparelli, EV; Foca, M; Hitti, J; Hu, C; Jimenez, E; Mirochnick, M; Nachman, S; Read, JS; Shearer, WT; Smith, E; Spector, SA; Stek, A; Thorpe, EM; Watts, H, 2008)
"To determine incidence and risk factors of nevirapine (NVP)-associated severe hepatitis that led to NVP discontinuation among HIV-infected patients with CD4 < 250 cells/microL."7.74Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL. ( Chaovavanich, A; Chimsuntorn, S; Chottanapund, S; Mankatitham, W; Manosuthi, W; Moolasart, V; Sittibusaya, C; Sungkanuparph, S; Tansuphaswadikul, S, 2008)
"There is limited comparative data between efavirenz (EFV) 600 mg/day and nevirapine (NVP) 400 mg/day-based antiretroviral therapy (ART) among HIV-1 patients with tuberculosis (TB) and receiving rifampicin."7.74Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. ( Chimsuntorn, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Sungkanuparph, S, 2008)
"Nelfinavir- or nevirapine-containing HAART regimens during pregnancy are well tolerated."7.73Nelfinavir and nevirapine side effects during pregnancy. ( Boer, K; de Wolf, F; Dieleman, J; Godfried, MH; Nellen, J; Schneider, ME; Sprenger, H; Tempelman, C; Timmermans, S; van der Ende, ME, 2005)
"The incidence of adverse events with nevirapine may be lower than previously reported (13% versus 29%) and may be primarily noted with initiating the drug late in pregnancy."7.73Third-trimester maternal toxicity with nevirapine use in pregnancy. ( Brady, MT; Fan-Havard, P; Hughes, L; Joy, S; Koletar, SL; Para, MF; Poi, M, 2005)
"In countries with high numbers of HIV/tuberculosis coinfection nevirapine and rifampin are used extensively."7.73Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. ( Anekthananon, T; Autar, RS; Burger, DM; Cooper, DA; Lange, JM; Mahanontharit, A; Mootsikapun, P; Phanuphak, P; Ruxrungtham, K; Sankote, J; Sujaikaew, K; Wit, FW, 2005)
"To describe the maternal tolerability of nevirapine as part of combination antiretroviral therapy in pregnancy at three HIV centres in Dublin, Ireland and to determine risk factors for development of significant hepatotoxicity."7.73Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. ( Bergin, C; Geoghegan, J; Hopkins, S; Kelleher, B; Lyons, F; McCormick, PA; McGeary, A; Mulcahy, FM; Sheehan, G, 2006)
"The influence of nevirapine, efavirenz and tenofovir co-administration on ritonavir-boosted atazanavir pharmacokinetics was investigated in HIV (human immunodeficiency virus)-infected patients."7.73Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. ( Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O, 2006)
" We describe a detailed case of fulminant hepatitis induced by nevirapine (Viramune) and treated by liver transplantation."7.73Liver transplantation for fulminant hepatitis related to nevirapine therapy. ( Antonini, T; Buyse, S; Castaing, D; Duclos-Vallée, JC; Ichai, P; Samuel, D; Sebagh, M; Vibert, E, 2006)
"Both chronic hepatitis C and nevirapine (NVP) use are risk factors for transaminase elevation under highly active antiretroviral therapy."7.72Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. ( González-Lahoz, J; González-Requena, D; Núñez, M; Soriano, V, 2003)
" We report the case of a pregnant human immunodeficiency virus type 1-infected woman who developed drug rash with eosinophilia and systemic symptoms syndrome and renal failure shortly after initiation of a nevirapine-containing antiretroviral regimen at 27 weeks' gestation."7.72Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. ( Boswell, H; Fan-Havard, P; Knudtson, E; Para, M, 2003)
"At the defined period, 306 patients started a nevirapine-containing regimen, of whom eight developed an acute hepatitis (2."7.72Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. ( Beijnen, JH; de Maat, MM; Mairuhu, AT; Mulder, JW; ter Heine, R; van Gorp, EC, 2003)
"HAART regimens including nevirapine are associated with faster liver fibrosis progression in HIV-infected patients with chronic hepatitis C."7.72Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. ( Castellano, V; García-García, JA; Gómez-Mateos, JM; Lozano, F; Macías, J; Merchante, N; Mira, JA; Palacios, RB; Pineda, JA; Sáez, C, 2004)
"To draw attention to the many cases of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) related to nevirapine detected in a multinational case-control study of SJS and TEN."7.71Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. ( Bouwes-Bavinck, JN; Fagot, JP; Mockenhaupt, M; Naldi, L; Roujeau, JC; Viboud, C, 2001)
"To determine whether rifampicin reduces serum concentrations of nevirapine and whether nevirapine modifies serum concentrations of rifampicin, levels of these agents were determined at steady state by high-performance liquid chromatography in 10 HIV-infected patients with tuberculosis."7.71Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. ( Crespo, M; Falco, V; Lopez, RM; Ocaña, I; Pahissa, A; Pou, L; Ribera, E; Ruiz, I, 2001)
"Bedaquiline is a novel drug for the treatment of multidrug-resistant (MDR) TB; combined use with antiretroviral drugs, nevirapine, or ritonavir-boosted lopinavir (LPV/r) is anticipated, but no clinical data from coinfected patients are available."6.79Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. ( Dooley, KE; Karlsson, MO; Svensson, EM, 2014)
"Twenty-two children received antituberculosis and antiretroviral therapy (ART) concurrently for 4 weeks before pharmacokinetic sampling."6.77Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. ( Burger, DM; Chintu, C; Cook, A; Gibb, DM; McIlleron, H; Merry, C; Mulenga, V; Oudijk, JM; Walker, AS, 2012)
" The one adverse event associated with nelfinavir occurred in a subject with a CD4 cell count less than 250 cells/microL."6.71Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. ( Baker, D; Foca, M; Frenkel, LM; Gandia, J; Gonzalez-Garcia, A; Hitti, J; Huang, S; McNamara, J; Nachman, SA; Paul, ME; Provisor, A; Stek, AM; Stevens, LM; Thorpe, EM; Watts, DH; Wei, LJ, 2004)
"The appearance of rash is one of the most frequent and limiting side-effects during the first 4 weeks of treatment with nevirapine (NVP)."6.69Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. ( Barreiro, P; Casas, E; de Requena, DG; Estrada, V; González-Lahoz, J; Hoetelmans, R; Jimenéz-Nácher, I; Soriano, V; Téllez, MJ, 2000)
"Ideally, an anti-HIV drug should (1) be highly active against wild-type and mutant HIV without allowing breakthrough; (2) have high oral bioavailability and long elimination half-life, allowing once-daily oral treatment at low doses; (3) have minimal adverse effects; and (4) be easy to synthesize and formulate."6.43In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). ( Andries, K; Arnold, E; Bohets, H; Clark, AD; Daeyaert, F; Das, K; de Béthune, MP; De Clerck, F; de Jonge, M; De Knaep, F; Frenkel, YV; Guillemont, J; Heeres, J; Hughes, SH; Janssen, PA; Koymans, L; Kukla, M; Lampo, A; Lewi, PJ; Ludovici, D; Medaer, B; Pasquier, E; Pauwels, R; Stoffels, P; Vinkers, M; Williams, P, 2005)
"The clinical significance of the reduced in vitro susceptibility of HIV to antiretroviral agents has been difficult to elucidate for nucleoside analogs such as zidovudine."6.17Resistance, drug failure, and disease progression. ( Richman, DD, 1994)
"Nevirapine has been used as antiretroviral agent since early '90."5.48Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. ( Cattaneo, D; Cheli, S; Clementi, E; Di Cristo, V; Falvella, FS; Galli, M; Giacomelli, A; Lupo, A; Oreni, ML; Renisi, G; Ridolfo, AL; Riva, A; Rusconi, S, 2018)
" Compared to RRC, Ugandan children exhibited reduced bioavailability of EFV and LPV; 11% (P=0."5.42The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda. ( Achan, J; Aweeka, F; Bartelink, IH; Capparelli, E; Charlebois, E; Dorsey, G; Gingrich, D; Havlir, D; Jullien, V; Kamya, M; Plenty, A; Ruel, T; Savic, RM; Scherpbier, HJ; Young, SL, 2015)
"To investigate if pregnancy is a risk factor for SJS among HIV-infected women taking NVP-containing regimens and registered within the Medunsa National Pharmacovigilance Centre database."5.39Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007 - 2012. ( Adewusi, E; Dube, N; Summers, R, 2013)
"Nevirapine Cmin was subtherapeutic (<3 mg/L) in six patients during antitubercular therapy (one of whom developed virological failure) and in none afterwards."5.35Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. ( Boulle, A; Cohen, K; Goemaere, E; Maartens, G; McIlleron, H; Smith, PJ; van Cutsem, G, 2008)
"Pregnancy has a moderate but significant lowering effect on NVP plasma concentrations."5.35Steady-state nevirapine plasma concentrations are influenced by pregnancy. ( Boer, K; Burger, DM; Damming, M; de Wolf, F; Godfried, MH; Nellen, JF; Prins, JM; van der Ende, ME; Wit, FW, 2008)
" The influence of gender, age, body weight and comedication on minimum and maximum concentrations (C(min), C(max)), area under the concentration-time curve (AUC), total clearance (CL(tot)), half-life (t(1/2)) and volume of distribution (V(d)) was analysed by multivariate techniques."5.33A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. ( Carlebach, A; Gute, P; Haberl, A; Harder, S; Klauke, S; Knecht, G; Kurowski, M; Rohrbacher, M; Staszewski, S; Stocker, H; von Hentig, N, 2006)
"Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis."5.32Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine. ( Krivoy, N; Pollack, S; Shahar, E; Weltfriend, S, 2004)
"Nevirapine is a non-nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents for the treatment of HIV infection."5.31Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. ( Farmer, KL; Hebert, AA; Lahart, CJ; Metry, DW, 2001)
"Nevirapine is a nonnucleoside reverse transcription inhibitor that is used as part of highly active antiretroviral therapeutic combinations."5.31Jaundice and hepatocellular damage associated with nevirapine therapy. ( Bonacini, M; Poreddy, V; Prakash, M; Tiyyagura, L, 2001)
"In this study the influence of first-line antimalarial drug artemether-lumefantrine on the pharmacokinetics of the antiretroviral drug nevirapine was investigated in the context of selected single nucleotide polymorphisms (SNPs) in a cohort of adult HIV-infected Nigerian patients."5.30Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction? ( Abdullahi, ST; Bakare-Odunola, MT; Bolarinwa, RA; Khoo, S; Olagunju, A; Olarewaju, OJ; Owen, A; Soyinka, JO, 2019)
" We hypothesize that Nevirapine is a cheaper alternative that possesses equal efficacy as Efavirenz in HIV-Tuberculosis (TB) co-infected patients."5.24Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study. ( Dhooria, S; Gupta, K; Pandey, RM; Ranjan, S; Sinha, S; Tripathy, S, 2017)
"This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique."5.19Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ( Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM, 2014)
"In the CHAPAS-3 trial, HIV-infected children (ART-naive or on d4T for ≥2 years without clinical lipodystrophy) were randomized to d4T, abacavir or zidovudine with lamivudine (3TC) plus a non-nucleoside reverse transcriptase inhibitor."5.19Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial. ( Abongomera, G; Arach, B; Asiimwe, AR; Cook, A; Gibb, DM; Kabamba, D; Kayiwa, J; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; Komunyena, J; Mirembe, G; Mulenga, V; Musiime, V; Nansubuga, C; Walker, SA; Wavamunno, P; Zangata, D, 2014)
" However, there was a high risk of recurrent parasitemia following AL treatment, which was significantly lower in children taking LPV/r-based ART compared with nevirapine-based ART."5.19Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. ( Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW, 2014)
"In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs."5.17Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. ( Bastos, R; Baudin, E; Bhatt, N; Bonnet, M; Calmy, A; Ciaffi, L; Jani, I; Michon, C; Nunes, E; Rouzioux, C; Silva, C; Sobry, A; Taburet, AM, 2013)
"HIV-infected, Zambian children were randomized to initiate antiretroviral therapy (ART) with full-dose twice-daily nevirapine versus 2-week nevirapine dose-escalation."5.17Is nevirapine dose-escalation appropriate in young, African, HIV-infected children? ( Burger, DM; Chintu, C; Cook, A; Fillekes, Q; Gibb, DM; Kabamba, D; Kankasa, C; Mulenga, V; Thomason, MJ; Walker, AS, 2013)
"To confirm whether 7 days of phenytoin, an enzyme inducer, would decrease the elimination half-life of single-dose nevirapine and to investigate its effect on the development of nevirapine resistance in pregnant, HIV-infected women."5.17Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. ( Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013)
"ART use did not affect risk of ovulation or pregnancy in women taking COCs, suggesting that nevirapine-containing ART does not interfere with COC contraceptive effectiveness."5.17Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness. ( Delany-Moretlwe, S; Dubé, K; Edward, VA; Kwok, C; Lendvay, A; Mirembe, FM; Molife, L; Mpairwe, B; Nakubulwa, S; Nanda, K, 2013)
"To describe the longitudinal changes in hepatic function among HIV-infected tuberculosis (TB) patients receiving once-daily nevirapine (NVP)- or efavirenz (EFV)-based antiretroviral treatment (ART) along with rifampin-containing anti-TB treatment."5.17Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy. ( Bhavani, PK; Chandrasekar, C; Hannah, E; Kumar, H; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Ramesh, C; Swaminathan, S; Tang, A; Wanke, C, 2013)
"Administration of rifampicin along with nevirapine reduces the plasma concentration of nevirapine in human immunodeficiency virus positive individuals with concomitant tuberculosis (HIV-TB patients)."5.17Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study. ( Ahmad, H; Chandrashekhar, R; Dhooria, S; Ekka, M; Khan, NH; Kumar, S; Pandey, RM; Raghunandan, P; Ranjan, S; Rewari, BB; Samantaray, JC; Sharma, SK; Sinha, S; Velpandian, T; Venkatesh, S, 2013)
"Although substantiated by little evidence, concerns about zidovudine-related anaemia in pregnancy have influenced antiretroviral (ARV) regimen choice for preventing mother-to-child transmission of HIV-1, especially in settings where anaemia is common."5.17Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three African countries. ( Chersich, MF; Farley, TM; Luchters, S; Meda, N; Mwaura, M; Newell, ML; Sartorius, BK; Temmerman, M, 2013)
"Pharmacokinetic data for lopinavir in late pregnancy and in breastfeeding are limited, and no data for abacavir in breast milk are available."5.17Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. ( Capparelli, E; Essex, M; Leidner, J; Lockman, S; Makhema, J; Moffat, C; Moss, M; Moyo, S; Ogwu, A; Rossi, S; Shapiro, RL, 2013)
"030 mg ethinyl estradiol with either nevirapine (NVP) or efavirenz (EFV) in 34 HIV-positive women."5.17Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives. ( Ahluwalia, J; Ananworanich, J; Chaithongwongwatthana, S; Gorowara, M; Kriengsinyot, R; Landolt, NK; Lange, JM; Phanuphak, N; Pinyakorn, S; Thammajaruk, N; Thongpaeng, P; Ubolyam, S, 2013)
"Nevirapine (NVP) resistance emerges in up to 70% of women exposed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency virus (HIV)."5.17Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. ( Bonhomme, J; Chan, ES; Halvas, EK; Hitti, J; Hong, F; Hughes, MD; Kabanda, J; Klingman, KL; Kumarasamy, N; McMahon, DK; Mellors, JW; Taulo, F; Wallis, CL; Zheng, L, 2013)
"Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy."5.16A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. ( Achalapong, J; Beck, IA; Britto, P; Chotivanich, N; Cressey, TR; Frenkel, L; Jourdain, G; Maupin, R; Mirochnick, M; Ngo-Giang-Huong, N; Prommas, S; Puthanakit, T; Rasri, W; Roongpisuthipong, A; Shapiro, DE; Van Dyke, RB; Yuthavisuthi, P, 2012)
"Women randomized to valacyclovir suppressive therapy during pregnancy and postpartum had greater increases in CD4 counts and smaller increases in plasma HIV-1 RNA levels than women in the placebo arm."5.16Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2. ( Drake, AL; Emery, S; Farquhar, C; John-Stewart, GC; Kiarie, JN; Matemo, DN; Ongecha-Owuor, F; Overbaugh, J; Richardson, B; Roxby, AC; Wald, A, 2012)
"In neonates whose mothers did not receive ART during pregnancy, prophylaxis with a two- or three-drug ART regimen is superior to zidovudine alone for the prevention of intrapartum HIV transmission; the two-drug regimen has less toxicity than the three-drug regimen."5.16Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. ( Bastos, FI; Bethel, J; Bryson, YJ; Camarca, M; Ceriotto, M; Dickover, R; Fonseca, R; Gray, G; Grinsztejn, B; Joao, EC; Kreitchmann, R; Machado, D; Mirochnick, M; Mofenson, LM; Moreira, RI; Morgado, MG; Moye, J; Mussi-Pinhata, MM; Nielsen-Saines, K; Pilotto, JH; Pinto, J; Santos, B; Siberry, G; Theron, G; Veloso, VG; Watts, DH; Xu, J, 2012)
"eighteen HIV-1/tuberculosis co-infected adults receiving rifampicin daily as part of anti-tuberculosis therapy were evenly randomized to nevirapine initiation by dose escalation (NVP200) or nevirapine initiation at 200 mg twice daily (NVP400)."5.15Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. ( Back, D; Boffito, M; Byakika-Kibwika, P; Coakley, P; Colebunders, R; Kalemeera, F; Khoo, S; Lamorde, M; Merry, C; Namakula, R; Okaba-Kayom, V; Ryan, M, 2011)
"From the French Hospital Database on HIV, we selected 439 patients with undetectable viral load (VL) on a first-line boosted PI-containing cART regimen who switched to a PI-free combination including efavirenz, nevirapine or abacavir."5.15Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir. ( Abgrall, S; Bommenel, T; Costagliola, D; Gilquin, J; Katlama, C; Lascaux, AS; Launay, O; Mahamat, A; Martinez, V; Meynard, JL; Pradier, C; Rouveix, E; Simon, A, 2011)
"Nevirapine (NVP) can be safely and effectively administered once-daily but has not been assessed in human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB)."5.15Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. ( Bhavani, PK; Dilip, M; Iliayas, S; Menon, PA; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Pooranagangadevi, NP; Ramachandran, R; Ramesh Kumar, S; Selvaraju, S; Swaminathan, S; Venkatesan, P, 2011)
"Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV-HBV coinfected patients from endemic settings where tenofovir is not readily available."5.15HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya. ( Cent, A; Chung, MH; Cook, L; Jerome, KR; John-Stewart, G; Kim, HN; Lule, G; Morrow, RA; Richardson, B; Scott, J; Tapia, K, 2011)
"Artemether-lumefantrine and nevirapine-based antiretroviral therapy (ART) are the most commonly recommended first-line treatments for malaria and HIV, respectively, in Africa."5.15Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. ( Barnes, KI; Cohen, K; Kredo, T; Maartens, G; Mauff, K; Smith, P; Van der Walt, JS; Wiesner, L, 2011)
" We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP; 30/15/28 mg) in HIV-infected children."5.15Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ( Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R, 2011)
"The aim was to develop a model to describe the population pharmacokinetics of nevirapine in South African human immunodeficiency virus (HIV)-infected patients who were taking nevirapine-based antiretroviral therapy concomitantly or in the absence of rifampicin-based tuberculosis therapy."5.14Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. ( Cohen, K; Elsherbiny, D; Jansson, B; McIlleron, H; Simonsson, US; Smith, P, 2009)
"Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission."5.14Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. ( Balasubramaniam, U; Bharadwaj, R; Bhore, AV; Bhosale, R; Bollinger, R; Gupta, A; Gupte, N; Kagal, A; Kulkarni, S; Kulkarni, V; Moorthy, A; Patil, S; Persaud, D; Sastry, J; Suryavanshi, N; Thakar, M; Tripathy, S; Venkataramani, V; Ziemniak, C, 2009)
"To our knowledge, to date, no prospective, randomized, clinical trial has compared standard doses of efavirenz- and nevirapine-based antiretroviral therapy among patients with concurrent human immunodeficiency virus type 1 (HIV-1) infection and tuberculosis (TB) who are receiving rifampicin."5.14A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. ( Burapatarawong, S; Likanonsakul, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Prasithsirskul, W; Prommool, V; Ruxrungtham, K; Sungkanuparph, S; Tantanathip, P; Thawornwa, U; Thongyen, S, 2009)
"The aim of this study was to evaluate the pharmacokinetics of lamivudine (3TC), stavudine (d4T) and nevirapine (NVP) in HIV-infected Malawian children receiving quartered tablet multiples of Triomune 40 (generic tablet [GT]) compared with individual generic liquid (GL) and trade liquid (TL)."5.14Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. ( Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Kazembe, P; Mkupani, P; Mwansambo, C; Nyirenda, J; Rezk, NL; Sichali, D; Tien, H; Weigel, R, 2010)
"For almost a decade, single-dose nevirapine (sdNVP) has been proven to be a safe and effective drug for the prevention of mother-to-child transmission (PMTCT) of HIV."5.14Is single-dose NVP relevant in the era of more efficacious PMTCT regimens? Lessons from Zambia. ( Bweupe, M; Dirks, R; Kabaso, M; Kasonde, P; Mandala, J; Sangiwa, G; Torpey, K, 2010)
"Among HIV-infected children previously exposed to nevirapine, switching to nevirapine-based therapy after achieving viral suppression with a ritonavir-boosted lopinavir regimen resulted in lower rates of viremia greater than 50 copies/mL than maintaining the primary ritonavir-boosted lopinavir regimen."5.14Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. ( Abrams, EJ; Coovadia, A; Hu, CC; Hunt, G; Kuhn, L; Martens, L; Meyers, T; Morris, L; Sherman, G; Stehlau, R; Tsai, WY, 2010)
"We aim here to determine the appropriate dose of nevirapine (NVP) in Thai HIV-tuberculosis (TB)-coinfected patients receiving rifampicin."5.13Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. ( Avihingsanon, A; Burger, D; Chuchotaworn, C; Cooper, DA; Gorowara, M; Ishikawa, N; Kantipong, P; Manosuthi, W; Mitarai, S; Moolphate, S; Phanuphak, P; Ruxrungtham, K; Sakornjun, W; Yamada, N; Yanai, H, 2008)
"Pregnant HIV-1 seropositive women (CD4+ T-cell count >250 and <500 cells/mm3) electing to breastfeed in Nairobi, Kenya were randomized to highly active antiretroviral therapy (HAART; zidovudine [ZDV], lamivudine and nevirapine [NVP]) during pregnancy and 6 months post-partum or to short-course ZDV plus single-dose NVP (ZDV/NVP)."5.13Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial. ( Chung, MH; John-Stewart, GC; Kiarie, JN; Kinuthia, J; Lehman, DA; Njiri, F; Overbaugh, J; Richardson, BA, 2008)
"In a setting of high perinatal nevirapine use, acute chorioamnionitis was not associated with vertical HIV-1 transmission."5.12Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-1 transmission. ( Chi, BH; Goldenberg, RL; Levy, J; Mudenda, V; Sinkala, M; Stringer, JS, 2006)
"Nevirapine has been widely used in pregnancy for its efficacy, low pill burden, bioavailability and rapid transplacental transfer."5.12Safety of nevirapine in pregnancy. ( Anderson, J; de Ruiter, A; Edwards, SG; Hay, P; McDonald, C; Natarajan, U; Pym, A; Taylor, GP; Velisetty, P; Welch, J, 2007)
"Large numbers of women receive single-dose nevirapine (sdNVP) to prevent mother-to-child transmission (MTCT) of HIV; over time, an increasing proportion will return to prevention of MTCT programs for a second pregnancy."5.12Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire. ( Becquet, R; Dabis, F; Dhlamini, P; Ekouevi, DK; Gray, GE; Leroy, V; Lupodwana, P; Martinson, NA; McIntyre, JA; Morris, L; Steyn, JG; Tonwe-Gold, B; Viho, I, 2007)
"We conducted a randomized, double-blind trial of three treatment regimens in Thai women who were receiving zidovudine therapy during the third trimester of pregnancy."5.11Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. ( Jourdain, G; Kanshana, S; Koetsawang, S; Lallemant, M; Le Coeur, S; Mary, JY; McIntosh, K; Ngo-Giang-Huong, N; Thaineua, V, 2004)
"We randomly assigned 1844 women in Thailand who received zidovudine during the third trimester of pregnancy to receive intrapartum nevirapine or placebo."5.11Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. ( Ariyadej, S; Bowonwatanuwong, C; Hammer, S; Jourdain, G; Kantipong, P; Lallemant, M; Le Coeur, S; Leechanachai, P; Leenasirimakul, P; Ngo-Giang-Huong, N, 2004)
"To examine the effect of 2 weeks of treatment with prednisone on the incidence of nevirapine-associated rash in HIV-1-infected patients receiving combination antiretroviral therapy."5.10Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. ( Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003)
" In a prospective study of 31 HIV-infected patients included in a salvage regimen with stavudine, nevirapine, nelfinavir, and saquinavir, viral load decreased a median of 1."5.09Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure. ( Antela, A; Casado, JL; Dehertogh, P; Dronda, F; Hertogs, K; Martí-Belda, P; Moreno, S; Sabido, R, 2001)
"To assess the virologic, immunologic, and clinical benefit of switching the PI to nevirapine in patients with HIV-associated lipodystrophy and sustained viral suppression before entry in the study."5.09Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. ( Balagué, M; Bonjoch, A; Clotet, B; Domingo, P; Francia, E; Fumaz, CR; Gel, S; Johnston, S; Lange, J; Negredo, E; Paredes, R; Romeu, J; Ruiz, L, 2001)
" However, zidovudine administered with lamivudine and indinavir was associated with increased risk of preterm births, zidovudine administered with nevirapine was associated with increased risk of stillbirths, and lamivudine administered with stavudine and efavirenz was associated with increased risk of low birth weight."4.98Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs. ( Antony, J; Ashoor, HM; Blondal, E; Finkelstein, Y; Ghassemi, M; Gough, K; Hemmelgarn, BR; Hutton, B; Ivory, JD; Khan, PA; Lillie, E; Straus, SE; Tricco, AC; Vafaei, A; Veroniki, AA, 2018)
" Second, we discuss the existing clinical data on this topic, including the observational study from Kenya showing women using implants plus efavirenz-based ART had three-fold higher rates of pregnancy than women using implants plus nevirapine-based ART."4.95Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines. ( Cohen, CR; Kiarie, J; Morroni, C; Patel, RC; Scarsi, KK; Sripipatana, T, 2017)
" We aimed to establish whether pregnancy rates differ between HIV-positive women who use various contraceptive methods and either efavirenz-based or nevirapine-based antiretroviral therapy (ART) regimens."4.91Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study. ( Blat, C; Bukusi, EA; Cohen, CR; Gandhi, M; Hagey, J; Newmann, SJ; Onono, M; Patel, RC; Shade, SB; Vittinghoff, E, 2015)
" Standard ART includes either nevirapine or efavirenz, however the efficacy of these drugs is limited in patients receiving rifampin treatment for tuberculosis (TB)."4.90Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. ( Chen, HJ; Deng, M; Jiang, HY; Ruan, B; Yang, Y; Zhang, MN, 2014)
" Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance."4.85Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009)
" Women appear to be at an especially high risk for lactic acidosis, nevirapine-associated rashes and hepatotoxicity, and fat redistribution after highly active antiretroviral therapy exposure."4.82Sex differences in antiretroviral therapy-associated intolerance and adverse events. ( Clark, R, 2005)
"Artemisinin-based combination therapies (ACTs) are the primary treatment for malaria."4.31Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. ( Aweeka, F; Ehrlich, H; Freeman, T; French, J; Goodwin, J; Huang, L; Kajubi, R; Kay, K; Li, F; Mwebaza, N; Ou, J; Parikh, S; Riggs, M; Ruiz-Garcia, A; Wade, M; Wang, K, 2023)
"Maternal HIV drug resistance and maternal viral load were independent risk factors for vertical transmission during breastfeeding, suggesting that nevirapine alone may be insufficient infant prophylaxis against drug-resistant variants in maternal breast milk."4.12Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants. ( Beck, IA; Boyce, CL; DeMarrais, P; Flynn, PM; Fowler, MG; Frenkel, LM; Ko, D; Owor, M; Sils, T; Stranix-Chibanda, L; Styrchak, SM; Taha, TE; Tierney, C; Wong-On-Wing, A, 2022)
"Nevirapine (NVP) is an effective drug for the treatment of HIV infections, but its use is limited by a high incidence of severe skin rash and liver injury."4.12Sulfation of 12-hydroxy-nevirapine by human SULTs and the effects of genetic polymorphisms of SULT1A1 and SULT2A1. ( Cao, Y; Kurogi, K; Liu, MC; Sakakibara, Y; Segawa, K; Suiko, M; Uetrecht, J, 2022)
" Younger age, male sex, less education, suboptimal adherence, receiving nevirapine, HIV non-disclosure, never having married and residing in Zimbabwe, Lesotho or Zambia were associated with higher odds of NVL."3.96Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys. ( Ao, TT; Barradas, DT; Bello, G; Birhanu, S; Brown, K; Frederix, K; Haas, AD; Hakim, AJ; Jahn, A; Jonnalagadda, S; Justman, JE; Kalua, T; Kim, E; Low, A; Mugurungi, O; Mulenga, LB; Musuka, G; Parekh, B; Patel, H; Philip, NM; Radin, E; Rogers, JH; Sachathep, K; Saito, S; Schwitters, AM; Sleeman, K; Thin, K; Tippett Barr, BA; Voetsch, AC; Williams, DB, 2020)
"Despite improved policies to prevent mother-to-child HIV transmission (MTCT), adherence to maternal antiretroviral therapy (ART) and infant Nevirapine prophylaxis (NVP) is low in South Africa."3.91Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa. ( Ayalew, K; Cheyip, M; Chirinda, W; Dinh, TH; Goga, A; Jackson, D; Kindra, G; Larsen, A; Lombard, C; Magasana, V; Ngandu, N, 2019)
"Nevirapine has an exceptional record for long-term tolerability with few side effects in human immunodeficiency virus (HIV) combined antiretroviral therapy (cART)."3.91Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management? ( Bregenzer, A; Kahlert, CR; Notter, J; Vernazza, P, 2019)
" This study utilized Bayesian logistic regression to examine maternal-level predictors of adherence to infant nevirapine prophylaxis, including intimate partner violence, maternal adherence, HIV serostatus disclosure reaction, recency of HIV diagnosis, and depression."3.88A Bayesian Analysis of Prenatal Maternal Factors Predicting Nonadherence to Infant HIV Medication in South Africa. ( Cook, RR; Jones, DL; Peltzer, K; Rodriguez, VJ; Weiss, SM, 2018)
"Nevirapine is used in developing countries for the treatment of HIV infection, but its use is associated with rare serious adverse reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)."3.88A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine. ( Borgiani, P; Ciccacci, C; Ciccacci, F; Lucaroni, F; Mancinelli, S; Marazzi, MC; Novelli, G; Palombi, L; Politi, C, 2018)
" No baseline differences in depression or suicidal ideation were found between patients ever exposed to efavirenz and those never exposed to efavirenz and receiving nevirapine (P > 0."3.88Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study. ( Bangsberg, DR; Boum, Y; Bwana, M; Chang, JL; Haberer, JE; Hunt, PW; Martin, JN; Musinguzi, N; Muzoora, C; Siedner, MJ; Tsai, AC, 2018)
"Clinical trials demonstrated intermittent preventive treatment in pregnancy with mefloquine (MQ) reduced malaria rates among pregnant women, yet an unexpected higher risk of mother-to-child transmission (MTCT) of HIV among HIV-positive women receiving MQ has also been observed."3.88Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy. ( Desai, M; Dinh, C; Gonzalez, R; Haaland, RE; Heneine, W; Katana, A; Martin, A; Menendez, C; Otieno, K; Slutsker, L; Williamson, J, 2018)
" We report a case of successive gynecomastia and Stevens-Johnson syndrome (SJS) respectively induced by efavirenz and nevirapine in a single patient."3.88Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report. ( Akakpo, AS; Bassowa, A; Dapam, AN; Kombaté, K; Laouali, AY; Mahamadou, G; Mensah, E; Mouhari-Toure, A; Pitché, P; Saka, B; Teclessou, JN, 2018)
"Syphilis is associated with increased human immunodeficiency virus acquisition and sexual transmission; we examined impact on human immunodeficiency virus mother-to-child transmission among mother-infant pairs enrolled in the India Six-Week Extended-Dose Nevirapine study."3.85Maternal Syphilis: An Independent Risk Factor for Mother to Infant Human Immunodeficiency Virus Transmission. ( Bharadwaj, R; Bhat, J; Bhosale, R; Bollinger, R; Gupta, A; Gupte, N; Kinikar, A; Kulkarni, V; Mave, V; McIntire, KN; Patil, S; Suryavanshi, N, 2017)
"All HIV-infected patients receiving a stable PI/r-based antiretroviral regimen, with persistently suppressed viremia, naïve to non-nucleoside analogues and to integrase strand transfer inhibitors, with mixed hyperlipidaemia, and who underwent a switch from PI/r to nevirapine (Group A) or raltegravir (Group B) or who started rosuvastatin at 10 mg daily (group C) with unchanged antiretroviral regimen were enrolled into the study."3.85Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). ( Bon, I; Borderi, M; Bussini, L; Calza, L; Colangeli, V; Magistrelli, E; Re, MC; Viale, P, 2017)
"The antiretroviral nevirapine is associated with hypersensitivity reactions in 6%-10% of patients, including hepatotoxicity, maculopapular exanthema, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)."3.85Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population. ( Alfirevic, A; Borgiani, P; Bourgeois, S; Carr, DF; Castro, EM; Chaponda, M; Dandara, C; Deloukas, P; Haldenby, S; Heyderman, RS; Holden, A; Jones, AR; Kampira, E; Khoo, S; Lalloo, DG; Morris, AP; Munderi, P; Nelson, MR; Novelli, G; Pirmohamed, M; Rigden, DJ; Ssali, F; Takeshita, LY; van Oosterhout, JJ, 2017)
" Patients were allocated to 2groups according to exposure to nevirapine during pregnancy."3.83[Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy]. ( Figueras-Nadal, C; Fortuny-Guasch, C; Iveli, P; Martín-Nalda, A; Noguera-Julian, A; Rovira-Girabal, N; Soler-Palacín, P, 2016)
"We investigated the influence of efavirenz (EFV)- or nevirapine (NVP)-based antiretroviral therapy (ART) on lumefantrine plasma exposure in HIV-malaria-coinfected patients and implication of pharmacogenetic variations."3.83CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2016)
" Antiretroviral treatment-naive women started a nevirapine-based triple combination regimen from the third trimester of pregnancy until at least 6 months of exclusive breastfeeding."3.83Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children. ( Amici, R; Andreotti, M; Baroncelli, S; Galluzzo, CM; Giuliano, M; Jere, H; Mancinelli, S; Marazzi, MC; Palombi, L; Vella, S, 2016)
" In the study, women with baseline CD4(+) <350/mm(3) received a combination of stavudine, lamivudine, and nevirapine during pregnancy (from week 25 of gestation) and continued it indefinitely after delivery."3.83Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi. ( Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Mancinelli, S; Marazzi, MC; Palombi, L; Pirillo, MF; Sagno, JB; Scarcella, P; Vella, S, 2016)
" We found that nevirapine use and pregnancy are independently associated with severe skin reaction."3.83Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis. ( Boulle, A; Cohen, K; de Waal, R; Lehloenya, R; Maartens, G; Stewart, A, 2016)
" We assessed the relationship between plasma lopinavir or nevirapine concentrations and the risk of subsequent viremia in children initially suppressed on antiretroviral therapy."3.83Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children. ( Abrams, EJ; Castel, S; Coovadia, A; Kuhn, L; Maartens, G; McIlleron, H; Moholisa, RR; Patel, F; Pinillos, F; Schomaker, M; Strehlau, R; Wiesner, L, 2016)
"We describe nevirapine and efavirenz exposure on and off tuberculosis treatment and consequences for virological efficacy and tolerance in patients included in the ANRS 12146/12214-CARINEMO trial."3.81Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship. ( Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; da Silva, C; Furlan, V; Grinsztejn, B; Meggi, B; Taburet, AM, 2015)
" The present work envisages the development of a stealth anti-CD4 conjugated immunoliposomes containing two anti-retroviral drugs (nevirapine and saquinavir) that can selectively home into HIV infected cells through the CD4 receptor."3.81Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs--modern Trojan horses to combat HIV. ( Krishnan, UM; Ramana, LN; Ranga, U; Sethuraman, S; Sharma, S, 2015)
"To determine the impact of nevirapine and subclinical mastitis on HIV-1 RNA in maternal plasma and breast milk after intrapartum single-dose nevirapine combined with either 1-week tail of Combivir (zidovudine/lamivudine) or single-dose Truvada (tenofovir/emtricitabine)."3.81Nevirapine, sodium concentration and HIV-1 RNA in breast milk and plasma among HIV-infected women receiving short-course antiretroviral prophylaxis. ( Bygbjerg, IC; Chiduo, MG; Gerstoft, J; Katzenstein, TL; Lemnge, M; Lüneborg-Nielsen, M; Salado-Rasmussen, K; Theilgaard, ZP, 2015)
"HIV-malaria co-infected patients in most parts of sub-Saharan Africa are treated with both artemether-lumefantrine (AL) and efavirenz (EFV) or nevirapine (NVP)-based antiretroviral therapy (ART)."3.81The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)
"The objective of this study was to determine the prevalence of drug resistance mutations among HIV-positive women in Malawi 18 months after discontinuing nevirapine-based ART for the prevention of mother-to-child transmission."3.81Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. ( Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Vella, S, 2015)
"An exit interview was conducted one year post-partum for 85 HIV-infected women who participated in a study of HIV-1 transmission rates among NVP-experienced compared with NVP-naïve women in "The Nevirapine Repeat Pregnancy (NVP-RP) Study" at the Makerere University-Johns Hopkins University Research Collaboration, Kampala-Uganda, between June 2004 and June 2006."3.81A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study". ( Bakaki, PM; Fowler, MG; Kiweewa, FM; Kusasira, F; McConnell, MS; Mubiru, MC; Musisi, M; Musoke, P; Nakayiwa, F; Nakintu, D; Namirembe, C, 2015)
"Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited."3.81Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015)
", maternal zidovudine and infant ARV prophylaxis) of the World Health Organization's 2010 guidelines, no studies have assessed adherence to ARVs during pregnancy up to the postpartum period."3.81Longitudinal adherence to antiretroviral drugs for preventing mother-to-child transmission of HIV in Zambia. ( Chirwa, M; Ishikawa, N; Jimba, M; Kapyata, H; Komada, K; Miyano, S; Msiska, CY; Okawa, S; Syakantu, G; Yasuoka, J, 2015)
"We report a case in which an HIV-positive man developed general malaise, skin rash and biochemical hepatitis within days of starting a nevirapine-based antiretroviral treatment regimen."3.80Rash and hepatitis within days of starting a new antiretroviral regimen: nevirapine hypersensitivity, secondary syphilis or both? ( Helbert, MR; Higgins, SP; Komolafe, AJ; Saxon, CJ, 2014)
"To determine whether residual plasma viremia in HIV(+) patients on nevirapine-including antiretroviral therapy (ART) is related to anti-HIV cellular immune responses, a case-control study was conducted comparing residual viremia in patients with detectable and undetectable Gag-specific T-cell responses."3.80Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response. ( Allavena, C; Billaud, E; Ferré, V; McIlroy, D; Raffi, F; Rodallec, A, 2014)
"Data from a prospective multisite cohort study were used to examine the effect of HIV exposure, untreated HIV infection, and single-dose nevirapine on infant growth velocity."3.80HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants. ( Chhagan, M; Doherty, T; Fadnes, LT; Goga, AE; Jackson, DJ; Lombard, C; Ramokolo, V; Van den Broeck, J, 2014)
"We modeled nevirapine (NVP) pharmacokinetics in HIV-infected Malawian patients to assess the relationship between drug exposure and patient characteristics, genetic polymorphisms, and development of hypersensitivity reaction (HSR)."3.80Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. ( Carr, DF; Chaponda, M; Dickinson, L; Heyderman, RS; Khoo, SH; Kumwenda, J; Lalloo, DG; Pirmohamed, M; van Oosterhout, JJ, 2014)
"Artesunate plus amodiaquine is used for malaria treatment in regions with overlapping HIV endemicity."3.80Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. ( Adedeji, WA; Adewole, IF; Akinola, IT; Akinyinka, OO; Aweeka, FT; Darin, KM; Fehintola, FA; Lindegardh, N; Ma, Q; Morse, GD; Murphy, RL; Ojengbede, O; Parikh, S; Scarsi, KK; Taiwo, B; Tarning, J, 2014)
"Data from cost studies and other published sources were used to determine the cost, per woman and per cohort (1000 breastfeeding and 1000 non-breastfeeding women), of switching from Option B (maternal triple antiretroviral [ARV] regimen during pregnancy and breastfeeding plus daily nevirapine for the infant for 6 weeks) to Option B+ (maternal triple ARV regimen initiated during pregnancy and continued for life)."3.80The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV. ( Abimbola, TO; O'Brien, L; Sangrujee, N; Shaffer, N, 2014)
"This was a prospective, non-randomized, open-label study conducted in Bagamoyo district, with three arms of HIV-infected adults: efavirenz-based treatment arm (EFV-arm) n = 66, nevirapine-based treatment arm (NVP-arm) n = 128, and control-arm n = 75, with uncomplicated malaria."3.80Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy. ( Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngasala, B; Sasi, PG, 2014)
"It has been proposed that hepatitis B virus (HBV) sub-genotype A1 infections have mild outcomes and a low risk of drug-resistance among patients infected with human immunodeficiency virus (HIV) receiving lamivudine-containing antiretroviral therapy (ART) without tenofovir in Africa."3.80Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi. ( Aoudjane, S; Beloukas, A; Chaponda, M; Geretti, AM; González Del Castillo, AA; Hopkins, M; Khoo, S; Noguera, M; O'Connor, J; van Oosterhout, JJ, 2014)
"We assessed the pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children while they were receiving nevirapine-containing fixed-dose combination tablets with rifampicin-based tuberculosis treatment and after discontinuation."3.78Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation. ( Capparelli, E; Chokephaibulkit, K; Cressey, TR; Lapphra, K; Prasitsuebsai, W; Vanprapar, N, 2012)
" We compared the pregnancy outcomes of women exposed to EFV and to nevirapine (NVP) during the first trimester."3.77Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire. ( Amani-Bosse, C; Anglaret, X; Coffie, PA; Dabis, F; Danel, C; Eholié, SP; Ekouevi, DK; Messou, E; Moh, R; Ouattara, E; Sissoko, M, 2011)
"To compare the level of HIV-1 residual viremia, defined by a viral load below 50 copies/ml in patients receiving a tenofovir/emtricitabine and nevirapine (NVP) or efavirenz (EFV)-containing regimen."3.77Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. ( Calvez, V; Flandre, P; Fourati, S; Girard, PM; Haïm-Boukobza, S; Katlama, C; Lavignon, M; Marcelin, AG; Morand-Joubert, L; Sayon, S; Simon, A; Valin, N, 2011)
"From the ATHENA cohort study, three scenarios were selected for which the guideline recommended TDM: 1) start of a combination of lopinavir/ritonavir + efavirenz or nevirapine (drug-drug interaction); 2) start of efavirenz (routine TDM); and 3) use of nelfinavir during pregnancy."3.77Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands. ( Burger, DM; de Wolf, F; Franssen, EJ; Kroon, F; Richter, C; Rigter, IM; Smit, C; van Luin, M; Wit, FW, 2011)
"Nevirapine resistance after failed prophylaxis to prevent mother-to-child human immunodeficiency virus (HIV) transmission can compromise subsequent nevirapine-based highly active antiretroviral therapy (HAART)."3.77Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. ( Abrams, EJ; Chen, YH; Coovadia, A; Kuhn, L; Meyers, T; Moorthy, A; Persaud, D; Sherman, G; Strehlau, R; Tsai, WY, 2011)
"To evaluate the effect of a previous single dose of nevirapine given to prevent mother-to-child transmission of human immunodeficiency virus (HIV) on virologic and immunologic measures after months of an antiretroviral regimen containing either efavirenz or lopinavir-ritonavir."3.77Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir. ( Dewar, RL; Dlamini, JN; Follmann, DA; Highbarger, HC; Hu, Z; Pau, AK; Somaroo, H, 2011)
" Simulations of the nevirapine concentration profile were performed with dosing regimens of 200 mg twice daily and 400 mg once daily for individuals with body weights of 50, 70 and 90 kg in combination with CYP2B6 genetic variation."3.77Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. ( Back, DJ; Brockmeyer, NH; Davies, G; Egan, D; Fätkenheuer, G; Hendra, H; Johnson, MA; Khoo, S; Mahungu, T; Owen, A; Rockstroh, J; Schipani, A; Siccardi, M; Wyen, C; Youle, M, 2011)
" We compared five PMTCT regimens at a fixed level of PMTCT medication uptake: 1) no antenatal ARVs (comparator); 2) sdNVP; 3) WHO 2010 guidelines using "Option A" (zidovudine during pregnancy/infant NVP during breastfeeding for women without advanced HIV disease; lifelong 3-drug antiretroviral therapy (ART) for women with advanced disease); 4) WHO "Option B" (ART during pregnancy/breastfeeding without advanced disease; lifelong ART with advanced disease); and 5) "Option B+:" lifelong ART for all pregnant/breastfeeding, HIV-infected women."3.77WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers. ( Chu, J; Ciaranello, AL; Dabis, F; Engelsmann, B; Freedberg, KA; Keatinge, J; Maruva, M; Mugwagwa, R; Mushavi, A; Perez, F; Walensky, RP, 2011)
" Patients were offered nevirapine-based triple ART initiated in pregnancy until 6 months postpartum."3.77Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. ( Buonomo, E; Ceffa, S; Haswell, J; Liotta, G; Magid, NA; Marazzi, MC; Narciso, P; Nielsen-Saines, K; Palombi, L; Paturzo, G; Scarcella, P; Zimba, I, 2011)
" Unbooked HIV positive pregnant women, who had not received antiretroviral drugs during the antenatal period but received nevirapine in labour, referred to as untreated-maternal HIV infection, were compared with women who received HAART early in pregnancy."3.77Pregnancy outcome among HIV positive women receiving antenatal HAART versus untreated maternal HIV infection. ( Biodun, O; Joseph, O; Michael, E, 2011)
"Compare the risk of HIV drug resistance in women stopping suppressive nelfinavir (NFV)-based or Nevirapine (NVP)-based antiretroviral therapy (ART) after pregnancy."3.77Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum. ( Ellis, GM; Frenkel, LM; Hitti, J; Huang, S, 2011)
"The objective of this cross-sectional observational ('real-world') study was to investigate the effect of three HAART regimens plus stable nevirapine therapy on morphological and metabolic components of lipodystrophy in HIV-infected patients."3.77Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study. ( Adorni, F; Bagni, P; Carli, F; Garlassi, E; Guaraldi, G; Luzi, K; Menozzi, M; Orlando, G; Stentarelli, C; Zona, S, 2011)
" Nevirapine induced rash and SJ syndrome developed within first month of treatment followed by anemia, hepatitis and gastritis which developed within 6 months after initiation of ART."3.77HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India. ( Anwikar, SR; Bandekar, MS; Kshirsagar, NA; Pazare, AP; Smrati, B; Tatke, PA, 2011)
" Baseline median CD4 T-cell count: 417 cell/ųl; 98% received antiretroviral drugs during pregnancy [2 nucleoside analogs plus either nevirapine (55%) or a protease inhibitor (32%)]."3.77HIV and pregnancy: maternal and neonatal evolution. ( Cecchini, D; Mecikovsky, D; Trinidad, P; Urueña, A; Vesperoni, F, 2011)
" Infection with Plasmodium falciparum malaria was confirmed and treatment with quinine commenced together with amoxicillin/clavulanic acid and clarithromycin for possible respiratory infection."3.77Malaria therapy in HIV: drug interactions between nevirapine and quinine. ( Lewthwaite, P; Uriel, A, 2011)
" All women received zidovudine and lamivudine during pregnancy; 76% also received nelfinavir and 8."3.76Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy. ( Cheng, I; Kuritzkes, DR; Paredes, R; Tuomala, RE, 2010)
"To report on 1) clinical, immunological and virological outcomes and 2) safety among human immunodeficiency virus (HIV) infected patients with tuberculosis (TB) who received concurrent nevirapine (NVP) and rifampicin (RMP) based treatment."3.76Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi. ( Bauerfeind, A; Foncha, C; Harries, AD; Kwanjana, J; Manzi, M; Misinde, D; Moses, M; Mwagomba, B; Tayler-Smith, K; Zachariah, R, 2010)
"Coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) in HIV-infected patients receiving a commonly used nevirapine-based antiretroviral therapy is a major concern for African clinicians owing to its high prevalence, the infrequent testing and treatment of viral hepatitis, and the impact of liver disease on the tolerability and effectiveness of anti-HIV treatment."3.76Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. ( Bourgeois, A; Calmy, A; Ciaffi, L; Delaporte, E; Ducos, J; Gwet, H; Kouanfack, C; Koulla-Shiro, S; Laurent, C; Mbougua, JB; Molinari, N; Mpoudi-Ngolé, E, 2010)
"Conflicting data exist regarding the effect of pregnancy on steady-state nevirapine pharmacokinetics (PK), although steady-state nevirapine concentrations during pregnancy have never been characterized in sub-Saharan Africa."3.76Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women. ( Back, DJ; Boffito, M; Byakika-Kibwika, P; Flaherty, JP; Khoo, S; Lamorde, M; Merry, C; Nakabiito, C; Namakula, R; Okaba-Kayom, V; Ryan, M; Scarsi, KK, 2010)
"We describe a case of nevirapine-induced Stevens-Johnson Syndrome (SJS) and fulminant hepatic failure (FHF) requiring liver transplantation."3.76Nevirapine-induced stevens johnson-syndrome and fulminant hepatic failure requiring liver transplantation. ( del Rio Martin, J; Fiel, MI; Huprikar, S; Jao, J; Schiano, T; Sturdevant, M, 2010)
"The concurrent use of nevirapine-based antiretroviral therapy (ART) and rifampin-containing anti-tuberculosis regimens for the treatment of HIV and tuberculosis (TB) is common in resource-limited countries."3.76Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. ( Chimsuntorn, S; Eampokarap, B; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Tantanathip, P; Thongyen, S, 2010)
"This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment."3.76Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. ( Biwolé-Sida, M; Bork, K; Coudray, M; Cournil, A; Delaporte, E; Essomba, CN; Kouanfack, C; Laurent, C; Tonfack, CA, 2010)
"Use of single dose nevirapine (sdNVP) to prevent HIV mother-to-child transmission is associated with the emergence of NVP resistance in many infants who are HIV infected despite prophylaxis."3.75In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. ( Bagenda, D; Bakaki, P; Church, JD; Donnell, D; Eshleman, SH; Eure, C; Fowler, MG; Guay, LA; Jackson, JB; Matovu, F; McConnell, M; Musoke, P; Mwatha, A; Nakabiito, C; Omer, SB; Thigpen, MC, 2009)
"To estimate whether the association between nevirapine (NVP) and hepatotoxicity differs according to pregnancy status in HIV-infected women."3.75Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. ( Brogly, SB; French, AL; Hershow, RC; Leighty, RM; Lu, M; Ouyang, DW; Shapiro, DE; Thompson, B; Tuomala, RE, 2009)
"Nevirapine (NVP) plasma levels are reduced in patients receiving rifampicin (RFM) for tuberculosis (TB) treatment."3.75Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. ( Bonkoungou, V; Carosi, G; Carvalho, AC; Dembele, M; Kouanda, S; Matteelli, A; Monno, L; Regazzi, M; Saleri, N; Sanou, MJ; Simporé, J; Villani, P, 2009)
"To determine the relationship between nutritional status and nevirapine exposure by comparing the pharmacokinetics of nevirapine in HIV-infected children of different ages with and without malnutrition receiving divided tablets of Triomune 30 (stavudine + lamivudine + nevirapine) in accordance with Malawi National Guidelines."3.75Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. ( Back, D; Else, L; Fraser, W; Khoo, S; Molyneux, E; Moons, P; Poerksen, G; Pollock, L; Walker, S, 2009)
"Limited information is currently available on the metabolic profile of nevirapine in pregnancy."3.75Plasma lipid profile in pregnant women with HIV receiving nevirapine. ( Anzidei, G; Dalzero, S; Floridia, M; Guaraldi, G; Guerra, B; Meloni, AM; Molinari, A; Pinnetti, C; Ravizza, M; Tamburrini, E; Tibaldi, C; Vimercati, A, 2009)
"The analysis included 2035 individuals who started antiretroviral therapy with efavirenz (1074 with concurrent tuberculosis) and 1935 with nevirapine (209 with concurrent tuberculosis)."3.74Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. ( Abrahams, M; Boulle, A; Coetzee, D; Cohen, K; Goemaere, E; Hilderbrand, K; Maartens, G; Mathee, S; Van Cutsem, G, 2008)
"Single-dose nevirapine (SD NVP) at birth plus NVP prophylaxis for the infant up to 6 weeks of age is superior to SD NVP alone for prevention of vertical transmission of human immunodeficiency virus (HIV) through breastfeeding."3.74Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. ( Church, JD; Eshleman, SH; Guay, LA; Huang, W; Jackson, JB; Lidstrom, J; Mmiro, F; Musoke, P; Omer, SB, 2008)
"PI substitution with nevirapine improved lipid profile in our patients, although this strategy did not show significant changes in body fat or lipodystrophy."3.74Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children. ( Amador, JT; Conejo, PR; Fontelos, PM; Gomez, ML; Gonzalez-Tome, MI; Peña, MJ, 2008)
"Single-dose nevirapine (SDNVP) for the prevention of mother-to-child HIV transmission (PMTCT) results in the selection of resistance mutants among HIV-infected mothers."3.74Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study. ( Aldrovandi, GM; Kankasa, C; Kuhn, L; Semrau, K; Sinkala, M; Thea, DM; Walter, J, 2008)
"a retrospective study was performed between January 2003 and December 2006 analysing all women prescribed nevirapine in pregnancy."3.74[Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital]. ( Astori, Ade A; Fernandes, Rde B; Gomes, Sel-K; Kondo, W; Sasaki, Md; Sbalqueiro, RL, 2008)
"Seventy patients with human immunodeficiency virus (HIV) and tuberculosis coinfection who initiated nevirapine-based antiretroviral therapy and had trough nevirapine levels determined while receiving rifampicin were enrolled in a study."3.74Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. ( Inthong, Y; Likanonsakul, S; Manosuthi, W; Phoorisri, T; Prasithsirikul, W; Ruxrungtham, K; Sungkanuparph, S, 2007)
"We prospectively followed 27 HIV-infected adult Malawians after starting Triomune (a generic fixed drug combination of stavudine, lamivudine and nevirapine) in the second week of tuberculosis treatment."3.74Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. ( Beadsworth, M; Burger, DM; Kumwenda, JJ; Longwe, T; Mateyu, G; van Oosterhout, JJ; Zijlstra, EE, 2007)
"Drug rash with eosinophilia and systemic symptoms (DRESS Syndrome) associated with nevirapine treatment has not been previously reported in children."3.74Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection. ( Barton, T; Ramilo, O; Santos, RP, 2007)
"Single-dose nevirapine (SDNVP) is widely used to prevent mother-to-child HIV transmission in resource-limited settings."3.74Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. ( Bagenda, D; Bakaki, P; Downing, R; Eure, C; Fowler, MG; Greenberg, AE; Matovu, F; McConnell, M; Mubiru, M; Thigpen, MC, 2007)
"A previously healthy young man experienced several episodes of syncope while being treated with tenofovir, emtricitabine and nevirapine initiated during primary HIV-1 infection."3.74Syncope as a probable side effect to combination antiretroviral therapy initiated during primary HIV-1 infection. ( Larsen, CS; Lybaek, D, 2008)
"To determine the impact of pregnancy on the pharmacokinetics (PK) of nevirapine (NVP) during chronic dosing in HIV-infected women and appropriate NVP dosing in this population."3.74Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. ( Aweeka, F; Best, B; Burchett, SK; Capparelli, EV; Foca, M; Hitti, J; Hu, C; Jimenez, E; Mirochnick, M; Nachman, S; Read, JS; Shearer, WT; Smith, E; Spector, SA; Stek, A; Thorpe, EM; Watts, H, 2008)
"To determine incidence and risk factors of nevirapine (NVP)-associated severe hepatitis that led to NVP discontinuation among HIV-infected patients with CD4 < 250 cells/microL."3.74Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL. ( Chaovavanich, A; Chimsuntorn, S; Chottanapund, S; Mankatitham, W; Manosuthi, W; Moolasart, V; Sittibusaya, C; Sungkanuparph, S; Tansuphaswadikul, S, 2008)
"There is limited comparative data between efavirenz (EFV) 600 mg/day and nevirapine (NVP) 400 mg/day-based antiretroviral therapy (ART) among HIV-1 patients with tuberculosis (TB) and receiving rifampicin."3.74Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. ( Chimsuntorn, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Sungkanuparph, S, 2008)
"In the Western Cape province of South Africa, an intensified regimen for the prevention-of-mother-to-child-transmission-of-HIV consisting of zidovudine (AZT) from 34 weeks of pregnancy plus single dose (sd) nevirapine (NVP) during labor was instituted in 2004."3.74Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. ( Claassen, M; Cotton, MF; Engelbrecht, S; Laten, JD; Preiser, W; Theron, GB; van Zyl, GU, 2008)
"This study used Markov modeling to define the circumstances under which the following interventions would be cost-effective: BF for 6 months with daily infant nevirapine (NVP) prophylaxis; maternal combination antiretroviral therapy (ART) during pregnancy and for 6 months of BF; and maternal combination ART only for women who meet CD4 criteria."3.73Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding. ( Maclean, CC; Stringer, JS, 2005)
"Nelfinavir- or nevirapine-containing HAART regimens during pregnancy are well tolerated."3.73Nelfinavir and nevirapine side effects during pregnancy. ( Boer, K; de Wolf, F; Dieleman, J; Godfried, MH; Nellen, J; Schneider, ME; Sprenger, H; Tempelman, C; Timmermans, S; van der Ende, ME, 2005)
"The incidence of adverse events with nevirapine may be lower than previously reported (13% versus 29%) and may be primarily noted with initiating the drug late in pregnancy."3.73Third-trimester maternal toxicity with nevirapine use in pregnancy. ( Brady, MT; Fan-Havard, P; Hughes, L; Joy, S; Koletar, SL; Para, MF; Poi, M, 2005)
"In countries with high numbers of HIV/tuberculosis coinfection nevirapine and rifampin are used extensively."3.73Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. ( Anekthananon, T; Autar, RS; Burger, DM; Cooper, DA; Lange, JM; Mahanontharit, A; Mootsikapun, P; Phanuphak, P; Ruxrungtham, K; Sankote, J; Sujaikaew, K; Wit, FW, 2005)
"To describe the maternal tolerability of nevirapine as part of combination antiretroviral therapy in pregnancy at three HIV centres in Dublin, Ireland and to determine risk factors for development of significant hepatotoxicity."3.73Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. ( Bergin, C; Geoghegan, J; Hopkins, S; Kelleher, B; Lyons, F; McCormick, PA; McGeary, A; Mulcahy, FM; Sheehan, G, 2006)
"The influence of nevirapine, efavirenz and tenofovir co-administration on ritonavir-boosted atazanavir pharmacokinetics was investigated in HIV (human immunodeficiency virus)-infected patients."3.73Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. ( Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O, 2006)
" We describe a detailed case of fulminant hepatitis induced by nevirapine (Viramune) and treated by liver transplantation."3.73Liver transplantation for fulminant hepatitis related to nevirapine therapy. ( Antonini, T; Buyse, S; Castaing, D; Duclos-Vallée, JC; Ichai, P; Samuel, D; Sebagh, M; Vibert, E, 2006)
"Both chronic hepatitis C and nevirapine (NVP) use are risk factors for transaminase elevation under highly active antiretroviral therapy."3.72Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. ( González-Lahoz, J; González-Requena, D; Núñez, M; Soriano, V, 2003)
" We report the case of a pregnant human immunodeficiency virus type 1-infected woman who developed drug rash with eosinophilia and systemic symptoms syndrome and renal failure shortly after initiation of a nevirapine-containing antiretroviral regimen at 27 weeks' gestation."3.72Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. ( Boswell, H; Fan-Havard, P; Knudtson, E; Para, M, 2003)
"At the defined period, 306 patients started a nevirapine-containing regimen, of whom eight developed an acute hepatitis (2."3.72Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. ( Beijnen, JH; de Maat, MM; Mairuhu, AT; Mulder, JW; ter Heine, R; van Gorp, EC, 2003)
"HAART regimens including nevirapine are associated with faster liver fibrosis progression in HIV-infected patients with chronic hepatitis C."3.72Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. ( Castellano, V; García-García, JA; Gómez-Mateos, JM; Lozano, F; Macías, J; Merchante, N; Mira, JA; Palacios, RB; Pineda, JA; Sáez, C, 2004)
" The majority of the HIV positive mothers received nevirapine in labour while 35% had combination ARV drugs in pregnancy."3.72Prevention of mother-to-child transmission of HIV at Maiduguri, Nigeria. ( Audu, BM; Chama, CM; Kyari, O, 2004)
"The following were determined using data from eight African countries: national program costs and impact on infant infections; reductions in adult HIV prevalence and unintended pregnancies among HIV-infected women that would have equivalent impact on infant HIV infections averted as the nevirapine intervention; and the cost threshold for drugs with greater efficacy than nevirapine yielding an equivalent cost per DALY saved."3.72Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries. ( de Zoysa, I; Denison, J; O'Reilly, KR; Schmid, GP; Sweat, MD, 2004)
" In one case, a 43-year-old female health-care worker required liver transplantation after developing fulminant hepatitis and end-stage hepatic failure while taking NVP, zidovudine, and lamivudine as PEP following a needlestick injury (1)."3.71Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000. ( , 2001)
"To draw attention to the many cases of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) related to nevirapine detected in a multinational case-control study of SJS and TEN."3.71Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. ( Bouwes-Bavinck, JN; Fagot, JP; Mockenhaupt, M; Naldi, L; Roujeau, JC; Viboud, C, 2001)
"To describe the experience of four London HIV centres prescribing nevirapine (NVP) to HIV-1 infected pregnant women with respect to immunological and virological response, tolerability and pregnancy outcome."3.71Experience of nevirapine use in a London cohort of HIV-infected pregnant women. ( de Ruiter, A; Easterbrook, P; Edwards, SG; Hay, P; Larbalestier, N; Taylor, GP; Welch, J, 2001)
"To determine whether rifampicin reduces serum concentrations of nevirapine and whether nevirapine modifies serum concentrations of rifampicin, levels of these agents were determined at steady state by high-performance liquid chromatography in 10 HIV-infected patients with tuberculosis."3.71Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. ( Crespo, M; Falco, V; Lopez, RM; Ocaña, I; Pahissa, A; Pou, L; Ribera, E; Ruiz, I, 2001)
" Risk factors were higher baseline alanine aminotransferase levels, chronic hepatitis B or C virus infection, antiretroviral therapy-naive patients undergoing their first HAART regimen, recent start of a regimen of nevirapine or high-dose ritonavir, and female sex."3.71Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. ( Jurriaans, S; Lange, JM; Weel, J; Weverling, GJ; Wit, FW, 2002)
"The nonnucleoside reverse transcriptase inhibitor nevirapine rapidly selects for mutant human immunodeficiency virus (HIV) in vivo."3.69Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. ( Eastman, S; Gamst, A; Havlir, DV; Richman, DD, 1996)
" As of September 1, 1996, ADAP began covering HIV protease inhibitors, viral load evaluations, and other crucial anti-HIV and opportunistic infection agents, including nevirapine for HIV, cidofovir for CMV, and DaunoXome for Kaposi's sarcoma."3.69New York ADAP to cover new AIDS drugs plus viral load testing. ( Link, D, 1996)
"Results of ACTG 076, a clinical trial funded by the National Institute of Allergy and Infectious Disease (NIAID), indicate that perinatal HIV transmission rates could be significantly reduced by treating HIV-positive pregnant women with an intensive zidovudine (AZT) regimen during the second half of pregnancy and during labor and delivery, and by treating the infants for the first six weeks of life."3.69Preventing HIV infection in infants in developing countries: NIAID's role. National Institute of Allergy and Infectious Diseases. ( , 1997)
" Participants provided sparse pharmacokinetic (PK) sampling at baseline and weeks 2 and 4 for trough nevirapine determination."3.01Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. ( Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Hakim, J; Kanyama, C; Langat, D; Leon-Cruz, J; Mwelase, N; Omoz-Oarhe, A; Podany, AT; Supparatpinyo, K; Swindells, S, 2021)
"Nevirapine exposure was assessed in all patients with available blood samples and safety was assessed in all participants."3.01Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. ( Bryson, Y; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Coletti, A; Cotton, MF; Hazra, R; Jean-Philippe, P; LeBlanc, R; Mirochnick, M; Naidoo, KL; Nelson, BS; Persaud, D; Reding, C; Ruel, TD; Spector, SA; Tierney, C; Zimmer, B, 2021)
" Associations between patient genotype and etonogestrel pharmacokinetic parameters were determined through univariate and multivariate linear regression."2.90Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. ( Achilles, SL; Chappell, CA; Chen, BA; Lamorde, M; Matovu, J; Nakalema, S; Neary, M; Owen, A; Scarsi, KK; Siccardi, M, 2019)
"Nevirapine (NVP) is a key component of antiretroviral prophylaxis and treatment for neonates."2.84Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates. ( Aarons, L; Borkird, T; Capparelli, EV; Cressey, TR; Jittayanun, K; Jourdain, G; Lallemant, M; Le Coeur, S; Luvira, A; Phanomcheong, S; Puangsombat, A; Punyawudho, B; Saenjum, C; Sukrakanchana, PO; Urien, S, 2017)
" Absence of hypersensitivity reactions, superior resistance profile and once-daily dosing favours abacavir for African children, supporting WHO 2013 guidelines."2.82Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. ( Abongomera, G; Asiimwe, A; Burger, D; Chabala, C; Chintu, C; Cook, AD; Gibb, DM; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; McIlleron, H; Mirembe, G; Mulenga, V; Musiime, V; Owen-Powell, E; Thomason, MJ; Walker, AS, 2016)
"Levonorgestrel implants were inserted at baseline in all women."2.82Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. ( Back, DJ; Buzibye, A; Byakika-Kibwika, P; Cohn, SE; Darin, KM; Dilly Penchala, S; Else, LJ; Lamorde, M; Merry, C; Nakalema, S; Scarsi, KK, 2016)
" Hence, this study was aimed to determine population pharmacokinetic parameters in Malaysian HIV-infected patients with a non-parametric approach which allows detection of outliers or non-normal distribution contrary to the parametric approach."2.82Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach. ( Choon, TS; Hassan, NB; Mustafa, S; Woillard, JB; Yusuf, WN, 2016)
" Substituting nevirapine for rilpivirine resulted in ongoing virological suppression and did not have clinically relevant pharmacokinetic effects by cytochrome P450 interactions."2.80The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients. ( Blonk, M; Burger, D; Rijnders, BJ; Rokx, C; Verbon, A, 2015)
"Etravirine RAMs were detected in five (4%) individuals."2.80Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. ( Aboulker, JP; Charreau, I; de Castro, N; Delaugerre, C; Gallien, S; Mahjoub, N; Molina, JM; Nere, ML; Simon, F, 2015)
"The metabolic pathways of dolutegravir and nevirapine suggest a potential pharmacokinetic interaction between these drugs."2.80Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1. ( Allavena, C; Billaud, E; Bouchez, S; Bouquié, R; Dailly, E; Deslandes, G; Grégoire, M; Hall, N; Hernando, H; Jolliet, P; Raffi, F; Reliquet, V, 2015)
" There were no differences in adverse events between study arms."2.79Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial. ( Aizire, J; Allen, M; Andrew, P; Brown, E; Chetty, V; Chipato, T; Coovadia, H; Eshleman, SH; Fawzi, W; Fowler, MG; George, K; Herron, CM; Jackson, JB; Kisenge, R; Maldonado, Y; Manji, K; Mofenson, LM; Moodley, D; Msweli, L; Musoke, P; Mwatha, A; Richardson, P; Stranix-Chibanda, L; Zwerski, S, 2014)
"To compare steady-state (ss) pharmacokinetic targets of nevirapine extended-release (NVP-XR) tablets once-daily (QD) with immediate-release (NVP-IR) tablet or oral suspension twice-daily in HIV-1-infected children and adolescents."2.79Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study. ( Anabwani, G; Feiterna-Sperling, C; Giaquinto, C; Königs, C; MacGregor, TR; Mensa, FJ; Mompati, K; Nguyen, T; Nuttall, J; Quinson, AM; Sabo, JP; Yong, CL, 2014)
"Etravirine is an NNRTI option for treatment-experienced paediatric patients."2.79Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study. ( Cahn, P; Chokephaibulkit, K; Dincq, S; Fourie, J; Kakuda, TN; Karatzios, C; Nijs, S; Opsomer, M; Tambuyzer, L; Tomaka, FL; Tudor-Williams, G, 2014)
"Bedaquiline is a novel drug for the treatment of multidrug-resistant (MDR) TB; combined use with antiretroviral drugs, nevirapine, or ritonavir-boosted lopinavir (LPV/r) is anticipated, but no clinical data from coinfected patients are available."2.79Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. ( Dooley, KE; Karlsson, MO; Svensson, EM, 2014)
" INH was associated with a 24% increase in median NVP area under the plasma concentration-time curve for the 12 h dosing interval, which was not statistically significant (P = 0."2.78The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals. ( Decloedt, EH; Denti, P; Maartens, G; McIlleron, H; Mwansa-Kambafwile, J; Rangaka, M; Smith, P; van der Walt, JS; Wiesner, L; Wilkinson, RJ, 2013)
" In a pharmacokinetic investigation, breast milk and plasma samples of mothers and newborns were collected."2.78Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns. ( Frank, M; Harms, G; Kloft, C; Kunz, A, 2013)
"Nevirapine was assayed by high-performance liquid chromatography (HPLC)."2.78Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state. ( Barrail-Tran, A; Chou, M; Fan-Havard, P; Haas, DW; Ling, Y; Liu, Z; Taburet, AM, 2013)
"We evaluated disease progression among HIV-infected women not on ART with CD4⁺ lymphocyte counts above 200 cells per microliter at delivery."2.78HIV disease progression in the first year after delivery among African women followed in the HPTN 046 clinical trial. ( Brown, ER; Chipato, T; Coovadia, H; Fawzi, W; Fowler, M; George, K; Herron, C; Maldonado, Y; Manji, K; Moodley, D; Nakabiito, C; Reddy, L; Richardson, P; Watts, DH; Zwerski, S, 2013)
" Subjects taking concomitant PIs exhibited increases in CsA and TAC exposure (AUC/dose) due to the increased apparent oral bioavailability and decreased apparent oral clearance."2.78Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. ( Barin, B; Benet, L; Browne, M; Carlson, L; Christians, U; Floren, L; Frassetto, L; Roland, M; Stock, P; Wolfe, A, 2013)
"Hepatotoxicity was a common adverse effect of NVP among men and women with CD4 >250 cells per microliter."2.78The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: a change in national treatment guidelines may be warranted. ( Ghanem, KG; Guo, F; Han, Y; Li, T; Li, Y; Qiu, Z; Wang, H; Wang, W; Xie, J; Zhang, C; Zhou, M, 2013)
" Adverse events (AEs) were recorded."2.77Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION). ( Arasteh, K; Cordes, C; Guo, J; Livrozet, JM; Orkin, C; Plettenberg, A; Quinson, A; Robinson, P; Wang, E; Ward, D; Yong, CL, 2012)
" The primary efficacy endpoint was HIV-1 infection in infants at 6 months and safety endpoints were adverse reactions in both groups."2.77Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. ( Andrew, P; Brown, ER; Chetty, V; Chipato, T; Coovadia, HM; Eshleman, SH; Fawzi, W; Fowler, MG; George, K; Guay, L; Kisenge, R; Lynn, DJ; Maldonado, Y; Manji, K; Mofenson, LM; Moodley, D; Msweli, L; Musoke, P; Mwatha, A; Nakabiito, C; Richardson, P; Stranix-Chibanda, L; Zwerski, S, 2012)
"Lamivudine resistance was detected by ASP in only 1 of 51 women who received CBV."2.77Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women. ( Boltz, VF; Chow, JY; Coffin, JM; Gray, GE; Hall, DB; Hopley, MJ; Maldarelli, F; Martinson, NA; Mayers, D; McIntyre, JA; Mellors, JW; Palmer, S; Robinson, P, 2012)
"NVP pharmacokinetics were modeled by population pharmacokinetic analysis."2.77Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. ( Aweeka, FT; Currier, JS; Dong, BJ; Frymoyer, A; Hughes, MD; Lizak, P; Lockman, S; Sawe, F; Verotta, D; Zheng, Y, 2012)
" However, long-term use poses adherence challenges, is associated with metabolic toxic effects, restricts second-line options, and is costly."2.77Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. ( Abrams, EJ; Coovadia, A; Hu, CC; Hunt, G; Kuhn, L; Martens, L; Meyers, T; Morris, L; Persaud, D; Sherman, G; Strehlau, R; Tsai, WY, 2012)
"Twenty-two children received antituberculosis and antiretroviral therapy (ART) concurrently for 4 weeks before pharmacokinetic sampling."2.77Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. ( Burger, DM; Chintu, C; Cook, A; Gibb, DM; McIlleron, H; Merry, C; Mulenga, V; Oudijk, JM; Walker, AS, 2012)
"Co-administration of artemether/lumefantrine with antiretroviral therapy has potential for pharmacokinetic drug interactions."2.77Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ( Back, D; Byakika-Kibwika, P; de Vries, PJ; Hanpithakpong, W; Katabira, E; Khoo, S; Lamorde, M; Lindegardh, N; Mayanja-Kizza, H; Mayito, J; Merry, C; Nabukeera, L; Namakula, R; Ntale, M; Pakker, N; Ryan, M; Tarning, J, 2012)
" Factors that may have contributed to the suboptimal results with nevirapine include elevated viral load at baseline, selection for nevirapine resistance, background regimen of nucleoside reverse-transcriptase inhibitors, and the standard ramp-up dosing strategy."2.77Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. ( Abrams, EJ; Barlow-Mosha, L; Bobat, R; Chi, BH; Cotton, MF; Eshleman, SH; Hughes, MD; Jean-Philippe, P; Kamthunzi, P; Khadse, S; Lindsey, JC; Millar, L; Mofenson, LM; Moultrie, H; Mujuru, HA; Palumbo, P; Petzold, E; Purdue, L; Schimana, W; Violari, A, 2012)
"42 women (37 VFs, five deaths; 17%) in the NVP and 50 (43 VFs, seven deaths; 20%) in the LPV/r arm reached the primary endpoint (HR 0."2.77Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. ( Alston-Smith, B; Amod, F; Asmelash, A; Chibowa, M; Chipato, T; Currier, J; Halvas, E; Hogg, E; Hosseinipour, M; Hughes, M; Kimaiyo, S; Lockman, S; McIntyre, J; Mellors, J; Mohapi, L; Rassool, M; Sawe, F; Schooley, R; Shaffer, D; Smith, L; Ssali, F; Zheng, Y, 2012)
"The nevirapine adducts were detected in 12/13 patient samples, and quantified in 11/12 samples (2."2.77Evidence for nevirapine bioactivation in man: searching for the first step in the mechanism of nevirapine toxicity. ( Antunes, AM; Branco, T; Caixas, U; Godinho, AL; Grilo, NM; Marinho, AT; Marques, MM; Monteiro, EC; Oliveira, MC; Pereira, SA, 2012)
"46%), underweight (27% vs."2.77Growth patterns among HIV-exposed infants receiving nevirapine prophylaxis in Pune, India. ( Bollinger, RC; Gupta, A; Gupte, N; Khandave, M; Kinikar, AA; Nayak, U; Ram, M; Sastry, J; Shankar, AV, 2012)
" A one-compartment model was used for mothers and neonates; the absorption rate constants for mothers and neonates were 0."2.76Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. ( Arrivé, E; Avit, D; Benaboud, S; Blanche, S; Dabis, F; Ekouévi, DK; Gray, G; Hirt, D; McIntyre, J; Nerrienet, E; Rey, E; Sim, KL; Tréluyer, JM; Urien, S, 2011)
" Multivariate analyses were performed to compare, between the ddI and ZDV groups, the proportion of patients with a viral load <500 copies/ml during follow-up; the increase in the CD4 cell count; survival; treatment changes and severe adverse events."2.76Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal. ( Delaporte, E; Diouf, A; Etard, JF; Girard, PM; Landman, R; Laurent, C; Molinari, N; Ndoye, I; Ngom Guèye, NF; Sow, PS; Tchatchueng Mbougua, JB, 2011)
"Birth defects were evaluated among infants on the Pediatric AIDS Clinical Trials Group 316 trial that studied addition of peripartum nevirapine to established ARV regimen for prevention of mother-to-child transmission."2.76Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. ( Culnane, M; Cunningham, CK; Delfraissy, JF; Huang, S; Kaiser, KA; Mandelbrot, L; Mofenson, L; Newell, ML; Scheuerle, A; Stanley, K; Watts, DH, 2011)
" nevirapine on the same background, in naïve HIV-1-infected patients) study compared prospectively ritonavir-boosted atazanavir (ATZ/r) 300 mg/100 mg once daily (qd) with immediate release nevirapine (NVP) 200 mg twice daily or 400 mg qd, each combined with fixed-dose tenofovir 300 mg/emtricitabine 200 mg qd in 569 ARV-naïve HIV-1-infected patients."2.76Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). ( Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S, 2011)
"ARTEN is a randomized, open-label, non-inferiority trial that compares nevirapine (NVP) 200 mg twice daily or 400 mg once daily to atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily, each combined with fixed-dose tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg once daily, in antiretroviral-naive HIV-1 patients with CD4(+) T-cell counts <400 (men) and <250 cells/mm(3) (women)."2.76Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. ( Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S, 2011)
"Severe hyperbilirubinemia (grade 3 or 4) occurred in 7 patients (5."2.76Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen. ( Lueangniyomkul, A; Mankhatitham, W; Manosuthi, W, 2011)
" The safety profile of NVP XR was similar to NVP IR, but showed numerically fewer treatment-related adverse events."2.76Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. ( Andrade-Villanueva, J; Bogner, J; Cahn, P; Drulak, M; Gathe, J; Horban, A; Nelson, M; Nguyen, T; Podzamczer, D; Quinson, AM; Santiago, S; Spencer, D; Yong, CL; Zhang, W, 2011)
" Similarly, the proportion of serious adverse events in the HIVIGLOB/sdNVP and sdNVP arms, respectively, for mothers (18."2.76Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). ( Antelman, G; Falksveden, L; Fowler, MG; Guay, L; Jackson, JB; Mmiro, F; Moulton, LH; Mubiru, M; Musoke, P; Nakabiito, C; Omer, SB; Onyango-Makumbi, C; Wahren, B; Wigzell, H; Zwerski, S, 2011)
"Nevirapine (NVP) is a widely used non-nucleoside reverse transcriptase inhibitor."2.76Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study. ( Arasteh, K; Battegay, M; Berger, F; Bogner, JR; Livrozet, JM; Macha, S; Mossdorf, E; Plettenberg, A; Quinson, AM; Robinson, P; Stern, J; Witt, MD; Yong, CL; Zhang, W, 2011)
" Frequency of adverse events (AEs) was similar between arms, with 88."2.76A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients. ( Bhatti, L; Conner, C; Dejesus, E; Mills, A; Storfer, S, 2011)
"Differences in disease progression occurred from the third year on ART, whereas higher rates of switch to second-line treatment occurred in LCM from the second year."2.75Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. ( Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E, 2010)
"Nevirapine was added at a dose of 200 mg once daily from Days 0 to 14 and 200 mg twice daily from Days 14 to 28."2.75Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir. ( Cedeño, S; Clotet, B; Deig, E; Maria Llibre, J; Miranda, C; Moltó, J; Negredo, E; Valero, S; Valle, M, 2010)
" Six-point pharmacokinetic sampling (0, 2, 4, 6, 8, and 12 h) was undertaken after observed intake with a standardized breakfast."2.75Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. ( Dickinson, L; Gibb, DM; Gilks, CF; Kayiwa, J; Khoo, S; Kityo, C; Lutwama, F; Munderi, P; Nalumenya, R; Reid, A; Ssali, F; Tumukunde, D; Walker, AS, 2010)
"The chewable FDC was safe and provided therapeutically adequate plasma drug exposures in human immunodeficiency virus-infected children."2.75A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand. ( Capparelli, E; Chokephaibulkit, K; Chotpitayasunondh, T; Cressey, TR; Eksaengsri, A; Hongsiriwan, S; McIntosh, K; Muresan, P; Plipat, N; Prasitsuebsai, W; Sirisanthana, V; Smith, ME; Toye, M; Vanprapar, N; Yogev, R, 2010)
"Nevirapine clearance was shown to be affected by CYP2B6 516G>T genetic polymorphism and creatinine clearance, although this explained only part of the interpatient variability, which remains low compared to that for other antiretroviral drugs."2.75Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. ( Becquemont, L; Bertrand, J; Borand, L; Chou, M; Comets, E; Le Tiec, C; Mentre, F; Ouk, V; Segeral, O; Taburet, AM; Verstuyft, C, 2010)
"Children were randomized to initiate antiretroviral therapy with full-dose (FD) nevirapine (Triomune Baby or Junior in the morning and evening) versus DE (half-dose nevirapine for 14 days [Triomune in the morning and stavudine-lamivudine {Lamivir-S} in the evening], then FD), in accordance with World Health Organization weight-band dosing tables."2.75Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial. ( Burger, D; Chijoka, C; Chintu, C; Cook, A; Ferrier, A; Gibb, DM; Kabamba, D; Kalengo, C; Kankasa, C; Kityo, C; Mulenga, V; Thomason, M; Walker, AS, 2010)
"Nevirapine is a nonnucleoside reverse transcriptase inhibitor used as part of combination therapy for human immunodeficiency virus (HIV) infection."2.74Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis. ( Cammett, AM; Felizarta, F; MacGregor, TR; Mallolas, J; Miailhes, P; Piliero, PJ; Wruck, JM, 2009)
"To investigate the pharmacokinetic interaction between darunavir/ritonavir (DRV/r) and nevirapine (NVP) in 19 HIV-infected patients."2.74Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients. ( De Pauw, M; Hoetelmans, RM; Lefebvre, E; Mariën, K; Pozniak, A; Sekar, V; Vangeneugden, T, 2009)
" Grade 3-4 adverse events occurred in 3 cases (2 peripheral neuropathy, and 1 suspected lactic acidosis)."2.74[Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients]. ( Chen, Z; Gong, G; He, Y; Liu, C; Liu, M; Yin, W; Zheng, Y; Zhou, H, 2009)
"This home-based HIV-care strategy is as effective as is a clinic-based strategy, and therefore could enable improved and equitable access to HIV treatment, especially in areas with poor infrastructure and access to clinic care."2.74Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. ( Amuron, B; Birungi, J; Bunnell, R; Coutinho, A; Foster, S; Grosskurth, H; Jaffar, S; Kyomuhangi, R; Levin, J; Mermin, J; Nabiryo, C; Namara, G; Ndembi, N; Opio, A; Tappero, JW, 2009)
" Daily drug dosage was 300 mg Tenofovir, 200mg Emtricitabine and 400 mg Nevirapine once daily."2.74Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial). ( Flux, K; Gholam, P; Hartmann, M; Hueter, E; Weberschock, T, 2009)
"We aimed to compare the steady-state pharmacokinetic parameters and tolerability of Triomune 40 (stavudine 40 mg, lamivudine 150 mg and nevirapine 200 mg) and branded formulations of these drugs in HIV-infected Ugandans."2.73Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults. ( Back, D; Boffito, M; Byakika-Kibwika, P; D'Avolio, A; Di Perri, G; Kalemeera, F; Khoo, S; Lamorde, M; Mauro, S; Mayanja-Kizza, H; Merry, C; Ryan, M, 2008)
"However, neutropenia was no longer associated with antenatal exposure to HAART after 1 month of age."2.73Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. ( Bae, WH; Essex, M; Lockman, S; Onyait, K; Shapiro, RL; Smeaton, LM; Thior, I; Wester, C, 2008)
"Nevirapine (NVP) is a nonnucleoside reverse transcriptase inhibitor used in HIV patients and recently evaluated as a differentiating and antiproliferative agent in human malignancies."2.73Nevirapine toxicity in non-HIV cancer patients. ( Barone, C; Cignarelli, M; De Vis, K; Fabiano, A; Fersini, A; Landriscina, M; Lombardi, V; Piscazzi, A; Santodirocco, M, 2008)
" We determined the pharmacokinetic profiles of stavudine, lamivudine and nevirapine in Pedimune and compared these with the branded products."2.73Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults. ( Burger, DM; Dijkema, T; Gibb, DM; L'homme, RF; van der Ven, AJ; Warris, A, 2007)
" Mothers in the usZDV/sdNVP group received a loading dose of zidovudine (600 mg administered orally) and continued to receive 300-mg doses of zidovudine orally every 3 h while in labor, and their infants received zidovudine at a dosage of 2 mg per kg of body weight 4 times per day orally for 72 h."2.73A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe. ( Arbess, G; Boyle, E; Chipato, T; Chitsike, I; Glazier, RH; Gottesman, M; Pilon, R; Silverman, M; Simor, A; Spitzer, RF; Thistle, P, 2007)
" Patients taking Triomune had notably higher stavudine Cmax values."2.73Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults. ( Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Mshali, I; Phakati, S; Rezk, NL; van der Horst, C, 2007)
"Disease progression was particularly rapid, 85% infants meeting WHO criteria for ART within 6 months."2.73High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. ( Blanckenberg, N; Goulder, P; Kiepiela, P; McCarthy, N; Mkhwanazi, N; Mphatswe, W; Prendergast, A; Thobakgale, C; Tudor-Williams, G; Walker, BD, 2007)
" Pharmacokinetic parameters were calculated using noncompartmental methods, and bioequivalence was assessed using an analysis of variance model."2.73Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products. ( Dimarco, M; Dodard, C; Guilbaud, R; Marier, JF; Monif, T; Morelli, G; Singla, AK; Thudi, NR; Tippabhotla, SK, 2007)
"For optimal adherence, once-daily dosing is best."2.73Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study. ( Arvieux, C; Chaillot, F; Le Moal, G; Massari, V; Parienti, JJ; Reliquet, V; Vabret, A; Verdon, R, 2007)
"HIV-infected women on selected ARV regimens or no ARV were administered DMPA 150 mg intramuscularly and evaluated for 12 weeks for adverse events, changes in CD4+ count and HIV RNA levels, and ovulation."2.73Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. ( Clax, PA; Cohn, SE; Hitti, J; Lertora, JJ; Muderspach, L; Park, JG; Stek, A; Watts, DH; Yu, S, 2008)
" The primary endpoint was any serious adverse event (SAE) definitely/probably or uncertain whether related to blinded nevirapine/abacavir."2.73Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). ( , 2008)
"Nevirapine C12h was subtherapeutic (< 3."2.73Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. ( Burger, DM; Chintu, C; Ewings, FM; Gibb, DM; Kabamba, D; Kankasa, C; L'homme, RF; Mulenga, V; Thomason, MJ; Walker, AS, 2008)
" However, pharmacokinetic knowledge is lacking for specific populations, especially patients with neglected tropical diseases and severe malnutrition."2.72Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review. ( Beijnen, JH; Dorlo, TPC; Huitema, ADR; Verrest, L; Wilthagen, EA, 2021)
"Nevirapine was detected in the cord blood of 244 of 259 (94%) infants whose mothers reported they took nevirapine in labor more than 1 h before delivery and in 12 of 13 (92%) infants whose mothers reported they took nevirapine less than 1 h before delivery."2.72Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission. ( Donnell, D; Fleming, T; Fowler, MG; Guay, L; Jackson, JB; Mirochnick, M; Mmiro, F; Mofenson, L; Musoke, P; Nakabiito, C; Parsons, T, 2006)
"Body weight was measured in kilograms with light clothes on."2.72The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients. ( Olatunji, PO; Olawumi, HO, 2006)
" Lower predose nevirapine concentrations were associated with lower cord blood concentrations and a shorter interval between maternal dosing and delivery."2.71Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. ( Blanchard, S; Culnane, M; Cunningham, CK; Dorenbaum, A; Gelber, RD; Mirochnick, M; Mofenson, L; Sullivan, JL, 2003)
"Nevirapine was associated with a 41% (95% CI 16-59) reduction in relative risk of transmission through to age 18 months."2.71Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. ( Allen, M; Bagenda, D; Bakaki, P; Bray, D; Deseyve, M; Ducar, C; Duefield, C; Emel, L; Fleming, T; Fowler, MG; Gigliotti, M; Guay, LA; Jackson, JB; Miotti, P; Mirochnick, M; Mmiro, F; Mofenson, L; Musoke, P; Mwatha, A; Nakabiito, C; Owor, M; Sherman, J, 2003)
"The A/S/D regimen had a low efficacy and a high frequency of adverse events and cannot be recommended."2.71Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. ( Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, L; Nielsen, H; Obel, N; Pedersen, C, 2003)
"Nevirapine was the most commonly prescribed NNRTI (96%)."2.71Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy. ( Alexander, C; Brumme, ZL; Harrigan, PR; Hertogs, K; Larder, B; Montaner, JS; O'Shaughnessy, MV; Tilley, J; Verbiest, W; Yip, B, 2003)
"Randomized, controlled, open-label trial of 233 protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-naive HIV-infected patients allocated to a regimen of nelfinavir and nevirapine (1250/200 mg twice daily; n = 118) or ritonavir and saquinavir (400/400 mg twice daily; n = 115), both in combination with two nucleoside reverse transcriptase inhibitors."2.71A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors. ( Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, LR; Nielsen, H; Obel, N; Pedersen, C, 2003)
"immediate allergy and increased hepatotoxicity (regardless of chronic infection with hepatitis B or C virus and methadone use) for nevirapine."2.71Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. ( Calza, L; Chiodo, F; Manfredi, R, 2004)
"Cetirizine has no preventive effect on nevirapine-associated rash."2.71Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial. ( Allaert, FA; Boukli, N; Caumes, E; David, F; Devidas, A; Dupont, B; Launay, O; Lortholary, O; Patey, O; Piketty, C; Prévoteau du Clary, F; Rey, E; Roudière, L; Tréluyer, JM; Urbinelli, R, 2004)
" The one adverse event associated with nelfinavir occurred in a subject with a CD4 cell count less than 250 cells/microL."2.71Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. ( Baker, D; Foca, M; Frenkel, LM; Gandia, J; Gonzalez-Garcia, A; Hitti, J; Huang, S; McNamara, J; Nachman, SA; Paul, ME; Provisor, A; Stek, AM; Stevens, LM; Thorpe, EM; Watts, DH; Wei, LJ, 2004)
" Twelve subjects in the QD Group (14%) discontinued treatment due to adverse events, mainly nevirapine-related hepatitis (6%)."2.71Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. ( Burger, D; Clotet, B; Galindos, MJ; Gel, S; Miralles, C; Moltó, J; Muñoz-Moreno, JA; Negredo, E; Pedrol, E; Puig, J; Ribera, E; Rodriguez Fumaz, C; Rodríguez, E; Ruiz, L; Viciana, P; Videla, S, 2004)
" Adjusting dosage by means of therapeutic drug monitoring would appear to be a reasonable way of maximising patient benefit from treatment."2.71Follow-up measurements of Nevirapine plasma levels over a prolonged period. ( Ebigbo, A; Klinker, H; Knipper, A; Langmann, P; Sienz, M; Winzer, R; Zilly, M, 2004)
"Rash is the most frequent adverse event associated with nevirapine."2.71Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study. ( Arranz, A; Arroyo, JA; Blanco, JL; Boix, V; Dalmau, D; De la Torre, J; Domingo, P; Force, L; González, A; Gonzalez, J; Knobel, H; Llibre, JM; Mahillo, B; Miró, JM; Montes, ML; Ribera, E; Rivero, A; Rodriguez, D; Sanz, J; Sarasa, M, 2004)
"The switching of a PI to nevirapine is a safe and well-tolerated option for maintaining long-term virological suppression and immunological control."2.71Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load. ( Arranz, A; de Górgolas, M; Estrada, V; Fernández-Guerrero, M; García, R; Gil, P; Granizo, JJ; Rivas, P; Yera, C, 2004)
"In antiretroviral-experienced subjects with sustained viral suppression, dual therapy with NVP plus LPV/rtv at standard dosage was as potent and safe as standard-of-care HAART at 48 weeks of follow-up."2.71Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). ( Burger, D; Clotet, B; Côté, H; López, S; Martínez, E; Miró, O; Moltó, J; Montaner, J; Negredo, E; Puig, J; Rey-Joly, C; Ribalta, J; Ruiz, L; Salazar, J, 2005)
"The median NVP level fell to 68 ng/mL (range: <50-228, n = 43) 8 to 14 days after dosing and to 51 ng/mL (range: <50-166, n = 25) between 15 and 21 days."2.71Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. ( Capparelli, E; Cressey, TR; Jackson, JB; Jourdain, G; Kunkeaw, S; Lallemant, MJ; Mirochnick, M; Musoke, P, 2005)
"The aim of this 2NN pharmacokinetic substudy was to investigate the population pharmacokinetics of nevirapine and efavirenz."2.71Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. ( Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, J; MacGregor, TR; van Leth, F, 2005)
" The incidence of rash in the NVP group was significantly higher in female patients with higher CD4 cell counts, while adverse events in the EFV group were not associated with CD4 cell count."2.71The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. ( Andrews, S; Grinsztejn, B; Lange, JM; Lazanas, MK; Montaner, J; van Leth, F; Wilkins, E, 2005)
"Lipodystrophy was evaluated by clinical examination and morphological measurements."2.71Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. ( Crespo, M; Ferrer, E; Fisac, C; Fumero, E; Gatell, JM; Podzamczer, D; Ribera, E; Roson, B; Virgili, N, 2005)
" Our objective was to determine intracellular (or cell-associated) nevirapine concentrations over the full dosing interval and to relate protein binding and P-glycoprotein (P-gp) expression to intracellular exposure."2.71Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. ( Almond, LM; Back, DJ; Bonington, A; Dalton, M; Edirisinghe, D; Khoo, SH, 2005)
" Therapy was discontinued in 18 patients due to virological failure in 11, adverse events in seven, loss to follow-up or withdrawal of consent in four and death in one."2.71Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. ( Blanco, JL; Crespo, M; Deig, E; Falcó, V; González, A; Miró, JM; Ocaña, I; Pahissa, A; Pedrol, E; Ribera, E; Rodríguez-Pardo, D; Rubio, M; Soler, A, 2005)
" Clinical assessment included plasma HIV-1 RNA, blood chemistry, haematology, lymphocyte counts and adverse events reports."2.71A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load. ( Arranz Caso, JA; Castilla, V; Estrada, V; Fernández Guerrero, M; Górgolas, M; López, JC; Molina, JP; Santos, I; Sanz, J, 2005)
" Intensive pharmacokinetic sampling occurred after 4 weeks of therapy."2.71Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. ( Acosta, EP; Aldrovandi, G; Chen, J; Damle, B; Hodge, J; Hughes, MD; King, JR; Nachman, S; Wiznia, A; Yogev, R, 2005)
"Nevirapine resistance was more frequent in infants with subtype C than with subtypes A and D (87 versus 50%, P = 0."2.71Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. ( Chen, S; Eshleman, SH; Fiscus, SA; Guay, LA; Hoover, DR; Hudelson, SE; Jackson, JB; Kumwenda, N; Mmiro, F; Musoke, P; Mwatha, A; Taha, T, 2005)
" Population pharmacokinetic parameters (apparent clearance (CL/F), volume of distribution (V/F), absorption rate constant (k a)) were estimated, as were interindividual, interoccasion, and residual variability in the pharmacokinetics."2.70Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. ( Beijnen, JH; de Maat, MM; Huitema, AD; Meenhorst, PL; Mulder, JW; van Gorp, EC, 2002)
"Hydroxyurea has been administered with nucleoside analogues to modulate intracellular dNTP pools and thus the ratio of drug triphosphate:endogenous triphosphate."2.70Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. ( Almond, LM; Back, DJ; De Vries, C; Gould, J; Hoggard, PG; Kewn, S; Khoo, SH; Lou, Y; Maherbe, A; Sales, SD; Wood, R, 2002)
" The differences between the pharmacokinetic parameters of efavirenz with and without nevirapine were analyzed, and the pharmacokinetics of nevirapine were compared with those in historical control patients."2.70The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. ( Beijnen, JH; Carlier, H; Gazzard, B; Harris, M; Hoetelmans, RM; Johnson, M; Kwakkelstein, MO; Lange, JM; Montaner, JS; Moyle, G; Reiss, P; van Leeuwen, R; Veldkamp, AI; Youle, M, 2001)
"The purpose of the current study was to determine the efficacy and safety of nevirapine combined with nelfinavir and two nucleoside reverse transcriptase inhibitors (NRTIs) in patients previously exposed to highly active antiretroviral therapy (HAART)."2.70The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study. ( Black, FT; Jensen-Fangel, S; Larsen, L; Obel, N; Thomsen, HF, 2001)
"Limited data are available on antiretroviral drug concentrations in seminal plasma during a dosing interval."2.70Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma. ( de Vries, JW; Hoetelmans, RM; Lange, JM; Prins, JM; Repping, S; van Praag, RM, 2001)
" Initial dose pharmacokinetic profiles in the pregnant women were similar to those seen in nonpregnant adults."2.70Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. ( Fenton, T; Lugo, M; Mirochnick, M; Siminski, S; Sullivan, JL, 2001)
" Three patients discontinued therapy for drug-related adverse events."2.70Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. ( Benson, CA; Brun, SC; Deeks, SG; Eron, JJ; Feinberg, J; Gulick, RM; Hicks, C; Hsu, A; Japour, AJ; Kempf, D; Kessler, HA; King, M; Murphy, RL; Real, K; Riddler, S; Sax, PE; Stryker, R; Sun, E; Thompson, M; Wheeler, D, 2002)
" Overall, in 12 patients treated with hydroxyurea, 33 adverse events were reported versus 19 reported for 12 patients who did not receive hydroxyurea (p <."2.70Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection. ( Cahn, P; Federico, A; Kijak, G; Montaner, JS; Ochoa, C; Perez, H; Salomon, H; Zala, C, 2002)
"As part of an on-going clinical trial in Malawi, infants born to women who received (early presenters) or did not receive (late presenters) standard intrapartum nevirapine (NVP) dosing were randomized to receive orally either single dose NVP alone or NVP plus zidovudine (twice daily for 1 week)."2.70Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants. ( Broadhead, R; Fiscus, S; Gibbons, A; Hoover, D; Kumwenda, N; Lema, V; Liomba, G; Mukiibi, J; Taha, TE, 2002)
"Concomitant administration of NVP at steady state with EE/NET resulted in a significant (29%) median reduction in the area under the plasma concentration time curve (AUC(infinity)) and a significant reduction in mean residence time (MRT) and half-life (t(1/2)) of EE."2.70Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. ( Hutman, HW; Lamson, M; Marshak, A; McDonough, M; Mildvan, D; Robinson, P; Yarrish, R, 2002)
"Rates of disease progression or death were 23% (11/47), 25% (13/53), and 12% (6/51) for the zidovudine plus nevirapine, zidovudine plus didanosine, and triple drug therapy groups, respectively (P=."2.69A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. ( Conway, B; Cooper, D; Hall, D; Harris, M; Lange, JM; Montaner, JS; Myers, M; Reiss, P; Robinson, P; Smith, D; Vella, S; Wainberg, MA, 1998)
"Nevirapine plasma levels were within the expected range, while indinavir levels were lower than expected."2.69A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy. ( Conway, B; Durakovic, C; Fransen, S; Harris, M; Montaner, JS; Raboud, J; Rae, S; Shillington, A, 1998)
"Nevirapine elimination was prolonged in both mothers and infants, with median half-lives ranging from 36."2.69Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. ( Beckerman, K; Fenton, T; Gagnier, P; Gwynne, M; Jimenez, E; Mirochnick, M; Pav, J; Siminski, S; Spector, SA; Sperling, RS; Sullivan, JL; Yogev, R, 1998)
" The relative bioavailability (F) of ZDV and ddI in the triple combination compared to that in the double combination was also evaluated."2.69Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. ( D'Aquila, RT; Fischl, MA; Hirsch, MS; Hughes, MD; Johnson, VA; Myers, M; Sheiner, LB; Sommadossi, JP; Zhou, XJ, 1999)
" Nevirapine significantly reduced median indinavir Cmin (47."2.69Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. ( Dusek, A; Hall, DB; Lamson, M; Murphy, RL; Myers, M; Sommadossi, JP, 1999)
"Nevirapine, 200 mg, was given as a single dose during labor to 21 HIV-1-infected pregnant Ugandan women."2.69A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). ( Allen, M; Bagenda, D; Dransfield, K; Elliott, T; Fleming, T; Fowler, MG; Guay, LA; Hom, D; Horton, S; Jackson, JB; Mirochnick, M; Mmiro, F; Mofenson, L; Murarka, A; Musoke, P; Nakabiito, C; Pav, JW, 1999)
"The dNN study evaluated the safety, efficacy and pharmacokinetic interactions of the combination of stavudine (2',3'-didehydro-2',3'-dideoxythymidine; D4T), nelfinavir and nevirapine in 25 HIV-infected subjects who received treatment for up to 29 weeks."2.69dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions. ( Skowron, G, 1998)
" Non-compartmental methods were used to calculate the area under the plasma concentration versus time curve (AUC[24h]), and the maximal (Cmax) and minimal plasma concentration (Cmin), the time to Cmax (t(max)), the plasma elimination half-life (t1/2), the apparent oral clearance (Cl/F) and the apparent volume of distribution (V/F)."2.69The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. ( Beijnen, JH; Danner, SA; Foudraine, NA; Hoetelmans, RM; Kwakkelstein, MO; Lange, JM; Meenhorst, PL; Mulder, JW; Reiss, P; van Heeswijk, RP; Veldkamp, AI; Wit, FW, 2000)
"The appearance of rash is one of the most frequent and limiting side-effects during the first 4 weeks of treatment with nevirapine (NVP)."2.69Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. ( Barreiro, P; Casas, E; de Requena, DG; Estrada, V; González-Lahoz, J; Hoetelmans, R; Jimenéz-Nácher, I; Soriano, V; Téllez, MJ, 2000)
" This pharmacokinetic interaction study was nested within a larger Phase III clinical trial conducted to characterize the safety and efficacy of coadministered nevirapine and lamivudine."2.69Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. ( Lamson, MJ; Leitz, G; MacGregor, TR; Sabo, JP; Yong, CL, 2000)
"Nevirapine was well tolerated in the doses tested."2.68Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. ( Cheeseman, SH; Greenough, TC; Hall, D; Hattox, SE; Havlir, D; McLaughlin, MM; Myers, M; Spector, SA; Stein, DS; Sullivan, JL, 1995)
"Risk for disease progression did not differ between the two groups (relative hazard of the triple-combination group, 1."2.68Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protoco ( Basgoz, N; D'Aquila, RT; Fischl, MA; Hirsch, MS; Hughes, MD; Johnson, VA; Liou, SH; Myers, M; Niu, M; Sommadossi, JP; Timpone, J, 1996)
"Nevirapine is a non-nucleoside reverse transcriptase inhibitor of HIV-1 which exhibits synergy in vitro with zidovudine (ZDV) and also is active against ZDV-resistant HIV."2.68A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group. ( Boucher, CA; Carr, A; Cooper, DA; de Jong, MD; Imrie, A; Sorice, F; Vella, S, 1996)
"To determine which non-nucleoside reverse transcriptase inhibitor, either EFV or NVP, is more effective in suppressing viral load when given in combination with two nucleoside reverse transcriptase inhibitors as part of initial antiretroviral therapy for HIV infection in adults and children."2.53Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. ( Irlam, JH; Mbuagbaw, L; Mursleen, S; Rutherford, GW; Siegfried, N; Spaulding, AB, 2016)
" However, there are challenges to initiation of ART in early life, including the possibility of drug resistance in the context of prevention of mother-to-child transmission (PMTCT) programs, a paucity of drug choices , uncertain dosing for some medications and long-term toxicities."2.50Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age. ( Abrams, E; Muhe, LM; Penazzato, M; Prendergast, AJ; Tindyebwa, D, 2014)
"Regimen simplification can be defined as a change in established effective therapy to reduce pill burden and dosing frequency, to enhance tolerability, or to decrease specific food and fluid requirements."2.49Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV. ( Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Parisi, SG; Serpelloni, G, 2013)
"We systematically reviewed adverse events among treatment-naive HIV-positive adults and children receiving either NVP or EFV as part of first-line antiretroviral therapy."2.49Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. ( Andrieux-Meyer, I; Calmy, A; Ford, N; Hargreaves, S; Mills, EJ; Renaud-Théry, F; Shaffer, N; Shubber, Z; Vitoria, M, 2013)
" However, there are challenges to initiate ART in early life, including the possibility of drug resistance in the context of prevention of mother-to-child transmission (PMTCT) programs, a paucity of drug choices , uncertain dosing for some medications and long-term toxicities."2.48Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. ( Cotton, M; Gibb, D; Penazzato, M; Prendergast, A; Tierney, J, 2012)
"We reviewed studies comparing serious adverse NVP-related events among ART-naive pregnant women who commenced therapy at higher v."2.48Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis. ( Bera, E; Mia, R, 2012)
" Currently, twice-a-day dosing is required for the successful application of NVP immediate release (IR), but there is potential for a more convenient once-a-day antiretroviral combination."2.47Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation. ( Parienti, JJ; Peytavin, G, 2011)
" The first trial began in April 1991 and assessed zidovudine (ZDV) versus placebo and since then, the type, dosage and duration of drugs to be compared has been modified in each subsequent trial."2.47Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. ( Brocklehurst, P; Siegfried, N; Sint, TT; van der Merwe, L, 2011)
"Nevirapine (NVP) was the first non-nucleoside reverse transcriptase inhibitor (NNRTI) approved for the treatment of HIV infection and quickly became one of the most extensively used antiretrovirals (ARVs) worldwide."2.47Guidelines for the use of extended-release nevirapine in HIV-infected patients. ( Corbett, AH; Heil, EL, 2011)
" More comprehensive in vivo pharmacokinetic data are required to justify the potential use of these agents as safe and effective options during pregnancy."2.47Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). ( Back, DJ; Else, LJ; Khoo, SH; Taylor, S, 2011)
"To determine which NNRTI, EFV or NVP, is more efficacious when given in combination with two NRTIs as part of initial ART for HIV infection in adults and children."2.46Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. ( Irlam, JH; Mbuagbaw, LC; Rutherford, GW; Siegfried, N; Spaulding, A, 2010)
" Sources included adverse event reports from pharmaceutical manufacturers and the US FDA, reports from peer-reviewed journals/scientific meetings and the Research on Adverse Drug events And Reports (RADAR) project."2.45Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. ( Bennett, CL; Chandler, KL; Differding, V; Johnson, S; McKoy, JM; Obadina, E; Palella, F; Parada, JP; Raisch, DW; Scarsi, KK; Scheetz, MH; Sutton, S; Yarnold, PR, 2009)
" The first trial began in April 1991 and assessed zidovudine (ZDV) versus placebo and since then, the type, dosage and duration of drugs to be compared has been modified in each subsequent trial."2.44Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. ( Brocklehurst, P; Siegfried, NL; van der Merwe, L; Volmink, J, 2007)
" Both drugs have demonstrated interindividual pharmacokinetic variability."2.44Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring? ( Dahri, K; Ensom, MH, 2007)
"Nevirapine has a long half-life and achieves high steady-state plasma concentrations relative to the concentration required to inhibit 50% viral replication in vitro (IC(50)) in patients."2.44Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. ( Cooper, CL; van Heeswijk, RP, 2007)
"Nevirapine resistance has been detected in a considerable proportion of women after single-dose nevirapine (SD-NVP) for the prevention of mother-to-child human immunodeficiency virus-1 transmission."2.44Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter? ( Eshleman, SH; Kourtis, AP; McConnell, MS; Stringer, JS; Weidle, PJ, 2007)
" All papers, abstracts, or presentations, regardless of study design, that made reference to the response of patients who were switched from one NNRTI to another as a result of an adverse drug reaction were included."2.44Is it safe to switch between efavirenz and nevirapine in the event of toxicity? ( Maartens, G; Mehta, U, 2007)
"Ideally, an anti-HIV drug should (1) be highly active against wild-type and mutant HIV without allowing breakthrough; (2) have high oral bioavailability and long elimination half-life, allowing once-daily oral treatment at low doses; (3) have minimal adverse effects; and (4) be easy to synthesize and formulate."2.43In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). ( Andries, K; Arnold, E; Bohets, H; Clark, AD; Daeyaert, F; Das, K; de Béthune, MP; De Clerck, F; de Jonge, M; De Knaep, F; Frenkel, YV; Guillemont, J; Heeres, J; Hughes, SH; Janssen, PA; Koymans, L; Kukla, M; Lampo, A; Lewi, PJ; Ludovici, D; Medaer, B; Pasquier, E; Pauwels, R; Stoffels, P; Vinkers, M; Williams, P, 2005)
" These data have now provided a clear and clinically relevant understanding of the individual profiles of drugs within the nucleoside analogue reverse transcriptase inhibitor , HIV protease inhibitor and non-nucleoside analogue reverse transcriptase inhibitor drug classes, and have provided a rational basis for assessing and monitoring these adverse effects in clinical practice."2.43Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. ( Mallal, S; Nolan, D; Reiss, P, 2005)
" Based on current knowledge, the immense benefits of antiretroviral prophylaxis in reducing the risk of MTCT, far outweigh the potential for adverse effects."2.43The safety of antiretroviral drugs in pregnancy. ( Newell, ML; Thorne, C, 2005)
" There was no statistically significant difference between once daily or twice-daily dosing of NVP, when used in combination with 3TC and d4T (RR = 1."2.43Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. ( Mahomed, FA; Rutherford, GW; Siegfried, NL; Van Deventer, PJ, 2006)
" To minimize toxicity, clinicians must adhere to dosing guidelines, avoid prescribing the drug in patients with known increased risk of toxicity, and promptly recognize toxicities, which are mainly cutaneous and hepatic."2.43Nevirapine toxicity. ( Taiwo, BO, 2006)
"Despite the benefits of protease inhibitor (PI)-based HIV treatment, issues of tolerability, dosing frequency, pill count and long-term metabolic complications necessitate evaluation of alternate treatment strategies."2.43Evaluation of nevirapine-switch strategies for HIV treatment. ( Cooper, CL, 2006)
" PI-based therapies often fail due to poor adherence caused by heavy pill burden, complex dosing schedules and undesirable side effects."2.42Clinical utility of current NNRTIs and perspectives of new agents in this class under development. ( Hamatake, R; Hong, Z; Zhang, Z, 2004)
"Nevirapine has a beneficial effect on the lipid profile in both treatment-naive and -experienced patients."2.42Nevirapine in the treatment of HIV. ( Martínez, E; Milinkovic, A, 2004)
"Nevirapine is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase."2.41Nevirapine: pharmacokinetic considerations in children and pregnant women. ( Clarke, DF; Dorenbaum, A; Mirochnick, M, 2000)
" Although possessing a common mechanism of action, these agents can be differentiated by both molecular and pharmacokinetic characteristics."2.41Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. ( DiCenzo, R; Morse, GD; Smith, PF, 2001)
"We describe two cases of toxic epidermal necrolysis developed during an antiretroviral therapy regimen containing nevirapine."2.41Toxic epidermal necrolysis induced by nevirapine therapy: description of two cases and review of the literature. ( Cattelan, AM; Lanzafame, M; Meneghetti, F; Sasset, L; Sgarabotto, D; Trevenzoli, M, 2001)
"Nevirapine is a potent antiretroviral agent whose use, especially as monotherapy, may be limited by rapid onset of resistance as well as by hypersensitivity reactions."2.39Current clinical experience with nevirapine for HIV infection. ( Carr, A; Cooper, DA, 1996)
"Thrombocytopenia was higher in children with WHO Stage III/IV, lower in children on zidovudine, and had no association with use of lamivudine or nevirapine, CD4 + suppression, age, and nutrition status."1.91Risk factors and prognostic significance of platelet count abnormalities in children with HIV infection on antiretroviral therapy. ( Airewele, G; Bulsara, S; Despotovic, J; Elyanu, P; Grimes, A; Haq, H; Kekitiinwa, A; Kim, TO; Lubega, J; Lumumba, M; Matshaba, M; Musoke, P; Peckham, E; Scheurer, M; Wanless, SR, 2023)
"Abacavir was found at high concentrations to a maximum of 40."1.91Case study on antiretroviral drugs uptake from soil irrigated with contaminated water: Bio-accumulation and bio-translocation to roots, stem, leaves, and fruits. ( Kunene, PN; Mahlambi, PN, 2023)
"Abacavir was dominant in water while efavirenz was dominant in soil/sediments."1.91Methods optimization and application: Solid phase extraction, ultrasonic extraction and Soxhlet extraction for the determination of antiretroviral drugs in river water, wastewater, sludge, soil and sediment. ( Mahlambi, P; Ngwenya, N, 2023)
"Nevirapine was the only ARVD detected in crops grown with NUC and struvite on both soils, but the concentrations were below the limit of quantification."1.91Uptake of selected antiretrovirals by pepper (Capsicum annum), radish (Raphanus sativus), and ryegrass (Lolium perenne) grown on two contrasting soils and fertilized with human urine-derived fertilizers. ( Abafe, OA; Badza, T; Hughes, JC; Lawal, MA; Martincigh, BS; Migeri, S; Odindo, AO, 2023)
" This study aimed to develop a population pharmacokinetic model to characterize the disposition of maraviroc in neonates to inform dosing regimens and expand available options."1.72Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. ( Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)
"Buprenorphine CL/F was 76% higher in HIV+ patients (n = 17) than HIV- patients (n = 37)."1.72Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability. ( Bart, G; Brundage, RC; Giang, LM; Jaber, M; Korthuis, PT, 2022)
"Methadone treatment of opioid use disorder in HIV-infected individuals is complicated by drug-drug interactions."1.62Effect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study. ( Bart, G; Brundage, RC; Giang, LM; Hodges, JS; Yen, H, 2021)
"Doravirine (DOR) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) that retains activity against common NNRTI resistance mutations."1.62Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients. ( Bociąga-Jasik, M; Hlebowicz, M; Jakubowski, P; Parczewski, M; Raczyńska, A; Scheibe, K; Szetela, B; Szymczak, A; Urbańska, A; Łojewski, W, 2021)
"NVP/ZDV/3TC started in the first week of life was safe and effective, even when trough NVP levels were below target."1.62Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life. ( Ajibola, G; Batlang, O; Bennett, K; Capparelli, EV; Hughes, MD; Jean-Philippe, P; Kuritzkes, DR; Lichterfeld, M; Lockman, S; Makhema, J; Maswabi, K; Mohammed, T; Moyo, S; Sakoi, M; Shapiro, RL, 2021)
"2% (30/185) with improper dosage or prescription errors."1.62Adverse Reactions to Antiretrovirals in Cuban Patients Living with HIV/AIDS. ( Morales-Pérez, M, 2021)
"Lopinavir was mostly requested in patients when adherence measures did not correlate with the clinical picture, suspected non-adherence, lopinavir-rifampicin interactions and for neonatal safety monitoring."1.56Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital. ( Decloedt, EH; Engelbrecht, AE; Norman, J; Rabie, H; Wiesner, L, 2020)
" There were no clinically relevant toxicities nor adverse events in both control and test arms."1.56Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria. ( Abideen, G; Adeniji, H; Adeuja, O; Agbaje, EO; Akanmu, AS; Akinleye, MO; Akinyede, AA; Busari, AW; Hassan, OO; Ken-Owotor, C; Kogbe, S; Ogunfowokan, T; Onwujuobi, AG; Oreagba, IA; Owolabi, ET; Usman, SO, 2020)
" We evaluated the adverse events associated with the use of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP) for neonatal PEP during the first 6 weeks of life."1.51Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants. ( Anugulruengkitt, S; Chokephaibulkit, K; Cressey, TR; Jantarabenjakul, W; Ounchanum, P; Pancharoen, C; Punnahitanon, S; Puthanakit, T; Sophonphan, J; Srirompotong, U; Suntarattiwong, P, 2019)
"Nevirapine has been used as antiretroviral agent since early '90."1.48Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. ( Cattaneo, D; Cheli, S; Clementi, E; Di Cristo, V; Falvella, FS; Galli, M; Giacomelli, A; Lupo, A; Oreni, ML; Renisi, G; Ridolfo, AL; Riva, A; Rusconi, S, 2018)
" Secondary endpoints were time to loss of virological response and adverse events."1.46Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan. ( Chang, HM; Chen, YS; Kunin, CM; Lee, CY; Lee, SS; Tsai, HC, 2017)
"Traditional medication adherence measures do not account for the pharmacokinetic (PK) properties of the drugs, potentially misrepresenting true therapeutic exposure."1.46Pharmacokinetics-based adherence measures for antiretroviral therapy in HIV-infected Kenyan children. ( Ayaya, SO; Liu, H; Nyandiko, WM; Scanlon, ML; Slaven, JE; Tu, W; Vreeman, RC, 2017)
"Sparse pharmacokinetic sampling of ENG, NVP, or EFV were performed at screening, entry, and then 1, 4, 12, and 24-week postimplant insertion."1.46Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy. ( Achilles, SL; Chappell, CA; Chen, BA; Cohn, SE; Darin, KM; Lamorde, M; Mackline, H; Nakalema, S; Riddler, SA; Scarsi, KK, 2017)
" However, studies have shown that this dosing strategy based on adult studies may not be appropriate in children, given that younger children have higher drug clearance rates."1.46Sub-therapeutic nevirapine concentration during antiretroviral treatment initiation among children living with HIV: Implications for therapeutic drug monitoring. ( A K, HK; D'souza, RR; Gopalan, BP; Mehta, K; Rajnala, N; Ramachandran, G; Shet, A, 2017)
"zidovudine (AZT)) were associated with earlier VF."1.46Long-term viral suppression and immune recovery during first-line antiretroviral therapy: a study of an HIV-infected adult cohort in Hanoi, Vietnam. ( Cuong, DD; Dung, NT; Dung, NTH; Haneuse, S; Kinh, NV; Matsumoto, S; Oka, S; Tanuma, J; Thuy, PTT; Trung, NV; Vu, TV, 2017)
" Here we aimed to quantify nevirapine and LPV/r drug-drug interaction effects on bedaquiline and M2 in patients co-infected with HIV and multidrug-resistant tuberculosis (MDR-TB) using population pharmacokinetic (PK) analysis and compare these with model-based predictions from single-dose studies in subjects without TB."1.46Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. ( Brill, MJ; Karlsson, MO; Maartens, G; Pandie, M; Svensson, EM, 2017)
" The most common adverse events potentially attributable to combination antiretroviral therapy were transient asymptomatic hyperlactatemia (26%), anemia (24."1.46Nevirapine Pharmacokinetics and Safety in Neonates Receiving Combination Antiretroviral Therapy for Prevention of Vertical HIV Transmission. ( Bitnun, A; Brophy, J; Campbell, DM; Colantonio, D; Kakkar, F; Lau, E; Murphy, K; Read, SE; Samson, L; Seto, W; Yudin, MH, 2017)
" Blood plasma was collected at 1, 4 and 24 hours post-ART dosing from 58 subjects receiving NVP-containing ART and used to determine cNVP and viral load (VL)."1.46Plasma nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure. ( Aman, RA; Kimulwo, MJ; Kokwaro, GO; Muigai, AW; Ochieng, DJ; Ochieng, W; Ogutu, BR; Okendo, J; Oloo, FA, 2017)
" The form is designed to obtain information on the demographics of the patients, WHO clinical stage of their HIV infection, HAART regimen for the patients, and suspected adverse events associated with the antiretroviral drugs used by the patients."1.43A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria. ( Awodele, O; Oshikoya, KA; Popoola, TD, 2016)
" Plasma concentrations were measured as therapeutic drug monitoring while a subset of patients underwent intensive 12-hour pharmacokinetic evaluation."1.43Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics. ( Bonora, S; Calcagno, A; Calza, L; Capetti, A; Cenderello, G; D'Avolio, A; Di Perri, G; Guaraldi, G; Lanzafame, M; Marinaro, L; Montrucchio, C; Tettoni, MC; Trentini, L, 2016)
"Compared with zidovudine-lamivudine, the use of tenofovir-lamivudine or emtricitabine in combination with nevirapine was a strong predictor of virologic failure in our cohort, which was not explained by other risk factors or criteria for regimen selection."1.43Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort. ( Agbaji, OO; Darin, KM; Eisen, G; Gashau, W; Kanki, PJ; Meloni, ST; Murphy, RL; Nkado, R; Okonkwo, P; Onwujekwe, DI; Rawizza, HE; Scarsi, KK; Tchetgen Tchetgen, EJ, 2016)
"Bedaquiline is a new anti-TB drug, which is metabolized by cytochrome P450 (CYP) 3A4."1.43Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. ( Conradie, F; Hughes, J; Maartens, G; McIlleron, H; Pandie, M; Siwendu, S; Variava, E; Wiesner, L, 2016)
"Universal multi drug antiretroviral treatment in pregnancy is a global priority in our bid to eliminate paediatric HIV infections although few studies have documented the impact of antiretroviral coverage on overall pregnancy outcomes."1.43Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa. ( Maharaj, N; Moodley, D; Moodley, T; Sartorius, B; Sebitloane, M, 2016)
" The aim of this study was to compare the rate of any discontinuation of antiretroviral (ARV) regimen because of virologic failure (VF), and/or adverse drug reaction (ADR) among patients receiving stable ARV regimens for at least 6 months."1.43Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study. ( Bani-Sadr, F; Cabie, A; Cotte, L; de Boissieu, P; Delobel, P; Dramé, M; Garraffo, R; Huleux, T; Poizot-Martin, I; Raffi, F; Rey, D, 2016)
"Nevirapine (39."1.43Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China. ( Bai, JS; Chen, JH; He, LP; Jin, YM; Kuang, YQ; Li, YY; Liu, J; Wen, J; Yu, M, 2016)
"Nevirapine is a reverse-transcriptase inhibitor widely used in combination therapy to treat HIV infection."1.43Exploring CYP2B6 activity by measuring the presence ofnevirapine hydroxy metabolites in plasma. ( Ab Rahman, AK; Hassan, NB; Low, LL; Mustafa, S; Tan, SC; Wan Yusuf, WN, 2016)
" In conclusion, this genotypic resistance analysis strongly suggests that the latest NNRTI, rilpivirine, may retain activity in a large proportion of HIV-1 patients in whom resistance failed while they were on an efavirenz- or nevirapine-containing regimen, and may present an attractive option for second-line treatment given its good safety profile and dosing convenience."1.42Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine. ( Camacho, RJ; Gomes, P; Rhee, SY; Theys, K; Vandamme, AM, 2015)
" Compared to RRC, Ugandan children exhibited reduced bioavailability of EFV and LPV; 11% (P=0."1.42The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda. ( Achan, J; Aweeka, F; Bartelink, IH; Capparelli, E; Charlebois, E; Dorsey, G; Gingrich, D; Havlir, D; Jullien, V; Kamya, M; Plenty, A; Ruel, T; Savic, RM; Scherpbier, HJ; Young, SL, 2015)
"Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are severe adverse drug reactions, characterized by extensive epidermal detachment and erosions of mucous membrane."1.42A pharmacogenetics study in Mozambican patients treated with nevirapine: full resequencing of TRAF3IP2 gene shows a novel association with SJS/TEN susceptibility. ( Borgiani, P; Buonomo, E; Ciccacci, C; Giardina, E; Mancinelli, S; Marazzi, MC; Novelli, G; Palombi, L; Rufini, S; Scarcella, P, 2015)
"Data on AIDS patients initially starting antiretroviral therapy during 2008 and 2013 were collected from Chinese HIV/AIDS integrated control system."1.42[Analysis on HIV suppression effect after initiating antiretroviral treatment and related factors among AIDS patients in Henan province during 2008 and 2013]. ( Fan, P; Li, J; Li, N; Liang, Y; Ma, Y; Sun, D; Wang, Z; Yang, W; Zhu, Q, 2015)
" Stavudine and lamivudine are administered as fixed combination while nevirapine as separate dosage form which often results in poor compliance and adherence to therapy by patients and therefore, there is a need to develop dosage forms that can overcome the problems of currently available dosage forms for treatment of HIV infection."1.42Simultaneous And Extended Delivery Of Stavudine, Lamivudine And Nevirapine In Fixed Dose Combination Using Sandwiched Osmotic Tablets For Hiv Therapy. ( Priya, MR; Rajendran, NN, 2015)
"HIV-associated Kaposi sarcoma (HIV-KS) is the most common cancer in Malawi."1.42Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi. ( Bazile, J; Beste, JA; Chingoli, F; Crocker, JT; Elmore, SN; Gopal, S; Herce, ME; Kalanga, N; Keck, JW; Mailosi, B; Phiri, A; Rigodon, J; Tengatenga, L; Wroe, EB, 2015)
"Nevirapine was the offending drug in 21/22 (95%) cases."1.42Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women. ( Knight, L; Lehloenya, RJ; Matjila, M; Muloiwa, R; Todd, G, 2015)
"983T>C could be important sources of nevirapine pharmacokinetic variability that could be considered for dosage optimization, while CYP1A2 g."1.42Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients. ( Castel, S; Dandara, C; Lacerda, M; Mhandire, D; Mhandire, K; Musingwini, T; Shamu, T; Smith, P; Stray-Pedersen, B; Swart, M; Wiesner, L; Zhou, D, 2015)
"Nevirapine exposure was unchanged before and after artemether-lumefantrine administration."1.42Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy. ( Adedeji, WA; Adewole, IF; Akinyinka, OO; Aweeka, FT; Darin, KM; Fehintola, F; Huang, L; Morse, GD; Murphy, RL; Olson, A; Parikh, S; Scarsi, KK; Taiwo, BO, 2015)
"Only zidovudine has adequate dosing recommendations for treating term and preterm infants and has an intravenous formulation, essential if feeding intolerance occurs."1.42The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants. ( Cotton, MF; Holgate, S; Mirochnick, M; Nelson, A; Rabie, H; Wedderburn, C, 2015)
" The purpose of the current study was to determine the population mean pharmacokinetic parameters and identify factors that influence pharmacokinetic parameters of nevirapine in Thai HIV-infected patients."1.40Population pharmacokinetics of nevirapine in Thai HIV-infected patients. ( Avihingsanon, A; Manosuthi, W; Punyawudho, B; Wattanakul, T, 2014)
"Nevirapine (NVP) was loaded in polycaprolactone (PCL) matrices to produce vaginal inserts with the aim of preventing HIV transmission."1.40Evaluation of polycaprolactone matrices for sustained vaginal delivery of nevirapine in the prevention of heterosexual HIV transmission. ( Coombes, AGA; Dang, N; Harrich, D; Shaw, PN; Sivakumaran, H, 2014)
"Nevirapine is an inducer of hepatic metabolism."1.40Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects. ( Allavena, C; André-Garnier, E; Billaud, E; Bonnet, B; Bouchez, S; Bouquié, R; Boutoille, D; Dailly, E; Pineau, S; Raffi, F; Raveleau, A; Reliquet, V, 2014)
"Stavudine was prescribed to 5."1.40Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database. ( Boettiger, DC; Chaiwarith, R; Choi, JY; Ditangco, R; Kamarulzaman, A; Kantipong, P; Kerr, S; Kiertiburanakul, S; Kumarasamy, N; Law, M; Lee, C; Li, CK; Merati, TP; Mustafa, M; Ng, OT; Oka, S; Pham, TT; Pujari, S; Ratanasuwan, W; Sohn, A; Van Kinh, N; Vonthanak, S; Wong, WW; Yunihastuti, E; Zhang, F, 2014)
"We document our experience with therapeutic drug monitoring (TDM) of antiretroviral agents (1807 determinations) carried out as day-by-day clinical practice for the optimization of drug dosing in HIV-infected patients."1.40Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint. ( Baldelli, S; Castoldi, S; Cattaneo, D; Charbe, N; Clementi, E; Cozzi, V; Fucile, S, 2014)
"Nevirapine (NVP) is an effective nonnucleoside reverse transcriptase inhibitor (NNRTI) of particular interest as it is often used in resource limited countries."1.40Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine. ( Janphen, K; Kumrapich, B; Praparattanapan, J; Roytrakul, S; Smith, DR; Supparatpinyo, K; Thongtan, T; Wongtrakul, J, 2014)
" We conducted a cross-sectional study of HIV-positive women to determine if protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) C(min) and Cmax values were significantly different than historical general population (predominantly male) averages and to evaluate correlates of higher concentrations."1.39Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study. ( Angel, JB; Blitz, SL; Burdge, D; Cohen, J; Conway, B; de Pokomandy, A; Gough, K; Haase, D; Klein, MB; la Porte, CJ; Loemba, H; Loutfy, MR; Pick, N; Raboud, J; Rachlis, AR; Smaill, FM; Trottier, S; Tseng, AL; Walmsley, SL, 2013)
" SJS can occur in children at any age, with any level of immunosuppression, and can occur during the lead-in dosing period of NVP."1.39Stevens-Johnson syndrome and HIV in children in Swaziland. ( Blank, DA; Draper, HR; Dziuban, EJ; Hughey, AB; Kochelani, D; Schutze, GE; Stewart, DA, 2013)
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor, widely prescribed for type 1 human immunodeficiency virus infection."1.39Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. ( Borgiani, P; Ciccacci, C; Di Fusco, D; Erba, F; Liotta, G; Marazzi, MC; Novelli, G; Palombi, L; Zimba, I, 2013)
" Our results demonstrate that the HIV PI lopinavir inhibits liver stage parasites at clinically relevant concentrations, that is, at drug levels achieved in HIV-infected patients on standard dosing regimens."1.39The effect of antiretrovirals on Plasmodium falciparum liver stages. ( Borkowsky, W; De La Vega, P; Duffy, PE; Hobbs, CV; Krzych, U; Penzak, SR; Sinnis, P; Van Vliet, J, 2013)
"To investigate if pregnancy is a risk factor for SJS among HIV-infected women taking NVP-containing regimens and registered within the Medunsa National Pharmacovigilance Centre database."1.39Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007 - 2012. ( Adewusi, E; Dube, N; Summers, R, 2013)
"Nevirapine is an important component of highly active antiretroviral therapy used in the treatment of HIV infection."1.39Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes? ( Bangsberg, DR; Chinn, LW; Kroetz, DL; Martin, JN; Micheli, JE; Patel, A; Shugarts, SB, 2013)
" After adjusting for age, gender, HIV risk factor, current CD4 count, pill burden and dosing interval, adherence was higher in patients with undetectable HIV RNA (P < 0."1.39Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy. ( Bocchiola, B; Cahua, T; Castagna, A; Danise, A; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Panzini, P; Pazzi, A; Salpietro, S; Zandonà, D, 2013)
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used for chronic human immunodeficiency virus infections in adults and children."1.39Evaluation of nevirapine dosing recommendations in HIV-infected children. ( Benaboud, S; Blanche, S; Bouazza, N; Dollfus, C; Faye, A; Foissac, F; Frange, P; Hirt, D; Lachassinne, E; Treluyer, JM; Urien, S, 2013)
"Nevirapine (NVP) treatment is associated with serious skin rashes that appear to be immune-mediated."1.39Nevirapine bioactivation and covalent binding in the skin. ( Klarskov, K; Sharma, AM; Uetrecht, J, 2013)
"Demographic, treatment and pregnancy related data were collected."1.38Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy. ( Boer, K; de Wolf, F; Godfried, MH; Nellen, JF; Smit, C; Snijdewind, IJ; van der Ende, ME, 2012)
"To propose a modelling strategy to efficiently integrate data from different sources in one simultaneous analysis, using nevirapine population pharmacokinetic data as an example."1.38Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. ( Barnes, KI; Cohen, K; Denti, P; Huitema, A; Karlsson, MO; Kredo, T; Nachega, JB; Svensson, E; van der Walt, JS, 2012)
"We compared adverse events among breast-feeding neonates born to Kenyan mothers receiving triple-antiretroviral therapy, including either nevirapine or nelfinavir."1.38Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission. ( Akoth, B; Angira, F; Masaba, R; Mills, LA; Minniear, TD; Ndivo, R; Oyaro, B; Peters, PJ; Polle, N; Thomas, TK; Zeh, C, 2012)
"Nevirapine was given at delivery to 93/135 (69%) women, and to 128/135 (95%) children."1.38HIV-1 mother-to-child transmission, post-test counselling, and antiretroviral prophylaxis in Northern Viet Nam: a prospective observational study. ( Anh, NM; Bao, NH; Cam, PD; Caridha, R; Ehrnst, A; Gaseitsiwe, S; Ha, TT; Hien, NT; Tuan, PL, 2012)
" The population pharmacokinetic approach represents a very useful tool for the description of the dose-concentration relationship, the quantification of variability in the target population of patients and the identification of influencing factors."1.38Dosage optimization of treatments using population pharmacokinetic modeling and simulation. ( Aouri, M; Arab-Alameddine, M; Buclin, T; Csajka, C; Decosterd, LA; Guidi, M; Rotger, M; Telenti, A, 2012)
"Nevirapine (NVP) is a nonnucleoside reverse transcriptase inhibitor (NNRTI) used worldwide as part of combination antiretroviral therapy in infants and children to treat HIV infection."1.38Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. ( Acosta, EP; Aweeka, FT; Burger, D; Capparelli, EV; Cressey, TR; Kabamba, D; Nikanjam, M; Spector, SA, 2012)
" Pressure of work and insufficient perceived benefit of side-effect recording are suspected causes."1.37Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, Malawi. ( Lungu, M; Mathews, T; Tapsfield, J; van Oosterhout, JJ, 2011)
"Ritonavir (RTV) was used initially for 138 children who were <6 months old or receiving antimycobacterial therapy; otherwise children received lopinavir/ritonavir (LPV/r)-based ART."1.37Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. ( Abrams, EJ; Coovadia, A; Hunt, G; Kuhn, L; Meyers, T; Morris, L; Sherman, G; Strehlau, R; Taylor, BS, 2011)
"Nevirapine is an important component of paediatric combination HIV therapy."1.37Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India. ( Agibothu Kupparam, HK; Karunaianandham, R; Mahalingam, V; Navaneethapandian, PG; Perumal Kannabiran, B; Ramachandran, G; Shah, I; Sikhamani, R; Soundararajan, L; Swaminathan, S, 2011)
" We characterized relationships between nevirapine-associated cutaneous and hepatic adverse events and genetic variants among HIV-infected adults."1.37Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. ( Cammett, AM; Distel, M; Guo, S; Haas, DW; Hall, D; Huang, Z; Jayadev, S; Mootsikapun, P; Podzamczer, D; Ruxrungtham, K; Storfer, S; Yuan, J, 2011)
"We retrospectively evaluated the durability and reasons for discontinuation of nevirapine (NVP) in combination with a tenofovir (TDF) and emtricitabine (FTC) or lamivudine (3TC)-containing antiretroviral therapy (ART) regimen in an Australian outpatient setting."1.37Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects. ( Chan, DJ; Jeganathan, S; Maruszak, H; Smith, DE, 2011)
" Pharmacokinetic parameter estimates and model-predicted HIV-1 transmission rates were very consistent with other studies."1.37Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes. ( Frank, M; Harms, G; Kloft, C; Kunz, A; Schütte, C; von Kleist, M, 2011)
" The correlation between nevirapine concentrations, efficacy and hepatotoxicity suggests the benefit of dosage adjustment based on therapeutic drug monitoring among Chinese HIV-infected patients to optimize nevirapine containing antiretroviral therapy."1.37Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection. ( Fu, Q; Han, Y; Kou, H; Li, T; Li, Y; Ma, Q; Qiu, Z; Wang, J; Ye, M; Zhu, Z; Zuo, L, 2011)
"7% oral bioavailability in rat, tolerated oral single dose toxicity in mice, and especially the feature of highly efficient suppression of the wild-type HIV-1 and Y181C mutant HIV-1 at an EC(50) = 7."1.36Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile. ( Chen, Z; Han, C; Hu, J; Li, Y; Liu, G; Liu, L; Liu, Z; Lu, X; Ma, T; Wang, L; Xue, H; Zheng, P, 2010)
"Etravirine (ETV) is a second-generation nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) introduced recently for salvage antiretroviral treatment after the emergence of NNRTI-resistant human immunodeficiency virus type 1 (HIV-1)."1.36Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine. ( Gatanaga, H; Hachiya, A; Hayashida, T; Ode, H; Oka, S; Sato, H, 2010)
"Nevirapine is widely used to treat HIV-1 infection to prevent mother-to-child transmission; unfortunately adverse drug reactions have been reported."1.36Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. ( Altan, AM; Borgiani, P; Bramanti, P; Ceffa, S; Ciccacci, C; Marazzi, MC; Novelli, G; Palombi, L; Paturzo, G; Sirianni, E, 2010)
"Etravirine has compromised activity in approximately half of the patients failing nevirapine-based first-line treatment in this cohort, which supports guidelines that caution against using it with NRTIs alone in such patients."1.36Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. ( Adewole, I; Akanmu, S; Chaplin, B; Gashau, W; Idoko, J; Kanki, P; Meloni, S; Murphy, R; Penugonda, S; Taiwo, B, 2010)
"To investigate uptake and provision of antenatal care (ANC) services in the Uzazi Bora project: a demonstration-intervention project for Safe Motherhood and prevention of mother-to-child transmission of HIV in Kenya."1.36A Safe Motherhood project in Kenya: assessment of antenatal attendance, service provision and implications for PMTCT. ( Chersich, MF; Delva, W; Luchters, S; Muigai, E; Oyier, V; Temmerman, M; Yard, E, 2010)
"We describe a 51-year-old female with acquired immunodeficiency syndrome (AIDS) and HIV-associated PAH."1.36Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension. ( Backman, ES; Farber, HW; Hardy, H, 2010)
"Full 12-hour pharmacokinetic profiles of nevirapine, stavudine, and lamivudine in HIV-infected children taking fixed-dose combination antiretroviral tablets have been reported previously by us."1.36Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets. ( Burger, D; Chintu, C; Ewings, F; Gibb, DM; Kabamba, D; Kankasa, C; L'homme, R; Mulenga, V; Thomason, M; Walker, AS, 2010)
"CHAP2 (Children with HIV Antibiotic Prophylaxis 2) is a prospective cohort of Zambian children using d4T/3TC/NVP adult Triomune30 dosed according to WHO guidelines."1.36Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine. ( Chintu, C; Ferrier, A; Ford, D; Gibb, DM; Grant, PR; Gupta, RK; Kabamba, D; Kalumbi, M; Mulenga, V; Pillay, D; Walker, AS, 2010)
" Children taking T30 for > 6 weeks from each dosing weight band (<5, 5-<8, 8-<12, 12-<14, 14-<19, 19-<26, 26-<30 and > or = 30 kg) were recruited."1.36Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets. ( Burger, D; Chesshyre, E; Khoo, S; Molyneux, E; Moons, P; Poerksen, G; Pollock, L, 2010)
"In resource-limited settings where nevirapine-containing regimen is the preferred regimen in women, data on severe adverse events (SAEs) according to CD4 cell count are limited."1.36Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire. ( Abrams, EJ; Amani-Bosse, C; Bédikou, G; Coffie, PA; Dabis, F; Ekouevi, DK; Tanon, AK; Tonwe-Gold, B, 2010)
"Nevirapine-based ART was initiated in 820 women and baseline ALT or AST results were abnormal (≥ grade 1) in 113 (14%) women."1.36Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya. ( Bolu, O; Borkowf, CB; Brooks, JT; Intalapaporn, P; Kiarie, J; McConnell, MS; Mutsotso, W; Peters, PJ; Potter, D; Ratanasuwan, W; Stringer, J; Weidle, PJ; Zulu, I, 2010)
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used against human immunodeficiency virus type-1 (HIV-1), mostly to prevent mother-to-child HIV-1 transmission in developing countries."1.36Protein adducts as prospective biomarkers of nevirapine toxicity. ( Antunes, AM; Beland, FA; Coelho, AV; Godinho, AL; Gomes, RA; Marques, MM; Martins, IL; Oliveira, MC, 2010)
"Predictors of adverse events (AE) associated with nevirapine use are needed to better understand reports of severe rash or liver enzyme elevation (LEE) in HIV+ women."1.36Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. ( Aaron, E; Bachmann, LH; Criniti, S; Gracely, E; Kempf, MC; Kumar, R; Tedaldi, E; Warriner, A, 2010)
"There are few studies from India documenting the adverse effects of generic HAART (Highly Active Anti-retroviral Therapy)."1.36Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India. ( Dasegowda, V; Sreenivasan, S, 2010)
"The aim of this study was to measure the cumulative incidence of adverse events (AEs) related to nevirapine in patients switched from efavirenz to immediate full-dose nevirapine (FDN)."1.35Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia. ( Chhneang, V; Fernandez, M; Laureillard, D; Moeung, S; Ngeth, C; Piketty, C; Prak, N; Quillet, C; Riel, V; Song, S, 2008)
"The aim of this study was to develop and validate a population pharmacokinetic model for nevirapine in a population of HIV-infected adults and to evaluate the influence of nevirapine dosing regimen and patient characteristics on nevirapine trough concentration."1.35Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. ( Cedeño, S; Clotet, B; Costa, J; Miranda, C; Miranda, J; Moltó, J; Negredo, E; Santos, JR; Valle, M; Vilaró, J, 2008)
"to give a description of HIV-AIDS and tuberculosis co-infection in Jakarta, viewed from the perspective of virologic and immunologic status and the correct selection of antiretrovirals."1.35Clinical manifestations and antiretroviral management of HIV/AIDS patients with tuberculosis co-infection in Kramat 128 Hospital. ( Djoerban, Z; Sumantri, S, 2008)
"Zidovudine was not detectable in any infant plasma samples obtained after the day of delivery, while the median concentrations in infant plasma samples from postpartum weeks 2, 6, and 14 were 67 ng/ml, 32 ng/ml, and 24 ng/ml for lamivudine and 987 ng/ml, 1,032 ng/ml, and 734 ng/ml for nevirapine, respectively."1.35Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. ( Capparelli, E; Fowler, MG; Holland, D; Masaba, R; Mirochnick, M; Odhiambo, P; Thigpen, MC; Thomas, T; Weidle, PJ; Zeh, C, 2009)
" The latter association was maintained with both 200 mg twice daily (bid) and 400 mg once daily (qd) dosing [GG, 3527 ng/mL (n=30); GT, 4525 ng/mL (n=32); TT, 7020 ng/mL (n=2); P(anova)=0."1.35Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. ( Back, Dj; Egan, D; Johnson, M; Khoo, S; Mahungu, T; Owen, A; Smith, C; Turner, F; Youle, M, 2009)
"By logistic regression, history of drug allergy apart from NVP (odds ratio [OR] 11."1.35Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash. ( Kiertiburanakul, S; Malathum, K; Sathapatayavongs, B; Sungkanuparph, S; Watcharananan, S, 2009)
"A 12 h pharmacokinetic analysis was performed in 18 patients: 7 HIV/HCV-coinfected and 11 HIV-monoinfected."1.35Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals. ( Bertram, N; Fätkenheuer, G; Reichel, C; Rockstroh, JK; Schwarze-Zander, C; Sudhop, T; Vogel, M; Voigt, E; Wasmuth, JC; Wyen, C, 2009)
"Liver diseases are common in patients with HIV due to viral hepatitis B and C co-infections, opportunistic infections or malignancies, antiretroviral drugs and drugs for opportunistic infections."1.35The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. ( Colebunders, R; Feld, J; Kambugu, A; Katabira, E; Katwere, M; Ocama, P; Opio, KC; Piloya, T; Ronald, A; Thomas, D, 2008)
"Small intensive pharmacokinetic (PK) studies of medications in early-phase trials cannot identify the range of factors that influence drug exposure in heterogenous populations."1.35Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. ( Anastos, K; Bacchetti, P; Benet, LZ; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Kalinowski, A; Minkoff, H; Wolfe, AR; Young, M, 2009)
" We investigated the relationship of NVP dosing with safety and efficacy."1.35Safety and efficacy of once-daily nevirapine dosing: a multicohort study. ( Battegay, M; Calmy, A; de Wolf, F; Hirschel, B; Hogg, RS; Lange, JM; Lima, VD; Montaner, JS; Nguyen, A; Reiss, P; Vallier, N; Wit, FW; Yip, B, 2009)
" Hepatitis C virus (HCV) coinfection, adverse events, and reasons for using nevirapine were also recorded."1.35Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine. ( Aguirrebengoa, K; Clotet, B; García, MA; Goikoetxea, J; Iribarren, JA; Martínez, E; Muñoz, J; Negredo, E; Perez-Alvarez, N; Portu, J; Rodríguez-Arrondo, F, 2009)
" Simplification of dosing schedules has prompted investigations into once-daily dosing regimens; nevirapine once-daily dosing strategies are currently under investigation."1.35Once-daily dosing of nevirapine in HAART. ( Clotet, B, 2008)
"Nevirapine Cmin was subtherapeutic (<3 mg/L) in six patients during antitubercular therapy (one of whom developed virological failure) and in none afterwards."1.35Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. ( Boulle, A; Cohen, K; Goemaere, E; Maartens, G; McIlleron, H; Smith, PJ; van Cutsem, G, 2008)
"The aim of this article is to present the clinical characteristics and management of an oral adverse effect stemming from the use of the antiretroviral medication Nevirapine (NVP)."1.35Oral adverse effects due to the use of Nevirapine. ( Fonseca, LM; Madureira, DF; Mesquita, RA; Moura, MD; Senna, MI, 2008)
"The influence of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics was investigated in HIV-infected patients with a population pharmacokinetic approach."1.35Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients. ( Allavena, C; Biron, C; Dailly, E; Jolliet, P; Raffi, F, 2008)
"We assessed the 18-month effectiveness of short-course (sc) antiretroviral peripartum regimens combined with alternatives to prolonged breastfeeding to prevent mother-to-child transmission (MTCT) of HIV-1 in Abidjan, Côte d'Ivoire."1.3518-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission. ( Becquet, R; Dabis, F; Dequae-Merchadou, L; Ekouevi, DK; Horo, A; Leroy, V; Rouet, F; Rouzioux, C; Sakarovitch, C; Timité-Konan, M; Tonwe-Gold, B; Viho, I, 2008)
"By logistic regression, history of drug allergy (OR, 3."1.35Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings. ( Chantratita, W; Charoenyingwattana, A; Kiertiburanakul, S; Mahasirimongkol, S; Sungkanuparph, S; Sura, T, 2008)
"Non-nevirapine regimens were initiated following biochemical and symptomatic improvement; symptoms did not recur."1.35Incidence of nevirapine-associated hepatitis in an antenatal clinic. ( Black, V; Rees, H, 2008)
"Fibrinogen is an inflammatory factor associated with atherosclerosis."1.35Association of antiretroviral therapy with fibrinogen levels in HIV-infection. ( Bacchetti, P; Grunfeld, C; Heymsfield, S; Kotler, DP; Lee, G; Lewis, CE; Madden, E; Scherzer, R; Shlipak, MG; Tracy, R; Wanke, C, 2008)
"Pregnancy has a moderate but significant lowering effect on NVP plasma concentrations."1.35Steady-state nevirapine plasma concentrations are influenced by pregnancy. ( Boer, K; Burger, DM; Damming, M; de Wolf, F; Godfried, MH; Nellen, JF; Prins, JM; van der Ende, ME; Wit, FW, 2008)
"To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 HIV-infected individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India."1.35Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. ( Balakrishnan, P; Cecelia, AJ; Devaleenal, B; Flanigan, TP; Kumarasamy, N; Lai, AR; Mayer, KH; Poongulali, S; Saghayam, S; Solomon, S; Venkatesh, KK; Yepthomi, T, 2008)
"0001 in both cases) influenced by the patient's status (mean KM estimate of 812 days for virological failures, 1294 for naive patients and 1657 for treatment simplifications) and by the dosing schedule (once-daily 1315 days; twice-daily 1198 days)."1.34Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort. ( Airoldi, M; Arici, C; Bombana, E; Gregis, G; Maggiolo, F; Quinzan, G; Ravasio, V; Ripamonti, D; Suter, F, 2007)
"Most antiretrovirals are metabolized in the liver, and lower dosing could be advisable in patients with severe liver insufficiency."1.34Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. ( Barreiro, P; Gonzalez-Lahoz, J; Jiménez-Nácher, I; Labarga, P; Martín-Carbonero, L; Rodríguez-Novoa, S; Ruiz, A; Soriano, V, 2007)
" The objectives were to compare NVP levels, adverse events, and 36-week efficacy of NVP-based ART between patients who did not receive FLU (group A) and those who received FLU 200 mg/day or 400 mg/day (group B)."1.34Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. ( Athichathanabadi, C; Manosuthi, W; Phoorisri, T; Sungkanuparph, S; Uttayamakul, S, 2007)
"Nevirapine was detected in 15/18 (83%) patients at 1 week, and 5/19 (26%) patients at 2 weeks but was not found any samples collected after 2 weeks."1.34Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. ( Gibb, DM; Grosskurth, H; Khoo, S; Kikaire, B; Mugyenyi, P; Munderi, P; Namale, L; Reid, A; Ssali, F; Walker, AS, 2007)
" Noncompartmental pharmacokinetic analysis was performed."1.34Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. ( Arroyo, E; Climent-Grana, E; Merino, E; Pérez-Ruixo, JJ; Portilla, J; Valenzuela, B, 2007)
" Neutropenia (usually transient) was the most common severe adverse event."1.34Safety of HIV-1 Perinatal Transmission Prophylaxis With Zidovudine and Nevirapine in Rural South India. ( Bethel, J; Dharmarajan, S; Jacob, SM; Junankar, V; Parameshwari, S; Read, JS; Samuel, NM; Stoszek, SK; Van Hook, HM; Xu, J, 2007)
"Nevirapine was quantifiable for up to 17 days after discontinuation of therapy; total nevirapine concentrations remained above the 90% inhibitory concentration for 6 days, and no differences were observed between breasts."1.34Persistence of nevirapine in breast milk after discontinuation of treatment. ( Acosta, EP; Aldrovandi, GM; Ashouri, N; Bennetto-Hood, C; King, JR; Woodman, K, 2007)
"In conclusion, NVP-associated skin rashes that lead to NVP discontinuation are common among HIV-infected patients with baseline CD4 <250 cells/microL."1.34Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL. ( Chaovavanich, A; Chimsuntorn, S; Chottanapund, S; Chumpathat, N; Inthong, Y; Mankatitham, W; Manosuthi, W; Moolasart, V; Prasithsirikul, W; Sittibusaya, C; Sungkanuparph, S; Tansuphaswadikul, S; Termvises, P, 2007)
" Newer HAART regimens have less toxicity and better dosing characteristics than first-generation regimens, but it is not known whether they are associated with improved clinical outcomes."1.34Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine. ( Crane, HM; Kitahata, MM; Van Rompaey, SE, 2007)
" Pharmacokinetic variables were compared between patients divided based on CD4 cell counts, sex, and BMI."1.34Steady-State Pharmacokinetics of Nevirapine in HIV-1 Infected Adults in India. ( Anitha, S; Hemanthkumar, AK; Kumaraswami, V; Narendran, G; Padmapriyadarsini, C; Rajasekaran, S; Ramachandran, G; Subramanyam, S; Swaminathan, S, 2007)
"All nevirapine side effects were developed in less than seven weeks."1.34Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital. ( Carraro, EA; Cornelsen, TC; Dias, JM; Kondo, W; Macedo, RL; Perini, J; Prandel, E; Sasaki, Md; Sbalquiero, R, 2007)
"Chronic viral hepatitis is common among persons with HIV-1 infection, because of shared modes of transmission, and coinfection results in accelerated liver damage, compared with persons with chronic viral hepatitis alone."1.33Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. ( Gerber, JG; Wyles, DL, 2005)
"Nevirapine plasma levels were remarkably high and associated with successful virological treatment results."1.33Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. ( Bodasing, N; Burger, DM; Cleary, PR; de Baar, MP; Kumwenda, JJ; Mallewa, J; Nyirenda, C; Schuurman, R; van Oosterhout, JJ; Zijlstra, EE, 2005)
"We have investigated the pharmacokinetics of nevirapine and paclitaxel in a patient who used both drugs concomitantly, as there are strong theoretical indications for a potential pharmacokinetic drug-drug interaction."1.33No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. ( Beijnen, JH; Huitema, AD; Kappelhoff, BS; Mairuhu, AT; Schellens, JH, 2005)
"Nevirapine plasma levels were determined by a validated high-performance liquid chromatography method with a lower limit of quantification of 0."1.33Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. ( Bosch, M; Burger, DM; Dolmans, W; Droste, JA; Hofstede, HT; Muro, E, 2005)
"The relationships between adverse events (AEs) and plasma concentrations of nevirapine (NVP) and efavirenz (EFV) were investigated as part of the large, international, randomized 2NN study."1.33Are adverse events of nevirapine and efavirenz related to plasma concentrations? ( Baraldi, E; Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Montella, F; Robinson, PA; Russell, DB; Thompson, MA; Uip, DE; van Leth, F, 2005)
"To compare the adverse events after initiation of NVP-based ART among HIV-infected patients who did not receive fluconazole (group A), received fluconazole 400 mg/week (group B), and received fluconazole 200 mg/day (group C)."1.33Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study. ( Chaovavanich, A; Chumpathat, N; Manosuthi, W; Sungkanuparph, S, 2005)
"Zidovudine (AZT) was provided antenatally from week 34 of gestation and during labour."1.33Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa. ( Abdullah, F; Boulle, A; Coetzee, D; Draper, B; Goemaere, E; Hilderbrand, K, 2005)
"Tenofovir disoproxil fumarate (DF) has been studied in combination with efavirenz in healthy volunteers and no interaction was found."1.33Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. ( Burger, DM; Droste, JA; Hekster, YA; Kearney, BP, 2006)
" Multivariate logistic regression was used to test independent association of CD4 and hepatitis C virus (HCV) infection related to the outcome of toxic effects of NVP."1.33Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. ( Calvet, GA; Cruz, ML; D'Ippolito, MM; João, EC; Matos, HJ; Menezes, JA; Salgado, LA, 2006)
" The objective was to find cutoff values of the Cmin and AUC24 below which the risk of virologic failure increased."1.33Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. ( Beijnen, JH; Boron-Kaczmarska, A; Hall, DB; Huitema, AD; Johnson, D; Kappelhoff, BS; Lange, JM; Leith, J; Leth, FV; Livrozet, JM; Losso, MH; Saag, MS; Wit, FW, 2006)
"7% of all adverse events reported during the investigation were attributable to NVP."1.33Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. ( Bonjoch, A; Cervantes, M; Cinquegrana, D; Clotet, B; Cucurull, J; Dalmau, D; Domingo, P; Force, L; Llibre, JM; Masabeu, A; Mascaró, J; Paredes, R; Pedrol, E; Pérez-Alvarez, N; Puig, J; Ribera, E; Vilaró, J, 2006)
" Our findings suggest that decreased bioavailability of nevirapine because of rifampicin coadministration could be overcome by increasing the dose of nevirapine from 200 to 300 mg twice daily without short-term adverse events."1.33Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. ( Hemanthkumar, AK; Kumaraswami, V; Narendran, G; Padmapriyadarsini, C; Raja, K; Rajasekaran, S; Ramachandran, G; Sathishnarayan, S; Sukumar, B; Swaminathan, S, 2006)
"The stage of liver fibrosis was assessed by liver biopsy and/or elastography."1.33Severe liver disease associated with prolonged exposure to antiretroviral drugs. ( Babudieri, S; Barreiro, P; Garcia-Samaniego, J; González-Lahoz, J; Maida, I; Martín-Carbonero, L; Mura, MS; Núñez, M; Ríos, MJ; Rivas, P; Soriano, V; Sotgiu, G; Toro, C, 2006)
" In a multivariate model, K103N detection was associated with HIV-1 subtype (C > A), after adjusting for log10 delivery viral load, the number of days between NVP dosing and sample collection, age, and parity."1.33Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. ( Chen, S; Church, JD; Eshleman, SH; Fiscus, SA; Flys, TS; Guay, LA; Hoover, DR; Jackson, JB; Jones, DC; Kumwenda, N; Mmiro, F; Musoke, P; Mwatha, A; Taha, TE, 2006)
" This is a retrospective analysis of virologic efficacy and changes in adverse neuropsychiatric effects and serum lipid levels after this switch."1.33Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. ( Curtin, JM; Ward, DJ, 2006)
" A pre-dose to 6 h post-dose steady-state pharmacokinetic analysis (n = 35) of the drugs on the day of the scheduled Caesarean section was performed."1.33Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. ( Belohradsky, BH; Eberle, J; Friese, K; Gingelmaier, A; Grubert, TA; Kästner, R; Kurowski, M; Mylonas, I, 2006)
"To assess the incidence and consequences of adverse reactions among African HIV-positive pregnant women treated with fixed-dose combinations of a nevirapine-containing antiretroviral (ARV) triple therapy."1.33Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. ( da Cruz Gomes, A; Germano, P; Guidotti, G; Liotta, G; Loureiro, S; Mancinelli, S; Marazzi, MC; Narciso, P; Palombi, L; Perno, CF; Valls Blazquez, MC, 2006)
"To reduce mother-to-child transmission (MTCT) of HIV, we assessed the stability of nevirapine suspension in an oral dosing syringe over a range of storage conditions."1.33Stability of nevirapine suspension in prefilled oral syringes used for reduction of mother-to-child HIV transmission. ( Dreyfuss, ML; Gray, RH; Hamzeh, FM; Li, X; Parsons, TL; Rexroad, VE; Stamper, PD, 2006)
" The influence of gender, age, body weight and comedication on minimum and maximum concentrations (C(min), C(max)), area under the concentration-time curve (AUC), total clearance (CL(tot)), half-life (t(1/2)) and volume of distribution (V(d)) was analysed by multivariate techniques."1.33A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. ( Carlebach, A; Gute, P; Haberl, A; Harder, S; Klauke, S; Knecht, G; Kurowski, M; Rohrbacher, M; Staszewski, S; Stocker, H; von Hentig, N, 2006)
"Simplification is safe and effective, but it should be offered to patients with shorter treatment duration, and in good clinical and immunovirological conditions."1.32Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. ( Adorni, F; Bini, T; Bongiovanni, M; Capetti, A; Castelnuovo, B; Chiesa, E; Cicconi, P; d'Arminio Monforte, A; Faggion, I; Melzi, S; Mussini, C; Rizzardini, G; Rusconi, S; Sollima, S; Tordato, F, 2003)
"Nevirapine was dosed according to the manufacturer's guidelines."1.32Nevirapine use in HIV-1-infected children. ( Ball, C; Dumont, G; Gibb, DM; Lyall, H; Novelli, V; Sharland, M; Tudor-Williams, G; Verweel, G; Walters, S; Wilkins, E, 2003)
" To have any understanding of drug-drug interactions in HIV treatment we need to appreciate the importance of key pharmacological areas including: 1) how each drug in a regimen is eliminated; 2) the potential for a drug to either induce or inhibit metabolic enzymes and/or transporters; 3) the therapeutic index of each drug."1.32Pharmacokinetic drug interactions with nevirapine. ( Back, D; Gibbons, S; Khoo, S, 2003)
" Using the recommended lead-in dosing schedule in conjunction with good health care management, this adverse event can be controlled in the vast majority of patients."1.32Defining the toxicity profile of nevirapine and other antiretroviral drugs. ( Murphy, RL, 2003)
"Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was first reported in the scientific literature in 1990."1.32Efficacy and durability of nevirapine in antiretroviral drug näive patients. ( Lange, JM, 2003)
" Assessment consisted of CD4+ cell count, plasma HIV-1 RNA load, and adverse effects of study medications."1.32Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection. ( Carroll, H; Conlon, V; Green, A; Green, DC; Green, R; Jefferson, R; Jordan, WC; Tolbert, L; Yemofio, F, 2003)
"In HIV-infected women receiving prenatal care and ART, adverse events were uncommon."1.32Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. ( Balasubramanian, R; Culnane, M; Cunningham, CK; Delfraissy, JF; Delke, I; Dorenbaum, A; Fiore, S; Gelber, RD; Maupin, RT; Mofenson, LM; Newell, ML; Watts, DH, 2004)
" Labor ward dosing to enhance nevirapine coverage should be considered as an adjunct to antenatal nevirapine administration for prevention of mother-to-child transmission of HIV."1.32Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings. ( Acosta, EP; Aldrovandi, GM; Goldenberg, RL; Kumwenda, R; Sinkala, M; Stout, JP; Stringer, JS; Vermund, SH, 2004)
"Evaluate pharmacokinetic interaction, short-term safety, and antiretroviral activity of stavudine (d4T), nevirapine (NVP), and nelfinavir (NFV) as combination HIV-1 therapy."1.32Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults. ( Fisher, A; Grosso, R; Hall, DB; Jacobs, M; Kerr, B; Leoung, G; Lewis, R; MacGregor, T; Odgen, R; Robinson, P; Skowron, G; Stevens, M; Yen-Lieberman, B, 2004)
"The prolonged elimination half-life of NVP compared with NRTIs, which persists even after 20 weeks of therapy, raises concern over the development of NNRTI resistance if all three drugs are stopped together."1.32Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. ( Back, D; Clarke, JR; Fidler, S; Mackie, NE; Tamm, N; Taylor, GP; Weber, JN, 2004)
"Insulin sensitivity was evaluated by the HOMA model assessment."1.32Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors. ( Bour, JB; Brindisi, MC; Buisson, M; Duong, M; Duvillard, L; Galland, F; Gambert, P; Guiguet, M; Masson, D; Petit, JM; Portier, H; Vergès, B, 2004)
"Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis."1.32Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine. ( Krivoy, N; Pollack, S; Shahar, E; Weltfriend, S, 2004)
"Nevirapine was given as 200 mg once daily for the first 2 weeks."1.32Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. ( Anekthananon, T; Ratanasuwan, W; Sonjai, A; Suwanagool, S; Techasathit, W, 2004)
"Nevirapine was provided to HIV-1-seropositive women and condoms distributed to all participants."1.32Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission. ( Farquhar, C; John, FN; John-Stewart, GC; Kabura, MN; Kiarie, JN; Mbori-Ngacha, DA; Nduati, RW; Richardson, BA, 2004)
"Prednisone is commonly used to treat rash, a potentially harmful side effect of nevirapine."1.31Nevirapine, prednisone and rash. ( , 2000)
"Mass treatment of nevirapine would increase access to antiretroviral drugs among pregnant women because they can access nevirapine without volunteer counseling and testing, which 31% of pregnant women in developing countries refused to accept due to the fear of stigmatization."1.31Mass treatment with nevirapine to prevent mother-to-child transmission of HIV/AIDS in sub-Saharan African countries. ( Hashimoto, H; Kapiga, SH; Murata, Y, 2002)
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy for the treatment of HIV infection."1.31Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy. ( Clarke, S; Condon, C; Harrington, P; Kelleher, D; Mulcahy, F; Smith, OP, 2000)
" RT sequences from plasma collected prior to NVP dosing were also analyzed."1.31Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. ( Becker-Pergola, G; Eshleman, SH; Fowler, MG; Guay, LA; Jackson, JB; Mirochnick, M; Mmiro, F; Mofenson, LM; Mracna, M; Musoke, P, 2000)
"NVP reaches concentrations in the semen approximately 60% of those in the blood plasma throughout the 12 h dosing period."1.31Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. ( Drake, SM; Hoetelmans, RM; Pillay, D; Taylor, S; van Heeswijk, RP; White, DJ; Workman, J, 2000)
"Eight patients who were infected with human immunodeficiency virus, and who had each sustained an adverse drug reaction while following a regimen including nevirapine, were switched to a regimen including efavirenz."1.31The tolerability of efavirenz after nevirapine-related adverse events. ( Barry, M; Clarke, S; Harrington, P; Mulcahy, F, 2000)
"Nevirapine is a nonnucleoside reverse transcriptase inhibitor (NNRTI) that has the most common treatment limiting side effect of rash."1.31Sex differences in nevirapine rash. ( Aberg, JA; Bersoff-Matcha, SJ; Hamrick, HJ; Miller, WC; Mundy, LM; Powderly, WG; van Der Horst, C, 2001)
" Nevirapine is well absorbed during labor, and sufficient drug for prophylaxis against perinatal transmission crosses the placenta if an oral dose is administered to the mother at least 1 hour before delivery."1.31Antiretroviral pharmacology in pregnant women and their newborns. ( Mirochnick, M, 2000)
"Nevirapine is a non-nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents for the treatment of HIV infection."1.31Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. ( Farmer, KL; Hebert, AA; Lahart, CJ; Metry, DW, 2001)
"Nevirapine is a nonnucleoside reverse transcription inhibitor that is used as part of highly active antiretroviral therapeutic combinations."1.31Jaundice and hepatocellular damage associated with nevirapine therapy. ( Bonacini, M; Poreddy, V; Prakash, M; Tiyyagura, L, 2001)
"Cutaneous and hepatic adverse reactions and clinical hepatitis were assessed."1.31Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. ( Arnaiz, JA; Blanco, JL; Carné, X; Cruceta, A; García-Viejo, MA; Gatell, JM; Mallolas, J; Marcos, MA; Martínez, E; Milinkovic, A; Mocroft, A; Pérez-Cuevas, JB; Phillips, A, 2001)
"Nevirapine plasma levels were measured in 70 HIV-infected patients, 33 of whom developed transaminase elevations."1.31Liver toxicity caused by nevirapine. ( González de Requena, D; Jiménez-Nácher, I; Núñez, M; Soriano, V, 2002)
"Blood samples were obtained at 0, 1, 2, 3, 4, 6 and 8 h after dosing on both study days."1.30The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. ( Back, DJ; Barry, MG; Breckenridge, AM; Halifax, KL; Merry, C; Mulcahy, F; Ryan, M; Tjia, JF, 1998)
"Antiretroviral therapy including zidovudine may yield replicating viruses with a two amino-acid insertion in RT in combination with amino-acid changes at codons 67 and 215, which are highly resistant to lamivudine and stavudine on top of zidovudine and have unpredictable susceptibility to didanosine and zalcitabine despite lack of previously reported corresponding resistance-associated amino-acid changes."1.30Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. ( Baan, E; Danner, SA; de Jong, JJ; de Wolf, F; Goudsmit, J; Hillebrand, ME; Huismans, R; Jurriaans, S; Lukashov, VV; ten Veen, JH, 1999)
"Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse."1.30Methadone withdrawal when starting an antiretroviral regimen including nevirapine. ( Heelon, MW; Meade, LB, 1999)
"(4) Nevirapine is a liver enzyme inducer, hence the possibility of drug interactions, especially with protease inhibitors of HIV; the clinical consequences are poorly known."1.30Nevirapine: new preparation. In second-line triple-drug anti-HIV regimens. ( , 1998)
"Nevirapine was shown to be most effective in trials with triple combination regimens."1.30NNRTIs: a neglected class. ( Cadman, J, 1998)
" Several studies of regimens that include protease inhibitors compare dosing twice daily to three times a day."1.30Antivirals update. ( , 1998)
"Genital warts are caused by the human papillomavirus (HPV) and are very common among the general population."1.30HIV transmission. ( Bartnof, HS, 1999)
"Nevirapine was rapidly absorbed at all doses from a tablet formulation."1.29Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. ( Andrews, C; Bova, CA; Cheeseman, SH; Hattox, SE; Keirns, JJ; Koup, RA; McLaughlin, MM; Pav, JW; Roy, T; Sullivan, JL, 1993)
"Nevirapine is a nonnucleoside inhibitor of reverse transcriptase (RT) which decreases the level of HIV-1 viral particles in the blood plasma of infected individuals."1.29Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo. ( Dornadula, G; Havlir, D; Pomerantz, RJ; Richman, DD; Wu, Y; Zhang, H, 1996)
"Nevirapine was added to the drug regiment of eight children with HIV infection treated with the combination of zidovudine and didanosine who had increasing levels of serum p24 antigen."1.29Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus. ( Anderson, B; Farley, M; Fox, C; Luzuriaga, K; Mueller, BU; Pizzo, PA; Schwartzentruber, DJ; Sei, S; Sullivan, JL; Tudor-Williams, G; Venzon, DJ, 1996)
" This small-animal model should be particularly useful in the preclinical prioritization of lead compounds within a common chemical class, in the evaluation of alternative in vivo dosing regimens, and in the determination of appropriate combination therapy in vivo."1.29Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds. ( Charpiot, B; Datema, R; Hincenbergs, M; Kaneshima, H; Linquist, V; McCune, JM; Moreno, MB; Rabin, L; Seifert, J; Warren, S, 1996)
"Nevirapine is a non-nucleoside HIV reverse transcriptase inhibitor."1.29Nevirapine: ethical dilemmas and care for HIV-infected mothers. ( Benson, M; Shannon, M, 1995)
"When nevirapine was combined with zidovudine (AZT) and didanosine (ddI), patients' CD4 counts rose significantly and viral load was reduced to below detectable levels."1.29FDA approves first new class of HIV drugs. Food and Drug Administration. ( , 1996)

Research

Studies (1,992)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's176 (8.84)18.2507
2000's986 (49.50)29.6817
2010's749 (37.60)24.3611
2020's81 (4.07)2.80

Authors

AuthorsStudies
Janssen, PA1
Lewi, PJ1
Arnold, E2
Daeyaert, F1
de Jonge, M1
Heeres, J1
Koymans, L1
Vinkers, M1
Guillemont, J1
Pasquier, E1
Kukla, M1
Ludovici, D1
Andries, K1
de Béthune, MP3
Pauwels, R1
Das, K2
Clark, AD1
Frenkel, YV1
Hughes, SH1
Medaer, B1
De Knaep, F1
Bohets, H1
De Clerck, F1
Lampo, A1
Williams, P1
Stoffels, P1
Jorgensen, WL2
Ruiz-Caro, J2
Tirado-Rives, J1
Basavapathruni, A3
Anderson, KS3
Hamilton, AD2
Kim, JT1
Bailey, CM2
Wang, L7
Zhang, Z3
Xu, W2
Koh, YH1
Shim, JH1
Girardet, JL1
Yeh, LT1
Hamatake, RK1
Hong, Z2
Zhan, P12
Liu, X14
Cao, Y3
Wang, Y4
Pannecouque, C17
De Clercq, E14
Van Neck, T1
Vanstreels, E1
Stevens, M2
Dehaen, W1
Daelemans, D4
Fletcher, P1
Harman, S1
Azijn, H2
Armanasco, N1
Manlow, P1
Perumal, D1
Nuttall, J2
Romano, J1
Shattock, R1
Varghese, V2
Mitsuya, Y1
Shahriar, R1
Bachmann, MH1
Fessel, WJ2
Kagan, RM2
Shafer, RW7
Fang, Z2
Li, Z2
Tirry, I1
Vingerhoets, J1
Kraus, G1
Boven, K1
Jochmans, D1
Van Craenenbroeck, E1
Picchio, G1
Rimsky, LT1
Maïga, AI2
Descamps, D4
Morand-Joubert, L7
Malet, I1
Derache, A2
Cisse, M2
Koita, V1
Akonde, A1
Diarra, B1
Wirden, M2
Tounkara, A2
Verlinden, Y1
Katlama, C12
Costagliola, D7
Masquelier, B6
Calvez, V9
Marcelin, AG7
Xue, H1
Lu, X5
Zheng, P2
Liu, L3
Han, C1
Hu, J1
Liu, Z5
Ma, T1
Li, Y6
Chen, Z5
Liu, G3
Gatanaga, H5
Ode, H1
Hachiya, A4
Hayashida, T1
Sato, H1
Oka, S8
Chauthe, SK1
Bharate, SB1
Sabde, S1
Mitra, D1
Bhutani, KK1
Singh, IP1
Gupta, S1
Fransen, S2
Paxinos, EE1
Stawiski, E1
Huang, W3
Petropoulos, CJ2
Qin, B1
Jiang, X2
Lu, H3
Tian, X1
Barbault, F1
Huang, L4
Qian, K1
Chen, CH2
Huang, R1
Jiang, S2
Lee, KH2
Xie, L1
Zeng, ZS1
He, QQ1
Liang, YH1
Feng, XQ1
Chen, FE1
Balzarini, J4
Casano, G1
Dumètre, A1
Hutter, S1
Azas, N1
Robin, M1
Banerjee, D1
Yogeeswari, P1
Bhat, P1
Thomas, A1
Srividya, M1
Sriram, D1
He, YP1
Long, J1
Zhang, SS1
Li, C2
Lai, CC1
Zhang, CS1
Li, DX1
Zhang, DH1
Wang, H2
Cai, QQ1
Zheng, YT1
Chen, X6
Li, X6
Li, D3
Tian, Y5
Chen, W5
Kim, J2
Park, C1
Ok, T1
So, W1
Jo, M1
Seo, M1
Kim, Y1
Sohn, JH1
Park, Y1
Ju, MK1
Han, SJ1
Kim, TH1
Cechetto, J1
Nam, J1
Sommer, P1
No, Z1
Clercq, ED1
Parrish, J1
Tong, L1
Wang, M2
Lansdon, EB1
Cannizzaro, C1
Zheng, X1
Desai, MC1
Xu, L2
Liu, H4
Rai, D1
Zhang, L6
Guo, J2
Patel, RV1
Park, SW1
Yang, J2
Kang, D4
Huang, B3
Devale, TL1
Parikh, J1
Miniyar, P1
Sharma, P1
Shrivastava, B1
Murumkar, P1
Curreli, F1
Kwon, YD1
Belov, DS1
Ramesh, RR1
Kurkin, AV1
Altieri, A1
Kwong, PD1
Debnath, AK1
Xue, P1
Lu, HH1
Zhu, YY1
Ju, XL1
Zheng, XJ1
Liu, GY1
Zhang, XL1
Gu, SX1
Zhang, H5
Xu, H2
Huo, Z1
Zhou, Z1
Yu, Z1
Meng, Q1
Wu, G1
Ding, X1
Liu, J6
Namasivayam, V1
Vanangamudi, M1
Kramer, VG1
Kurup, S1
Kongsted, J1
Byrareddy, SN1
Sang, Y1
Han, S1
Zhuang, C1
Chen, F1
Zhu, M1
Ma, L3
Wen, J2
Dong, B1
Wang, Z7
Zhou, J3
Zhang, G2
Wang, J5
Guo, Y2
Liang, C1
Cen, S1
Cherukupalli, S1
Xie, M1
Wang, W7
Jia, R1
Boyce, CL1
Sils, T1
Ko, D1
Wong-On-Wing, A1
Beck, IA8
Styrchak, SM1
DeMarrais, P1
Tierney, C4
Stranix-Chibanda, L9
Flynn, PM3
Taha, TE23
Owor, M8
Fowler, MG44
Frenkel, LM14
Bart, G4
Giang, LM4
Yen, H1
Hodges, JS1
Brundage, RC5
Kwara, A3
Pressiat, C1
Toni, TD3
Treluyer, JM6
Yonaba, C1
Dahourou, DL1
Malateste, K1
Seguin-Devaux, C2
Leroy, V13
Hirt, D4
Ngayo, MO2
Oluka, M1
Bulimo, WD1
Okalebo, FA1
Chaúque, S1
Mohole, J1
Zucula, H1
Lambo, L1
Lisboa, A1
Ferreira, D1
Nguyen, H1
Chowdhary, H1
Macmillian, B1
Elias, B1
Seni, A1
Buck, WC3
Dollfus, C2
Le Chenadec, J1
Mandelbrot, L2
Tubiana, R2
Faye, A4
Brossard, M1
Frange, P2
Blanche, S5
Warszawski, J1
Cuco, RM1
Loquiha, O1
Juga, A1
Couto, A2
Meggi, B3
Vubil, A1
Sevene, E1
Osman, N2
Temermam, M1
Degomme, O1
Sidat, M2
Bhatt, N3
Abdullahi, ST2
Soyinka, JO2
Bolarinwa, RA2
Olarewaju, OJ2
Salami, AK1
Bakare-Odunola, MT2
Scheibe, K1
Urbańska, A1
Jakubowski, P1
Hlebowicz, M1
Bociąga-Jasik, M1
Raczyńska, A1
Szymczak, A1
Szetela, B1
Łojewski, W1
Parczewski, M2
Maseng, MJ1
Tawe, L2
Thami, PK1
Moyo, S8
Kasvosve, I2
Novitsky, V8
Essex, M17
Russo, G3
Gaseitsiwe, S4
Paganotti, GM2
Opoku, S1
Sakyi, SA1
Ayisi-Boateng, NK1
Enimil, AK1
Senu, E1
Ansah, RO1
Aning, BD1
Ojuang, DA1
Wekesa, DN1
Ahmed, FO1
Okeke, CB1
Sarfo, AD1
Chua, KY1
Tey, KE1
Pham, MM1
Podany, AT4
Mwelase, N3
Supparatpinyo, K4
Mohapi, L4
Gupta, A10
Samaneka, W2
Omoz-Oarhe, A2
Langat, D2
Benson, CA4
Chaisson, RE6
Swindells, S3
Fletcher, CV4
Liyanage, M1
Nikanjam, M2
McFadyen, L1
Vourvahis, M1
Rogg, L1
Moye, J6
Chadwick, EG2
Jean-Philippe, P7
Mirochnick, M23
Whitson, K1
Bradford, S1
Capparelli, EV9
Best, BM1
Adedeji, TA1
Adedeji, NO1
Ajeigbe, AK1
Smith, OS1
Jeje, OA1
Fawale, MB1
Ajose, AO1
Adebisi, SA1
Akande, AA1
Okesina, BA1
Stalter, RM2
Amorim, G1
Mocello, AR1
Jakait, B2
Shepherd, BE2
Musick, B1
Bernard, C1
Bukusi, EA4
Wools-Kaloustian, K4
Cohen, CR6
Yiannoutsos, CT3
Patel, RC5
Kurogi, K1
Segawa, K1
Sakakibara, Y1
Suiko, M1
Uetrecht, J2
Liu, MC1
Lubega, J1
Kim, TO1
Airewele, G1
Grimes, A1
Bulsara, S1
Peckham, E1
Wanless, SR1
Haq, H1
Elyanu, P1
Musoke, P42
Lumumba, M1
Kekitiinwa, A8
Matshaba, M1
Scheurer, M1
Despotovic, J1
Mukhatayeva, A1
Mustafa, A1
Dzissyuk, N1
Issanov, A1
Mukhatayev, Z1
Bayserkin, B1
Vermund, SH16
Ali, S1
Jao, J4
Sun, S1
Bonner, LB1
Legbedze, J1
Mmasa, KN1
Makhema, J13
Mmalane, M1
Kgole, S1
Masasa, G1
Gerschenson, M2
Mohammed, T3
Abrams, EJ26
Kurland, IJ3
Geffner, ME3
Powis, KM2
Kay, K1
Goodwin, J1
Ehrlich, H1
Ou, J1
Freeman, T1
Wang, K1
Li, F1
Wade, M1
French, J1
Aweeka, F4
Mwebaza, N1
Kajubi, R1
Riggs, M1
Ruiz-Garcia, A1
Parikh, S4
Penda, CI1
Moukoko Mbonjo, M1
Fokam, J2
Djeuda, ABD1
Grace, N1
Ateba Ndongo, F1
Bilong, S1
Eyoum Bille, B1
Koki Ndombo, P1
Aghokeng, A2
Ndjolo, A2
Eboumbou Moukoko, CE1
Namara-Lugolobi, E1
Namukwaya, Z3
Ouma, J1
Namale-Matovu, J1
Nakabiito, C15
Ndugwa, C1
Jaber, M3
Korthuis, PT3
Omondi, EO1
Muigai, A1
Mungiria, J1
Lihana, R1
Kunene, PN1
Mahlambi, PN1
Chen, M1
Wu, M1
Zeng, L1
Zhang, Y2
Huobu-Mo, M1
Li, J4
Xiao, H1
Ajibola, G2
Maswabi, K2
Hughes, MD19
Bennett, K2
Pretorius-Holme, M1
Batlang, O2
Sakoi, M2
Ricci, L1
Lockman, S29
Kuritzkes, DR5
Lichterfeld, M2
Shapiro, RL12
Penazzato, M6
Kasirye, I1
Ruel, T4
Mukui, I1
Bekker, A1
Archary, M2
Essajee, S3
Siberry, GK4
Mahy, M1
Simnoue, D1
Simione, B1
Zech, JM1
Mushavi, A2
Do, NT1
Boupha, P1
Newton, PN1
Caillet, C1
Ngwenya, N1
Mahlambi, P1
Elwitigala, J1
Rajapaksa, L1
Inzaule, SC1
Ariyaratne, KAM1
Jayasena, S1
Kurle, S1
Patil, A1
Kale, D1
Siriwardna, L1
Samaraweera, G1
Perera, H1
Jayakody, C1
de Wet, JJ1
Ban, JK1
Verdier, G1
Ling, J1
Eberg, M1
Bunko, A1
McKimm, M1
Vhembo, T2
Baltrusaitis, K1
Dadabhai, S1
Violari, A8
Theron, G5
Moodley, D16
Mukwasi-Kahari, C1
George, K7
Shepherd, J1
Browning, R3
Migeri, S1
Lawal, MA1
Hughes, JC1
Badza, T1
Abafe, OA1
Martincigh, BS1
Odindo, AO1
Tukei, VJ1
Herrera, N2
Masitha, M1
Masenyetse, L1
Mokone, M2
Maile, L1
Gill, MM1
Rattanabunyong, S1
Choengpanya, K1
Suwattanasophon, C1
Kiriwan, D1
Wolschann, P2
Lamtha, T1
Shaikh, AR1
Rattanasrisomporn, J1
Choowongkomon, K1
Weng, YW1
Chen, IT1
Tsai, HC3
Wu, KS1
Tseng, YT2
Sy, CL1
Chen, JK1
Lee, SS4
Chen, YS3
Boltz, VF4
Shao, W1
Bale, MJ1
Halvas, EK4
Luke, B1
McIntyre, JA10
Schooley, RT4
Currier, JS9
Sawe, F7
Hogg, E5
Kearney, MF2
Coffin, JM4
Mellors, JW7
Favarel-Garrigues, M1
Hentzien, M1
Berger, JL1
Brunet, A1
Bani-Sadr, F2
Larsen, A1
Magasana, V1
Dinh, TH2
Ngandu, N1
Lombard, C3
Cheyip, M1
Ayalew, K1
Chirinda, W1
Kindra, G1
Jackson, D3
Goga, A3
Onyango-Makumbi, C2
Owora, AH1
Mwiru, RS1
Mwatha, A18
Young, AM1
Coovadia, HM6
Manji, K4
Maldonado, Y6
Richardson, P5
Andrew, P3
Fawzi, W5
Hompe, ED1
Jacobson, DL1
Eudailey, JA1
Butler, K2
Edwards, W1
Pollara, J1
Brummel, SS1
Fouda, GG1
Chinula, L1
Kamanga, M1
Kinikar, A4
Permar, SR2
Engelbrecht, AE1
Wiesner, L11
Norman, J2
Rabie, H4
Decloedt, EH2
Venkatesh, KK4
Farhad, M1
Fenton, T5
Naik, S1
Fairlie, L3
Stringer, JSA1
Chi, BH19
Lanzafame, M8
Lattuada, E5
Vincenzi, M1
Vecchi, M1
Luise, D1
Diani, E1
Gibellini, D1
Couffignal, C1
Kolta, S1
Flamant, M1
Cazanave, C1
Haymann, JP1
Mentré, F3
Duval, X2
Leport, C2
Raffi, F25
Ogar, CK1
Abiola, A1
Yuah, D1
Ibrahim, A1
Oreagba, IA2
Amadi, EC1
Adeyeye, MC1
Oshikoya, KA2
Teshale, AB1
Tsegaye, AT1
Wolde, HF1
Hasan, M1
Yunihastuti, E3
Teguh H, K1
Abdullah, M1
Lallemant, M15
Amzal, B2
Sripan, P1
Urien, S4
Cressey, TR16
Ngo-Giang-Huong, N12
Klinbuayaem, V5
Rawangban, B1
Sabsanong, P3
Siriwachirachai, T1
Jarupanich, T2
Kanjanavikai, P2
Wanasiri, P1
Koetsawang, S4
Jourdain, G13
Le Coeur, S7
Zulu, SS1
Abboussi, O1
Simola, N1
Mabandla, MV1
Daniels, WMU1
Suryavanshi, N5
Kadam, A1
Gupte, N9
Hegde, A1
Kanade, S1
Sivalenka, S1
Kumar, VS1
Bollinger, RC6
Shankar, A2
McKenzie-White, J1
Mave, V3
De Benedetto, I1
Trunfio, M1
Guastamacchia, G1
Bonora, S6
Calcagno, A4
Haas, DW9
Bao, Y3
Baker, P1
Lain, MG1
Chicumbe, S1
de Araujo, AR1
Karajeanes, E1
Giaquinto, C5
Vaz, P2
Usman, SO1
Akinyede, AA1
Agbaje, EO1
Akinleye, MO1
Onwujuobi, AG1
Ken-Owotor, C1
Adeuja, O1
Ogunfowokan, T1
Kogbe, S1
Owolabi, ET1
Adeniji, H1
Busari, AW1
Hassan, OO1
Abideen, G1
Akanmu, AS1
Kahlert, CR2
Cipriani, M1
Vernazza, P3
Napyo, A1
Tylleskär, T1
Mukunya, D1
Tumuhamye, J1
Musaba, MW1
Ojok Arach, AA1
Waako, P1
Tumwine, JK2
Ndeezi, G1
Yoon, HY1
Cho, YA1
Yee, J1
Gwak, HS1
Rich, SN1
Cook, RL1
Yaghjyan, L1
Francois, K1
Puttkammer, N1
Robin, E1
Bae, J1
Joseph, N1
Pessoa-Brandão, L1
Delcher, C1
Mulisa, D1
Tolossa, T1
Wakuma, B1
Etafa, W1
Yadesa, G1
Bhattacharya, D1
Guo, R1
Tseng, CH1
Emel, L4
Sun, R1
Chiu, SH1
Chipato, T12
Mohtashemi, NZ1
Kintu, K1
Manji, KP1
Thio, CL2
Haas, AD1
Radin, E1
Hakim, AJ1
Jahn, A4
Philip, NM1
Jonnalagadda, S1
Saito, S1
Low, A1
Patel, H1
Schwitters, AM1
Rogers, JH1
Frederix, K2
Kim, E1
Bello, G2
Williams, DB1
Parekh, B1
Sachathep, K1
Barradas, DT1
Kalua, T1
Birhanu, S1
Musuka, G1
Mugurungi, O3
Tippett Barr, BA1
Sleeman, K1
Mulenga, LB1
Thin, K1
Ao, TT1
Brown, K1
Voetsch, AC1
Justman, JE1
Mehta, G1
Sharma, A1
Arora, SK1
Leon-Cruz, J1
Hakim, J6
Kanyama, C5
Waitt, C1
Myer, L1
Khoo, S20
Ruel, TD1
Nelson, BS1
Coletti, A1
Bryson, Y3
Cotton, MF8
Spector, SA8
LeBlanc, R1
Reding, C1
Zimmer, B2
Persaud, D5
Bwakura-Dangarembizi, M4
Naidoo, KL1
Hazra, R1
Celerino da Silva, R1
Segat, L1
Kuhn, L25
Chies, JAB1
Crovella, S1
Yang, H1
Chu, L1
Wu, Y2
Zhang, Q2
Qiao, S1
Shen, Z2
Zhou, Y2
Liu, S2
Deng, H2
Menegotto, M1
Magdaleno, AM1
da Silva, CLO1
Friedrich, L1
da Silva, CH1
Marinho, AT2
Batuca, JR1
Miranda, JP1
Caixas, U2
Dias, CG1
Branco, T2
Soto, K1
Pinheiro, P1
Bourbon, M1
Marques, MM4
Antunes, AM4
Monteiro, EC2
Pereira, SA2
Aguti, I1
Kimbugwe, C1
Apai, P1
Munyaga, S1
Nyeko, R1
Bitarakwate, E2
Ashburn, K1
Kazooba, P1
Khamasi, R1
Natumanya, E1
Owomugisha, B1
Malkin, RA2
Kisaakye, L1
Kubota Kilengelela, J1
Jarreau, PH1
Marcou, V1
Kebaya, LMN1
Wamalwa, D4
Kariuki, N1
Admani, B1
Ayieko, P1
Nduati, R1
Morales-Pérez, M1
Nibamureke, UMC1
Wagenaar, GM1
Verrest, L1
Wilthagen, EA1
Beijnen, JH19
Huitema, ADR1
Dorlo, TPC1
Cababasay, M1
Mofenson, LM24
Fiscus, S6
Coutsoudis, A4
Gnanashanmugam, D2
Chakhtoura, N1
McCarthy, K1
Frenkel, L4
Beck, I2
Mukuzunga, C1
Makanani, B1
Nematadzira, T2
Kusakara, B2
Patil, S4
Bobat, R5
Mmbaga, BT4
Masenya, M1
Nyati, M1
Mulenga, H1
Shapiro, DE6
Afrane, AKA1
Goka, BQ1
Renner, L1
Yawson, AE1
Alhassan, Y1
Owiafe, SN1
Agyeman, S1
Sagoe, KWC1
Pinilla, M1
Aizire, J4
Chipoka, G1
Mallewa, M1
Naidoo, M1
Mbengeranwa, T2
Njau, B1
Mubiana-Mbewe, M1
Khadse, S3
Mechi, A1
Al-Khalidi, A1
Al-Darraji, R1
Al-Dujaili, MN1
Al-Buthabhak, K1
Alareedh, M1
Shaghee, F1
Nafakhi, H1
Neto, FR1
Dorneles, JR1
Carneiro Leão Veloso, JH1
Gonçalves, CW1
Gomes Costa, RR1
Velaer, KN1
Welk, B1
Ginsberg, D1
Myers, J1
Shem, K1
Elliott, C1
Shi, Y1
Meng, D1
Wang, S1
Geng, P1
Xu, T1
Zhou, Q1
Li, W2
Wakene, W1
Asmamaw, S1
Kahaliw, W1
Zenebe, E1
Washo, A1
Addis Gesese, A1
Halley, E1
Giai, J1
Chappuis, M1
Tomasino, A1
Henaine, R1
Letrilliart, L1
Nikolaus, S1
Wittsack, HJ1
Antke, C1
Beu, M1
Hautzel, H1
Decheva, C1
Mamlins, E1
Mori, Y1
Huston, JP1
Antoch, G1
Müller, HW1
Li, R1
Qi, Y1
Shi, L1
Zhang, A1
Luo, Y1
Kung, WK1
Jiao, Z1
Li, H3
Dalkner, N1
Bengesser, SA1
Birner, A1
Fellendorf, FT1
Fleischmann, E1
Großschädl, K1
Lenger, M1
Maget, A1
Platzer, M1
Queissner, R1
Schönthaler, E1
Tmava-Berisha, A1
Reininghaus, EZ1
Sun, Y1
Song, Z1
Zheng, W1
Xiong, W1
Yang, Y3
Yuan, L1
Chiu, PY1
Wei, CY1
Hung, GU1
Wu, SL1
Qi, Z1
Cao, F1
Zhao, L1
Fang, X1
Lu, Y1
Chen, H2
Zhang, J4
Tang, B1
Ma, C1
Tang, X1
Li, L3
Wu, J1
Wei, J1
Li, S1
Yang, L1
Han, L1
Lu, C1
Jin, G1
Yao, K1
Chang, R1
Zhu, Z3
Jin, X2
Yin, J1
Zhu, H1
Yu, K1
Liu, M4
Zhang, X2
Lu, M3
Wan, Z1
Huang, X2
Hu, S1
Liu, Y2
Huang, J2
Hong, W1
Fang, J1
Kulikov, A1
Shipaeva, E1
Dmitrieva, A1
Batrak, V1
Shipunov, G1
Guy, C1
Smith, J1
Zhang, R1
Zhang, M2
Duan, J2
Chestukhin, A1
Barbashov, S1
Samsonov, M1
Lavrovsky, Y1
Qu, Q1
Cui, W1
Xing, X1
Zou, R1
Wang, X4
Wu, T1
Bello-Onaghise, G1
Yuan, S1
Li, T4
Wang, PJ1
Zhang, ZW1
Huang, JQ1
Elzayat, MT1
Markofski, MM1
Simpson, RJ1
Laughlin, M1
LaVoy, EC1
Ntamatungiro, AJ1
Muri, L1
Glass, TR1
Erb, S2
Battegay, M7
Furrer, H4
Hatz, C2
Tanner, M2
Felger, I1
Klimkait, T2
Letang, E2
Lee, CY1
Chang, HM2
Kunin, CM1
Girma, M1
Wendaferash, R1
Shibru, H1
Berhane, Y1
Hoelscher, M1
Kroidl, A1
Murnane, PM1
Strehlau, R10
Shiau, S6
Patel, F5
Mbete, N1
Hunt, G8
Coovadia, A14
McIlleron, H11
Denti, P4
Cohn, S1
Mashabela, F1
Hoffmann, JD1
Shembe, S1
Msandiwa, R1
Velaphi, S2
Lala, SG2
Martinson, N7
Dooley, KE3
Punyawudho, B2
Saenjum, C1
Jittayanun, K1
Phanomcheong, S1
Luvira, A1
Borkird, T1
Puangsombat, A1
Aarons, L1
Sukrakanchana, PO1
Bhat, J1
Bharadwaj, R3
Kulkarni, V4
Bhosale, R6
McIntire, KN1
Bollinger, R2
Szubert, AJ2
Spyer, M3
Katuramu, R1
Musiime, V6
Mhute, T1
Bakeera-Kitaka, S2
Senfuma, O1
Walker, AS23
Gibb, DM27
Morroni, C1
Scarsi, KK11
Sripipatana, T2
Kiarie, J6
Svärd, J1
Mugusi, S1
Mloka, D1
Neogi, U1
Meini, G1
Mugusi, F1
Incardona, F1
Zazzi, M2
Sönnerborg, A2
Tu, W2
Nyandiko, WM3
Slaven, JE2
Scanlon, ML3
Ayaya, SO3
Vreeman, RC3
Mukeba-Tshialala, D2
Nachega, JB5
Mutombo-Tshingwali, M1
Arendt, V4
Gilson, G1
Moutschen, M3
Birlie, B1
Braekers, R1
Awoke, T1
Kasim, A3
Shkedy, Z2
Calza, L8
Magistrelli, E2
Colangeli, V3
Borderi, M2
Bussini, L1
Bon, I1
Re, MC2
Viale, P2
Chappell, CA2
Lamorde, M10
Nakalema, S3
Chen, BA2
Mackline, H1
Riddler, SA1
Cohn, SE4
Darin, KM6
Achilles, SL2
Canals, F1
Masiá, M1
Gutiérrez, F2
Dow, DE3
Schimana, W7
Nyombi, BM1
Shayo, AM1
Bartlett, JA7
Massambu, CG2
Kifaro, EG1
Turner, EL1
DeMarco, T1
Cai, F2
Cunningham, CK8
Buchanan, AM2
Gopalan, BP1
Mehta, K1
D'souza, RR1
Rajnala, N1
A K, HK1
Ramachandran, G11
Shet, A2
Ayele, TA1
Worku, A1
Kebede, Y1
Alemu, K1
Mwau, M1
Bwana, P1
Kithinji, L1
Ogollah, F1
Ochieng, S1
Akinyi, C1
Adhiambo, M1
Ogumbo, F1
Sirengo, M1
Boeke, C1
De Luca, A5
Sidumo, ZJ1
Zanelli, G1
Magid, NA3
Luhanga, R3
Brambilla, D1
Liotta, G9
Mancinelli, S9
Marazzi, MC14
Palombi, L14
Ceffa, S4
Kirmse, B3
Yu, C2
Epie, F2
Nshom, E2
Sperling, RS3
Leroith, D2
Côté, HCF1
Eloy, P1
Tessier, A1
Fan-Havard, P4
Chou, M4
Verstuyft, C5
Taburet, AM8
Bertrand, J3
Padmapriyadarsini, C6
Ramesh, K4
Sekar, L1
Reddy, D1
Narendran, G7
Sekar, S1
Chandrasekar, C2
Anbarasu, D1
Wanke, C4
Swaminathan, S15
Nakku, D1
Nyaiteera, V1
Llowet, E1
Nanseera, D1
Nakalema, G1
Westerberg, B1
Bajunirwe, F6
Boyd, MA2
Cooper, DA11
Gilks, CF10
Su, S1
Fairley, CK1
Sasadeusz, J1
He, J1
Wei, X2
Zeng, H1
Jing, J1
Mao, L1
Dimala, CA1
Bechem, NN1
Aroke, D1
Kadia, BM1
Tanuma, J2
Matsumoto, S1
Haneuse, S1
Cuong, DD2
Vu, TV1
Thuy, PTT1
Dung, NT1
Dung, NTH1
Trung, NV1
Kinh, NV1
Sinha, S2
Gupta, K1
Tripathy, S5
Dhooria, S2
Ranjan, S2
Pandey, RM2
Cook, RR1
Peltzer, K3
Weiss, SM1
Rodriguez, VJ1
Jones, DL1
Sousa, MJ1
Cadinha, S1
Mota, M1
Teixeira, T1
Malheiro, D1
Moreira da Silva, JP1
Popoola, TD1
Awodele, O2
Castelnuovo, B6
Mubiru, F2
Kiragga, AN2
Musomba, R1
Mbabazi, O1
Gonza, P1
Kambugu, A6
Ratanshi, RP1
Tchetnya, X1
Ngwasiri, CA1
Munge, T1
Aminde, LN1
Sikhondze, N1
Mahomed, OH1
Diphoko, T1
Okatch, H1
Musonda, R2
Wainberg, M1
Marlink, R3
Ciccacci, C4
Politi, C1
Ciccacci, F1
Lucaroni, F1
Novelli, G5
Borgiani, P5
Bokore, A1
Korme, B1
Bayisa, G1
Veroniki, AA1
Antony, J2
Straus, SE1
Ashoor, HM1
Finkelstein, Y1
Khan, PA1
Ghassemi, M1
Blondal, E1
Ivory, JD1
Hutton, B1
Gough, K2
Hemmelgarn, BR1
Lillie, E1
Vafaei, A1
Tricco, AC1
Piacentini, D1
Rizzardo, S1
Chiesi, S1
Vento, S4
Chang, JL1
Tsai, AC1
Musinguzi, N1
Haberer, JE2
Boum, Y1
Muzoora, C1
Bwana, M1
Martin, JN4
Hunt, PW3
Bangsberg, DR6
Siedner, MJ1
Duthaler, U1
Berger, B1
Gaugler, S1
Natamatungiro, A1
Mnzava, D1
Donzelli, M1
Krähenbühl, S1
Haschke, M1
Ahir-Bist, S1
Chavan, V1
Samant-Mavani, P1
Nanavati, R1
Mehta, P1
Mania-Pramanik, J1
Nkenfou, CN1
Temgoua, ES1
Ndzi, EN1
Mekue, LCM1
Ngoufack, MN1
Dambaya, B1
Anoubissi, JD1
Domkam, I1
Elong, E1
Fainguem, N1
Thèze, J1
Colizzi, V2
Bissek, ACZK1
Nasuuna, E1
Kigozi, J4
Babirye, L1
Muganzi, A2
Sewankambo, NK2
Nakanjako, D2
Haaland, RE1
Otieno, K1
Martin, A1
Katana, A1
Dinh, C1
Slutsker, L1
Menendez, C2
Gonzalez, R1
Williamson, J1
Heneine, W6
Desai, M1
Anugulruengkitt, S2
Suntarattiwong, P2
Ounchanum, P2
Srirompotong, U2
Jantarabenjakul, W2
Sophonphan, J2
Tawon, Y3
Punnahitanon, S2
Pancharoen, C3
Chokephaibulkit, K10
Puthanakit, T6
Saka, B4
Akakpo, AS1
Bassowa, A1
Dapam, AN1
Mahamadou, G1
Teclessou, JN1
Mouhari-Toure, A5
Laouali, AY1
Mensah, E1
Kombaté, K3
Pitché, P6
Ogalo, EA1
Adina, JO1
Ooko, H1
Batuka, J1
Kimaiyo, S3
Aliu, R1
Ali, I1
Oni, Y1
Adeyeye, CM1
Singh, H1
Lata, S1
Gangakhedkar, RR2
Bila, D1
Auld, A1
Houston, J1
Cossa, L1
Alfredo, C1
Jobarteh, K1
Sabatier, J1
Macassa, E1
Sousa, A1
DeVos, J1
Jani, I2
Yang, C2
Ramalingam, VV1
Demosthenes, JP1
Ghale, BC1
Rupali, P1
Varghese, GM1
Abraham, OC1
Kannangai, R1
Giacomelli, A1
Riva, A1
Falvella, FS1
Oreni, ML1
Cattaneo, D2
Cheli, S1
Renisi, G1
Di Cristo, V1
Lupo, A1
Clementi, E2
Rusconi, S2
Galli, M1
Ridolfo, AL1
Olagunju, A2
Owen, A7
Allavena, C15
Volteau, C1
André-Garnier, E4
Guimard, T1
Hall, N2
Khatchatourian, L1
Morrier, M1
Billaud, E8
Rodallec, A3
Reliquet, V15
Jovelin, T1
Le Guen, L1
Perré, P8
Grégoire, M2
Liu, JX1
Shen, J1
Wilson, N1
Janumpalli, S1
Stadler, P1
Padian, N1
Guo, G1
Zheng, J1
Lu, L1
Sterrantino, G1
Borghi, V1
Callegaro, AP1
Bruzzone, B1
Saladini, F1
Maggiolo, F3
Maffongelli, G2
Andreoni, M3
De Gennaro, M1
Gianotti, N3
Bagnarelli, P1
Vergori, A1
Antinori, A5
Zaccarelli, M4
Mohamed Saleem, TS1
Jyothi, K1
Babu, SC1
Chendi, BH1
Okomo Assoumou, MC1
Jacobs, GB1
Yekwa, EL1
Lyonga, E1
Mesembe, M1
Eyoh, A1
Ikomey, GM1
O'Donnell, MR1
Padayatchi, N1
Daftary, A1
Orrell, C2
Rivet Amico, K1
Friedland, G1
Ji, S1
Xu, Y1
Han, D1
Peng, X1
Brockmeyer, NH3
Wu, N1
Britto, GR1
Augustine, M1
Luo, XL1
Mo, LD1
Su, GS1
Huang, JP1
Wu, JY1
Su, HZ1
Huang, WH1
Luo, SD1
Ni, ZY1
Potty, RS1
Sinha, A1
Sethumadhavan, R1
Isac, S1
Washington, R1
Notter, J1
Bregenzer, A1
Apangu, P1
Izudi, J2
Mulogo, E1
Batwala, V1
Shiferaw, MB1
Endalamaw, D1
Hussien, M1
Agegne, M1
Amare, D1
Estifanos, F1
Temesgen, D1
Paximadis, M2
Burke, M2
Technau, KG2
Sherman, GG5
Ledwaba, J3
Mazanderani, AH2
Tiemessen, CT5
Sudjaritruk, T1
Boettiger, DC2
Nguyen, LV1
Mohamed, TJ1
Wati, DK1
Bunupuradah, T4
Hansudewechakul, R1
Ly, PS1
Lumbiganon, P2
Nallusamy, RA1
Fong, MS1
Nik Yusoff, NK1
Truong, KH1
Do, VC1
Sohn, AH1
Sirisanthana, V6
Murray, TY1
Snyman, T1
George, J1
Avenant, T1
Goga, AE2
Pepper, MS2
du Plessis, N1
Thomas, K1
Yiannoutsos, C1
Onono, M2
Wools-Kaloustian, KK1
Omooja, J1
Nannyonjo, M1
Sanyu, G1
Nabirye, SE1
Nassolo, F1
Lunkuse, S1
Kapaata, A1
Segujja, F1
Kateete, DP1
Ssebaggala, E1
Bbosa, N1
Aling, E1
Nsubuga, RN1
Kaleebu, P8
Ssemwanga, D1
Hu, K1
Xiang, Q1
Mu, GY1
Ma, LY1
Xie, QF1
Chen, SQ1
Zhou, S1
Zhang, XD1
Cui, YM1
Neary, M2
Matovu, J2
Siccardi, M4
Thomas, KK1
Tamraz, B1
Blue, SW1
Erikson, DW1
Kim, CJ1
Kelly, EJ1
Nanda, K2
Kourtis, AP9
Lingappa, JR1
Mugo, N1
Baeten, JM1
Mwansa-Kambafwile, J1
van der Walt, JS3
Smith, P5
Rangaka, M1
Wilkinson, RJ2
Maartens, G14
Prendergast, AJ3
Hermans, SM1
Manabe, YC1
Hoepelman, AI1
Lange, JM38
van Leth, F13
Ton, Q1
Bonnet, M3
Baudin, E3
Silva, C2
Michon, C1
Ciaffi, L6
Sobry, A1
Bastos, R1
Nunes, E1
Rouzioux, C8
Calmy, A10
Bayonne Kombo, ES1
Gathse, A1
Frank, M3
Harms, G10
Kunz, A10
Kloft, C3
Meng, X1
Howarth, A1
Earnshaw, CJ1
Jenkins, RE1
French, NS1
Back, DJ13
Naisbitt, DJ1
Park, BK1
Reynolds, HW2
Gachuno, O1
Kayita, J2
Hays, MA1
Otterness, C1
Rakwar, J1
Tapsfield, J1
Mathews, T1
Lungu, M1
van Oosterhout, JJ11
Ling, Y1
Barrail-Tran, A3
Darak, S1
Darak, T1
Kulkarni, S3
Parchure, R1
Hutter, I1
Janssen, F1
Wang, R2
Weng, J1
Pain, D1
Barr, CD1
Maruapula, D1
Mongwato, D1
Iqbal, HS1
Solomon, SS1
Saravanan, S1
Vidya, M1
Kumarasamy, N12
Solomon, S6
Balakrishnan, P5
Audureau, E2
Kahn, JG4
Besson, MH2
Saba, J2
Ladner, J2
Lilian, RR1
Kalk, E1
Kiage, JN1
Heimburger, DC1
Nyirenda, CK1
Wellons, MF1
Bagchi, S1
Koethe, JR1
Arnett, DK1
Kabagambe, EK1
Fillekes, Q5
Mulenga, V11
Kabamba, D7
Kankasa, C14
Thomason, MJ4
Cook, A6
Chintu, C8
Burger, DM21
Bannaga, A1
Rahama, O1
Barlow, G1
Lowenthal, ED1
Ellenberg, JH1
Machine, E1
Sagdeo, A1
Boiditswe, S1
Steenhoff, AP1
Rutstein, R1
Anabwani, G3
Gross, R1
Holmes, D1
Patel, K3
Panchasara, A1
Purohit, B1
Tripathi, CB1
Pombo, M1
Olalla, J1
Del Arco, A1
De La Torre, J3
Urdiales, D1
Aguilar, A1
Prada, JL1
García-Alegría, J1
Ruiz-Mateas, F1
Taverne, B1
Desclaux, A1
Koita Fall, MB1
Delaporte, E8
Ndoye, I3
Otegbayo, JA1
Kuti, MA1
Ogunbode, O1
Irabor, AE1
Adewoles, IF1
Balkus, JE1
Richardson, BA10
Mochache, V1
Chohan, V1
Chan, JD1
Masese, L2
Shafi, J1
Marrazzo, J1
Farquhar, C5
McClelland, RS2
Vardhanabhuti, S1
Acosta, EP10
Ribaudo, HJ3
Severe, P1
Lalloo, U1
Taulo, F2
Kabanda, J3
Oneko, O1
Ive, P1
Sambarey, P2
Chan, ES2
Hitti, J9
Hong, F3
McMahon, D1
Tang, MW2
Rhee, SY3
Bertagnolio, S1
Ford, N6
Holmes, S1
Sigaloff, KC2
Hamers, RL3
de Wit, TF3
Fleury, HJ6
Kanki, PJ4
Ruxrungtham, K11
Hawkins, CA1
Wallis, CL2
Stevens, W2
van Zyl, GU4
Manosuthi, W28
Hosseinipour, MC11
Belec, L2
Peeters, M2
Burda, S1
Cane, P1
Cappelli, G1
Charpentier, C2
Dagnra, AY1
Deshpande, AK1
El-Katib, Z1
Eshleman, SH39
Gody, JC2
Katzenstein, D2
Koyalta, DD1
Kumwenda, JJ4
Lynen, L5
Marconi, VC2
Margot, NA1
Moussa, S1
Ndung'u, T4
Nyambi, PN1
Schapiro, JM2
Schuurman, R5
Sirivichayakul, S3
Smith, D3
Zolfo, M2
Jordan, MR1
Kyaw, NL2
Thanachartwet, V2
Kiertiburanakul, S13
Desakorn, V4
Chamnanchanunt, S1
Chierakul, W1
Pitisuttithum, P5
Sungkanuparph, S25
Abgrall, S4
Ingle, SM1
May, MT1
Mercie, P1
Cavassini, M3
Reekie, J2
Samji, H1
Gill, MJ2
Crane, HM2
Tate, J1
Sterling, TR2
Reiss, P27
Saag, MS4
Mugavero, MJ1
Phillips, A3
Manzardo, C1
Wasmuth, JC2
Stephan, C2
Guest, JL1
Gomez Sirvent, JL1
Sterne, JA1
Werayingyong, P1
Phanuphak, N5
Tantivess, S1
Kullert, N1
Tosanguan, K1
Butchon, R1
Voramongkol, N1
Boonsuk, S1
Pilasant, S1
Kulpeng, W1
Teerawattananon, Y2
Loutfy, MR1
Walmsley, SL1
Klein, MB1
Raboud, J2
Tseng, AL1
Blitz, SL1
Pick, N1
Conway, B9
Angel, JB1
Rachlis, AR1
Cohen, J6
Haase, D1
Burdge, D1
Smaill, FM1
de Pokomandy, A1
Loemba, H1
Trottier, S1
la Porte, CJ1
Vispo, E2
Fernández-Montero, JV1
Labarga, P3
Barreiro, P7
Soriano, V15
Cruciani, M1
Mengoli, C1
Serpelloni, G1
Parisi, SG2
Malena, M1
Bosco, O1
Dziuban, EJ1
Hughey, AB1
Stewart, DA1
Blank, DA1
Kochelani, D1
Draper, HR1
Schutze, GE2
Mghamba, FW1
Minzi, OM5
Massawe, A1
Sasi, P1
Chijioke-Nwauche, I1
van Wyk, A1
Nwauche, C1
Beshir, KB1
Kaur, H1
Sutherland, CJ1
Di Fusco, D1
Zimba, I2
Erba, F1
Bendle, M1
Bajpai, S1
Choudhary, A2
Pazare, A1
Bach-Ngohou, K1
Sécher, S2
Dejoie, T1
Fakhouri, F1
Watts, DH9
Brown, ER6
Herron, C1
Reddy, L1
Zwerski, S7
Coovadia, H8
Fowler, M1
Gupta-Wright, A1
Wood, R10
Bekker, LG1
Lawn, SD1
Takuva, S1
Evans, D1
Zuma, K1
Okello, V1
Louwagie, G1
Baffoin, S1
Ferré, V5
Muro, EP4
Chunda, C1
Aitken, S1
Kisanga, ER3
Geretti, AM5
Fox, Z1
Johnson, JA6
Booth, C1
Lipscomb, J2
Stuyver, LJ1
Tachedjian, G3
Baxter, J1
Touloumi, G1
Lehmann, C1
Pillay, P1
Shubber, Z2
Ferrand, RA1
Hobbs, CV2
De La Vega, P1
Penzak, SR2
Van Vliet, J1
Krzych, U1
Sinnis, P1
Borkowsky, W2
Duffy, PE2
Cohan, D1
Mwesigwa, J1
Natureeba, P1
Aliba Luwedde, F1
Ades, V1
Plenty, A2
Kakuru, A3
Achan, J3
Clark, T1
Osterbauer, B1
Kamya, M4
Havlir, D9
Salazar, MG1
Gao, F1
Learn, GH1
Kalilani, L1
Hahn, BH1
Shaw, GM2
Salazar-Gonzalez, JF1
Saxon, CJ1
Helbert, MR1
Komolafe, AJ1
Higgins, SP1
Dube, N1
Adewusi, E1
Summers, R1
Nii-Trebi, NI1
Ibe, S1
Barnor, JS1
Ishikawa, K1
Brandful, JA1
Ofori, SB1
Yamaoka, S1
Ampofo, WK1
Sugiura, W3
Gedefaw, L1
Yemane, T1
Sahlemariam, Z1
Yilma, D2
Micheli, JE1
Chinn, LW2
Shugarts, SB1
Patel, A1
Kroetz, DL2
Manasa, J1
Lessells, RJ1
Skingsley, A1
Naidu, KK1
Newell, ML15
McGrath, N1
de Oliveira, T2
Sarfo, FS1
Sarfo, MA1
Phillips, R1
Booth, M1
Chadwick, D1
Bock, P1
Fatti, G1
Grimwood, A1
Frassetto, L1
Floren, L1
Barin, B1
Browne, M1
Wolfe, A1
Roland, M1
Stock, P1
Carlson, L1
Christians, U1
Benet, L1
Blanco, J1
Gunda, DW1
Kasang, C1
Kidenya, BR1
Kabangila, R1
Mshana, SE1
Kidola, J1
Kalluvya, SE1
Kongola, GW1
Klinker, H7
Delany-Moretlwe, S1
Dubé, K1
Lendvay, A1
Kwok, C1
Molife, L1
Nakubulwa, S1
Edward, VA1
Mpairwe, B1
Mirembe, FM1
León, W1
McIlroy, D1
Kawalec, P1
Kryst, J1
Mikrut, A1
Pilc, A1
Bhavani, PK2
Tang, A1
Kumar, H1
Ponnuraja, C3
Hannah, E1
Ramesh, C1
Donnell, D6
Mmiro, F28
Allen, M5
Jackson, JB39
Guay, LA26
Raghunandan, P1
Chandrashekhar, R1
Sharma, SK1
Kumar, S1
Ekka, M1
Velpandian, T2
Ahmad, H1
Samantaray, JC1
Venkatesh, S1
Rewari, BB4
Khan, NH1
Chirouze, C1
Muret, P1
Peytavin, G14
Bettinger, D2
Hoen, B3
Fortes Déguénonvo, L1
Diop, SA1
Leye, MM1
Seydi, M2
Dieng, AB1
Bentaleb, H1
Diouf, A2
Lakhe, NA1
Ka, D1
Cisse, VM1
Dia Badiane, NM2
Manga, MN1
Ndour, CT2
Soumaré, M2
Diop, BM2
Sow, PS5
Gandhi, M7
Yang, Q2
Bacchetti, P6
Huang, Y4
Herron, CM1
Chetty, V2
Msweli, L2
Kisenge, R3
Brown, E3
Sartorius, BK1
Chersich, MF4
Mwaura, M1
Meda, N1
Temmerman, M6
Farley, TM1
Luchters, S2
Ramokolo, V2
Fadnes, LT1
Doherty, T4
Jackson, DJ1
Chhagan, M1
Van den Broeck, J1
Dickinson, L2
Chaponda, M5
Carr, DF4
Kumwenda, J4
Lalloo, DG5
Pirmohamed, M4
Heyderman, RS4
Khoo, SH7
Li, JZ2
George, L1
Ndaro, A1
Dolmans, W3
Shen, Y1
Qi, T1
Feiterna-Sperling, C2
Mompati, K1
Königs, C2
Mensa, FJ1
Sabo, JP3
Yong, CL5
MacGregor, TR6
Nguyen, T2
Quinson, AM3
Cain, LE1
Hernán, MA1
Perry, SH1
Swamy, P1
Preidis, GA1
Mwanyumba, A1
Motsa, N1
Sarero, HN1
Kayentao, K1
Guirou, EA1
Doumbo, OK1
Venkatesan, M1
Plowe, CV1
Parsons, TL4
Hendrix, CW1
Nyunt, MM1
Mwafongo, A1
Nkanaunena, K5
Zheng, Y8
Mulenga, L1
Siika, A5
Currier, J5
Hosseinipour, M4
Fehintola, FA1
Ma, Q3
Aweeka, FT5
Morse, GD5
Akinola, IT1
Adedeji, WA2
Lindegardh, N2
Tarning, J2
Ojengbede, O1
Adewole, IF2
Taiwo, B3
Murphy, RL11
Akinyinka, OO2
Ngemu, EK1
Khayeka-Wandabwa, C1
Kweka, EJ1
Choge, JK1
Anino, E1
Oyoo-Okoth, E1
Goel, R1
Rai, M1
Chakravarty, J1
Meena, LP1
Tiwary, NK1
Sundar, S1
Bharti, A1
Wattanakul, T1
Avihingsanon, A3
Martens, L5
Meredith, S1
Arpadi, SM1
Kumar, AK3
Rajesh, L3
Chandrasekharan, C1
Mora-Peris, B2
Watson, V2
Vera, JH1
Weston, R1
Waldman, AD1
Kaye, S1
Mackie, NE3
Back, D11
Winston, A5
van Griensven, J4
Phirum, L1
Choun, K2
Thai, S3
De Weggheleire, A1
Slyker, JA1
Casper, C1
Tapia, K4
Richardson, B3
Bunts, L1
Huang, ML1
Benki-Nugent, S4
John-Stewart, G5
Nyombi, B1
Shayo, A1
Musoke, R1
Feng, S1
Shaffer, D6
Moses, A1
Manicklal, S1
van Niekerk, AM1
Kroon, SM2
Hutto, C1
Novak, Z1
Pati, SK1
Chowdhury, N1
Hsiao, NY1
Boppana, SB1
Tudor-Williams, G6
Cahn, P10
Fourie, J1
Karatzios, C1
Dincq, S1
Opsomer, M1
Kakuda, TN1
Nijs, S1
Tambuyzer, L1
Tomaka, FL1
Micek, MA4
Dross, S3
Blanco, AJ4
Matunha, L3
Seidel, K3
Montoya, P4
Matediana, E2
Gantt, S3
Gloyd, S4
Landolt, NK2
Ubolyam, S2
Pinyakorn, S3
Kerr, S2
Ahluwalia, J2
Thongpaeng, P2
Thammajaruk, N2
Cremers, S1
Thomas, T2
Chaithongwongwatthana, S3
Ananworanich, J5
Tran, DA1
Wilson, DP1
Shakeshaft, A1
Ngo, AD1
Doran, C1
Kityo, C18
Goodall, RL5
Mambule, I3
Pillay, D9
Kasirye, R2
Mugyenyi, P9
Dunn, DT5
Bhatt, NB2
Barau, C1
Amin, A1
Furlan, V2
Grinsztejn, B4
Hickey, MD1
Salmen, CR1
Tessler, RA1
Omollo, D1
Magerenge, R1
Mattah, B1
Salmen, MR1
Zoughbie, D1
Fiorella, KJ1
Geng, E1
Njoroge, B1
Jin, C3
Baranyai, D1
Muro, E2
Gödtel-Armbrust, U1
Schirmer, MA1
Kisanga, E1
Diczfalusy, U1
Burger, D14
Wojnowski, L1
O'Brien, L1
Shaffer, N7
Sangrujee, N1
Abimbola, TO1
Andreotti, M8
Pirillo, MF6
Jere, H4
Maulidi, M1
Sagno, JB3
Amici, R6
Mancini, MG2
Gennaro, E1
Vella, S17
Giuliano, M8
Price, AJ1
Kayange, M2
Zaba, B1
Chimbwandira, FM1
Chirwa, Z2
Dasgupta, AN1
Katundu, C1
Saul, JL1
Glynn, JR2
Koole, O2
Crampin, AC2
Kayiwa, J4
Zangata, D1
Nansubuga, C1
Arach, B1
Kenny, J2
Wavamunno, P2
Komunyena, J1
Asiimwe, AR1
Mirembe, G2
Abongomera, G3
Walker, SA1
Klein, N2
Chetty, T1
Carter, RJ2
Bland, RM3
Gare, J1
Ryan, CE1
David, M1
Timbi, D1
Kaima, P1
Kombati, Z1
Imara, U1
Kelly-Hanku, A1
Siba, PM1
Crowe, SM1
Hearps, AC1
Mir, F1
Qamar, FN1
Baig-Ansari, N1
Abro, AG1
Abbas, SQ1
Kazi, MA1
Rizvi, A1
Zaidi, AK1
Mukherjee, A1
Singla, M1
Sirohiwal, A1
Vajpayee, M1
Singh, R1
Kabra, SK2
Lodha, R2
Muhindo, MK1
Ikilezi, G1
Arinaitwe, E1
Mwangwa, F1
Clark, TD1
Charlebois, E2
Rosenthal, PJ1
Kamya, MR4
Tappero, JW4
Dorsey, G3
Hamela, G1
Kabondo, C1
Tembo, T1
Zimba, C2
Kamanga, E1
Mofolo, I1
Bulla, B1
Sellers, C1
Nakanga, RC1
Lee, C2
Martinson, F4
Hoffman, I3
van der Horst, C9
Muhe, LM1
Tindyebwa, D1
Abrams, E2
Dang, N1
Sivakumaran, H2
Harrich, D2
Shaw, PN2
Coombes, AGA1
Guo, W1
Zhuang, D2
Jiao, L1
Gui, T1
Jia, L1
Maganda, BA3
Kamuhabwa, AA3
Ngasala, B1
Sasi, PG1
Dang, NT1
Davis-Poynter, N1
Coombes, AG1
Saegusa, T1
Di, C1
Chen, YQ2
Dailly, E8
Bonnet, B1
Pineau, S1
Boutoille, D1
Bouquié, R3
Raveleau, A1
Bouchez, S2
Keane, NM1
Pavlos, RK1
McKinnon, E1
Lucas, A1
Rive, C1
Blyth, CC1
Dunn, D5
Lucas, M1
Mallal, S3
Phillips, E5
Jiang, HY1
Zhang, MN1
Chen, HJ1
Deng, M1
Ruan, B1
Udomphanit, T1
Rattanamanee, S1
Harnlakorn, P1
Sopharak, C1
Sringam, J1
Anutchatchaval, S1
Tharnprisan, P1
Kosalaraksa, P1
Asmelash, A6
Kaloustian, KW1
Ogwu, A3
Salata, R3
de Waal, R2
Holgate, SL1
Horn, AR1
Tooke, LJ1
Blockman, M1
McIlleron, HM1
Cohen, K7
Houben, RM1
Mzembe, T1
Van Boeckel, TP1
Chimbwandira, F2
McCarthy, M2
Clumeck, N4
Mwamba, C1
Kabeya, K1
Matanda, S1
Vaira, D2
Necsoi, C1
Kadiebwe, D1
Delforge, M1
Kasamba, E1
Milolo, C1
Ilunga, J1
Kapend, L1
Crawford, KW1
Aoudjane, S1
González Del Castillo, AA1
O'Connor, J1
Noguera, M1
Beloukas, A2
Hopkins, M1
Svensson, EM2
Karlsson, MO3
Liechty, EA1
Busakhala, N1
Bartelink, IH2
Savic, RM2
Blaschke, TF1
Eshelman, C1
Langat, A2
Okinyi, HM1
Cornejo Castro, EM1
Jorgensen, AL2
Dandara, C3
Kampira, E2
Ssali, F11
Munderi, P12
Sigaloff, K1
Buzibye, A2
Merry, C9
Nakatudde-Katumba, L1
Ditangco, R3
Merati, TP3
Pham, TT1
Chaiwarith, R1
Li, CK1
Vonthanak, S1
Van Kinh, N1
Pujari, S3
Wong, WW1
Kamarulzaman, A4
Zhang, F2
Choi, JY1
Ng, OT1
Kantipong, P4
Mustafa, M1
Ratanasuwan, W3
Sohn, A1
Law, M2
Lindsey, JC4
Barlow-Mosha, L7
Kamthunzi, P5
Sambo, PM1
Moultrie, H3
Petzold, E4
Palumbo, P7
Alvarez-Uria, G1
Pakam, R1
Naik, PK1
Midde, M1
Mutsvangwa, J1
Gwanzura, L1
Manhanzva, MT1
da Silva, C1
Rokx, C1
Blonk, M1
Verbon, A1
Rijnders, BJ1
Mavura, DR1
Masenga, EJ1
Minja, E1
Grossmann, H1
Crump, JA2
Dross, SE1
Rossi, SS1
Seidel, KD1
Yang, CJ1
Chang, SY3
Lin, SW3
Tsai, MS1
Liu, WC2
Wu, PY2
Su, YC2
Luo, YZ2
Yang, SP2
Hung, CC3
Chang, SC2
Bhutia, E1
Hemal, A1
Yadav, TP1
Ramesh, KL1
Gallien, S1
Charreau, I1
Nere, ML1
Mahjoub, N1
Simon, F1
de Castro, N1
Aboulker, JP4
Molina, JM4
Delaugerre, C4
Shearer, K1
Brennan, AT1
Maskew, M1
Long, L1
Berhanu, R1
Sanne, I4
Fox, MP2
Tsuchiya, N3
Pathipvanich, P5
Wichukchinda, N2
Rojanawiwat, A4
Auwanit, W4
Ariyoshi, K4
Sawanpanyalert, P4
Mgelea, EM1
Aboud, S1
Motta, I1
Milia, MG1
Rostagno, R2
Simiele, M2
Libanore, V2
Fontana, S1
D'Avolio, A5
Ghisetti, V1
Di Perri, G8
Čolić, A1
Alessandrini, M1
Baldelli, S1
Castoldi, S1
Charbe, N1
Cozzi, V1
Fucile, S1
Mistry, N1
Sereboe, L1
Oakeshott, P1
So-Ngern, A1
Montakantikul, P1
Olds, PK1
Kiwanuka, JP1
Nansera, D1
Iveli, P1
Noguera-Julian, A1
Soler-Palacín, P1
Martín-Nalda, A1
Rovira-Girabal, N1
Fortuny-Guasch, C1
Figueras-Nadal, C1
Feucht, UD2
Meyer, A1
Kruger, M1
Ramana, LN1
Sharma, S2
Sethuraman, S1
Ranga, U1
Krishnan, UM1
Sanjeeva, GN1
Sukanya, V1
Pavithra, HB1
Dodderi, SK1
Govindaraj, M1
Shivananda, S1
Premalatha, R1
Cucchetto, G2
Nicolè, S2
Concia, E2
Wongtrakul, J1
Thongtan, T1
Roytrakul, S1
Kumrapich, B1
Janphen, K1
Praparattanapan, J1
Smith, DR1
Inui, TS1
Gnassingbé, W1
Akakpo, S2
Aho, K1
Tchangaï-Walla, K3
Theys, K2
Camacho, RJ1
Gomes, P2
Vandamme, AM1
Sawe, FK2
Obiero, E1
Yegon, P1
Langat, RC1
Aoko, A1
Tarus, J1
Kiptoo, I1
Langat, RK1
Maswai, J1
Bii, M1
Khamadi, S1
Shikuku, KP1
Close, N1
Sinei, S1
Shaffer, DN1
Gingrich, D1
Scherpbier, HJ1
Capparelli, E11
Jullien, V1
Young, SL1
Rufini, S1
Buonomo, E3
Giardina, E1
Scarcella, P4
Marszalek, RM1
Bae-Harboe, YS1
Mahalingam, M1
Masterpol, K1
Salado-Rasmussen, K1
Theilgaard, ZP1
Chiduo, MG1
Bygbjerg, IC1
Gerstoft, J4
Lüneborg-Nielsen, M1
Lemnge, M1
Katzenstein, TL4
Chohan, BH2
Khasimwa, B1
Ngayo, M1
Maleche-Obimbo, E1
Overbaugh, J11
Phan, CT1
Pham, HV1
Bi, X1
Ishizaki, A1
Saina, M1
Phung, CD1
Khu, DT1
Ichimura, H2
Geng, EH2
Neilands, TB1
Thièbaut, R4
Bwana, MB2
Nash, D2
Moore, RD2
Zannou, DM1
Althoff, KN1
Lim, PL1
Easterbrook, PJ4
Little, F1
Nakigozi, G1
Kiggundu, V1
Ki Li, PC1
Prozesky, H1
Davies, MA2
Reynolds, SJ3
Egger, M2
Vittinghoff, EV1
Deeks, SG4
Ciaranello, AL3
Doherty, K1
Harrison, L1
Kelly, K1
Walensky, RP5
Losina, E2
Muhe, L1
Ayaya, S1
Weinstein, MC1
Freedberg, KA5
Yang, W1
Fan, P1
Liang, Y1
Ma, Y1
Li, N1
Sun, D1
Zhu, Q1
Sando, D1
Spiegelman, D1
Machumi, L1
Mwanyika-Sando, M1
Aris, E1
Muya, A1
Jackson, E1
Baernighausen, T1
Hertzmark, E1
Chalamilla, G1
Desmond, AC1
Conolly, CA1
Castel, SA1
Ngaimisi, E2
Aklillu, E2
Abecasis, AB1
van Laethem, K1
Gleason, RL1
Caulk, AW1
Seifu, D1
Parker, I1
Vidakovic, B1
Getenet, H1
Assefa, G1
Amogne, W1
Aslanyan, S1
Morrow, JS2
Samuel, R2
Paredes, R12
Parboosing, R2
Moodley, P3
Singh, L2
Naidoo, A2
Gordon, M3
Priya, MR1
Rajendran, NN1
Lepik, KJ1
Yip, B8
McGovern, RA1
Ding, E1
Nohpal, A1
Watson, BE1
Toy, J1
Akagi, L1
Harrigan, PR8
Moore, DM1
Hogg, RS7
Montaner, JS22
Barrios, R1
Dominguez, K1
Cotton, M4
Abdissa, A1
Olsen, MF1
Tesfaye, M1
Girma, T1
Christiansen, M1
Hagen, CM1
Castel, S3
Aseffa, A1
Pedersen, C4
Friis, H1
Andersen, AB1
Herce, ME1
Kalanga, N1
Wroe, EB1
Keck, JW1
Chingoli, F1
Tengatenga, L1
Gopal, S1
Phiri, A1
Mailosi, B1
Bazile, J1
Beste, JA1
Elmore, SN1
Crocker, JT1
Rigodon, J1
Baxi, SM1
Greenblatt, RM3
French, AL3
Keller, MJ1
Augenbraun, MH1
Gange, SJ2
Liu, C4
Mack, WJ1
Zhao, J1
Sun, J3
Yin, Q1
Jiao, Y1
Shao, Y1
Rodrigues, M1
Galluzzo, CM6
Qiu, Y1
Powis, K3
Tih, PM3
Woldesenbet, S1
Puren, A4
Sherman, G11
Mogashoa, M1
Bhardwaj, S1
Chopra, M3
Pillay, Y1
Antunes, F3
Zindoga, P1
Augusto, O1
Mahumane, I1
Veloso, L1
Valadas, E1
Camacho, R1
Nelson, JA2
Fokar, A1
Hudgens, MG4
Compliment, KJ1
Hawkins, JT1
Tegha, G4
Kamwendo, DD3
Kayira, D5
Mofolo, IA3
Jamieson, DJ7
Van Der Horst, CM2
Fiscus, SA14
Nathoo, K2
Nahirya-Ntege, P1
Mutasa, K1
Williams, DE1
Mwesigire, DM1
Wu, AW2
Martin, F1
Katamba, A1
Seeley, J1
Pedrol, E8
Llibre, JM8
Tasias, M1
Currán, A1
Guardiola, JM1
Deig, E3
Guelar, A2
Martínez-Madrid, O1
Tikhomirova, L1
Ramírez, R1
Sobze, MS1
Mayaka, GB1
Muthoga, CW1
Martinelli, A1
Romano, R1
Vullo, V2
Knight, L1
Todd, G1
Muloiwa, R1
Matjila, M2
Lehloenya, RJ1
Hernando, H1
Deslandes, G3
Jolliet, P7
Sibanda, EL1
Bernays, S1
Weller, IV1
Hakim, JG1
Cowan, FM1
Poongulali, S2
Shastri, S1
Kumar, DS1
Arumugam, K1
De Costa, A1
D'Souza, G1
Kiselinova, M1
Malatinkova, E2
Vervisch, K1
Messiaen, P1
Bonczkowski, P2
Trypsteen, W1
Callens, S1
Verhofstede, C2
De Spiegelaere, W2
Vandekerckhove, L2
Mhandire, D1
Lacerda, M1
Mhandire, K1
Zhou, D1
Swart, M1
Shamu, T1
Musingwini, T1
Stray-Pedersen, B6
Rougemont, M1
Nchotu Ngang, P1
Stoll, B1
Delhumeau, C1
Hill, A1
Bonnet, F2
Menga, G1
Fampou, JC1
Krogstad, P5
Rigo, F1
Sirirungsi, W2
Traisathit, P1
Mcintosh, K9
Fehintola, F1
Olson, A1
Taiwo, BO2
Conti, M2
Mancini, R1
Montrucchio, C1
Capetti, A2
Guaraldi, G4
Cenderello, G1
Marinaro, L1
Tettoni, MC1
Trentini, L1
Kiweewa, FM1
Bakaki, PM2
McConnell, MS8
Musisi, M1
Namirembe, C1
Nakayiwa, F1
Kusasira, F1
Nakintu, D1
Mubiru, MC2
Wiener, J3
Chang, TS1
Dollard, SC1
Amin, MM1
Ellington, S3
Chim, B1
Lorent, N1
Nsagha, DS1
Pokam, BT1
Assob, JC1
Njunda, AL1
Kibu, OD1
Tanue, EA1
Ayima, CW1
Weledji, PE1
Okawa, S1
Chirwa, M1
Ishikawa, N3
Kapyata, H1
Msiska, CY1
Syakantu, G1
Miyano, S2
Komada, K1
Jimba, M1
Yasuoka, J1
Vogt, F1
Ferreyra, C2
Bernasconi, A1
Ncube, L1
Taziwa, F2
Marange, W1
Wachi, D1
Becher, H1
Lee, YC1
Chen, MY1
Kuo, CH1
Sheng, WH1
Hsieh, SM1
Sun, HY1
Chang, HY1
Wu, MR1
Zhang, JY1
Cook, AD1
Chabala, C2
Asiimwe, A2
Owen-Powell, E1
Seenivasan, S1
Vaitheeswaran, N1
Seetha, V1
Anbalagan, S1
Karunaianantham, R2
Blat, C1
Hagey, J1
Shade, SB1
Vittinghoff, E1
Newmann, SJ1
Yogev, R6
Pinillos, F2
Tsai, WY5
De Nardo, P1
Gentilotti, E1
Nguhuni, B1
Vairo, F1
Chaula, Z1
Nicastri, E2
Ippolito, G2
Eisen, G2
Meloni, ST1
Rawizza, HE1
Tchetgen Tchetgen, EJ1
Agbaji, OO1
Onwujekwe, DI2
Gashau, W2
Nkado, R1
Okonkwo, P1
Baroncelli, S2
Holgate, S1
Nelson, A1
Wedderburn, C1
Byakika-Kibwika, P6
Else, LJ2
Dilly Penchala, S1
Makadzange, AT1
Higgins-Biddle, M1
Chimukangara, B1
Birri, R1
Mahlanza, T1
McHugh, G1
van Dijk, JH1
Masimirembwa, C1
Phelps, B1
Amzel, A1
Ojikutu, BO1
Walker, BD3
Ndhlovu, CE1
Nakanga, W1
Patel, P1
Panjwani, S1
Kennedy, N1
Kawaza, K1
Pandie, M3
Hughes, J1
Siwendu, S1
Conradie, F3
Variava, E1
Bolaris, MA1
Keller, MA1
Robbins, BL1
Likanonsakul, S6
Suntisuklappon, B1
Nitiyanontakij, R1
Prasithsirikul, W5
Nakayama, EE1
Shioda, T2
Sangsajja, C1
Moodley, T1
Sebitloane, M1
Maharaj, N1
Sartorius, B1
Cha, A1
Elsamadisi, P1
Su, CP1
Phipps, E1
Birnbaum, JM1
Mustafa, S2
Yusuf, WN1
Woillard, JB1
Choon, TS1
Hassan, NB2
Stevens, E1
Ferretti, F1
Underwood, J1
Taylor, S6
Mendoza, Y1
Castillo Mewa, J1
Martínez, AA1
Zaldívar, Y1
Sosa, N1
Arteaga, G1
Armién, B1
Bautista, CT1
García-Morales, C1
Tapia-Trejo, D1
Ávila-Ríos, S1
Reyes-Terán, G1
Pascale, JM1
Teeranaipong, P1
Mekprasan, S1
Ohata, PJ1
Putcharoen, O1
Aliyu, MH1
Blevins, M2
Audet, CM1
Kalish, M1
Gebi, UI1
Onwujekwe, O1
Lindegren, ML1
Wester, CW3
Dahinten, AP1
Msuya, LJ1
Barnett, BS1
Chaweza, T1
Tweya, H1
Ngambi, W1
Phiri, S1
Naik, NM1
Bacha, J1
Gesase, AE1
Barton, T2
Wanless, RS1
Minde, MM1
Mwita, LF1
Tolle, MA1
Costa, S1
Machado, M1
Cavadas, C1
do Céu Sousa, M1
Capretti, MG1
Marsico, C1
Corvaglia, LT1
Arcuri, S1
Faldella, G1
Kiragga, A2
Julian, MN1
Jegede, AI1
Offor, U1
Onanuga, IO1
Naidu, EC1
Azu, OO1
Liang, B1
Jiang, J1
Pan, P1
Chen, R1
Zhao, F1
Su, Q1
Cao, C1
Liang, H2
Ye, L1
Angelidou, K1
Lindsey, J1
Dittmer, S1
Kabugho, E1
Msuya, L1
Sambo, P1
Barr, E1
Jean-Phillipe, P1
Mofenson, L11
Stewart, A1
Lehloenya, R1
Boulle, A6
Bergmann, JN1
Wanyenze, RK1
Makumbi, F1
Naigino, R1
Kiene, SM1
Stockman, JK1
Moholisa, RR1
Schomaker, M1
Olana, T1
Bacha, T1
Worku, W1
Tadesse, BT1
de Boissieu, P1
Dramé, M1
Cabie, A1
Poizot-Martin, I1
Cotte, L1
Garraffo, R2
Delobel, P1
Huleux, T1
Rey, D6
Birbal, S1
Dheda, M1
Ojewole, E1
Oosthuizen, F1
Wang, Q3
Fang, L2
Wang, A1
Wang, F1
Qiao, Y1
Sullivan, SG1
Rutherford, S1
Abach, J1
Thomason, M3
Colebunders, R6
Alioni, S1
Kerukadho, E1
Ndungutse, D1
Li, YY1
Jin, YM1
He, LP1
Bai, JS1
Yu, M1
Chen, JH1
Kuang, YQ1
Qin, M1
McIntyre, J17
Coletti, AS1
Klingman, KL2
Martinson, FE1
Theron, GB3
Mlay, P1
Loftis, AJ1
Purdue, L3
Basar, M1
L Machado, S1
Gonçalves, GS1
Dudley, D1
O'Connor, D1
Keiko Toma, H1
Fernandes, JC1
Tanuri, A2
De Scheerder, MA1
Borch, A1
Melkova, Z1
Koenig, R1
Gregson, J1
van Vuuren, C1
Ndembi, N6
Kanki, P5
Hoffmann, CJ1
Kerschberger, B1
Raizes, E1
Kantor, R3
Gupta, RK3
Gabriel, EE1
Tauzie, J2
Ilmet, T1
Neal, J1
Deygoo, N1
Jean Philippe, P1
Prescott, W1
Chen, J5
Palma, P1
Zangari, P1
Alteri, C1
Tchidjou, HK1
Manno, EC1
Liuzzi, G1
Perno, CF3
Rossi, P1
Bertoli, A1
Bernardi, S1
Tooke, L1
Riemer, L1
Harrison, M1
Mbuagbaw, L1
Mursleen, S1
Irlam, JH2
Spaulding, AB1
Rutherford, GW4
Siegfried, N4
Van Tam, V1
El-Khatib, Z1
Santacatterina, M1
Marrone, G1
Chuc, NT1
Diwan, V1
Thorson, A1
Le, NK1
An, PN1
Larsson, M1
Brill, MJ1
Bienczak, A1
Bourgeois, S1
Takeshita, LY1
Morris, AP1
Castro, EM1
Alfirevic, A2
Jones, AR1
Rigden, DJ1
Haldenby, S1
Nelson, MR4
Holden, A1
Deloukas, P1
Shilaih, M1
Marzel, A1
Braun, DL1
Scherrer, AU1
Kovari, H1
Young, J1
Darling, K1
Hoffmann, M1
Bernasconi, E3
Thurnheer, MC1
Günthard, HF2
Kouyos, RD1
Tan, SC1
Ab Rahman, AK1
Low, LL1
Wan Yusuf, WN1
Lau, E1
Brophy, J1
Samson, L1
Kakkar, F1
Campbell, DM1
Yudin, MH1
Murphy, K1
Seto, W1
Colantonio, D1
Read, SE1
Bitnun, A1
Nkurunziza, P1
Mugarura, L1
Pattery, T1
Gilks, C4
Jindal, AB1
Bachhav, SS1
Devarajan, PV1
Kimulwo, MJ1
Okendo, J1
Aman, RA1
Ogutu, BR1
Kokwaro, GO1
Ochieng, DJ1
Muigai, AW1
Oloo, FA1
Ochieng, W1
Monera-Penduka, TG1
Maponga, CC2
Wolfe, AR2
Nhachi, CF1
Kanthula, R1
Rossouw, TM1
van Dyk, G1
Silverman, R1
Olson, S1
Salyer, C1
Cassol, S2
de Beaudrap, P1
Etard, JF2
Guèye, FN1
Guèye, M1
Landman, R2
Girard, PM3
Turriziani, O1
Lichtner, M1
Stano, A1
Tsague, G1
Maida, P1
Antonelli, G1
Shear, NH1
Milpied, B2
Bruynzeel, DP1
Phillips, EJ1
Kouanfack, C5
Laurent, C6
Ngolle, M1
Nkene, YM1
Essomba, C1
Mpoudi-Ngolé, E4
Koulla-Shiro, S3
Chintu, N8
Cantrell, RA4
Kruse, G3
Mbewe, F4
Sinkala, M26
Smith, PJ2
Stringer, EM10
Stringer, JS27
Kumwenda, NI9
Hoover, DR17
Thigpen, MC11
Kafulafula, G7
Li, Q5
Mipando, L4
Mebrahtu, T1
Bulterys, M7
Gray, GE11
Saloojee, H1
Dokekias, AE1
Galiba, FO1
Bokilo, AD1
Ntsimba, P1
Nsitou, MB1
Malanda, F1
Basseila, GB1
Laureillard, D1
Prak, N1
Fernandez, M1
Ngeth, C1
Moeung, S1
Riel, V1
Chhneang, V1
Song, S1
Quillet, C1
Piketty, C2
Onah, HE1
Ibeziako, N1
Nkwo, PO1
Obi, SN1
Nwankwo, TO1
Lapphra, K2
Vanprapar, N4
Chearskul, S1
Phongsamart, W2
Chearskul, P1
Prasitsuebsai, W3
Bain, AM1
White, EA1
Rutherford, WS1
Rahman, AP1
Busti, AJ1
Prendergast, A3
Mphatswe, W2
Rakgotho, M1
Pillay, V5
Thobakgale, C2
McCarthy, N2
Morris, L17
Goulder, P2
Flys, TS4
Matovu, F4
Church, JD10
Bagenda, D10
Khaki, L1
Bakaki, P5
Eure, C3
Moltó, J6
Valle, M2
Miranda, C2
Cedeño, S2
Miranda, J2
Santos, JR2
Negredo, E12
Vilaró, J2
Costa, J1
Clotet, B25
Hughes, V1
Lehman, DA7
Chung, MH6
John-Stewart, GC10
Kinuthia, J3
Karamchand, L1
Dawood, H1
Chuturgoon, AA1
Lionel, J1
Aleyamma, TK1
Varghese, L1
Buck, J1
Gopalakrishnan, G1
Chaguturu, S1
Cu-Uvin, S1
Mayer, K2
Kalemeera, F2
Mauro, S1
Ryan, M5
Mayanja-Kizza, H3
Boffito, M5
Pornprasert, S2
Leechanachai, P3
Leenasirimakul, P2
Sukunthamala, K1
Thunjai, B1
Phusua, A1
Saetung, R1
Sanguansermsri, T1
Kitkungvan, D1
Apisarnthanarak, A3
Laowansiri, P1
Mundy, LM3
Ena, J2
Leach, A1
Nguyen, P1
Naniche, D1
Lahuerta, M1
Bardaji, A1
Sigauque, B1
Romagosa, C1
Berenguera, A1
Mandomando, I1
David, C1
Sanz, S1
Aponte, J1
Ordi, J1
Alonso, P1
Puig, T2
Ruiz, L10
Pini, P1
Kleinert, S1
Phadke, MA1
Bulakh, PM1
Kshirsagar, NA2
Bedri, A3
Gudetta, B2
Isehak, A2
Kumbi, S2
Lulseged, S2
Mengistu, Y2
Bhore, AV2
Varadhrajan, V1
Sastry, J5
Mubiru, M9
Onyango, C1
Taylor, A4
Abashawl, A2
Adamu, R2
Antelman, G2
Bright, P1
Chaudhary, MA1
Coberly, J1
Guay, L5
Hassen, E2
Moulton, LH2
Nayak, U3
Omer, SB8
Propper, L1
Ram, M2
Rexroad, V1
Ruff, AJ1
Bae, WH1
Wester, C8
Smeaton, LM5
Onyait, K1
Thior, I10
Sathia, L1
Obiorah, I1
Taylor, G1
Kon, O1
O'Donoghue, M1
Gibbins, S1
Walsh, J1
Chuchotaworn, C1
Moolphate, S1
Sakornjun, W1
Gorowara, M2
Yamada, N1
Yanai, H1
Mitarai, S1
Phanuphak, P8
Lapadula, G3
Calabresi, A2
Castelnuovo, F2
Costarelli, S3
Quiros-Roldan, E4
Paraninfo, G2
Ceresoli, F1
Gargiulo, F1
Manca, N1
Carosi, G5
Torti, C4
Van Cutsem, G4
Hilderbrand, K2
Mathee, S1
Abrahams, M1
Goemaere, E4
Coetzee, D3
Draper, B3
Abdullah, F2
Lidstrom, J2
Brück, S1
Witte, S2
Brust, J3
Schuster, D3
Mosthaf, F3
Procaccianti, M3
Rump, JA3
Petzold, D1
Hartmann, M5
Spensley, A1
Turner, AN1
Hoblitzelle, C1
Robinson, J2
Wilfert, C4
van Schalkwyk, JE1
Alimenti, A1
Khoo, D1
Maan, E1
Forbes, JC1
Burdge, DR1
Gilgoff, S1
Money, DM1
Leng, K1
Lonsdorf, A1
Villani, P4
Floridia, M4
Cusato, M3
Pinnetti, C2
Sabbatini, F1
Molinari, A2
Tamburrini, E2
Regazzi, M4
Elsherbiny, D1
Jansson, B1
Simonsson, US1
Ekouevi, DK18
Coffie, PA8
Becquet, R10
Tonwe-Gold, B10
Horo, A3
Dabis, F26
Stöhr, W2
Sabin, C1
Gilson, R2
Hill, T2
Ainsworth, J1
Pozniak, A5
Leen, C3
Bansi, L1
Fisher, M5
Orkin, C3
Anderson, J3
Johnson, M5
Easterbrook, P3
Gibbons, S3
Redfield, RR2
Towler, WI3
Eshleman, JR3
Chasela, C4
Ahmed, Y1
Knight, R1
Hudgens, M1
Kazembe, P3
Bentley, M1
Adair, L2
Piwoz, E1
Duerr, A1
Kourtis, A1
Loeliger, AE1
Tohill, B2
Jamieson, D1
Landriscina, M1
Fabiano, A1
Lombardi, V1
Santodirocco, M1
Piscazzi, A1
Fersini, A1
De Vis, K1
Barone, C1
Cignarelli, M1
Hislop, M1
Dowdy, DW1
Gallant, JE2
Regensberg, L1
Tebruegge, M1
Ritz, N1
Connell, T1
Curtis, N1
Sumantri, S1
Djoerban, Z1
Kiarie, JN7
Njiri, F2
Tantanathip, P3
Prasithisirikul, W1
Chan, DJ2
Ray, JE1
McNally, L1
Batterham, M1
Smith, DE2
L'homme, RF4
Droste, JA5
Wolters, LR1
van Ewijk-Beneken Kolmer, NW1
Gonzalez-Tome, MI1
Amador, JT1
Peña, MJ1
Gomez, ML1
Conejo, PR1
Fontelos, PM1
Mills, J1
Mugenyi, K7
Kabasinguzi, R4
Weidenhammer, A1
Kurowski, M6
Read, JS5
Sharma, U2
Hoffman, IF2
Pikora, C1
Goldenberg, R3
Rollins, NC2
Basson, AE1
Ntsala, M2
Tlale, E1
Corrigan, GE1
Shao, X1
Gray, G13
Shiri, T1
Welte, A1
Chavanet, P3
Schmitt, MP1
Hoizey, G1
Meyer, P1
Spire, B2
Diemer, M1
May, T3
Schmit, JL1
Duong, M4
Lang, JM4
Darwich, L1
Esteve, A1
Bellido, R2
Martinez-Picado, J2
Metzner, KJ2
Giulieri, SG1
Knoepfel, SA1
Rauch, P1
Burgisser, P1
Yerly, S2
Smeaton, L1
Rossenkhan, R2
Stevens, L5
Moffat, C5
Arimi, P3
Ndase, P3
Leidner, J3
Byakika-Tusiime, J2
Oyugi, JH2
Obua, C1
Kiptoo, M1
Wembe, RL1
Ng'Ang'a, Z1
Mueke, J1
Kinyua, J1
Lagat, N1
Okoth, F1
Songok, EM1
Chantarangsu, S3
Mushiroda, T2
Mahasirimongkol, S4
Tantisiriwat, W2
Charoenyingwattana, A3
Sura, T3
Chantratita, W8
Nakamura, Y2
Zeh, C2
Holland, D1
Masaba, R2
Odhiambo, P1
Weidle, PJ6
Walter, J2
Semrau, K5
Thea, DM6
Aldrovandi, GM10
Moorthy, A3
Thakar, M2
Kagal, A2
Venkataramani, V1
Balasubramaniam, U1
Ziemniak, C2
George, C1
Yesoda, A1
Jayakumar, B1
Lal, L2
Delvaux, T1
Elul, B2
Ndagije, F1
Munyana, E1
Roberfroid, D1
Chow, JY2
Meyers, T7
Barry, G1
Malan, E1
Marais, B1
Stehlau, R2
Hammer, SM2
Kondo, W2
Astori, Ade A1
Gomes, Sel-K1
Fernandes, Rde B1
Sasaki, Md2
Sbalqueiro, RL1
Patel, AK3
Patel, KK2
Sharma, R2
Ranjan, RR1
Shukla, RK1
Patel, JA1
Parienti, JJ6
Aurpibul, L3
Sirisanthana, T3
Chigwedere, P1
Seage, GR1
Gruskin, S1
Lee, TH2
Kombat, K1
Sundaram, M1
Srinivas, CN1
Shankar, EM1
Hemanth Kumar, AK2
Jagan, I1
Vasantha, M1
Rajasekaran, S5
Mahungu, T2
Smith, C1
Turner, F1
Egan, D3
Youle, M3
Ryan, CT1
Jongwutiwes, U1
Malathum, K2
McKoy, JM1
Bennett, CL2
Scheetz, MH1
Differding, V1
Chandler, KL1
Yarnold, PR1
Sutton, S1
Palella, F1
Johnson, S3
Obadina, E1
Raisch, DW1
Parada, JP1
Harris, M9
Côté, H2
Ochoa, C2
Thorne, A1
Zala, C4
Singer, J1
Montaner, J5
Maleewong, U1
Kulsomboon, V1
Watcharananan, S1
Sathapatayavongs, B1
Vogel, M2
Bertram, N1
Wyen, C3
Voigt, E1
Schwarze-Zander, C1
Sudhop, T1
Fätkenheuer, G6
Rockstroh, JK2
Reichel, C1
Mary, JY2
Limtrakul, A1
Rugpao, S1
Sirivatanapa, P1
Gomuthbutra, V1
Matanasaravoot, W1
Barré-Sinoussi, F4
Menu, E2
Shipton, LK1
Stock, S1
Ndwapi, N1
Gaolathe, T1
Avalos, A1
Moffat, HJ1
Mboya, JJ1
Widenfelt, E1
Martinson, NA7
Johnson, J1
Dhlamini, P3
Cohen, S2
Steyn, J2
Rutta, E1
Gongo, R1
Mwansasu, A1
Mutasingwa, D1
Rwegasira, V1
Kishumbu, S1
Tabayi, J1
Masini, T1
Ramadhani, H1
Tebas, P2
Hafner, R1
Tashima, K1
Shevitz, A1
Yarasheski, K2
Berzins, B2
Owens, S1
Forand, J1
Evans, S1
Murphy, R5
Virgili, N3
Fisac, C3
Martínez, E14
Ribera, E12
Gatell, JM15
Podzamczer, D14
Han, J1
Jiang, Y1
Yao, J1
Arrivé, E3
Chaix, ML6
Nerrienet, E3
Kruy Leang, S1
Avit, D2
Srey, VH1
N'Dri-Yoman, T2
Diallo, A1
Garcia, MV1
Yasuda, T1
Mukoyama, Y1
Matsubayashi, T1
Saeng-aroon, S3
Matsuyama, A1
Dahl, V1
Palmer, S4
Wind-Rotolo, M1
Durand, C1
Cranmer, L1
Reid, A7
Doherty, M1
Jilek, BL1
Kagaayi, J2
Kizza, A1
Laeyendecker, O1
Lau, B1
Ray, SC1
Siliciano, JD1
Quinn, TC2
Siliciano, RF1
Charurat, M1
Datong, P1
Matawal, B1
Ajene, A1
Blattner, W1
Abimiku, A1
Annan, NT1
Nelson, M6
Mandalia, S5
Bower, M4
Gazzard, BG6
Stebbing, J2
Ocama, P2
Katwere, M1
Piloya, T1
Feld, J1
Opio, KC1
Katabira, E6
Thomas, D1
Ronald, A3
Zaki, SA1
Phulsunder, A1
Shanbag, P1
Guidozzi, F1
Black, V2
Benet, LZ1
Kalinowski, A1
Anastos, K3
Young, M2
Cohen, M2
Minkoff, H1
van Vonderen, MG1
Lips, P1
van Agtmael, MA1
Hassink, EA1
Brinkman, K4
Geerlings, SE1
Sutinen, J1
Ristola, M1
Danner, SA5
Hauser, A4
Bluethgen, K1
Kuecherer, C4
Lalloo, UG2
Lueangniyomkul, A3
Mankatitham, W4
Prasithsirskul, W1
Burapatarawong, S1
Thongyen, S3
Thawornwa, U1
Prommool, V1
Behets, F2
Mutombo, GM1
Edmonds, A1
Dulli, L1
Belting, MT1
Kapinga, M1
Pantazis, A1
Tomlin, H1
Okitolonda, E1
Irunde, H1
Moshiro, C1
Foster, C1
Lyall, H2
Olmscheid, B1
Pearce, G2
Zhang, S1
Colafigli, M1
Di Giambenedetto, S4
Bracciale, L1
Fanti, I1
Prosperi, M1
Cauda, R1
Martin, J1
Kesselring, AM2
Wit, FW20
Sabin, CA4
Lundgren, JD8
Rauch, A1
de Wolf, F13
Mocroft, A5
Mabuka, JM1
Ramachandran, S1
Scott, N2
Kasonde, P7
Mwiya, M3
Decker, D1
Elens, L1
Haufroid, V1
Doyen, C1
Vandercam, B2
Yombi, JC1
Ammann, AJ1
Chalermchockcharoenkit, A1
Culnane, M5
Chotpitayasunondh, T2
Vanprapa, N1
Leelawiwat, W1
Mock, PA1
Asavapiriyanont, S1
Teeraratkul, A1
McNicholl, JM1
Agmon-Levin, N1
Elbirt, D1
Asher, I1
Torten, D1
Cohen, Y1
Gradestein, S1
Werner, B1
Turner, D1
Chowers, M2
Gottesman, G1
Maayan, S1
Risenberg, K2
Levi, I2
Sthoeger, Z1
Feinberg, J3
McConnell, M2
Megazzini, KM2
Redden, DT2
Krebs, DW2
Simwenda, M1
Tambatamba, B1
Johnson, N2
Palmer, P4
Samuels, LA1
Morgan, O1
Onyonyor, A1
Anderson, M1
Moore, J2
Billings, C1
Harvey, KM2
Mullings, A1
McDonald, D2
Alexander, G2
Smikle, MF3
Williams, EW1
Davis, D1
Christie, CD5
White, YR1
Pierre, RB1
Steel-Duncan, J1
Evans-Gilbert, T2
Rodriguez, B1
Ouyang, DW2
Brogly, SB2
Leighty, RM2
Thompson, B2
Tuomala, RE3
Hershow, RC2
Mmiro, FA1
Mwatha, AK1
Musoke, PM3
Zoppini, G1
Cammett, AM2
Wruck, JM1
Felizarta, F1
Miailhes, P1
Mallolas, J4
Piliero, PJ2
Parkin, N4
Marlowe, N1
Wilkinson, KA1
Seldon, R1
Meintjes, G1
Rangaka, MX1
Hanekom, WA1
Sekar, V1
Lefebvre, E1
Mariën, K1
De Pauw, M1
Vangeneugden, T1
Hoetelmans, RM9
Miró, O3
Rodríguez-Santiago, B2
Garrabou, G1
Estany, C1
Masabeu, A2
Force, L5
Barrufet, P2
Cucurull, J2
Domingo, P12
Alonso-Villaverde, C1
Bonjoch, A7
Morén, C1
Pérez-Alvarez, N3
Mwinga, K1
Urassa, W1
Carpenetti, N1
Valentine, M2
Goldenberg, RL12
Franssen, R1
Sankatsing, RR2
Hassink, E2
Hutten, B1
Ackermans, MT1
Oesterholt, R1
Arenas-Pinto, A1
Storfer, SP1
Kastelein, JJ4
Sauerwein, HP1
Stroes, ES2
Kurewa, EN1
Gumbo, FZ5
Munjoma, MW3
Mapingure, MP4
Chirenje, MZ5
Rusakaniko, S5
Galegov, GA1
Matteelli, A1
Saleri, N1
Bonkoungou, V1
Carvalho, AC1
Kouanda, S2
Sanou, MJ1
Simporé, J4
Monno, L1
Dembele, M1
Zachariah, R5
Rasschaert, F2
Mugabo, J1
Atté, EF1
Reid, T1
Zhou, H1
He, Y3
Gong, G1
Yin, W2
Tozzi, V3
Becker, S1
Mlay, R1
Schwandt, HM1
Lyamuya, E1
Ilboudo, D1
Sanou, DS1
Karou, D1
Sia, DJ1
Ouermi, D1
Bisseye, C1
Sagna, T1
Odolini, S1
Buelli, F1
Pietra, V3
Pignatelli, S2
Gnoula, C1
Nikiema, JB2
Castelli, F3
Namala, W1
Kizito, H1
Fox, ZV1
Booth, CL1
Smith, CJ1
Phillips, AN6
Li, JF3
Shalekoff, S1
Meddows-Taylor, S2
Schramm, DB4
Sim, MS1
Cumberland, WG1
Duan, N1
Bryson, YJ2
Pollock, L2
Else, L1
Poerksen, G2
Molyneux, E3
Moons, P2
Walker, S1
Fraser, W1
Birbeck, GL1
Cole, SR2
Thigpen, M1
Hopley, M1
Eklund, M1
Hall, DB10
Robinson, P12
Mayers, D5
Un, P1
Phe, T1
Anzidei, G1
Tibaldi, C1
Guerra, B1
Meloni, AM1
Vimercati, A1
Dalzero, S1
Ravizza, M1
Ellis, GM2
Warrier, R1
Nakamura, K1
Nsibande, D1
Mngoma, D1
Narayanan, PR2
Cheng, I1
Vallier, N1
Nguyen, A1
Lima, VD4
Hirschel, B5
Rodríguez-Arrondo, F1
Aguirrebengoa, K1
Portu, J1
Muñoz, J1
García, MA1
Goikoetxea, J1
Iribarren, JA1
Mwanza, J1
Ivanovic, J1
Anceschi, MM1
Ascenzi, P1
Signore, F1
Pisani, G1
Vallone, C1
Mattia, E1
Notari, S1
Tempestilli, M1
Pucillo, LP1
Narciso, P4
McCormick, A2
Burke, A2
Lyagoba, F3
Katundu, P4
Robertson, V3
Yirrell, DL1
Jaffar, S1
Amuron, B2
Foster, S3
Birungi, J1
Levin, J4
Namara, G1
Nabiryo, C1
Kyomuhangi, R1
Opio, A1
Bunnell, R1
Mermin, J3
Coutinho, A2
Grosskurth, H8
Mudiope, P3
Ajuna, P2
Esimone, CO1
Eck, G1
Nworu, CS1
Hoffmann, D1
Uberla, K1
Proksch, P1
Toni, TA1
Brenner, BG1
Asahchop, EL1
Ntemgwa, M1
Moisi, D1
Wainberg, MA5
Kumwenda, N11
Sebunya, TK1
Hagan, JE1
Shapiro, R1
Moyo, SM1
Mitchell, R1
Kim, S3
van Widenfelt, E4
Darbyshire, JH5
Bray, D4
Babiker, AG3
Kabuye, G3
Nsibambi, D2
Zalwango, E1
Nakazibwe, M1
Kikaire, B2
Nassuna, G1
Massa, R1
Fadhiru, K2
Namyalo, M1
Zalwango, A1
Generous, L1
Khauka, P2
Rutikarayo, N1
Nakahima, W1
Mugisha, A1
Todd, J1
Muyingo, S1
Ruberantwari, A1
Yirrell, D2
Hughes, P1
Aber, M1
Lara, AM2
Amurwon, J2
Wakholi, BN2
Whitworth, J1
Wangati, K1
Kajungu, D1
Nakiyingi, J1
Omony, W1
Tumukunde, D2
Otim, T1
Musana, H1
Akao, J1
Kyomugisha, H1
Byamukama, A1
Sabiiti, J1
Komugyena, J1
Mukiibi, S1
Drasiku, A1
Byaruhanga, R1
Labeja, O1
Tugume, S2
Awio, P1
Namazzi, A1
Bakeinyaga, GT1
Katabira, H1
Abaine, D1
Tukamushaba, J1
Anywar, W1
Ojiambo, W1
Angweng, E1
Murungi, S2
Haguma, W1
Atwiine, S1
Namale, L2
Mukose, A1
Mulindwa, G1
Atwiine, D1
Muhwezi, A1
Nimwesiga, E1
Barungi, G1
Takubwa, J1
Mwebesa, D1
Kagina, G1
Mulindwa, M1
Ahimbisibwe, F1
Mwesigwa, P1
Akuma, S1
Zawedde, C1
Nyiraguhirwa, D1
Tumusiime, C1
Bagaya, L1
Namara, W1
Karungi, J1
Kankunda, R1
Enzama, R1
Latif, A2
Chidziva, E1
Bulaya-Tembo, R1
Musoro, G1
Chimbetete, C1
Chakonza, L1
Mawora, A1
Muvirimi, C1
Tinago, G1
Svovanapasis, P1
Simango, M1
Chirema, O1
Machingura, J1
Mutsai, S1
Phiri, M1
Bafana, T1
Chirara, M2
Muchabaiwa, L2
Muzambi, M2
Mutowo, J1
Chivhunga, T1
Chigwedere, E1
Pascoe, M1
Warambwa, C1
Zengeza, E1
Mapinge, F1
Makota, S1
Jamu, A1
Ngorima, N1
Chirairo, H1
Chitsungo, S1
Chimanzi, J1
Maweni, C1
Warara, R1
Matongo, M1
Mudzingwa, S1
Jangano, M1
Moyo, K1
Vere, L1
Mdege, N1
Machingura, I1
Kambungu, A1
Lutwama, F3
Nanfuka, A1
Walusimbi, J1
Nabankema, E1
Nalumenya, R2
Namuli, T1
Kulume, R1
Namata, I1
Nyachwo, L1
Florence, A1
Kusiima, A1
Lubwama, E1
Nairuba, R1
Oketta, F1
Buluma, E1
Waita, R1
Ojiambo, H1
Sadik, F1
Wanyama, J1
Nabongo, P1
Oyugi, J1
Sematala, F1
Twijukye, C1
Byakwaga, H1
Ochai, R1
Muhweezi, D1
Etukoit, B1
Boocock, K1
Puddephatt, C1
Grundy, C1
Bohannon, J1
Winogron, D1
Babiker, A2
Wilkes, H1
Rauchenberger, M1
Sheehan, S1
Spencer-Drake, C1
Taylor, K1
Ferrier, A3
Naidoo, B1
Goodall, R2
Peto, L1
Nanfuka, R1
Mufuka-Kapuya, C1
Weller, I1
Bahendeka, S1
Bassett, M2
Wapakhabulo, AC1
Gazzard, B7
Mapuchere, C1
Burke, C1
Jones, S1
Newland, C1
Rahim, S2
Rooney, J2
Smith, M1
Snowden, W2
Steens, JM1
Breckenridge, A1
McLaren, A1
Hill, C1
Matenga, J1
Serwadda, D2
Peto, T1
Palfreeman, A1
Borok, M1
Sirianni, E1
Altan, AM1
Paturzo, G2
Bramanti, P1
Wakeham, K1
Parkes-Ratanshi, R1
Ggayi, AB1
Vignoles, M2
Barboni, G1
Agosti, MR1
Quarleri, J1
García, MK1
Ayala, SG1
Salomón, H5
Maria Llibre, J1
Valero, S1
Hudelson, SE7
Piwowar-Manning, E3
Nolan, ML1
Elzi, L2
Marzolini, C1
Ledergerber, B3
Weber, R2
Ndirangu, J1
Tanser, F1
Herbst, AJ1
Bland, R1
Moses, M1
Tayler-Smith, K1
Misinde, D1
Foncha, C1
Manzi, M2
Bauerfeind, A1
Mwagomba, B1
Kwanjana, J1
Harries, AD2
Liu, ZY1
Guo, FP1
Han, Y4
Qiu, ZF1
Zuo, LY1
Li, YL1
Li, TS1
Hou, T1
Liu, JS1
Mlambo, M1
Phaswana-Mafuya, N1
Ladzani, R1
Weberschock, T1
Gholam, P1
Hueter, E1
Flux, K1
Traisaithit, P1
Collins, IJ1
Sukhumanant, T1
Achalapong, J2
Chotivanich, N2
Winiyakul, N1
Ariyadej, S2
Kanjanasing, A1
Ratanakosol, J1
Hemvuttiphan, J1
Kengsakul, K1
Wannapira, W1
Sittipiyasakul, V1
Pornkitprasarn, W1
Liampongsabuddhi, P1
Van Dyke, RB2
Kanchana, S1
Chaplin, B1
Penugonda, S2
Meloni, S2
Akanmu, S1
Idoko, J4
Adewole, I1
Corbett, AH4
Nyirenda, J1
Rezk, NL4
Mkupani, P1
Sichali, D1
Tien, H1
Kashuba, AD6
Mwansambo, C1
Weigel, R2
Medrano, J1
Seclen, E1
Poveda, E1
Rodriguez-Novoa, S2
Morello, J1
de Mendoza, C1
Bolu, O3
Anekthananon, T3
Jariyasethpong, T1
Potter, D2
Mutsotso, W2
Borkowf, CB2
Mbori-Ngacha, D1
Muiruri, P1
Ong'ech, JO1
Zulu, I3
Njobvu, L1
Jetsawang, B1
Pathak, S1
Chu, KM2
Boulle, AM1
Asselman, V1
Wagner, TA3
Kress, CM1
Techapornroong, M2
Wittayapraparat, P2
Tansuphasawasdikul, S2
Wiboonchutikul, S1
Sukasem, C2
Mbougua, JB1
Bourgeois, A3
Gwet, H1
Ducos, J1
Molinari, N2
Munerato, P1
Sucupira, MC1
Oliveros, MP1
Janini, LM1
de Souza, DF1
Pereira, AA1
Inocencio, LA1
Diaz, RS1
Oliveira, I1
Jensen-Fangel, S2
da Silva, D1
Ndumba, A1
Medina, C1
Nanadje, A1
Rasmussen, DN1
Rudolf, F1
Wejse, C1
da Silva, ZJ1
Sodemann, M1
Laursen, AL1
Emmett, SD1
Kinabo, GD1
Swai, ME1
Reddy, EA1
Delva, W3
Yard, E1
Muigai, E1
Oyier, V1
Conkling, M1
Shutes, EL1
Karita, E2
Chomba, E1
Tichacek, A1
Vwalika, B1
Iwanowski, M1
Allen, SA1
Kurewa, NE4
Kandawasvika, GQ2
Duri, K3
Pazvakavambwa, IE1
Hardy, H1
Backman, ES1
Farber, HW1
Rowley, CF3
Boutwell, CL2
Lee, EJ2
MacLeod, IJ2
Deshpande, A3
Jeannot, AC1
Schrive, MH2
Wittkop, L1
Pinson, P2
Zhou, HY1
Zheng, YH3
Fregonese, F1
Nantasen, I1
Halue, G1
Nilmanat, A1
Chalermpolprapa, V1
Yuthavisuthi, P2
Ayuthaya, PI1
Kannagi, M2
Matediane, E1
Jamisse, L3
Ewings, F1
L'homme, R2
Potard, V1
Chassany, O1
Lavignon, M2
Torpey, K3
Dirks, R2
Bweupe, M2
Kabaso, M2
Mandala, J2
Sangiwa, G1
Datay, MI1
Mant, D1
Yudkin, P1
Giacometti, A1
Butini, L1
Cirioni, O1
Costantini, A1
Montroni, M1
Scalise, G1
Kuonza, LR1
Tshuma, CD1
Shambira, GN1
Tshimanga, M1
Verdon, R4
Coquerel, A1
Lagakos, SW1
Gray, RJ1
Muresan, P2
Plipat, N2
Hongsiriwan, S1
Eksaengsri, A2
Toye, M2
Smith, ME3
Pirillo, M1
Palmisano, L1
Pellegrini, M1
Galluzzo, C1
Weimer, L1
Bucciardini, R4
Fragola, V4
Marchei, E1
Pichini, S1
Sax, PE5
Reuman, EC1
Holmes, SP1
Ndekha, M1
Moore, E1
Zijlstra, EE3
Manary, M1
Giganti, MJ2
Putta, NB1
Sadoki, E1
Butler, DM1
Richman, DD6
Smith, DM2
Beldjebel, I1
Vujcikova, J1
Sokolova, J1
Krcmery, V1
Ford, D1
Kalumbi, M1
Grant, PR1
Chesshyre, E1
Weaver, MA1
Bryan, G1
Mukonka, V1
Mwale, F1
Chasela, CS2
Knight, RJ2
Ahmed, YI1
Ellington, SR2
Kacheche, Z2
Soko, A2
Wiener, JB2
Chigwenembe, M2
Sichali, DS2
Kitch, D1
Tumbare, E1
Handelsman, E1
Mburu, K1
Jayeoba, O1
Moko, E1
Souda, S1
Lubega, E1
Akhtar, M1
Tuomola, R1
Martinez-Tristani, M1
Mazhani, L2
O'Gorman, DA1
Nyirenda, LJ1
Theobald, SJ1
Tanon, AK1
Amani-Bosse, C5
Bédikou, G2
Sophan, S1
Meng, CY1
Pean, P1
Harwell, J1
Hutton, E1
Trzmielina, S1
Somasundaran, M1
Luzuriaga, K3
Pugatch, D1
Gelinck, LB1
Emadi, SN1
Akhavan-Mogaddam, J1
Yousefi, M1
Sobhani, B1
Moshkforoush, A1
Emadi, SE1
Decha, P1
Intharathep, P1
Udommaneethanakit, T1
Sompornpisut, P1
Hannongbua, S1
Parasuk, V1
Cramer, YS1
Rosenkranz, SL1
Hall, SD1
Szczech, LA1
Amorosa, V1
Gupta, SK1
Lawson-Evi, K1
Tchama, R1
Akakpo, SA1
Atakouma, DY2
Beauvais, L1
Kochar, R1
Nevah, MI1
Lukens, FJ1
Fallon, MB1
Machicao, VI1
Okaba-Kayom, V2
Flaherty, JP1
Namakula, R3
Yao, Y1
Sun, F1
Tougri, H1
Doulougou, B1
Ouedraogo, G1
Ouedraogo, CM1
Soudre, R1
Sondo, B1
Creek, TL1
Stinson, K1
Welty, TK2
Wilfert, CM4
Sturdevant, M1
del Rio Martin, J1
Schiano, T1
Fiel, MI1
Huprikar, S1
Bersoff-Matcha, SJ2
Rourke, D1
Blank, J1
Peters, PJ2
Stringer, J1
Intalapaporn, P1
Brooks, JT2
Barigye, H1
Maher, D1
Tindiwegi, G1
Atuhumuza, E1
Nakibinge, S1
Gadhamsetty, S1
Dixit, NM1
Farr, SL1
Ng'ombe, TJ1
Tegha, GL1
Eron, JJ6
Banda, HN1
Mpaso, M1
Matiki, C1
Kristiansen, KI1
Muller, F1
Kabue, MM1
Kazembe, PN1
Kline, MW1
Segeral, O1
Borand, L1
Comets, E1
Le Tiec, C1
Becquemont, L2
Ouk, V1
Godinho, AL2
Martins, IL1
Oliveira, MC3
Gomes, RA1
Coelho, AV1
Beland, FA2
Sedlacek, D1
Gatell, J3
Hu, CC2
Bancheno, WM1
Mwanyumba, F3
Mareverwa, J1
Aaron, E1
Kempf, MC1
Criniti, S1
Tedaldi, E1
Gracely, E1
Warriner, A1
Kumar, R1
Bachmann, LH1
Manabe, Y1
Chijoka, C1
Kalengo, C1
Chimsuntorn, S4
Eampokarap, B1
Nilkamhang, S1
Nielsen-Saines, K5
Haswell, J2
Doro Altan, AM1
Bachani, D1
Chan, PL1
Srikantiah, P1
Graham, SM1
Gitau, R1
Jalalian-Lechak, Z1
Peshu, N1
Mandaliya, K4
Jaoko, W1
Ndinya-Achola, J1
Spaulding, A2
Sonderup, M1
Meissner, P1
Mendelson, M1
Stringer, E4
Mngqibisa, R1
Atwine, D1
Salata, RA1
Alston-Smith, B2
Walawander, A1
Purcelle-Smith, E1
Eshleman, S1
Millar, L2
Lurie, MN1
Triche, EW1
De Bruyn, G1
Harwell, JI1
McGarvey, ST1
Benaboud, S2
Rey, E2
Sim, KL1
Cournil, A1
Coudray, M1
Essomba, CN1
Tonfack, CA1
Biwolé-Sida, M1
Bork, K1
Coakley, P1
Tattevin, P3
Arvieux, C6
Courpotin, C1
Ouattara, E1
Moh, R2
Messou, E1
Sissoko, M1
Anglaret, X3
Eholié, SP1
Danel, C2
Tchatchueng Mbougua, JB1
Ngom Guèye, NF2
Snowden, WB1
Mosteller, M1
Thoofer, NK1
Hughes, AR1
Kayma, S1
Salmond, W1
Maganda, A1
Galla, M1
Byamugisha, J1
Eley, B2
Giddy, J1
Technau, K1
Keiser, O2
Tsague, L1
Tsiouris, FO1
Mugisha, V1
Tene, G2
Nyankesha, E1
Koblavi-Deme, S1
Mugwaneza, P1
Kayirangwa, E1
Sahabo, R1
Huang, S3
Kaiser, KA1
Scheuerle, A1
Stanley, K4
Delfraissy, JF4
Ravich, VL1
Masso, M1
Vaisman, II1
Hanna, LE1
Mbuagbaw, LC1
Haïm-Boukobza, S1
Flandre, P3
Valin, N1
Fourati, S1
Sayon, S1
Simon, A4
van Luin, M1
Smit, C2
Rigter, IM1
Franssen, EJ1
Richter, C2
Kroon, F1
Dorton, BJ1
Mulindwa, J1
Li, MS1
Chintu, NT1
Chibwesha, CJ1
Joshi, S1
Khandekar, M1
Karmarkar, A1
Paranjape, R1
Jamkar, A1
de Vincenzi, I1
Ashworth, R1
Ruff, A2
Van Dyke, R1
Cababasay, MP1
Louw, J1
Smith, E2
Maupin, R2
Sreenivasan, S1
Dasegowda, V1
Auephanwiriyakul, S1
Sumonphan, E1
Theera-Umpon, N1
Tayapiwatana, C2
Lipscomb, JT1
Chen, YH1
Jeena, PM1
Reichert, K1
Adhikari, M2
Popat, M1
Carlin, JB1
Weber, MW1
Hamer, DH1
Basu, S1
Kumar, A1
Das, BK1
Dlamini, JN1
Hu, Z1
Somaroo, H1
Highbarger, HC1
Follmann, DA1
Dewar, RL1
Pau, AK1
Hughes, M3
Chu, J3
Holmes, CB2
Pillay, S1
Pilger, D1
Somogyi, S1
Wensing, AM1
Back, NK1
Arcilla, MS1
Frissen, JP1
Taylor, BS1
Azcoaga-Lorenzo, A1
Alvarez, A1
Palma, PP1
Velilla, E1
del Amo, J1
Bolhaar, MG1
Karstaedt, AS1
Sikwane, E1
Majaja, M1
Neveu, D1
Viljoen, J1
Nagot, N1
Danaviah, S1
Van de Perre, P1
Lengruber, RB1
Delviks-Frankenberry, KA1
Nikolenko, GN1
Baumann, J1
Santos, AF1
Pathak, VK1
Soares, MA1
Agibothu Kupparam, HK1
Mahalingam, V1
Soundararajan, L1
Perumal Kannabiran, B1
Navaneethapandian, PG1
Shah, I2
Karunaianandham, R1
Sikhamani, R1
Ukwe, CV1
Ekwunife, OI1
Udeogaranya, OP1
Iwuamadi, UI1
Welz, T1
Childs, K1
Post, FA1
Parham, L1
de Rivera, IL1
Murillo, W1
Naver, L1
Largaespada, N1
Albert, J2
Karlsson, AC1
Kieffer, MP1
Nhlabatsi, B1
Mahdi, M1
Hoffman, HJ1
Kudiabor, K1
Schipani, A1
Hendra, H2
Davies, G1
Rockstroh, J3
Johnson, MA3
Maserati, R2
Brandolini, M1
Cattelan, A1
Orani, A2
Sighinolfi, L1
Uglietti, A1
Sotgiu, G2
Manga, NM2
Poda, A1
Bazolo, N1
Sané, O1
Batista, G1
Guèye, NF1
Badiane, CI1
Dolgin, E1
Fogel, J1
Taylor, AW1
Paintsil, E1
Østergaard, LR1
Bula, A1
Mossdorf, E2
Stoeckle, M1
Mwaigomole, EG1
Chiweka, E1
Kibatala, PL1
Geubbels, E1
Urassa, H1
Abdulla, S1
Yuan, J1
Guo, S1
Hall, D11
Jayadev, S1
Distel, M1
Storfer, S4
Huang, Z1
Mootsikapun, P2
Maruszak, H1
Jeganathan, S1
Andrade-Villanueva, J3
Gellermann, HJ1
de Rossi, L2
Cairns, V1
Gómez Q, CH1
Vesga G, JF1
Lowenstein De M, E1
Suárez R, JO1
Gil L, FA1
Valderrama B, SL1
Tamara, JR1
Castro P, NA1
Alvarez M, CA1
Ciampa, PJ1
Burlison, JR1
Moon, TD1
Rothman, RL1
Goray, A1
Chaddha, U1
Tayal, S1
Lala, M1
Arastéh, K4
Migrone, H1
Lutz, T1
Opravil, M1
Gellermann, H1
Stitelman, OM1
De Gruttola, V1
van der Laan, MJ1
Górgolas, M4
Hidalgo, C1
Williams, F2
Guerrero, MF1
Chibowa, MC1
Nair, A1
Owino-Ong'or, W1
Hunt, GM1
Bommenel, T1
Launay, O5
Meynard, JL1
Gilquin, J1
Lascaux, AS1
Mahamat, A1
Martinez, V2
Pradier, C1
Rouveix, E1
Perez, F2
Maruva, M1
Engelsmann, B1
Keatinge, J1
Mugwagwa, R1
Gras, A1
Schneider, S2
Karasi, JC1
Ternes, AM1
Sauvageot, N1
Karasi-Omes, C1
Henry, AP1
Schmit, JC2
Tudor Car, L1
van-Velthoven, MH1
Brusamento, S1
Elmoniry, H1
Car, J1
Majeed, A1
Atun, R2
Mankhatitham, W2
Joseph, O1
Biodun, O1
Michael, E1
van der Merwe, L3
Brocklehurst, P4
Sint, TT2
Schrijvers, R1
Desimmie, BA1
Debyser, Z1
Schouten, EJ1
Midiani, D1
Makombe, SD1
Mnthambala, A1
Meguid, T1
Ben-Smith, A1
Van Damme, W1
Shawa, M1
Ranopa, M1
Bacheler, L2
Van Houtte, M1
Takahashi, A1
Kubo, M1
Kamatani, N1
Chen, S11
Gathe, J1
Santiago, S1
Horban, A8
Bogner, J2
Spencer, D1
Zhang, W2
Drulak, M1
Gozalo, C1
Gérard, L4
Loiseau, P1
Dellamonica, P4
Wigzell, H1
Falksveden, L1
Wahren, B2
Bambara, RA1
Wu, H2
Smith, HM1
Lowe, NR1
Demeter, LM1
Dykes, C1
Claassen, M2
Zeier, M1
Preiser, W2
Puertas, MC1
Bannister, W1
Kisic, M1
Cozzi-Lepri, A3
Pou, C1
Betancor, G1
Gargalianos, P1
Bánhegyi, D2
Lundgren, J1
Menéndez-Arias, L1
Yoon, K1
Lei, Y1
Shi, R1
Gee, W1
Lin, ET1
Kjaer, J1
Von Wyl, V1
Kronborg, G1
Castagna, A3
Bogner, JR4
Kanhon, SK1
Touré, H2
Ettiegne-Traoré, V1
Martins, AN1
Arruda, MB1
Aleixo, AW1
Pires, AF1
Greco, DB1
de M Brindeiro, R1
Calis, JC1
Geelen, SP1
van Vugt, M1
Plettenberg, A2
Livrozet, JM3
Witt, MD1
Macha, S1
Berger, F1
Stern, J1
Venkatesan, P1
Ramesh Kumar, S1
Iliayas, S1
Menon, PA1
Selvaraju, S1
Pooranagangadevi, NP1
Dilip, M1
Ramachandran, R1
Lim, HC1
Curlin, ME1
Mittler, JE1
Kim, HN1
Scott, J1
Cent, A1
Cook, L1
Morrow, RA1
Jerome, KR1
Lule, G1
Zona, S1
Orlando, G1
Carli, F1
Stentarelli, C1
Luzi, K1
Garlassi, E1
Menozzi, M1
Bagni, P1
Adorni, F3
Kay, J1
Wanzira, H1
Sandison, T1
Bigira, V1
Homsy, J2
Shah, SK1
Dawson, L1
Dixon, DO1
Lie, RK1
von Kleist, M1
Schütte, C1
Kredo, T2
Mauff, K1
Barnes, KI2
Diero, LO1
Somi, GR1
Okong, P3
Otieno, JA2
Wabwire, D2
Braitstein, P1
Musick, BS1
Novais, DA1
da Silva, JL1
Santos, PP1
Dejesus, E2
Mills, A1
Bhatti, L1
Conner, C1
Cabello Úbeda, A1
Sanz Moreno, J1
Meesters, R1
Hooff, G1
van Huizen, N1
Gruters, R1
Luider, T1
Anwikar, SR1
Bandekar, MS1
Smrati, B1
Pazare, AP1
Tatke, PA1
Chetchotisakd, P1
Jirajariyavej, S1
Munsakul, W1
Bowonwattanuwong, C1
Petoumenos, K1
Bhakeecheep, S1
Hoffmann, C2
Schewe, CK1
Weitner, L1
Stellbrink, HJ2
Heil, EL1
Lau, TC1
Tsui, SK1
Kang, Y1
Zheng, B1
Cecchini, D1
Urueña, A1
Trinidad, P1
Vesperoni, F1
Mecikovsky, D1
Kou, H2
Fu, Q2
Qiu, Z3
Zuo, L1
Ye, M2
López-Martínez, A1
O'Brien, NM1
Caro-Vega, Y1
Crabtree-Ramírez, B1
Sierra-Madero, J1
Brown, KC1
Hoskins, JM1
Thirumaran, RK1
Tien, HC1
Shumba, I1
Lamba, JK1
Schuetz, EG1
McLeod, HL1
Rosso, R1
Rossotti, R1
Di Biagio, A1
Nicolini, L1
Viscoli, C1
Porter, KA2
Poole, C1
Skinner-Adams, TS2
D'Amico, R2
McCarthy, JS2
Meshnick, SR2
Ribaudo, H1
Parekh, N1
Sang-a-gad, P1
Lertkoonalak, R1
Eiamsirikit, N1
Buranawanitchakorn, Y1
Yutthakasemsunt, N1
Mekviwattanawong, S1
Aitken, SC1
Mariki, G1
Van der Ven, AJ2
Ward, D1
Cordes, C2
Wang, E1
Quinson, A1
Britto, P2
Roongpisuthipong, A1
Prommas, S1
Rasri, W1
Drake, AL2
Roxby, AC2
Ongecha-Owuor, F2
Wald, A2
Emery, S3
Hongsiriwon, S1
Ngampiyaskul, C1
Limwongse, C1
Wittawatmongkol, O1
Kabat, B1
Tisserand, P1
Matta, M1
Péré, H1
Fournier, J1
Mbitikon, O1
Uriel, A1
Lewthwaite, P1
Lynn, DJ1
Schmidt, NC1
Roman-Pouriet, J1
Fernandez, AD2
Beck-Sagué, CM1
Leonardo-Guerrero, J1
Nicholas, SW1
Elbireer, A2
Nolan, M1
Janoff, EN1
Snijdewind, IJ1
Godfried, MH5
Nellen, JF2
Boer, K5
van der Ende, ME13
Wongsawat, J1
Bentley, ME1
Mkhomawanthu, C1
King, CC2
Chitsulo, P1
Tembo, M1
Piwoz, EG1
Mapingure, PM1
Tamalet, C1
Cottalorda, J1
Izopet, J1
Trabaud, MA1
Rogez, S1
Ruffault, A1
Henquell, C1
Signori-Schmuck, A1
Bouvier-Alias, M1
Vallet, S1
Wann, SR1
Hopley, MJ1
Maldarelli, F2
Karmacharya, BM1
Tansuphaswadikul, S3
Sahassananda, D1
Dhitavat, J2
Maek-a-nantawat, W1
Svensson, E1
Huitema, A1
Dong, BJ1
Frymoyer, A1
Verotta, D1
Lizak, P1
Kromdijk, W1
Mulder, JW11
Rosing, H2
Smit, PM1
Huitema, AD10
Vanpouille, C1
Lisco, A1
Introini, A1
Grivel, JC1
Munawwar, A1
Merbah, M1
Schinazi, RF1
Derudas, M1
McGuigan, C1
Margolis, L1
Amoroso, A1
Etienne-Mesubi, M1
Edozien, A1
Ojoo, S1
Sheneberger, R1
Obiefune, M1
Hossain, MB1
Stafford, K1
Heil, SG1
Schenk, PW1
van der Heiden, I1
Lindemans, J1
van Schaik, RH1
Kemal, KS1
Ramirez, CM1
Burger, H1
Foley, B1
Hamy, F1
Petrovic, K1
Minin, VN1
Suchard, MA1
Weiser, B1
Eluwa, GI1
Badru, T1
Agu, KA1
Akpoigbe, KJ1
Chabikuli, O1
Hamelmann, C1
Sewangi, J1
Mbezi, P2
Dugange, F1
Lau, I1
Ziske, J1
Theuring, S1
Wamalwa, DC1
McCoy, CO1
Matsen, FA1
Custers-Allen, R1
Bushman, FD1
Ouattara, EN1
Wong, AY1
Hsu, HE1
Eholié, S1
Gabillard, D1
Uthman, O1
Hougardy, JM1
Husson, C1
Van Vooren, JP1
Gastaldello, K1
Nortier, JL1
Goffard, JC1
van Hoog, S1
Nellen, J2
Scherpbier, H1
Nachman, S8
Luaengniyomkul, A1
Carlsson, J1
Butterworth, AS1
Anquetil, D1
Zongo, D1
Le Bihan, L1
Pinson, PR1
Adair, LS1
Oudijk, JM1
Qiu, M1
Chu, Y1
Yuan, Z1
Song, H1
Wu, Z1
Sikazwe, I1
Balamane, M1
Melikian, GL1
Katzenstein, DA2
Moyo, T1
Weaver, M1
Suzuki, C1
Hayashi, C1
Cusato, J1
Baietto, L1
Pennings, PS1
Mayito, J1
Nabukeera, L1
Ntale, M1
Pakker, N2
Hanpithakpong, W1
de Vries, PJ1
Matemo, DN1
Mujuru, HA1
Veloso, VG2
Joao, EC2
Pilotto, JH2
Santos, B1
Fonseca, R1
Kreitchmann, R1
Pinto, J2
Mussi-Pinhata, MM1
Ceriotto, M1
Machado, D1
Bethel, J3
Morgado, MG1
Dickover, R1
Camarca, M2
Siberry, G1
Moreira, RI1
Bastos, FI1
Xu, J2
Rassool, M1
Chibowa, M1
Amod, F1
Halvas, E1
Smith, L1
Schooley, R1
Mellors, J2
Yap, SH2
Herman, BD1
Radzio, J1
Sluis-Cremer, N2
Nugroho, AW1
Wiria, MS1
Grilo, NM1
Okomo, U1
Togun, T1
Oko, F1
Peterson, K1
Townend, J1
Peterson, I1
Jaye, A1
Minniear, TD1
Polle, N1
Oyaro, B1
Akoth, B1
Ndivo, R1
Angira, F1
Mills, LA1
Thomas, TK1
Tierney, J1
Gibb, D1
Ha, TT1
Anh, NM1
Bao, NH1
Tuan, PL1
Caridha, R1
Hien, NT1
Cam, PD1
Ehrnst, A1
Zuniga, I1
Biot, M1
Ford, NP1
Katile, D1
Diallo, F1
Fofana, DB1
Maiga, MY1
Sylla, A1
Traore, HA1
Bellosillo, N1
Guidi, M1
Arab-Alameddine, M1
Rotger, M2
Aouri, M1
Telenti, A2
Decosterd, LA1
Buclin, T2
Csajka, C1
Sarmati, L1
Montano, M1
Andreis, S1
Scaggiante, R1
Galgani, A1
Viscione, M1
Ricciardi, A1
Andreoni, C1
Boros, S1
Palù, G1
Zhang, HJ1
Zhang, XM1
Xu, HF1
Huang, JD1
Zheng, BJ1
Galli, L1
Bocchiola, B1
Cahua, T1
Panzini, P1
Zandonà, D1
Salpietro, S1
Maillard, M2
Danise, A1
Pazzi, A1
Lazzarin, A2
Lee, H1
Rath, BA1
Olshen, RA1
Halpern, J1
Merigan, TC2
Htun, WL1
Bowonwatanuwong, C3
Phonrat, B1
Uttayamakul, S2
Khusmith, S1
Richardson, DM1
Leger, PD1
Kinikar, AA1
Khandave, M1
Shankar, AV1
Nyesigire Ruhinda, E1
Kiwanuka, J1
Bera, E1
Mia, R1
Rossi, S1
Moss, M1
Kriengsinyot, R2
Schoenenberger, JA1
Aragones, AM1
Cano, SM1
Castello, A1
Gomez-Arbones, X1
Porcel, JM1
Agbaji, O1
Graham, C1
Muazu, M1
Nimzing, L1
Sankalé, JL3
Ekong, E1
Hawkins, C1
Arpadi, S1
Teeratakulpisarn, N1
Jadwattanakul, T2
Kerr, SJ1
Chomchey, N1
Hongchookiat, P1
Mathajittiphun, P1
Rungrojrat, P1
Praihirunyakit, P1
Valcour, V1
Kim, JH1
Shikuma, C1
Fogel, JM1
Alexandre, M1
Kozal, MJ1
Svarovskaia, ES1
Jakobsen, MR2
Hullsiek, KH1
Ostergaard, L2
Miller, MD1
Mudzviti, T1
Sibanda, M1
Gavi, S1
Foissac, F1
Bouazza, N1
Lachassinne, E2
Zhang, C1
Zhou, M1
Xie, J2
Guo, F1
Ghanem, KG1
Mudiope, PK2
Nyende, L1
Mulira, R1
Elbireer, S1
McMahon, DK1
Zheng, L1
Bonhomme, J1
Lederman, MM3
Hinkle, J3
Rousseau, F3
Pavlos, R1
James, I1
Mallal, SA1
Andrieux-Meyer, I2
Vitoria, M1
Renaud-Théry, F1
Hargreaves, S1
Mills, EJ1
Neubert, J1
Pfeffer, M1
Borkhardt, A1
Niehues, T2
Adams, O1
Bolten, M1
Reuter, S1
Stannigel, H1
Laws, HJ1
Du, X1
Castro, EC1
Barlow-Mosha, LN1
Bagenda, DS1
Butler, LM1
Sharma, AM1
Klarskov, K1
Mukherjee, S1
Ghosh, S1
Goswami, DN1
Samanta, A1
Siu, V1
Teque, F1
Levy, JA1
Chan, J1
Ribalta, J2
Ferré, R1
Sirera, G3
Salazar, J2
Masana, L1
Achmat, Z1
Baleta, A10
Woods, D1
Das, P2
Casado, JL5
Moreno, A4
Hertogs, K5
Dronda, F5
Moreno, S5
Anderson, JR2
Cingolani, A3
Forbici, F1
Rizzo, MG2
Trotta, MP1
Ammassari, A3
Girardi, E2
Ferrer, E6
Consiglio, E1
Perez, P1
Perez, JL2
Luna, E1
González, A6
Lozano, L2
Ocaña, I3
Casiró, A1
Aranda, M3
Martínez-Lacasa, J1
Miró, JM5
Badía, X1
Casado, A1
Lupo, S1
Maños, M1
Estela, J1
Morlese, JF1
Qazi, NA1
De Maat, MM6
Mathôt, RA1
Veldkamp, AI5
Huitma, AD1
Meenhorst, PL6
Van Gorp, EC5
Carlier, H3
Volmink, J7
Nachega, J1
Mandel, L1
Surattanont, F1
Guiramand-Hugon, S2
Joly, V2
Certain, A1
Lévy, C1
Rivet, S1
Jacomet, C1
Yéni, P2
Lawson-Ayayi, S1
Ramanampamonjy, R1
Lacoste, D1
Bernard, N1
Malvy, D1
Bonarek, M1
Djossou, F1
Beylot, J1
Morlat, P1
Arribas, JR2
Pulido, F2
Fleming, T8
Mracna, M5
Becker-Pergola, G4
Hoggard, PG2
Kewn, S1
Maherbe, A1
Almond, LM3
Sales, SD1
Gould, J1
Lou, Y2
De Vries, C2
Kreiss, JK1
James, JS8
Klosinski, L1
Hashimoto, H1
Kapiga, SH1
Murata, Y1
Bateman, C5
Annas, GJ1
Barnett, S1
Apuzzo, L1
Raines, C1
Hendrix, C1
Hamzeh, F1
Gallant, J1
Oliva, J1
Sanz, J4
Molina, JA1
Rubio, R1
Casas, E2
Mariño, A1
Moodley, J4
Hofmyer, J1
Nikodem, C1
Gigliotti, M3
Boshoff, L1
Sullivan, JL11
Arnedo, M2
Fumero, E5
McKenna, P1
Rinehart, A1
Barberá, MJ2
Pumarola, T3
Gudiol, F1
Bell, C1
Matthews, GV3
Stout, JP4
Chapman, V2
Kumwenda-Phiri, R1
Núñez, M3
González-Requena, D1
González-Lahoz, J9
van Leeuwen, R4
Squires, K2
Staszewski, S7
van Eeden, A1
Moroni, M1
Pavia, AT1
Schmidt, RE3
Gulick, R1
van der Valk, M2
van Weert, L2
Johnson, VA3
Sommadossi, JP5
Chiesa, E1
Bini, T1
Rizzardini, G1
Faggion, I1
Mussini, C1
Sollima, S1
Melzi, S1
Bongiovanni, M1
Tordato, F1
Cicconi, P1
d'Arminio Monforte, A1
Marseille, E3
Torralba, M1
Laurence, J4
Boyle, BA4
Knudtson, E1
Para, M1
Boswell, H1
Sullivan, JR1
Rachlis, A1
Verweij-Van Wissen, CP1
Schneider, L2
Paris, L1
Legrand, M3
Herson, S1
Casssetti, LI1
Losso, M1
Wruck, J1
McDonough, M2
Robinson, PA4
de Vries-Sluijs, TE1
Dieleman, JP5
Arts, D1
Schutten, M1
Dorenbaum, A4
Blanchard, S1
Gelber, RD3
Mzyece, E1
Makuka, I1
Kwape, P1
Chilufya, M1
Pérez-Elías, MJ2
Antela, A3
Gutiérrez, C1
Kontorinis, N1
Dieterich, DT2
Quaghebeur, A2
Matsuoka-Aizawa, S1
Tsuchiya, K1
Kimura, S2
Tatsumi, M1
Meldrum, J1
Verweel, G1
Sharland, M1
Novelli, V1
Dumont, G1
Ball, C1
Wilkins, E3
Walters, S1
Mudenda, V2
Kumwenda, R2
Pillay, C2
Chezzi, C1
Lupondwana, P1
Levin, L1
Venter, F1
Kappelhoff, BS5
Kironde, S1
Lukwago, J1
Ssenyonga, R1
Rely, K1
Bertozzi, SM1
Avila-Figueroa, C1
Guijarro, MT1
ter Heine, R2
Mairuhu, AT3
Bruun, JN1
Lackmann, GM1
Schmidt, B1
Vermund, S1
Acosta, E2
Moyle, GJ3
Arnaiz, JA4
Dalmau, D6
Knobel, H8
Riera, M2
Segura, F2
Richart, C1
Cortés, C1
Javaloyas, M1
Cruceta, A3
de Lazzari, E3
Beckerman, KP2
Sherman, J2
Ducar, C2
Deseyve, M4
Duefield, C1
Miotti, P2
Kirk, O4
Obel, N5
Mathiesen, L1
Nielsen, H2
Bertolli, J1
Hu, DJ1
Nieburg, P1
Macalalad, A1
Simonds, RJ2
Caumes, E2
Bossi, P1
Bricaire, F1
Leen, CL1
Law, WP1
Dore, GJ1
Duncombe, CJ1
Mahanontharit, A2
Chaguturu, SK1
Mahajan, AP1
Flanigan, TP3
Mayer, KH4
Stern, JO2
Love, J2
Lanes, S1
Imperiale, MS1
Mayers, DL1
Gibbons, A2
Broadhead, RL3
Lema, V2
Liomba, G3
Nkhoma, C4
Miotti, PG3
Seminari, E1
Ravasi, G1
Marubbi, F1
Meneghetti, G1
Kapiriri, L1
Robberstad, B1
Robbestad, B1
Frithjof Norheim, O1
Ayouba, A1
Cunin, P1
Foupouapouognigni, Y1
Kfutwah, A1
Thonnon, J1
Scarlatti, G1
Monny-Lobé, M1
Eteki, N2
Tardy, M1
Leke, R1
Nkam, M2
Nlend, AE1
Martin, PM1
Wood, E2
O'Shaughnessy, MV3
Moorman, A1
Tong, TC1
Holmberg, S1
Greenberg, AE2
Vilarasau, C1
Amador, C1
Benito, C1
Fenoll, V1
Pasquau, F2
Verbiest, W1
Larder, B3
Brumme, ZL1
Alexander, C1
Tilley, J1
Weissbrich, B1
Langmann, P3
Schubert, J1
Jassoy, C1
Yang, X1
Chang, WH1
Rouse, DJ3
Marseille, EA1
Perez-Then, E1
Peña, R1
Tavarez-Rojas, M1
Peña, C1
Quiñonez, S1
Buttler, M1
Ammann, A1
Hernández, W1
Goyanes, M1
Miguez, MJ1
Shor-Posner, G2
Lambert, JS1
Harris, DR1
Stiehm, ER1
Meyer, WA1
Sankatsing, SU2
Weverling, GJ4
van't Klooster, G1
Gruzdev, B1
Rakhmanova, A2
Jurriaans, S5
Prins, JM5
Heath, KV1
de la Rosa, R1
Lee, N1
Azoulay, S1
Nevers, MC1
Créminon, C1
Heripret, L1
Durant, J1
Grassi, J1
Guedj, R1
Duval, D1
Jordan, WC1
Jefferson, R1
Yemofio, F1
Tolbert, L1
Conlon, V1
Carroll, H1
Green, DC1
Green, A1
Green, R1
Dubuisson, JG1
King, JR3
Turner, ML1
Bennetto, C1
Hudson, CP5
Cooper, E1
Jackson, B2
Yoakim, C1
Bonneau, PR1
Déziel, R1
Doyon, L1
Guse, I1
Landry, S2
Malenfant, E1
Naud, J1
Ogilvie, WW1
O'Meara, JA1
Plante, R1
Simoneau, B1
Thavonekham, B1
Bös, M1
Cordingley, MG1
Mathiesen, LR2
Gerntholtz, L1
Balasubramanian, R1
Maupin, RT1
Delke, I1
Fiore, S1
Ngwena, C1
Schattenkerk, JK1
Schneider, MM1
Frissen, PH1
Vibhagool, A2
Rattanasiri, S3
Thakkinstian, A2
Arranz-Caso, JA1
Estrada, V5
García-Diaz, JD1
Manfredi, R6
Chiodo, F4
Baylor, MS1
Johann-Liang, R1
Rodríguez Guardado, A1
Maradona Hidalgo, JA1
Asensi Alvarez, V1
Cartón Sánchez, JA1
López, S2
Milinkovic, A3
Soler, A2
García-Viejo, MA2
Nunes, V1
Casademont, J1
Cardellach, F1
Jaspan, HB1
Garry, RF1
Grossman, Z1
Istomin, V1
Averbuch, D1
Lorber, M1
Bar Yaacov, N1
Macías, J1
Castellano, V1
Merchante, N1
Palacios, RB1
Mira, JA1
Sáez, C1
García-García, JA1
Lozano, F1
Gómez-Mateos, JM1
Pineda, JA1
Blanckenberg, DH1
Beniowski, M2
Boron-Kaczmarska, A2
Trocha, H1
Halota, W1
Jessen, H2
Smith, N1
Fletcher, C1
Parmar, D1
Carr, A4
Baraldi, E2
Miller, S1
van der Westhuizen, IP1
Malan, DR1
Santos, BR1
Mulcahy, F5
Levi, GC1
Reboredo, G1
Cassetti, I1
Petit, D1
Dam, JP1
Roudière, L1
Boukli, N1
Dupont, B1
Prévoteau du Clary, F1
Patey, O1
David, F1
Lortholary, O1
Devidas, A1
Urbinelli, R1
Allaert, FA1
Skowron, G3
Leoung, G1
Lewis, R1
Grosso, R1
Jacobs, M1
Kerr, B1
MacGregor, T1
Fisher, A1
Odgen, R1
Yen-Lieberman, B1
Smart, T1
Fleck, F1
Servais, J1
Lambert, C1
Vanhove, D1
Fischer, A1
Baurith, T1
Schneider, F1
Hemmer, R1
Thompson, CA1
Massari, V3
Vabret, A2
Bouvet, E1
Larouzé, B1
Fidler, S1
Tamm, N1
Clarke, JR1
Weber, JN1
Taylor, GP4
Jones, SA2
Coovadia, AH2
Urban, MF2
Bolton, KD1
Breurec, S1
Léautez, S1
Bourin, M1
Rouet, F6
Inwoley, A1
Viho, I9
Bequet, L5
Kravchenko, AV2
Miroshnichenko, AV1
Beliaeva, VV1
Serebrovskaia, LV1
Bogoslovskaia, EV1
Sitdykova, IuR1
Waters, L1
Jones, R1
Michailidis, C1
Sawleshwarkar, S1
Chama, CM1
Audu, BM1
Kyari, O1
Urban, M3
Chersich, M2
Stek, AM1
Nachman, SA1
Baker, D2
Gonzalez-Garcia, A1
Provisor, A1
Thorpe, EM2
Paul, ME1
Foca, M2
Gandia, J1
Wei, LJ2
Stevens, LM1
McNamara, J3
Mukotekwa, T1
Miller, A1
Orne-Gliemann, J1
Glenshaw, M1
Chitsike, I2
Meyer-Kleinmann, J1
Cunningham, SP1
Henry, K2
Claxton, S1
Kane, E1
Bordenave, B1
Klebert, M1
Powderly, WG2
Kanshana, S1
Thaineua, V1
Hammer, S2
Nour, S1
Muñoz-Moreno, JA2
Viciana, P1
Galindos, MJ1
Miralles, C2
Rodriguez Fumaz, C1
Puig, J3
Gel, S4
Rodríguez, E1
Videla, S2
Hamatake, R1
Check, E1
Fleming, TR1
Sweat, MD1
O'Reilly, KR1
Schmid, GP1
Denison, J1
de Zoysa, I1
Santamariña, E1
Lopez, JC3
Barrios, A1
LaFraniere, S1
Petit, JM1
Masson, D1
Buisson, M3
Duvillard, L1
Bour, JB1
Brindisi, MC1
Galland, F1
Guiguet, M1
Gambert, P1
Portier, H3
Vergès, B1
Raiteri, R2
Reynolds, HE2
Garazzino, S2
Sinicco, A2
Chiesi, A1
Mulchany, F1
Machala, L1
Mutunga, L1
Sienz, M1
Zilly, M2
Ebigbo, A1
Knipper, A1
Winzer, R1
Kodama, E1
Ikeuchi, M1
Matsuoka, M2
Harada, S1
Mitsuya, H1
Mahillo, B1
Rivero, A1
Gonzalez, J1
Blanco, JL4
Boix, V1
Arroyo, JA2
Rodriguez, D1
Montes, ML1
Arranz, A2
Sarasa, M1
Gil, P1
de Górgolas, M1
Rivas, P2
Yera, C1
García, R1
Granizo, JJ1
Fernández-Guerrero, M1
Burke, J1
Stocker, H2
Kreckel, P1
Herzmann, C2
Claus, J1
Hintsche, B1
Schlote, F1
Shahar, E1
Krivoy, N1
Weltfriend, S1
Pollack, S1
Techasathit, W1
Sonjai, A1
Suwanagool, S1
Karcher, H4
Stroes, E1
Bloch, M1
Schechter, M1
Goulder, PJ1
Blanckenberg, N2
Dong, K1
Laplumé, H1
Martin, D2
Jelaska, A1
Tempelman, C2
Timmermans, S2
Pujari, SN1
Naik, E1
Dravid, A1
Patel, JK1
Mane, AA1
Bhagat, S1
Kabura, MN1
John, FN1
Nduati, RW1
Mbori-Ngacha, DA2
González de Requena, D3
Gallego, O1
Corral, A1
Jiménez-Nácher, I6
Mbu, RE1
Mbopi-Keou, FX1
Alemnji, G1
Alemdji, G1
Nkengasong, JN2
Meli, C1
Nana, PN1
Ako, SN1
Tonye, RN1
Leke, RJ1
Partisani, M2
Hess-Kempf, G1
Krantz, V2
Priester, M2
Cheneau, C1
Bernard-Henry, C2
de Mautort, E2
Decroix, L1
Lecossier, D1
Shulman, NS1
Zolopa, AR1
Clavel, F1
Hance, AJ1
Rey-Joly, C1
Wyles, DL1
Gerber, JG2
Lyons, FE1
Coughlan, S1
Byrne, CM1
Hopkins, SM1
Hall, WW1
Mulcahy, FM3
Singer, E1
Roehr, B1
Boeri, E1
Serra, G1
Ratti, D1
Gallotta, G1
Vacchini, D1
Tremolada, Y1
León, A2
Laguno, M1
Mullings, AA1
Williams, E1
Whorms, S2
Figueroa, JP2
Steel-Duncan, JC2
Pierre, R2
Rodriquez, B1
Hambleton, I1
Gabay, L1
Massaquoi, I1
Asiimwe, S1
Arts, EJ3
Whalen, CC2
Ahmad, K1
Aranzabal, L1
Moya, J1
Quereda, C1
Diz, S1
Moreno, L1
Marín, A1
Hernandez-Ranz, F1
Kohli, E2
Piroth, L2
Martha, B1
Grappin, M2
Mommeja-Marin, H1
Wakeford, C1
Shaw, A2
Quinn, J1
Gish, RG1
Sakarovitch, C3
Fassinou, P2
Dequae-Merchadou, L2
Welffens-Ekra, C1
Chitale, R1
Mukiibi, J2
Hoover, D2
Broadhead, R2
Petzoldt, D2
Marcellin, F1
Lallemant, MJ1
Kunkeaw, S1
Huisamen, CB1
Badaro, R1
de Wet, J1
Lane, HC2
Folkers, GK1
Fauci, AS1
Lange, J5
Turner, VF1
Andrews, S1
Lazanas, MK1
Schellens, JH2
Maclean, CC2
Nolan, D2
Thorne, C2
Poirier, JM1
Robidou, P1
Jaillon, P1
Kamenga, C1
de Zoysa, IF1
Vwalika, C2
Shutes, E1
Aldrovandi, G2
Montero, M2
García-Gibert, L1
Giménez-Arnau, AM1
Lee, J1
Leith, J3
Hinzmann, R2
Couzin, J1
Dreyfuss, ML2
Kigozi, G1
Chen, MZ1
Wabwire-Mangen, F1
Wawer, MJ1
Nalugoda, F1
Kiwanuka, N1
Kiddugavu, M1
Gray, RH2
Bodasing, N1
Nyirenda, C1
Mallewa, J1
Cleary, PR1
de Baar, MP1
Colombo, S1
Bleiber, G1
Lee, BL1
Biollaz, J1
Décosterd, L1
Mougnutou, R2
Nkoué, N2
Lactuock, B1
Liégeois, F1
Zekeng, L2
Winters, MA1
Kovari, L1
Heseltine, PN1
Dieleman, J1
Sprenger, H1
Schneider, ME1
Stephenson, J2
Crespo, M3
Roson, B2
Crommentuyn, KM1
Tin, EE1
Wilairatana, P1
Krudsood, S1
Oberdorfer, A1
Akarathum, N1
Kanjanavanit, S1
Wannarit, P1
Flys, T1
Nissley, DV1
Claassen, CW1
Jones, D2
Shi, C1
Strathern, JN1
Taha, T2
Han, XX1
Cui, WG1
Liu, BG1
Wang, Yn1
Zhang, ZN1
Geng, WQ1
Diao, YY1
Dai, D1
Jiang, YJ1
Shang, H1
Tampellini, L1
Sebastiani, T1
Pocaterra, D1
Morini, JP1
Deleuze, J1
Krivine, A1
Gorin, I1
Perrin, L1
Dupin, N1
Galvez, J1
Prieto, A1
Vilades, C1
De Requena, DG2
Weinberg, WG1
Piliero, P1
Hofstede, HT1
Bosch, M1
Tuldrà, A2
Fumaz, CR3
Garcés, B1
Johnston, S3
Arnó, A3
Balagué, M3
Jou, A2
Tural, C2
Romeu, J4
Cruz, L2
Francia, E2
Arrizabalaga, J2
Ruiz, I2
Hascoet, C3
Besnier, JM3
Bellein, V3
Breux, JP3
Zucman, D2
Rozenbaum, W3
Montella, F1
Uip, DE1
Thompson, MA2
Russell, DB1
Koopmans, PP3
Hekster, YA3
Lemmer, P1
Schuman, M1
Omes, C1
Tayari, JC1
Fundira, L1
Wennig, R1
Bolton, C1
van Niekerk, R1
Levy, J2
Degroot, A1
Edirisinghe, D1
Dalton, M1
Bonington, A1
Holland, DT1
Peter, T2
Connor, JD1
Ochoa de Echagüen, A1
Xercavins, M1
Chumpathat, N4
Chaovavanich, A5
Urassa, P1
Gosling, R1
Pool, R1
Reyburn, H1
Idigbe, EO2
Adewole, TA1
Odunukwe, NN1
Audu, RA2
Araoyinbo, ID1
Onyewuche, JI1
Salu, OB2
Adedoyin, JA1
Musa, AZ2
Sciandra, M1
Marrone, R1
De Rosa, FG1
Mahlat, U1
Kolladarungkri, T1
Zijenah, L2
Sheldon, W1
Mateta, P2
Johnston, E2
Wells, J1
Shetty, AK1
Contag, CH1
Upadhyay, A1
Rodríguez-Pardo, D1
Rubio, M1
Falcó, V2
Pahissa, A2
Arranz Caso, JA1
Santos, I1
Castilla, V1
Molina, JP1
Fernández Guerrero, M1
Hodge, J1
Wiznia, A6
Damle, B1
Sheriff, M1
van't Hoog, AH1
Marum, LH1
Misore, AO1
Nganga, LW1
Decock, KM1
Joy, S1
Poi, M1
Hughes, L1
Brady, MT1
Koletar, SL1
Para, MF1
Cuzin, L1
Pugliese, P1
Bugnon, F1
Delpierre, C1
Cua, E1
Massip, P1
Friedland, GH2
Welty, ER1
Ndikintum, G1
Nkuoh, G1
Nkfusai, J1
Sutthent, R1
Arworn, D1
Kaoriangudom, S1
Chokphaibulkit, K1
Chaisilwatana, P1
Wirachsilp, P1
Thiamchai, V1
Sirapraphasiri, T1
Tanprasertsuk, S1
Clark, R1
Girault, V1
Kearney, BP1
Vallabhaneni, S1
Cecelia, AJ4
Yepthomi, T3
Saghayam, S3
Carpenter, CC1
Quian, J1
Visconti, A1
Gutiérrez, S3
Galli, A1
Maturo, M1
Galeano, V1
Serra, M1
Lioni, M1
Jooste, JP1
Van Zyl, AJ1
Baker, A1
Crawford, W1
Jassen, A1
Savadogo, A1
Nadembega, WM1
Yara, J1
Zoungrana, N1
Bakouan, D1
Musumeci, S1
Lazaro, E1
Dore-Mbami, M1
Ba-Gomis, FO1
Téa-Diop, Y1
Kouakou, K1
Diby, J1
Sia, E1
Soppi, S1
Essien, S1
Chenal, H1
Calvet, GA1
Menezes, JA1
D'Ippolito, MM1
Cruz, ML1
Salgado, LA1
Matos, HJ1
Vezina, HE1
Ravindran, GD1
Kurpad, AV1
Raj, TD1
Fox, K1
Weller, D1
Cavert, W1
Balfour, HH1
Mohey, R2
Tolstrup, M2
Jørgensen, LB2
Møller, BK1
Black, FT2
Kjems, J1
Daniel, OJ1
Krain, AB1
Ogun, SA1
Odusoga, OL1
Kumar, PN1
Rodriguez-French, A1
Tashima, KT1
Averitt, D1
Wannamaker, PG1
Williams, VC1
Shaefer, MS1
Pakes, GE1
Pappa, KA1
Menan, H2
Autar, RS1
Sankote, J1
Sujaikaew, K1
Drobacheff-Thiebaut, C1
Gavignet, B1
Mercier, M1
Laurent, R2
Greiner, T1
Janowitz, B1
Homan, R1
Johnson, L1
Schmitz, T1
Kleinkauf, N1
Klempa, B1
Ringe, H1
Varnholt, V1
Grosch-Wörner, I1
Parsons, T2
Leth, FV1
Johnson, D1
Losso, MH2
Koh, MT1
Loubser, S1
Balfe, P1
Oleske, JM1
Talbot, M2
Cervantes, M1
Mascaró, J1
Cinquegrana, D1
Siegfried, NL2
Van Deventer, PJ1
Mahomed, FA1
Lyons, F1
Hopkins, S2
Kelleher, B1
McGeary, A1
Sheehan, G1
Geoghegan, J1
Bergin, C1
McCormick, PA1
Hemanthkumar, AK2
Sukumar, B1
Sathishnarayan, S1
Raja, K1
Kumaraswami, V2
Soorapanth, S1
Sansom, S1
Besser, M1
Boltz, V1
Coffin, J1
Kouam, L1
Nsangou, I1
Mbanya, D1
Kongnyuy, EJ1
Ngassa, P1
Tebeu, PM1
Elobe, N1
Kamgaing, NG1
Doh, AS1
Maida, I1
Ríos, MJ1
Martín-Carbonero, L2
Toro, C1
Mura, MS1
Babudieri, S1
Garcia-Samaniego, J1
Pinoges, L1
Szumilin, E1
Ferradini, L1
Zheng, H1
Geffen, N1
Nattrass, N2
Kalamya, JN1
Obonyo, J1
Ojwang, J1
Mugumya, R1
Opio, C1
Kankasa, MP1
Germinario, EA1
Bassani, L1
Dehò, L1
Vyankandondera, J2
Tribut, O1
Jones, DC1
Saradha, B1
Gilbert, PB2
Heymann, SJ2
Lagakos, S3
Mouly, S1
Rizzo-Padoin, N1
Simoneau, G1
Aymard, G3
Salvat, C1
Mahé, I1
Bergmann, JF1
Littera, R1
Carcassi, C1
Masala, A1
Piano, P1
Serra, P1
Ortu, F1
Corso, N1
Casula, B1
La Nasa, G1
Contu, L1
Manconi, PE1
Nightingale, S1
Ward, DJ1
Curtin, JM1
Olawumi, HO1
Olatunji, PO1
Muangchana, K1
Kebaabetswe, P1
Mazonde, P1
Ritchie, MD1
Motsinger, AA1
Donahue, JP1
Erdem, H1
Raffanti, S1
Rebeiro, P1
George, AL1
Kim, RB2
Haines, JL1
Andersen, JW1
Wilkinson, GR1
Ingram, CD1
François-Brunet, C1
Garré, M3
Souala, F1
Poggensee, G1
Gingelmaier, A1
Kästner, R1
Eberle, J1
Mylonas, I1
Belohradsky, BH1
Friese, K1
Grubert, TA1
Summers, K1
Wire, MB1
Stein, DS2
Masterman, A1
Min, SS1
Shelton, MJ1
Germano, P2
Guidotti, G2
Loureiro, S2
da Cruz Gomes, A1
Valls Blazquez, MC1
Sagay, AS1
Musa, J1
Adewole, AS1
Imade, GE1
Ekwempu, CC1
Kapiga, S1
Rexroad, VE1
Hamzeh, FM1
Stamper, PD1
Yeni, PG2
Bouchaud, O2
von Hentig, N1
Carlebach, A3
Gute, P3
Knecht, G1
Klauke, S1
Rohrbacher, M1
Harder, S1
Haberl, A3
Dijkema, T1
Warris, A1
Phanupak, P1
Pujary, S1
Getahun, A1
Tansuphasawadikul, S1
Cooper, CL2
Bhayroo, S1
Buyse, S1
Vibert, E1
Sebagh, M1
Antonini, T1
Ichai, P1
Castaing, D1
Samuel, D1
Duclos-Vallée, JC1
Thistle, P1
Spitzer, RF1
Glazier, RH1
Pilon, R1
Arbess, G1
Simor, A1
Boyle, E1
Gottesman, M1
Silverman, M1
Inthong, Y2
Phoorisri, T2
Gu, SM1
Mshali, I1
Phakati, S1
Rampon, O1
De Rossi, A1
Park, JG2
Stek, A3
Clax, PA2
Yu, S2
Lertora, JJ2
Mayer, A1
Simo, S1
Ali, M1
Yazaki, H1
Honda, M1
Genka, I2
Teruya, K2
Tachikawa, N2
Kikuchi, Y2
Piyavong, B1
Onyewuche, J1
Funso-Adebayo, EO1
Iroha, EO1
Ezeaka, VC1
Adetifa, IM1
Okoeguale, B1
Chand, F1
Timite-Konan, M2
Dahri, K1
Ensom, MH1
Arici, C1
Airoldi, M2
Ripamonti, D1
Quinzan, G1
Gregis, G1
Ravasio, V1
Bombana, E1
Suter, F1
Leyes, M1
Balkus, J1
Manuel, R1
Djedje, M1
Seoighe, C1
Ketwaroo, F1
Scheffler, K1
Wood, N1
Duffet, R1
Zvelebil, M1
Hide, W2
Forna, F1
Liechty, CA1
Solberg, P1
Asiimwe, F1
Were, W1
Behumbiize, P1
Tong, T1
Westreich, D1
Eron, J1
Horst, Cv1
Van Rie, A1
Rakhmanina, NY1
van den Anker, JN1
Williams, K1
Sever, JL1
Spiegel, HM1
Soldin, SJ1
van Heeswijk, RP4
Paton, NI1
Chen, YM1
Lee, CK1
Li, PC1
Chuah, J2
Frost, KR1
Law, MG2
Natarajan, U1
Pym, A1
McDonald, C1
Velisetty, P1
Edwards, SG2
Hay, P4
Welch, J2
de Ruiter, A2
Erhabor, O1
Ejele, OA1
Nwauche, CA1
Ruiz, A1
Patel, J1
Shah, N1
Patel, B1
Maniar, JK1
Shah, SR1
Verma, R1
Kamath, R1
Gupte, P1
Maniar, A1
Mbamanya, F1
Natarajan, V1
Alfaro, RM1
Formentini, E1
Masur, H1
Athichathanabadi, C1
Khongnorasat, S1
Niamba, P1
Traoré, A1
Taïeb, A1
Lupodwana, P1
Steyn, JG1
Mtonga, V1
Lee, A1
Lu, D1
Shi, Q1
Tien, PC1
Kaplan, RC1
Hessol, NA1
Cole, S1
Vigen, C1
Justman, J1
Arroyo, E1
Valenzuela, B1
Portilla, J1
Climent-Grana, E1
Pérez-Ruixo, JJ1
Merino, E1
Suksomboon, N1
Poolsup, N1
Ket-Aim, S1
Ellis, JC1
Ewings, FM2
Bell, F1
Chileshe, R1
Abernethy, J1
Asboe, D1
Williams, IG2
Hooker, MH1
Kasenga, F1
Hurtig, AK1
Emmelin, M1
Patel, D1
Cortina-Borja, M1
Alcorn, K1
Haddow, LJ1
Wood, CW1
Ainsworth, JG1
Kurle, SN1
Sen, S1
Hayatnagarkar, SS1
Tripathy, SP1
Paranjape, RS1
Perre, PV1
Natu, SA1
Daga, SR1
Hahn, JA1
Maier, M1
Samuel, NM3
Parameshwari, S1
Dharmarajan, S1
Van Hook, HM1
Jacob, SM1
Junankar, V1
Stoszek, SK1
Piwowar, E1
Bertelsen, L1
Laursen, A1
Mkhwanazi, N1
Kiepiela, P1
Rollins, N2
Little, K1
Mzolo, S1
Horwood, C1
Tam, LW1
Brumme, CJ1
Lalonde, MS2
Troyer, RM2
Syed, AR1
Bulime, S1
Demers, K1
Poubeau, P1
Sandrine, PF1
Sylvie, A1
André, E1
Abdoulaye, D1
Bernard, L1
André, C1
Gasiorowski, J1
Panos, G1
Monforte, Ad2
Mahajan, A1
Sharma, H1
Bhagat, A1
Tandon, VR1
Bennetto-Hood, C1
Woodman, K1
Ashouri, N1
Igumbor, OJ1
Pengpid, S1
Obi, CL1
Brasme, JF1
Mille, F1
Benhayoun, M1
Bavoux, F1
Teissier, N1
Dauger, S1
Nangola, S1
Pattarawarapan, M1
Yue, J1
Wu, S1
Yan, Y1
Jahnke, N2
Faye, MM1
Sow, AI1
Songa, PM1
Mugasha, EB1
Colvin, M1
Willumsen, J1
Apornpong, T1
Teeratakulpisarn, S1
Taweepolcharoen, C1
Mangclaviraj, S1
Limpongsanurak, S1
Eiamapichart, P1
Luesomboon, W1
Kamudhamas, A1
Tangsathapornpong, A1
Vitavasiri, C1
Singhakowinta, N1
Attakornwattana, V1
Methajittiphun, P1
Chunloy, K1
Preetiyathorn, W1
Aumchantr, T1
Toro, P1
El-Sadr, W1
Abdel-Megeed, MF1
Beadsworth, M1
Mateyu, G1
Longwe, T1
Pensi, T1
Donninger, S1
Semitala, F1
Mwebaze-Songa, P1
Schaefer, P1
Spacek, LA1
Gasasira, AF1
Thomas, DL2
Devaleenal, B2
Palanivel, V1
Muthu, S1
Flanigan, T1
Toure, S2
El-Sadr, WM1
Schouten, WE1
Ramírez-Hernández, M1
Sánchez-Sierra, B1
Martínez-Escribano, JA1
Kassaye, S1
Lee, E1
Winters, M1
Pandey, N1
Chandrakar, AK1
Adile, SL1
Garg, ML1
Patel, S1
Dao, H1
Ekpini, R1
Barnhart, M1
Song, R1
Jelagat, J1
Dzombo, D1
Mwalimu, M1
Shikely, K1
D'costa, GF1
Khadke, K1
Patil, YV1
Kumar, P1
Anitha, S2
Bharucha, KE1
Kulkarni, P1
Phadke, M1
Chantratitra, W1
Leng, LK1
Thisyakorn, U1
Trinavarat, P1
Sosothikul, D1
Mehta, U1
Marier, JF1
Dimarco, M1
Guilbaud, R1
Dodard, C1
Morelli, G1
Tippabhotla, SK1
Singla, AK1
Thudi, NR1
Monif, T1
Djadou, KE1
Ocloo, A1
Dokounor, D1
Agbodjan-Djossou, O1
Akakpossa, A1
Santos, RP1
Ramilo, O1
Safrit, JT1
Chottanapund, S2
Sittibusaya, C2
Moolasart, V2
Termvises, P1
De Silvestri, A1
Cologni, G1
Puoti, M1
Sheen, CW1
Fahey, J1
Zanin, M1
Tyssen, D1
Wynhoven, B1
Kuiper, M1
Götte, M1
Mahajan, VK1
Sharma, NL1
Sarin, S1
Bansal, A1
Sud, N1
Nagdeo, N1
Thombare, VR1
Shekelle, P1
Maglione, M1
Geotz, MB1
Wagner, G1
Hilton, L1
Carter, J1
Tringle, C1
Mojica, W1
Newberry, S1
Saitoh, A1
Sarles, E1
Kovacs, A2
Burchett, SK2
Chaillot, F1
Le Moal, G1
Jarrousse, B1
Ba, M1
Dakouo, ML1
Doumbia, A1
Haidara, I1
Maïga, A1
Carcelain, G1
Van Rompaey, SE1
Kitahata, MM1
Yoshida, LM1
Taguchi, M1
Matsuda, M1
Ly, N1
Phoung, V1
Min, DC2
Srey, C1
Kruy, LS2
Koum, K1
Chhum, V1
Glaziou, P2
Reynes, JM1
Ojesina, AI1
Mullins, C1
Imade, G1
Samuels, J1
Pam, S1
Sagay, S1
Downing, R1
Berenguer, J1
Bellón, JM1
Miralles, P1
Alvarez, E1
Castillo, I1
Cosín, J1
Sánchez Conde, M1
Padilla, B1
Resino, S1
Kigonya, C1
Moura, MD1
Senna, MI1
Madureira, DF1
Fonseca, LM1
Mesquita, RA1
Bannister, WP1
Loveday, C1
Karlsson, A1
Lewden, C1
Chêne, G2
Clarisse, AB1
Carmona, A1
Luque, S1
Berenguer, N1
Matthias, R1
Scullard, G1
Schwenk, A1
Meyssonnier, V1
Caumes, PE1
Kodama, EN1
Sarafianos, SG1
Schuckmann, MM1
Sakagami, Y1
Takiguchi, M1
Subramanyam, S1
Muderspach, L1
Dandona, L1
Kumar, SG1
Ramesh, YK1
Rao, MC1
Dandona, R1
Lee, B1
Mangklabruks, A1
Biron, C1
Ou, QY1
Huang, ZL1
Gras, L1
Knechten, H1
Esser, S1
Jaeger, H1
Harrer, T1
Mauss, S1
van Lunzen, J1
Skoetz, N1
Jetter, A1
Groneuer, C1
Fraundorf, E1
Demers, KR1
Kyeyune, F1
Syed, A1
Vitezica, ZG1
Lonjou, C1
Borot, N1
Ledger, TN1
Lefebvre, A1
Hovnanian, A1
Hayden, A1
Wright, E1
Brew, BJ2
Ali, ST1
Arayawichanont, A1
Imran, D1
Kongsaengdao, S1
Kruy, L1
Samintharapanya, K1
Sarim, C1
Tau, G1
Thangsing, C1
Vin-Samnang, C1
Wesselingh, SL1
Eyakuze, C1
Jones, DA1
Starrs, AM1
Sorkin, N1
Saekang, N1
Pairoj, W1
Dube, S1
Boily, MC1
Mahomva, A1
Chikhata, F1
Gregson, S1
Carraro, EA1
Prandel, E1
Dias, JM1
Perini, J1
Macedo, RL1
Cornelsen, TC1
Sbalquiero, R1
Rees, H1
Madden, E1
Lee, G1
Kotler, DP1
Lewis, CE1
Tracy, R1
Heymsfield, S1
Shlipak, MG1
Scherzer, R1
Grunfeld, C1
Kirere Mathe, M1
Sondag-Thull, D1
Lepage, P1
Lybaek, D1
Larsen, CS1
Hu, C1
Best, B1
Watts, H1
Jimenez, E4
Shearer, WT1
Asenjo, MA1
Damming, M1
Pérez, H2
Laufer, N1
Gómez, A1
Coll, P1
Lottner, J1
Rolón, M1
Gomutbutra, V1
Ghosh, M1
Bii, SC1
Otieno-Nyunya, B1
Rotich, JK1
Green, H1
Compagnucci, A1
Saidi, Y1
Lai, AR1
Kouadio, B1
Seyler, C1
Traore, M1
Dakoury-Dogbo, N1
Duvignac, J1
Diakite, N1
Karcher, S1
Grundmann, C1
Engelbrecht, S1
Laten, JD1
Millogo, A1
Lankoandé, D1
Yaméogo, I1
Yaméogo, AA1
Sawadogo, AB1
Izzo, I1
Oberdorfer, P1
Washington, CH1
Jittamala, P1
Gozlan, M1
Corbeil, J1
Looney, D1
Ignacio, C1
Sullivan, J1
Cheeseman, S1
Barringer, K1
Pauletti, D1
Emini, EA1
Byrnes, VW1
Condra, JH1
Schleif, WA1
Sardana, VV1
Cheeseman, SH3
McLaughlin, MM2
Greenough, TC2
Hattox, SE2
Myers, M9
McLaughlin, M1
Erice, A1
de Jong, MD4
Loewenthal, M1
Boucher, CA5
van der Ende, I1
Schipper, P1
Imrie, A3
Weigel, HM2
Kauffmann, RH2
Koster, R1
Koup, RA1
Andrews, C1
Bova, CA1
Pav, JW3
Roy, T1
Keirns, JJ1
Dornadula, G2
Pomerantz, RJ2
Nowak, MA2
D'Aquila, RT3
Fischl, MA2
Liou, SH1
Timpone, J1
Basgoz, N1
Niu, M1
Hirsch, MS3
Zhu, QY1
Scarborough, A1
Polsky, B1
Chou, TC2
Voelker, R1
Sorice, F1
Mueller, BU2
Sei, S1
Anderson, B1
Farley, M1
Venzon, DJ1
Schwartzentruber, DJ1
Fox, C1
Pizzo, PA1
Kilby, JM1
Rabin, L1
Hincenbergs, M1
Moreno, MB1
Warren, S1
Linquist, V1
Datema, R1
Charpiot, B1
Seifert, J1
Kaneshima, H1
McCune, JM1
Havlir, DV1
Eastman, S1
Gamst, A1
Tucker, TJ1
Lumma, WC1
Culberson, JC1
Bonhoeffer, S1
May, RM1
Rutschmann, O1
Stechenberg, B1
Lamson, M3
Cort, S1
Grob, PM1
Muchmore, E1
Ho, DD1
Norris, S1
Shih, CK1
Adams, J1
Beveridge, A1
Genn, W1
Vizzard, J1
Collins, DO1
Sakamoto, A1
de Boer, RJ1
Foudraine, NA2
Goudsmit, J3
Miller, V3
Phair, JP1
Max, B1
Mourikes, N1
Alaeus, A1
Cox, S1
Holtzer, CD1
Coleman, RL1
Warren, KJ1
Boxwell, DE1
Kim, NY1
Drolet, BA1
Cooper, D5
Durakovic, C1
Rae, S4
Shillington, A1
Montaner, JG1
Dohnanyi, C1
Leitze, Z1
Nadeem, A1
Saul, Z1
Roberts, I1
Manthous, CA1
Barry, MG2
Tjia, JF1
Halifax, KL1
Breckenridge, AM1
Gagnier, P1
Pav, J1
Gwynne, M1
Siminski, S2
Beckerman, K1
Lukashov, VV2
Notermans, DW1
Roos, M1
Schuitemaker, H1
Mo, T1
Raboud, JM3
Ho, TT1
Wong, KH1
Chan, KC1
Bourezane, Y1
Salard, D1
Vandel, S1
Drobacheff, C1
Markus, R1
Zhou, XJ1
Sheiner, LB1
Everall, IP1
Clay, PG1
Rathbun, RC1
Slater, LN1
Haubrich, R1
Richman, D1
Hillebrand-Haverkort, ME1
Sturkenboom, MC2
Stricker, BH2
Dusek, A2
Elliott, T1
Horton, S1
Dransfield, K2
Murarka, A1
Hom, D1
Antón, P1
Rodriguez-Rosado, R1
Dona, MC1
Barreiro, PM1
Pakker, NG1
Kroon, ED1
Roos, MT1
Otto, SA1
Hamann, D1
Claessen, FA1
Kroon, FP1
ten Napel, CH1
Sprenger, HG1
Schellekens, PT1
Miedema, F1
de Jong, JJ1
Hillebrand, ME1
Baan, E1
Huismans, R1
ten Veen, JH2
Heelon, MW1
Meade, LB1
Hellmann, NS1
Grant, RM1
Parkin, NT1
Becker, M1
Symonds, W1
Chesney, M1
Volberding, PA1
De Wit, S1
Sternon, J1
Conget, I1
Casamitjana, R1
Aldeen, T1
Wells, C1
Davidson, F1
Lau, R1
Descamps, V1
L'Heriteau, F1
Schortgen, F1
Regnier, B1
Altice, FL1
Cooney, EL1
Otero, MJ1
Fuertes, A1
Sánchez, R1
Luna, G1
Shaw, AJ1
McLean, KA1
François, C2
Michau, C1
Gyssens, IC1
Sturkenboom, MJ1
Niesters, HG1
Demoly, P1
Messaad, D1
Fabre, J1
Reynes, J1
Bousquet, J1
Cattelan, AM2
Erne, E1
Salatino, A1
Trevenzoli, M3
Carretta, G1
Meneghetti, F2
Cadrobbi, P1
Vázquez-Rosales, G1
García Lerma, JG1
Yamamoto, S1
Switzer, WM1
Folks, TM1
Renault, B1
Birmingham, K2
Pilcher, CD1
Ngo, L1
Sista, P1
Gleavy, J1
Brooks, D1
Venetta, T1
DiMassimo, E1
Crowe, S1
Kempf, G1
Nicolle, M1
Lurie, P1
Wolfe, SM1
Campa, AM1
Baum, MK1
Temesgen, Z1
Wright, AJ1
Simon-Meyer, J1
Nkoghe, D1
Léonard, P1
Demonty, J1
Van Cauwenberge, A1
Garcia-Arata, I1
Bloor, S1
Blazquez, J1
Magenta, L1
Piffaretti, JC1
Carota, A1
Moccetti, T1
Baño Rodrigo, MD1
Agujetas Rodríguez, M1
López García, ML1
Guillén Llera, JL1
Nisius, G1
Auger, S1
Sidley, P2
Ricciardulli, D3
Clarke, SM2
Healy, CM1
Condon, S1
Butler, KM1
Little, J1
Halifax, K1
Drake, S1
Belloso, WH1
Benetucci, JA1
Cahn, PE1
Lasala, MC1
Lopardo, G1
Saracco, M1
Nelson, E1
Davey, RT1
Allende, MC1
Clarke, S2
Harrington, P2
Condon, C1
Kelleher, D1
Smith, OP1
Blanco, F1
Casimiro, C1
de la Cruz, JJ1
Berthelot, JM1
Kwakkelstein, MO3
Briones, C1
Dona, C2
Lyall, EG1
Ward, C1
Pinzani, V1
Faucherre, V1
Peyriere, H1
Blayac, JP1
Cheesbrough, A1
Reynolds, B1
Goldfarb-Rumyantzev, AS1
Jeyakumar, A1
Gumpeni, R1
Rubin, D1
Taylor, DL1
Ahmed, PS1
Tyms, AS1
Wood, LJ1
Kelly, LA1
Chambers, P1
Clarke, J1
Bedard, J1
Bowlin, TL1
Rando, RF1
Johnson, G3
Lee, S4
Mendez, H2
Aguayo, R2
Dieudonne, A2
Bamji, M1
Rana, S1
Sever, J1
Galluzzo, MC1
Giannini, G2
Tomino, C2
Binelli, A1
Weimer, LE2
Baldini, F2
Murri, R2
Cooper, PA1
Jivkov, BI1
Schorn, MC1
Hollanders, RM1
van Ewijk-Beneken Kolmer, EW1
Wuis, EW1
Workman, J1
Drake, SM1
White, DJ1
Stinnett, AA1
Barry, M1
Téllez, MJ1
Hoetelmans, R1
Clarke, DF1
Nielsen, C1
O'Farrell, N1
Escolano, C1
Mora, A1
Gregori, J1
Nogueira, E1
García, F1
Sambeat, MA2
Gomez-Sirvent, JL1
Gallart, T1
Mirra, M1
Marzi, M1
Massella, M1
Baraboutis, JG1
Sha, BE1
Proia, LA1
Kessler, HA2
Akue, JP1
Babaki, P2
Charpak, N2
de Thé, G2
Rea, MF1
Huraux, C2
Ndiaye, B2
Pratomo, H2
Zetterström, R2
Miller, WC1
Aberg, JA1
Hamrick, HJ1
Resch, W1
Stuelke, EL1
Watkins, T1
Swanstrom, R1
Morris, K1
Lhotska, L1
Armstrong, H1
McNeeley, DF1
Raguin, G1
Metry, DW1
Lahart, CJ1
Farmer, KL1
Hebert, AA1
Sabido, R1
Martí-Belda, P1
Dehertogh, P1
Haehl, M1
Gulick, RM2
Tung, R1
Snyder, S1
Palacios Muñoz, R1
Santos González, J1
Bosch García, R1
Márquez Solero, M1
Izzedine, H1
Launay-Vacher, V1
Deray, G1
Dionisio, D1
Mininni, S1
Bartolozzi, D1
Esperti, F1
Vivarelli, A1
Leoncini, F1
Moyle, G3
Yamamoto, Y1
Yasuoka, A1
Yasuoka, C1
Dovie Akue, JP1
Ferreira Rea, M1
Benn, PD1
Mercey, DE1
Brink, N1
Scott, G1
Larger, E1
Longuet, P1
Vilde, JL1
Math t, RA1
de Villar, N1
Serrano-Ríos, M1
Jeffrey, S1
Hanna, G1
D'Aquila, R1
Wallace, L1
Logue, K1
Cordova, B1
Buckery, R1
Gallagher, K1
Scarnati, H1
Tritch, R1
Rizzo, C1
Gilden, D1
Benson, M1
Shannon, M1
Bowers, M1
Mascolini, M1
Link, D1
Bowersox, J1
Doepel, L1
Folkers, G1
MacDougall, DS2
Wool, M1
Bartlett, JG1
Cadman, J1
Kasper, T1
Fornataro, K2
Lindsay, MK1
Bartnof, HS1
Shalit, P1
Farrell, P1
Lindgren, P1
Wang, YG1
Cunningham, S4
Wantman, M1
Prakash, M1
Poreddy, V1
Tiyyagura, L1
Bonacini, M1
Zuber, B1
Böttiger, D1
Benthin, R1
ten Haaft, P1
Heeney, J1
Oberg, B1
Churchill, D1
Williams, I1
Thomsen, HF1
Larsen, L1
Hankins, C1
Curry, R1
Pérez-Cuevas, JB1
Marcos, MA1
Carné, X1
Rovere, P1
De Checchi, G1
Turazzini, M1
Parrinello, A1
Newson, R1
Ives, N1
Pereira, S1
Kollmann, C1
Tremblay, C1
Giguel, F1
Barracchini, A1
De Longis, P1
Goldschmidt, RH1
Bangsberg, D1
Das, S1
Allan, PS1
Wade, AA1
van Praag, RM2
Repping, S1
de Vries, JW1
Suzuki, K1
Kaufmann, GR1
Mukaide, M1
Cunningham, P1
Harris, C1
Leas, L1
Kondo, M1
Imai, M1
Pett, SL1
Finlayson, R1
Zaunders, J1
Kelleher, A1
Tjia, J1
Gibbons, SE1
Hudson, J1
Hoy, J1
Doong, N1
French, M1
Fagot, JP1
Mockenhaupt, M1
Bouwes-Bavinck, JN1
Naldi, L1
Viboud, C1
Roujeau, JC1
Smith, AN2
Arribas, J1
Lafeuillade, A2
Rohban, R1
Mouroux, M1
Tricot, C1
Agher, R1
Huraux, JM1
Matías-Guiu, X1
Pujol, RM1
Domingo, JC1
Vázquez, G1
Glenn Fowler, M1
Römer, K1
Kamps, R1
Salzberger, B1
Neau, D1
Larbère, J1
Birac, V1
Ragnaud, JM1
Street, JC1
Obee, EM1
Dileanis, J1
Lugo, M1
Smith, PF1
DiCenzo, R1
Rottmann, C1
Larbalestier, N1
Glesby, M1
Behrens, G1
Stellato, RK1
Molhuizen, HO1
Paes, D1
Lampe, F1
Lamson, MJ1
Leitz, G1
Pou, L1
Lopez, RM1
L'Héritier, A1
Florence, KJ1
Sulkowski, MS1
Mehta, SH1
Bundow, D1
Rosoff, L1
Aboulafia, DM1
Seifert, LL1
Yozviak, JL1
Doerfler, RE1
Woodward, WC1
Bonard, D1
Faure, M1
Huët, C1
Caumont, A1
Roques, P1
Salamon, R1
Fleury, H1
Pelton, S1
Rathore, MH1
Song, LY1
Ashraf, H1
Schirmer, D1
Väth, T1
Desch, S1
Brun, SC1
Hicks, C1
King, M1
Wheeler, D1
Stryker, R1
Riddler, S1
Thompson, M1
Real, K1
Hsu, A1
Kempf, D1
Japour, AJ1
Sun, E1
Sasset, L1
Sgarabotto, D1
Olivieri, J1
Khoury, M1
Jones, TT1
van Rossum, AM1
Fraaij, PL1
de Groot, R1
von Giesen, HJ1
Köller, H1
Theisen, A1
Arendt, G1
Kijak, G1
Federico, A1
Saman, M1
Rekacewicz, C2
Leng, C1
Abdool Karim, S1
Abdool Karim, Q1
Cooper, P1
Hussey, G1
Madhi, S1
Pettifor, JM1
Thula, S1
Williamson, C1
Moretti, F1
Fausti, C1
Pan, A1
Casari, S1
Mildvan, D1
Yarrish, R1
Marshak, A1
Hutman, HW1
Jambroes, M1
Juttmann, J1
Dodi, F1
Alessandrini, A1
Camera, M1
Gaffuri, L1
Morandi, N1
Pagano, G1
Huff, B1
Titier, K1
Lagrange, F1
Péhourcq, F1
Edno-Mcheik, L1
Moore, N1
Molimard, M1
Skordis, J1
Tidwell, RR1
Gebbie, KM1
Imperiale, M1
Cullinan, K2
Weel, J1
Cunningham-Schrader, B1

Clinical Trials (139)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Phase 3 Trial to Evaluate Two Simplified Antiretroviral Treatment Strategies in HIV Infected Children, Treated by Antiretroviral Triple Therapy Before One Year of Age, in Virological Success in Africa (Burkina Faso, Côte d'Ivoire, Rwanda)[NCT01127204]Phase 2/Phase 3161 participants (Actual)Interventional2011-06-30Completed
"Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk"[NCT05761509]200 participants (Anticipated)Observational2023-06-08Recruiting
Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection[NCT01404312]Phase 33,000 participants (Actual)Interventional2012-05-23Completed
BHP Early Infant Treatment Study: A Clinical Treatment Trial of HIV+ Infants in Botswana[NCT02369406]Phase 2/Phase 367 participants (Actual)Interventional2015-05-04Active, not recruiting
Optimal Combination Therapy After Nevirapine Exposure[NCT00089505]Phase 3745 participants (Actual)Interventional2006-11-30Completed
PHPT-5 Second Phase: Perinatal Antiretroviral Intensification for the Prevention of Mother-to-child Transmission of HIV in Thai Women Having Received Less Than 8 Weeks of HAART During Pregnancy[NCT01511237]Phase 3379 participants (Actual)Interventional2011-12-31Completed
A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding[NCT00074412]Phase 32,026 participants (Actual)Interventional2007-01-31Completed
Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study[NCT02140255]Phase 1/Phase 2905 participants (Anticipated)Interventional2015-01-23Recruiting
Short Duration Exclusive Breastfeeding With Abrupt Weaning to Reduce the Risk of Mother-to-Child HIV Transmission[NCT00310726]1,435 participants (Actual)Interventional2001-05-31Completed
Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)[NCT01061151]Phase 33,747 participants (Actual)Interventional2011-03-01Completed
Treatment Options for Protease Inhibitor-exposed Children[NCT01146873]Phase 3300 participants (Actual)Interventional2010-07-31Completed
A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in HIV-Infected Ugandan Women[NCT02082652]Phase 460 participants (Actual)Interventional2014-10-31Completed
Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin in Antiretroviral Naive Patients Co-infected With HIV and Tuberculosis in India.[NCT01805258]Phase 3135 participants (Actual)Interventional2007-06-30Completed
Novel Approaches to Monitoring and Utilizing Adherence to HIV Therapy in Uganda[NCT01596322]750 participants (Actual)Observational2004-09-30Completed
Evaluation of Conditional Cash Transfers to Increase Retention in PMTCT Services in Akwa Ibom State, Nigeria[NCT02447159]554 participants (Actual)Interventional2015-08-31Completed
Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa[NCT05633056]360 participants (Anticipated)Interventional2023-02-28Not yet recruiting
Randomized Non-inferiority Trial Comparing the Nevirapine-based Antiretroviral Therapy Versus the Standard Efavirenz-based ART for the Treatment of HIV-TB Co-infected Patients on Rifampicin-based Therapy (ANRS 12146 CARINEMO)[NCT00495326]Phase 2/Phase 3570 participants (Actual)Interventional2007-12-31Completed
Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand[NCT00433030]2,816 participants (Actual)Observational2007-01-31Completed
EuroSIDA Prospective Observational Cohort Study on Clinical and Virological Outcome of European Patients Infected With HIV[NCT02699736]23,000 participants (Actual)Observational [Patient Registry]1994-01-31Enrolling by invitation
Predictors of Antiretroviral Pharmacokinetics in HIV-infected Women With Virologic Suppression on Combination Antiretroviral Therapy[NCT00433979]88 participants (Actual)Observational2007-02-28Completed
The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance After a Single Dose Nevirapine (VIramune®), Which is Part of ARV Prophylaxis for PMTCT in Moshi, TAnzania, and in Lusaka, Zambia (VITA2 Trial)[NCT01187719]Phase 266 participants (Actual)Interventional2010-05-31Completed
Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women[NCT00993031]Phase 3389 participants (Actual)Interventional2009-12-15Completed
Solid Organ Transplantation in HIV: Multi-Site Study[NCT00074386]275 participants (Actual)Observational2003-10-31Completed
Interactions Between Antiretrovirals and Combined Oral Contraceptive Pills[NCT00829114]Phase 4370 participants (Anticipated)Interventional2009-03-31Completed
PROMISE EBF: Promoting Infant Health and Nutrition in Sub-Saharan Africa: Safety and Efficacy of Exclusive Breastfeeding Promotion in the Era of HIV[NCT00397150]2,579 participants (Actual)Interventional2006-11-30Completed
A Long-term Follow-up Study for HIV-infected Individuals Who Have Participated in HIV-NAT Study Protocols[NCT00411983]10,000 participants (Anticipated)Observational2002-11-30Recruiting
Clinical Relevance of Nevirapine Resistance[NCT00117728]Phase 3250 participants (Anticipated)Interventional2005-04-30Recruiting
Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya (0-4.5 Month Randomized Controlled Trial)[NCT00428116]140 participants (Actual)Interventional2007-09-30Terminated (stopped due to DSMB recommended termination because TI was safe but not durable.)
URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299]Phase 4302 participants (Actual)Interventional2017-04-07Completed
A Randomized Open Label Trial of HIV Protease Inhibitors for the Prevention of Malaria in HIV-Infected Children[NCT00978068]Phase 3176 participants (Actual)Interventional2009-09-30Completed
Nevirapine vs Ritonavir-boosted Lopinavir in ART HIV-infected Adults in a Resource-limited Setting; a Randomized, Multicenter, Parallel Group Study[NCT01772940]Phase 4425 participants (Actual)Interventional2008-12-31Completed
A Phase I, Open-label, Randomized Crossover Trial to Investigate the Pharmacokinetic Interaction Between Steady-state Lopinavir/Ritonavir and Single-dose TMC207 in Healthy Subjects.[NCT00828529]Phase 116 participants (Actual)Interventional2009-02-28Completed
A Phase I, Open-label, Single-sequence Drug-drug Interaction Trial to Investigate the Pharmacokinetic Interaction Between Steady-state Nevirapine and Single-dose TMC207 in HIV-1 Infected Subjects.[NCT00910806]Phase 116 participants (Actual)Interventional2009-06-30Completed
Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811]625 participants (Anticipated)Observational2020-01-30Recruiting
Phase II, Parallel, Randomized, Clinical Trials Comparing the Responses to Initiation of NNRTI-Based Versus PI-Based Antiretroviral Therapy in HIV Infected Infants Who Have and Have Not Previously Received Single Dose Nevirapine for Prevention of Mother-t[NCT00307151]Phase 2452 participants (Actual)Interventional2005-12-31Completed
Vicente Ferrer HIV Cohort Study[NCT02454569]30,000 participants (Anticipated)Observational [Patient Registry]2009-09-30Recruiting
The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients[NCT03789968]411 participants (Actual)Observational2019-09-01Completed
Clinic-based ART Diagnostic Evaluation[NCT01791556]820 participants (Actual)Interventional2010-01-26Completed
Therapeutic Drug Monitoring of Corticosteroids/β2-agonists in Hair in Asthmatic Patients: an Open-label Feasibility Study[NCT03691961]24 participants (Actual)Interventional2018-09-20Active, not recruiting
Urine Tenofovir Point-of-care Test to Identify Patients in Need of ART Adherence Support (UTRA Study)[NCT05333679]200 participants (Anticipated)Interventional2022-03-02Recruiting
Phase 2 Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults[NCT02067767]Phase 253 participants (Actual)Interventional2014-02-28Completed
Maternal and Infant Peripartum Nevirapine, Versus Infant Only Peripartum Nevirapine, or Maternal Lopinavir/Ritonavir in Addition to Standard Zidovudine Prophylaxis for the Prevention of Perinatal HIV in Thailand.[NCT00409591]Phase 3435 participants (Actual)Interventional2008-07-31Terminated (stopped due to Change in National PMTCT guidelines in Thailand)
A Pharmacokinetic Evaluation of Levonorgestrel Implant and Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in HIV-infected Ugandan Women[NCT01789879]Phase 260 participants (Actual)Interventional2014-03-04Completed
Optimizing Integrated PMTCT Services in Rural North-Central Nigeria: A Cluster Randomized Trial[NCT01805752]369 participants (Actual)Interventional2013-03-31Completed
P1060 Substudy Comparing Differences in Malaria Parasitemia by Real Time Quantitative PCR in HIV-Infected Infants and Children on PI-Based HAART Versus NNRTI-Based HAART[NCT00719602]Early Phase 1105 participants (Actual)Interventional2009-08-31Completed
A Randomised Controlled Trial to Assess Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure[NCT01433601]640 participants (Actual)Interventional2007-08-31Active, not recruiting
Effect of Moringa Oleifera (Moringa, Drumstick/Horseradish Tree) on The Pharmacokinetics of Efavirenz and Nevirapine In-vivo.[NCT01410058]19 participants (Actual)Observational2013-01-31Completed
Addition of Single-dose, Maternal Tenofovir and Emtricitabine to Reduce Non-nucleoside Reverse Transcriptase Inhibitor Resistance Mutations in the Setting of Zidovudine and Nevirapine for Prevention of Mother-to-child HIV Transmission[NCT00204308]Phase 2400 participants (Actual)Interventional2005-03-31Completed
Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission[NCT00115648]Phase 33,300 participants (Anticipated)Interventional2004-04-30Completed
Presumptive and Definitive Virologic HIV Diagnosis in Hospitalized Malawian Infants[NCT01388452]300 participants (Actual)Interventional2011-06-30Completed
ARVs to Prevent Breastmilk HIV:Viral and Immune Responses[NCT00167674]Phase 258 participants (Actual)Interventional2003-05-31Completed
Effect of Intermittent Preventive Treatment (IPTp) With Sulfadoxine-Pyrimethamine Plus Insecticide Treated Nets, Delivered Through Antenatal Clinics for the Prevention of Malaria in Mozambican Pregnant Women[NCT00209781]1,028 participants Interventional2003-08-31Active, not recruiting
Prevention of Maternal to Infant HIV Transmission in India[NCT00061321]Phase 3770 participants (Actual)Interventional2002-08-31Completed
Nevirapine (NVP) Use to Prevent Maternal-Infant HIV Transmission: A Randomized Clinical Trial of Two Doses of NVP Compared to Six Weeks of NVP for the Prevention of Maternal-Infant HIV Transmission in the Breastfeeding Infant[NCT00074399]Phase 3775 participants (Actual)Interventional2001-02-28Completed
A Phase III Randomized Clinical Trial of the Standard Two Dose Nevirapine (NVP) Regimen With the Addition of HIV Immune Globulin(HIVIGLOB) or Extended Infant NVP Dosing Compared With the Standard NVP Regimen Alone for the Prevention of Maternal-Infant HIV[NCT00639938]Phase 3722 participants (Actual)Interventional2004-07-31Completed
A 48 Week, Randomized, Open-label, 2 Arm Study to Compare the Efficacy, Safety and Tolerability of HAART Containing Nevirapine 400mg/Day Versus Nevirapine 600 mg/Day in HIV-1 Infected Patients Started at 2-6 Weeks After Initiating Rifampin Containing Anti[NCT00476853]Phase 242 participants (Actual)Interventional2005-10-31Completed
Durability of Stavudine, Lamivudine and Nevirapine Among Advanced HIV-1 Infected Patients With/Without Prior Co-Administration of Rifampicin: A 144-Week Prospective Study[NCT00703898]Phase 4140 participants (Actual)Interventional2004-11-30Completed
A Cohort Study To Assess The Impact Of A Breastfeeding Counselling And Support Strategy To Promote Exclusive Breastfeeding On Post-Natal Transmission Of HIV In African Women[NCT01948557]3,465 participants (Actual)Interventional2001-10-31Completed
Botswana Diarrheal Diseases Study[NCT00197652]1,350 participants (Actual)Observational2001-03-31Completed
Botswana Pediatric Respiratory Disease and Bloodstream Infection[NCT00197691]0 participants Observational2001-03-31Completed
Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-infected Ugandan Adults[NCT01025830]Phase 420 participants (Actual)Interventional2006-02-28Completed
A Restrictively Randomized, Open-Label, Controlled, Pilot Study of the Effect of a Thymidine Analogue Substitution or Change to a Nucleoside-Sparing Regimen on Peripheral Fat Wasting[NCT00028314]150 participants Interventional2002-03-31Completed
Phase II Trial, Multicentre, Opened Label Evaluating the Pharmacokinetics and the Safety and Toxicity of the Tenofovir-Emtricitabine Combination in Pregnant Women and Infants in Africa and Asia[NCT00334256]Phase 272 participants (Actual)Interventional2006-10-31Completed
MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)[NCT00122226]Phase 450 participants Interventional2003-01-31Active, not recruiting
Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin[NCT00483054]Phase 3142 participants (Actual)Interventional2007-01-31Completed
Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)[NCT01066858]1,765 participants (Actual)Observational2011-03-22Completed
Randomised, Prospective Multicentre Clinical Study on the Effect of the Combination of Lopinavir/Rtv + Nevirapine as Maintenance Bitherapy (Without Nucleoside Analogues) in Comparison With a Triple Therapy Including Lopinavir/Rtv + Nucleoside Analogues in[NCT00335686]Phase 467 participants (Actual)Interventional2003-10-31Completed
Phase III Trial of Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission[NCT00021671]Phase 33,720 participants InterventionalCompleted
HIV Exposure, Disease Acquisition and Progression Among Children: Role of Maternal Immunogenetics, Viral Genetic Diversity, HAART Exposure, Co-morbidities and Psycho-Social Status: (UZ-CHS Birth Cohort)[NCT04087239]1,200 participants (Actual)Observational2016-01-26Active, not recruiting
Efavirenz Pharmacokinetics and Pharmacogenomics in Older HIV-infected Patients[NCT01886404]30 participants (Actual)Observational [Patient Registry]2013-12-01Completed
An Open-label Study Evaluating the Resistance Profile of Single Dose Nevirapine(NVP) When Combined With a 4 or 7 Day Course of Combivir® (ZDV/3TC) Compared to Single Dose Nevirapine for the Prevention of Mother to Child Transmission (pMTCT) of HIV - Treat[NCT00144183]Phase 3407 participants Interventional2003-01-31Completed
Optimizing the Delivery of Maternal and Child Health Services to Strengthen the Primary Health Care System in Rural South Africa[NCT02626351]3,172 participants (Actual)Interventional2015-07-15Completed
Short-term Effectiveness of a Community Health Worker Intervention for HIV-infected Pregnant Women in Tanzania to Improve Treatment Adherence and Retention in Care: A Cluster-Randomized Trial[NCT03058484]1,830 participants (Actual)Interventional2015-05-01Completed
Community ART for Retention in Zambia: Evaluating the Feasibility, Effectiveness, and Efficiency of Decentralized and Streamlined Antiretroviral Therapy Care Models[NCT02776254]3,100 participants (Actual)Interventional2016-03-31Completed
A Phase 2, One Arm, Open Label, Feasibility Study Assessing One Month Zidovudine/Didanosine Postpartum Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine to Prevent Mother to Child Transmission of HIV[NCT00142337]Phase 2244 participants (Actual)Interventional2004-12-31Completed
Efavirenz to Nevirapine Switch in HIV-1 Infected Patients With Severe Dyslipidemia: A Randomized Controlled Study[NCT00405171]Phase 440 participants Interventional2003-06-30Completed
A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Stavudine (d4T), Lamivudine (3TC), and Nevirapine (NVP) as GPO-VIR Pediatric Chewable Tablets Versus the Individual Liquid Formulations in HIV Infected Children 6 Months[NCT00312091]Phase 1/Phase 244 participants (Actual)Interventional2006-12-31Completed
HIV Infection and Breastfeeding: Interventions for Maternal and Infant Health[NCT00164736]Phase 32,369 participants (Actual)Interventional2004-03-31Completed
Pharmacokinetics and Safety of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants[NCT04862975]200 participants (Anticipated)Observational2024-01-08Not yet recruiting
Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana[NCT00270296]Phase 2730 participants (Actual)Interventional2006-06-30Completed
Z 1303 - Point-of-Care Virologic Testing to Improve Outcomes of HIV-Infected Children[NCT02682810]4,000 participants (Actual)Interventional2016-02-29Completed
Nevirapine Pharmacodynamics and Resistance Among HIV-Infected Mothers in Lilongwe, Malawi[NCT00164762]126 participants (Actual)Observational2005-06-30Completed
A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177]Phase 496 participants (Actual)Interventional2013-01-31Completed
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years[NCT01504841]Phase 1/Phase 226 participants (Actual)Interventional2013-03-14Completed
Comparison of Nevirapine Levels With and Without Dose Escalation in HIV-infected Patients Commencing Antiretroviral Therapy Who Are Also Receiving Rifampicin Based Anti-tuberculous Therapy[NCT00617643]Phase 418 participants (Anticipated)Interventional2008-05-31Completed
Randomized, Open Label Study Evaluating the Lipid Profile Difference and Efficacy of a Combined Therapy Including Tenofovir, Emtricitabine + Atazanavir / r or NVP in Naive HIV - 1 Infected Patients.[NCT00389207]Phase 3576 participants (Actual)Interventional2006-10-31Completed
A Randomised, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada®[NCT00561925]Phase 31,068 participants (Actual)Interventional2007-11-30Completed
Evaluation of Safety and Efficacy of Two Different Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment in Patients With HIV-1 and Tuberculosis[NCT00332306]Phase 3180 participants (Anticipated)Interventional2006-06-30Active, not recruiting
Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Nevirapine in HIV-infected Adults[NCT00790881]Phase 436 participants (Anticipated)Interventional2008-10-31Completed
The HIV Second-line Therapy AntiRetroviral Study in Patients Who Failed NNRTI-based Regimens[NCT00627055]Phase 4200 participants (Actual)Interventional2008-05-31Completed
The Effect of Single Dose Carbamazepine on the Pharmacokinetics of Single Dose Nevirapine (Viramune, NVP) and Development of NVP Resistance, PMTCT Program of Moshi, Tanzania (VITA1)[NCT00294892]Phase 2144 participants (Actual)Interventional2006-02-28Completed
[NCT00398684]Phase 31,792 participants Interventional2001-01-31Completed
Phase II Study of the Pharmacokinetics of Nevirapine and the Incidence of Nevirapine Resistance Mutations in HIV-Infected Women Receiving a Single Intrapartum Dose of Nevirapine With the Concomitant Administration of Zidovudine/Didanosine or Zidovudine/Di[NCT00109590]Phase 2175 participants (Actual)Interventional2006-06-30Completed
HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding[NCT00530777]Phase 2148 participants (Actual)Interventional2008-04-30Completed
Phase III Randomized Trial of the Safety and Efficacy of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV-1 Transmission[NCT00099359]Phase 31,735 participants (Actual)Interventional2004-02-29Completed
A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection[NCT01780831]Phase 152 participants (Actual)Interventional2014-01-28Completed
Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine[NCT00099632]Phase 2484 participants (Actual)Interventional2006-03-31Completed
Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients[NCT00872417]Phase 4750 participants (Anticipated)Interventional2009-03-31Not yet recruiting
A Phase III Placebo-Controlled Trial to Determine the Efficacy of Oral AZT and the Efficacy of Oral Nevirapine for the Prevention of Vertical Transmission of HIV-1 Infection in Pregnant Ugandan Women and Their Neonates[NCT00006396]Phase 31,500 participants InterventionalCompleted
A Phase III Randomized, Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women[NCT00000869]Phase 32,009 participants InterventionalCompleted
A Phase III Randomized Trial of the Safety and Antiretroviral Effects of Zidovudine/Lamivudine/Abacavir Versus Zidovudine/Lamivudine/Lopinavir/Ritonavir in the Prevention of Perinatal Transmission of HIV[NCT00086359]Phase 319 participants (Actual)Interventional2004-07-31Completed
Assessment of Safety and Toxicity Among Infants Born to HIV-1-Infected Women Enrolled in Antiretroviral Treatment Protocols in Diverse Areas of the World[NCT00100867]236 participants (Actual)Observational2006-06-30Completed
Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum[NCT00042289]1,578 participants (Actual)Observational2003-06-09Completed
A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women[NCT00001135]Phase 32,009 participants InterventionalCompleted
A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women[NCT00000942]Phase 31,244 participants InterventionalCompleted
Hepatic Safety of Currently Used Antiretroviral Regimens in HIV-infected Patients With Chronic Hepatitis B and/or Hepatitis C Under Real Life Conditions: The HEPAVIR HEPATIC SAFETY Cohort.[NCT01908660]192 participants (Actual)Observational [Patient Registry]2007-01-31Completed
Tenofovir, Emtricitabine, and Nevirapine for Recently HIV-Infected Subjects: Can Short-Course, Once Daily Therapy Reduce the Viral Load at 12 Months From Estimated Date of Infection?[NCT00087464]0 participants (Actual)InterventionalWithdrawn (stopped due to study was withdrawn before any participants were recruited and enrolled)
Randomized Trial of Protease Inhibitor-Including vs. Protease Inhibitor-Sparing Regimens for Women Who Initiate Therapy of HIV Infection During Pregnancy[NCT00017719]Phase 3440 participants Interventional2002-05-31Completed
An Open-Label, Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Pre-menopausal Women[NCT00961272]6 participants (Actual)Observational2009-07-31Completed
A Phase IV, Open-Label, Single-Sequence Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Women[NCT00774683]1 participants (Actual)Observational2008-08-31Completed
A Phase IV, Open-Label Study to Characterize the First-Dose and Multiple-Dose Pharmacokinetics of Raltegravir in the Gastrointestinal Tract of Healthy Male Volunteers[NCT01325051]Phase 115 participants (Actual)Interventional2011-04-30Completed
A Cohort Observational Study to Assess the Virologic Response to Standard HIV Treatment in Bamako, Mali[NCT00703404]76 participants (Actual)Observational2008-06-18Completed
A Phase I Study of the Safety, Tolerance, and Pharmacokinetics of Tenofovir Disoproxil Fumarate (TDF) and the Combination of TDF Plus Emtricitabine in HIV-1 Infected Pregnant Women and Their Infants[NCT00076791]Phase 166 participants (Actual)Interventional2004-03-31Completed
Phase I/II Study to Assess the Safety and Plasma Concentrations of Nevirapine Given Daily, Twice a Week or Weekly as Prophylaxis in Breastfeeding Infants From Birth to 6 Months[NCT00006279]Phase 175 participants InterventionalCompleted
A Randomized, Open-Label Study of the Long-Term Effectiveness of Three Initial Highly Active Antiretroviral Therapy (HAART) Strategies in HAART-Niave, HIV-Infected Persons[NCT00000922]1,710 participants InterventionalCompleted
A Phase II Randomized, Multicenter Protocol Evaluating Two Antiretroviral Regimens Containing Combinations of Protease Inhibitors, NRTIs, and an NNRTI[NCT00000924]Phase 2120 participants InterventionalCompleted
"Prevention of Milk-Borne Transmission of HIV-1C in Botswana (Mashi)"[NCT00197587]1,200 participants (Actual)Interventional2002-08-31Completed
A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Zidovudine (ZDV), Lamivudine (3TC), and Nevirapine (NVP) as GPO-Vir Z30 Pediatric Tablets Versus the Individual Liquid Formulations in HIV-Infected Children Greater Than[NCT00672412]Phase 1/Phase 242 participants (Actual)Interventional2008-10-31Completed
Phase I Three-way Crossover Bioequivalence Study of Pediatric Formulations of Lamivudine/Zidovudine/Nevirapine Using Healthy Adult Volunteers[NCT01469520]Phase 124 participants (Actual)Interventional2010-10-31Active, not recruiting
ART Readiness in HIV-infected Pregnant Women: From Formative Qualitative Research to Individual Randomized Trial[NCT02459678]454 participants (Actual)Interventional2015-05-31Completed
RAD-1: A Phase I/II Antiretroviral Management Algorithm for Pediatric Subjects of Four-Drug Combination Therapies Based on Prior Antiretroviral Experience[NCT00000902]Phase 1217 participants InterventionalCompleted
A Phase II Rolling Arm Master Protocol (PRAM) of Novel Antiretroviral Therapy in Stable Experienced HIV-Infected Children. PRAM-2: A Phase I/II Randomized, Multicenter Protocol Comparing Four Antiretroviral Regimens Containing Combinations of Protease Inh[NCT00001091]Phase 1200 participants InterventionalCompleted
[NCT00466180]Phase 462 participants (Actual)Interventional2004-06-30Completed
An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Between Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) and Selected Protease Inhibitor (PI) and Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapies Among HIV-Infected W[NCT00016601]76 participants Interventional2001-06-30Completed
An Open Label, Staggered Rising Dose Cohort Study Assessing Safety, Tolerance, and Activity of BI-RG-587 in Patients With HIV Infection (CD4+ Cell Count < 400 Cells/mm3)[NCT00000962]Phase 130 participants InterventionalCompleted
An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)[NCT00000649]Phase 130 participants InterventionalCompleted
A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine[NCT00000770]Phase 2400 participants InterventionalCompleted
Pharmacokinetics, Safety, Tolerance, and Activity of Nevirapine (BI-RG-587) Alone and in Combination With AZT in Mildly to Moderately Symptomatic HIV-1 Infected Children[NCT00001111]35 participants InterventionalCompleted
Global Initiative to Characterize Differences in Antiretroviral Pharmacokinetics in HIV-Infected Populations[NCT00054743]Phase 424 participants (Actual)Interventional2003-02-06Completed
A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers[NCT00000808]Phase 149 participants InterventionalCompleted
A Phase I Study of Tenofovir Disoproxil Fumarate (PMPA Prodrug), A Novel Nucleotide Analog Reverse Transcriptase Inhibitor in Children With HIV Infection[NCT00024986]Phase 130 participants Interventional2001-10-31Completed
A 48-Weeks National Multicenter Randomized Open Clinical Trial Evaluating Tolerance and Efficacy of a Treatment Simplification by Lopinavir/Ritonavir Versus Continuation of Current Treatment in HIV-Infected Patients With a Viral Load Inferior to 50 Copies[NCT00140751]Phase 3186 participants (Actual)Interventional2005-10-31Completed
Mother-Infant Rapid Intervention at Delivery (MIRIAD)[NCT00046436]7,500 participants ObservationalTerminated
A Phase II Study of 1) Amprenavir (141W94/VX478) Plus 3TC Plus ZDV (or d4T) or 2) IDV Plus NVP Plus 3TC Plus d4T in Subjects Previously Treated With Amprenavir and 3) Other Treatment Regimens (Observational ARM) in Subjects Previously Treated With Amprena[NCT00001095]Phase 294 participants InterventionalCompleted
A Pilot Study to Evaluate the Immunologic Consequences of a Highly Active Antiretroviral Therapy Regimen (HAART) Consisting of Ritonavir (ABT-538), Zidovudine (AZT), and Lamivudine (3TC) in Moderately Advanced HIV-1 Disease[NCT00001075]55 participants InterventionalCompleted
Antiretroviral Activity and Tolerability of Once Daily Etravirine in Treatment-Naïve Adults With HIV-1 Infection[NCT00959894]Phase 280 participants (Actual)Interventional2009-09-30Completed
Multicenter, Pilot Study of Telbivudine (LdT) Anti-HBV Treatment Prior to the Initiation of Highly Active Antiretroviral Therapy Containing Lamivudine in Subjects Coinfected With HBV and HIV[NCT00051090]0 participants (Actual)InterventionalWithdrawn
A Phase II Rolling Arm Master Protocol (PRAM) of Novel Antiretroviral Therapy in Stable Experienced HIV- Infected Children; PRAM-1: ZDV+3TC vs. d4T+Ritonavir vs. ZDV+3TC+Ritonavir; PRAM-1, Step 2: d4T+Nevirapine+Ritonavir; PRAM-1, Step 3: d4T+Indinavir vs[NCT00001083]Phase 2240 participants InterventionalCompleted
A Phase II Pharmacokinetic Study of the Transdermal Contraceptive System and Oral Contraceptive in HIV-1 Infected Women on Lopinavir/Ritonavir[NCT00125983]Phase 232 participants (Actual)InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Incidence of First Diagnosis of Active Tuberculosis, Death Related to Tuberculosis, or Death From Unknown Cause

Incidence rate (events per 100 person-years) was estimated, and 95.1% confidence interval used to account for interim analysis of primary efficacy outcome. (NCT01404312)
Timeframe: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)

InterventionEvents per 100 person-years (Number)
RPT Plus INH Regimen (Arm A)0.6506
INH Regimen (Arm B)0.6736

Cumulative Incidence of Death Due to a Non-TB Event

Cumulative incidence function estimated nonparametrically, treating TB-related deaths as competing risks. (NCT01404312)
Timeframe: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)

,
Interventionevents per 100 participants (Number)
Cumulative incidence by 1 year post-randomizationCumulative incidence by 2 years post-randomizationCumulative incidence by 3 years post-randomizationCumulative incidence by 4 years post-randomization
INH Regimen (Arm B)0.51.01.52.0
RPT Plus INH Regimen (Arm A)0.30.40.91.6

Cumulative Incidence of Death From Any Cause

Data table estimates for percentage who died by each time point were estimated using Kaplan-Meier at 1, 2, 3, and 4 years post-entry. (NCT01404312)
Timeframe: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)

,
Interventionevents per 100 participants (Number)
1 year post-entry2 years post-entry3 years post-entry4 years post-entry
INH Regimen (Arm B)0.631.151.622.29
RPT Plus INH Regimen (Arm A)0.350.491.052.00

Efavirenz (EFV) Plasma Concentrations in Arm A

"Mean and standard deviation.~Week 16 samples have not yet been analyzed because the metabolite assay is being validated, and requires submission for approval by the Clinical Pharmacology Quality Assurance Program. Analysis of week 16 samples are anticipated to be available in September 2019." (NCT01404312)
Timeframe: Measured at Weeks 0, 2, 4, and 16

Interventionnanograms per mL (Mean)
Week 0Week 2Week 4
RPT Plus INH Regimen (Arm A)378738704082

Nevirapine (NVP) Plasma Concentrations in Arm A

Mean and standard deviation (NCT01404312)
Timeframe: Measured at Weeks 0, 2, and 4

Interventionnanograms per mL (Mean)
Week0Week 2Week 4
RPT Plus INH Regimen (Arm A)757362345797

Number of Participants With Antibiotic Resistance Among Mycobacterium Tuberculosis (MTB) Isolates in Participants Who Develop Active Tuberculosis

Among MTB-diagnosed participants who underwent drug-susceptibility testing, the number who had any resistance to a particular drug. (NCT01404312)
Timeframe: After TB diagnosis

InterventionParticipants (Count of Participants)
Rifampin72268104Rifampin72268105Isoniazid72268104Isoniazid72268105Ethambutol72268104Ethambutol72268105Pyrazinamide72268104Pyrazinamide72268105
Developed ResistanceDid not Develop Resistance
RPT Plus INH Regimen (Arm A)1
INH Regimen (Arm B)1
RPT Plus INH Regimen (Arm A)14
INH Regimen (Arm B)11
RPT Plus INH Regimen (Arm A)2
RPT Plus INH Regimen (Arm A)12
RPT Plus INH Regimen (Arm A)0
RPT Plus INH Regimen (Arm A)7
INH Regimen (Arm B)7
INH Regimen (Arm B)0
RPT Plus INH Regimen (Arm A)6
INH Regimen (Arm B)6

Number of Participants Who Experienced HIV-related Disease Progression or Death

Worsening to WHO stage III/IV (among subjects who had WHO stage I/II at baseline) and death were the composite secondary endpoint. WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents is an approach for use in resource limited settings in studies of progression to symptomatic HIV disease. There are 4 stages of disease staging, 1 being the least severe and 4 being the most severe disease stage based on the HIV related symptoms and diagnoses. Please refer to the following web page for detailed staging criteria: http://www.who.int/docstore/hiv/scaling/anex1.html (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.

Interventionparticipants (Number)
NVP/NVP6
NVP/LPV_r4
NoNVP/NVP19
NoNVP/LPV_r26

Number of Participants Who Experienced Treatment-related Toxicity That Led to Discontinuation of Randomized Regimen.

The outcome is defined as treatment-related toxicity (as evaluated by sites), regardless of grade, that led to discontinuation of randomized regimen. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.

Interventionparticipants (Number)
NVP/NVP15
NVP/LPV_r0
NoNVP/NVP35
NoNVP/LPV_r0

Number of Participants Who Experienced Virologic Failure or Died.

Virologic failure (VF) is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.

Interventionparticipants (Number)
NVP/NVP32
NVP/LPV_r10
NoNVP/NVP42
NoNVP/LPV_r50

Number of Participants Who Received NVP-containing Regimens at Randomization and Experienced NVP-associated Rash or Grade 2+ Liver Lab Abnormality

Any grade of rash or grade 2+ liver lab abnormality events that were claimed to be NVP associated (definitely, probably, or possibly) by site investigators were evaluated. Grade 2+ liver lab abnormality is defined as aspartate aminotransferase (AST)>=2.6 x ULN or alanine aminotransferase (ALT)>=2.6 x ULN. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP arm. Throughout study for NoNVP/NVP arm.

Interventionparticipants (Number)
NVP/NVP20
NoNVP/NVP51

CD4 Count Change From Randomization

Change was calculated as the CD4 count at Week 48 (or at Week 96) minus the baseline CD4 count (last CD4 before/on treatment start date). For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r. Week 48 and 96.

,,,
Interventioncells/mm^3 (Median)
Week 48 CD4 count change from randomizationWeek 96 CD4 count change from randomization
NoNVP/LPV_r172256
NoNVP/NVP172223
NVP/LPV_r201278
NVP/NVP191291

Percent of Participants Who Experienced Virologic Failure or Died

Results report cumulative percent of participants reaching virologic failure (VF) or death by week 48 and week 96 calculated using the Kaplan-Meier method. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.

,,,
InterventionPercent of participants (Number)
week 48 percent of virologic failure or deathweek 96 percent of virologic failure or death
NoNVP/LPV_r1420
NoNVP/NVP1417
NVP/LPV_r412
NVP/NVP2331

Percent of Participants Who Reported to Never Missed Any of the Study Drug Regimen in the Past Month

Self-reported adherence at week 48 and 96 while participants remained on randomized regimen. Adherence interviews for each antiretroviral drug drug the participant is taking was performed by site personnel every 24 weeks. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.

,,,
Interventionpercent of participants (Number)
week 48 percent of full adherence in past monthweek 96 percent of full adherence in past month
NoNVP/LPV_r8687
NoNVP/NVP9093
NVP/LPV_r8895
NVP/NVP8994

Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study Entry

5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) with median follow-up 72 weeks and range from 0 to 144 weeks.

,
Interventionweeks (Number)
5th percentile10th percentile25th percentile
NVP/LPV_r6084NA
NVP/NVP121260

Time From Randomization to Virologic Failure or Death for Participants Without SD NVP Exposure Prior to Study Entry

5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Throughout study with median follow-up 72 weeks and range from 0 to 180 weeks.

,
Interventionweeks (Number)
5th percentile10th percentile25th percentile
NoNVP/LPV_r1236132
NoNVP/NVP2436NA

Frequency and Severity of Adverse Reactions Among Participating Infants

For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness. (NCT00074412)
Timeframe: 6 weeks through 18 months

,
InterventionNumber of Adverse Events (Number)
DeathLife-ThreateningSevereModerateMild
Nevirapine2687375694832
Placebo3087332677838

HIV Infection in Infants Determined to be HIV Uninfected at 6 Weeks Enrolled in Each Arm of the Study

(NCT00074412)
Timeframe: At Month 6

,
Interventionparticipants (Number)
# of HIV infections at 6 months# of Infants at risk for HIV infection at 6 months
Nevirapine8700
Placebo18699

Infant Survival Rates (Mortality Regardless of HIV Infection) in the Two Arms

(NCT00074412)
Timeframe: At Month 18

,
Interventionparticipants (Number)
# Infant Deaths at 18 months# Infants at risk of death at 18 months
Nevirapine26678
Placebo30684

Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms

(NCT00074412)
Timeframe: At Months 6 and 18

,
Interventionparticipants (Number)
Number of Infants Alive and HIV-free at 6 monthsNumber of Infants Alive and HIV-free at 18 months
Nevirapine689629
Placebo683616

Relative Rates of HIV Infection in the Two Arms

(NCT00074412)
Timeframe: At Month 18

,
Interventionparticipants (Number)
# of infants with HIV infection at 18 months# of infants @ risk for HIV infection at 18 months
Nevirapine16664
Placebo23663

Antepartum Component: Number of Confirmed Infant HIV Infections

Defined as HIV nucleic acid test (NAT) positivity of the specimen drawn at either the birth (Day 0-5) or Week 1 (Day 6-14) visit, confirmed by HIV NAT positivity of a second specimen collected at a different time point (NCT01061151)
Timeframe: Measured at birth or Week 1 study visit

InterventionParticipants (Count of Participants)
Antepartum Arm A25
Antepartum Arm B7
Antepartum Arm C2

Antepartum Component: Number of Infant HIV Infections

Detected by HIV NAT positivity (NCT01061151)
Timeframe: Measured at the birth (<= 3 days postpartum) visit

InterventionParticipants (Count of Participants)
Antepartum Arm A22
Antepartum Arm B4
Antepartum Arm C2

Maternal Health Component: Incidence of AIDS-defining Illness

"AIDS-defining illness refers to the WHO Clinical Stage 4 illnesses listed in Appendix IV. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

InterventionNew cases per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)0.08
Maternal Health Arm B (Discontinue Triple ARVs)0.25

Maternal Health Component: Incidence of Death

Number of women who died during the maternal health component; that is, who had been randomized to either continue or discontinue ART after risk of HIV vertical transmission through breastfeeding was over. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

InterventionNew cases per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)0.24
Maternal Health Arm B (Discontinue Triple ARVs)0.43

Maternal Health Component: Incidence of HIV/AIDS-related Event or Death

"HIV/AIDS-related event refers to the WHO Clinical Stage 4 illnesses, pulmonary tuberculosis, and other serious bacterial infections listed in Appendix IV of the protocol. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

InterventionNew cases per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)1.30
Maternal Health Arm B (Discontinue Triple ARVs)1.43

Maternal Health Component: Incidence of HIV/AIDS-related Event or World Health Organization (WHO) Clinical Stage 2 or 3 Events

"HIV/AIDS-related event refers to the WHO Clinical Stage 4 illnesses, pulmonary tuberculosis, and other serious bacterial infections listed in Appendix IV of the protocol. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

InterventionNew cases per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)3.47
Maternal Health Arm B (Discontinue Triple ARVs)5.61

Maternal Health Component: Incidence of HIV/AIDS-related Events

"HIV/AIDS-related event refers to the WHO Clinical Stage 4 illnesses, pulmonary tuberculosis, and other serious bacterial infections listed in Appendix IV of the protocol. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

InterventionNew cases per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)1.14
Maternal Health Arm B (Discontinue Triple ARVs)1.24

Maternal Health Component: Incidence of Progression to AIDS-defining Illness or Death

AIDS-defining illness refers to the WHO Clinical Stage 4 illnesses in Appendix IV of the protocol. These events were reviewed and confirmed by an Endpoint review group. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

InterventionNew cases per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)0.24
Maternal Health Arm B (Discontinue Triple ARVs)0.49

Maternal Health Component: Incidence of Tuberculosis

Incidence of tuberculosis. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

InterventionNew cases per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)0.40
Maternal Health Arm B (Discontinue Triple ARVs)0.31

Maternal Health Component: Incidence Rate of Cardiovascular or Other Metabolic Events

"Cardiovascular or metabolic events of particular concern were included in this analysis. A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates.~Metabolic events considered were diabetes mellitus, lipodystrophy, or dyslipidemia. Cardiovascular events considered were hypertension, congestive heart failure, stroke, Transient Ischemia Event (TIA), pulmonary embolism, myocardial infarction (whether acute symptomatic or silent), coronary artery disease, deep vein thrombosis, peripheral vascular disease, or symptomatic HIV-associated cardiomyopathy." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

Interventionevents per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)2.9
Maternal Health Arm B (Discontinue Triple ARVs)5.7

Maternal Health Component: Incidence Rate of Death or Any Condition of Particular Concern

Particular events were targeted as those of particular concern. This outcome considered all such events: death, events defining WHO stages II, III, or IV, targeted cardiovascular adverse events, other targeted adverse events, or cancers which were not AIDS-defining. A complete list can be found in Appendix IV of the Protocol. A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

Interventionevents per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)9.0
Maternal Health Arm B (Discontinue Triple ARVs)14.0

Maternal Health Component: Incidence Rate of Progression to AIDS-defining Illness, Death, or a Serious Non-AIDS Cardiovascular, Hepatic, or Renal Event

"This outcome included AIDS-defining illnesses or cardiovascular, hepatic, or renal adverse events of particular concern which were evaluated as serious. Serious outcomes were both those defined as serious according to the International Conference on Harmonization (ICH) definition, or outcomes with grades equal to or worse than 3 (Severe). A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates. Cardiovascular events considered were hypertension, congestive heart failure, stroke, Transient Ischemia Event (TIA), pulmonary embolism, myocardial infarction (whether acute symptomatic or silent), coronary artery disease, deep vein thrombosis, peripheral vascular disease, or symptomatic HIV-associated cardiomyopathy. Hepatic events considered were cirrhosis and idiopathic sclerosing cholangitis. Renal events considered were renal insufficiency, acute or chronic." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

Interventionevents per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)0.5
Maternal Health Arm B (Discontinue Triple ARVs)0.9

Maternal Health Component: Other Targeted Medical Conditions

Other (non-cardiologic) medical conditions of particular concern were included in this outcome. A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates. Events included were metabolic events, hepatic events, renal events, infections such as pulmonary tuberculosis, malaria, or other serious bacterial infections, and others. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

Interventionevents per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)4.0
Maternal Health Arm B (Discontinue Triple ARVs)4.6

Maternal Health Component: Toxicity: Incidence of Grade 3 or Greater Laboratory Results or Signs and Symptoms and Selected Grade 2 Hematologic, Renal, and Hepatic Laboratory Results

The maternal safety endpoints summarized include grade 2, 3 or 4 hematologies (hemoglobin (Hb), White Blood Cells (WBC), Absolute Neutrophil Count (ANC), platelet count), chemistries (Alanine Aminotransferase (ALT or SGPT), serum creatinine), and grade 3 or 4 signs and symptoms that occurred post-randomization. These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com). (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

InterventionNew cases per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)15.3
Maternal Health Arm B (Discontinue Triple ARVs)13.9

Postpartum Component: Incidence of Confirmed Infant HIV Infection

Defined as infant HIV NAT positivity of a specimen drawn at any post-randomization visit (i.e., any visit after the Week 1 [Day 6-14] visit), confirmed by HIV NAT positivity of a second specimen drawn at a different time point. Analyses were conducted at the Mother-Infant (M-I) pair level, hence the worst outcome for multiple births was counted as a single event. (NCT01061151)
Timeframe: Measured through site recommended duration of breastfeeding, complete cessation of breastfeeding or 18 months of age, whichever comes first

InterventionNew cases per 100 person-years (Number)
Postpartum Arm A (Maternal Prophylaxis)0.56
Postpartum Arm B (Infant Prophylaxis)0.55

Postpartum Component: Incidence of Grade 3 or Higher Adverse Events and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events

These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com). (NCT01061151)
Timeframe: Measured through site recommended duration of breastfeeding, complete cessation of breastfeeding or 18 months of age, whichever comes first

InterventionNew cases per 100 person-years (Number)
Postpartum Arm A (Maternal Prophylaxis)14.4
Postpartum Arm B (Infant Prophylaxis)14.1

Postpartum Component: Proportion of Mother-Infant Pairs With no Death or HIV Diagnosis Through 24 Months Post-delivery

Defined as infant HIV NAT positivity of a specimen drawn at any post-randomization visit, confirmed by HIV NAT positivity of a second specimen drawn at a different time point, or infant death. Analyses (Kaplan-Meier probabilities) were conducted at the Mother-Infant (M-I) pair level, hence the worst outcome for multiple births was counted as a single event. (NCT01061151)
Timeframe: Measured through 24 months post-delivery

InterventionProbability (Number)
Postpartum Arm A (Maternal Prophylaxis)0.971
Postpartum Arm B (Infant Prophylaxis)0.977

Antepartum Component: Number of Mothers With Adverse Pregnancy Outcomes (e.g.,Stillbirth, Preterm Delivery (< 37 Weeks), Low Birth Weight (< 2,500 Grams), and Congenital Anomalies)

Composite outcome (NCT01061151)
Timeframe: Measured at birth

InterventionParticipants (Count of Participants)
Period 2
Antepartum Arm C111

Antepartum Component: Number of Mothers With Adverse Pregnancy Outcomes (e.g.,Stillbirth, Preterm Delivery (< 37 Weeks), Low Birth Weight (< 2,500 Grams), and Congenital Anomalies)

Composite outcome (NCT01061151)
Timeframe: Measured at birth

,
InterventionParticipants (Count of Participants)
Periods 1 and 2Period 2
Antepartum Arm A38991
Antepartum Arm B563123

Antepartum Component: Number of Mothers With Grade 3 or Higher Toxicities and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events

These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com). (NCT01061151)
Timeframe: Measured through the Week 1 postpartum study visit

InterventionParticipants (Count of Participants)
Period 2
Antepartum Arm C60

Antepartum Component: Number of Mothers With Grade 3 or Higher Toxicities and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events

These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com). (NCT01061151)
Timeframe: Measured through the Week 1 postpartum study visit

,
InterventionParticipants (Count of Participants)
Periods 1 and 2Period 2
Antepartum Arm A26159
Antepartum Arm B31861

Antepartum Component: Number of Mothers With Obstetrical Complications

"Complications included deaths, diagnoses, signs/symptoms, chemistry lab tests, or hematological lab tests, with grades of 3 (Severe) or worse. Obstetrical complications were those classified by the MedDra coding system as Pregnancy, puerperium and perinatal conditions, except if the condition was the death of the fetus: Abortions not specified as induced or spontaneous, Abortions spontaneous, or Stillbirth and foetal death." (NCT01061151)
Timeframe: Measured through the Week 1 postpartum study visit

InterventionParticipants (Count of Participants)
Period 2
Antepartum Arm C23

Antepartum Component: Number of Mothers With Obstetrical Complications

"Complications included deaths, diagnoses, signs/symptoms, chemistry lab tests, or hematological lab tests, with grades of 3 (Severe) or worse. Obstetrical complications were those classified by the MedDra coding system as Pregnancy, puerperium and perinatal conditions, except if the condition was the death of the fetus: Abortions not specified as induced or spontaneous, Abortions spontaneous, or Stillbirth and foetal death." (NCT01061151)
Timeframe: Measured through the Week 1 postpartum study visit

,
InterventionParticipants (Count of Participants)
Periods 1 and 2Period 2
Antepartum Arm A8920
Antepartum Arm B7512

Antepartum Component: Probability of Overall and HIV-free Infant Survival Until 104 Weeks of Age, by Antepartum Arm (in Conjunction With Infants in the Postpartum Component)

For overall survival, failure was defined to be death. For HIV-free survival, failure was defined to be either death or developing HIV. The probability of living, or living without HIV infection, at 104 weeks was calculated by Kaplan-Meier estimation of the survival function. (NCT01061151)
Timeframe: Measured from birth through 104 weeks of age

InterventionProportional probability (Number)
Overall survival, period 2 groupHIV-free survival, period 2 group
Antepartum Arm C0.9420.921

Antepartum Component: Probability of Overall and HIV-free Infant Survival Until 104 Weeks of Age, by Antepartum Arm (in Conjunction With Infants in the Postpartum Component)

For overall survival, failure was defined to be death. For HIV-free survival, failure was defined to be either death or developing HIV. The probability of living, or living without HIV infection, at 104 weeks was calculated by Kaplan-Meier estimation of the survival function. (NCT01061151)
Timeframe: Measured from birth through 104 weeks of age

,
InterventionProportional probability (Number)
Overall survival, Periods 1 & 2 group (arms A & B only)Overall survival, period 2 groupHIV-free survival, Periods 1&2 group (arms A&B only)HIV-free survival, period 2 group
Antepartum Arm A0.9590.9510.9370.936
Antepartum Arm B0.9670.9820.9470.940

Postpartum Component: Proportion of Infants Alive Through 12 and 24 Months Post-delivery

Analyses (Kaplan-Meier probabilities) conducted for all individual infants (rather than M-I pair) (NCT01061151)
Timeframe: Measured at 12 and 24 months post-delivery

,
InterventionProbability (Number)
12 months post delivery24 months post delivery
Postpartum Arm A (Maternal Prophylaxis)0.9880.978
Postpartum Arm B (Infant Prophylaxis)0.9890.987

Antepartum Component: Maternal HIV RNA Less Than 400 Copies/mL at Delivery

Analysis used the principle of intent to treat. (NCT01061151)
Timeframe: Measured at the time of delivery

InterventionParticipants (Count of Participants)Participants (Count of Participants)
Periods 1 and 272329519Periods 1 and 272329520Period 272329520Period 272329519Period 272329521
HIV RNA < 400 copies/mLHIV RNA >= 400 copies/mL
Antepartum Arm A415
Antepartum Arm B1092
Antepartum Arm A929
Antepartum Arm B275
Antepartum Arm A102
Antepartum Arm B259
Antepartum Arm C225
Antepartum Arm A210
Antepartum Arm B62
Antepartum Arm C79

Postpartum Component: Adherence to the Maternal and/or Infant ARV Regimens, as Measured by Maternal Report and Hair Measures

"Adherence is by maternal report; adherence through hair analysis is not included here.~The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome since adherence was not a focus of the study." (NCT01061151)
Timeframe: Week 6 visit (14 days - 9 weeks postpartum); Week 14 visit (10-19 weeks postpartum); Week 26 visit (20 to 31 weeks postpartum); Week 50 visit (44 to 55 weeks postpartum); and Week 74 visit (68 to 80 weeks postpartum).

InterventionParticipants (Count of Participants)
Week 6 visit72329524Week 6 visit72329525Week 14 visit72329524Week 14 visit72329525Week 26 visit72329524Week 26 visit72329525Week 50 visit72329524Week 50 visit72329525Week 74 visit72329524Week 74 visit72329525
Missed dose over 1 month agoNever missed a doseMissed dose 2-4 weeks agoMissed dose within last 2 weeks
Postpartum Arm A (Maternal Prophylaxis)1003
Postpartum Arm B (Infant Prophylaxis)1104
Postpartum Arm A (Maternal Prophylaxis)12
Postpartum Arm A (Maternal Prophylaxis)17
Postpartum Arm B (Infant Prophylaxis)4
Postpartum Arm A (Maternal Prophylaxis)140
Postpartum Arm B (Infant Prophylaxis)74
Postpartum Arm A (Maternal Prophylaxis)956
Postpartum Arm B (Infant Prophylaxis)1081
Postpartum Arm A (Maternal Prophylaxis)20
Postpartum Arm B (Infant Prophylaxis)0
Postpartum Arm A (Maternal Prophylaxis)35
Postpartum Arm A (Maternal Prophylaxis)112
Postpartum Arm B (Infant Prophylaxis)50
Postpartum Arm A (Maternal Prophylaxis)888
Postpartum Arm B (Infant Prophylaxis)1035
Postpartum Arm A (Maternal Prophylaxis)48
Postpartum Arm A (Maternal Prophylaxis)31
Postpartum Arm B (Infant Prophylaxis)8
Postpartum Arm A (Maternal Prophylaxis)103
Postpartum Arm B (Infant Prophylaxis)47
Postpartum Arm A (Maternal Prophylaxis)716
Postpartum Arm B (Infant Prophylaxis)841
Postpartum Arm A (Maternal Prophylaxis)37
Postpartum Arm A (Maternal Prophylaxis)34
Postpartum Arm B (Infant Prophylaxis)7
Postpartum Arm A (Maternal Prophylaxis)64
Postpartum Arm B (Infant Prophylaxis)30
Postpartum Arm A (Maternal Prophylaxis)311
Postpartum Arm B (Infant Prophylaxis)377
Postpartum Arm A (Maternal Prophylaxis)15
Postpartum Arm B (Infant Prophylaxis)2
Postpartum Arm B (Infant Prophylaxis)1
Postpartum Arm B (Infant Prophylaxis)9

CD4 Cell Percentage at 48 Weeks After Randomization

CD4 Cell Percentage at 48 Weeks After Randomization (NCT01146873)
Timeframe: 48 weeks

Interventionpercentage of cells (Mean)
Group 1: Lopinavir/Ritonavir (LPV/r)34.7
Group 2: Efavirenz (EFV)37.5

Viral Failure

Probability of viral failure defined as >= 2 HIV RNA measurements >1000 copies/ml using survival analysis by 48 weeks post-randomization. (NCT01146873)
Timeframe: 48 weeks

Interventionprobability of viral failure (Mean)
Group 1: Lopinavir/Ritonavir (LPV/r)0.020
Group 2: Efavirenz (EFV)0.027

Viral Rebound

Probability of viral rebound defined as >=1 HIV RNA measurements >50 copies/ml using survival analysis by 48 weeks post-randomization. (NCT01146873)
Timeframe: 48 weeks

Interventionprobability of viral rebound (Mean)
Group 1: Lopinavir/Ritonavir (LPV/r)0.284
Group 2: Efavirenz (EFV)0.176

Highest Grade ALT After Randomization

Highest grade ALT after randomization. Grading was determined based on the Division of AIDS (2004) Toxicity Tables to grade adverse reactions. Grading scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe), 4 (potentially life-threatening). (NCT01146873)
Timeframe: through 48 weeks post randomization

,
Interventionnumber of participants (Number)
Grade 0Grade 1Grade 2Grade 3Grade 4
Group 1: Lopinavir/Ritonavir (LPV/r)1398010
Group 2: Efavirenz (EFV)120161031

Percentage of Participants With Elevated Total Cholesterol, Elevated LDL, Abnormal HDL, or Abnormal Triglycerides at 40 Weeks After Randomization

Percentage of participants with elevated total cholesterol, elevated LDL, abnormal HDL, or abnormal triglycerides at 40 weeks after randomization (NCT01146873)
Timeframe: 40 weeks

,
Interventionpercentage of participants (Number)
Elevated total cholesterolElevated LDLAbnormal HDLAbnormal triglycerides
Group 1: Lopinavir/Ritonavir (LPV/r)24.818.64.822.8
Group 2: Efavirenz (EFV)13.39.84.210.5

ART Levels in Hair Samples at Delivery

antiretroviral hair concentrations (per doubling) (NCT00993031)
Timeframe: delivery

Interventionantiretroviral hair concentration(ng/mg) (Mean)
Without Protease Inhibitor5.7
With Protease Inhibitor6.6

Change in Maternal CD4 Cell Counts

CD4 cell count recovery efavirenz at delivery (NCT00993031)
Timeframe: Time of randomization to delivery, an average of 20 weeks

InterventionCD4 cell count (Median)
Without Protease Inhibitor-7
With Protease Inhibitor57

Incidence of Pre-eclampsia Defined by Hypertension > 140/90 on Two Occasions Measured > 6 Hours Apart With ≥1+ Proteinuria on Clean Catch Urine Dipstick

Pre-eclampsia Defined by Hypertension > 140/90 on Two Occasions Measured > 6 Hours Apart With ≥1+ Proteinuria on Clean Catch Urine Dipstick (NCT00993031)
Timeframe: Time from randomization until delivery

InterventionParticipants (Count of Participants)
Without Protease Inhibitor0
With Protease Inhibitor0

Maternal Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk After Pregnancy

(NCT00993031)
Timeframe: Number of treatments given for clinical malaria based on postive blood smear from time from delivery until 24 months after delivery or cessation of breastfeeding

Interventiontreatments (Number)
Group A21
Group B13

Maternal Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk During Pregnancy

(NCT00993031)
Timeframe: Number of treatments given for clinical malaria based on postive blood smear from time from randomization until 24 months after delivery or cessation of breastfeeding

Interventiontreatments (Number)
With Protease Inhibitor17
Without Protease Inhibitor17

Number of Participants With Grade 3 or 4 Toxicity in the Two Treatment Groups in Women

(NCT00993031)
Timeframe: Randomization to one month postpartum

InterventionParticipants (Count of Participants)
Without Protease Inhibitor12
With Protease Inhibitor8

Number of Participants With Maternal HIV RNA Suppression of <400 Copies/mL

Virologic suppression was defined as plasma HIV-1 RNA 400 copies/ml or less based on the lower limit of detection of the available test. (NCT00993031)
Timeframe: Time from randomization until delivery, an average of 20 weeks

InterventionParticipants (Count of Participants)
Without Protease Inhibitor166
With Protease Inhibitor153

Number of Participants With Maternal to Child Transmission of HIV, Measured by Infant HIV DNA PCR

HIV tested by DNA PCR (NCT00993031)
Timeframe: Delivery to 48 weeks postpartum

InterventionParticipants (Count of Participants)
Without Protease Inhibitor0
With Protease Inhibitor2

Number of Participants With Severe Maternal Anemia Defined by Hemoglobin < 8g/dl at Any Point During the Trial in Each Treatment Group

Proportion of women with severe maternal Anemia (hemoglobin < 8g/dl by hemacue or CBC) at any point during the trial in Each Treatment Group (NCT00993031)
Timeframe: Time from randomization until one year follow up

InterventionParticipants (Count of Participants)
Without Protease Inhibitor11
With Protease Inhibitor11

Placental Malaria Defined as Positive Placental RDT

Number of participants with positive placental RDT for malaria. Malaria rapid diagnostic tests (RDTs) assist in the diagnosis of malaria by detecting evidence of malaria parasites (antigens) in human blood. RDTs permit a reliable detection of malaria infections particularly in remote areas with limited access to good quality microscopy services. (NCT00993031)
Timeframe: Delivery

Interventionparticipants (Number)
With Protease Inhibitor6
Without Protease Inhibitor7

Placental Malaria Defined Placental Histopathologic Analysis

Number of participants with positive placental histopathology slide for malaria (NCT00993031)
Timeframe: Delivery

Interventionparticipants (Number)
With Protease Inhibitor62
Without Protease Inhibitor47

Prevalence of Composite Clinical Outcome Defined by LBW, Stillbirth(Intrauterine Fetal Demise >20wks GA), Late Spontaneous Abortion(Miscarriage 12-20wks GA), Preterm Delivery(<37wks Gestation), Neonatal Death(Death of Liveborn Infant Within First 28days)

Percent of evaluated participants with composite clinical outcome defined by LBW, stillbirth (intrauterine fetal demise >20wks GA), late spontaneous abortion(miscarriage 12-20wks GA), preterm delivery(<37wks gestation), neonatal death(death of live-born infant within first 28 days) (NCT00993031)
Timeframe: Time from randomization until 24 months postpartum or cessation of breastfeeding

Intervention% of evaluated participants with outcome (Number)
With Protease Inhibitor33.9
Without Protease Inhibitor27.8

Prevalence of Malaria Defined as Positive Placental Blood PCR

Number of participants with positive placental blood PCR for malaria (NCT00993031)
Timeframe: Delivery

Interventionparticipants (Number)
With Protease Inhibitor6
Without Protease Inhibitor7

Prevalence of Malaria Defined as Positive Placental Blood Smear

Number of participants with positive placental blood smear for malaria (NCT00993031)
Timeframe: Delivery

Interventionparticipants (Number)
With Protease Inhibitor5
Without Protease Inhibitor6

Exclusive Breastfeeding Rates in Burkina Faso

The EBF prevalences (24-h recall) at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age

Interventionparticipants (Number)
Intervention310
No Intervention161

Exclusive Breastfeeding Rates in South Africa

The EBF prevalences based on 24-h recall at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age

Interventionparticipants (Number)
Intervention56
No Intervention30

Exclusive Breastfeeding Rates in Uganda

The EBF prevalences (24-h recall) at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age

Interventionparticipants (Number)
Intervention323
No Intervention161

Infant Morbidity, 2 Week Diarrhoea Prevalence

(NCT00397150)
Timeframe: at 3 months of age

Interventionparticipants (Number)
Intervention104
No Intervention101

Growth at 18 Months Post-randomization

Weight and height will be transformed to the weight-for-age Z-score (i.e., WAZ) and height-for-age Z-score (i.e., HAZ) using World Health Organization Child Growth Standards, taking into account the infant's age and gender. (NCT00428116)
Timeframe: 18 months of post-randomization follow-up

,
Interventionz-score (Median)
WAZ (z-score)HAZ (z-score)
Continued HAART-0.57-1.04
Interrupted HAART-0.17-0.78

Morbidity

severe adverse events including death, pneumonia, diarrhea, and other adverse events (NCT00428116)
Timeframe: 18 months post-randomization

,
Interventionparticipants (Number)
Severe adverse eventsPneumoniaDiarrheaDeath
Continue HAART2471
Interrupted HAART13120

Cumulative Incidence of Participants Experiencing a Grade 3/4 Hepatotoxicity

Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.

Interventionpercent (Number)
INH and Vitamin B68.3

Number of Participants Who Discontinued Treatment

Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.

InterventionParticipants (Count of Participants)
INH and Vitamin B632

Number of Participants With Alanine Transaminase (ALT) or Aspartate Transaminase (AST) Elevations at Study Screening

Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit

InterventionParticipants (Count of Participants)
Study Screening80

Number of Participants With Latent Tuberculosis at Study Screening.

Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit

InterventionParticipants (Count of Participants)
Study Screening308

INH Concentration in Hair: (INH Pmol + Acetyl INH Pmol) Per mg of Hair

INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation

Interventionpmol/mg (Median)
at 3 monthsat 6 months
INH and Vitamin B636.037.8

Percentage of Participants With Suboptimal INH Medication Adherence

Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)

Interventionpercentage of participants (Number)
at 3 monthsat 6 months
INH and Vitamin B631.343.9

Self-reported INH Medication Adherence: Number of Days Taking INH in the Past 30 Days

"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH

Interventiondays (Median)
at 3 monthsat 6 months
INH and Vitamin B63030

Self-reported INH Medication Adherence by the Self Rating Single Item (SRSI) Scale

The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH

InterventionParticipants (Count of Participants)
At 3 months72558043At 6 months72558043
ExcellentVery goodGoodFairPoorVery poor
INH and Vitamin B6160
INH and Vitamin B679
INH and Vitamin B638
INH and Vitamin B62
INH and Vitamin B6124
INH and Vitamin B690
INH and Vitamin B641
INH and Vitamin B64
INH and Vitamin B60
INH and Vitamin B61

28-day Risk of Recurrent Parasitemia

To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent parasitemia at 28 days were compared between the two groups. (NCT00978068)
Timeframe: 28 days after antimalarial therapy

InterventionCummulative Risk Percentage (Number)
LPV/r + 2 NRTIs14.0
NVP or EFV + 2 NRTIs40.8

63-day Risk of Recurrent Malaria

To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent malaria at 63 days were compared between the two groups. (NCT00978068)
Timeframe: 28 days after antimalarial therapy

InterventionCumulative Risk Percentage (Number)
LPV/r + 2 NRTIs28.1
NVP or EFV + 2 NRTIs54.2

Estimates of the 6-month Risk of a First Episode of Malaria

To assess the effect of ART independently of potential interactions with antimalarial therapy after treatment for malaria, we compared the two groups with respect to the time to the first episode of malaria. Cumulative risk was estimated using the Kaplan-Meier product-limit formula. (NCT00978068)
Timeframe: Enrollment to 6 months follow up

InterventionCumulative Risk Percentage (Number)
LPV/r + 2 NRTIs40.7
NVP or EFV + 2 NRTIs52.5

Incidence-density of Malaria Defined as the Number of Incident Episodes of Complicated Malaria Per Time at Risk.

(NCT00978068)
Timeframe: Time from randomization to at least 24 months of follow up or until end of the study

InterventionEpisodes/ Person-Yr at Risk (Number)
Group 10.024
Group 20.026

Incidence-density of Malaria Defined as the Number of Incident Episodes of Malaria Per Time at Risk.

(NCT00978068)
Timeframe: Time from randomization to at least 24 months of follow up or until end of the study

InterventionEpisodes/ Person-Yr at Risk (Number)
Group 1: LPV/r + 2 NRTIs1.32
Group 2: Nevirapine (NVP) or Efavirenz (EFV) + 2 NRTIs2.25

Percentage of Uncomplicated Malaria Episodes With Accompanying Adverse Events That Occurred in the 28 Days Following Antimalarial Therapy

The rates of adverse events, defined as severity grade 2 or higher that are possibly, probably or definitely related to study drugs over the course of the 28-day period after antimalarial therapy with artemether-lumefantrine (AL). (NCT00978068)
Timeframe: 28 days after antimalarial therapy

Intervention% uncomplicated malaria episodes w/ AEs (Number)
LPV/r + 2 NRTIs71.0
NVP or EFV + 2 NRTIs79.3

Change in CD4 Percent From Entry to Week 48

Change was calculated as CD4 percent at week 48 minus entry CD4 percent (last CD4 percent before randomization date). Only subjects who reached 48 weeks of follow-up before DSMB decisions to unblind each Cohort were included in summary. (NCT00307151)
Timeframe: 48 weeks if before date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)

InterventionPercent of CD4 (Mean)
Coh I: NVP13.9
Coh I: LPV/r12.0
Coh II: NVP15.2
Coh II: LPV/r14.3

Number of Participants Developing New NRTI, NNRTI or PI-resistant Virus

Numbers of participants developing new NRTI, NNRTI or PI-resistant virus after reaching a virologic failure endpoint (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)

Interventionparticipants (Number)
Coh I: NVP16
Coh I: LPV/r1
Coh II: NVP10
Coh II: LPV/r4

Percent of Participants Experiencing Virologic Failure

Virologic failure is defined as a confirmed plasma HIV-1 RNA level that is <1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level >400 copies/mL at 24 weeks OR death on or before 24 weeks. Results report percent of participants reaching a virologic failure endpoint by week 24 calculated using the Kaplan-Meier method. (NCT00307151)
Timeframe: Earlier of 24 weeks or date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)

InterventionPercent of participants (Number)
Coh I: NVP27.4
Coh I: LPV/r10.4
Coh II: NVP28.6
Coh II: LPV/r12.9

Percent of Participants With Treatment Failure, Defined as a Confirmed Virologic Failure or Permanent Discontinuation of the Randomized NNRTI or PI Component of Study Treatment

Treatment failure is defined as a confirmed plasma HIV-1 RNA level that is <1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level >400 copies/mL at 24 weeks OR permanent discontinuation of the randomized NNRTI or PI component of study treatment at or prior to 24 weeks of treatment for any reason including death. Results report percent of participants reaching a treatment failure endpoint by week 24 calculated using the Kaplan-Meier method. (NCT00307151)
Timeframe: Earlier of 24 weeks or date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)

InterventionPercent of participants (Number)
Coh I: NVP39.6
Coh I: LPV/r21.7
Coh II: NVP40.8
Coh II: LPV/r19.3

Time From Randomization to Death

Results report 2nd percentile of time from randomization to death (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)

InterventionWeeks (Number)
Coh I: NVP11
Coh I: LPV/r3
Coh II: NVP2
Coh II: LPV/r83

Time From Randomization to HIV-related Disease Progression or Death

HIV-related disease progression was defined as progression in WHO clinical stage from stage at entry or death. For subjects in WHO Stage IV at entry, disease progression was defined as death. (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)

,,,
InterventionWeeks (Number)
5th percentile10th percentile
Coh I: LPV/r24
Coh I: NVP1117
Coh II: LPV/r35132
Coh II: NVP835

Time From Randomization to Treatment Failure, Defined as Virologic Failure or Permanent Discontinuation of the Randomized NNRTI or PI Component of Study Treatment

Treatment failure is defined as a confirmed plasma HIV-1 RNA level that is <1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level >400 copies/mL at 24 weeks OR a confirmed viral rebound >4000 copies/mL after week 24 OR permanent discontinuation of the randomized NNRTI or PI component of study treatment for any reason including death. (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)

,,,
InterventionWeeks (Number)
10th percentile25th percentile
Coh I: LPV/r436
Coh I: NVP1216
Coh II: LPV/r1436
Coh II: NVP416

Time From Randomization to Virologic Failure

Virologic failure is defined as the earlier of a confirmed plasma HIV-1 RNA level that is <1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level >400 copies/mL at 24 weeks OR a confirmed viral rebound >4000 copies/mL after week 24 OR death. (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)

,,,
InterventionWeeks (Number)
5th percentile10th percentile
Coh I: LPV/r1624
Coh I: NVP1212
Coh II: LPV/r1624
Coh II: NVP1216

Time From Start of Study Treatment to First New Grade >=3 Lab Abnormality, Sign or Symptom Occurring on Study Treatment

Safety events include lab abnormalities, signs or symptoms of grade 3 or higher. Events were graded according to the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events, Version 1.0. Events defined as new if first occurrence was after initiation of study treatment or if severity increased from entry and while on the NNRTI or PI component of study treatment. (NCT00307151)
Timeframe: On randomized NNRTI or PI component of study treatment and until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)

,,,
InterventionWeeks (Number)
10th percentile25th percentile
Coh I: LPV/r836
Coh I: NVP424
Coh II: LPV/r412
Coh II: NVP34

AUC

Area under the plasma concentration time curve, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h (NCT01410058)
Timeframe: Baseline (day 22), Post-moringa (day 35)

,
Interventionh*microgram/mL (Geometric Mean)
Baseline (Day 22)Post-moringa (Day 35)
Efavirenz34.6732.58
Nevirapine94.17100.44

C12h

plasma concentration 12h post dose, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h (NCT01410058)
Timeframe: Baseline (Day 22); Post-moringa (Day 35)

,
Interventionmicrogram/mL (Geometric Mean)
Baseline (Day 22)Post-moringa (Day 35)
Efavirenz2.962.53
Nevirapine7.307.55

Cmax

Maximum plasma concentration post does, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h (NCT01410058)
Timeframe: Baseline (day 22), Post-moringa (day 35)

,
Interventionmicrogram/mL (Geometric Mean)
Baseline (Day 22)Post-moringa (Day 35)
Efavirenz5.085.51
Nevirapine9.9210.57

Area Under the Concentration-Time Curve(AUC)

Mean Area Under the Plasma Concentration-Time Curve for each drug, log transformed (NCT01025830)
Timeframe: Assessed at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 10 and 12 hr post-dosing

Interventionhour*milligram/liter (Geometric Mean)
Generic Stavudine3.6
Brand Stavudine3.4
Generic Nevirapine85.8
Brand Nevirapine79.2
Generic Lamivudine5.2
Brand Lamivudine6.4

Maximum Plasma Concentration of Drug

Maximum concentration of drug in plasma that was attained post dosing (NCT01025830)
Timeframe: Assessed at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 10 and 12 hr post-dosing

Interventionmilligram/liter (Geometric Mean)
Generic Stavudine1.6
Brand Stavudine1.3
Generic Nevirapine8.8
Brand Nevirapine8.4
Generic Lamivudine1.0
Brand Lamivudine1.3

Number of HIV+ Infants

Number of infants with HIV-positive status (NCT00270296)
Timeframe: Throughout study, including breastfeeding, assessed up to 24 months

InterventionInfants (Number)
TZV Arm6
Kaletra Arm1
NVP Arm1

Number of Participants With Virologic Suppression

Suppression of the plasma HIV-1 RNA level to less than 400 copies per milliliter (NCT00270296)
Timeframe: Throughout study, including breastfeeding, assessed up to 24 months

InterventionParticipants (Count of Participants)
TZV Arm274
Kaletra Arm256
NVP Arm160

Area Under the Plasma Concentration-Time Curve Over 12 Hours of ETR

Geometric Mean (Standard Deviation) of the area under the plasma concentration-time curve over 12 hours (AUC12h) of ETR. (NCT01504841)
Timeframe: Pre-dose, 1, 2, 4, 6, 9, and 12 hours post-dose measured at intensive PK visit (within 7-10 days after last dose of study drug administration)

Interventionng*h/mL (Geometric Mean)
Cohort I: Treatment Experienced, 2 to 6 Years of Age5512.85
Cohort II: Treatment Experienced, 1 to 2 Years of Age4821.76

Decline in Absolute CD4 Percent of Greater Than 5 Percent Any Time After 12 Weeks of Therapy

Number (%) of participants with a >5% decline in absolute CD4 percent from baseline at weeks 12, 24, and 48, by Cohort, including Clopper-Pearson confidence intervals. (NCT01504841)
Timeframe: Measured at baseline and at Weeks 12, 24, and 48

InterventionParticipants (Count of Participants)
Week 1272045667Week 1272045668Week 2472045667Week 2472045668Week 4872045667Week 4872045668
>5% decline in CD4 % from baselineIncrease or <5% decline in CD4 % from baseline
Cohort I: Treatment Experienced, 2 to 6 Years of Age1
Cohort II: Treatment Experienced, 1 to 2 Years of Age2
Cohort I: Treatment Experienced, 2 to 6 Years of Age10
Cohort II: Treatment Experienced, 1 to 2 Years of Age1
Cohort II: Treatment Experienced, 1 to 2 Years of Age3
Cohort I: Treatment Experienced, 2 to 6 Years of Age2
Cohort I: Treatment Experienced, 2 to 6 Years of Age9

HIV-1 RNA Virologic Failure Status at Weeks 24 and 48

Number (%) of participants with confirmed Virologic Failure, defined as: failure to suppress plasma HIV-1 RNA to fewer than 400 copies/ml and failure to achieve at least a 2-log10 reduction (from baseline) in HIV-1 RNA at Weeks 24 or 48, by Cohort, with Clopper-Pearson confidence intervals. The initial HIV-1 RNA results that met the Virologic Failure definition were each confirmed by a second result obtained within 1 to 4 weeks of the initial result obtained at Week 24 and/or 48. (NCT01504841)
Timeframe: Baseline, Week 24, and Week 48

InterventionParticipants (Count of Participants)
Week 2472045667Week 2472045668Week 4872045667Week 4872045668
Virologic FailureNo Virologic Failure
Cohort I: Treatment Experienced, 2 to 6 Years of Age2
Cohort I: Treatment Experienced, 2 to 6 Years of Age9
Cohort I: Treatment Experienced, 2 to 6 Years of Age3
Cohort II: Treatment Experienced, 1 to 2 Years of Age3
Cohort I: Treatment Experienced, 2 to 6 Years of Age8
Cohort II: Treatment Experienced, 1 to 2 Years of Age1

Proportion of Patients Reporting CNS (Central Nervous System) Side Effects of Any Severity

Proportion of Patients reporting CNS (central nervous system) side effects of any severity (NCT00389207)
Timeframe: week 148

Interventionparticipants (Number)
Nevirapine QD41
Nevirapine BID41
Atazanvir/Ritonavir37

Proportion of Patients Reporting Hepatic Events of Any Severity

Proportion of Patients reporting hepatic events of any severity (NCT00389207)
Timeframe: week 148

Interventionparticipants (Number)
Nevirapine QD26
Nevirapine BID24
Atazanvir/Ritonavir92

Proportion of Patients Reporting Rash of Any Severity

Proportion of Patients reporting rash of any severity (NCT00389207)
Timeframe: week 148

Interventionparticipants (Number)
Nevirapine QD75
Nevirapine BID64
Atazanvir/Ritonavir74

Time to Loss of Virologic Response (Rebound)

Time to loss of virologic response (TLOVR) was defined as the time from start of treatment to the first measurement showing VL ≥ 50 copies/mL in the first virologic rebound, after having a confirmed virological response. (NCT00389207)
Timeframe: Baseline to week 144

Interventionweeks (Median)
Nevirapine QD143.86
Nevirapine BID143.21
Nevirapine QD+BID143.71
Atazanvir/Ritonavir143.00

Time to Treatment Failure

Treatment failure is defined as the occurrence of the first of at least one of the following events: early discontinuation of trial drug, change in ARV therapy, failure to achieve an HIV RNA count < 50 copies/mL up to Visit 10 (week 48) or loss of virologic response (NCT00389207)
Timeframe: baseline to week 144

Interventionweeks (Median)
Nevirapine QD143.86
Nevirapine BID143.21
Nevirapine QD+BID143.71
Atazanvir/Ritonavir143.00

Time to Treatment Response (First Confirmed VL<50 Copies/mL)

Time to treatment response was defined as the time from start of treatment until the first measurement of the first confirmed virological response (NCT00389207)
Timeframe: baseline to week 144

Interventionweeks (Median)
Nevirapine QD12.00
Nevirapine BID12.14
Nevirapine QD+BID12.00
Atazanvir/Ritonavir23.71

Change in CD4+ Count From Baseline

Change in CD4+ cell count from baseline among patients on treatment at each visit, with the final visit at Week 144 or EOT (NCT00389207)
Timeframe: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT

,
Interventioncells/mm^3 (Mean)
Change in CD4+ count to Week 4Change in CD4+ count to Week 8Change in CD4+ count to Week 12Change in CD4+ count to Week 24Change in CD4+ count to Week 36Change in CD4+ count to Week 48Change in CD4+ count to Week 60Change in CD4+ count to Week 72Change in CD4+ count to Week 84Change in CD4+ count to Week 96Change in CD4+ count to Week 108Change in CD4+ count to Week 120Change in CD4+ count to Week 132Change in CD4+ count to Week 144/EOT
Atazanvir/Ritonavir86.198.0110.9133.8163.4183.6208.2231.9246.4251.6267.2269.2281.3285.8
Nevirapine QD+BID77.2105.6120.3134.4160.1168.2184.8213.7223.0217.7231.2231.3243.4251.0

Change in Framingham Score From Baseline

Change in the estimated risk of cardiovascular disease using the Framingham algorithm from baseline to after 48, 96 and 144 weeks, last observation carried forward (LOCF). The score is based on age, gender, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol and smoking status. Scores range from 0 to 21 with higher scores indicating a greater risk. (NCT00389207)
Timeframe: From baseline to Weeks 48, 96 and 144/EOT

,
InterventionUnits on a scale (Mean)
Change in Framingham score to Week 48Change in Framingham score to Week 96Change in Framingham score to Week 144/EOT
Atazanvir/Ritonavir0.661.190.82
Nevirapine QD+BID0.500.931.14

Change in Mental Health Summary (MHS) Score From Baseline

Quality of life (QoL) assessment by change in MHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the Medical Outcomes Study HIV Health Survey (MOS-HIV), a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The MHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL. (NCT00389207)
Timeframe: From baseline to Weeks 48, 96 and 144/EOT

,
InterventionUnits on a scale (Mean)
Change in MHS score to Week 48Change in MHS score to Week 96Change in MHS score to Week 144/EOT
Atazanvir/Ritonavir4.524.894.70
Nevirapine QD+BID6.096.104.76

Change in Physical Health Summary (PHS) Score From Baseline

QoL assessment by change in PHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the MOS-HIV, a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The PHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL. (NCT00389207)
Timeframe: From baseline to Weeks 48, 96 and 144/EOT

,
InterventionUnits on a scale (Mean)
Change in PHS score to Week 48Change in PHS score to Week 96Change in PHS score to Week 144/EOT
Atazanvir/Ritonavir3.353.003.35
Nevirapine QD+BID3.343.192.22

Change in the Calculated Glomerular Filtration Rate (GFR) at Week 48, 96 and 144

Calculations based on the MDRD algorithm. (NCT00389207)
Timeframe: From baseline to Week 48, 96, 144

,,,
InterventionmL/min/1.73 m^2 (Mean)
change baseline to week 48 (N=143, 128, 271, 173)change baseline to week 96 (N=130, 122, 252, 157)change baseline to week 144 (N=163, 168, 331, 174)
Atazanvir/Ritonavir-7.18-11.53-9.56
Nevirapine BID-5.92-10.02-6.33
Nevirapine QD-3.91-6.93-3.27
Nevirapine QD+BID-4.86-8.42-4.82

Change of Cholesterol Values From Baseline to Week 48, 96, 144

Changes frombaseline in total cholesterol, LDL-cholesterol(LDL-c) and HDL (NCT00389207)
Timeframe: baseline to week 48, 96, 144

,,
Interventionmg/dL (Mean)
total cholesterol, week 48 (N=138,122,164)total cholesterol, week 96 (N=124,114,147)total cholesterol, week 144 (N=154,155,160)LDL-c, week 48 (N=136,117,159)LDL-c, week 96 (N=119,110,145)LDL-c, week 144 (N=151,150,157)HDL, week 48(N=138,122,164)HDL, week 96 (N=124,114,147)HDL, week 144(N=154,155,160)
Atazanvir/Ritonavir20.8429.9928.1310.5819.1917.613.494.745.73
Nevirapine BID29.5436.8730.6617.7021.6617.9511.5913.3310.47
Nevirapine QD29.2839.1733.1216.5421.9321.4212.0613.8612.61

Change of hsCRP From Baseline to Week 48, 96, 144

Change of hsCRP from baseline to week 48, 96, 144 (NCT00389207)
Timeframe: baseline to week 48, 96, 144

,,
Interventionmg/L (Mean)
hsCRP, week 48 (N=142,126,173)hsCRP, week 96 (N=128,120,157)hsCRP, week 144 (N=160,164,174)
Atazanvir/Ritonavir-0.700.350.04
Nevirapine BID-0.67-0.79-0.02
Nevirapine QD-1.01-1.54-0.09

Change of Total Cholesterol to HDL-cholesterol Ratio From Baseline to Week 48, 96, 144

Change of Total cholesterol to HDL-cholesterol ratio from baseline to week 48, 96, 144 (NCT00389207)
Timeframe: baseline to week 48, 96, 144

,,
Interventionratio (Mean)
total triglycerides, week 48 (N=138,122,164)total triglycerides, week 96 (N=124,114,147)total triglycerides, week 144 (N=154,155,160)
Atazanvir/Ritonavir0.200.280.17
Nevirapine BID-0.33-0.25-0.07
Nevirapine QD-0.37-0.22-0.24

Change of Total Triglycerides From Baseline to Week 48, 96, 144

Change of total triglycerides from baseline to week 48, 96, 144 (NCT00389207)
Timeframe: baseline to week 48, 96, 144

,,
Interventionmg/dL (Mean)
total triglycerides, week 48 (N=138,120,164)total triglycerides, week 96 (N=124,113,147)total triglycerides, week 144 (N=153,153,159)
Atazanvir/Ritonavir36.2830.4527.11
Nevirapine BID1.675.356.11
Nevirapine QD0.089.34-3.46

Changes of Apolipoprotein Values From Baseline to Week 48, 96, 144

Changes frombaseline apolipoprotein A1 & B (NCT00389207)
Timeframe: baseline to week 48, 96, 144

,,
Interventiong/L (Mean)
apolipoprotein A1, week 48 (N=134,121,156)apolipoprotein A1, week 96 (N=115,106,141)apolipoprotein A1, week 144 (N=144,140,148)apolipoprotein B, week 48 (N=134,120,156)apolipoprotein B, week 96 (N=115,106,141)apolipoprotein B, week 144 (N=144,139,148)
Atazanvir/Ritonavir0.080.070.060.030.030.03
Nevirapine BID0.230.230.140.03-0.000.05
Nevirapine QD0.230.230.160.000.000.01

Genotypic Resistance Associated With Virologic Failure

Number of treatment-emergent drug-associated substitutions in patients with virological failure up to Week 48. The total number of genotypic mutations in those patients who were virologic failures is given, not the number of patients with mutations. (NCT00389207)
Timeframe: From baseline to Week 48

,
InterventionNumber of substitutions (Number)
Emtricitabine-associated substitutions at Week 48Tenofovir-associated substitutions at Week 48Nevirapine-associated substitutions at Week 48
Atazanvir/Ritonavir000
Nevirapine QD+BID211134

Glycaemic Abnormalities

Number of patients with AE elevated serum glucose (NCT00389207)
Timeframe: From baseline to Week 144

,
InterventionPatients (Number)
Number with glycaemic abnormalitiesNumber without glycaemic abnormalities
Atazanvir/Ritonavir3190
Nevirapine QD+BID0376

Lipodystrophy

Number of patients with AE lipodystrophy (NCT00389207)
Timeframe: From baseline to Week 144

,
InterventionPatients (Number)
Number with lipodystrophyNumber without lipodystrophy
Atazanvir/Ritonavir1192
Nevirapine QD+BID1375

Non-scheduled Physician Visits

Cost effectiveness assessment by number of patients with non-scheduled physician visits (NCT00389207)
Timeframe: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT

,
Interventionpatients (Number)
Number between baseline and Week 24Number between Week 24 and Week 48Number between Week 48 and Week 96Number between Week 96 and Wk 144/EOT
Atazanvir/Ritonavir35352835
Nevirapine QD+BID74455858

Number of Patients Hospitalized

Cost effectiveness assessment by number of patients hospitalized (NCT00389207)
Timeframe: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT

,
InterventionPatients (Number)
Number hospitalized between baseline and Week 24Number hospitalized between Week 24 and Week 48Number hospitalized between Week 48 and Week 96Number hospitalized between Week 96 and Wk 144/EOT
Atazanvir/Ritonavir2551
Nevirapine QD+BID8659

Proportion of Patients With >= DAIDS Grade 2 Laboratory Abnormalities

(NCT00389207)
Timeframe: week 148

,,
Interventionparticipants (Number)
DAIDS 2 moderateDAIDS 3 severeDAIDS 4 potential lifethreatening
Atazanvir/Ritonavir72399
Nevirapine BID842815
Nevirapine QD74309

Proportion of Patients With Virologic Failure at Week 48, 96, 144

(NCT00389207)
Timeframe: at Week 48, 96, 144

,,,
Interventionparticipants (Number)
virologic failure at Week 48virologic failure at Week 96virologic failure at Week 144
Atazanvir/Ritonavir251317
Nevirapine BID252528
Nevirapine QD201519
Nevirapine QD+BID454047

Proportion of Patients With Virological Rebound With VL >=400 Copies/mL After CVR at Week 24, 48, 96, 144

The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL) (NCT00389207)
Timeframe: at Week 24, 48, 96, 144

,,,
Interventionparticipants (Number)
virologic rebound after CVR at Week 24virologic rebound after CVR at Week 48virologic rebound after CVR at Week 96virologic rebound after CVR at Week 144
Atazanvir/Ritonavir2225
Nevirapine BID2366
Nevirapine QD2334
Nevirapine QD+BID46910

Proportion of Patients With Virological Rebound With VL >=50 Copies/mL After CVR (Confirmed Virological Response) at Week 24, 48, 96, 144

The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL) (NCT00389207)
Timeframe: at Week 24, 48, 96, 144

,,,
Interventionparticipants (Number)
virologic rebound after CVR at Week 24virologic rebound after CVR at Week 48virologic rebound after CVR at Week 96virologic rebound after CVR at Week 144
Atazanvir/Ritonavir5121015
Nevirapine BID2569
Nevirapine QD3448
Nevirapine QD+BID591017

Proportion of Patients With VL < 400 Copies/ml

VL <400 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT) (NCT00389207)
Timeframe: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT

,
InterventionProportion of patients (Number)
Proportion with VL<400 copies /mL at Week 4Proportion with VL<400 copies /mL at Week 8Proportion with VL<400 copies /mL at Week 12Proportion with VL<400 copies /mL at Week 24Proportion with VL<400 copies /mL at Week 36Proportion with VL<400 copies /mL at Week 48Proportion with VL<400 copies /mL at Week 60Proportion with VL<400 copies /mL at Week 72Proportion with VL<400 copies /mL at Week 84Proportion with VL<400 copies /mL at Week 96Proportion with VL<400 copies /mL at Week 108Proportion with VL<400 copies /mL at Week 120Proportion with VL<400 copies /mL at Week 132Proportion with VL<400 copies /mL at Week 144/EOT
Atazanvir/Ritonavir0.2870.6790.8340.9560.9660.9770.9880.9880.9940.9871.0000.9940.9930.986
Nevirapine QD+BID0.3650.7140.8560.9240.9680.9850.9930.9960.9881.0000.9961.0000.9960.991

Proportion of Patients With VL < 50 Copies/ml

VL <50 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT) for the patient (NCT00389207)
Timeframe: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT

,
InterventionProportion of patients (Number)
Proportion with VL<50 copies /mL at Week 4Proportion with VL<50 copies /mL at Week 8Proportion with VL<50 copies /mL at Week 12Proportion with VL<50 copies /mL at Week 24Proportion with VL<50 copies /mL at Week 36Proportion with VL<50 copies /mL at Week 48Proportion with VL<50 copies /mL at Week 60Proportion with VL<50 copies /mL at Week 72Proportion with VL<50 copies /mL at Week 84Proportion with VL<50 copies /mL at Week 96Proportion with VL<50 copies /mL at Week 108Proportion with VL<50 copies /mL at Week 120Proportion with VL<50 copies /mL at Week 132Proportion with VL<50 copies /mL at Week 144/EOT
Atazanvir/Ritonavir0.090.250.4120.7790.830.8860.9010.9150.8960.9240.9680.9550.9470.929
Nevirapine QD+BID0.1070.3040.5150.8420.9070.9310.9590.9650.9720.980.9640.9760.9710.952

Serum Lipid Abnormalities

Number of patients with AE elevated serum lipids (i.e. hypercholesterolaemia) (NCT00389207)
Timeframe: From baseline to Week 144

,
Interventionpatients (Number)
Number with serum lipid abnormalitiesNumber without serum lipid abnormalities
Atazanvir/Ritonavir4189
Nevirapine QD+BID9367

Treatment Response at Week 144

Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 144 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 144. (NCT00389207)
Timeframe: From baseline to Week 144

,,,
Interventionparticipants (Number)
Number of respondersNumber of non-responders
Atazanvir/Ritonavir14350
Nevirapine BID11375
Nevirapine QD12167
Nevirapine QD+BID234142

Treatment Response at Week 48

Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 48 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 48. (NCT00389207)
Timeframe: From baseline to Week 48

,,,
InterventionPatients (Number)
Number of respondersNumber of non-responders
Atazanvir/Ritonavir12667
Nevirapine BID12464
Nevirapine QD12662
Nevirapine QD+BID250126

Treatment Response at Week 48 (TLOVR Algorithm)

Treatment response is defined as a VL <50 copies/mL measured at two consecutive visits up to Week 48 and without subsequent rebound or change of ARV therapy up to Week 48, based on time to loss of virologic response (TLOVR) algorithm, as a sensitivity analysis for the primary analysis. (NCT00389207)
Timeframe: From baseline to Week 48

,
InterventionPatients (Number)
Number of respondersNumber of non-responders
Atazanvir/Ritonavir14251
Nevirapine QD+BID261115

Treatment Response at Week 96

Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 96 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 96. (NCT00389207)
Timeframe: From baseline to Week 96

,,,
Interventionparticipants (Number)
Number of respondersNumber of non-responders
Atazanvir/Ritonavir14944
Nevirapine BID12266
Nevirapine QD13157
Nevirapine QD+BID253123

Treatment-emergent AIDS-defining Illness

Treatment-emergent AIDS-defining illness (tr.-emerg. AIDS-def.illness) including worsening during treatment (NCT00389207)
Timeframe: From baseline to Week 144

,
InterventionPatients (Number)
Number with tr.-emerg. AIDS-def.illnessNumber without tr.-emerg. AIDS-def.illness
Atazanvir/Ritonavir7186
Nevirapine QD+BID26350

Treatment-emergent AIDS-defining Illness Leading to Death

Patients with an AIDS-defining illness leading to death broken out by treatment. Statistical analysis shows time to death from AIDS-defining illness. (NCT00389207)
Timeframe: From baseline to Week 144

,
InterventionPatients (Number)
Number with AIDS-def. illness leading to deathNumber without AIDS-def. illness leading to death
Atazanvir/Ritonavir0193
Nevirapine QD+BID3373

Comparison of CD4+ Cell Count (Cells/Cubic Millimeter) Change From Baseline at Week 144, Full Analysis Set Population

(NCT00561925)
Timeframe: baseline, week 144

Interventioncells/cubic millimeter (Mean)
NVP IR 200mg BID239.3
NVP XR 400mg QD270.7

Comparison of HIV-1 Viral Load (log10 Copies/mL) Change From Baseline at Week 144, Full Analysis Set Population

(NCT00561925)
Timeframe: baseline, week 144

Interventionlog10 copies/mL (Mean)
NVP IR 200mg BID-2.7
NVP XR 400mg QD-2.8

Occurrence of Hepatic Events

Frequency of patients with hepatitis symptoms (NCT00561925)
Timeframe: until last patient completed 144 weeks (up to 193 weeks)

Interventionparticipants (Number)
NVP IR10
NVP XR8
IR-IR/XR2
XR-IR/XR0

Relative Bioavailability Trough C_pre,ss,1

Relative bioavailability measured of trough concentrations. Analysis based on adjusted by-treatment geometric means, the adjusted geometric mean ratio of NVP XR : NVP IR and it's 90% confidence interval with p-value and the inter-individual geometric coefficient of variation. (NCT00561925)
Timeframe: week 132

Interventionng/mL (Geometric Mean)
NVP IR4567.03
NVP XR3634.26

Comparison of Proportion of Virologic Response at Week 48 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population

Primary endpoint was the number of patients with a sustained virologic response through week 48 using LLOQ = 50 copies/mL (NCT00561925)
Timeframe: week 48

,
Interventionparticipants (Number)
ResponderNon responder
NVP IR 200mg BID384122
NVP XR 400mg QD40996

Kaplan -Meier Estimate of Cumulative Probability of Clinical Hepatic Events

(NCT00561925)
Timeframe: week 0 to 72

,
Interventioncumulative probability (Number)
Interval Week 0 to <2Interval Week 2 to <4Interval Week 4 to <6Interval Week 6 to <8Interval Week 8 to <12Interval Week 12 to <16Interval Week 16 to <24Interval Week 24 to <32Interval Week 32 to <40Interval Week 40 to <48Interval Week 48 to <60Interval Week 60 to <72Interval Week >=72
NVP IR0.0000.0000.0120.0220.0240.0260.0260.0260.0260.0290.0290.0320.038
NVP XR0.0000.0020.0100.0160.0180.0180.0180.0200.0220.0220.0220.0220.026

Kaplan -Meier Estimate of Cumulative Probability of Grade 3 or 4 ALT/AST Abnormalities

(NCT00561925)
Timeframe: week 0 to 72

,
Interventioncumulative probability (Number)
Interval Week 0 to <2Interval Week 2 to <4Interval Week 4 to <6Interval Week 6 to <8Interval Week 8 to <12Interval Week 12 to <16Interval Week 16 to <24Interval Week 24 to <32Interval Week 32 to <40Interval Week 40 to <48Interval Week 48 to <60Interval Week 60 to <72Interval Week >=72
NVP IR0.0000.0000.0120.0490.0590.0630.0630.0670.0700.0760.0760.0760.076
NVP XR0.0000.0020.0140.0260.0340.0360.0360.0430.0490.0560.0580.0580.070

Kaplan -Meier Estimate of Cumulative Probability of Grade 3 or 4 Asymptotic Transaminases Abnormalities

(NCT00561925)
Timeframe: week 0 to 72

,
Interventioncumulative probability (Number)
Interval Week 0 to <2Interval Week 2 to <4Interval Week 4 to <6Interval Week 6 to <8Interval Week 8 to <12Interval Week 12 to <16Interval Week 16 to <24Interval Week 24 to <32Interval Week 32 to <40Interval Week 40 to <48Interval Week 48 to <60Interval Week 60 to <72Interval Week >=72
NVP IR0.0000.0000.0060.0270.0330.0390.0390.0420.0440.0530.0530.0530.053
NVP XR0.0000.0000.0020.0060.0080.0080.0080.0150.0190.0280.0310.0330.033

Kaplan -Meier Estimate of Cumulative Probability of Group III or IV Drug-related Rash

(NCT00561925)
Timeframe: week 0 to 72

,
Interventioncumulative probability (Number)
Interval Week 0 to <2Interval Week 2 to <4Interval Week 4 to <6Interval Week 6 to <8Interval Week 8 to <12Interval Week 12 to <16Interval Week 16 to <24Interval Week 24 to <32Interval Week 32 to <40Interval Week 40 to <48Interval Week 48 to <60Interval Week 60 to <72Interval Week >=72
NVP IR0.0000.0000.0020.0040.0040.0040.0040.0040.0040.0040.0040.0040.004
NVP XR0.0000.0000.0060.0080.0100.0100.0100.0100.0100.0100.0100.0100.010

Kaplan -Meier Estimate of Cumulative Probability of Permanent Discontinuation of Study Medication

(NCT00561925)
Timeframe: week 0 to 144

,
Interventioncumulative probability (Number)
Interval Week 0 to <2Interval Week 2 to <4Interval Week 4 to <6Interval Week 6 to <8Interval Week 8 to <12Interval Week 12 to <16Interval Week 16 to <24Interval Week 24 to <32Interval Week 32 to <40Interval Week 40 to <48Interval Week 48 to <60Interval Week 60 to <72Interval Week 72 to <84Interval Week 84 to <96Interval Week 96 to <108Interval Week 108 to <120Interval Week 120 to <132Interval Week 132 to <144
NVP IR0.0000.0000.0340.0670.0810.0930.1130.1300.1560.1720.1920.2020.2130.2290.2430.2670.2750.289
NVP XR0.0000.0000.0260.0460.0590.0670.0830.1150.1390.1560.1620.1760.1880.2060.2180.2320.2360.244

Kaplan-Meier Estimates for Time to New AIDS or AIDS-related Progression Event or Death, Full Analysis Set Population

(NCT00561925)
Timeframe: week 0 to 144

,
Interventionproportion of participants (Number)
Interval Week 0 to <2Interval Week 2 to <4Interval Week 4 to <6Interval Week 6 to <8Interval Week 8 to <12Interval Week 12 to <16Interval Week 16 to <24Interval Week 24 to <32Interval Week 32 to <40Interval Week 40 to <48Interval Week 48 to <60Interval Week 60 to <72Interval Week 72 to <84Interval Week 84 to <96Interval Week 96 to <108Interval Week 108 to <120Interval Week 120 to <132Interval Week 132 to <144Interval Week 144 to <168
NVP IR 200mg BID00.0060.0060.0230.0290.0290.0310.040.0420.0470.0470.0520.0540.0540.0570.0570.060.060.062
NVP XR 400mg QD00.0020.0060.0080.010.0190.0210.0250.0250.0270.0270.0320.0350.040.040.0450.0470.0470.047

Kaplan-Meier Estimates of the Proportions of Patients Without Loss of Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population

(NCT00561925)
Timeframe: week 0 to 144

,
Interventionproportion of participants (Number)
Interval Week 0 to <2Interval Week 2 to <4Interval Week 4 to <6Interval Week 6 to <8Interval Week 8 to <12Interval Week 12 to <16Interval Week 16 to <24Interval Week 24 to <32Interval Week 32 to <40Interval Week 40 to <48Interval Week 48 to <60Interval Week 60 to <72Interval Week 72 to <84Interval Week 84 to <96Interval Week 96 to <108Interval Week 108 to <120Interval Week 120 to <132Interval Week 132 to <144Interval Week 144 to <168
NVP IR 200mg BID10.840.8380.8340.8340.8320.830.8220.8060.7920.7770.7590.7330.7130.6860.6620.650.630.61
NVP XR 400mg QD10.8650.8650.8650.8630.8610.8590.8480.8320.8160.8080.7880.7660.7450.7190.6970.6810.6710.66

Occurrence of Elevations in Laboratory Measurement by DAIDS Grade

(NCT00561925)
Timeframe: until last patient completed 144 weeks (up to 193 weeks)

,,,
Interventionparticipants (Number)
DAIDS grade 3 or 4 AEsDAIDS grade 4 AEs
IR-IR/XR7111
NVP IR5317
NVP XR11125
XR-IR/XR83

Occurrence of Rashes

Frequency of patients with drug related rash events by functional grouping (NCT00561925)
Timeframe: until last patient completed 144 weeks (up to 193 weeks)

,,,
Interventionparticipants (Number)
rash group Irash group IIrash group IIArash group IIIrash group IV
IR-IR/XR63100
NVP IR96430
NVP XR1113550
XR-IR/XR00000

Proportion of Sustained Virologic Response at Week 144 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population

Endpoint was the number of patients with a sustained virologic response through week 144 using LLOQ = 50 copies/mL (NCT00561925)
Timeframe: week 144

,
Interventionparticipants (Number)
ResponderNon responder
NVP IR 200mg BID296210
NVP XR 400mg QD321184

Area Under the Curve Pharmacokinetic Outcome for LPV/r. (AUC ug*hr/mL)

Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum

Interventionug*hr/mL (Median)
Within 72 Hrs Ppm99.7
At Day 30 PpmNA

Four (4) Hour Concentration Pharmacokinetic Outcome for LPV/r (C4hour ug/mL).

Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum

Interventionug/mL (Median)
Within 72 Hrs Ppm10.78
At Day 30 Ppm12.96

Maximum Concentration Pharmacokinetic Outcome for LPV/r (Cmax ug/mL) .

Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum

Interventionug/mL (Median)
Within 72 Hrs Ppm11.2
At Day 30 PpmNA

Median HIV-1 Viral Load at 24 Weeks Postpartum in Women

(NCT00109590)
Timeframe: at 24 weeks postpartum

Interventionlog10 copies/mL (Median)
Arm A : LPV/r x 7d4.3
Arm B : no LPV/r3.9
Arm C: LPV/r x 30d4.0

Number of Women With Grade >=3 Events After Start of Study Treatment

Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading > the Severity of Adult and Pediatric Adverse Events (December 2004). All grade 3 and higher signs, symptoms, and laboratory toxicities (and events of any grade that led to a change in study treatment) were included. (NCT00109590)
Timeframe: After start of study Treatment (postpartum)

Interventionparticipants (Number)
Arm A : LPV/r x 7d2
Arm B : no LPV/r0
Arm C: LPV/r x 30d2

Pre-dose Concentration Pharmacokinetic Outcome for LPV/r (Cpredose ug/mL).

Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum

Interventionug/mL (Median)
Within 72 Hrs Ppm6.08
At Day 30 Ppm9.17

Resistance Mutations in HIV Infected Infants

Resistance mutations as identified by consensus sequencing or OLA (NCT00109590)
Timeframe: 24 weeks postpartum

Interventionparticipants (Number)
Arm B : no LPV/r0
Arm C: LPV/r x 30d0

The Proportion of Women in Each Randomized Arm Who Have One or More New NVP Resistance Mutations as Identified by Consensus Sequencing or Oligonucleotide Ligation Assay (OLA) in Plasma

The incidence of new NVP resistance mutations at day 10 or week 6 postpartum in each randomized arm. Samples with viral load <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: at Day 10 or Week 6 postpartum.

Interventionpercent of participants (Number)
Arm A : LPV/r x 7d3.6
Arm B : no LPV/r7.1
Arm C : LPV/r x 30d5.3

The Proportion of Women in Each Randomized Arm Who Have One or More New NVP Resistance Mutations for the Subgroup of Women With Plasma HIV RNA >= 500 Copies/ml At Entry

The incidence of new NVP resistance mutations at day 10 or week 6 postpartum in each randomized arm. Samples with viral load <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: at Day 10 or Week 6 postpartum.

Interventionpercent of participants (Number)
Arm A: LPV/r x 7d4.9
Arm B: no LPV/r9.5
Arm C : LPV/r x 30d7.0

The Proportion of Women Who Develop One or More New NVP Resistance Mutations as Identified by Consensus Sequencing or Oligonucleotide Ligation Assay in Plasma (Sampling Was Done at Days 10,21,30, and Weeks 5,6, and 8 Postpartum).

The incidence of new NVP resistance mutation in plasma HIV within 8 weeks postpartum in each randomized arm was estimated using an exact binomial confidence interval. If a resistance mutation was detected at any of the timepoints then an endpoint was met. Samples with VL <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml (e.g.missed visit), it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: within 8 weeks postpartum.

Interventionpercent of participants (Number)
Arm A : LPV/r x 7d7.1
Arm B : no LPV/r12.5
Arm C: LPV/r x 30d5.3

Proportion of Women With New NVP Resistance Mutation Within 8 Weeks Postpartum Who Had a NVP Resistance Mutation Detected at 72 Weeks Postpartum.

Resistance mutations as identified by OLA in plasma samples or PBMC at 72 weeks postpartum amongst women who had new NVP resistance mutations within 8 weeks postpatrum. These results were based on the 13 women who developed a new NVP resistance mutation in the first 8 weeks postpartum. For the primary outcome measure 1, one particpant in arm A was unavailable for follow-up after week 5 and was conservatively imputed to have developed resistance mutation. (NCT00109590)
Timeframe: within 72 weeks postpartum

,,
Interventionparticipants (Number)
OLA in plasma samplesOLA in PBMC
Arm A : LPV/r x 7d00
Arm B : no LPV/r00
Arm C: LPV/r x 30d01

The Proportion of Women With Any New ZDV, ddI, or LPV/r Resistance Mutations.

(NCT00109590)
Timeframe: At Week 5 postpartum (ZDV) and at the first timepoint with viral load >=500 copies/ml after treatment discontinuation (ddI and LPV/r).

,,
Interventionpercent of participants (Number)
The proportion of women with new ZDV resistanceThe proportion of women with new ddI resistanceThe proportion of women with new LPV/r resistance
Arm A : LPV/r x 7d000
Arm B : no LPV/r1.7800
Arm C: LPV/r x 30d000

Mean Change in HIV-1 Levels in Plasma Between 34 and 38 Weeks Gestation

Calculated as log10 plasma viral load at 34 weeks gestation - log10 plasma viral load at 38 weeks gestation (NCT00530777)
Timeframe: 4 weeks

Interventionlog10 copies/mL (Mean)
Valacyclovir-0.53
Placebo0.03

Vertical HIV-1 Transmission

Mother-to-child HIV transmission (NCT00530777)
Timeframe: 1 year postpartum

InterventionParticipants (Number)
Valacyclovir6
Placebo4

Infant HIV Infection Status

Intrapartum HIV infection at 3 Months (NCT00099359)
Timeframe: 3 months

Interventionparticipants (Number)
ARM A (ZDV - Standard of Care)24
ARM B (ZDV + NVP)11
ARM C (ZDV +3TC+NFV)12

Infant HIV-1 Infection Status

In utero HIV-1 infection rate (NCT00099359)
Timeframe: birth

Interventionparticipants (Number)
Arm A (ZDV Only)37
ARM B (ZDV + NVP)28
ARM C (ZDV + 3TC + NFV)28

Participant Deaths

(NCT00099359)
Timeframe: through age 6 months

Interventionparticipants (Number)
Arm A (ZDV Only)11
ARM B (ZDV + NVP)15
ARM C (ZDV + 3TC + NFV)17

Participants With Serious Adverse Events

Serious Adverse Events by System Organ Class=Blood and lymphatic system disorders (NCT00099359)
Timeframe: through age 6 months.

Interventionparticipants (Number)
ARM A (ZDV Only)86
ARM B (ZDV + NVP)59
ARM C (ZDV + 3TC/NFV)110

3TC and NFV Pharmacokinetics

Descriptive study of 3TC and NFV pharmacokinetics during first two weeks of life using weight band dosing regimen in a subset of enrolled infants. (NCT00099359)
Timeframe: through age 14 days

Interventionug*h/mL (Median)
(NFV-AUC-12h) 4-7 day(NFV-AUC-12h) 10-14 day(3TC-AUC-12 h) 4-7 day(3TC-AUC-12h) 10-14 day
ARM C (ZDV + 3TC/NFV)20.725.54.07.9

NVP Pharmacokinetics

Descriptive study of NVP pharmacokinetics during first two weeks of life using weight band dosing in a subset of enrolled infants. (NCT00099359)
Timeframe: 14 days

Interventionng/mL (Median)
NVP conc prior to 3rd doseNVP peak conc (Cmax) post 3rd doseNVP conc 3-5 day post 3rd doseNVP conc 7 day post 3rd dose
ARM B (ZDV + NVP)362228645976

Risk Factors for Perinatal HIV-1 Transmission

Risk factors to be assessed include maternal HIV-1 RNA levels at delivery, maternal syphilis and other infections, obstetrical factors such as duration of membrane rupture, and adherence to neonatal medication. (NCT00099359)
Timeframe: through age 3 months

,
Interventionparticipants (Number)
Treatment Arm C (ZDV+3TC/NFV)Treatment Arm B (ZDV+NFV)Treatment Arm A (ZDV only)Illegal Substance Abuse during pregnancy
Infected1211247
Uninfected516523505130

AUC24 for Cohort 1 RAL Dose #1 (Within 48 Hours of Birth)

Area Under the Concentration-time Curve at 24-hour interval (AUC24) based on intensive PK sampling around Cohort 1 RAL dose #1 (within 48 hours of birth) (NCT01780831)
Timeframe: Cohort 1 RAL dose #1 (within 48 hours of birth) intensive PK sampling: within 30 min pre-dose; and 1-2, 4-8, 12 (±1), 24 (±1) hours post-dose.

Interventionmg*h/L (Geometric Mean)
Cohort 1 RAL-naive: 3 mg/kg for First Dose53.88
Cohort 1 RAL-naive: 2 mg/kg for First Dose44.26
Cohort 1 RAL-exposed 1.5 mg/kg37.42

AUC24 for Cohort 2 Initial RAL Dose (Within 48 and 12-60 Hours of Birth for RAL-naive and RAL-exposed Groups, Respectively)

Area Under the Concentration-time Curve at the 24-hour interval (AUC24) for Cohort 2 initial RAL dose (within 48 and between 12-60 hours of birth for RAL-naive and RAL-exposed, respectively). (NCT01780831)
Timeframe: Cohort 2 initial dose (within 48 and between 12-60 hours of birth for RAL-naive and RAL-exposed, respectively) intensive PK sampling: within 1 hour pre-dose; and 1-2, 6-10, 20-24 hours post-dose.

Interventionmg*h/L (Geometric Mean)
Cohort 2 RAL-naive: 1.5 mg/kg Once Daily on Days 1-7 of Life38.2
Cohort 2 RAL-exposed: 1.5mg/kg Once Daily on Days 1-7 of Life42.89

Clast for Cohort 2 Initial RAL Dose (Within 48 and Between 12-60 Hours of Birth for RAL-naïve and RAL-exposed Groups, Respectively)

Last concentration of the drug (Clast) at 24 hour interval post dosing for the Cohort 2 initial RAL dose (within 48 and at 12-60 hours of birth for RAL-naive and RAL-exposed, respectively). This is the plasma RAL concentration from a sample collected at or close to 24 hours post dose. (NCT01780831)
Timeframe: Cohort 2 initial dose (within 48 and between 12-60 hours of birth for RAL-naive and RAL-exposed groups, respectively) intensive PK sampling: within 1 hour pre-dose; and 1-2, 6-10, 20-24 hours post-dose.

Interventionng/mL (Geometric Mean)
Cohort 2 RAL-naive: 1.5 mg/kg Once Daily on Days 1-7 of Life947.90
Cohort 2 RAL-exposed: 1.5 mg/kg Once Daily on Days 1-7 of Life946.24

Cmax for Cohort 1 RAL Dose #1 (Within 48 Hours of Birth)

Maximum concentration (Cmax) for Cohort 1 dose #1 (within 48 hours of birth) (NCT01780831)
Timeframe: Cohort 1 dose #1(within 48 hours of birth) intensive PK sampling: within 30 min pre-dose; and 1-2, 4-8, 12 (±1), 24 (±1) hours post-dose.

Interventionng/mL (Geometric Mean)
Cohort 1 RAL-naive: 3 mg/kg for First Dose3360.89
Cohort 1 RAL-naive: 2 mg/kg for First Dose3405.24
Cohort 1 RAL-exposed: 1.5 mg/kg for First Dose2188.82

Cohort 1 Dose #1 Neonatal RAL Elimination (CL/F) by UGT1A1 Genotype Group

Cohort 1 Dose #1 neonatal RAL elimination was represented by Clearance (CL/F), which is the volume of plasma cleared of the drug per unit time. Genotyping for polymorphisms of UGT1A1 were performed on infants who were eligible for PK sampling and were consented by their mothers/guardians (i.e. genotyping was optional) . (NCT01780831)
Timeframe: Cohort 1 Dose #1 Intensive PK sampling: within 30 min pre-dose; and 1-2, 4-8, 12, 24 hours post-dose. Samples for UGT1A1 genotype testing were collected at study entry.

InterventionL/hr (Median)
(TA)6(TA)60.11
(TA)6(TA)70.06

Cohort 2 Initial Dose Neonatal RAL Elimination (CL/F) by UGT1A1 Genotype Group

Cohort 2 initial dose neonatal RAL elimination was represented by Clearance (CL/F), which is defined as the volume of plasma cleared of the drug per unit time. Genotyping for polymorphisms of UGT1A1 were performed on infants who were eligible for PK sampling and were consented by their mothers/guardians (i.e. genotyping was optional) . (NCT01780831)
Timeframe: Intensive PK sampling for Cohort 2 initial dose: within 1 hour pre-dose; and 1-2, 6-10, 20-24 hours post-dose. Samples for UGT1A1 genotype testing were collected at study entry.

InterventionL/hr (Median)
(TA)6(TA)6 Wildtype0.1
Mutation0.1

Cohort 2 Neonatal RAL Elimination (CL/F) at 15-18 Days of Life by UGT1A1 Genotype Group

Cohort 2 15-18 days of life dose neonatal RAL elimination was represented by Clearance (CL/F), which is defined as the volume of plasma cleared of the drug per unit time at 15-18 days of life when RAL dosing would have been 3 mg/kg twice daily. Genotyping for polymorphisms of UGT1A1 were performed on infants who were eligible for PK sampling and were consented by their mothers/guardians(i.e. genotyping was optional) . (NCT01780831)
Timeframe: Intensive PK sampling for Cohort 2 at 15-18 days of life: within 1 hour pre-dose; and 1-2 hours post-dose, 4-6, 8-12 hours post-dose. Samples for UGT1A1 genotype testing were collected at study entry.

InterventionL/hr (Median)
(TA)6(TA)6 Wildtype0.5
Mutation0.5

Number of Infants Who Died or Had Grade 3/4 Adverse Event Through 24 Weeks of Life

Number of infants who died or had adverse events (AEs) of Grade 3 or 4 as defined in DAIDS AE Grading Table. Events with onset dates prior to first RAL dosing and congenital anomalies assessed as baseline by the study team were considered baseline events and not AEs. (NCT01780831)
Timeframe: From first RAL dose through 24 weeks of life

InterventionParticipants (Count of Participants)
Cohort 1 RAL-naive2
Cohort 1 RAL-exposed2
Cohort 1 Total4
Cohort 2 RAL-naive11
Cohort 2 RAL-exposed4
Cohort 2 Total15

Number of Infants Who Died or Had Grade 3/4 Adverse Event Through 6 Weeks of Life

Number of infants who died or had adverse events (AEs) of Grade 3 or 4 as defined in DAIDS AE Grading Table. Events with onset dates prior to first RAL dosing and congenital anomalies assessed as baseline by the study team were considered baseline events and not AEs. (NCT01780831)
Timeframe: From first dosing of RAL through 6 weeks of life

InterventionParticipants (Count of Participants)
Cohort 1 RAL-naive2
Cohort 1 RAL-exposed2
Cohort 1 Total4
Cohort 2 RAL-naive7
Cohort 2 RAL-exposed4
Cohort 2 Total11

Number of Infants Who Died or Had SADR of Grade 3 or 4 Through 24 Weeks of Life

"Number of infants who died or had Suspected Adverse Drug Reaction (SADR) of Grade 3 or 4 as defined in DAIDS AE Grading Table.~Events with onset dates prior to the first RAL dosing and congenital anomalies assessed as baseline by the study team were considered baseline events and not AEs. SADRs are AEs assessed as definitely related, probably related or possibly related to RAL." (NCT01780831)
Timeframe: From first RAL dose through 24 weeks of life

InterventionParticipants (Count of Participants)
Cohort 1 RAL-naive1
Cohort 1 RAL-exposed0
Cohort 1 Total1
Cohort 2 RAL-naive0
Cohort 2 RAL-exposed0
Cohort 2 Total0

Number of Infants Who Died or Had SADR of Grade 3 or 4 Through 6 Weeks of Life

"Number of infants who died or had Suspected Adverse Drug Reaction (SADR) of Grade 3 or 4 as defined in DAIDS AE Grading Table.~Events with onset dates prior to the first RAL dosing and congenital anomalies assessed as baseline by the study team were considered baseline events and not AEs. SADRs are AEs assessed as definitely related, probably related or possibly related to RAL." (NCT01780831)
Timeframe: From first RAL dose through 6 weeks of life

InterventionParticipants (Count of Participants)
Cohort 1 RAL-naive1
Cohort 1 RAL-exposed0
Cohort 1 Total1
Cohort 2 RAL-naive0
Cohort 2 RAL-exposed0
Cohort 2 Total0

RAL AUC12 for Cohort 2 at 15-18 Days of Life

Area Under the Concentration-time Curve at 12-hour interval (AUC12) of RAL for Cohort 2 at 15-18 days of life. (NCT01780831)
Timeframe: Intensive PK sampling for Cohort 2 at 15-18 days of life: within 1 hour pre-dose; and 1-2, 4-6, 8-12 hours post-dose.

Interventionmg*h/L (Geometric Mean)
Cohort 2 RAL-naive: 3 mg/kg Twice Daily on Days 8-18 of Life14.3
Cohort 2 RAL-exposed: 3 mg/kg Twice Daily on Days 8-28 of Life18.25

RAL C12 for Cohort 2 at 15-18 Days of Life

RAL concentration at 12 hours (C12) for Cohort 2 at 15-18 days of life. (NCT01780831)
Timeframe: Intensive PK sampling for Cohort 2 at 15-18 days of life: within 1 hour pre-dose; and 1-2, 4-6, 8-12 hours post-dose.

Interventionmg*h/L (Geometric Mean)
Cohort 2 RAL-naive: 3 mg/kg Twice Daily on Days 8-28 of Life176.11
Cohort 2 RAL-exposed: 3 mg/kg Twice Daily on Days 8-28 of Life273.59

Number of Participants Who Discontinued Study Treatment Prematurely

participants assigned to 7-day treatment arm and 21-day treatment arm were supposed to stay in study treatment for 7 days and 21 days respectively. (NCT00099632)
Timeframe: From first day of study treatment to last day of study treatment (up to 21 days)

Interventionparticipants (Number)
7-day Lamivudine/Zidovudine (3TC/ZDV)0
21-day Lamivudine/Zidovudine (3TC/ZDV)2
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)0
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)0
7-day Lopinavir/Ritonavir (LPV/r)0
21-day Lopinavir/Ritonavir (LPV/r)5

Number of Participants With New Circulating Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant Variants as Detected by Standard Composite (Bulk) Genotyping

"For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed to the primary endpoint; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed to primary endpoint.~10 participants who did not have resistance samples available were excluded from the primary endpoint analysis." (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment

Interventionparticipants (Number)
7-day Lamivudine/Zidovudine (3TC/ZDV)1
21-day Lamivudine/Zidovudine (3TC/ZDV)0
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)0
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)0
7-day Lopinavir/Ritonavir (LPV/r)3
21-day Lopinavir/Ritonavir (LPV/r)1

Number of Participants With New Circulating NRTI-resistant Variants Detected by Standard Composite (Bulk) Genotyping.

For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed. (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment

Interventionparticipants (Number)
7-day Lamivudine/Zidovudine (3TC/ZDV)0
21-day Lamivudine/Zidovudine (3TC/ZDV)1
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)1
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)1
7-day Lopinavir/Ritonavir (LPV/r)1
21-day Lopinavir/Ritonavir (LPV/r)0

Number of Participants With New PI-resistant Variants as Detected by Standard Composite (Bulk) Genotyping.

For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed. (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment

Interventionparticipants (Number)
7-day Lamivudine/Zidovudine (3TC/ZDV)0
21-day Lamivudine/Zidovudine (3TC/ZDV)0
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)0
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)0
7-day Lopinavir/Ritonavir (LPV/r)0
21-day Lopinavir/Ritonavir (LPV/r)0

Severe (Grade 3) and Higher Adverse Events and Any Grade Adverse Event That Leads to a Treatment Change From First Day of Study Treatment to Week 12

"Grade 3 or higher signs and symptoms, laboratory abnormalities, events that are reported through the EAE system, and any grade event that leads to a treatment change from first day of study treatment to week 12.~Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death" (NCT00099632)
Timeframe: From first day of study treatment to week 12

Interventionparticipants (Number)
7-day Lamivudine/Zidovudine (3TC/ZDV)5
21-day Lamivudine/Zidovudine (3TC/ZDV)1
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)1
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)0
7-day Lopinavir/Ritonavir (LPV/r)2
21-day Lopinavir/Ritonavir (LPV/r)2

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs

Infant plasma concentrations were collected and measured during the first 9 days of life. Half-life is defined as 0.693/k, where k, the elimination rate constant, is the slope of the decline in concentrations. (NCT00042289)
Timeframe: Infant plasma samples at 2-10, 18-28, 36-72 hours and 5-9 days after birth.

Interventionhour (Median)
DTG 50mg q.d.32.8
EVG/COBI 150/150mg q.d.7.6
DRV/COBI 800/150 mg q.d.NA
EFV 600 mg q.d. (Outside THA)65.6

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs

Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.

Interventionunitless (Median)
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.0.15
DTG 50mg q.d.1.25
EVG/COBI 150/150mg q.d.0.91
DRV/COBI 800/150 mg q.d.0.07
ATV/COBI 300/150 mg q.d.0.07
TFV 300mg q.d.0.88

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs

Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. For arms with zero overall participants analyzed, samples were below the limit of quantification and ratios could not be calculated. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.

Interventionunitless (Median)
TAF 10mg q.d. w/COBI0.97
EFV 600 mg q.d. (Outside THA)0.67
EFV 600mg q.d.0.49
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.0.2
RAL 400mg b.i.d.1.5
ETR 200mg b.i.d.0.52
MVC 150 or 300mg b.i.d.0.33
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.0.14
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.0.16
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.0.19
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)0.12
RPV 25mg q.d.0.55
ATV/RTV 300/100mg q.d. or TFV/ATV/RTV 300/300/100mg q.d.0.18
DRV/RTV 800/100mg q.d. or DRV/RTV 600/100mg b.i.d.0.18

Plasma Concentration for Contraceptives

Serum concentrations of the contraceptives. Note that no historical controls were provided by team pharmacologists and thus no comparisons were done for contraceptive concentrations in women using hormonal contraceptives and selected ARV drugs as compared to historical controls not using those ARV drugs. (NCT00042289)
Timeframe: Measured at 6-7 weeks after contraceptive initiation postpartum

Interventionpg/mL (Median)
ATV/RTV/TFV 300/100/300mg q.d. With ENG604
LPV/RTV 400/100 b.i.d. With ENG428
EFV 600mg q.d. With ENG125

Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12h (area-under-the-curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8 and 12 hours post dosing.

Interventionmcg*hr/mL (Median)
Before contraceptive initiationAfter contraceptive initiation
LPV/RTV 400/100 b.i.d. With ENG115.97100.20

Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8, 12, and 24 hours post dosing.

,
Interventionmcg*hr/mL (Median)
Before contraceptive initiationAfter contraceptive initiation
ATV/RTV/TFV 300/100/300mg q.d. With ENG53.9655.25
EFV 600mg q.d. With ENG53.6456.65

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.

,
InterventionParticipants (Count of Participants)
3rd TrimesterPostpartum
EFV 600mg q.d.2021
MVC 150 or 300mg b.i.d.87

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.

,,,,,,,,,,,,,,,,,,,,,,
InterventionParticipants (Count of Participants)
2nd Trimester3rd TrimesterPostpartum
ATV/RTV Arm 1: 300/100mg q.d.11212
DRV/COBI 800/150 mg q.d.3414
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.71622
DRV/RTV 600/100mg b.i.d.71922
DRV/RTV 800/100mg q.d.91922
DTG 50mg q.d.92023
EFV 600 mg q.d. (Outside THA)123334
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.82927
ETR 200mg b.i.d.5137
EVG/COBI 150/150mg q.d.81018
FPV/RTV 700/100mg b.i.d.82622
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)101926
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.93027
ATV/COBI 300/150 mg q.d.125
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA1514
RAL 400mg b.i.d.113330
RPV 25mg q.d.142625
TAF 10mg q.d. w/COBI152322
TAF 25mg q.d.132324
TAF 25mg q.d. w/COBI or RTV Boosting102418
TFV 300mg q.d.22727
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.11112
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.72332

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs

Infant plasma concentrations were collected and measured during the first 9 days of life. (NCT00042289)
Timeframe: Blood samples were collected at 2-10, 18-28, 36-72 hours and 5-9 days after birth.

,,,
Interventionmcg/mL (Median)
2-10 hours after birth18-28 hours after birth36-72 hours after birth5-9 days after birth
DRV/COBI 800/150 mg q.d.0.351.431.871.72
DTG 50mg q.d.1.731.531.000.06
EFV 600 mg q.d. (Outside THA)1.11.00.90.4
EVG/COBI 150/150mg q.d.0.1320.0320.0050.005

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs

Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

Interventionng*hour/mL (Geometric Mean)
2nd Trimester3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.NA27173645

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.55.151.879.6
DRV/RTV 600/100mg b.i.d.45.845.961.7
FPV/RTV 700/100mg b.i.d.43.5032.1551.60
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA34.233.5

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.4.58.35.3
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)14.916.127.1
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.7296133
RAL 400mg b.i.d.6.65.411.6

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24 (area under the curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

,,,,,,,,,,,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.25.3318.8536.20
ATV/RTV Arm 1: 300/100mg q.d.88.241.957.9
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.30.645.748.8
DRV/COBI 800/150 mg q.d.50.0042.0595.55
DRV/RTV 800/100mg q.d.64.663.5103.9
DTG 50mg q.d.47.649.265.0
EFV 600 mg q.d. (Outside THA)47.3060.0262.70
EVG/COBI 150/150mg q.d.15.314.021.0
TAF 10mg q.d. w/COBI0.1970.2060.216
TAF 25mg q.d.0.1710.2120.271
TAF 25mg q.d. w/COBI or RTV Boosting0.1810.2570.283
TFV 300mg q.d.1.92.43.0
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.14.528.839.6
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.26.237.758.7

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

Interventionmg*hour/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.55.458.3

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
RPV 25mg q.d.1.9691.6692.387

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

Interventionmg/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.5.445.10

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,,,,,,,,,,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.2.822.203.90
ATV/RTV Arm 1: 300/100mg q.d.NA3.64.1
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.3.114.514.52
DRV/COBI 800/150 mg q.d.4.593.677.04
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.6.226.558.96
DRV/RTV 600/100mg b.i.d.5.645.537.78
DRV/RTV 800/100mg q.d.6.775.788.11
DTG 50mg q.d.3.623.544.85
EFV 600 mg q.d. (Outside THA)3.875.134.41
FPV/RTV 700/100mg b.i.d.5.615.126.75
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)3.893.625.37
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA5.15.0
TFV 300mg q.d.0.2500.2450.298
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.1.22.54.1
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.2.733.565.43

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.0.701.010.63
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.8.410.714.6
RAL 400mg b.i.d.2.2501.7703.035
RPV 25mg q.d.0.1450.1340.134

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

Interventionng/mL (Median)
3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.448647

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,
Interventionng/mL (Median)
2nd Trimester3rd TrimesterPostpartum
EVG/COBI 150/150mg q.d.1447.11432.81713.1
TAF 10mg q.d. w/COBI80.491.298.2
TAF 25mg q.d.69.796133
TAF 25mg q.d. w/COBI or RTV Boosting87.8107141

PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

Interventionng/mL (Geometric Mean)
3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.108128

PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.2.842.524.51
DRV/RTV 600/100mg b.i.d.2.122.222.51
FPV/RTV 700/100mg b.i.d.2.121.642.87
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA0.470.52

PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.0.360.480.38
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)0.130.130.28
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.3.75.17.2
RAL 400mg b.i.d.0.06210.0640.0797

PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs

"Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose.~For the TAF 25 mg q.d., 10 mg q.d. w/COBI, and 25 mg q.d. w/COBI or RTV boosting arms, samples were all below the limit of quantification and statistical analyses were not conducted." (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

,,,,,,,,,,,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.0.210.210.61
ATV/RTV Arm 1: 300/100mg q.d.2.00.71.2
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.0.490.710.90
DRV/COBI 800/150 mg q.d.0.330.271.43
DRV/RTV 800/100mg q.d.0.991.172.78
DTG 50mg q.d.0.730.931.28
EFV 600 mg q.d. (Outside THA)1.491.481.94
EVG/COBI 150/150mg q.d.0.02580.04870.3771
TAF 10mg q.d. w/COBI0.001950.001950.00195
TAF 25mg q.d.0.001950.001950.00195
TAF 25mg q.d. w/COBI or RTV Boosting0.001950.001950.00195
TFV 300mg q.d.0.0390.0540.061
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.0.30.50.8
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.0.440.571.26

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

Interventionmg/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.1.602.05

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
RPV 25mg q.d.0.0630.0560.081

Change in CD4+ Cell Count From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

The per-protocol analysis of change in CD4+ cell count from baseline to Week 24 was calculated using the measurement closest to schedule and within the analysis window, and quantified with an estimated median and distribution-free 95% confidence interval (CI). (NCT00959894)
Timeframe: Baseline to 24 weeks

Interventioncells/uL (Median)
Etravirine 400 mg Once Daily156

Change in CD4+ Cell Count From Baseline to Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

The per-protocol intention-to-treat analysis of change in CD4+ cell count from baseline to Week 48 was calculated using the measurement closest to schedule and within the analysis window, and quantified with an estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 48 weeks

Interventioncells/uL (Median)
Etravirine 400 mg Once Daily163

Change in CD4+ Cell Count From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

The per-protocol intention-to-treat analysis of change in CD4+ cell count from baseline to Week 96 was calculated using the measurement closest to schedule and within the analysis window, and quantified with an estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 96 weeks

Interventioncells/uL (Median)
Etravirine 400 mg Once Daily224

Change in Fat Mass Ratio as Measured by DEXA Scan, in the Same Subgroup of up to 40 Participants (as in Aim 8), From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Change from baseline to follow-up in fat mass ratio was calculated. Whole body Dual X-ray Absorptiometry (DEXA) scans (Hologic Discovery W, Hologic Inc., Bedford, MA) were conducted at baseline, Week 24, and Week 96 to assess body fat distribution. Fat mass ratio was calculated as the ratio of trunk fat percentage and lower limb fat percentage (% trunk fat mass / % lower limb fat mass). Calculations of change from baseline to follow-up used the value closest to schedule and within the analysis window, and were quantified with the estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 24 weeks

Interventionratio of trunk fat % : lower limb fat % (Median)
Etravirine 400 mg Once Daily0.02

Change in Fat Mass Ratio as Measured by DEXA Scan, in the Same Subgroup of up to 40 Participants (as in Aim 8), From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Change from baseline to follow-up in fat mass ratio was calculated. Whole body Dual X-ray Absorptiometry (DEXA) scans (Hologic Discovery W, Hologic Inc., Bedford, MA) were conducted at baseline, Week 24, and Week 96 to assess body fat distribution. Fat mass ratio was calculated as the ratio of trunk fat percentage and lower limb fat percentage (% trunk fat mass / % lower limb fat mass). Calculations of change from baseline to follow-up used the value closest to schedule and within the analysis window, and were quantified with the estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 96 weeks

Interventionratio of trunk fat % : lower limb fat % (Median)
Etravirine 400 mg Once Daily0.06

Change in Glucose Metabolism (Insulin Resistance), in a Subgroup of up to 40 Participants, From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Metabolic data analyses were conducted as-treated. Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR), and was calculated as [fasting insulin (µU/mL) × fasting glucose (mmol/L)]/22.5. Changes from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. (NCT00959894)
Timeframe: Baseline to 24 weeks

InterventionµU/ml*mmol/L (Median)
Etravirine 400 mg Once Daily-0.08

Change in Glucose Metabolism (Insulin Resistance), in a Subgroup of up to 40 Participants, From Baseline to Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Metabolic data analyses were conducted as-treated. Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR), and was calculated as [fasting insulin (µU/mL) × fasting glucose (mmol/L)]/22.5. Changes from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. (NCT00959894)
Timeframe: Baseline to 48 weeks

InterventionµU/ml*mmol/L (Median)
Etravirine 400 mg Once Daily0.71

Change in Glucose Metabolism (Insulin Resistance), in a Subgroup of up to 40 Participants, From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Metabolic data analyses were conducted as-treated. Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR), and was calculated as [fasting insulin (µU/mL) × fasting glucose (mmol/L)]/22.5. Changes from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. (NCT00959894)
Timeframe: Baseline to 96 weeks

InterventionµU/ml*mmol/L (Median)
Etravirine 400 mg Once Daily0.23

Pharmacokinetics of Etravirine in Genital Secretions of up to 10 Men and up to 10 Women at Week 4 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

This secondary outcome measure assessed the ratio of semen:plasma concentration of etravirine in paired semen and plasma samples collected from 14 male participants at Week 4 of treatment with etravirine and fixed dose tenofovir/emtricitabine. (NCT00959894)
Timeframe: 4 weeks

Interventionratio of semen:plasma drug concentration (Median)
Etravirine 400 mg Once Daily0.192

Population Pharmacokinetics of Etravirine 400 mg Once Daily, in Combination With Fixed-dose Emtricitabine-tenofovir Among Treatment-naïve HIV-1 Infected Adults: Etravirine AUC-24 Hours at Steady State

Population pharmacokinetics were calculated using sparse sampling. Plasma concentrations of etravirine measured in samples from participants who provided blood samples at multiple study visits, with variation in sampling times relative to dosing of etravirine used to cover the spectrum of the dosing schedule. Model simulations and fitting were performed with NONMEM ® 7.3. (ICON, plc) and model exploration was performed with Berkeley Madonna (Berkeley, CA, USA) (NCT00959894)
Timeframe: At or after 4 weeks

Interventionng*hr/mL (Median)
Etravirine 400 mg Once Daily8024.40

Probability of Remaining Free of a Safety/Tolerability Event at 96 Weeks

The Kaplan-Meier method was used to estimate the proportion of participants ever exposed to etravirine who remained event-free through Week 96, with a 95% CI using Greenwood's variance estimate and a log-log transformation. Time was handled as continuous (weeks from treatment start to event or censoring). (NCT00959894)
Timeframe: 96 weeks

Interventionproportion of participants (Number)
Etravirine 400 mg Once Daily0.69

The Antiretroviral Activity of Etravirine 400 mg Given Once Daily, With Fixed-dose Truvada Once Daily, Among Treatment-naïve HIV-1 Infected Adults as Measured by the Percentage of Participants With HIV RNA < 50 Copies/mL at Week 24

The primary study endpoint was the proportion of participants who achieved HIV-1 RNA <50 copies/ml at Week 24 of study participation. The per-protocol primary analysis was conducted intention-to-treat, with missing evaluations counted as failures. Achievement of HIV-1 viral load below 50 copies/ml was defined as having HIV-1 RNA <50 copies/ml during the Week 24 analysis window (>18 and <30 weeks post-entry). (NCT00959894)
Timeframe: 24 weeks

Interventionproportion of participants (Number)
Etravirine 400 mg Once Daily0.87

The Proportion of Participants With HIV RNA <200 Copies/mL at Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA <200 copies/ml at Week 24 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 24 weeks

Interventionproportion of participants (Number)
Etravirine 400 mg Once Daily0.89

The Proportion of Participants With HIV RNA <200 Copies/mL at Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA <200 copies/ml at Week 48 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 48 weeks

Interventionproportion of participants (Number)
Etravirine 400 mg Once Daily0.82

The Proportion of Participants With HIV RNA <200 Copies/mL at Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA 200 copies/ml at Week 96 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 96 weeks

Interventionproportion of participants (Number)
Etravirine 400 mg Once Daily0.77

The Proportion of Participants With HIV RNA <50 Copies/mL at Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA <50 copies/ml at Week 48 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 48 weeks

Interventionproportion of participants (Number)
Etravirine 400 mg Once Daily0.77

The Proportion of Participants With HIV RNA <50 Copies/mL at Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA <50 copies/ml at Week 96 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 96 weeks

Interventionproportion of participants (Number)
Etravirine 400 mg Once Daily0.71

Change in Limb and Trunk Fat Distribution as Measured by DEXA Scan, in the Same Subgroup of up to 40 Participants (as in Aim 8), From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Changes from baseline to follow-up in limb fat, trunk fat, total body fat, and lean mass were calculated. Whole body Dual X-ray Absorptiometry (DEXA) scans (Hologic Discovery W, Hologic Inc., Bedford, MA) were conducted at baseline, Week 24, and Week 96 to assess body fat distribution. Calculations of change from baseline to follow-up used the value closest to schedule and within the analysis window, and were quantified with the estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 24 weeks

Interventionpercentage of body fat (Median)
Total body fatLimb fatTrunk fat
Etravirine 400 mg Once Daily0.430.480.32

Change in Limb and Trunk Fat Distribution as Measured by DEXA Scan, in the Same Subgroup of up to 40 Participants (as in Aim 8), From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Changes from baseline to follow-up in limb fat, trunk fat, total body fat, and lean mass were calculated. Whole body Dual X-ray Absorptiometry (DEXA) scans (Hologic Discovery W, Hologic Inc., Bedford, MA) were conducted at baseline, Week 24, and Week 96 to assess body fat distribution. Calculations of change from baseline to follow-up used the value closest to schedule and within the analysis window, and were quantified with the estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 96 weeks

Interventionpercentage of body fat (Median)
Total body fatLimb fatTrunk fat
Etravirine 400 mg Once Daily1.440.821.93

Change in the Lipid Profile and Glucose Metabolism, in a Subgroup of up to 40 Participants, From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Metabolic data analyses were conducted as-treated. Changes in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and fasting blood glucose from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. (NCT00959894)
Timeframe: Baseline to 24 weeks

Interventionmg/dL (Median)
Total cholesterolHDL-cholesterolLDL-cholesterolTriglyceridesFasting glucose
Etravirine 400 mg Once Daily-71-9-161

Change in the Lipid Profile and Glucose Metabolism, in a Subgroup of up to 40 Participants, From Baseline to Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Metabolic data analyses were conducted as-treated. Changes in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and fasting blood glucose from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. (NCT00959894)
Timeframe: Baseline to 48 weeks

Interventionmg/dL (Median)
Total cholesterolHDL-cholesterolLDL-cholesterolTriglyceridesFasting glucose
Etravirine 400 mg Once Daily65-1-102

Change in the Lipid Profile and Glucose Metabolism, in a Subgroup of up to 40 Participants, From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine

Metabolic data analyses were conducted as-treated. Changes in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and fasting blood glucose from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR), and was calculated as [fasting insulin (µU/mL) × fasting glucose (mmol/L)]/22.5. (NCT00959894)
Timeframe: Baseline to 96 weeks

Interventionmg/dL (Median)
Total cholesterolHDL-cholesterolLDL-cholesterolTriglyceridesFasting glucose
Etravirine 400 mg Once Daily64-532

Population Pharmacokinetics of Etravirine 400 mg Once Daily, in Combination With Fixed-dose Emtricitabine-tenofovir Among Treatment-naïve HIV-1 Infected Adults

Population pharmacokinetics were calculated using sparse sampling. Plasma concentrations of etravirine measured in samples from participants who provided blood samples at multiple study visits, with variation in sampling times relative to dosing of etravirine used to cover the spectrum of the dosing schedule. Model simulations and fitting were performed with NONMEM ® 7.3. (ICON, plc) and model exploration was performed with Berkeley Madonna (Berkeley, CA, USA) (NCT00959894)
Timeframe: At or after 4 weeks

Interventionng/mL (Median)
Etravirine trough plasma concentrationEtravirine peak plasma concentration
Etravirine 400 mg Once Daily217.47480.99

Resistance Mutations in the Subset of Patients With Confirmed Virologic Failure Who Have HIV RNA >500 Copies/mL and Genotype Resistance Results

Per-protocol, genotype testing was conducted at confirmation of virologic failure if the confirmatory HIV-1 RNA was above the laboratory-specified threshold of 500 copies/mL. HIV-1 genotype was determined using the TRUGENE® HIV-1 assay (Siemens Healthcare Diagnostics, Tarrytown, NY) (NCT00959894)
Timeframe: 96 weeks

Interventionparticipants (Number)
Y181CE138KE138K, Y181C, M230L, M184I, K219E, V75INo resistance-associated mutations detected
Etravirine 400 mg Once Daily1113

Tolerability of Etravirine in HIV-1 Infected Adults Initiating Antiretroviral Therapy

"The safety/tolerability endpoint was defined as the first grade 3 or higher sign, symptom or laboratory abnormality that was at least one grade higher than baseline among participants ever exposed to etravirine (regardless of treatment status), or permanent discontinuation of etravirine due to any toxicity (regardless of grade). Modification of tenofovir/emtricitabine was not a safety/tolerability event.~The Kaplan-Meier method was used to estimate the proportion of participants ever exposed to etravirine who remained event-free through Week 96, with a 95% CI using Greenwood's variance estimate and a log-log transformation. Time was handled as continuous (weeks from treatment start to event or censoring)." (NCT00959894)
Timeframe: 96 weeks

Interventionparticipants (Number)
At least one safety/tolerability eventSigns or SymptomsLaboratory Abnormalities
Etravirine 400 mg Once Daily231310

Reviews

132 reviews available for nevirapine and HIV Infections

ArticleYear
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
    Journal of medicinal chemistry, 2005, Mar-24, Volume: 48, Issue:6

    Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; Crystallography, X-Ray; Drug Design;

2005
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
    Journal of medicinal chemistry, 2005, Mar-24, Volume: 48, Issue:6

    Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; Crystallography, X-Ray; Drug Design;

2005
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
    Bioorganic & medicinal chemistry, 2015, Sep-01, Volume: 23, Issue:17

    Topics: Anti-HIV Agents; Drug Discovery; HIV; HIV Fusion Inhibitors; HIV Infections; HIV Integrase; HIV Inte

2015
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
    Bioorganic & medicinal chemistry, 2015, Sep-01, Volume: 23, Issue:17

    Topics: Anti-HIV Agents; Drug Discovery; HIV; HIV Fusion Inhibitors; HIV Infections; HIV Integrase; HIV Inte

2015
Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana.
    AIDS research and therapy, 2022, 05-25, Volume: 19, Issue:1

    Topics: Adult; Anti-HIV Agents; Ghana; HIV Infections; Humans; Lamivudine; Nevirapine; Retrospective Studies

2022
Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana.
    AIDS research and therapy, 2022, 05-25, Volume: 19, Issue:1

    Topics: Adult; Anti-HIV Agents; Ghana; HIV Infections; Humans; Lamivudine; Nevirapine; Retrospective Studies

2022
A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs.
    Journal of neurovirology, 2020, Volume: 26, Issue:5

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Astrocytes; Atazanavir Sulfate; Ben

2020
A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs.
    Journal of neurovirology, 2020, Volume: 26, Issue:5

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Astrocytes; Atazanavir Sulfate; Ben

2020
Effects of CYP2B6 polymorphisms on plasma nevirapine concentrations: a systematic review and meta-analysis.
    Scientific reports, 2020, 10-15, Volume: 10, Issue:1

    Topics: Cytochrome P-450 CYP2B6; HIV Infections; Humans; Nevirapine; Polymorphism, Genetic; Reverse Transcri

2020
Effects of CYP2B6 polymorphisms on plasma nevirapine concentrations: a systematic review and meta-analysis.
    Scientific reports, 2020, 10-15, Volume: 10, Issue:1

    Topics: Cytochrome P-450 CYP2B6; HIV Infections; Humans; Nevirapine; Polymorphism, Genetic; Reverse Transcri

2020
Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review.
    Clinical pharmacokinetics, 2021, Volume: 60, Issue:9

    Topics: HIV Infections; Humans; Malaria; Malnutrition; Nevirapine; Pharmaceutical Preparations; Poverty

2021
Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review.
    Clinical pharmacokinetics, 2021, Volume: 60, Issue:9

    Topics: HIV Infections; Humans; Malaria; Malnutrition; Nevirapine; Pharmaceutical Preparations; Poverty

2021
Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines.
    Journal of the International AIDS Society, 2017, 05-11, Volume: 20, Issue:1

    Topics: Adult; Alkynes; Benzoxazines; Contraception; Contraceptive Agents; Counseling; Cyclopropanes; Drug I

2017
Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines.
    Journal of the International AIDS Society, 2017, 05-11, Volume: 20, Issue:1

    Topics: Adult; Alkynes; Benzoxazines; Contraception; Contraceptive Agents; Counseling; Cyclopropanes; Drug I

2017
Developments in early diagnosis and therapy of HIV infection in newborns.
    Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:1

    Topics: Anti-HIV Agents; Early Diagnosis; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transm

2018
Developments in early diagnosis and therapy of HIV infection in newborns.
    Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:1

    Topics: Anti-HIV Agents; Early Diagnosis; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transm

2018
Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies.
    Systematic reviews, 2017, 08-25, Volume: 6, Issue:1

    Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Com

2017
Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies.
    Systematic reviews, 2017, 08-25, Volume: 6, Issue:1

    Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Com

2017
Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs.
    PloS one, 2018, Volume: 13, Issue:6

    Topics: Abnormalities, Drug-Induced; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Congenital Abnormalities

2018
Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs.
    PloS one, 2018, Volume: 13, Issue:6

    Topics: Abnormalities, Drug-Induced; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Congenital Abnormalities

2018
Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis.
    BMC infectious diseases, 2019, Jul-05, Volume: 19, Issue:1

    Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; Female; HIV Infections; HLA Antigens; Hu

2019
Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis.
    BMC infectious diseases, 2019, Jul-05, Volume: 19, Issue:1

    Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; Female; HIV Infections; HLA Antigens; Hu

2019
HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission.
    Current HIV research, 2013, Volume: 11, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Aptamers, Nucleotide; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; D

2013
HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission.
    Current HIV research, 2013, Volume: 11, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Aptamers, Nucleotide; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; D

2013
HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.
    Current opinion in virology, 2013, Volume: 3, Issue:2

    Topics: Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-

2013
HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.
    Current opinion in virology, 2013, Volume: 3, Issue:2

    Topics: Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-

2013
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    The Cochrane database of systematic reviews, 2013, Jun-05, Issue:6

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynuc

2013
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    The Cochrane database of systematic reviews, 2013, Jun-05, Issue:6

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynuc

2013
Prevention of perinatal HIV I transmission by protease inhibitor based triple drug antiretroviral therapy versus nevirapine as single dose at the time of delivery.
    The Journal of the Association of Physicians of India, 2012, Volume: 60

    Topics: Anti-HIV Agents; Delivery, Obstetric; Drug Therapy, Combination; Female; HIV Infections; HIV Proteas

2012
Prevention of perinatal HIV I transmission by protease inhibitor based triple drug antiretroviral therapy versus nevirapine as single dose at the time of delivery.
    The Journal of the Association of Physicians of India, 2012, Volume: 60

    Topics: Anti-HIV Agents; Delivery, Obstetric; Drug Therapy, Combination; Female; HIV Infections; HIV Proteas

2012
Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Treatment Outcome;

2013
Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Treatment Outcome;

2013
Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HI

2013
Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HI

2013
Antiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi baby.
    Expert review of anti-infective therapy, 2014, Volume: 12, Issue:3

    Topics: Age Factors; Anti-HIV Agents; Clinical Protocols; Female; HIV Infections; Humans; Infant; Infant, Ne

2014
Antiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi baby.
    Expert review of anti-infective therapy, 2014, Volume: 12, Issue:3

    Topics: Age Factors; Anti-HIV Agents; Clinical Protocols; Female; HIV Infections; Humans; Infant; Infant, Ne

2014
Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
    The Cochrane database of systematic reviews, 2014, May-22, Issue:5

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Combi

2014
Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
    The Cochrane database of systematic reviews, 2014, May-22, Issue:5

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Combi

2014
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2014, Volume: 25

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines

2014
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2014, Volume: 25

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines

2014
Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.
    Drug metabolism reviews, 2015, Volume: 47, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Black People; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytoch

2015
Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.
    Drug metabolism reviews, 2015, Volume: 47, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Black People; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytoch

2015
Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Jun-01, Volume: 60 Suppl 3

    Topics: Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Dideoxynucleosides; Drug Combinations; Fem

2015
Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Jun-01, Volume: 60 Suppl 3

    Topics: Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Dideoxynucleosides; Drug Combinations; Fem

2015
Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study.
    The lancet. HIV, 2015, Volume: 2, Issue:11

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents; Cyclopropanes; Drug

2015
Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study.
    The lancet. HIV, 2015, Volume: 2, Issue:11

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents; Cyclopropanes; Drug

2015
Efavirenz-based antiretroviral therapy versus nevirapine-including regimens for prevention of mother-to-child transmission of HIV option B plus in resource-limited settings: is there anything missing?
    Expert review of anti-infective therapy, 2016, Volume: 14, Issue:1

    Topics: Adult; Africa South of the Sahara; Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; D

2016
Efavirenz-based antiretroviral therapy versus nevirapine-including regimens for prevention of mother-to-child transmission of HIV option B plus in resource-limited settings: is there anything missing?
    Expert review of anti-infective therapy, 2016, Volume: 14, Issue:1

    Topics: Adult; Africa South of the Sahara; Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; D

2016
Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    The Cochrane database of systematic reviews, 2016, 12-10, Volume: 12

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infecti

2016
Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    The Cochrane database of systematic reviews, 2016, 12-10, Volume: 12

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infecti

2016
A review of drug patch testing and implications for HIV clinicians.
    AIDS (London, England), 2008, May-31, Volume: 22, Issue:9

    Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; HIV Infections; Humans; Nevirapine; Patc

2008
A review of drug patch testing and implications for HIV clinicians.
    AIDS (London, England), 2008, May-31, Volume: 22, Issue:9

    Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; HIV Infections; Humans; Nevirapine; Patc

2008
A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
    Pharmacotherapy, 2008, Volume: 28, Issue:7

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dyslip

2008
A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
    Pharmacotherapy, 2008, Volume: 28, Issue:7

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dyslip

2008
Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials.
    HIV medicine, 2008, Volume: 9, Issue:9

    Topics: Adult; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infec

2008
Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials.
    HIV medicine, 2008, Volume: 9, Issue:9

    Topics: Adult; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infec

2008
Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.
    Drug safety, 2009, Volume: 32, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur

2009
Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.
    Drug safety, 2009, Volume: 32, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur

2009
[A fixed dose anti-HIV combination for the poor? Triomune].
    Revue medicale de Liege, 2009, Volume: 64, Issue:1

    Topics: Africa; Anti-HIV Agents; Developing Countries; Drug Administration Schedule; Drug Combinations; HIV

2009
[A fixed dose anti-HIV combination for the poor? Triomune].
    Revue medicale de Liege, 2009, Volume: 64, Issue:1

    Topics: Africa; Anti-HIV Agents; Developing Countries; Drug Administration Schedule; Drug Combinations; HIV

2009
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
    HIV medicine, 2009, Volume: 10, Issue:7

    Topics: Adenine; Adult; Africa South of the Sahara; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly

2009
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
    HIV medicine, 2009, Volume: 10, Issue:7

    Topics: Adenine; Adult; Africa South of the Sahara; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly

2009
Optimal versus suboptimal treatment for HIV-infected pregnant women and HIV-exposed infants in clinical research studies.
    Journal of acquired immune deficiency syndromes (1999), 2009, Aug-15, Volume: 51, Issue:5

    Topics: Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Drug Resistance, Viral; Female; HIV

2009
Optimal versus suboptimal treatment for HIV-infected pregnant women and HIV-exposed infants in clinical research studies.
    Journal of acquired immune deficiency syndromes (1999), 2009, Aug-15, Volume: 51, Issue:5

    Topics: Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Drug Resistance, Viral; Female; HIV

2009
[Highly efficient chemoprophylaxis of perinatal transmission of HIV 1 infection in HIV-infected pregnant women].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2009, Volume: 54, Issue:3-4

    Topics: Animals; Anti-HIV Agents; Azides; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant,

2009
[Highly efficient chemoprophylaxis of perinatal transmission of HIV 1 infection in HIV-infected pregnant women].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2009, Volume: 54, Issue:3-4

    Topics: Animals; Anti-HIV Agents; Azides; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant,

2009
Pharmacogenetics of antiretrovirals.
    Antiviral research, 2010, Volume: 85, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Cycloprop

2010
Pharmacogenetics of antiretrovirals.
    Antiviral research, 2010, Volume: 85, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Cycloprop

2010
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.
    Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:1

    Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Child; Cyclopropanes; Drug Interactions; HIV In

2010
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.
    Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:1

    Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Child; Cyclopropanes; Drug Interactions; HIV In

2010
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    The Cochrane database of systematic reviews, 2010, Oct-06, Issue:10

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Deoxycytidine; Drug Th

2010
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    The Cochrane database of systematic reviews, 2010, Oct-06, Issue:10

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Deoxycytidine; Drug Th

2010
Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    The Cochrane database of systematic reviews, 2010, Dec-08, Issue:12

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infecti

2010
Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    The Cochrane database of systematic reviews, 2010, Dec-08, Issue:12

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infecti

2010
Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.
    Expert opinion on drug metabolism & toxicology, 2011, Volume: 7, Issue:4

    Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Clinical Trials as Topic; Delayed-Action Preparations; D

2011
Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.
    Expert opinion on drug metabolism & toxicology, 2011, Volume: 7, Issue:4

    Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Clinical Trials as Topic; Delayed-Action Preparations; D

2011
Integrating prevention of mother-to-child HIV transmission (PMTCT) programmes with other health services for preventing HIV infection and improving HIV outcomes in developing countries.
    The Cochrane database of systematic reviews, 2011, Jun-15, Issue:6

    Topics: Anti-HIV Agents; Developing Countries; Female; HIV Infections; Humans; Infectious Disease Transmissi

2011
Integrating prevention of mother-to-child HIV transmission (PMTCT) programmes with other health services for preventing HIV infection and improving HIV outcomes in developing countries.
    The Cochrane database of systematic reviews, 2011, Jun-15, Issue:6

    Topics: Anti-HIV Agents; Developing Countries; Female; HIV Infections; Humans; Infectious Disease Transmissi

2011
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    The Cochrane database of systematic reviews, 2011, Jul-06, Issue:7

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudi

2011
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    The Cochrane database of systematic reviews, 2011, Jul-06, Issue:7

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudi

2011
HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.
    The Lancet. Infectious diseases, 2011, Volume: 11, Issue:10

    Topics: Adolescent; Africa; Alkynes; Anti-HIV Agents; Asia; Benzoxazines; Child; Child, Preschool; Cross-Sec

2011
HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.
    The Lancet. Infectious diseases, 2011, Volume: 11, Issue:10

    Topics: Adolescent; Africa; Alkynes; Anti-HIV Agents; Asia; Benzoxazines; Child; Child, Preschool; Cross-Sec

2011
Guidelines for the use of extended-release nevirapine in HIV-infected patients.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:17

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Delayed-Action Preparations; HIV Infections; Humans; Nevirapi

2011
Guidelines for the use of extended-release nevirapine in HIV-infected patients.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:17

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Delayed-Action Preparations; HIV Infections; Humans; Nevirapi

2011
Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
    Drugs, 2011, Nov-12, Volume: 71, Issue:16

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Ch

2011
Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
    Drugs, 2011, Nov-12, Volume: 71, Issue:16

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Ch

2011
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
    Antiviral therapy, 2011, Volume: 16, Issue:8

    Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fet

2011
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
    Antiviral therapy, 2011, Volume: 16, Issue:8

    Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fet

2011
Noncirrhotic portal hypertension associated with didanosine: a case report and literature review.
    Japanese journal of infectious diseases, 2012, Volume: 65, Issue:1

    Topics: Aged, 80 and over; Antiretroviral Therapy, Highly Active; Ascites; Chemical and Drug Induced Liver I

2012
Noncirrhotic portal hypertension associated with didanosine: a case report and literature review.
    Japanese journal of infectious diseases, 2012, Volume: 65, Issue:1

    Topics: Aged, 80 and over; Antiretroviral Therapy, Highly Active; Ascites; Chemical and Drug Induced Liver I

2012
A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 54, Issue:6

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine;

2012
A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 54, Issue:6

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine;

2012
NNRTIs: future prospects.
    Medecine et maladies infectieuses, 2012, Volume: 42, Issue:7

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Forecasting; HIV Infections; Humans; Nevirapine; Reverse Trans

2012
NNRTIs: future prospects.
    Medecine et maladies infectieuses, 2012, Volume: 42, Issue:7

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Forecasting; HIV Infections; Humans; Nevirapine; Reverse Trans

2012
Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    The Cochrane database of systematic reviews, 2012, Jul-11, Issue:7

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Combi

2012
Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    The Cochrane database of systematic reviews, 2012, Jul-11, Issue:7

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Combi

2012
Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2012, Oct-08, Volume: 102, Issue:11 Pt 1

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Contraindications; Female; HIV Infections; Humans; Nevirapine

2012
Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2012, Oct-08, Volume: 102, Issue:11 Pt 1

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Contraindications; Female; HIV Infections; Humans; Nevirapine

2012
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.
    AIDS (London, England), 2013, Jun-01, Volume: 27, Issue:9

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; HIV Infections; Humans; Nevirap

2013
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.
    AIDS (London, England), 2013, Jun-01, Volume: 27, Issue:9

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; HIV Infections; Humans; Nevirap

2013
Mother to child transmission of HIV.
    Clinical evidence, 2002, Issue:7

    Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Combined Modality Therapy; Female; HIV Infections

2002
Mother to child transmission of HIV.
    Clinical evidence, 2002, Issue:7

    Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Combined Modality Therapy; Female; HIV Infections

2002
Mother to child transmission of HIV.
    Clinical evidence, 2002, Issue:8

    Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Combined Modality Therapy; Female; HIV Infections

2002
Mother to child transmission of HIV.
    Clinical evidence, 2002, Issue:8

    Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Combined Modality Therapy; Female; HIV Infections

2002
Non-nucleoside reverse transcriptase inhibitors--an overview.
    International journal of STD & AIDS, 2003, Volume: 14, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1

2003
Non-nucleoside reverse transcriptase inhibitors--an overview.
    International journal of STD & AIDS, 2003, Volume: 14, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1

2003
NNRTI hepatotoxicity: efavirenz versus nevirapine.
    Journal of HIV therapy, 2002, Volume: 7 Suppl 2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Hepat

2002
NNRTI hepatotoxicity: efavirenz versus nevirapine.
    Journal of HIV therapy, 2002, Volume: 7 Suppl 2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Hepat

2002
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
    Seminars in liver disease, 2003, Volume: 23, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Ind

2003
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
    Seminars in liver disease, 2003, Volume: 23, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Ind

2003
Protease inhibitor-sparing regimens: new evidence strengthens position.
    Journal of acquired immune deficiency syndromes (1999), 2003, Jun-01, Volume: 33 Suppl 1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Protocols; Clinical Trials as

2003
Protease inhibitor-sparing regimens: new evidence strengthens position.
    Journal of acquired immune deficiency syndromes (1999), 2003, Jun-01, Volume: 33 Suppl 1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Protocols; Clinical Trials as

2003
HIV: mother to child transmission.
    Clinical evidence, 2003, Issue:9

    Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Drug Therapy, Combination; Female; HIV Infections

2003
HIV: mother to child transmission.
    Clinical evidence, 2003, Issue:9

    Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Drug Therapy, Combination; Female; HIV Infections

2003
[Antiretroviral-induced toxiderma in HIV-infected patients].
    Presse medicale (Paris, France : 1983), 2003, Sep-06, Volume: 32, Issue:28

    Topics: Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides;

2003
[Antiretroviral-induced toxiderma in HIV-infected patients].
    Presse medicale (Paris, France : 1983), 2003, Sep-06, Volume: 32, Issue:28

    Topics: Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides;

2003
Perspectives on HAART: switch maintenance therapy.
    International journal of STD & AIDS, 2003, Volume: 14, Issue:9

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV

2003
Perspectives on HAART: switch maintenance therapy.
    International journal of STD & AIDS, 2003, Volume: 14, Issue:9

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV

2003
Efficacy and durability of nevirapine in antiretroviral-experienced patients.
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Salvage Therapy

2003
Efficacy and durability of nevirapine in antiretroviral-experienced patients.
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Salvage Therapy

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Issues in antiretroviral toxicity.
    The AIDS reader, 2003, Volume: 13, Issue:10

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Exanthema; Female; HIV

2003
Issues in antiretroviral toxicity.
    The AIDS reader, 2003, Volume: 13, Issue:10

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Exanthema; Female; HIV

2003
Nevirapine to prevent mother-to-child transmission of HIV-1 among women of unknown serostatus.
    Lancet (London, England), 2003, Nov-29, Volume: 362, Issue:9398

    Topics: Africa; AIDS Serodiagnosis; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infectious Disea

2003
Nevirapine to prevent mother-to-child transmission of HIV-1 among women of unknown serostatus.
    Lancet (London, England), 2003, Nov-29, Volume: 362, Issue:9398

    Topics: Africa; AIDS Serodiagnosis; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infectious Disea

2003
The continuing evolution of HIV therapy.
    The AIDS reader, 2003, Volume: 13, Issue:12

    Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzox

2003
The continuing evolution of HIV therapy.
    The AIDS reader, 2003, Volume: 13, Issue:12

    Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzox

2003
Hepatotoxicity associated with nevirapine use.
    Journal of acquired immune deficiency syndromes (1999), 2004, Apr-15, Volume: 35, Issue:5

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Female; HIV Infec

2004
Hepatotoxicity associated with nevirapine use.
    Journal of acquired immune deficiency syndromes (1999), 2004, Apr-15, Volume: 35, Issue:5

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Female; HIV Infec

2004
Preventing neonatal HIV: a review.
    Current HIV research, 2003, Volume: 1, Issue:3

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious

2003
Preventing neonatal HIV: a review.
    Current HIV research, 2003, Volume: 1, Issue:3

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious

2003
Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
    Antiviral chemistry & chemotherapy, 2004, Volume: 15, Issue:3

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resis

2004
Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
    Antiviral chemistry & chemotherapy, 2004, Volume: 15, Issue:3

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resis

2004
Nevirapine in the treatment of HIV.
    Expert review of anti-infective therapy, 2004, Volume: 2, Issue:3

    Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Viral; HIV I

2004
Nevirapine in the treatment of HIV.
    Expert review of anti-infective therapy, 2004, Volume: 2, Issue:3

    Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Viral; HIV I

2004
[Combined antiretroviral therapy with nevirapine of HIV-infected adults].
    Terapevticheskii arkhiv, 2004, Volume: 76, Issue:11

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Nevirapine; Reverse

2004
[Combined antiretroviral therapy with nevirapine of HIV-infected adults].
    Terapevticheskii arkhiv, 2004, Volume: 76, Issue:11

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Nevirapine; Reverse

2004
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardi

2005
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardi

2005
The safety of antiretroviral drugs in pregnancy.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and

2005
The safety of antiretroviral drugs in pregnancy.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and

2005
The safety of antiretroviral drugs in pregnancy.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and

2005
The safety of antiretroviral drugs in pregnancy.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and

2005
The safety of antiretroviral drugs in pregnancy.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and

2005
The safety of antiretroviral drugs in pregnancy.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and

2005
The safety of antiretroviral drugs in pregnancy.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and

2005
The safety of antiretroviral drugs in pregnancy.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and

2005
Nevirapine toxicity--implications for management of South African patients.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2005, Volume: 95, Issue:4

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; HIV-1; Humans; Infectious Disease

2005
Nevirapine toxicity--implications for management of South African patients.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2005, Volume: 95, Issue:4

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; HIV-1; Humans; Infectious Disease

2005
Preventing mother-to-child transmission of HIV: successes and challenges.
    BJOG : an international journal of obstetrics and gynaecology, 2005, Volume: 112, Issue:9

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Drug Resistance, Viral; Fema

2005
Preventing mother-to-child transmission of HIV: successes and challenges.
    BJOG : an international journal of obstetrics and gynaecology, 2005, Volume: 112, Issue:9

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Drug Resistance, Viral; Fema

2005
HIV: mother to child transmission.
    Clinical evidence, 2005, Issue:13

    Topics: Administration, Intravaginal; Anti-HIV Agents; Breast Feeding; Cesarean Section; Female; HIV Infecti

2005
HIV: mother to child transmission.
    Clinical evidence, 2005, Issue:13

    Topics: Administration, Intravaginal; Anti-HIV Agents; Breast Feeding; Cesarean Section; Female; HIV Infecti

2005
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
    Drug safety, 2005, Volume: 28, Issue:12

    Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; HIV Infection

2005
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
    Drug safety, 2005, Volume: 28, Issue:12

    Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; HIV Infection

2005
Sex differences in antiretroviral therapy-associated intolerance and adverse events.
    Drug safety, 2005, Volume: 28, Issue:12

    Topics: Acidosis, Lactic; Anti-Retroviral Agents; Didanosine; Exanthema; Female; HIV Infections; Humans; Liv

2005
Sex differences in antiretroviral therapy-associated intolerance and adverse events.
    Drug safety, 2005, Volume: 28, Issue:12

    Topics: Acidosis, Lactic; Anti-Retroviral Agents; Didanosine; Exanthema; Female; HIV Infections; Humans; Liv

2005
[The treatment of HIV infection].
    Presse medicale (Paris, France : 1983), 2005, Nov-19, Volume: 34, Issue:20 Pt 2

    Topics: Adenine; Anti-Retroviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Clinical Trials

2005
[The treatment of HIV infection].
    Presse medicale (Paris, France : 1983), 2005, Nov-19, Volume: 34, Issue:20 Pt 2

    Topics: Adenine; Anti-Retroviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Clinical Trials

2005
Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:6

    Topics: Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Dis

2006
Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:6

    Topics: Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Dis

2006
HIV infection.
    Clinical evidence, 2005, Issue:14

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Early Diagnosis; H

2005
HIV infection.
    Clinical evidence, 2005, Issue:14

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Early Diagnosis; H

2005
Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.
    The Cochrane database of systematic reviews, 2006, Apr-19, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV I

2006
Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.
    The Cochrane database of systematic reviews, 2006, Apr-19, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV I

2006
Nevirapine toxicity.
    International journal of STD & AIDS, 2006, Volume: 17, Issue:6

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Liver; Nevirapine; Pregnancy; Pregnancy Complicatio

2006
Nevirapine toxicity.
    International journal of STD & AIDS, 2006, Volume: 17, Issue:6

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Liver; Nevirapine; Pregnancy; Pregnancy Complicatio

2006
Evidence behind the WHO guidelines: hospital care for children: what antiretroviral agents and regimens are effective in the prevention of mother-to-child transmission of HIV?
    Journal of tropical pediatrics, 2006, Volume: 52, Issue:4

    Topics: Anti-HIV Agents; Breast Feeding; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; I

2006
Evidence behind the WHO guidelines: hospital care for children: what antiretroviral agents and regimens are effective in the prevention of mother-to-child transmission of HIV?
    Journal of tropical pediatrics, 2006, Volume: 52, Issue:4

    Topics: Anti-HIV Agents; Breast Feeding; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; I

2006
[The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    Nederlands tijdschrift voor geneeskunde, 2006, Aug-05, Volume: 150, Issue:31

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug R

2006
[The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    Nederlands tijdschrift voor geneeskunde, 2006, Aug-05, Volume: 150, Issue:31

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug R

2006
HIV infection.
    Clinical evidence, 2006, Issue:15

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug T

2006
HIV infection.
    Clinical evidence, 2006, Issue:15

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug T

2006
Evaluation of nevirapine-switch strategies for HIV treatment.
    HIV medicine, 2006, Volume: 7, Issue:8

    Topics: Adult; Australia; CD4 Lymphocyte Count; Drug Administration Schedule; Europe; Female; HIV Infections

2006
Evaluation of nevirapine-switch strategies for HIV treatment.
    HIV medicine, 2006, Volume: 7, Issue:8

    Topics: Adult; Australia; CD4 Lymphocyte Count; Drug Administration Schedule; Europe; Female; HIV Infections

2006
Antiretroviral therapy for prevention of mother-to-child HIV transmission : focus on single-dose nevirapine.
    Clinical drug investigation, 2006, Volume: 26, Issue:11

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant, Newborn; Infectious

2006
Antiretroviral therapy for prevention of mother-to-child HIV transmission : focus on single-dose nevirapine.
    Clinical drug investigation, 2006, Volume: 26, Issue:11

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant, Newborn; Infectious

2006
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    The Cochrane database of systematic reviews, 2007, Jan-24, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi

2007
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    The Cochrane database of systematic reviews, 2007, Jan-24, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi

2007
Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?
    Clinical pharmacokinetics, 2007, Volume: 46, Issue:2

    Topics: Algorithms; Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopro

2007
Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?
    Clinical pharmacokinetics, 2007, Volume: 46, Issue:2

    Topics: Algorithms; Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopro

2007
Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.
    HIV medicine, 2007, Volume: 8, Issue:1

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Tolerance; Exanthema; HIV Infections;

2007
Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.
    HIV medicine, 2007, Volume: 8, Issue:1

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Tolerance; Exanthema; HIV Infections;

2007
Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.
    Journal of clinical pharmacy and therapeutics, 2007, Volume: 32, Issue:3

    Topics: Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Child; Female; HIV Infectio

2007
Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.
    Journal of clinical pharmacy and therapeutics, 2007, Volume: 32, Issue:3

    Topics: Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Child; Female; HIV Infectio

2007
Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.
    International journal of epidemiology, 2007, Volume: 36, Issue:5

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1

2007
Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.
    International journal of epidemiology, 2007, Volume: 36, Issue:5

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1

2007
International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update.
    American journal of obstetrics and gynecology, 2007, Volume: 197, Issue:3 Suppl

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Breast Feeding; Clinical Trials as Topic; Drug Administrati

2007
International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update.
    American journal of obstetrics and gynecology, 2007, Volume: 197, Issue:3 Suppl

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Breast Feeding; Clinical Trials as Topic; Drug Administrati

2007
Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter?
    American journal of obstetrics and gynecology, 2007, Volume: 197, Issue:3 Suppl

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Drug Resistance; Female; HIV Infections; Humans; Infectious

2007
Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter?
    American journal of obstetrics and gynecology, 2007, Volume: 197, Issue:3 Suppl

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Drug Resistance; Female; HIV Infections; Humans; Infectious

2007
Is it safe to switch between efavirenz and nevirapine in the event of toxicity?
    The Lancet. Infectious diseases, 2007, Volume: 7, Issue:11

    Topics: Alkynes; Benzoxazines; Chemical and Drug Induced Liver Injury; Cross Reactions; Cyclopropanes; Drug

2007
Is it safe to switch between efavirenz and nevirapine in the event of toxicity?
    The Lancet. Infectious diseases, 2007, Volume: 7, Issue:11

    Topics: Alkynes; Benzoxazines; Chemical and Drug Induced Liver Injury; Cross Reactions; Cyclopropanes; Drug

2007
Antiretroviral (ARV) drug resistance in the developing world.
    Evidence report/technology assessment, 2007, Issue:156

    Topics: Africa; Anti-HIV Agents; Asia; Child; Developing Countries; Drug Resistance, Viral; Female; HIV; HIV

2007
Antiretroviral (ARV) drug resistance in the developing world.
    Evidence report/technology assessment, 2007, Issue:156

    Topics: Africa; Anti-HIV Agents; Asia; Child; Developing Countries; Drug Resistance, Viral; Female; HIV; HIV

2007
Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Drug Therapy,

2008
Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Drug Therapy,

2008
The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors.
    Archives of virology. Supplementum, 1994, Volume: 9

    Topics: Antiviral Agents; Benzodiazepines; Benzoxazoles; Clinical Trials as Topic; Drug Resistance, Microbia

1994
The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors.
    Archives of virology. Supplementum, 1994, Volume: 9

    Topics: Antiviral Agents; Benzodiazepines; Benzoxazoles; Clinical Trials as Topic; Drug Resistance, Microbia

1994
Resistance, drug failure, and disease progression.
    AIDS research and human retroviruses, 1994, Volume: 10, Issue:8

    Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; H

1994
Resistance, drug failure, and disease progression.
    AIDS research and human retroviruses, 1994, Volume: 10, Issue:8

    Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; H

1994
AIDS pathogenesis: from models to viral dynamics in patients.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1995, Volume: 10 Suppl 1

    Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; HIV; HIV Infection

1995
AIDS pathogenesis: from models to viral dynamics in patients.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1995, Volume: 10 Suppl 1

    Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; HIV; HIV Infection

1995
Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine.
    Advances in experimental medicine and biology, 1996, Volume: 394

    Topics: Benzoxazoles; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Pyridines; Pyrid

1996
Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine.
    Advances in experimental medicine and biology, 1996, Volume: 394

    Topics: Benzoxazoles; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Pyridines; Pyrid

1996
Current clinical experience with nevirapine for HIV infection.
    Advances in experimental medicine and biology, 1996, Volume: 394

    Topics: Antiviral Agents; Clinical Trials as Topic; HIV Infections; HIV-1; Humans; Nevirapine; Pyridines

1996
Current clinical experience with nevirapine for HIV infection.
    Advances in experimental medicine and biology, 1996, Volume: 394

    Topics: Antiviral Agents; Clinical Trials as Topic; HIV Infections; HIV-1; Humans; Nevirapine; Pyridines

1996
Development of nonnucleoside HIV reverse transcriptase inhibitors.
    Methods in enzymology, 1996, Volume: 275

    Topics: Anti-HIV Agents; Cell Line; Cell Survival; Drug Design; HIV Infections; HIV Reverse Transcriptase; H

1996
Development of nonnucleoside HIV reverse transcriptase inhibitors.
    Methods in enzymology, 1996, Volume: 275

    Topics: Anti-HIV Agents; Cell Line; Cell Survival; Drug Design; HIV Infections; HIV Reverse Transcriptase; H

1996
Antiretroviral therapy: a guide to the most important trials.
    Schweizerische medizinische Wochenschrift, 1997, Mar-15, Volume: 127, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Ther

1997
Antiretroviral therapy: a guide to the most important trials.
    Schweizerische medizinische Wochenschrift, 1997, Mar-15, Volume: 127, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Ther

1997
Antiviral chemotherapy.
    Current opinion in pediatrics, 1997, Volume: 9, Issue:2

    Topics: Adult; Antiviral Agents; Child; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Protease

1997
Antiviral chemotherapy.
    Current opinion in pediatrics, 1997, Volume: 9, Issue:2

    Topics: Adult; Antiviral Agents; Child; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Protease

1997
Clinical experience with non-nucleoside reverse transcriptase inhibitors.
    AIDS (London, England), 1997, Volume: 11 Suppl A

    Topics: Acetamides; Acetophenones; Animals; Anti-HIV Agents; Delavirdine; HIV; HIV Infections; Nevirapine; N

1997
Clinical experience with non-nucleoside reverse transcriptase inhibitors.
    AIDS (London, England), 1997, Volume: 11 Suppl A

    Topics: Acetamides; Acetophenones; Animals; Anti-HIV Agents; Delavirdine; HIV; HIV Infections; Nevirapine; N

1997
Use of nonnucleoside reverse-transcriptase inhibitors.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1998, Feb-01, Volume: 55, Issue:3

    Topics: Anti-HIV Agents; Delavirdine; Drug Interactions; HIV Infections; Humans; Nevirapine; Reverse Transcr

1998
Use of nonnucleoside reverse-transcriptase inhibitors.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1998, Feb-01, Volume: 55, Issue:3

    Topics: Anti-HIV Agents; Delavirdine; Drug Interactions; HIV Infections; Humans; Nevirapine; Reverse Transcr

1998
The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
    Antiviral research, 1998, Volume: 38, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Therapy, Combination; HIV I

1998
The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
    Antiviral research, 1998, Volume: 38, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Therapy, Combination; HIV I

1998
Antiretroviral chemotherapy.
    Current clinical topics in infectious diseases, 1998, Volume: 18

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides;

1998
Antiretroviral chemotherapy.
    Current clinical topics in infectious diseases, 1998, Volume: 18

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides;

1998
Natural endogenous reverse transcription of HIV-1.
    Journal of reproductive immunology, 1998, Volume: 41, Issue:1-2

    Topics: Animals; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Nevirapine; Reverse Transcriptase Inhibitor

1998
Natural endogenous reverse transcription of HIV-1.
    Journal of reproductive immunology, 1998, Volume: 41, Issue:1-2

    Topics: Animals; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Nevirapine; Reverse Transcriptase Inhibitor

1998
[Nevirapine (Viramune): a new HIV inhibitor].
    Revue medicale de Bruxelles, 1999, Volume: 20, Issue:2

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhib

1999
[Nevirapine (Viramune): a new HIV inhibitor].
    Revue medicale de Bruxelles, 1999, Volume: 20, Issue:2

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhib

1999
New reverse transcriptase inhibitors.
    Advances in experimental medicine and biology, 1999, Volume: 458

    Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Dideoxynucleosides; HIV Infections; HIV

1999
New reverse transcriptase inhibitors.
    Advances in experimental medicine and biology, 1999, Volume: 458

    Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Dideoxynucleosides; HIV Infections; HIV

1999
Antiretrovirals.
    Mayo Clinic proceedings, 1999, Volume: 74, Issue:12

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; D

1999
Antiretrovirals.
    Mayo Clinic proceedings, 1999, Volume: 74, Issue:12

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; D

1999
Efavirenz: resistance and cross-resistance.
    International journal of clinical practice. Supplement, 1999, Volume: 103

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Geno

1999
Efavirenz: resistance and cross-resistance.
    International journal of clinical practice. Supplement, 1999, Volume: 103

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Geno

1999
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
    Journal of acquired immune deficiency syndromes (1999), 1999, Nov-01, Volume: 22, Issue:3

    Topics: Adult; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Mul

1999
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
    Journal of acquired immune deficiency syndromes (1999), 1999, Nov-01, Volume: 22, Issue:3

    Topics: Adult; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Mul

1999
Nevirapine: pharmacokinetic considerations in children and pregnant women.
    Clinical pharmacokinetics, 2000, Volume: 39, Issue:4

    Topics: Adult; Area Under Curve; Child; Drug Administration Schedule; Drug Interactions; Female; Half-Life;

2000
Nevirapine: pharmacokinetic considerations in children and pregnant women.
    Clinical pharmacokinetics, 2000, Volume: 39, Issue:4

    Topics: Adult; Area Under Curve; Child; Drug Administration Schedule; Drug Interactions; Female; Half-Life;

2000
Management of the infant born to a mother infected with human immunodeficiency virus type 1 (HIV-1): current concepts.
    American journal of perinatology, 2000, Volume: 17, Issue:8

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Female; HIV In

2000
Management of the infant born to a mother infected with human immunodeficiency virus type 1 (HIV-1): current concepts.
    American journal of perinatology, 2000, Volume: 17, Issue:8

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Female; HIV In

2000
The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
    Drugs, 2001, Volume: 61, Issue:1

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Clinical Trials as Topic; Cyclopropane

2001
The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
    Drugs, 2001, Volume: 61, Issue:1

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Clinical Trials as Topic; Cyclopropane

2001
International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.
    Journal of acquired immune deficiency syndromes (1999), 2001, Mar-01, Volume: 26 Suppl 1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Delavirdine; Drug R

2001
International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.
    Journal of acquired immune deficiency syndromes (1999), 2001, Mar-01, Volume: 26 Suppl 1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Delavirdine; Drug R

2001
The role of NNRTIs in antiretroviral combination therapy: an introduction.
    International journal of STD & AIDS, 2001, Volume: 12 Suppl 4

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideox

2001
The role of NNRTIs in antiretroviral combination therapy: an introduction.
    International journal of STD & AIDS, 2001, Volume: 12 Suppl 4

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideox

2001
Comparison of NNRTIs in antiretroviral-naïve patients.
    International journal of STD & AIDS, 2001, Volume: 12 Suppl 4

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropane

2001
Comparison of NNRTIs in antiretroviral-naïve patients.
    International journal of STD & AIDS, 2001, Volume: 12 Suppl 4

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropane

2001
Comparison of NNRTIs in antiretroviral-experienced patients.
    International journal of STD & AIDS, 2001, Volume: 12 Suppl 4

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV In

2001
Comparison of NNRTIs in antiretroviral-experienced patients.
    International journal of STD & AIDS, 2001, Volume: 12 Suppl 4

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV In

2001
Factors affecting adherence and convenience in antiretroviral therapy.
    International journal of STD & AIDS, 2001, Volume: 12 Suppl 4

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Oxazines;

2001
Factors affecting adherence and convenience in antiretroviral therapy.
    International journal of STD & AIDS, 2001, Volume: 12 Suppl 4

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Oxazines;

2001
Other issues: penetration into sanctuary sites, immune reconstitution and NNRTI sequencing.
    International journal of STD & AIDS, 2001, Volume: 12 Suppl 4

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Oxazines;

2001
Other issues: penetration into sanctuary sites, immune reconstitution and NNRTI sequencing.
    International journal of STD & AIDS, 2001, Volume: 12 Suppl 4

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Oxazines;

2001
Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy.
    Journal of acquired immune deficiency syndromes (1999), 2001, Dec-01, Volume: 28, Issue:4

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Therapy, Combinat

2001
Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy.
    Journal of acquired immune deficiency syndromes (1999), 2001, Dec-01, Volume: 28, Issue:4

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Therapy, Combinat

2001
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.
    Clinical pharmacokinetics, 2001, Volume: 40, Issue:12

    Topics: Alkynes; Benzoxazines; Biological Availability; Cyclopropanes; Delavirdine; Drug Interactions; Femal

2001
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.
    Clinical pharmacokinetics, 2001, Volume: 40, Issue:12

    Topics: Alkynes; Benzoxazines; Biological Availability; Cyclopropanes; Delavirdine; Drug Interactions; Femal

2001
Prevention of mother-to-child transmission of HIV: challenges for the current decade.
    Bulletin of the World Health Organization, 2001, Volume: 79, Issue:12

    Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Drug Resistance, Microbial; Female; Health Resour

2001
Prevention of mother-to-child transmission of HIV: challenges for the current decade.
    Bulletin of the World Health Organization, 2001, Volume: 79, Issue:12

    Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Drug Resistance, Microbial; Female; Health Resour

2001
The role of nevirapine in the treatment of HIV-1 disease.
    Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:12

    Topics: Anti-HIV Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Interac

2001
The role of nevirapine in the treatment of HIV-1 disease.
    Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:12

    Topics: Anti-HIV Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Interac

2001
Toxic epidermal necrolysis induced by nevirapine therapy: description of two cases and review of the literature.
    The Journal of infection, 2001, Volume: 43, Issue:4

    Topics: Adult; Anti-HIV Agents; Communication Barriers; Female; HIV Infections; Humans; Nevirapine; Patient

2001
Toxic epidermal necrolysis induced by nevirapine therapy: description of two cases and review of the literature.
    The Journal of infection, 2001, Volume: 43, Issue:4

    Topics: Adult; Anti-HIV Agents; Communication Barriers; Female; HIV Infections; Humans; Nevirapine; Patient

2001
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    The Cochrane database of systematic reviews, 2002, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi

2002
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    The Cochrane database of systematic reviews, 2002, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi

2002
HIV-1 drug resistance and mother-to-child transmission.
    SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging, 2001, Volume: 56, Issue:12

    Topics: Anti-HIV Agents; Developing Countries; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans

2001
HIV-1 drug resistance and mother-to-child transmission.
    SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging, 2001, Volume: 56, Issue:12

    Topics: Anti-HIV Agents; Developing Countries; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans

2001
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
    The Lancet. Infectious diseases, 2002, Volume: 2, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Clinical Trial

2002
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
    The Lancet. Infectious diseases, 2002, Volume: 2, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Clinical Trial

2002
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    The Cochrane database of systematic reviews, 2002, Issue:2

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi

2002
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    The Cochrane database of systematic reviews, 2002, Issue:2

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi

2002

Trials

426 trials available for nevirapine and HIV Infections

ArticleYear
Lower Insulin Sensitivity in Newborns With In Utero HIV and Antiretroviral Exposure Who Are Uninfected in Botswana.
    The Journal of infectious diseases, 2022, 11-28, Volume: 226, Issue:11

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Botswana; Female; HIV Infections; Humans; Infant; Infant, N

2022
Lower Insulin Sensitivity in Newborns With In Utero HIV and Antiretroviral Exposure Who Are Uninfected in Botswana.
    The Journal of infectious diseases, 2022, 11-28, Volume: 226, Issue:11

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Botswana; Female; HIV Infections; Humans; Infant; Infant, N

2022
Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial.
    Journal of acquired immune deficiency syndromes (1999), 2023, 04-15, Volume: 92, Issue:5

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Botswana; CD4 Lymphocyte Count; HIV Infections; HIV-1; Huma

2023
Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial.
    Journal of acquired immune deficiency syndromes (1999), 2023, 04-15, Volume: 92, Issue:5

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Botswana; CD4 Lymphocyte Count; HIV Infections; HIV-1; Huma

2023
Bone and Renal Health in Infants With or Without Breastmilk Exposure to Tenofovir-Based Maternal Antiretroviral Treatment in the PROMISE Randomized Trial.
    Journal of acquired immune deficiency syndromes (1999), 2023, 08-15, Volume: 93, Issue:5

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Bone Density; Female; HIV Infections; Humans; Kidney; Lumba

2023
Bone and Renal Health in Infants With or Without Breastmilk Exposure to Tenofovir-Based Maternal Antiretroviral Treatment in the PROMISE Randomized Trial.
    Journal of acquired immune deficiency syndromes (1999), 2023, 08-15, Volume: 93, Issue:5

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Bone Density; Female; HIV Infections; Humans; Kidney; Lumba

2023
Linked dual-class HIV resistance mutations are associated with treatment failure.
    JCI insight, 2019, 10-03, Volume: 4, Issue:19

    Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Viral; Emtricitabi

2019
Linked dual-class HIV resistance mutations are associated with treatment failure.
    JCI insight, 2019, 10-03, Volume: 4, Issue:19

    Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Viral; Emtricitabi

2019
Maternal Humoral Immune Responses Do Not Predict Postnatal HIV-1 Transmission Risk in Antiretroviral-Treated Mothers from the IMPAACT PROMISE Study.
    mSphere, 2019, 10-23, Volume: 4, Issue:5

    Topics: Adolescent; Adult; Anti-Retroviral Agents; Antibody-Dependent Cell Cytotoxicity; Breast Feeding; Coh

2019
Maternal Humoral Immune Responses Do Not Predict Postnatal HIV-1 Transmission Risk in Antiretroviral-Treated Mothers from the IMPAACT PROMISE Study.
    mSphere, 2019, 10-23, Volume: 4, Issue:5

    Topics: Adolescent; Adult; Anti-Retroviral Agents; Antibody-Dependent Cell Cytotoxicity; Breast Feeding; Coh

2019
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
    AIDS (London, England), 2019, 12-01, Volume: 33, Issue:15

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination;

2019
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
    AIDS (London, England), 2019, 12-01, Volume: 33, Issue:15

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination;

2019
A mobile health-facilitated behavioural intervention for community health workers improves exclusive breastfeeding and early infant HIV diagnosis in India: a cluster randomized trial.
    Journal of the International AIDS Society, 2020, Volume: 23, Issue:7

    Topics: Adult; Anti-HIV Agents; Behavior Therapy; Breast Feeding; Cluster Analysis; Community Health Workers

2020
A mobile health-facilitated behavioural intervention for community health workers improves exclusive breastfeeding and early infant HIV diagnosis in India: a cluster randomized trial.
    Journal of the International AIDS Society, 2020, Volume: 23, Issue:7

    Topics: Adult; Anti-HIV Agents; Behavior Therapy; Breast Feeding; Cluster Analysis; Community Health Workers

2020
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine.
    Pharmacogenetics and genomics, 2021, Volume: 31, Issue:1

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Arylamine N-Acetyltransferase; Benzoxazines; Cyclopropa

2021
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine.
    Pharmacogenetics and genomics, 2021, Volume: 31, Issue:1

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Arylamine N-Acetyltransferase; Benzoxazines; Cyclopropa

2021
Maternal HBV Viremia and Association With Adverse Infant Outcomes in Women Living With HIV and HBV.
    The Pediatric infectious disease journal, 2021, 02-01, Volume: 40, Issue:2

    Topics: Anti-HIV Agents; Birth Weight; Coinfection; Double-Blind Method; Female; Hepatitis B; Hepatitis B vi

2021
Maternal HBV Viremia and Association With Adverse Infant Outcomes in Women Living With HIV and HBV.
    The Pediatric infectious disease journal, 2021, 02-01, Volume: 40, Issue:2

    Topics: Anti-HIV Agents; Birth Weight; Coinfection; Double-Blind Method; Female; Hepatitis B; Hepatitis B vi

2021
Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.
    The Journal of antimicrobial chemotherapy, 2021, 02-11, Volume: 76, Issue:3

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antitubercular Agents; Female; HIV Infections; Humans; Iso

2021
Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.
    The Journal of antimicrobial chemotherapy, 2021, 02-11, Volume: 76, Issue:3

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antitubercular Agents; Female; HIV Infections; Humans; Iso

2021
Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.
    The lancet. HIV, 2021, Volume: 8, Issue:3

    Topics: Anti-HIV Agents; Female; Gestational Age; HIV Infections; Humans; Infant; Infant, Newborn; Infectiou

2021
Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.
    The lancet. HIV, 2021, Volume: 8, Issue:3

    Topics: Anti-HIV Agents; Female; Gestational Age; HIV Infections; Humans; Infant; Infant, Newborn; Infectiou

2021
Efficacy of Mobile phone use on adherence to Nevirapine prophylaxis and retention in care among the HIV-exposed infants in prevention of mother to child transmission of HIV: a randomized controlled trial.
    BMC pediatrics, 2021, 04-20, Volume: 21, Issue:1

    Topics: Anti-HIV Agents; Cell Phone Use; Child; Female; HIV Infections; Humans; Infant; Infectious Disease T

2021
Efficacy of Mobile phone use on adherence to Nevirapine prophylaxis and retention in care among the HIV-exposed infants in prevention of mother to child transmission of HIV: a randomized controlled trial.
    BMC pediatrics, 2021, 04-20, Volume: 21, Issue:1

    Topics: Anti-HIV Agents; Cell Phone Use; Child; Female; HIV Infections; Humans; Infant; Infectious Disease T

2021
Association of Maternal Viral Load and CD4 Count With Perinatal HIV-1 Transmission Risk During Breastfeeding in the PROMISE Postpartum Component.
    Journal of acquired immune deficiency syndromes (1999), 2021, 10-01, Volume: 88, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Female; HIV Infections; HIV Seropositivity; H

2021
Association of Maternal Viral Load and CD4 Count With Perinatal HIV-1 Transmission Risk During Breastfeeding in the PROMISE Postpartum Component.
    Journal of acquired immune deficiency syndromes (1999), 2021, 10-01, Volume: 88, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Female; HIV Infections; HIV Seropositivity; H

2021
Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial.
    PloS one, 2021, Volume: 16, Issue:8

    Topics: Adult; Anti-Retroviral Agents; Child Development; Female; HIV Infections; Humans; Infant; Male; Milk

2021
Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial.
    PloS one, 2021, Volume: 16, Issue:8

    Topics: Adult; Anti-Retroviral Agents; Child Development; Female; HIV Infections; Humans; Infant; Male; Milk

2021
Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Aug-01, Volume: 65, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child, Preschool; Cyclopropanes; Femal

2017
Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Aug-01, Volume: 65, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child, Preschool; Cyclopropanes; Femal

2017
Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates.
    Journal of acquired immune deficiency syndromes (1999), 2017, 08-15, Volume: 75, Issue:5

    Topics: Anti-HIV Agents; Breast Feeding; Chemoprevention; Clinical Protocols; Dose-Response Relationship, Dr

2017
Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates.
    Journal of acquired immune deficiency syndromes (1999), 2017, 08-15, Volume: 75, Issue:5

    Topics: Anti-HIV Agents; Breast Feeding; Chemoprevention; Clinical Protocols; Dose-Response Relationship, Dr

2017
Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:12

    Topics: Adult; Anti-HIV Agents; Asian People; Cambodia; Cytochrome P-450 CYP2B6; Female; HIV Infections; Hum

2017
Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:12

    Topics: Adult; Anti-HIV Agents; Asian People; Cambodia; Cytochrome P-450 CYP2B6; Female; HIV Infections; Hum

2017
Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
    BMC infectious diseases, 2017, 12-11, Volume: 17, Issue:1

    Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HI

2017
Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
    BMC infectious diseases, 2017, 12-11, Volume: 17, Issue:1

    Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HI

2017
Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?
    British journal of clinical pharmacology, 2019, Volume: 85, Issue:3

    Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Cross-Over Studies; Cytochrome P-45

2019
Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?
    British journal of clinical pharmacology, 2019, Volume: 85, Issue:3

    Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Cross-Over Studies; Cytochrome P-45

2019
Conditional cash transfers to prevent mother-to-child transmission in low facility-delivery settings: evidence from a randomised controlled trial in Nigeria.
    BMC pregnancy and childbirth, 2019, Jan-16, Volume: 19, Issue:1

    Topics: Adult; Delivery, Obstetric; Female; HIV Infections; Hospitals, Public; Humans; Infant, Newborn; Infa

2019
Conditional cash transfers to prevent mother-to-child transmission in low facility-delivery settings: evidence from a randomised controlled trial in Nigeria.
    BMC pregnancy and childbirth, 2019, Jan-16, Volume: 19, Issue:1

    Topics: Adult; Delivery, Obstetric; Female; HIV Infections; Hospitals, Public; Humans; Infant, Newborn; Infa

2019
Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
    The Journal of antimicrobial chemotherapy, 2019, 10-01, Volume: 74, Issue:10

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Desogestrel;

2019
Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
    The Journal of antimicrobial chemotherapy, 2019, 10-01, Volume: 74, Issue:10

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Desogestrel;

2019
The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2013, Volume: 17, Issue:3

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biotransformation; Cytochrome P-450

2013
The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2013, Volume: 17, Issue:3

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biotransformation; Cytochrome P-450

2013
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:4

    Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzo

2013
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:4

    Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzo

2013
Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns.
    Journal of clinical pharmacology, 2013, Volume: 53, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Dise

2013
Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns.
    Journal of clinical pharmacology, 2013, Volume: 53, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Dise

2013
Cluster randomised trial of the uptake of a take-home infant dose of nevirapine in Kenya.
    East African medical journal, 2010, Volume: 87, Issue:7

    Topics: Adolescent; Adult; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission,

2010
Cluster randomised trial of the uptake of a take-home infant dose of nevirapine in Kenya.
    East African medical journal, 2010, Volume: 87, Issue:7

    Topics: Adolescent; Adult; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission,

2010
Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:5

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Biotransforma

2013
Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:5

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Biotransforma

2013
Short communication: effect of short-course antenatal zidovudine and single-dose nevirapine on the BED capture enzyme immunoassay levels in HIV type 1 subtype C infection.
    AIDS research and human retroviruses, 2013, Volume: 29, Issue:6

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Female; HIV Antibodies; HIV Infections; HIV-1;

2013
Short communication: effect of short-course antenatal zidovudine and single-dose nevirapine on the BED capture enzyme immunoassay levels in HIV type 1 subtype C infection.
    AIDS research and human retroviruses, 2013, Volume: 29, Issue:6

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Female; HIV Antibodies; HIV Infections; HIV-1;

2013
Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?
    AIDS (London, England), 2013, Aug-24, Volume: 27, Issue:13

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Exanthema; Female; HIV; HIV Infections; Humans

2013
Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?
    AIDS (London, England), 2013, Aug-24, Volume: 27, Issue:13

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Exanthema; Female; HIV; HIV Infections; Humans

2013
Livolin ameliorates elevations in alanine transaminase in HIV infected patients commencing highly active antiretroviral therapy.
    African journal of medicine and medical sciences, 2012, Volume: 41, Issue:4

    Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Anti-HIV Agents; Antiretroviral Therapy, Highly A

2012
Livolin ameliorates elevations in alanine transaminase in HIV infected patients commencing highly active antiretroviral therapy.
    African journal of medicine and medical sciences, 2012, Volume: 41, Issue:4

    Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Anti-HIV Agents; Antiretroviral Therapy, Highly A

2012
Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.
    The Journal of infectious diseases, 2013, Aug-15, Volume: 208, Issue:4

    Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Chemoprevention; Cytochrome P-450 CYP2B6; Fem

2013
Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.
    The Journal of infectious diseases, 2013, Aug-15, Volume: 208, Issue:4

    Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Chemoprevention; Cytochrome P-450 CYP2B6; Fem

2013
HIV disease progression in the first year after delivery among African women followed in the HPTN 046 clinical trial.
    Journal of acquired immune deficiency syndromes (1999), 2013, Nov-01, Volume: 64, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Disease Progression; Doubl

2013
HIV disease progression in the first year after delivery among African women followed in the HPTN 046 clinical trial.
    Journal of acquired immune deficiency syndromes (1999), 2013, Nov-01, Volume: 64, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Disease Progression; Doubl

2013
Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:11

    Topics: Adult; Anti-HIV Agents; Anticonvulsants; Drug Interactions; Drug Resistance, Viral; Female; Half-Lif

2013
Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:11

    Topics: Adult; Anti-HIV Agents; Anticonvulsants; Drug Interactions; Drug Resistance, Viral; Female; Half-Lif

2013
WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity.
    Journal of acquired immune deficiency syndromes (1999), 2013, Mar-01, Volume: 62, Issue:3

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte Count; Cohort S

2013
WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity.
    Journal of acquired immune deficiency syndromes (1999), 2013, Mar-01, Volume: 62, Issue:3

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte Count; Cohort S

2013
Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
    International health, 2013, Volume: 5, Issue:2

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyc

2013
Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
    International health, 2013, Volume: 5, Issue:2

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyc

2013
Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients.
    Biopharmaceutics & drug disposition, 2013, Volume: 34, Issue:8

    Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazin

2013
Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients.
    Biopharmaceutics & drug disposition, 2013, Volume: 34, Issue:8

    Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazin

2013
Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Monitoring; Female; HIV Infections; HIV-1; Humans;

2013
Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Monitoring; Female; HIV Infections; HIV-1; Humans;

2013
Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness.
    AIDS (London, England), 2013, Volume: 27 Suppl 1

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Contraceptives, Oral; Dru

2013
Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness.
    AIDS (London, England), 2013, Volume: 27 Suppl 1

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Contraceptives, Oral; Dru

2013
Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2013, Volume: 17, Issue:12

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymp

2013
Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2013, Volume: 17, Issue:12

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymp

2013
Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival.
    Journal of acquired immune deficiency syndromes (1999), 2013, Dec-15, Volume: 64, Issue:5

    Topics: Anthropometry; Anti-HIV Agents; Body Height; Body Weight; Chemoprevention; Child, Preschool; Female;

2013
Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival.
    Journal of acquired immune deficiency syndromes (1999), 2013, Dec-15, Volume: 64, Issue:5

    Topics: Anthropometry; Anti-HIV Agents; Body Height; Body Weight; Chemoprevention; Child, Preschool; Female;

2013
Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.
    BMC infectious diseases, 2013, Oct-17, Volume: 13

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropa

2013
Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.
    BMC infectious diseases, 2013, Oct-17, Volume: 13

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropa

2013
Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial.
    Journal of acquired immune deficiency syndromes (1999), 2014, Mar-01, Volume: 65, Issue:3

    Topics: Adolescent; Adult; Africa; Anti-HIV Agents; Breast Feeding; Chemoprevention; Double-Blind Method; Fe

2014
Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial.
    Journal of acquired immune deficiency syndromes (1999), 2014, Mar-01, Volume: 65, Issue:3

    Topics: Adolescent; Adult; Africa; Anti-HIV Agents; Breast Feeding; Chemoprevention; Double-Blind Method; Fe

2014
Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three African countries.
    BMC infectious diseases, 2013, Nov-06, Volume: 13

    Topics: Adult; Africa South of the Sahara; Anemia; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; I

2013
Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three African countries.
    BMC infectious diseases, 2013, Nov-06, Volume: 13

    Topics: Adult; Africa South of the Sahara; Anemia; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; I

2013
Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study.
    The Pediatric infectious disease journal, 2014, Volume: 33, Issue:7

    Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Over Studies; Dela

2014
Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study.
    The Pediatric infectious disease journal, 2014, Volume: 33, Issue:7

    Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Over Studies; Dela

2014
Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.
    The Journal of infectious diseases, 2014, Mar-01, Volume: 209, Issue:5

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Genotype; HI

2014
Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.
    The Journal of infectious diseases, 2014, Mar-01, Volume: 209, Issue:5

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Genotype; HI

2014
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.
    AIDS (London, England), 2014, May-15, Volume: 28, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Creatinine; Deoxycytidine; Drug Therapy, Combination; Emtricitabin

2014
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.
    AIDS (London, England), 2014, May-15, Volume: 28, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Creatinine; Deoxycytidine; Drug Therapy, Combination; Emtricitabin

2014
Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women.
    BMC research notes, 2014, Jan-21, Volume: 7

    Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4

2014
Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women.
    BMC research notes, 2014, Jan-21, Volume: 7

    Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4

2014
Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
    BMC pediatrics, 2014, Feb-12, Volume: 14

    Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant

2014
Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
    BMC pediatrics, 2014, Feb-12, Volume: 14

    Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant

2014
Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
    Journal of acquired immune deficiency syndromes (1999), 2014, Jun-01, Volume: 66, Issue:2

    Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active;

2014
Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
    Journal of acquired immune deficiency syndromes (1999), 2014, Jun-01, Volume: 66, Issue:2

    Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active;

2014
Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.
    HIV medicine, 2014, Volume: 15, Issue:9

    Topics: Adolescent; Area Under Curve; Child; Drug Eruptions; Drug Resistance, Viral; Female; HIV Infections;

2014
Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.
    HIV medicine, 2014, Volume: 15, Issue:9

    Topics: Adolescent; Area Under Curve; Child; Drug Eruptions; Drug Resistance, Viral; Female; HIV Infections;

2014
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cross-Sectional Studies; D

2014
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cross-Sectional Studies; D

2014
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:6

    Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; Half-Life;

2014
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:6

    Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; Half-Life;

2014
Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
    Antiviral therapy, 2014, Volume: 19, Issue:3

    Topics: Anthropometry; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Dideoxynucleosides

2014
Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
    Antiviral therapy, 2014, Volume: 19, Issue:3

    Topics: Anthropometry; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Dideoxynucleosides

2014
Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Aug-01, Volume: 59, Issue:3

    Topics: Antimalarials; Artemisinins; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Female; HI

2014
Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Aug-01, Volume: 59, Issue:3

    Topics: Antimalarials; Artemisinins; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Female; HI

2014
Hypothesis testing for an extended cox model with time-varying coefficients.
    Biometrics, 2014, Volume: 70, Issue:3

    Topics: Algorithms; Biometry; Computer Simulation; Data Interpretation, Statistical; Female; HIV Infections;

2014
Hypothesis testing for an extended cox model with time-varying coefficients.
    Biometrics, 2014, Volume: 70, Issue:3

    Topics: Algorithms; Biometry; Computer Simulation; Data Interpretation, Statistical; Female; HIV Infections;

2014
Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa.
    BMC infectious diseases, 2014, Jun-17, Volume: 14

    Topics: Adenine; Adult; Africa; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxycyti

2014
Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa.
    BMC infectious diseases, 2014, Jun-17, Volume: 14

    Topics: Adenine; Adult; Africa; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxycyti

2014
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
    AIDS (London, England), 2014, May-15, Volume: 28, Issue:8

    Topics: Adenine; Adult; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combinati

2014
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
    AIDS (London, England), 2014, May-15, Volume: 28, Issue:8

    Topics: Adenine; Adult; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combinati

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru

2014
Correlates of age at attainment of developmental milestones in HIV-infected infants receiving early antiretroviral therapy.
    The Pediatric infectious disease journal, 2015, Volume: 34, Issue:1

    Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child Development; Female; Follow-Up

2015
Correlates of age at attainment of developmental milestones in HIV-infected infants receiving early antiretroviral therapy.
    The Pediatric infectious disease journal, 2015, Volume: 34, Issue:1

    Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child Development; Female; Follow-Up

2015
Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.
    The Pediatric infectious disease journal, 2014, Volume: 33, Issue:8

    Topics: Africa South of the Sahara; Anti-HIV Agents; Child, Preschool; Female; HIV Infections; HIV-1; Humans

2014
Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.
    The Pediatric infectious disease journal, 2014, Volume: 33, Issue:8

    Topics: Africa South of the Sahara; Anti-HIV Agents; Child, Preschool; Female; HIV Infections; HIV-1; Humans

2014
The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2015, Jan-01, Volume: 68, Issue:1

    Topics: HIV Infections; HIV-1; Humans; Nevirapine; Nitriles; Prospective Studies; Pyrimidines; Reverse Trans

2015
The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2015, Jan-01, Volume: 68, Issue:1

    Topics: HIV Infections; HIV-1; Humans; Nevirapine; Nitriles; Prospective Studies; Pyrimidines; Reverse Trans

2015
Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:2

    Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resis

2015
Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:2

    Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resis

2015
Kericho CLinic-based ART Diagnostic Evaluation (CLADE): design, accrual, and baseline characteristics of a randomized controlled trial conducted in predominately rural, district-level, HIV clinics of Kenya.
    PloS one, 2015, Volume: 10, Issue:2

    Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Female; HIV Infections; HIV-1; Humans; Kenya; Male; M

2015
Kericho CLinic-based ART Diagnostic Evaluation (CLADE): design, accrual, and baseline characteristics of a randomized controlled trial conducted in predominately rural, district-level, HIV clinics of Kenya.
    PloS one, 2015, Volume: 10, Issue:2

    Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Female; HIV Infections; HIV-1; Humans; Kenya; Male; M

2015
Nevirapine Resistance in Previously Nevirapine-Unexposed HIV-1-Infected Kenyan Infants Initiating Early Antiretroviral Therapy.
    AIDS research and human retroviruses, 2015, Volume: 31, Issue:8

    Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Genot

2015
Nevirapine Resistance in Previously Nevirapine-Unexposed HIV-1-Infected Kenyan Infants Initiating Early Antiretroviral Therapy.
    AIDS research and human retroviruses, 2015, Volume: 31, Issue:8

    Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Genot

2015
Evaluation of adherence measures of antiretroviral prophylaxis in HIV exposed infants in the first 6 weeks of life.
    BMC pediatrics, 2015, Mar-19, Volume: 15

    Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Infant,

2015
Evaluation of adherence measures of antiretroviral prophylaxis in HIV exposed infants in the first 6 weeks of life.
    BMC pediatrics, 2015, Mar-19, Volume: 15

    Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Infant,

2015
Nevirapine extended-release formulation tablets in HIV-1-infected children--long-term follow-up.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Aug-01, Volume: 61, Issue:3

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Delayed-Action Preparations; Drug-Related Side

2015
Nevirapine extended-release formulation tablets in HIV-1-infected children--long-term follow-up.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Aug-01, Volume: 61, Issue:3

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Delayed-Action Preparations; Drug-Related Side

2015
Lipid-based nutrient supplements do not affect efavirenz but lower plasma nevirapine concentrations in Ethiopian adult HIV patients.
    HIV medicine, 2015, Volume: 16, Issue:7

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cyclopropanes; Cy

2015
Lipid-based nutrient supplements do not affect efavirenz but lower plasma nevirapine concentrations in Ethiopian adult HIV patients.
    HIV medicine, 2015, Volume: 16, Issue:7

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cyclopropanes; Cy

2015
Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:12

    Topics: Adult; Aged; Anti-HIV Agents; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infecti

2015
Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:12

    Topics: Adult; Aged; Anti-HIV Agents; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infecti

2015
Safety of zidovudine dose reduction in treatment-naïve HIV infected patients. A randomized controlled study (MiniZID).
    HIV medicine, 2016, Volume: 17, Issue:3

    Topics: Adult; Anemia; Anti-HIV Agents; Cameroon; Dose-Response Relationship, Drug; Drug Therapy, Combinatio

2016
Safety of zidovudine dose reduction in treatment-naïve HIV infected patients. A randomized controlled study (MiniZID).
    HIV medicine, 2016, Volume: 17, Issue:3

    Topics: Adult; Anemia; Anti-HIV Agents; Cameroon; Dose-Response Relationship, Drug; Drug Therapy, Combinatio

2016
Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand.
    AIDS (London, England), 2015, Nov-28, Volume: 29, Issue:18

    Topics: Adult; Anti-HIV Agents; Chemoprevention; DNA, Viral; Double-Blind Method; Female; HIV Infections; Hu

2015
Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand.
    AIDS (London, England), 2015, Nov-28, Volume: 29, Issue:18

    Topics: Adult; Anti-HIV Agents; Chemoprevention; DNA, Viral; Double-Blind Method; Female; HIV Infections; Hu

2015
Cytomegalovirus IgG Level and Avidity in Breastfeeding Infants of HIV-Infected Mothers in Malawi.
    Clinical and vaccine immunology : CVI, 2015, Volume: 22, Issue:12

    Topics: Anti-HIV Agents; Antibodies, Viral; Antibody Affinity; Breast Feeding; Cytomegalovirus; Cytomegalovi

2015
Cytomegalovirus IgG Level and Avidity in Breastfeeding Infants of HIV-Infected Mothers in Malawi.
    Clinical and vaccine immunology : CVI, 2015, Volume: 22, Issue:12

    Topics: Anti-HIV Agents; Antibodies, Viral; Antibody Affinity; Breast Feeding; Cytomegalovirus; Cytomegalovi

2015
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
    The Lancet. Infectious diseases, 2016, Volume: 16, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Prescho

2016
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
    The Lancet. Infectious diseases, 2016, Volume: 16, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Prescho

2016
Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.
    JAMA, 2015, Nov-03, Volume: 314, Issue:17

    Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Therapy,

2015
Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.
    JAMA, 2015, Nov-03, Volume: 314, Issue:17

    Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Therapy,

2015
Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Mar-15, Volume: 62, Issue:6

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Co

2016
Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Mar-15, Volume: 62, Issue:6

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Co

2016
Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach.
    European journal of clinical pharmacology, 2016, Volume: 72, Issue:7

    Topics: Adult; Aged; Anti-HIV Agents; Area Under Curve; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infec

2016
Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach.
    European journal of clinical pharmacology, 2016, Volume: 72, Issue:7

    Topics: Adult; Aged; Anti-HIV Agents; Area Under Curve; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infec

2016
Evolution of changes in cognitive function after the initiation of antiretroviral therapy.
    AIDS research and therapy, 2016, Volume: 13

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cognition; Cognition Disorders; Emtricitabine, Tenofovir

2016
Evolution of changes in cognitive function after the initiation of antiretroviral therapy.
    AIDS research and therapy, 2016, Volume: 13

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cognition; Cognition Disorders; Emtricitabine, Tenofovir

2016
Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural north-central Nigeria: a cluster-randomised controlled trial.
    The lancet. HIV, 2016, Volume: 3, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delive

2016
Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural north-central Nigeria: a cluster-randomised controlled trial.
    The lancet. HIV, 2016, Volume: 3, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delive

2016
Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 10-15, Volume: 63, Issue:8

    Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child, Preschool; Female; Follow-Up Stu

2016
Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 10-15, Volume: 63, Issue:8

    Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child, Preschool; Female; Follow-Up Stu

2016
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.
    The New England journal of medicine, 2016, 11-03, Volume: 375, Issue:18

    Topics: Adult; Anti-Retroviral Agents; Black or African American; CD4 Lymphocyte Count; Drug Therapy, Combin

2016
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.
    The New England journal of medicine, 2016, 11-03, Volume: 375, Issue:18

    Topics: Adult; Anti-Retroviral Agents; Black or African American; CD4 Lymphocyte Count; Drug Therapy, Combin

2016
Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060.
    PloS one, 2016, Volume: 11, Issue:12

    Topics: Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Coinfection; Drug Therapy, Combination

2016
Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060.
    PloS one, 2016, Volume: 11, Issue:12

    Topics: Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Coinfection; Drug Therapy, Combination

2016
Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam.
    BMC infectious diseases, 2016, 12-16, Volume: 16, Issue:1

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cluster Analysis; Counseling; Female; HIV Infections;

2016
Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam.
    BMC infectious diseases, 2016, 12-16, Volume: 16, Issue:1

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cluster Analysis; Counseling; Female; HIV Infections;

2016
The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.
    Clinical pharmacology and therapeutics, 2017, Volume: 102, Issue:3

    Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Constitutive Androstane Receptor; Contraceptive Agen

2017
The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.
    Clinical pharmacology and therapeutics, 2017, Volume: 102, Issue:3

    Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Constitutive Androstane Receptor; Contraceptive Agen

2017
Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission.
    Journal of acquired immune deficiency syndromes (1999), 2008, Jun-01, Volume: 48, Issue:2

    Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine

2008
Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission.
    Journal of acquired immune deficiency syndromes (1999), 2008, Jun-01, Volume: 48, Issue:2

    Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine

2008
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
    The New England journal of medicine, 2008, 07-10, Volume: 359, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Drug Administration Schedule; Drug Therapy, C

2008
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
    The New England journal of medicine, 2008, 07-10, Volume: 359, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Drug Administration Schedule; Drug Therapy, C

2008
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
    The New England journal of medicine, 2008, 07-10, Volume: 359, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Drug Administration Schedule; Drug Therapy, C

2008
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
    The New England journal of medicine, 2008, 07-10, Volume: 359, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Drug Administration Schedule; Drug Therapy, C

2008
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
    The New England journal of medicine, 2008, 07-10, Volume: 359, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Drug Administration Schedule; Drug Therapy, C

2008
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
    The New England journal of medicine, 2008, 07-10, Volume: 359, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Drug Administration Schedule; Drug Therapy, C

2008
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
    The New England journal of medicine, 2008, 07-10, Volume: 359, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Drug Administration Schedule; Drug Therapy, C

2008
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
    The New England journal of medicine, 2008, 07-10, Volume: 359, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Drug Administration Schedule; Drug Therapy, C

2008
Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2008, Volume: 12, Issue:6

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; C

2008
Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2008, Volume: 12, Issue:6

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; C

2008
Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    AIDS (London, England), 2008, Jul-11, Volume: 22, Issue:11

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dru

2008
Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    AIDS (London, England), 2008, Jul-11, Volume: 22, Issue:11

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dru

2008
HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission.
    AIDS (London, England), 2008, Jul-31, Volume: 22, Issue:12

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cell-Free Syste

2008
HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission.
    AIDS (London, England), 2008, Jul-31, Volume: 22, Issue:12

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cell-Free Syste

2008
Lymphocyte mitochondrial depolarization and apoptosis in HIV-1-infected HAART patients.
    Journal of acquired immune deficiency syndromes (1999), 2008, Aug-01, Volume: 48, Issue:4

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Apoptosis; Benzoxazines; CD4-Positive T-Lymphocytes;

2008
Lymphocyte mitochondrial depolarization and apoptosis in HIV-1-infected HAART patients.
    Journal of acquired immune deficiency syndromes (1999), 2008, Aug-01, Volume: 48, Issue:4

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Apoptosis; Benzoxazines; CD4-Positive T-Lymphocytes;

2008
Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 62, Issue:5

    Topics: Adult; Anti-HIV Agents; Chromatography, High Pressure Liquid; Drugs, Generic; Female; HIV Infections

2008
Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 62, Issue:5

    Topics: Adult; Anti-HIV Agents; Chromatography, High Pressure Liquid; Drugs, Generic; Female; HIV Infections

2008
Mother-to-child transmission of HIV-1: association with malaria prevention, anaemia and placental malaria.
    HIV medicine, 2008, Volume: 9, Issue:9

    Topics: Adult; Anemia; Anti-HIV Agents; Antimalarials; CD4 Lymphocyte Count; Drug Combinations; Female; HIV

2008
Mother-to-child transmission of HIV-1: association with malaria prevention, anaemia and placental malaria.
    HIV medicine, 2008, Volume: 9, Issue:9

    Topics: Adult; Anemia; Anti-HIV Agents; Antimalarials; CD4 Lymphocyte Count; Drug Combinations; Female; HIV

2008
Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants.
    AIDS (London, England), 2008, Aug-20, Volume: 22, Issue:13

    Topics: Alanine Transaminase; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active

2008
Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants.
    AIDS (London, England), 2008, Aug-20, Volume: 22, Issue:13

    Topics: Alanine Transaminase; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active

2008
Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:7

    Topics: Adult; Alkynes; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Ch

2008
Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:7

    Topics: Adult; Alkynes; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Ch

2008
Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
    Antiviral therapy, 2008, Volume: 13, Issue:4

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Therapy, Combination; Female; HIV Infections; Hu

2008
Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
    Antiviral therapy, 2008, Volume: 13, Issue:4

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Therapy, Combination; Female; HIV Infections; Hu

2008
Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
    European journal of clinical pharmacology, 2009, Volume: 65, Issue:1

    Topics: Administration, Oral; Adult; Antibiotics, Antitubercular; Computer Simulation; Cross-Sectional Studi

2009
Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
    European journal of clinical pharmacology, 2009, Volume: 65, Issue:1

    Topics: Administration, Oral; Adult; Antibiotics, Antitubercular; Computer Simulation; Cross-Sectional Studi

2009
Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi.
    Contemporary clinical trials, 2009, Volume: 30, Issue:1

    Topics: Anti-Retroviral Agents; Breast Feeding; Clinical Protocols; Female; HIV Infections; Humans; Infant,

2009
Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi.
    Contemporary clinical trials, 2009, Volume: 30, Issue:1

    Topics: Anti-Retroviral Agents; Breast Feeding; Clinical Protocols; Female; HIV Infections; Humans; Infant,

2009
Nevirapine toxicity in non-HIV cancer patients.
    Chemotherapy, 2008, Volume: 54, Issue:6

    Topics: Aged; HIV Infections; Humans; Middle Aged; Neoplasm Staging; Nevirapine; Thyroid Neoplasms

2008
Nevirapine toxicity in non-HIV cancer patients.
    Chemotherapy, 2008, Volume: 54, Issue:6

    Topics: Aged; HIV Infections; Humans; Middle Aged; Neoplasm Staging; Nevirapine; Thyroid Neoplasms

2008
Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
    Antiviral therapy, 2008, Volume: 13, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Seroposit

2008
Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
    Antiviral therapy, 2008, Volume: 13, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Seroposit

2008
Determining an optimal testing strategy for infants at risk for mother-to-child transmission of HIV-1 during the late postnatal period.
    AIDS (London, England), 2008, Nov-12, Volume: 22, Issue:17

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Developing Countries; Female; HIV Infections; H

2008
Determining an optimal testing strategy for infants at risk for mother-to-child transmission of HIV-1 during the late postnatal period.
    AIDS (London, England), 2008, Nov-12, Volume: 22, Issue:17

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Developing Countries; Female; HIV Infections; H

2008
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:2

    Topics: Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Vir

2009
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:2

    Topics: Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Vir

2009
Risk factors for early and late transmission of HIV via breast-feeding among infants born to HIV-infected women in a randomized clinical trial in Botswana.
    The Journal of infectious diseases, 2009, Feb-01, Volume: 199, Issue:3

    Topics: Adult; Anti-HIV Agents; Botswana; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Inf

2009
Risk factors for early and late transmission of HIV via breast-feeding among infants born to HIV-infected women in a randomized clinical trial in Botswana.
    The Journal of infectious diseases, 2009, Feb-01, Volume: 199, Issue:3

    Topics: Adult; Anti-HIV Agents; Botswana; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Inf

2009
Risk factors for early and late transmission of HIV via breast-feeding among infants born to HIV-infected women in a randomized clinical trial in Botswana.
    The Journal of infectious diseases, 2009, Feb-01, Volume: 199, Issue:3

    Topics: Adult; Anti-HIV Agents; Botswana; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Inf

2009
Risk factors for early and late transmission of HIV via breast-feeding among infants born to HIV-infected women in a randomized clinical trial in Botswana.
    The Journal of infectious diseases, 2009, Feb-01, Volume: 199, Issue:3

    Topics: Adult; Anti-HIV Agents; Botswana; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Inf

2009
Risk factors for early and late transmission of HIV via breast-feeding among infants born to HIV-infected women in a randomized clinical trial in Botswana.
    The Journal of infectious diseases, 2009, Feb-01, Volume: 199, Issue:3

    Topics: Adult; Anti-HIV Agents; Botswana; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Inf

2009
Risk factors for early and late transmission of HIV via breast-feeding among infants born to HIV-infected women in a randomized clinical trial in Botswana.
    The Journal of infectious diseases, 2009, Feb-01, Volume: 199, Issue:3

    Topics: Adult; Anti-HIV Agents; Botswana; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Inf

2009
Risk factors for early and late transmission of HIV via breast-feeding among infants born to HIV-infected women in a randomized clinical trial in Botswana.
    The Journal of infectious diseases, 2009, Feb-01, Volume: 199, Issue:3

    Topics: Adult; Anti-HIV Agents; Botswana; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Inf

2009
Risk factors for early and late transmission of HIV via breast-feeding among infants born to HIV-infected women in a randomized clinical trial in Botswana.
    The Journal of infectious diseases, 2009, Feb-01, Volume: 199, Issue:3

    Topics: Adult; Anti-HIV Agents; Botswana; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Inf

2009
Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.
    PloS one, 2008, Volume: 3, Issue:12

    Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Drugs, Generic; Drugs, Investigational; Female; HIV Infe

2008
Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.
    PloS one, 2008, Volume: 3, Issue:12

    Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Drugs, Generic; Drugs, Investigational; Female; HIV Infe

2008
Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
    PloS one, 2009, Volume: 4, Issue:1

    Topics: Anti-HIV Agents; Breast Feeding; Drug Resistance, Viral; Female; Genotype; HIV; HIV Infections; Huma

2009
Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
    PloS one, 2009, Volume: 4, Issue:1

    Topics: Anti-HIV Agents; Breast Feeding; Drug Resistance, Viral; Female; Genotype; HIV; HIV Infections; Huma

2009
Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less.
    The Pediatric infectious disease journal, 2009, Volume: 28, Issue:3

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HIV Infec

2009
Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less.
    The Pediatric infectious disease journal, 2009, Volume: 28, Issue:3

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HIV Infec

2009
A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2009, Mar-01, Volume: 50, Issue:3

    Topics: Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibit

2009
A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2009, Mar-01, Volume: 50, Issue:3

    Topics: Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibit

2009
Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:5

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV-Associated Li

2009
Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:5

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV-Associated Li

2009
Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China.
    International journal of STD & AIDS, 2009, Volume: 20, Issue:4

    Topics: Adult; CD4 Lymphocyte Count; China; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combinatio

2009
Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China.
    International journal of STD & AIDS, 2009, Volume: 20, Issue:4

    Topics: Adult; CD4 Lymphocyte Count; China; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combinatio

2009
Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
    AIDS (London, England), 2009, Apr-27, Volume: 23, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Cambodia; Cote d'Ivoire; Deoxycytidine; Drug Administration Schedul

2009
Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
    AIDS (London, England), 2009, Apr-27, Volume: 23, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Cambodia; Cote d'Ivoire; Deoxycytidine; Drug Administration Schedul

2009
Timing and determinants of mother-to-child transmission of HIV in Nigeria.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2009, Volume: 106, Issue:1

    Topics: Adult; Anti-HIV Agents; Birth Weight; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Hum

2009
Timing and determinants of mother-to-child transmission of HIV in Nigeria.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2009, Volume: 106, Issue:1

    Topics: Adult; Anti-HIV Agents; Birth Weight; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Hum

2009
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
    AIDS (London, England), 2009, Jul-17, Volume: 23, Issue:11

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; HIV I

2009
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
    AIDS (London, England), 2009, Jul-17, Volume: 23, Issue:11

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; HIV I

2009
A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2009
A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2009
Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.
    Journal of acquired immune deficiency syndromes (1999), 2009, Aug-15, Volume: 51, Issue:5

    Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Base Sequence; DNA

2009
Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.
    Journal of acquired immune deficiency syndromes (1999), 2009, Aug-15, Volume: 51, Issue:5

    Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Base Sequence; DNA

2009
Predictors of rapid HIV testing acceptance and successful nevirapine administration in Zambian labor wards.
    Journal of acquired immune deficiency syndromes (1999), 2009, Oct-01, Volume: 52, Issue:2

    Topics: Anti-HIV Agents; Chemoprevention; Clinical Laboratory Techniques; Female; HIV Infections; Humans; In

2009
Predictors of rapid HIV testing acceptance and successful nevirapine administration in Zambian labor wards.
    Journal of acquired immune deficiency syndromes (1999), 2009, Oct-01, Volume: 52, Issue:2

    Topics: Anti-HIV Agents; Chemoprevention; Clinical Laboratory Techniques; Female; HIV Infections; Humans; In

2009
Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda.
    Journal of acquired immune deficiency syndromes (1999), 2009, Sep-01, Volume: 52, Issue:1

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious

2009
Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda.
    Journal of acquired immune deficiency syndromes (1999), 2009, Sep-01, Volume: 52, Issue:1

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious

2009
Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:10

    Topics: Adult; Aged; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Middle A

2009
Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:10

    Topics: Adult; Aged; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Middle A

2009
Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.
    British journal of clinical pharmacology, 2009, Volume: 68, Issue:1

    Topics: Adult; Cross-Over Studies; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infe

2009
Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.
    British journal of clinical pharmacology, 2009, Volume: 68, Issue:1

    Topics: Adult; Cross-Over Studies; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infe

2009
Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Sep-15, Volume: 49, Issue:6

    Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composit

2009
Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Sep-15, Volume: 49, Issue:6

    Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composit

2009
Selected hematologic and biochemical measurements in African HIV-infected and uninfected pregnant women and their infants: the HIV Prevention Trials Network 024 protocol.
    BMC pediatrics, 2009, Aug-07, Volume: 9

    Topics: Adult; Anti-HIV Agents; Blood Cell Count; Double-Blind Method; Female; Follow-Up Studies; Gestationa

2009
Selected hematologic and biochemical measurements in African HIV-infected and uninfected pregnant women and their infants: the HIV Prevention Trials Network 024 protocol.
    BMC pediatrics, 2009, Aug-07, Volume: 9

    Topics: Adult; Anti-HIV Agents; Blood Cell Count; Double-Blind Method; Female; Follow-Up Studies; Gestationa

2009
Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:9

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apolipoprotein A-I; Cholesterol, HDL;

2009
Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production.
    Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:9

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apolipoprotein A-I; Cholesterol, HDL;

2009
[Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2009, Volume: 34, Issue:8

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; China; Didanosi

2009
[Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2009, Volume: 34, Issue:8

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; China; Didanosi

2009
Comparing couples' and individual voluntary counseling and testing for HIV at antenatal clinics in Tanzania: a randomized trial.
    AIDS and behavior, 2010, Volume: 14, Issue:3

    Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Counseling; Family Characteristics; Female; HIV Infectio

2010
Comparing couples' and individual voluntary counseling and testing for HIV at antenatal clinics in Tanzania: a randomized trial.
    AIDS and behavior, 2010, Volume: 14, Issue:3

    Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Counseling; Family Characteristics; Female; HIV Infectio

2010
Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:6

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressu

2009
Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:6

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressu

2009
Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
    The Journal of infectious diseases, 2009, Nov-15, Volume: 200, Issue:10

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte

2009
Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
    The Journal of infectious diseases, 2009, Nov-15, Volume: 200, Issue:10

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte

2009
Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.
    PLoS medicine, 2009, Volume: 6, Issue:10

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2009
Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.
    PLoS medicine, 2009, Volume: 6, Issue:10

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2009
Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:11

    Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Sched

2009
Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:11

    Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Sched

2009
Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:11

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Didanosine; Dru

2009
Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:11

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Didanosine; Dru

2009
A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia.
    AIDS (London, England), 2010, Jan-28, Volume: 24, Issue:3

    Topics: Adult; Anti-HIV Agents; Female; Fetal Blood; Health Services Accessibility; HIV Infections; Humans;

2010
A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia.
    AIDS (London, England), 2010, Jan-28, Volume: 24, Issue:3

    Topics: Adult; Anti-HIV Agents; Female; Fetal Blood; Health Services Accessibility; HIV Infections; Humans;

2010
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
    The Journal of infectious diseases, 2010, Jan-01, Volume: 201, Issue:1

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Dru

2010
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
    The Journal of infectious diseases, 2010, Jan-01, Volume: 201, Issue:1

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Dru

2010
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
    Lancet (London, England), 2009, Dec-19, Volume: 374, Issue:9707

    Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I

2009
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
    Lancet (London, England), 2009, Dec-19, Volume: 374, Issue:9707

    Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I

2009
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
    Lancet (London, England), 2009, Dec-19, Volume: 374, Issue:9707

    Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I

2009
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
    Lancet (London, England), 2009, Dec-19, Volume: 374, Issue:9707

    Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I

2009
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
    Lancet (London, England), 2009, Dec-19, Volume: 374, Issue:9707

    Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I

2009
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
    Lancet (London, England), 2009, Dec-19, Volume: 374, Issue:9707

    Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I

2009
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
    Lancet (London, England), 2009, Dec-19, Volume: 374, Issue:9707

    Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I

2009
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
    Lancet (London, England), 2009, Dec-19, Volume: 374, Issue:9707

    Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I

2009
Temporal reduction of HIV type 1 viral load in breast milk by single-dose nevirapine during prevention of MTCT.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:12

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmiss

2009
Temporal reduction of HIV type 1 viral load in breast milk by single-dose nevirapine during prevention of MTCT.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:12

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmiss

2009
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
    Lancet (London, England), 2010, Jan-09, Volume: 375, Issue:9709

    Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Crea

2010
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
    Lancet (London, England), 2010, Jan-09, Volume: 375, Issue:9709

    Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Crea

2010
Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans.
    The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:2

    Topics: Adult; Anti-HIV Agents; Antifungal Agents; Cryptococcosis; Drug Interactions; Female; Fluconazole; H

2010
Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans.
    The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:2

    Topics: Adult; Anti-HIV Agents; Antifungal Agents; Cryptococcosis; Drug Interactions; Female; Fluconazole; H

2010
Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
    Therapeutic drug monitoring, 2010, Volume: 32, Issue:1

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; Drug Monitoring; Drug Therapy, Combination;

2010
Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
    Therapeutic drug monitoring, 2010, Volume: 32, Issue:1

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; Drug Monitoring; Drug Therapy, Combination;

2010
Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
    HIV medicine, 2010, Volume: 11, Issue:5

    Topics: Adult; Body Weight; CD4 Lymphocyte Count; Dideoxynucleosides; Disease Progression; Double-Blind Meth

2010
Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
    HIV medicine, 2010, Volume: 11, Issue:5

    Topics: Adult; Body Weight; CD4 Lymphocyte Count; Dideoxynucleosides; Disease Progression; Double-Blind Meth

2010
Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial).
    European journal of medical research, 2009, Volume: 14

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Fema

2009
Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial).
    European journal of medical research, 2009, Volume: 14

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Fema

2009
Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.
    Antiviral therapy, 2010, Volume: 15, Issue:1

    Topics: Adolescent; Anti-HIV Agents; Body Weight; Child; Child, Preschool; Cross-Over Studies; Dosage Forms;

2010
Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.
    Antiviral therapy, 2010, Volume: 15, Issue:1

    Topics: Adolescent; Anti-HIV Agents; Body Weight; Child; Child, Preschool; Cross-Over Studies; Dosage Forms;

2010
Is single-dose NVP relevant in the era of more efficacious PMTCT regimens? Lessons from Zambia.
    AIDS care, 2010, Volume: 22, Issue:2

    Topics: Anti-HIV Agents; Clinical Protocols; Developing Countries; Disease Transmission, Infectious; Drug Re

2010
Is single-dose NVP relevant in the era of more efficacious PMTCT regimens? Lessons from Zambia.
    AIDS care, 2010, Volume: 22, Issue:2

    Topics: Anti-HIV Agents; Clinical Protocols; Developing Countries; Disease Transmission, Infectious; Drug Re

2010
Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:7

    Topics: Adult; Aged; Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Female; HIV

2010
Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:7

    Topics: Adult; Aged; Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Female; HIV

2010
A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.
    The Pediatric infectious disease journal, 2010, Volume: 29, Issue:10

    Topics: Administration, Oral; Anti-HIV Agents; Child; Child, Preschool; Cross-Over Studies; Female; HIV Infe

2010
A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.
    The Pediatric infectious disease journal, 2010, Volume: 29, Issue:10

    Topics: Administration, Oral; Anti-HIV Agents; Child; Child, Preschool; Cross-Over Studies; Female; HIV Infe

2010
Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda.
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:5

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Administration Schedu

2010
Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda.
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:5

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Administration Schedu

2010
Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: a substudy of the ISS-PART Trial.
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:5

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Dr

2010
Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: a substudy of the ISS-PART Trial.
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:5

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Dr

2010
Eighteen-month follow-up of HIV-1-infected mothers and their children enrolled in the Kesho Bora study observational cohorts.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 54, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Burkina Faso; CD4 Lym

2010
Eighteen-month follow-up of HIV-1-infected mothers and their children enrolled in the Kesho Bora study observational cohorts.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 54, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Burkina Faso; CD4 Lym

2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The

2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The

2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The

2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The

2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The

2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The

2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The

2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The

2010
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U

2010
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U

2010
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U

2010
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U

2010
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U

2010
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U

2010
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U

2010
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U

2010
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette

2010
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette

2010
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    JAMA, 2010, Sep-08, Volume: 304, Issue:10

    Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans;

2010
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    JAMA, 2010, Sep-08, Volume: 304, Issue:10

    Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans;

2010
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    JAMA, 2010, Sep-08, Volume: 304, Issue:10

    Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans;

2010
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    JAMA, 2010, Sep-08, Volume: 304, Issue:10

    Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans;

2010
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    JAMA, 2010, Sep-08, Volume: 304, Issue:10

    Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans;

2010
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    JAMA, 2010, Sep-08, Volume: 304, Issue:10

    Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans;

2010
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    JAMA, 2010, Sep-08, Volume: 304, Issue:10

    Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans;

2010
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
    JAMA, 2010, Sep-08, Volume: 304, Issue:10

    Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans;

2010
Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges.
    Contemporary clinical trials, 2011, Volume: 32, Issue:1

    Topics: Africa, Eastern; Africa, Southern; Africa, Western; Anti-Retroviral Agents; Breast Feeding; Child, P

2011
Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges.
    Contemporary clinical trials, 2011, Volume: 32, Issue:1

    Topics: Africa, Eastern; Africa, Southern; Africa, Western; Anti-Retroviral Agents; Breast Feeding; Child, P

2011
Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Nov-01, Volume: 51, Issue:9

    Topics: Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartate Aminotransfe

2010
Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Nov-01, Volume: 51, Issue:9

    Topics: Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartate Aminotransfe

2010
Antiretroviral therapies in women after single-dose nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug T

2010
Antiretroviral therapies in women after single-dose nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug T

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Growth of infants born to HIV-infected women in South Africa according to maternal and infant characteristics.
    Tropical medicine & international health : TM & IH, 2010, Volume: 15, Issue:11

    Topics: Adult; Anti-HIV Agents; Body Height; Body Weight; CD4 Lymphocyte Count; Epidemiologic Methods; Femal

2010
Growth of infants born to HIV-infected women in South Africa according to maternal and infant characteristics.
    Tropical medicine & international health : TM & IH, 2010, Volume: 15, Issue:11

    Topics: Adult; Anti-HIV Agents; Body Height; Body Weight; CD4 Lymphocyte Count; Epidemiologic Methods; Femal

2010
Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:1

    Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Infan

2011
Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:1

    Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Infan

2011
Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Anti-HIV Agents; Drug Interactions; Female; HIV Infections; HIV-1; Hum

2011
Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:1

    Topics: Adult; Anti-Bacterial Agents; Anti-HIV Agents; Drug Interactions; Female; HIV Infections; HIV-1; Hum

2011
Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
    Tropical medicine & international health : TM & IH, 2011, Volume: 16, Issue:2

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2011
Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
    Tropical medicine & international health : TM & IH, 2011, Volume: 16, Issue:2

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2011
Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
    Tropical medicine & international health : TM & IH, 2011, Volume: 16, Issue:2

    Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Hypersensitivity; Gene Frequen

2011
Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
    Tropical medicine & international health : TM & IH, 2011, Volume: 16, Issue:2

    Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Hypersensitivity; Gene Frequen

2011
Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication.
    Journal of perinatal medicine, 2011, Volume: 39, Issue:2

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Congenital Abnormalities; Double-Blind Method; Female; Heart

2011
Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication.
    Journal of perinatal medicine, 2011, Volume: 39, Issue:2

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Congenital Abnormalities; Double-Blind Method; Female; Heart

2011
"Forgiving" a missed daily dose.
    AIDS research and human retroviruses, 2011, Volume: 27, Issue:4

    Topics: Anti-HIV Agents; Delayed-Action Preparations; Double-Blind Method; HIV Infections; Humans; Medicatio

2011
"Forgiving" a missed daily dose.
    AIDS research and human retroviruses, 2011, Volume: 27, Issue:4

    Topics: Anti-HIV Agents; Delayed-Action Preparations; Double-Blind Method; HIV Infections; Humans; Medicatio

2011
CD4+ cell count and risk for antiretroviral drug resistance among women using peripartum nevirapine for perinatal HIV prevention.
    BJOG : an international journal of obstetrics and gynaecology, 2011, Volume: 118, Issue:4

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV Seroposit

2011
CD4+ cell count and risk for antiretroviral drug resistance among women using peripartum nevirapine for perinatal HIV prevention.
    BJOG : an international journal of obstetrics and gynaecology, 2011, Volume: 118, Issue:4

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV Seroposit

2011
Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus.
    The Journal of infectious diseases, 2011, Feb-01, Volume: 203, Issue:3

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis

2011
Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus.
    The Journal of infectious diseases, 2011, Feb-01, Volume: 203, Issue:3

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis

2011
Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
    The Lancet. Infectious diseases, 2011, Volume: 11, Issue:3

    Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Thera

2011
Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
    The Lancet. Infectious diseases, 2011, Volume: 11, Issue:3

    Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Thera

2011
Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.
    AIDS research and human retroviruses, 2011, Volume: 27, Issue:8

    Topics: Base Sequence; Breast Feeding; Child; Drug Administration Schedule; Drug Resistance, Viral; Ethiopia

2011
Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.
    AIDS research and human retroviruses, 2011, Volume: 27, Issue:8

    Topics: Base Sequence; Breast Feeding; Child; Drug Administration Schedule; Drug Resistance, Viral; Ethiopia

2011
Rapid intrapartum or postpartum HIV testing at a midwife obstetric unit and a district hospital in South Africa.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2011, Volume: 113, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Cluster Analysis; Feasibility Studies; Female; HIV Infections; H

2011
Rapid intrapartum or postpartum HIV testing at a midwife obstetric unit and a district hospital in South Africa.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2011, Volume: 113, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Cluster Analysis; Feasibility Studies; Female; HIV Infections; H

2011
Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count.
    AIDS (London, England), 2011, Mar-27, Volume: 25, Issue:6

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female

2011
Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count.
    AIDS (London, England), 2011, Mar-27, Volume: 25, Issue:6

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female

2011
Postexposure prophylaxis of breastfeeding HIV-exposed infants with antiretroviral drugs to age 14 weeks: updated efficacy results of the PEPI-Malawi trial.
    Journal of acquired immune deficiency syndromes (1999), 2011, Aug-01, Volume: 57, Issue:4

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Infectious Disease Transmis

2011
Postexposure prophylaxis of breastfeeding HIV-exposed infants with antiretroviral drugs to age 14 weeks: updated efficacy results of the PEPI-Malawi trial.
    Journal of acquired immune deficiency syndromes (1999), 2011, Aug-01, Volume: 57, Issue:4

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Infectious Disease Transmis

2011
Improved detection of incident HIV infection and uptake of PMTCT services in labor and delivery in a high HIV prevalence setting.
    Journal of acquired immune deficiency syndromes (1999), 2011, Aug-01, Volume: 57, Issue:4

    Topics: Anti-HIV Agents; Eswatini; Female; Fetal Blood; HIV Antibodies; HIV Infections; Humans; Incidence; I

2011
Improved detection of incident HIV infection and uptake of PMTCT services in labor and delivery in a high HIV prevalence setting.
    Journal of acquired immune deficiency syndromes (1999), 2011, Aug-01, Volume: 57, Issue:4

    Topics: Anti-HIV Agents; Eswatini; Female; Fetal Blood; HIV Antibodies; HIV Infections; Humans; Incidence; I

2011
Once-a-day (QD) vs. twice-daily (BID) nevirapine as simplification in PI-treated patients after 2 mos. of BID induction.
    Current HIV research, 2011, Volume: 9, Issue:3

    Topics: Adolescent; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Fem

2011
Once-a-day (QD) vs. twice-daily (BID) nevirapine as simplification in PI-treated patients after 2 mos. of BID induction.
    Current HIV research, 2011, Volume: 9, Issue:3

    Topics: Adolescent; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Fem

2011
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
    HIV medicine, 2011, Volume: 12, Issue:6

    Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Dyslipidemia

2011
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
    HIV medicine, 2011, Volume: 12, Issue:6

    Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Dyslipidemia

2011
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
    Antiviral therapy, 2011, Volume: 16, Issue:3

    Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cardiovascular Diseases; Deoxycytidine; Emtrici

2011
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
    Antiviral therapy, 2011, Volume: 16, Issue:3

    Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cardiovascular Diseases; Deoxycytidine; Emtrici

2011
Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine.
    Proceedings of the National Academy of Sciences of the United States of America, 2011, May-31, Volume: 108, Issue:22

    Topics: Alleles; Anti-HIV Agents; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Fe

2011
Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine.
    Proceedings of the National Academy of Sciences of the United States of America, 2011, May-31, Volume: 108, Issue:22

    Topics: Alleles; Anti-HIV Agents; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Fe

2011
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:8

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies

2011
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:8

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies

2011
Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
    The Southeast Asian journal of tropical medicine and public health, 2011, Volume: 42, Issue:3

    Topics: Adult; Alkynes; Antibiotics, Antitubercular; Benzoxazines; Chemical and Drug Induced Liver Injury; C

2011
Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
    The Southeast Asian journal of tropical medicine and public health, 2011, Volume: 42, Issue:3

    Topics: Adult; Alkynes; Antibiotics, Antitubercular; Benzoxazines; Chemical and Drug Induced Liver Injury; C

2011
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:10

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; HI

2011
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:10

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; HI

2011
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
    Antiviral therapy, 2011, Volume: 16, Issue:5

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Double-Blind Method; Drug Adminis

2011
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
    Antiviral therapy, 2011, Volume: 16, Issue:5

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Double-Blind Method; Drug Adminis

2011
Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial.
    Basic & clinical pharmacology & toxicology, 2011, Volume: 109, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Bi

2011
Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial.
    Basic & clinical pharmacology & toxicology, 2011, Volume: 109, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Bi

2011
Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY).
    Journal of acquired immune deficiency syndromes (1999), 2011, Dec-01, Volume: 58, Issue:4

    Topics: Adolescent; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Immunoglobulins, Intravenous; In

2011
Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY).
    Journal of acquired immune deficiency syndromes (1999), 2011, Dec-01, Volume: 58, Issue:4

    Topics: Adolescent; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Immunoglobulins, Intravenous; In

2011
Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.
    Clinical therapeutics, 2011, Volume: 33, Issue:9

    Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Biological Availability; Delayed-Action Pr

2011
Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.
    Clinical therapeutics, 2011, Volume: 33, Issue:9

    Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Biological Availability; Delayed-Action Pr

2011
Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Volume: 53, Issue:7

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzo

2011
Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Volume: 53, Issue:7

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzo

2011
HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:10

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Drug Resistance, Viral; F

2011
HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya.
    Journal of viral hepatitis, 2011, Volume: 18, Issue:10

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Drug Resistance, Viral; F

2011
Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:12

    Topics: Adult; Anti-HIV Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug

2011
Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:12

    Topics: Adult; Anti-HIV Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug

2011
A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
    International journal of clinical practice, 2011, Volume: 65, Issue:12

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Combinations; Drug Therapy, Combinat

2011
A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
    International journal of clinical practice, 2011, Volume: 65, Issue:12

    Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Combinations; Drug Therapy, Combinat

2011
Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
    Antiviral therapy, 2011, Volume: 16, Issue:7

    Topics: Adenine; Adult; Africa; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Creatinine; Did

2011
Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
    Antiviral therapy, 2011, Volume: 16, Issue:7

    Topics: Adenine; Adult; Africa; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Creatinine; Did

2011
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Antiviral therapy, 2011, Volume: 16, Issue:7

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2011
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Antiviral therapy, 2011, Volume: 16, Issue:7

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2011
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease

2012
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease

2012
Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention.
    Journal of acquired immune deficiency syndromes (1999), 2012, Mar-01, Volume: 59, Issue:3

    Topics: Adolescent; Adult; Carbamazepine; CD4 Lymphocyte Count; Chi-Square Distribution; Drug Interactions;

2012
Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention.
    Journal of acquired immune deficiency syndromes (1999), 2012, Mar-01, Volume: 59, Issue:3

    Topics: Adolescent; Adult; Carbamazepine; CD4 Lymphocyte Count; Chi-Square Distribution; Drug Interactions;

2012
Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
    HIV medicine, 2012, Volume: 13, Issue:4

    Topics: Adult; Analysis of Variance; Anti-HIV Agents; Delayed-Action Preparations; Drug Substitution; Female

2012
Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
    HIV medicine, 2012, Volume: 13, Issue:4

    Topics: Adult; Analysis of Variance; Anti-HIV Agents; Delayed-Action Preparations; Drug Substitution; Female

2012
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-15, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI

2012
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-15, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI

2012
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-15, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI

2012
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-15, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI

2012
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-15, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI

2012
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-15, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI

2012
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-15, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI

2012
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-15, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI

2012
Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.
    The Journal of infectious diseases, 2012, Feb-01, Volume: 205, Issue:3

    Topics: Acyclovir; Adolescent; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; HIV-1; H

2012
Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.
    The Journal of infectious diseases, 2012, Feb-01, Volume: 205, Issue:3

    Topics: Acyclovir; Adolescent; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; HIV-1; H

2012
Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
    Antiviral therapy, 2011, Volume: 16, Issue:8

    Topics: Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Body Weig

2011
Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
    Antiviral therapy, 2011, Volume: 16, Issue:8

    Topics: Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Body Weig

2011
Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2012, Jan-21, Volume: 379, Issue:9812

    Topics: Administration, Oral; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Hi

2012
Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2012, Jan-21, Volume: 379, Issue:9812

    Topics: Administration, Oral; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Hi

2012
A lipid-based nutrient supplement mitigates weight loss among HIV-infected women in a factorial randomized trial to prevent mother-to-child transmission during exclusive breastfeeding.
    The American journal of clinical nutrition, 2012, Volume: 95, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; Dietary Supplements; Female; HIV Infections; HIV-1; H

2012
A lipid-based nutrient supplement mitigates weight loss among HIV-infected women in a factorial randomized trial to prevent mother-to-child transmission during exclusive breastfeeding.
    The American journal of clinical nutrition, 2012, Volume: 95, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; Dietary Supplements; Female; HIV Infections; HIV-1; H

2012
Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women.
    Antiviral therapy, 2012, Volume: 17, Issue:2

    Topics: Anti-HIV Agents; Drug Combinations; Drug Resistance, Viral; Female; Genotype; HIV Infections; Humans

2012
Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women.
    Antiviral therapy, 2012, Volume: 17, Issue:2

    Topics: Anti-HIV Agents; Drug Combinations; Drug Resistance, Viral; Female; Genotype; HIV Infections; Humans

2012
Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.
    AIDS (London, England), 2012, Apr-24, Volume: 26, Issue:7

    Topics: Adult; Africa South of the Sahara; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Dru

2012
Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.
    AIDS (London, England), 2012, Apr-24, Volume: 26, Issue:7

    Topics: Adult; Africa South of the Sahara; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Dru

2012
Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics.
    Journal of acquired immune deficiency syndromes (1999), 2012, Jul-01, Volume: 60, Issue:3

    Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Deoxycy

2012
Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics.
    Journal of acquired immune deficiency syndromes (1999), 2012, Jul-01, Volume: 60, Issue:3

    Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Deoxycy

2012
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
    The Lancet. Infectious diseases, 2012, Volume: 12, Issue:7

    Topics: Alanine Transaminase; Anti-HIV Agents; Body Height; Body Weight; Chi-Square Distribution; Child, Pre

2012
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
    The Lancet. Infectious diseases, 2012, Volume: 12, Issue:7

    Topics: Alanine Transaminase; Anti-HIV Agents; Body Height; Body Weight; Chi-Square Distribution; Child, Pre

2012
Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2012, Volume: 95, Issue:2

    Topics: Adolescent; Adult; Alkynes; Benzoxazines; Cholesterol, HDL; Coinfection; Cyclopropanes; Female; HIV

2012
Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2012, Volume: 95, Issue:2

    Topics: Adolescent; Adult; Alkynes; Benzoxazines; Cholesterol, HDL; Coinfection; Cyclopropanes; Female; HIV

2012
The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Malaria; Nevirapine; Ritonavir

2012
The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Malaria; Nevirapine; Ritonavir

2012
Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial.
    Lancet (London, England), 2012, Jun-30, Volume: 379, Issue:9835

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; Female; Follow-Up Studies; HIV Infections; HIV-1; Hum

2012
Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial.
    Lancet (London, England), 2012, Jun-30, Volume: 379, Issue:9835

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; Female; Follow-Up Studies; HIV Infections; HIV-1; Hum

2012
Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
    AIDS (London, England), 2012, Jul-31, Volume: 26, Issue:12

    Topics: Anti-HIV Agents; Antibiotics, Antitubercular; Case-Control Studies; Child, Preschool; Coinfection; F

2012
Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
    AIDS (London, England), 2012, Jul-31, Volume: 26, Issue:12

    Topics: Anti-HIV Agents; Antibiotics, Antitubercular; Case-Control Studies; Child, Preschool; Coinfection; F

2012
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:9

    Topics: Adult; Alkynes; Anti-HIV Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisin

2012
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:9

    Topics: Adult; Alkynes; Anti-HIV Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisin

2012
Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.
    PloS one, 2012, Volume: 7, Issue:6

    Topics: Acyclovir; Antiviral Agents; Biomarkers; CD4 Antigens; Disease Progression; Female; Herpes Genitalis

2012
Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.
    PloS one, 2012, Volume: 7, Issue:6

    Topics: Acyclovir; Antiviral Agents; Biomarkers; CD4 Antigens; Disease Progression; Female; Herpes Genitalis

2012
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
    The New England journal of medicine, 2012, Jun-21, Volume: 366, Issue:25

    Topics: Anti-Retroviral Agents; CD4 Lymphocyte Count; Child, Preschool; Drug Therapy, Combination; Female; H

2012
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
    The New England journal of medicine, 2012, Jun-21, Volume: 366, Issue:25

    Topics: Anti-Retroviral Agents; CD4 Lymphocyte Count; Child, Preschool; Drug Therapy, Combination; Female; H

2012
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
    The New England journal of medicine, 2012, Jun-21, Volume: 366, Issue:25

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2012
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
    The New England journal of medicine, 2012, Jun-21, Volume: 366, Issue:25

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2012
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
    The New England journal of medicine, 2012, Jun-21, Volume: 366, Issue:25

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2012
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
    The New England journal of medicine, 2012, Jun-21, Volume: 366, Issue:25

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2012
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
    The New England journal of medicine, 2012, Jun-21, Volume: 366, Issue:25

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2012
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
    The New England journal of medicine, 2012, Jun-21, Volume: 366, Issue:25

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2012
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
    The New England journal of medicine, 2012, Jun-21, Volume: 366, Issue:25

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2012
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
    The New England journal of medicine, 2012, Jun-21, Volume: 366, Issue:25

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2012
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.
    PLoS medicine, 2012, Volume: 9, Issue:6

    Topics: Adult; Africa; Anti-HIV Agents; CD4 Lymphocyte Count; Death; Drug Resistance, Viral; Endpoint Determ

2012
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.
    PLoS medicine, 2012, Volume: 9, Issue:6

    Topics: Adult; Africa; Anti-HIV Agents; CD4 Lymphocyte Count; Death; Drug Resistance, Viral; Endpoint Determ

2012
Evidence for nevirapine bioactivation in man: searching for the first step in the mechanism of nevirapine toxicity.
    Toxicology, 2012, Nov-15, Volume: 301, Issue:1-3

    Topics: Adult; Aged; Anti-HIV Agents; Biomarkers; Case-Control Studies; Chromatography, Liquid; Female; Hapt

2012
Evidence for nevirapine bioactivation in man: searching for the first step in the mechanism of nevirapine toxicity.
    Toxicology, 2012, Nov-15, Volume: 301, Issue:1-3

    Topics: Adult; Aged; Anti-HIV Agents; Biomarkers; Case-Control Studies; Chromatography, Liquid; Female; Hapt

2012
Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
    BMC pediatrics, 2012, Jul-08, Volume: 12

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Ch

2012
Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
    BMC pediatrics, 2012, Jul-08, Volume: 12

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Ch

2012
Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:12

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross-Sectional

2012
Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:12

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross-Sectional

2012
Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:1

    Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infa

2013
Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:1

    Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infa

2013
Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy.
    The Southeast Asian journal of tropical medicine and public health, 2012, Volume: 43, Issue:1

    Topics: Adult; Alkynes; Analysis of Variance; Antiretroviral Therapy, Highly Active; Antitubercular Agents;

2012
Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy.
    The Southeast Asian journal of tropical medicine and public health, 2012, Volume: 43, Issue:1

    Topics: Adult; Alkynes; Analysis of Variance; Antiretroviral Therapy, Highly Active; Antitubercular Agents;

2012
Growth patterns among HIV-exposed infants receiving nevirapine prophylaxis in Pune, India.
    BMC infectious diseases, 2012, Oct-31, Volume: 12

    Topics: Adult; Anthropometry; Female; HIV Infections; HIV Seropositivity; Humans; India; Infant; Infant, New

2012
Growth patterns among HIV-exposed infants receiving nevirapine prophylaxis in Pune, India.
    BMC infectious diseases, 2012, Oct-31, Volume: 12

    Topics: Adult; Anthropometry; Female; HIV Infections; HIV Seropositivity; Humans; India; Infant; Infant, New

2012
Anaemia in HIV-infected children: severity, types and effect on response to HAART.
    BMC pediatrics, 2012, Oct-31, Volume: 12

    Topics: Adolescent; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool;

2012
Anaemia in HIV-infected children: severity, types and effect on response to HAART.
    BMC pediatrics, 2012, Oct-31, Volume: 12

    Topics: Adolescent; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool;

2012
Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
    AIDS research and human retroviruses, 2013, Volume: 29, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2013
Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
    AIDS research and human retroviruses, 2013, Volume: 29, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2013
Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.
    Antiviral therapy, 2013, Volume: 18, Issue:4

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Botswana; Breast Feeding; Dideoxynucl

2013
Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.
    Antiviral therapy, 2013, Volume: 18, Issue:4

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Botswana; Breast Feeding; Dideoxynucl

2013
Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives.
    Journal of acquired immune deficiency syndromes (1999), 2013, Apr-15, Volume: 62, Issue:5

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptives, Oral, Synthetic; Cyclopro

2013
Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives.
    Journal of acquired immune deficiency syndromes (1999), 2013, Apr-15, Volume: 62, Issue:5

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptives, Oral, Synthetic; Cyclopro

2013
Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.
    Archives of disease in childhood, 2013, Volume: 98, Issue:4

    Topics: Anti-HIV Agents; Body Composition; Child; Child, Preschool; Cross-Sectional Studies; Drug Therapy, C

2013
Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.
    Archives of disease in childhood, 2013, Volume: 98, Issue:4

    Topics: Anti-HIV Agents; Body Composition; Child; Child, Preschool; Cross-Sectional Studies; Drug Therapy, C

2013
A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.
    Antiviral therapy, 2012, Volume: 17, Issue:8

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Diet; Drug Administrati

2012
A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.
    Antiviral therapy, 2012, Volume: 17, Issue:8

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Diet; Drug Administrati

2012
Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants.
    The Pediatric infectious disease journal, 2013, Volume: 32, Issue:4

    Topics: Anti-Retroviral Agents; Breast Feeding; Chemoprevention; Drug Resistance, Viral; Female; Genotype; H

2013
Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants.
    The Pediatric infectious disease journal, 2013, Volume: 32, Issue:4

    Topics: Anti-Retroviral Agents; Breast Feeding; Chemoprevention; Drug Resistance, Viral; Female; Genotype; H

2013
The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: a change in national treatment guidelines may be warranted.
    Journal of acquired immune deficiency syndromes (1999), 2013, Apr-15, Volume: 62, Issue:5

    Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; CD4 Lymphocyte Count; Chemical

2013
The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: a change in national treatment guidelines may be warranted.
    Journal of acquired immune deficiency syndromes (1999), 2013, Apr-15, Volume: 62, Issue:5

    Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; CD4 Lymphocyte Count; Chemical

2013
Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:7

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV;

2013
Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:7

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV;

2013
Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.
    Journal of acquired immune deficiency syndromes (1999), 2013, Feb-01, Volume: 62, Issue:2

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Aspartate Aminotransfer

2013
Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.
    Journal of acquired immune deficiency syndromes (1999), 2013, Feb-01, Volume: 62, Issue:2

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Aspartate Aminotransfer

2013
Comparison of nevirapine plasma concentrations between lead-in and steady-state periods in Chinese HIV-infected patients.
    PloS one, 2013, Volume: 8, Issue:1

    Topics: Adolescent; Aged; Anti-HIV Agents; China; Female; HIV Infections; Humans; Male; Middle Aged; Nevirap

2013
Comparison of nevirapine plasma concentrations between lead-in and steady-state periods in Chinese HIV-infected patients.
    PloS one, 2013, Volume: 8, Issue:1

    Topics: Adolescent; Aged; Anti-HIV Agents; China; Female; HIV Infections; Humans; Male; Middle Aged; Nevirap

2013
Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.
    AIDS (London, England), 2002, Jul-05, Volume: 16, Issue:10

    Topics: Adult; Anti-HIV Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; HIV Infections; HIV

2002
Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.
    AIDS (London, England), 2002, Jul-05, Volume: 16, Issue:10

    Topics: Adult; Anti-HIV Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; HIV Infections; HIV

2002
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Antiviral therapy, 2002, Volume: 7, Issue:2

    Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Argentina; Cohort Studies; Drug Therapy, Combina

2002
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Antiviral therapy, 2002, Volume: 7, Issue:2

    Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Argentina; Cohort Studies; Drug Therapy, Combina

2002
Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Nov-01, Volume: 35, Issue:9

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Lamivu

2002
Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Nov-01, Volume: 35, Issue:9

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Lamivu

2002
Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
    British journal of clinical pharmacology, 2002, Volume: 54, Issue:4

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Male; Nevirapine

2002
Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
    British journal of clinical pharmacology, 2002, Volume: 54, Issue:4

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Male; Nevirapine

2002
Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea.
    AIDS (London, England), 2002, Dec-06, Volume: 16, Issue:18

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Interactions

2002
Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea.
    AIDS (London, England), 2002, Dec-06, Volume: 16, Issue:18

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Interactions

2002
Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya.
    AIDS (London, England), 2003, Jan-03, Volume: 17, Issue:1

    Topics: Adult; Anti-HIV Agents; Female; Focus Groups; Follow-Up Studies; Health Knowledge, Attitudes, Practi

2003
Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya.
    AIDS (London, England), 2003, Jan-03, Volume: 17, Issue:1

    Topics: Adult; Anti-HIV Agents; Female; Focus Groups; Follow-Up Studies; Health Knowledge, Attitudes, Practi

2003
A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk.
    AIDS (London, England), 2003, Mar-07, Volume: 17, Issue:4

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Follow-Up Studies; Hepatitis C; HIV Infection

2003
A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk.
    AIDS (London, England), 2003, Mar-07, Volume: 17, Issue:4

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Follow-Up Studies; Hepatitis C; HIV Infection

2003
A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
    The Journal of infectious diseases, 2003, Mar-01, Volume: 187, Issue:5

    Topics: Adult; Anti-HIV Agents; Delivery, Obstetric; Drug Therapy, Combination; Female; HIV Infections; HIV-

2003
A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
    The Journal of infectious diseases, 2003, Mar-01, Volume: 187, Issue:5

    Topics: Adult; Anti-HIV Agents; Delivery, Obstetric; Drug Therapy, Combination; Female; HIV Infections; HIV-

2003
Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.
    The Journal of infectious diseases, 2003, Feb-15, Volume: 187, Issue:4

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Argentina; Cohort Studies; Drug

2003
Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.
    The Journal of infectious diseases, 2003, Feb-15, Volume: 187, Issue:4

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Argentina; Cohort Studies; Drug

2003
Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings.
    Journal of acquired immune deficiency syndromes (1999), 2003, Apr-15, Volume: 32, Issue:5

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; N

2003
Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings.
    Journal of acquired immune deficiency syndromes (1999), 2003, Apr-15, Volume: 32, Issue:5

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; N

2003
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.
    AIDS (London, England), 2003, May-02, Volume: 17, Issue:7

    Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV In

2003
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.
    AIDS (London, England), 2003, May-02, Volume: 17, Issue:7

    Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV In

2003
Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2003, May-01, Volume: 33, Issue:1

    Topics: CD4 Lymphocyte Count; Drug Administration Schedule; Exanthema; Female; HIV; HIV Infections; Humans;

2003
Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2003, May-01, Volume: 33, Issue:1

    Topics: CD4 Lymphocyte Count; Drug Administration Schedule; Exanthema; Female; HIV; HIV Infections; Humans;

2003
Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose.
    Journal of acquired immune deficiency syndromes (1999), 2003, Jun-01, Volume: 33, Issue:2

    Topics: Adult; Anti-HIV Agents; Bahamas; Brazil; Double-Blind Method; Europe; Female; Fetal Blood; HIV Infec

2003
Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose.
    Journal of acquired immune deficiency syndromes (1999), 2003, Jun-01, Volume: 33, Issue:2

    Topics: Adult; Anti-HIV Agents; Bahamas; Brazil; Double-Blind Method; Europe; Female; Fetal Blood; HIV Infec

2003
Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine.
    AIDS (London, England), 2003, Jul-25, Volume: 17, Issue:11

    Topics: Adolescent; Adult; Breast Feeding; Drug Administration Schedule; Female; HIV Infections; HIV Seropos

2003
Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine.
    AIDS (London, England), 2003, Jul-25, Volume: 17, Issue:11

    Topics: Adolescent; Adult; Breast Feeding; Drug Administration Schedule; Female; HIV Infections; HIV Seropos

2003
Feeding risk cut for HIV-infected women.
    Lancet (London, England), 2003, Jul-26, Volume: 362, Issue:9380

    Topics: Anti-HIV Agents; Breast Feeding; Didanosine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn;

2003
Feeding risk cut for HIV-infected women.
    Lancet (London, England), 2003, Jul-26, Volume: 362, Issue:9380

    Topics: Anti-HIV Agents; Breast Feeding; Didanosine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn;

2003
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Disease Progression; Drug The

2003
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Disease Progression; Drug The

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.
    AIDS (London, England), 2003, Sep-26, Volume: 17, Issue:14

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosin

2003
Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.
    AIDS (London, England), 2003, Sep-26, Volume: 17, Issue:14

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosin

2003
Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial.
    Lancet (London, England), 2003, Oct-11, Volume: 362, Issue:9391

    Topics: Anti-HIV Agents; Female; Follow-Up Studies; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infan

2003
Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial.
    Lancet (London, England), 2003, Oct-11, Volume: 362, Issue:9391

    Topics: Anti-HIV Agents; Female; Follow-Up Studies; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infan

2003
Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaoundé, Cameroon.
    Journal of acquired immune deficiency syndromes (1999), 2003, Nov-01, Volume: 34, Issue:3

    Topics: Anti-HIV Agents; Cameroon; Female; HIV Infections; HIV-1; Humans; Immunoenzyme Techniques; Infant; I

2003
Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaoundé, Cameroon.
    Journal of acquired immune deficiency syndromes (1999), 2003, Nov-01, Volume: 34, Issue:3

    Topics: Anti-HIV Agents; Cameroon; Female; HIV Infections; HIV-1; Humans; Immunoenzyme Techniques; Infant; I

2003
A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.
    The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:11

    Topics: Adult; Anti-HIV Agents; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination

2003
A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.
    The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:11

    Topics: Adult; Anti-HIV Agents; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination

2003
Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
    Antiviral therapy, 2003, Volume: 8, Issue:5

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2003
Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
    Antiviral therapy, 2003, Volume: 8, Issue:5

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2003
Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection.
    Journal of acquired immune deficiency syndromes (1999), 2003, Dec-15, Volume: 34, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; DNA, Viral; HIV Infections; HIV-1; Humans; Infa

2003
Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection.
    Journal of acquired immune deficiency syndromes (1999), 2003, Dec-15, Volume: 34, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; DNA, Viral; HIV Infections; HIV-1; Humans; Infa

2003
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.
    AIDS (London, England), 2003, Dec-05, Volume: 17, Issue:18

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosi

2003
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.
    AIDS (London, England), 2003, Dec-05, Volume: 17, Issue:18

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosi

2003
A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Antiviral therapy, 2003, Volume: 8, Issue:6

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Ther

2003
A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Antiviral therapy, 2003, Volume: 8, Issue:6

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Ther

2003
Treatment of HIV-infected patients with a combination of efavirenz, nevirapine and nucleoside reverse transcriptase inhibitors.
    HIV medicine, 2004, Volume: 5, Issue:2

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Huma

2004
Treatment of HIV-infected patients with a combination of efavirenz, nevirapine and nucleoside reverse transcriptase inhibitors.
    HIV medicine, 2004, Volume: 5, Issue:2

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Huma

2004
Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.
    Journal of acquired immune deficiency syndromes (1999), 2004, Apr-15, Volume: 35, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Diseases

2004
Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.
    Journal of acquired immune deficiency syndromes (1999), 2004, Apr-15, Volume: 35, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Diseases

2004
Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects.
    AIDS (London, England), 2004, Mar-05, Volume: 18, Issue:4

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; H

2004
Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects.
    AIDS (London, England), 2004, Mar-05, Volume: 18, Issue:4

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; H

2004
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
    AIDS (London, England), 2004, Feb-20, Volume: 18, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2004
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
    AIDS (London, England), 2004, Feb-20, Volume: 18, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    Lancet (London, England), 2004, Apr-17, Volume: 363, Issue:9417

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug The

2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    Lancet (London, England), 2004, Apr-17, Volume: 363, Issue:9417

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug The

2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    Lancet (London, England), 2004, Apr-17, Volume: 363, Issue:9417

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug The

2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    Lancet (London, England), 2004, Apr-17, Volume: 363, Issue:9417

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug The

2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    Lancet (London, England), 2004, Apr-17, Volume: 363, Issue:9417

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug The

2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    Lancet (London, England), 2004, Apr-17, Volume: 363, Issue:9417

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug The

2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    Lancet (London, England), 2004, Apr-17, Volume: 363, Issue:9417

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug The

2004
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    Lancet (London, England), 2004, Apr-17, Volume: 363, Issue:9417

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug The

2004
Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Apr-15, Volume: 38, Issue:8

    Topics: Adult; Anti-HIV Agents; Cetirizine; Double-Blind Method; Exanthema; Female; Histamine H1 Antagonists

2004
Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Apr-15, Volume: 38, Issue:8

    Topics: Adult; Anti-HIV Agents; Cetirizine; Double-Blind Method; Exanthema; Female; Histamine H1 Antagonists

2004
A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts.
    The Journal of antimicrobial chemotherapy, 2004, Volume: 54, Issue:2

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cycloprop

2004
A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts.
    The Journal of antimicrobial chemotherapy, 2004, Volume: 54, Issue:2

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cycloprop

2004
Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.
    Journal of acquired immune deficiency syndromes (1999), 2004, Jul-01, Volume: 36, Issue:3

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Inf

2004
Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.
    Journal of acquired immune deficiency syndromes (1999), 2004, Jul-01, Volume: 36, Issue:3

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Inf

2004
Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.
    AIDS research and human retroviruses, 2004, Volume: 20, Issue:6

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections;

2004
Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.
    AIDS research and human retroviruses, 2004, Volume: 20, Issue:6

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections;

2004
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.
    AIDS research and human retroviruses, 2004, Volume: 20, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Blood Glucose; Body Composition; Bone Density; C-Peptide; Cy

2004
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.
    AIDS research and human retroviruses, 2004, Volume: 20, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Blood Glucose; Body Composition; Bone Density; C-Peptide; Cy

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial.
    JAMA, 2004, Jul-14, Volume: 292, Issue:2

    Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Delivery, Obstetric; Drug Therapy, Combination; Female;

2004
Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial.
    JAMA, 2004, Jul-14, Volume: 292, Issue:2

    Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Delivery, Obstetric; Drug Therapy, Combination; Female;

2004
Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
    Antiviral therapy, 2004, Volume: 9, Issue:3

    Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Chemical and Drug Induced Live

2004
Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
    Antiviral therapy, 2004, Volume: 9, Issue:3

    Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Chemical and Drug Induced Live

2004
Follow-up measurements of Nevirapine plasma levels over a prolonged period.
    European journal of medical research, 2004, Aug-31, Volume: 9, Issue:8

    Topics: Anti-HIV Agents; Body Weight; Drug Monitoring; Female; Follow-Up Studies; HIV; HIV Infections; Human

2004
Follow-up measurements of Nevirapine plasma levels over a prolonged period.
    European journal of medical research, 2004, Aug-31, Volume: 9, Issue:8

    Topics: Anti-HIV Agents; Body Weight; Drug Monitoring; Female; Follow-Up Studies; HIV; HIV Infections; Human

2004
Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study.
    Journal of acquired immune deficiency syndromes (1999), 2004, Oct-01, Volume: 37, Issue:2

    Topics: Cetirizine; Double-Blind Method; Exanthema; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged

2004
Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study.
    Journal of acquired immune deficiency syndromes (1999), 2004, Oct-01, Volume: 37, Issue:2

    Topics: Cetirizine; Double-Blind Method; Exanthema; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged

2004
Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Oct-01, Volume: 39, Issue:7

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; H

2004
Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Oct-01, Volume: 39, Issue:7

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; H

2004
Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients.
    Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:11

    Topics: Adult; Aged; Analgesics, Opioid; Anti-HIV Agents; Area Under Curve; Dose-Response Relationship, Drug

2004
Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients.
    Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:11

    Topics: Adult; Aged; Analgesics, Opioid; Anti-HIV Agents; Area Under Curve; Dose-Response Relationship, Drug

2004
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
    PLoS medicine, 2004, Volume: 1, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol, HDL; Cyclopropanes; Female; HIV Infectio

2004
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
    PLoS medicine, 2004, Volume: 1, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol, HDL; Cyclopropanes; Female; HIV Infectio

2004
Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz.
    Antiviral therapy, 2004, Volume: 9, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV

2004
Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz.
    Antiviral therapy, 2004, Volume: 9, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV

2004
Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India.
    Journal of acquired immune deficiency syndromes (1999), 2004, Dec-15, Volume: 37, Issue:5

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Generic; Fem

2004
Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India.
    Journal of acquired immune deficiency syndromes (1999), 2004, Dec-15, Volume: 37, Issue:5

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Generic; Fem

2004
Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2005, Jan-01, Volume: 38, Issue:1

    Topics: Adult; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Base Sequence; Benzoxazines; Cyclopropanes

2005
Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2005, Jan-01, Volume: 38, Issue:1

    Topics: Adult; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Base Sequence; Benzoxazines; Cyclopropanes

2005
Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).
    Journal of acquired immune deficiency syndromes (1999), 2005, Jan-01, Volume: 38, Issue:1

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol, HDL; Cholesterol, LDL; D

2005
Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).
    Journal of acquired immune deficiency syndromes (1999), 2005, Jan-01, Volume: 38, Issue:1

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol, HDL; Cholesterol, LDL; D

2005
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.
    The Journal of infectious diseases, 2005, Mar-15, Volume: 191, Issue:6

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Drug Therapy, Combination

2005
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.
    The Journal of infectious diseases, 2005, Mar-15, Volume: 191, Issue:6

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Drug Therapy, Combination

2005
Haematological changes in African children who received short-term prophylaxis with nevirapine and zidovudine at birth.
    Annals of tropical paediatrics, 2004, Volume: 24, Issue:4

    Topics: Agranulocytosis; Anemia; Anti-HIV Agents; Blood Cell Count; Drug Therapy, Combination; Female; Hemat

2004
Haematological changes in African children who received short-term prophylaxis with nevirapine and zidovudine at birth.
    Annals of tropical paediatrics, 2004, Volume: 24, Issue:4

    Topics: Agranulocytosis; Anemia; Anti-HIV Agents; Blood Cell Count; Drug Therapy, Combination; Female; Hemat

2004
[Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2005, Volume: 56, Issue:9

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Comorbidity; Cyclopropanes; Exanthema; Female; Germany; HIV

2005
[Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2005, Volume: 56, Issue:9

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Comorbidity; Cyclopropanes; Exanthema; Female; Germany; HIV

2005
Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081).
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans

2005
Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081).
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans

2005
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission,

2005
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission,

2005
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission,

2005
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission,

2005
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission,

2005
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission,

2005
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission,

2005
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission,

2005
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV

2005
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV

2005
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
    Antiviral therapy, 2005, Volume: 10, Issue:1

    Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzox

2005
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
    Antiviral therapy, 2005, Volume: 10, Issue:1

    Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzox

2005
A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients.
    European journal of clinical pharmacology, 2005, Volume: 61, Issue:2

    Topics: Adult; Anti-HIV Agents; Bayes Theorem; Drug Interactions; Female; HIV Infections; Humans; Lopinavir;

2005
A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients.
    European journal of clinical pharmacology, 2005, Volume: 61, Issue:2

    Topics: Adult; Anti-HIV Agents; Bayes Theorem; Drug Interactions; Female; HIV Infections; Humans; Lopinavir;

2005
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
    AIDS (London, England), 2005, Mar-25, Volume: 19, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2005
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
    AIDS (London, England), 2005, Mar-25, Volume: 19, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2005
Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
    Antiviral therapy, 2005, Volume: 10, Issue:2

    Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance, Viral; Drug

2005
Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
    Antiviral therapy, 2005, Volume: 10, Issue:2

    Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance, Viral; Drug

2005
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
    AIDS (London, England), 2005, Jun-10, Volume: 19, Issue:9

    Topics: Adult; Alkynes; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines;

2005
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
    AIDS (London, England), 2005, Jun-10, Volume: 19, Issue:9

    Topics: Adult; Alkynes; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines;

2005
Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study.
    Journal of acquired immune deficiency syndromes (1999), 2005, Jun-01, Volume: 39, Issue:2

    Topics: Adult; Aged; Anti-HIV Agents; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies;

2005
Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study.
    Journal of acquired immune deficiency syndromes (1999), 2005, Jun-01, Volume: 39, Issue:2

    Topics: Adult; Aged; Anti-HIV Agents; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies;

2005
The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
    The Southeast Asian journal of tropical medicine and public health, 2005, Volume: 36, Issue:2

    Topics: Adolescent; Adult; Age Factors; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antire

2005
The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
    The Southeast Asian journal of tropical medicine and public health, 2005, Volume: 36, Issue:2

    Topics: Adolescent; Adult; Age Factors; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antire

2005
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.
    AIDS (London, England), 2005, Jul-01, Volume: 19, Issue:10

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bezafibrate; C

2005
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.
    AIDS (London, England), 2005, Jul-01, Volume: 19, Issue:10

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bezafibrate; C

2005
Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort).
    International journal of STD & AIDS, 2005, Volume: 16, Issue:6

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Huma

2005
Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort).
    International journal of STD & AIDS, 2005, Volume: 16, Issue:6

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Huma

2005
Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.
    Journal of acquired immune deficiency syndromes (1999), 2005, Jul-01, Volume: 39, Issue:3

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resista

2005
Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.
    Journal of acquired immune deficiency syndromes (1999), 2005, Jul-01, Volume: 39, Issue:3

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resista

2005
Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Antiviral therapy, 1999, Volume: 4 Suppl 3

    Topics: Adult; Anthropometry; Anti-HIV Agents; Body Size; Drug Administration Schedule; Drug Therapy, Combin

1999
Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Antiviral therapy, 1999, Volume: 4 Suppl 3

    Topics: Adult; Anthropometry; Anti-HIV Agents; Body Size; Drug Administration Schedule; Drug Therapy, Combin

1999
Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Antiviral therapy, 1999, Volume: 4 Suppl 3

    Topics: Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections

1999
Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Antiviral therapy, 1999, Volume: 4 Suppl 3

    Topics: Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections

1999
A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers.
    AIDS (London, England), 2005, Aug-12, Volume: 19, Issue:12

    Topics: Anti-HIV Agents; Bottle Feeding; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Infa

2005
A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers.
    AIDS (London, England), 2005, Aug-12, Volume: 19, Issue:12

    Topics: Anti-HIV Agents; Bottle Feeding; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Infa

2005
Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals.
    Clinical pharmacology and therapeutics, 2005, Volume: 78, Issue:2

    Topics: Adult; Anti-HIV Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Female; HIV

2005
Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals.
    Clinical pharmacology and therapeutics, 2005, Volume: 78, Issue:2

    Topics: Adult; Anti-HIV Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Female; HIV

2005
Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment.
    The Journal of infectious diseases, 2005, Sep-01, Volume: 192, Issue:5

    Topics: Adult; Anti-HIV Agents; Botswana; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Inf

2005
Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment.
    The Journal of infectious diseases, 2005, Sep-01, Volume: 192, Issue:5

    Topics: Adult; Anti-HIV Agents; Botswana; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Inf

2005
Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
    AIDS (London, England), 2005, Sep-02, Volume: 19, Issue:13

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopro

2005
Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
    AIDS (London, England), 2005, Sep-02, Volume: 19, Issue:13

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopro

2005
Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine.
    AIDS (London, England), 2005, Sep-02, Volume: 19, Issue:13

    Topics: Adult; Anti-HIV Agents; DNA, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant

2005
Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine.
    AIDS (London, England), 2005, Sep-02, Volume: 19, Issue:13

    Topics: Adult; Anti-HIV Agents; DNA, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant

2005
Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.
    Journal of acquired immune deficiency syndromes (1999), 2005, Sep-01, Volume: 40, Issue:1

    Topics: Academies and Institutes; Administration, Oral; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort

2005
Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.
    Journal of acquired immune deficiency syndromes (1999), 2005, Sep-01, Volume: 40, Issue:1

    Topics: Academies and Institutes; Administration, Oral; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort

2005
Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine.
    The Journal of infectious diseases, 2005, Oct-01, Volume: 192, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infectious Disease T

2005
Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine.
    The Journal of infectious diseases, 2005, Oct-01, Volume: 192, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infectious Disease T

2005
Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Antiviral therapy, 2005, Volume: 10, Issue:5

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Resista

2005
Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Antiviral therapy, 2005, Volume: 10, Issue:5

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Resista

2005
A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    HIV medicine, 2005, Volume: 6, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; Follow-

2005
A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    HIV medicine, 2005, Volume: 6, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; Follow-

2005
Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
    The Pediatric infectious disease journal, 2005, Volume: 24, Issue:10

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool;

2005
Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
    The Pediatric infectious disease journal, 2005, Volume: 24, Issue:10

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool;

2005
Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024.
    AIDS (London, England), 2005, Nov-04, Volume: 19, Issue:16

    Topics: Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; Humans;

2005
Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024.
    AIDS (London, England), 2005, Nov-04, Volume: 19, Issue:16

    Topics: Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; Humans;

2005
Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns.
    AIDS (London, England), 2005, Dec-02, Volume: 19, Issue:18

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newb

2005
Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns.
    AIDS (London, England), 2005, Dec-02, Volume: 19, Issue:18

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newb

2005
Reduction of mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso.
    Journal of medical virology, 2006, Volume: 78, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Burkina Faso; Drug Administratio

2006
Reduction of mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso.
    Journal of medical virology, 2006, Volume: 78, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Burkina Faso; Drug Administratio

2006
Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-1 transmission.
    American journal of obstetrics and gynecology, 2006, Volume: 194, Issue:1

    Topics: Acute Disease; Adult; Anti-HIV Agents; Chorioamnionitis; Chronic Disease; Female; Fetal Blood; HIV I

2006
Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-1 transmission.
    American journal of obstetrics and gynecology, 2006, Volume: 194, Issue:1

    Topics: Acute Disease; Adult; Anti-HIV Agents; Chorioamnionitis; Chronic Disease; Female; Fetal Blood; HIV I

2006
A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India.
    Journal of acquired immune deficiency syndromes (1999), 2006, Feb-01, Volume: 41, Issue:2

    Topics: Administration, Oral; Adult; Anti-HIV Agents; Cohort Studies; Confidence Intervals; Cross-Over Studi

2006
A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India.
    Journal of acquired immune deficiency syndromes (1999), 2006, Feb-01, Volume: 41, Issue:2

    Topics: Administration, Oral; Adult; Anti-HIV Agents; Cohort Studies; Confidence Intervals; Cross-Over Studi

2006
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.
    HIV medicine, 2006, Volume: 7, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or African American; CD4 Lymphocyte Co

2006
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.
    HIV medicine, 2006, Volume: 7, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or African American; CD4 Lymphocyte Co

2006
Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission.
    AIDS (London, England), 2006, Jan-09, Volume: 20, Issue:2

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Female; Fetal Blood; HIV Infections; HIV-1; Hu

2006
Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission.
    AIDS (London, England), 2006, Jan-09, Volume: 20, Issue:2

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Female; Fetal Blood; HIV Infections; HIV-1; Hu

2006
Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:1

    Topics: Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV-1; Humans; Infant; Infant, Newborn

2006
Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:1

    Topics: Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV-1; Humans; Infant; Infant, Newborn

2006
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.
    AIDS (London, England), 2006, Jun-12, Volume: 20, Issue:9

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Botswana; Drug Administration

2006
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.
    AIDS (London, England), 2006, Jun-12, Volume: 20, Issue:9

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Botswana; Drug Administration

2006
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.
    AIDS (London, England), 2006, Jun-12, Volume: 20, Issue:9

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Botswana; Drug Administration

2006
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.
    AIDS (London, England), 2006, Jun-12, Volume: 20, Issue:9

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Botswana; Drug Administration

2006
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.
    AIDS (London, England), 2006, Jun-12, Volume: 20, Issue:9

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Botswana; Drug Administration

2006
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.
    AIDS (London, England), 2006, Jun-12, Volume: 20, Issue:9

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Botswana; Drug Administration

2006
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.
    AIDS (London, England), 2006, Jun-12, Volume: 20, Issue:9

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Botswana; Drug Administration

2006
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.
    AIDS (London, England), 2006, Jun-12, Volume: 20, Issue:9

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Botswana; Drug Administration

2006
The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients.
    HIV medicine, 2006, Volume: 7, Issue:6

    Topics: Adult; Anti-HIV Agents; Body Weight; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Lamivudin

2006
The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients.
    HIV medicine, 2006, Volume: 7, Issue:6

    Topics: Adult; Anti-HIV Agents; Body Weight; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Lamivudin

2006
Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.
    JAMA, 2006, Aug-16, Volume: 296, Issue:7

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Botswana; Breast Feeding; Disease-Free Survi

2006
Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.
    JAMA, 2006, Aug-16, Volume: 296, Issue:7

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Botswana; Breast Feeding; Disease-Free Survi

2006
Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    HIV medicine, 2006, Volume: 7, Issue:7

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Female; Fo

2006
Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    HIV medicine, 2006, Volume: 7, Issue:7

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Female; Fo

2006
Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:9

    Topics: Adult; Anti-HIV Agents; Carbamates; Drug Interactions; Female; Furans; HIV; HIV Infections; HIV Prot

2006
Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:9

    Topics: Adult; Anti-HIV Agents; Carbamates; Drug Interactions; Female; Furans; HIV; HIV Infections; HIV Prot

2006
Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults.
    The Journal of antimicrobial chemotherapy, 2007, Volume: 59, Issue:1

    Topics: Adult; Age Factors; Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Drugs, Gene

2007
Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults.
    The Journal of antimicrobial chemotherapy, 2007, Volume: 59, Issue:1

    Topics: Adult; Age Factors; Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Drugs, Gene

2007
Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database.
    Journal of acquired immune deficiency syndromes (1999), 2006, Dec-01, Volume: 43, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Ind

2006
Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database.
    Journal of acquired immune deficiency syndromes (1999), 2006, Dec-01, Volume: 43, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Ind

2006
Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2006, Volume: 89, Issue:9

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Combinatio

2006
Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2006, Volume: 89, Issue:9

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Combinatio

2006
A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jan-01, Volume: 44, Issue:1

    Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-

2007
A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jan-01, Volume: 44, Issue:1

    Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-

2007
Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program.
    Journal of acquired immune deficiency syndromes (1999), 2007, Mar-01, Volume: 44, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infectio

2007
Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program.
    Journal of acquired immune deficiency syndromes (1999), 2007, Mar-01, Volume: 44, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infectio

2007
Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
    AIDS (London, England), 2007, Jan-02, Volume: 21, Issue:1

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lymphocyte Coun

2007
Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
    AIDS (London, England), 2007, Jan-02, Volume: 21, Issue:1

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lymphocyte Coun

2007
Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:3

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Human

2007
Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:3

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Human

2007
Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions.
    Clinical pharmacology and therapeutics, 2007, Volume: 81, Issue:2

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Area Under Curve; Benzoxazines; CD4 Lymphocyt

2007
Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions.
    Clinical pharmacology and therapeutics, 2007, Volume: 81, Issue:2

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Area Under Curve; Benzoxazines; CD4 Lymphocyt

2007
Intrapartum transmission after mucosal exposure to HIV was not observed with single-dose nevirapine for mother and child.
    Journal of acquired immune deficiency syndromes (1999), 2007, Apr-15, Volume: 44, Issue:5

    Topics: Adult; Anti-HIV Agents; Cervix Uteri; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn

2007
Intrapartum transmission after mucosal exposure to HIV was not observed with single-dose nevirapine for mother and child.
    Journal of acquired immune deficiency syndromes (1999), 2007, Apr-15, Volume: 44, Issue:5

    Topics: Adult; Anti-HIV Agents; Cervix Uteri; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn

2007
Response to antiretroviral therapy after a single, peripartum dose of nevirapine.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Anti-Retroviral Agents; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combinatio

2007
Response to antiretroviral therapy after a single, peripartum dose of nevirapine.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Anti-Retroviral Agents; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combinatio

2007
Two-year morbidity-mortality and alternatives to prolonged breast-feeding among children born to HIV-infected mothers in Côte d'Ivoire.
    PLoS medicine, 2007, Volume: 4, Issue:1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Cohort Studies; Cote d'Ivoir

2007
Two-year morbidity-mortality and alternatives to prolonged breast-feeding among children born to HIV-infected mothers in Côte d'Ivoire.
    PLoS medicine, 2007, Volume: 4, Issue:1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Cohort Studies; Cote d'Ivoir

2007
Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.
    AIDS (London, England), 2007, Jan-30, Volume: 21, Issue:3

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Dis

2007
Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.
    AIDS (London, England), 2007, Jan-30, Volume: 21, Issue:3

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Dis

2007
Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
    Journal of acquired immune deficiency syndromes (1999), 2007, Apr-01, Volume: 44, Issue:4

    Topics: Adult; Alanine Transaminase; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asparta

2007
Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
    Journal of acquired immune deficiency syndromes (1999), 2007, Apr-01, Volume: 44, Issue:4

    Topics: Adult; Alanine Transaminase; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asparta

2007
Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission.
    The Journal of infectious diseases, 2007, Mar-01, Volume: 195, Issue:5

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV

2007
Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission.
    The Journal of infectious diseases, 2007, Mar-01, Volume: 195, Issue:5

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV

2007
Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection.
    Therapeutic drug monitoring, 2007, Volume: 29, Issue:1

    Topics: Anti-HIV Agents; Child; Data Interpretation, Statistical; Drug Monitoring; Female; HIV Infections; H

2007
Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection.
    Therapeutic drug monitoring, 2007, Volume: 29, Issue:1

    Topics: Anti-HIV Agents; Child; Data Interpretation, Statistical; Drug Monitoring; Female; HIV Infections; H

2007
Safety of nevirapine in pregnancy.
    HIV medicine, 2007, Volume: 8, Issue:1

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Exanthema

2007
Safety of nevirapine in pregnancy.
    HIV medicine, 2007, Volume: 8, Issue:1

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Exanthema

2007
Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2007, Volume: 90, Issue:2

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infections; HIV-

2007
Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2007, Volume: 90, Issue:2

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infections; HIV-

2007
Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire.
    Journal of acquired immune deficiency syndromes (1999), 2007, Jun-01, Volume: 45, Issue:2

    Topics: Adult; Anti-HIV Agents; Cote d'Ivoire; Drug Administration Schedule; Female; HIV Infections; Humans;

2007
Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire.
    Journal of acquired immune deficiency syndromes (1999), 2007, Jun-01, Volume: 45, Issue:2

    Topics: Adult; Anti-HIV Agents; Cote d'Ivoire; Drug Administration Schedule; Female; HIV Infections; Humans;

2007
A virological benefit from an induction/maintenance strategy: the Forte trial.
    Antiviral therapy, 2007, Volume: 12, Issue:1

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Disease Progression;

2007
A virological benefit from an induction/maintenance strategy: the Forte trial.
    Antiviral therapy, 2007, Volume: 12, Issue:1

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Disease Progression;

2007
Late postnatal transmission of HIV-1 and associated factors.
    The Journal of infectious diseases, 2007, Jul-01, Volume: 196, Issue:1

    Topics: Breast Feeding; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Incidence; Infant; Infant,

2007
Late postnatal transmission of HIV-1 and associated factors.
    The Journal of infectious diseases, 2007, Jul-01, Volume: 196, Issue:1

    Topics: Breast Feeding; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Incidence; Infant; Infant,

2007
Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy.
    The Journal of infectious diseases, 2007, Jul-01, Volume: 196, Issue:1

    Topics: Adult; Africa; Anti-HIV Agents; Apolipoproteins; Blood Chemical Analysis; Breast Feeding; Cholestero

2007
Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy.
    The Journal of infectious diseases, 2007, Jul-01, Volume: 196, Issue:1

    Topics: Adult; Africa; Anti-HIV Agents; Apolipoproteins; Blood Chemical Analysis; Breast Feeding; Cholestero

2007
High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis.
    AIDS (London, England), 2007, Jun-19, Volume: 21, Issue:10

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Thera

2007
High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis.
    AIDS (London, England), 2007, Jun-19, Volume: 21, Issue:10

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Thera

2007
Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jul-15, Volume: 45, Issue:2

    Topics: Alkynes; Benzoxazines; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Cyclopropanes; Dose-R

2007
Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jul-15, Volume: 45, Issue:2

    Topics: Alkynes; Benzoxazines; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Cyclopropanes; Dose-R

2007
Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.
    Antiviral therapy, 2007, Volume: 12, Issue:3

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Argentina; CD

2007
Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.
    Antiviral therapy, 2007, Volume: 12, Issue:3

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Argentina; CD

2007
HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:6

    Topics: Africa; Anti-HIV Agents; Black People; DNA Mutational Analysis; Drug Administration Schedule; Drug R

2007
HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:6

    Topics: Africa; Anti-HIV Agents; Black People; DNA Mutational Analysis; Drug Administration Schedule; Drug R

2007
Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV infection: a preliminary report.
    Indian pediatrics, 2007, Volume: 44, Issue:7

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Combinations; Follow-Up Studies

2007
Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV infection: a preliminary report.
    Indian pediatrics, 2007, Volume: 44, Issue:7

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Combinations; Follow-Up Studies

2007
Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting.
    Journal of acquired immune deficiency syndromes (1999), 2007, Aug-15, Volume: 45, Issue:5

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical

2007
Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting.
    Journal of acquired immune deficiency syndromes (1999), 2007, Aug-15, Volume: 45, Issue:5

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical

2007
Data shows long-term nevirapine efficacy and increases in good cholesterol.
    AIDS patient care and STDs, 2007, Volume: 21, Issue:8

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cholesterol, HDL; Cyclopropanes; Drug

2007
Data shows long-term nevirapine efficacy and increases in good cholesterol.
    AIDS patient care and STDs, 2007, Volume: 21, Issue:8

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cholesterol, HDL; Cyclopropanes; Drug

2007
Pathology of placenta in HIV infection.
    Indian journal of pathology & microbiology, 2007, Volume: 50, Issue:3

    Topics: Anti-HIV Agents; Chorioamnionitis; Female; Fetal Death; HIV Infections; Humans; Hyperplasia; Infant,

2007
Pathology of placenta in HIV infection.
    Indian journal of pathology & microbiology, 2007, Volume: 50, Issue:3

    Topics: Anti-HIV Agents; Chorioamnionitis; Female; Fetal Death; HIV Infections; Humans; Hyperplasia; Infant,

2007
Mother-to-child transmission of HIV among women who chose not to exclusively breastfeed their infants in Pune, India.
    The Indian journal of medical research, 2007, Volume: 126, Issue:2

    Topics: Adult; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Cohort Studies; Drug Administration Schedule

2007
Mother-to-child transmission of HIV among women who chose not to exclusively breastfeed their infants in Pune, India.
    The Indian journal of medical research, 2007, Volume: 126, Issue:2

    Topics: Adult; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Cohort Studies; Drug Administration Schedule

2007
Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products.
    Journal of clinical pharmacology, 2007, Volume: 47, Issue:11

    Topics: Adolescent; Adult; Cross-Sectional Studies; Drug Combinations; Drug Therapy, Combination; Female; HI

2007
Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products.
    Journal of clinical pharmacology, 2007, Volume: 47, Issue:11

    Topics: Adolescent; Adult; Cross-Sectional Studies; Drug Combinations; Drug Therapy, Combination; Female; HI

2007
Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.
    Lancet (London, England), 2007, Nov-17, Volume: 370, Issue:9600

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV

2007
Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.
    Lancet (London, England), 2007, Nov-17, Volume: 370, Issue:9600

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV

2007
Independent effects of nevirapine prophylaxis and HIV-1 RNA suppression in breast milk on early perinatal HIV-1 transmission.
    Journal of acquired immune deficiency syndromes (1999), 2007, Dec-01, Volume: 46, Issue:4

    Topics: Adult; Anti-HIV Agents; DNA, Viral; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transm

2007
Independent effects of nevirapine prophylaxis and HIV-1 RNA suppression in breast milk on early perinatal HIV-1 transmission.
    Journal of acquired immune deficiency syndromes (1999), 2007, Dec-01, Volume: 46, Issue:4

    Topics: Adult; Anti-HIV Agents; DNA, Viral; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transm

2007
Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study.
    AIDS (London, England), 2007, Oct-18, Volume: 21, Issue:16

    Topics: Adult; Aged; Drug Administration Schedule; HIV Infections; HIV-1; Humans; Linear Models; Logistic Mo

2007
Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study.
    AIDS (London, England), 2007, Oct-18, Volume: 21, Issue:16

    Topics: Adult; Aged; Drug Administration Schedule; HIV Infections; HIV-1; Humans; Linear Models; Logistic Mo

2007
High uptake of exclusive breastfeeding and reduced early post-natal HIV transmission.
    PloS one, 2007, Dec-26, Volume: 2, Issue:12

    Topics: Breast Feeding; Female; HIV Infections; Humans; Infant; Infant Food; Infant, Newborn; Infectious Dis

2007
High uptake of exclusive breastfeeding and reduced early post-natal HIV transmission.
    PloS one, 2007, Dec-26, Volume: 2, Issue:12

    Topics: Breast Feeding; Female; HIV Infections; Humans; Infant; Infant Food; Infant, Newborn; Infectious Dis

2007
Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093.
    Contraception, 2008, Volume: 77, Issue:2

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2008
Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093.
    Contraception, 2008, Volume: 77, Issue:2

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2008
[Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Zhonghua yi xue za zhi, 2007, Nov-13, Volume: 87, Issue:42

    Topics: Acquired Immunodeficiency Syndrome; Adult; Amylases; Anti-HIV Agents; Antiretroviral Therapy, Highly

2007
[Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Zhonghua yi xue za zhi, 2007, Nov-13, Volume: 87, Issue:42

    Topics: Acquired Immunodeficiency Syndrome; Adult; Amylases; Anti-HIV Agents; Antiretroviral Therapy, Highly

2007
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Mar-15, Volume: 46, Issue:6

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cohort Studies

2008
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Mar-15, Volume: 46, Issue:6

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cohort Studies

2008
Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).
    Tropical medicine & international health : TM & IH, 2008, Volume: 13, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Com

2008
Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).
    Tropical medicine & international health : TM & IH, 2008, Volume: 13, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Com

2008
Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.
    AIDS (London, England), 2008, Mar-12, Volume: 22, Issue:5

    Topics: Adolescent; Antiretroviral Therapy, Highly Active; Area Under Curve; Body Weight; Child; Child, Pres

2008
Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.
    AIDS (London, England), 2008, Mar-12, Volume: 22, Issue:5

    Topics: Adolescent; Antiretroviral Therapy, Highly Active; Area Under Curve; Body Weight; Child; Child, Pres

2008
Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:3

    Topics: Adult; Anemia; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combin

2008
Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:3

    Topics: Adult; Anemia; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combin

2008
Trial studies extended release Viramune.
    AIDS patient care and STDs, 2008, Volume: 22, Issue:3

    Topics: Anti-HIV Agents; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; HIV

2008
Trial studies extended release Viramune.
    AIDS patient care and STDs, 2008, Volume: 22, Issue:3

    Topics: Anti-HIV Agents; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; HIV

2008
Temporal and lateral dynamics of HIV shedding and elevated sodium in breast milk among HIV-positive mothers during the first 4 months of breast-feeding.
    Journal of acquired immune deficiency syndromes (1999), 2008, Mar-01, Volume: 47, Issue:3

    Topics: Breast Feeding; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn

2008
Temporal and lateral dynamics of HIV shedding and elevated sodium in breast milk among HIV-positive mothers during the first 4 months of breast-feeding.
    Journal of acquired immune deficiency syndromes (1999), 2008, Mar-01, Volume: 47, Issue:3

    Topics: Breast Feeding; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn

2008
Nevirapine concentrations in newborns receiving an extended prophylactic regimen.
    Journal of acquired immune deficiency syndromes (1999), 2008, Mar-01, Volume: 47, Issue:3

    Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; HIV

2008
Nevirapine concentrations in newborns receiving an extended prophylactic regimen.
    Journal of acquired immune deficiency syndromes (1999), 2008, Mar-01, Volume: 47, Issue:3

    Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; HIV

2008
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, May-15, Volume: 46, Issue:10

    Topics: Adolescent; Alkynes; Benzoxazines; CD4 Lymphocyte Count; CD4-CD8 Ratio; Child; Child, Preschool; Cyc

2008
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, May-15, Volume: 46, Issue:10

    Topics: Adolescent; Alkynes; Benzoxazines; CD4 Lymphocyte Count; CD4-CD8 Ratio; Child; Child, Preschool; Cyc

2008
Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Apr-01, Volume: 46, Issue:7

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination;

2008
Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Apr-01, Volume: 46, Issue:7

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination;

2008
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1995, Feb-01, Volume: 8, Issue:2

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combi

1995
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1995, Feb-01, Volume: 8, Issue:2

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combi

1995
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1995, Feb-01, Volume: 8, Issue:2

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combi

1995
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1995, Feb-01, Volume: 8, Issue:2

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combi

1995
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1995, Feb-01, Volume: 8, Issue:2

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combi

1995
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1995, Feb-01, Volume: 8, Issue:2

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combi

1995
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1995, Feb-01, Volume: 8, Issue:2

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combi

1995
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1995, Feb-01, Volume: 8, Issue:2

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combi

1995
High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection.
    The Journal of infectious diseases, 1995, Volume: 171, Issue:3

    Topics: Adult; Antiviral Agents; HIV Core Protein p24; HIV Infections; Humans; Middle Aged; Nevirapine; Pyri

1995
High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection.
    The Journal of infectious diseases, 1995, Volume: 171, Issue:3

    Topics: Adult; Antiviral Agents; HIV Core Protein p24; HIV Infections; Humans; Middle Aged; Nevirapine; Pyri

1995
Resistance, drug failure, and disease progression.
    AIDS research and human retroviruses, 1994, Volume: 10, Issue:8

    Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; H

1994
Resistance, drug failure, and disease progression.
    AIDS research and human retroviruses, 1994, Volume: 10, Issue:8

    Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; H

1994
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protoco
    Annals of internal medicine, 1996, Jun-15, Volume: 124, Issue:12

    Topics: Adult; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Com

1996
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protoco
    Annals of internal medicine, 1996, Jun-15, Volume: 124, Issue:12

    Topics: Adult; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Com

1996
A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.
    AIDS (London, England), 1996, Volume: 10, Issue:6

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Core Protein p24; HIV Infections; HIV

1996
A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.
    AIDS (London, England), 1996, Volume: 10, Issue:6

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Core Protein p24; HIV Infections; HIV

1996
Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
    The New England journal of medicine, 1997, May-08, Volume: 336, Issue:19

    Topics: Administration, Oral; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination;

1997
Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
    The New England journal of medicine, 1997, May-08, Volume: 336, Issue:19

    Topics: Administration, Oral; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination;

1997
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
    JAMA, 1998, Mar-25, Volume: 279, Issue:12

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method;

1998
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
    JAMA, 1998, Mar-25, Volume: 279, Issue:12

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method;

1998
A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy.
    The Journal of infectious diseases, 1998, Volume: 177, Issue:6

    Topics: Anti-HIV Agents; Consumer Product Safety; Drug Therapy, Combination; Female; HIV Infections; HIV Pro

1998
A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy.
    The Journal of infectious diseases, 1998, Volume: 177, Issue:6

    Topics: Anti-HIV Agents; Consumer Product Safety; Drug Therapy, Combination; Female; HIV Infections; HIV Pro

1998
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team.
    The Journal of infectious diseases, 1998, Volume: 178, Issue:2

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; In

1998
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team.
    The Journal of infectious diseases, 1998, Volume: 178, Issue:2

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; In

1998
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.
    AIDS (London, England), 1998, Sep-10, Volume: 12, Issue:13

    Topics: Anti-HIV Agents; Australia; Canada; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Ther

1998
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.
    AIDS (London, England), 1998, Sep-10, Volume: 12, Issue:13

    Topics: Anti-HIV Agents; Australia; Canada; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Ther

1998
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
    Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Didanosine; Double-Blind Met

1999
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
    Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Didanosine; Double-Blind Met

1999
Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
    The Journal of infectious diseases, 1999, Volume: 179, Issue:5

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Drug Interactions;

1999
Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
    The Journal of infectious diseases, 1999, Volume: 179, Issue:5

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Drug Interactions;

1999
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).
    AIDS (London, England), 1999, Mar-11, Volume: 13, Issue:4

    Topics: Anti-HIV Agents; Consumer Product Safety; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Inf

1999
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).
    AIDS (London, England), 1999, Mar-11, Volume: 13, Issue:4

    Topics: Anti-HIV Agents; Consumer Product Safety; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Inf

1999
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
    The Journal of infectious diseases, 1999, Volume: 179, Issue:6

    Topics: Adult; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infect

1999
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
    The Journal of infectious diseases, 1999, Volume: 179, Issue:6

    Topics: Adult; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infect

1999
[Experience with nevirapine taken once daily in 93 HIV-infected patients].
    Pathologie-biologie, 1999, Volume: 47, Issue:5

    Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV Infect

1999
[Experience with nevirapine taken once daily in 93 HIV-infected patients].
    Pathologie-biologie, 1999, Volume: 47, Issue:5

    Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV Infect

1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
    Lancet (London, England), 1999, Sep-04, Volume: 354, Issue:9181

    Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H

1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
    Lancet (London, England), 1999, Sep-04, Volume: 354, Issue:9181

    Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H

1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
    Lancet (London, England), 1999, Sep-04, Volume: 354, Issue:9181

    Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H

1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
    Lancet (London, England), 1999, Sep-04, Volume: 354, Issue:9181

    Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H

1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
    Lancet (London, England), 1999, Sep-04, Volume: 354, Issue:9181

    Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H

1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
    Lancet (London, England), 1999, Sep-04, Volume: 354, Issue:9181

    Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H

1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
    Lancet (London, England), 1999, Sep-04, Volume: 354, Issue:9181

    Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H

1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
    Lancet (London, England), 1999, Sep-04, Volume: 354, Issue:9181

    Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H

1999
Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users.
    Antiviral therapy, 1998, Volume: 3 Suppl 4

    Topics: Adult; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; H

1998
Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users.
    Antiviral therapy, 1998, Volume: 3 Suppl 4

    Topics: Adult; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; H

1998
Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
    Antiviral therapy, 1998, Volume: 3 Suppl 4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Female; HIV Infections; Humans; Male; Nevi

1998
Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
    Antiviral therapy, 1998, Volume: 3 Suppl 4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Female; HIV Infections; Humans; Male; Nevi

1998
dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions.
    Antiviral therapy, 1998, Volume: 3 Suppl 4

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Nelfinavir

1998
dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions.
    Antiviral therapy, 1998, Volume: 3 Suppl 4

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Nelfinavir

1998
[Encouraging study results. HIV from birth on--virostatic drugs can decrease the risk].
    MMW Fortschritte der Medizin, 1999, Aug-26, Volume: 141, Issue:34

    Topics: Anti-HIV Agents; Female; Follow-Up Studies; HIV Infections; Humans; Infant, Newborn; Infectious Dise

1999
[Encouraging study results. HIV from birth on--virostatic drugs can decrease the risk].
    MMW Fortschritte der Medizin, 1999, Aug-26, Volume: 141, Issue:34

    Topics: Anti-HIV Agents; Female; Follow-Up Studies; HIV Infections; Humans; Infant, Newborn; Infectious Dise

1999
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
    Journal of acquired immune deficiency syndromes (1999), 1999, Nov-01, Volume: 22, Issue:3

    Topics: Adult; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Mul

1999
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
    Journal of acquired immune deficiency syndromes (1999), 1999, Nov-01, Volume: 22, Issue:3

    Topics: Adult; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Mul

1999
South Africa's Medicines Control Council contradicts Health Minister.
    Lancet (London, England), 2000, Apr-15, Volume: 355, Issue:9212

    Topics: Adverse Drug Reaction Reporting Systems; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Inf

2000
South Africa's Medicines Control Council contradicts Health Minister.
    Lancet (London, England), 2000, Apr-15, Volume: 355, Issue:9212

    Topics: Adverse Drug Reaction Reporting Systems; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Inf

2000
Nevirapine and perinatal transmission.
    AIDS patient care and STDs, 2000, Volume: 14, Issue:4

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infe

2000
Nevirapine and perinatal transmission.
    AIDS patient care and STDs, 2000, Volume: 14, Issue:4

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infe

2000
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
    The Journal of infectious diseases, 2000, Volume: 181, Issue:5

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response

2000
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
    The Journal of infectious diseases, 2000, Volume: 181, Issue:5

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response

2000
Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.
    AIDS (London, England), 2000, May-05, Volume: 14, Issue:7

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV

2000
Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.
    AIDS (London, England), 2000, May-05, Volume: 14, Issue:7

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV

2000
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
    AIDS (London, England), 2000, May-26, Volume: 14, Issue:8

    Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination;

2000
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
    AIDS (London, England), 2000, May-26, Volume: 14, Issue:8

    Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination;

2000
Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clin
    AIDS research and human retroviruses, 2000, Aug-10, Volume: 16, Issue:12

    Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Ethnicity; Female; HIV Infectio

2000
Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clin
    AIDS research and human retroviruses, 2000, Aug-10, Volume: 16, Issue:12

    Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Ethnicity; Female; HIV Infectio

2000
Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment.
    Antiviral research, 2000, Volume: 47, Issue:3

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combina

2000
Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment.
    Antiviral research, 2000, Volume: 47, Issue:3

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combina

2000
Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids.
    AIDS (London, England), 2000, Sep-29, Volume: 14, Issue:14

    Topics: Anti-HIV Agents; Anti-Inflammatory Agents; Exanthema; HIV Infections; Humans; Nevirapine; Prednisone

2000
Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids.
    AIDS (London, England), 2000, Sep-29, Volume: 14, Issue:14

    Topics: Anti-HIV Agents; Anti-Inflammatory Agents; Exanthema; HIV Infections; Humans; Nevirapine; Prednisone

2000
Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.
    AIDS (London, England), 2000, Nov-10, Volume: 14, Issue:16

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combina

2000
Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.
    AIDS (London, England), 2000, Nov-10, Volume: 14, Issue:16

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combina

2000
Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients.
    AIDS (London, England), 2000, Nov-10, Volume: 14, Issue:16

    Topics: Adult; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infe

2000
Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients.
    AIDS (London, England), 2000, Nov-10, Volume: 14, Issue:16

    Topics: Adult; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infe

2000
The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.
    Antiviral therapy, 2000, Volume: 5, Issue:4

    Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans

2000
The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.
    Antiviral therapy, 2000, Volume: 5, Issue:4

    Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans

2000
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    AIDS research and human retroviruses, 2001, Jan-20, Volume: 17, Issue:2

    Topics: Adult; Aged; Anti-HIV Agents; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combinati

2001
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
    AIDS research and human retroviruses, 2001, Jan-20, Volume: 17, Issue:2

    Topics: Adult; Aged; Anti-HIV Agents; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combinati

2001
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.
    The Journal of infectious diseases, 2001, Mar-01, Volume: 183, Issue:5

    Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Cross-Over Studies; Dose-Response Relation

2001
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.
    The Journal of infectious diseases, 2001, Mar-01, Volume: 183, Issue:5

    Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Cross-Over Studies; Dose-Response Relation

2001
Viramune triple combo reduces viral load below limit of detection.
    AIDS patient care and STDs, 1997, Volume: 11, Issue:6

    Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans

1997
Viramune triple combo reduces viral load below limit of detection.
    AIDS patient care and STDs, 1997, Volume: 11, Issue:6

    Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans

1997
Viramune cleared for use in combination with protease inhibitors.
    AIDS patient care and STDs, 1998, Volume: 12, Issue:11

    Topics: Adult; Anti-HIV Agents; Drug Approval; Drug Therapy, Combination; Female; HIV Infections; HIV Protea

1998
Viramune cleared for use in combination with protease inhibitors.
    AIDS patient care and STDs, 1998, Volume: 12, Issue:11

    Topics: Adult; Anti-HIV Agents; Drug Approval; Drug Therapy, Combination; Female; HIV Infections; HIV Protea

1998
New double vs. triple antiviral combination study, CD4 200-500, no prior treatment.
    AIDS treatment news, 1995, Dec-01, Issue:no 236

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Human

1995
New double vs. triple antiviral combination study, CD4 200-500, no prior treatment.
    AIDS treatment news, 1995, Dec-01, Issue:no 236

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Human

1995
Maintaining a low viral load with Nevirapine?
    TreatmentUpdate, 1998, Volume: 10, Issue:10

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combina

1998
Maintaining a low viral load with Nevirapine?
    TreatmentUpdate, 1998, Volume: 10, Issue:10

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combina

1998
Major advance in protecting newborns: one Nevirapine dose cuts infection in half.
    AIDS treatment news, 1999, Jul-16, Issue:No 323

    Topics: Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Dis

1999
Major advance in protecting newborns: one Nevirapine dose cuts infection in half.
    AIDS treatment news, 1999, Jul-16, Issue:No 323

    Topics: Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Dis

1999
Virus sidesteps convergent therapy.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:1

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Human

1995
Virus sidesteps convergent therapy.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:1

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Human

1995
Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting.
    AIDS (London, England), 2001, Apr-13, Volume: 15, Issue:6

    Topics: Adult; Aged; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine;

2001
Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting.
    AIDS (London, England), 2001, Apr-13, Volume: 15, Issue:6

    Topics: Adult; Aged; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine;

2001
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    The Journal of infectious diseases, 2001, Jun-15, Volume: 183, Issue:12

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cohort

2001
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    The Journal of infectious diseases, 2001, Jun-15, Volume: 183, Issue:12

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cohort

2001
Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2001, Apr-15, Volume: 26, Issue:5

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Follow-Up Studies; HIV Infections; HIV-1; Huma

2001
Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2001, Apr-15, Volume: 26, Issue:5

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Follow-Up Studies; HIV Infections; HIV-1; Huma

2001
Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease.
    International journal of antimicrobial agents, 2001, Volume: 17, Issue:6

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infe

2001
Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease.
    International journal of antimicrobial agents, 2001, Volume: 17, Issue:6

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infe

2001
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    The Journal of infectious diseases, 2001, Jul-01, Volume: 184, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug The

2001
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    The Journal of infectious diseases, 2001, Jul-01, Volume: 184, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug The

2001
The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study.
    Journal of acquired immune deficiency syndromes (1999), 2001, Jun-01, Volume: 27, Issue:2

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV

2001
The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study.
    Journal of acquired immune deficiency syndromes (1999), 2001, Jun-01, Volume: 27, Issue:2

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV

2001
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
    AIDS (London, England), 2001, Jun-15, Volume: 15, Issue:9

    Topics: Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV-1;

2001
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
    AIDS (London, England), 2001, Jun-15, Volume: 15, Issue:9

    Topics: Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV-1;

2001
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
    AIDS (London, England), 2001, Jul-06, Volume: 15, Issue:10

    Topics: Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combinat

2001
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
    AIDS (London, England), 2001, Jul-06, Volume: 15, Issue:10

    Topics: Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combinat

2001
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
    Journal of acquired immune deficiency syndromes (1999), 2001, Jul-01, Volume: 27, Issue:3

    Topics: Adult; Anthropometry; Anti-HIV Agents; Body Composition; CD4 Lymphocyte Count; Cholesterol; Drug The

2001
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
    Journal of acquired immune deficiency syndromes (1999), 2001, Jul-01, Volume: 27, Issue:3

    Topics: Adult; Anthropometry; Anti-HIV Agents; Body Composition; CD4 Lymphocyte Count; Cholesterol; Drug The

2001
Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).
    The Journal of infectious diseases, 2001, Oct-01, Volume: 184, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Microbial; Female; HIV Infections; HIV-1; Humans; Infant; Infectio

2001
Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).
    The Journal of infectious diseases, 2001, Oct-01, Volume: 184, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Microbial; Female; HIV Infections; HIV-1; Humans; Infant; Infectio

2001
Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma.
    Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:10

    Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Indinavir; Male; Nevirapine; Semen

2001
Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma.
    Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:10

    Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Indinavir; Male; Nevirapine; Semen

2001
Spanish study looks at the effect of nevirapine on the liver.
    TreatmentUpdate, 2001, Volume: 13, Issue:3

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; HIV Infections; Humans; Liver; Live

2001
Spanish study looks at the effect of nevirapine on the liver.
    TreatmentUpdate, 2001, Volume: 13, Issue:3

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; HIV Infections; Humans; Liver; Live

2001
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
    AIDS (London, England), 2001, Sep-28, Volume: 15, Issue:14

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Carnitine; Dideox

2001
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
    AIDS (London, England), 2001, Sep-28, Volume: 15, Issue:14

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Carnitine; Dideox

2001
Switching to nevirapine--results after one year.
    TreatmentUpdate, 2001, Volume: 13, Issue:4

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Fema

2001
Switching to nevirapine--results after one year.
    TreatmentUpdate, 2001, Volume: 13, Issue:4

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Fema

2001
Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy.
    The Journal of infectious diseases, 2001, Nov-01, Volume: 184, Issue:9

    Topics: Adipocytes; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apoptosis; Blood Glucose;

2001
Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy.
    The Journal of infectious diseases, 2001, Nov-01, Volume: 184, Issue:9

    Topics: Adipocytes; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apoptosis; Blood Glucose;

2001
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    AIDS (London, England), 2001, Oct-19, Volume: 15, Issue:15

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H

2001
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    AIDS (London, England), 2001, Oct-19, Volume: 15, Issue:15

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H

2001
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    AIDS (London, England), 2001, Oct-19, Volume: 15, Issue:15

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H

2001
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    AIDS (London, England), 2001, Oct-19, Volume: 15, Issue:15

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H

2001
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    AIDS (London, England), 2001, Oct-19, Volume: 15, Issue:15

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H

2001
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    AIDS (London, England), 2001, Oct-19, Volume: 15, Issue:15

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H

2001
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    AIDS (London, England), 2001, Oct-19, Volume: 15, Issue:15

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H

2001
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    AIDS (London, England), 2001, Oct-19, Volume: 15, Issue:15

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H

2001
Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA.
    Journal of acquired immune deficiency syndromes (1999), 2001, Dec-01, Volume: 28, Issue:4

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Drug Therapy, Combin

2001
Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA.
    Journal of acquired immune deficiency syndromes (1999), 2001, Dec-01, Volume: 28, Issue:4

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Drug Therapy, Combin

2001
Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy.
    Journal of acquired immune deficiency syndromes (1999), 2001, Dec-01, Volume: 28, Issue:4

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Therapy, Combinat

2001
Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy.
    Journal of acquired immune deficiency syndromes (1999), 2001, Dec-01, Volume: 28, Issue:4

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Therapy, Combinat

2001
Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda.
    Journal of clinical microbiology, 2001, Volume: 39, Issue:12

    Topics: Anti-HIV Agents; Female; Genotype; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Diseas

2001
Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda.
    Journal of clinical microbiology, 2001, Volume: 39, Issue:12

    Topics: Anti-HIV Agents; Female; Genotype; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Diseas

2001
Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure.
    The Pediatric infectious disease journal, 2001, Volume: 20, Issue:8

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease T

2001
Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure.
    The Pediatric infectious disease journal, 2001, Volume: 20, Issue:8

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease T

2001
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.
    AIDS (London, England), 2001, Dec-07, Volume: 15, Issue:18

    Topics: Adult; Anti-HIV Agents; Coronary Artery Disease; Drug Therapy, Combination; Female; HIV Infections;

2001
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.
    AIDS (London, England), 2001, Dec-07, Volume: 15, Issue:18

    Topics: Adult; Anti-HIV Agents; Coronary Artery Disease; Drug Therapy, Combination; Female; HIV Infections;

2001
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.
    AIDS (London, England), 2001, Dec-07, Volume: 15, Issue:18

    Topics: Adult; Anti-HIV Agents; Anti-Inflammatory Agents; Dideoxynucleosides; Drug Hypersensitivity; Female;

2001
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.
    AIDS (London, England), 2001, Dec-07, Volume: 15, Issue:18

    Topics: Adult; Anti-HIV Agents; Anti-Inflammatory Agents; Dideoxynucleosides; Drug Hypersensitivity; Female;

2001
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.
    AIDS (London, England), 2002, Jan-04, Volume: 16, Issue:1

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Administrat

2002
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.
    AIDS (London, England), 2002, Jan-04, Volume: 16, Issue:1

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Administrat

2002
Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection.
    AAPS pharmSci, 2000, Volume: 2, Issue:1

    Topics: Adult; Age Factors; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Inf

2000
Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection.
    AAPS pharmSci, 2000, Volume: 2, Issue:1

    Topics: Adult; Age Factors; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Inf

2000
Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Feb-15, Volume: 34, Issue:4

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HI

2002
Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Feb-15, Volume: 34, Issue:4

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HI

2002
Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection.
    The Pediatric infectious disease journal, 2002, Volume: 21, Issue:2

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Co

2002
Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection.
    The Pediatric infectious disease journal, 2002, Volume: 21, Issue:2

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Co

2002
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
    The Journal of infectious diseases, 2002, Mar-01, Volume: 185, Issue:5

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female

2002
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
    The Journal of infectious diseases, 2002, Mar-01, Volume: 185, Issue:5

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female

2002
Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Apr-01, Volume: 34, Issue:7

    Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Drug Therapy, Combination; Fem

2002
Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Apr-01, Volume: 34, Issue:7

    Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Drug Therapy, Combination; Fem

2002
Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2002, Apr-01, Volume: 29, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Viral Diseases; Cyclopropanes;

2002
Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2002, Apr-01, Volume: 29, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Viral Diseases; Cyclopropanes;

2002
Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection.
    Journal of acquired immune deficiency syndromes (1999), 2002, Apr-01, Volume: 29, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Inf

2002
Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection.
    Journal of acquired immune deficiency syndromes (1999), 2002, Apr-01, Volume: 29, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Inf

2002
Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants.
    AIDS (London, England), 2002, Apr-12, Volume: 16, Issue:6

    Topics: Alanine Transaminase; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newb

2002
Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants.
    AIDS (London, England), 2002, Apr-12, Volume: 16, Issue:6

    Topics: Alanine Transaminase; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newb

2002
Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women.
    Journal of acquired immune deficiency syndromes (1999), 2002, Apr-15, Volume: 29, Issue:5

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Contraceptives, Oral, Combined; Drug Interactions; Drug Th

2002
Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women.
    Journal of acquired immune deficiency syndromes (1999), 2002, Apr-15, Volume: 29, Issue:5

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Contraceptives, Oral, Combined; Drug Interactions; Drug Th

2002
Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.
    JAMA, 2002, Jul-10, Volume: 288, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cesarean Section; Drug

2002
Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.
    JAMA, 2002, Jul-10, Volume: 288, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cesarean Section; Drug

2002

Other Studies

1437 other studies available for nevirapine and HIV Infections

ArticleYear
Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Bioorganic & medicinal chemistry letters, 2006, Volume: 16, Issue:3

    Topics: Computer-Aided Design; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase;

2006
Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Bioorganic & medicinal chemistry letters, 2006, Volume: 16, Issue:3

    Topics: Computer-Aided Design; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase;

2006
Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Bioorganic & medicinal chemistry letters, 2006, Volume: 16, Issue:3

    Topics: Amines; Drug Resistance, Multiple, Viral; Heterocyclic Compounds; HIV Infections; HIV Reverse Transc

2006
Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Bioorganic & medicinal chemistry letters, 2006, Volume: 16, Issue:3

    Topics: Amines; Drug Resistance, Multiple, Viral; Heterocyclic Compounds; HIV Infections; HIV Reverse Transc

2006
A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2

    Topics: Administration, Oral; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Dog

2007
A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2

    Topics: Administration, Oral; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Dog

2007
1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry letters, 2008, Oct-15, Volume: 18, Issue:20

    Topics: Anti-HIV Agents; Biological Assay; Cell Line; Chemistry, Pharmaceutical; Drug Design; Drug Evaluatio

2008
1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry letters, 2008, Oct-15, Volume: 18, Issue:20

    Topics: Anti-HIV Agents; Biological Assay; Cell Line; Chemistry, Pharmaceutical; Drug Design; Drug Evaluatio

2008
Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action.
    Bioorganic & medicinal chemistry, 2008, Nov-01, Volume: 16, Issue:21

    Topics: Acrylates; Active Transport, Cell Nucleus; Binding Sites; Exportin 1 Protein; HeLa Cells; HIV Infect

2008
Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action.
    Bioorganic & medicinal chemistry, 2008, Nov-01, Volume: 16, Issue:21

    Topics: Acrylates; Active Transport, Cell Nucleus; Binding Sites; Exportin 1 Protein; HeLa Cells; HIV Infect

2008
Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:2

    Topics: Anti-HIV Agents; Cells, Cultured; Cervix Uteri; Dose-Response Relationship, Drug; Female; HIV Infect

2009
Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:2

    Topics: Anti-HIV Agents; Cells, Cultured; Cervix Uteri; Dose-Response Relationship, Drug; Female; HIV Infect

2009
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:5

    Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse

2009
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:5

    Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse

2009
Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:11

    Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Hum

2009
Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:11

    Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Hum

2009
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cells, Cultured; Cyclopropanes; Drug Resistance,

2010
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cells, Cultured; Cyclopropanes; Drug Resistance,

2010
Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:2

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nitriles

2010
Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:2

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nitriles

2010
Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Animals; Anti-HIV Agents; Biological Availability; Brain; Cell Line; Cell Survival; HIV Infections;

2010
Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Animals; Anti-HIV Agents; Biological Availability; Brain; Cell Line; Cell Survival; HIV Infections;

2010
Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:4

    Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Vir

2010
Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:4

    Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Vir

2010
Biomimetic synthesis and anti-HIV activity of dimeric phloroglucinols.
    Bioorganic & medicinal chemistry, 2010, Mar-01, Volume: 18, Issue:5

    Topics: Anti-HIV Agents; Biomimetic Materials; Dimerization; HIV Infections; HIV Reverse Transcriptase; Huma

2010
Biomimetic synthesis and anti-HIV activity of dimeric phloroglucinols.
    Bioorganic & medicinal chemistry, 2010, Mar-01, Volume: 18, Issue:5

    Topics: Anti-HIV Agents; Biomimetic Materials; Dimerization; HIV Infections; HIV Reverse Transcriptase; Huma

2010
Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reve

2010
Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reve

2010
Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Journal of medicinal chemistry, 2010, Jul-08, Volume: 53, Issue:13

    Topics: Aniline Compounds; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Hydrogen Bonding; Magne

2010
Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Journal of medicinal chemistry, 2010, Jul-08, Volume: 53, Issue:13

    Topics: Aniline Compounds; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Hydrogen Bonding; Magne

2010
Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
    Bioorganic & medicinal chemistry, 2010, Jul-15, Volume: 18, Issue:14

    Topics: Anti-HIV Agents; Cell Line; Cell Survival; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans;

2010
Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
    Bioorganic & medicinal chemistry, 2010, Jul-15, Volume: 18, Issue:14

    Topics: Anti-HIV Agents; Cell Line; Cell Survival; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans;

2010
Anti-HIV and antiplasmodial activity of original flavonoid derivatives.
    Bioorganic & medicinal chemistry, 2010, Aug-15, Volume: 18, Issue:16

    Topics: Anti-HIV Agents; Antimalarials; Cell Line; Cell Survival; Flavonoids; HIV; HIV Infections; Humans; M

2010
Anti-HIV and antiplasmodial activity of original flavonoid derivatives.
    Bioorganic & medicinal chemistry, 2010, Aug-15, Volume: 18, Issue:16

    Topics: Anti-HIV Agents; Antimalarials; Cell Line; Cell Survival; Flavonoids; HIV; HIV Infections; Humans; M

2010
Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:1

    Topics: Anti-Bacterial Agents; Anti-HIV Agents; Cell Line; HIV; HIV Infections; HIV Reverse Transcriptase; I

2011
Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:1

    Topics: Anti-Bacterial Agents; Anti-HIV Agents; Cell Line; HIV; HIV Infections; HIV Reverse Transcriptase; I

2011
Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyl-oxopyrimidines (S-DACOs) as high active anti-HIV agents.
    Bioorganic & medicinal chemistry letters, 2011, Jan-15, Volume: 21, Issue:2

    Topics: Anti-HIV Agents; Cell Line; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Nevirapine; Pyri

2011
Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyl-oxopyrimidines (S-DACOs) as high active anti-HIV agents.
    Bioorganic & medicinal chemistry letters, 2011, Jan-15, Volume: 21, Issue:2

    Topics: Anti-HIV Agents; Cell Line; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Nevirapine; Pyri

2011
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:10

    Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Hum

2011
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:10

    Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Hum

2011
Discovery of 3,4-dihydropyrimidin-2(1H)-ones with inhibitory activity against HIV-1 replication.
    Bioorganic & medicinal chemistry letters, 2012, Mar-01, Volume: 22, Issue:5

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV-1; Humans; Pyrimidinones; Stereoisomerism; Structu

2012
Discovery of 3,4-dihydropyrimidin-2(1H)-ones with inhibitory activity against HIV-1 replication.
    Bioorganic & medicinal chemistry letters, 2012, Mar-01, Volume: 22, Issue:5

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV-1; Humans; Pyrimidinones; Stereoisomerism; Structu

2012
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
    Bioorganic & medicinal chemistry, 2012, Dec-01, Volume: 20, Issue:23

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Mole

2012
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
    Bioorganic & medicinal chemistry, 2012, Dec-01, Volume: 20, Issue:23

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Mole

2012
Synthesis and biological evaluation of phosphonate analogues of nevirapine.
    Bioorganic & medicinal chemistry letters, 2013, Mar-01, Volume: 23, Issue:5

    Topics: HIV Infections; HIV-1; Humans; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Str

2013
Synthesis and biological evaluation of phosphonate analogues of nevirapine.
    Bioorganic & medicinal chemistry letters, 2013, Mar-01, Volume: 23, Issue:5

    Topics: HIV Infections; HIV-1; Humans; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Str

2013
Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry, 2013, Apr-01, Volume: 21, Issue:7

    Topics: Cell Line; Delavirdine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Pyrida

2013
Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry, 2013, Apr-01, Volume: 21, Issue:7

    Topics: Cell Line; Delavirdine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Pyrida

2013
Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry, 2013, Dec-01, Volume: 21, Issue:23

    Topics: Anti-HIV Agents; Cell Line; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; M

2013
Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry, 2013, Dec-01, Volume: 21, Issue:23

    Topics: Anti-HIV Agents; Cell Line; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; M

2013
Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
    European journal of medicinal chemistry, 2014, Nov-24, Volume: 87

    Topics: Anti-HIV Agents; Catalytic Domain; Dose-Response Relationship, Drug; Drug Design; HIV Infections; HI

2014
Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
    European journal of medicinal chemistry, 2014, Nov-24, Volume: 87

    Topics: Anti-HIV Agents; Catalytic Domain; Dose-Response Relationship, Drug; Drug Design; HIV Infections; HI

2014
Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti-HIV-1 Agents.
    Chemical biology & drug design, 2015, Volume: 86, Issue:3

    Topics: Aniline Compounds; Anti-HIV Agents; Cell Line; Drug Design; Ether; HIV Infections; HIV-1; Humans; Mo

2015
Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti-HIV-1 Agents.
    Chemical biology & drug design, 2015, Volume: 86, Issue:3

    Topics: Aniline Compounds; Anti-HIV Agents; Cell Line; Drug Design; Ether; HIV Infections; HIV-1; Humans; Mo

2015
Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
    European journal of medicinal chemistry, 2016, Feb-15, Volume: 109

    Topics: Anti-HIV Agents; Binding Sites; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Human

2016
Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
    European journal of medicinal chemistry, 2016, Feb-15, Volume: 109

    Topics: Anti-HIV Agents; Binding Sites; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Human

2016
Dihydropyrimidinone-isatin hybrids as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Bioorganic chemistry, 2017, Volume: 70

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Isatin; Mole

2017
Dihydropyrimidinone-isatin hybrids as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Bioorganic chemistry, 2017, Volume: 70

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Isatin; Mole

2017
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
    Journal of medicinal chemistry, 2017, 04-13, Volume: 60, Issue:7

    Topics: Anti-HIV Agents; Biomimetic Materials; CD4 Antigens; Cell Line; Crystallography, X-Ray; HIV Envelope

2017
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
    Journal of medicinal chemistry, 2017, 04-13, Volume: 60, Issue:7

    Topics: Anti-HIV Agents; Biomimetic Materials; CD4 Antigens; Cell Line; Crystallography, X-Ray; HIV Envelope

2017
Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
    Bioorganic & medicinal chemistry letters, 2017, 04-15, Volume: 27, Issue:8

    Topics: Anti-HIV Agents; Cell Line; Drug Design; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HI

2017
Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
    Bioorganic & medicinal chemistry letters, 2017, 04-15, Volume: 27, Issue:8

    Topics: Anti-HIV Agents; Cell Line; Drug Design; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HI

2017
Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
    Journal of medicinal chemistry, 2017, 05-25, Volume: 60, Issue:10

    Topics: Animals; Anti-HIV Agents; Drug Resistance, Viral; HEK293 Cells; HIV Infections; HIV Reverse Transcri

2017
Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
    Journal of medicinal chemistry, 2017, 05-25, Volume: 60, Issue:10

    Topics: Animals; Anti-HIV Agents; Drug Resistance, Viral; HEK293 Cells; HIV Infections; HIV Reverse Transcri

2017
Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
    European journal of medicinal chemistry, 2018, May-10, Volume: 151

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Do

2018
Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
    European journal of medicinal chemistry, 2018, May-10, Volume: 151

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Do

2018
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
    Journal of medicinal chemistry, 2019, 05-23, Volume: 62, Issue:10

    Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Discovery; HIV Infections; HIV-1; Humans; R

2019
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
    Journal of medicinal chemistry, 2019, 05-23, Volume: 62, Issue:10

    Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Discovery; HIV Infections; HIV-1; Humans; R

2019
Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
    Journal of medicinal chemistry, 2019, 12-26, Volume: 62, Issue:24

    Topics: Administration, Oral; Animals; Anti-HIV Agents; Apoptosis; Drug Design; Female; HIV Infections; HIV-

2019
Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
    Journal of medicinal chemistry, 2019, 12-26, Volume: 62, Issue:24

    Topics: Administration, Oral; Animals; Anti-HIV Agents; Apoptosis; Drug Design; Female; HIV Infections; HIV-

2019
Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase.
    European journal of medicinal chemistry, 2020, Jan-15, Volume: 186

    Topics: Anti-HIV Agents; Cell Line; Coumarins; Dose-Response Relationship, Drug; Drug Design; HIV Infections

2020
Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase.
    European journal of medicinal chemistry, 2020, Jan-15, Volume: 186

    Topics: Anti-HIV Agents; Cell Line; Coumarins; Dose-Response Relationship, Drug; Drug Design; HIV Infections

2020
Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
    Journal of medicinal chemistry, 2022, 03-10, Volume: 65, Issue:5

    Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Heterocyclic Compounds, 1-Ring; HIV Infections; HIV Reve

2022
Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
    Journal of medicinal chemistry, 2022, 03-10, Volume: 65, Issue:5

    Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Heterocyclic Compounds, 1-Ring; HIV Infections; HIV Reve

2022
Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 06-10, Volume: 74, Issue:11

    Topics: Anti-HIV Agents; Breast Feeding; Case-Control Studies; Drug Resistance; Female; HIV; HIV Infections;

2022
Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 06-10, Volume: 74, Issue:11

    Topics: Anti-HIV Agents; Breast Feeding; Case-Control Studies; Drug Resistance; Female; HIV; HIV Infections;

2022
Effect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study.
    Drug and alcohol dependence, 2021, 10-01, Volume: 227

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Constitutive Androstane Receptor; HIV Infecti

2021
Effect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study.
    Drug and alcohol dependence, 2021, 10-01, Volume: 227

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Constitutive Androstane Receptor; HIV Infecti

2021
Could pharmacogenetics aid the prediction of nevirapine pharmacokinetics and allow individualized treatment?
    Pharmacogenomics, 2021, Volume: 22, Issue:14

    Topics: Anti-HIV Agents; Cytochrome P-450 CYP2B6; HIV Infections; Humans; Nevirapine; Pharmacogenetics; Prec

2021
Could pharmacogenetics aid the prediction of nevirapine pharmacokinetics and allow individualized treatment?
    Pharmacogenomics, 2021, Volume: 22, Issue:14

    Topics: Anti-HIV Agents; Cytochrome P-450 CYP2B6; HIV Infections; Humans; Nevirapine; Pharmacogenetics; Prec

2021
High nevirapine levels in breast milk and consequences in HIV-infected child when initiated on antiretroviral therapy.
    AIDS (London, England), 2021, 11-15, Volume: 35, Issue:14

    Topics: Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; M

2021
High nevirapine levels in breast milk and consequences in HIV-infected child when initiated on antiretroviral therapy.
    AIDS (London, England), 2021, 11-15, Volume: 35, Issue:14

    Topics: Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; M

2021
Association between social psychological status and efavirenz and nevirapine plasma concentration among HIV patients in Kenya.
    Scientific reports, 2021, 11-11, Volume: 11, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; HIV I

2021
Association between social psychological status and efavirenz and nevirapine plasma concentration among HIV patients in Kenya.
    Scientific reports, 2021, 11-11, Volume: 11, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; HIV I

2021
HIV Encephalopathy in ART-Naïve, Hospitalized Infants in Mozambique.
    Journal of tropical pediatrics, 2021, 12-08, Volume: 67, Issue:6

    Topics: AIDS Dementia Complex; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infant; Infectious Di

2021
HIV Encephalopathy in ART-Naïve, Hospitalized Infants in Mozambique.
    Journal of tropical pediatrics, 2021, 12-08, Volume: 67, Issue:6

    Topics: AIDS Dementia Complex; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infant; Infectious Di

2021
Improved Hematologic Outcomes in HIV1-Exposed Infants Receiving Nevirapine Compared With Zidovudine for Postnatal Prophylaxis in a High Resource Setting.
    The Pediatric infectious disease journal, 2022, 05-01, Volume: 41, Issue:5

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical;

2022
Improved Hematologic Outcomes in HIV1-Exposed Infants Receiving Nevirapine Compared With Zidovudine for Postnatal Prophylaxis in a High Resource Setting.
    The Pediatric infectious disease journal, 2022, 05-01, Volume: 41, Issue:5

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical;

2022
Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child prevention program in Maputo city, Mozambique.
    PloS one, 2022, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Combinations; Female; Hair; HI

2022
Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child prevention program in Maputo city, Mozambique.
    PloS one, 2022, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Combinations; Female; Hair; HI

2022
Trough plasma nevirapine levels, immunologic and virologic responses in composite CYP2B6*6/*18 HIV-infected adult Nigerian patients.
    Basic & clinical pharmacology & toxicology, 2022, Volume: 131, Issue:1

    Topics: Adult; Anti-HIV Agents; Cytochrome P-450 CYP2B6; HIV Infections; Humans; Nevirapine; Nigeria; Retros

2022
Trough plasma nevirapine levels, immunologic and virologic responses in composite CYP2B6*6/*18 HIV-infected adult Nigerian patients.
    Basic & clinical pharmacology & toxicology, 2022, Volume: 131, Issue:1

    Topics: Adult; Anti-HIV Agents; Cytochrome P-450 CYP2B6; HIV Infections; Humans; Nevirapine; Nigeria; Retros

2022
Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
    Antiviral therapy, 2021, Volume: 26, Issue:3-5

    Topics: Agammaglobulinemia; Anti-HIV Agents; Drug Resistance, Viral; Genetic Diseases, X-Linked; HIV Infecti

2021
Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
    Antiviral therapy, 2021, Volume: 26, Issue:3-5

    Topics: Agammaglobulinemia; Anti-HIV Agents; Drug Resistance, Viral; Genetic Diseases, X-Linked; HIV Infecti

2021
The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana.
    Medicine, 2022, Apr-29, Volume: 101, Issue:17

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; Cyclopropanes; Cytochrome P-450 CYP2B6; Genotype;

2022
The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana.
    Medicine, 2022, Apr-29, Volume: 101, Issue:17

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; Cyclopropanes; Cytochrome P-450 CYP2B6; Genotype;

2022
Cutaneous adverse drug reactions among people living with human immunodeficiency virus in a tertiary care hospital in Johor, Malaysia.
    International journal of STD & AIDS, 2022, Volume: 33, Issue:9

    Topics: Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Female; HIV; HIV Infection

2022
Cutaneous adverse drug reactions among people living with human immunodeficiency virus in a tertiary care hospital in Johor, Malaysia.
    International journal of STD & AIDS, 2022, Volume: 33, Issue:9

    Topics: Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Female; HIV; HIV Infection

2022
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
    Antimicrobial agents and chemotherapy, 2022, 09-20, Volume: 66, Issue:9

    Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; HIV Infections;

2022
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
    Antimicrobial agents and chemotherapy, 2022, 09-20, Volume: 66, Issue:9

    Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; HIV Infections;

2022
Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life.
    The Pediatric infectious disease journal, 2022, 11-01, Volume: 41, Issue:11

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Infant; Infant, Newborn; Maravi

2022
Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life.
    The Pediatric infectious disease journal, 2022, 11-01, Volume: 41, Issue:11

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Infant; Infant, Newborn; Maravi

2022
Serum Interleukin-6 and Weight Loss in Antiretroviral-naïve and Antiretroviral-treated Patients with HIV/AIDS: Relationships and Predictors.
    Current HIV research, 2022, Volume: 20, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral T

2022
Serum Interleukin-6 and Weight Loss in Antiretroviral-naïve and Antiretroviral-treated Patients with HIV/AIDS: Relationships and Predictors.
    Current HIV research, 2022, Volume: 20, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral T

2022
Contraceptive implant use duration is not associated with breakthrough pregnancy among women living with HIV and using efavirenz: a retrospective, longitudinal analysis.
    Journal of the International AIDS Society, 2022, Volume: 25, Issue:9

    Topics: Adolescent; Adult; Alkynes; Benzoxazines; Contraceptive Agents; Cyclopropanes; Female; HIV Infection

2022
Contraceptive implant use duration is not associated with breakthrough pregnancy among women living with HIV and using efavirenz: a retrospective, longitudinal analysis.
    Journal of the International AIDS Society, 2022, Volume: 25, Issue:9

    Topics: Adolescent; Adult; Alkynes; Benzoxazines; Contraceptive Agents; Cyclopropanes; Female; HIV Infection

2022
Sulfation of 12-hydroxy-nevirapine by human SULTs and the effects of genetic polymorphisms of SULT1A1 and SULT2A1.
    Biochemical pharmacology, 2022, Volume: 204

    Topics: Animals; Arylsulfotransferase; Cytosol; Exanthema; HIV Infections; Humans; Isoenzymes; Nevirapine; P

2022
Sulfation of 12-hydroxy-nevirapine by human SULTs and the effects of genetic polymorphisms of SULT1A1 and SULT2A1.
    Biochemical pharmacology, 2022, Volume: 204

    Topics: Animals; Arylsulfotransferase; Cytosol; Exanthema; HIV Infections; Humans; Isoenzymes; Nevirapine; P

2022
Risk factors and prognostic significance of platelet count abnormalities in children with HIV infection on antiretroviral therapy.
    AIDS (London, England), 2023, 03-01, Volume: 37, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Case-Control Studies; CD4 Lymphocyte Count; Child; HIV Infection

2023
Risk factors and prognostic significance of platelet count abnormalities in children with HIV infection on antiretroviral therapy.
    AIDS (London, England), 2023, 03-01, Volume: 37, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Case-Control Studies; CD4 Lymphocyte Count; Child; HIV Infection

2023
Antiretroviral therapy resistance mutations among HIV infected people in Kazakhstan.
    Scientific reports, 2022, 10-13, Volume: 12, Issue:1

    Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Ka

2022
Antiretroviral therapy resistance mutations among HIV infected people in Kazakhstan.
    Scientific reports, 2022, 10-13, Volume: 12, Issue:1

    Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Ka

2022
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
    Clinical pharmacology and therapeutics, 2023, Volume: 113, Issue:3

    Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Comb

2023
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
    Clinical pharmacology and therapeutics, 2023, Volume: 113, Issue:3

    Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Comb

2023
Rate of virological failure and HIV-1 drug resistance among HIV-infected adolescents in routine follow-up on health facilities in Cameroon.
    PloS one, 2022, Volume: 17, Issue:10

    Topics: Adolescent; Anti-HIV Agents; Cameroon; Drug Resistance, Viral; Follow-Up Studies; Health Facilities;

2022
Rate of virological failure and HIV-1 drug resistance among HIV-infected adolescents in routine follow-up on health facilities in Cameroon.
    PloS one, 2022, Volume: 17, Issue:10

    Topics: Adolescent; Anti-HIV Agents; Cameroon; Drug Resistance, Viral; Follow-Up Studies; Health Facilities;

2022
Twenty years of Prevention of Mother to Child HIV Transmission: research to implementation at a national referral hospital in Uganda.
    African health sciences, 2022, Volume: 22, Issue:Spec Issue

    Topics: Anti-HIV Agents; Child; Female; HIV Infections; Hospitals; Humans; Infant, Newborn; Infectious Disea

2022
Twenty years of Prevention of Mother to Child HIV Transmission: research to implementation at a national referral hospital in Uganda.
    African health sciences, 2022, Volume: 22, Issue:Spec Issue

    Topics: Anti-HIV Agents; Child; Female; HIV Infections; Hospitals; Humans; Infant, Newborn; Infectious Disea

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
    Drug and alcohol dependence, 2022, Dec-01, Volume: 241

    Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders

2022
Nevirapine plasma concentration is associated with virologic failure and the emergence of drug-resistant mutations among HIV patients in Kenya: A cross sectional study.
    Medicine, 2022, Dec-16, Volume: 101, Issue:50

    Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Drug Resistance, Viral; HIV Infections; HIV-1; Huma

2022
Nevirapine plasma concentration is associated with virologic failure and the emergence of drug-resistant mutations among HIV patients in Kenya: A cross sectional study.
    Medicine, 2022, Dec-16, Volume: 101, Issue:50

    Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Drug Resistance, Viral; HIV Infections; HIV-1; Huma

2022
Case study on antiretroviral drugs uptake from soil irrigated with contaminated water: Bio-accumulation and bio-translocation to roots, stem, leaves, and fruits.
    Environmental pollution (Barking, Essex : 1987), 2023, Feb-15, Volume: 319

    Topics: Bioaccumulation; Fruit; HIV Infections; Humans; Nevirapine; Soil; Soil Pollutants; Vegetables; Water

2023
Case study on antiretroviral drugs uptake from soil irrigated with contaminated water: Bio-accumulation and bio-translocation to roots, stem, leaves, and fruits.
    Environmental pollution (Barking, Essex : 1987), 2023, Feb-15, Volume: 319

    Topics: Bioaccumulation; Fruit; HIV Infections; Humans; Nevirapine; Soil; Soil Pollutants; Vegetables; Water

2023
Virologic status and pattern of drug resistance mutation among ART-experienced HIV-infected patients in Butuo County, China.
    Journal of global antimicrobial resistance, 2023, Volume: 32

    Topics: Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine; HIV Infections; Humans; Lamivudine; Lopinav

2023
Virologic status and pattern of drug resistance mutation among ART-experienced HIV-infected patients in Butuo County, China.
    Journal of global antimicrobial resistance, 2023, Volume: 32

    Topics: Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine; HIV Infections; Humans; Lamivudine; Lopinav

2023
Antiretroviral postnatal prophylaxis to prevent HIV vertical transmission: present and future strategies.
    Journal of the International AIDS Society, 2023, Volume: 26, Issue:2

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Inf

2023
Antiretroviral postnatal prophylaxis to prevent HIV vertical transmission: present and future strategies.
    Journal of the International AIDS Society, 2023, Volume: 26, Issue:2

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Inf

2023
The quality of antiretroviral medicines: an uncertain problem.
    BMJ global health, 2023, Volume: 8, Issue:3

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; HIV Infections; Humans; Nevirapine

2023
The quality of antiretroviral medicines: an uncertain problem.
    BMJ global health, 2023, Volume: 8, Issue:3

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; HIV Infections; Humans; Nevirapine

2023
Methods optimization and application: Solid phase extraction, ultrasonic extraction and Soxhlet extraction for the determination of antiretroviral drugs in river water, wastewater, sludge, soil and sediment.
    Journal of pharmaceutical and biomedical analysis, 2023, Jun-15, Volume: 230

    Topics: Ecosystem; HIV Infections; Humans; Nevirapine; Rivers; Sewage; Soil; Solid Phase Extraction; Ultraso

2023
Methods optimization and application: Solid phase extraction, ultrasonic extraction and Soxhlet extraction for the determination of antiretroviral drugs in river water, wastewater, sludge, soil and sediment.
    Journal of pharmaceutical and biomedical analysis, 2023, Jun-15, Volume: 230

    Topics: Ecosystem; HIV Infections; Humans; Nevirapine; Rivers; Sewage; Soil; Solid Phase Extraction; Ultraso

2023
Prevalence of pretreatment drug resistance in persons initiating and reinitiating antiretroviral therapy in Sri Lanka: results from a national representative survey.
    The Journal of antimicrobial chemotherapy, 2023, 06-01, Volume: 78, Issue:6

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Cross-Sectional Studies; Drug Resistance, Viral; Fem

2023
Prevalence of pretreatment drug resistance in persons initiating and reinitiating antiretroviral therapy in Sri Lanka: results from a national representative survey.
    The Journal of antimicrobial chemotherapy, 2023, 06-01, Volume: 78, Issue:6

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Cross-Sectional Studies; Drug Resistance, Viral; Fem

2023
A real-world observational retrospective cohort study of Canadian people living with HIV switching from nevirapine plus two nucleoside reverse transcriptase inhibitors to dolutegravir/lamivudine.
    International journal of antimicrobial agents, 2023, Volume: 62, Issue:2

    Topics: Anti-HIV Agents; Canada; HIV Infections; Humans; Lamivudine; Nevirapine; Oxazines; Patient Acceptanc

2023
A real-world observational retrospective cohort study of Canadian people living with HIV switching from nevirapine plus two nucleoside reverse transcriptase inhibitors to dolutegravir/lamivudine.
    International journal of antimicrobial agents, 2023, Volume: 62, Issue:2

    Topics: Anti-HIV Agents; Canada; HIV Infections; Humans; Lamivudine; Nevirapine; Oxazines; Patient Acceptanc

2023
Uptake of selected antiretrovirals by pepper (Capsicum annum), radish (Raphanus sativus), and ryegrass (Lolium perenne) grown on two contrasting soils and fertilized with human urine-derived fertilizers.
    The Science of the total environment, 2023, Sep-20, Volume: 892

    Topics: Animals; Capsicum; Crops, Agricultural; Fertilizers; HIV Infections; Humans; Lolium; Nevirapine; Rap

2023
Uptake of selected antiretrovirals by pepper (Capsicum annum), radish (Raphanus sativus), and ryegrass (Lolium perenne) grown on two contrasting soils and fertilized with human urine-derived fertilizers.
    The Science of the total environment, 2023, Sep-20, Volume: 892

    Topics: Animals; Capsicum; Crops, Agricultural; Fertilizers; HIV Infections; Humans; Lolium; Nevirapine; Rap

2023
Optimizing antiretroviral therapy for children living with HIV: Experience from an observational cohort in Lesotho.
    PloS one, 2023, Volume: 18, Issue:7

    Topics: Anti-HIV Agents; Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Lesotho; Lopinavir

2023
Optimizing antiretroviral therapy for children living with HIV: Experience from an observational cohort in Lesotho.
    PloS one, 2023, Volume: 18, Issue:7

    Topics: Anti-HIV Agents; Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Lesotho; Lopinavir

2023
Biochemical and structural comparisons of non-nucleoside reverse transcriptase inhibitors against feline and human immunodeficiency viruses.
    Journal of veterinary science, 2023, Volume: 24, Issue:5

    Topics: Animals; Anti-HIV Agents; Cat Diseases; Cats; HIV Infections; HIV Reverse Transcriptase; HIV-1; Huma

2023
Biochemical and structural comparisons of non-nucleoside reverse transcriptase inhibitors against feline and human immunodeficiency viruses.
    Journal of veterinary science, 2023, Volume: 24, Issue:5

    Topics: Animals; Anti-HIV Agents; Cat Diseases; Cats; HIV Infections; HIV Reverse Transcriptase; HIV-1; Huma

2023
Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.
    BMC infectious diseases, 2019, Aug-23, Volume: 19, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2019
Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.
    BMC infectious diseases, 2019, Aug-23, Volume: 19, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2019
Life-threatening rhabdomyolysis and Fanconi syndrome related to tenofovir disoproxil fumarate administration in an HIV-infected patient.
    Medecine et maladies infectieuses, 2020, Volume: 50, Issue:1

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Fanconi Syndrome; Fluid Therapy; Glo

2020
Life-threatening rhabdomyolysis and Fanconi syndrome related to tenofovir disoproxil fumarate administration in an HIV-infected patient.
    Medecine et maladies infectieuses, 2020, Volume: 50, Issue:1

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Fanconi Syndrome; Fluid Therapy; Glo

2020
Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa.
    BMC infectious diseases, 2019, Sep-16, Volume: 19, Issue:Suppl 1

    Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Female; Follow-Up Studi

2019
Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa.
    BMC infectious diseases, 2019, Sep-16, Volume: 19, Issue:Suppl 1

    Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Female; Follow-Up Studi

2019
Extended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants.
    Journal of acquired immune deficiency syndromes (1999), 2019, 12-01, Volume: 82, Issue:4

    Topics: Anti-HIV Agents; Child Development; Female; Growth; HIV Infections; Humans; Infant; Infectious Disea

2019
Extended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants.
    Journal of acquired immune deficiency syndromes (1999), 2019, 12-01, Volume: 82, Issue:4

    Topics: Anti-HIV Agents; Child Development; Female; Growth; HIV Infections; Humans; Infant; Infectious Disea

2019
Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital.
    Journal of tropical pediatrics, 2020, 08-01, Volume: 66, Issue:4

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Ch

2020
Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital.
    Journal of tropical pediatrics, 2020, 08-01, Volume: 66, Issue:4

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Ch

2020
'High' antiretroviral deintensification strategy and cellular HIV DNA levels.
    Journal of chemotherapy (Florence, Italy), 2020, Volume: 32, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; DNA, V

2020
'High' antiretroviral deintensification strategy and cellular HIV DNA levels.
    Journal of chemotherapy (Florence, Italy), 2020, Volume: 32, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; DNA, V

2020
Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy.
    AIDS research and human retroviruses, 2020, Volume: 36, Issue:5

    Topics: Absorptiometry, Photon; Adult; Bone Density; Cross-Sectional Studies; Female; Follow-Up Studies; HIV

2020
Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy.
    AIDS research and human retroviruses, 2020, Volume: 36, Issue:5

    Topics: Absorptiometry, Photon; Adult; Bone Density; Cross-Sectional Studies; Female; Follow-Up Studies; HIV

2020
Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 02-01, Volume: 72, Issue:3

    Topics: Anti-HIV Agents; Botswana; Child; Child, Preschool; HIV Infections; Humans; Infant; Infant, Newborn;

2021
Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 02-01, Volume: 72, Issue:3

    Topics: Anti-HIV Agents; Botswana; Child; Child, Preschool; HIV Infections; Humans; Infant; Infant, Newborn;

2021
A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
    Pharmaceutical medicine, 2019, Volume: 33, Issue:2

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anemia; Anti-HIV Agents; Anti-Retroviral Agent

2019
A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
    Pharmaceutical medicine, 2019, Volume: 33, Issue:2

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anemia; Anti-HIV Agents; Anti-Retroviral Agent

2019
Incidence and predictors of loss to follow up among adult HIV patients on antiretroviral therapy in University of Gondar Comprehensive Specialized Hospital: A competing risk regression modeling.
    PloS one, 2020, Volume: 15, Issue:1

    Topics: Adolescent; Adult; Ambulatory Care; Anti-Retroviral Agents; Drug Therapy, Combination; Female; Follo

2020
Incidence and predictors of loss to follow up among adult HIV patients on antiretroviral therapy in University of Gondar Comprehensive Specialized Hospital: A competing risk regression modeling.
    PloS one, 2020, Volume: 15, Issue:1

    Topics: Adolescent; Adult; Ambulatory Care; Anti-Retroviral Agents; Drug Therapy, Combination; Female; Follo

2020
Incidence and predictors of nevirapine and efavirenz-associated rash among Indonesian HIV patients.
    Asian Pacific journal of allergy and immunology, 2022, Volume: 40, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Exanthema;

2022
Incidence and predictors of nevirapine and efavirenz-associated rash among Indonesian HIV patients.
    Asian Pacific journal of allergy and immunology, 2022, Volume: 40, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Exanthema;

2022
Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before Delivery.
    Journal of acquired immune deficiency syndromes (1999), 2020, 07-01, Volume: 84, Issue:3

    Topics: Adult; Anti-HIV Agents; Bayes Theorem; Drug Combinations; Female; HIV Infections; Humans; Infant, Ne

2020
Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before Delivery.
    Journal of acquired immune deficiency syndromes (1999), 2020, 07-01, Volume: 84, Issue:3

    Topics: Adult; Anti-HIV Agents; Bayes Theorem; Drug Combinations; Female; HIV Infections; Humans; Infant, Ne

2020
Anti-HIV drugs promote β-amyloid deposition and impair learning and memory in BALB/c mice.
    Acta neuropsychiatrica, 2020, Volume: 32, Issue:5

    Topics: Administration, Oral; AIDS Dementia Complex; Amyloid beta-Peptides; Amyloid beta-Protein Precursor;

2020
Anti-HIV drugs promote β-amyloid deposition and impair learning and memory in BALB/c mice.
    Acta neuropsychiatrica, 2020, Volume: 32, Issue:5

    Topics: Administration, Oral; AIDS Dementia Complex; Amyloid beta-Peptides; Amyloid beta-Protein Precursor;

2020
Correlates of loss to follow-up and missed diagnosis among HIV-exposed infants throughout the breastfeeding period in southern Mozambique.
    PloS one, 2020, Volume: 15, Issue:8

    Topics: Anti-Retroviral Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Infectious Disease T

2020
Correlates of loss to follow-up and missed diagnosis among HIV-exposed infants throughout the breastfeeding period in southern Mozambique.
    PloS one, 2020, Volume: 15, Issue:8

    Topics: Anti-Retroviral Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Infectious Disease T

2020
Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria.
    Journal of pharmacological sciences, 2020, Volume: 144, Issue:3

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Be

2020
Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria.
    Journal of pharmacological sciences, 2020, Volume: 144, Issue:3

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Be

2020
Novel dual HIV maintenance therapy with nevirapine plus lamivudine retain viral suppression through 144 weeks-A proof-of-concept study.
    PloS one, 2020, Volume: 15, Issue:9

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; P

2020
Novel dual HIV maintenance therapy with nevirapine plus lamivudine retain viral suppression through 144 weeks-A proof-of-concept study.
    PloS one, 2020, Volume: 15, Issue:9

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; P

2020
Barriers and enablers of adherence to infant nevirapine prophylaxis against HIV 1 transmission among 6-week-old HIV exposed infants: A prospective cohort study in Northern Uganda.
    PloS one, 2020, Volume: 15, Issue:10

    Topics: Adult; Age Factors; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Disea

2020
Barriers and enablers of adherence to infant nevirapine prophylaxis against HIV 1 transmission among 6-week-old HIV exposed infants: A prospective cohort study in Northern Uganda.
    PloS one, 2020, Volume: 15, Issue:10

    Topics: Adult; Age Factors; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Disea

2020
Risk factors for delayed viral suppression on first-line antiretroviral therapy among persons living with HIV in Haiti, 2013-2017.
    PloS one, 2020, Volume: 15, Issue:10

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool;

2020
Risk factors for delayed viral suppression on first-line antiretroviral therapy among persons living with HIV in Haiti, 2013-2017.
    PloS one, 2020, Volume: 15, Issue:10

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool;

2020
Magnitude of first line antiretroviral therapy treatment failure and associated factors among adult patients on ART in South West Shoa, Central Ethiopia.
    PloS one, 2020, Volume: 15, Issue:11

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Ethiopia; Female; HIV

2020
Magnitude of first line antiretroviral therapy treatment failure and associated factors among adult patients on ART in South West Shoa, Central Ethiopia.
    PloS one, 2020, Volume: 15, Issue:11

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Ethiopia; Female; HIV

2020
Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys.
    Journal of the International AIDS Society, 2020, Volume: 23, Issue:11

    Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Eswatini; Female;

2020
Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys.
    Journal of the International AIDS Society, 2020, Volume: 23, Issue:11

    Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Eswatini; Female;

2020
Human Immunodeficiency Virus-1 Subtype-C Genetically Diversify to Acquire Higher Replication Competence in Human Host with Comorbidities.
    AIDS research and human retroviruses, 2021, Volume: 37, Issue:5

    Topics: Cross-Sectional Studies; HIV Infections; HIV-1; Humans; Lamivudine; Nevirapine

2021
Human Immunodeficiency Virus-1 Subtype-C Genetically Diversify to Acquire Higher Replication Competence in Human Host with Comorbidities.
    AIDS research and human retroviruses, 2021, Volume: 37, Issue:5

    Topics: Cross-Sectional Studies; HIV Infections; HIV-1; Humans; Lamivudine; Nevirapine

2021
Advancing knowledge in perinatal HIV treatment.
    The lancet. HIV, 2021, Volume: 8, Issue:3

    Topics: Anti-Retroviral Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis

2021
Advancing knowledge in perinatal HIV treatment.
    The lancet. HIV, 2021, Volume: 8, Issue:3

    Topics: Anti-Retroviral Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis

2021
Association of SNPs in HLA-C and ZNRD1 Genes With HIV-1 Mother-to-Child Transmission in Zambia Population.
    Journal of acquired immune deficiency syndromes (1999), 2021, 04-01, Volume: 86, Issue:4

    Topics: Adult; Anti-HIV Agents; DNA-Binding Proteins; Female; Genetic Predisposition to Disease; Genotype; H

2021
Association of SNPs in HLA-C and ZNRD1 Genes With HIV-1 Mother-to-Child Transmission in Zambia Population.
    Journal of acquired immune deficiency syndromes (1999), 2021, 04-01, Volume: 86, Issue:4

    Topics: Adult; Anti-HIV Agents; DNA-Binding Proteins; Female; Genetic Predisposition to Disease; Genotype; H

2021
LC-MS/MS Quantification of Nevirapine and Its Metabolites in Hair for Assessing Long-Term Adherence.
    Molecules (Basel, Switzerland), 2020, Dec-02, Volume: 25, Issue:23

    Topics: Adult; Aged; Anti-HIV Agents; Chromatography, Liquid; Female; Hair; HIV; HIV Infections; Humans; Mal

2020
LC-MS/MS Quantification of Nevirapine and Its Metabolites in Hair for Assessing Long-Term Adherence.
    Molecules (Basel, Switzerland), 2020, Dec-02, Volume: 25, Issue:23

    Topics: Adult; Aged; Anti-HIV Agents; Chromatography, Liquid; Female; Hair; HIV; HIV Infections; Humans; Mal

2020
Mother-to-Child HIV Transmission among Pregnant Women in a City with the Highest Rates of HIV in Brazil.
    American journal of perinatology, 2022, Volume: 39, Issue:13

    Topics: Brazil; Child; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmiss

2022
Mother-to-Child HIV Transmission among Pregnant Women in a City with the Highest Rates of HIV in Brazil.
    American journal of perinatology, 2022, Volume: 39, Issue:13

    Topics: Brazil; Child; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmiss

2022
The 2-hydroxy-nevirapine metabolite as a candidate for boosting apolipoprotein A1 and for modulating anti-HDL antibodies.
    Pharmacological research, 2021, Volume: 165

    Topics: Adult; Aged; Animals; Anti-HIV Agents; Apolipoprotein A-I; Cells, Cultured; Cholesterol, HDL; Cross-

2021
The 2-hydroxy-nevirapine metabolite as a candidate for boosting apolipoprotein A1 and for modulating anti-HDL antibodies.
    Pharmacological research, 2021, Volume: 165

    Topics: Adult; Aged; Animals; Anti-HIV Agents; Apolipoprotein A-I; Cells, Cultured; Cholesterol, HDL; Cross-

2021
HIV-free survival among breastfed infants born to HIV-positive women in northern Uganda: a facility-based retrospective study.
    The Pan African medical journal, 2020, Volume: 37

    Topics: Anti-HIV Agents; Breast Feeding; Cohort Studies; Female; HIV Infections; Humans; Infant; Infant, New

2020
HIV-free survival among breastfed infants born to HIV-positive women in northern Uganda: a facility-based retrospective study.
    The Pan African medical journal, 2020, Volume: 37

    Topics: Anti-HIV Agents; Breast Feeding; Cohort Studies; Female; HIV Infections; Humans; Infant; Infant, New

2020
Effects of the Pratt pouch model of dispensing nevirapine prophylaxis on HIV exposed infant completion of 6 weeks of prophylaxis in Uganda.
    PloS one, 2021, Volume: 16, Issue:3

    Topics: Adult; Anti-HIV Agents; Drug Implants; Drug Packaging; Female; HIV Infections; Humans; Infant; Infan

2021
Effects of the Pratt pouch model of dispensing nevirapine prophylaxis on HIV exposed infant completion of 6 weeks of prophylaxis in Uganda.
    PloS one, 2021, Volume: 16, Issue:3

    Topics: Adult; Anti-HIV Agents; Drug Implants; Drug Packaging; Female; HIV Infections; Humans; Infant; Infan

2021
Nevirapine Pharmacokinetics in Neonates Between 25 and 32 Weeks Gestational Age for the Prevention of Mother-to-Child Transmission of HIV.
    The Pediatric infectious disease journal, 2021, 04-01, Volume: 40, Issue:4

    Topics: Administration, Oral; Anti-HIV Agents; Female; Gestational Age; HIV Infections; HIV-1; Humans; Infan

2021
Nevirapine Pharmacokinetics in Neonates Between 25 and 32 Weeks Gestational Age for the Prevention of Mother-to-Child Transmission of HIV.
    The Pediatric infectious disease journal, 2021, 04-01, Volume: 40, Issue:4

    Topics: Administration, Oral; Anti-HIV Agents; Female; Gestational Age; HIV Infections; HIV-1; Humans; Infan

2021
Adverse Reactions to Antiretrovirals in Cuban Patients Living with HIV/AIDS.
    MEDICC review, 2021, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Child, Preschool; Cuba; Female; HIV Infections; Humans; I

2021
Adverse Reactions to Antiretrovirals in Cuban Patients Living with HIV/AIDS.
    MEDICC review, 2021, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Child, Preschool; Cuba; Female; HIV Infections; Humans; I

2021
Histopathological changes in Oreochromis mossambicus (Peters, 1852) ovaries after a chronic exposure to a mixture of the HIV drug nevirapine and the antibiotics sulfamethoxazole and trimethoprim.
    Chemosphere, 2021, Volume: 274

    Topics: Africa; Animals; Anti-Bacterial Agents; COVID-19; Female; HIV Infections; Humans; Nevirapine; Ovary;

2021
Histopathological changes in Oreochromis mossambicus (Peters, 1852) ovaries after a chronic exposure to a mixture of the HIV drug nevirapine and the antibiotics sulfamethoxazole and trimethoprim.
    Chemosphere, 2021, Volume: 274

    Topics: Africa; Animals; Anti-Bacterial Agents; COVID-19; Female; HIV Infections; Humans; Nevirapine; Ovary;

2021
HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study.
    BMC infectious diseases, 2021, Aug-02, Volume: 21, Issue:1

    Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Sectional Studies;

2021
HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study.
    BMC infectious diseases, 2021, Aug-02, Volume: 21, Issue:1

    Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Sectional Studies;

2021
    International journal of diabetes in developing countries, 2022, Volume: 42, Issue:1

    Topics: Adolescent; Adult; Aged; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under

2022
    International journal of diabetes in developing countries, 2022, Volume: 42, Issue:1

    Topics: Adolescent; Adult; Aged; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under

2022
Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression.
    The Journal of antimicrobial chemotherapy, 2017, 07-01, Volume: 72, Issue:7

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies;

2017
Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression.
    The Journal of antimicrobial chemotherapy, 2017, 07-01, Volume: 72, Issue:7

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies;

2017
Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan.
    BMC infectious diseases, 2017, 04-11, Volume: 17, Issue:1

    Topics: Adult; Anti-HIV Agents; Delayed-Action Preparations; Drug Administration Schedule; Drug Monitoring;

2017
Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan.
    BMC infectious diseases, 2017, 04-11, Volume: 17, Issue:1

    Topics: Adult; Anti-HIV Agents; Delayed-Action Preparations; Drug Administration Schedule; Drug Monitoring;

2017
Uptake and performance of prevention of mother-to-child transmission and early infant diagnosis in pregnant HIV-infected women and their exposed infants at seven health centres in Addis Ababa, Ethiopia.
    Tropical medicine & international health : TM & IH, 2017, Volume: 22, Issue:6

    Topics: Adolescent; Adult; Anti-HIV Agents; Ethiopia; Female; Follow-Up Studies; Guideline Adherence; Health

2017
Uptake and performance of prevention of mother-to-child transmission and early infant diagnosis in pregnant HIV-infected women and their exposed infants at seven health centres in Addis Ababa, Ethiopia.
    Tropical medicine & international health : TM & IH, 2017, Volume: 22, Issue:6

    Topics: Adolescent; Adult; Anti-HIV Agents; Ethiopia; Female; Follow-Up Studies; Guideline Adherence; Health

2017
Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
    The Journal of antimicrobial chemotherapy, 2017, 07-01, Volume: 72, Issue:7

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Breast Feeding; Case-Control Studies; Drug Therapy, C

2017
Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
    The Journal of antimicrobial chemotherapy, 2017, 07-01, Volume: 72, Issue:7

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Breast Feeding; Case-Control Studies; Drug Therapy, C

2017
Maternal Syphilis: An Independent Risk Factor for Mother to Infant Human Immunodeficiency Virus Transmission.
    Sexually transmitted diseases, 2017, Volume: 44, Issue:6

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cost-Benefit Anal

2017
Maternal Syphilis: An Independent Risk Factor for Mother to Infant Human Immunodeficiency Virus Transmission.
    Sexually transmitted diseases, 2017, Volume: 44, Issue:6

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cost-Benefit Anal

2017
Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.
    The Pediatric infectious disease journal, 2017, Volume: 36, Issue:6

    Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; F

2017
Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.
    The Pediatric infectious disease journal, 2017, Volume: 36, Issue:6

    Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; F

2017
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    PloS one, 2017, Volume: 12, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxaz

2017
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    PloS one, 2017, Volume: 12, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxaz

2017
Pharmacokinetics-based adherence measures for antiretroviral therapy in HIV-infected Kenyan children.
    Journal of the International AIDS Society, 2017, Jun-15, Volume: 20, Issue:1

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Kenya;

2017
Pharmacokinetics-based adherence measures for antiretroviral therapy in HIV-infected Kenyan children.
    Journal of the International AIDS Society, 2017, Jun-15, Volume: 20, Issue:1

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Kenya;

2017
[Obesity, high blood pressure, hypercholesterolaemia, and untreated diabetes in HIV-infected and HIV-uninfected Adults in Mbuji-Mayi (Democratic republic of congo)].
    Bulletin de la Societe de pathologie exotique (1990), 2017, Volume: 110, Issue:5

    Topics: Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cross-Sectional Studies; Delayed

2017
[Obesity, high blood pressure, hypercholesterolaemia, and untreated diabetes in HIV-infected and HIV-uninfected Adults in Mbuji-Mayi (Democratic republic of congo)].
    Bulletin de la Societe de pathologie exotique (1990), 2017, Volume: 110, Issue:5

    Topics: Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cross-Sectional Studies; Delayed

2017
Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
    BMC infectious diseases, 2017, 06-27, Volume: 17, Issue:1

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Co

2017
Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
    BMC infectious diseases, 2017, 06-27, Volume: 17, Issue:1

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Co

2017
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
    Infectious diseases (London, England), 2017, Volume: 49, Issue:10

    Topics: Adult; Anti-HIV Agents; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Cholesterol

2017
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
    Infectious diseases (London, England), 2017, Volume: 49, Issue:10

    Topics: Adult; Anti-HIV Agents; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Cholesterol

2017
Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.
    AIDS (London, England), 2017, 09-10, Volume: 31, Issue:14

    Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Contraception; Contraceptive Agent

2017
Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.
    AIDS (London, England), 2017, 09-10, Volume: 31, Issue:14

    Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Contraception; Contraceptive Agent

2017
HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern Tanzania.
    AIDS research and human retroviruses, 2017, Volume: 33, Issue:11

    Topics: Anti-HIV Agents; Blood; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infec

2017
HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern Tanzania.
    AIDS research and human retroviruses, 2017, Volume: 33, Issue:11

    Topics: Anti-HIV Agents; Blood; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infec

2017
Sub-therapeutic nevirapine concentration during antiretroviral treatment initiation among children living with HIV: Implications for therapeutic drug monitoring.
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Child; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Monitoring; Fema

2017
Sub-therapeutic nevirapine concentration during antiretroviral treatment initiation among children living with HIV: Implications for therapeutic drug monitoring.
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Child; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Monitoring; Fema

2017
Mother-to-child transmission of HIV in Kenya: A cross-sectional analysis of the national database over nine years.
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Databases, Factual;

2017
Mother-to-child transmission of HIV in Kenya: A cross-sectional analysis of the national database over nine years.
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Databases, Factual;

2017
Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
    BMC infectious diseases, 2017, 09-05, Volume: 17, Issue:1

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cycloprop

2017
Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
    BMC infectious diseases, 2017, 09-05, Volume: 17, Issue:1

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cycloprop

2017
Lower mitochondrial DNA and altered mitochondrial fuel metabolism in HIV-exposed uninfected infants in Cameroon.
    AIDS (London, England), 2017, 11-28, Volume: 31, Issue:18

    Topics: Amino Acids, Branched-Chain; Anti-Retroviral Agents; Cameroon; Carnitine; DNA, Mitochondrial; Energy

2017
Lower mitochondrial DNA and altered mitochondrial fuel metabolism in HIV-exposed uninfected infants in Cameroon.
    AIDS (London, England), 2017, 11-28, Volume: 31, Issue:18

    Topics: Amino Acids, Branched-Chain; Anti-Retroviral Agents; Cameroon; Carnitine; DNA, Mitochondrial; Energy

2017
Factors affecting high-density lipoprotein cholesterol in HIV-infected patients on nevirapine-based antiretroviral therapy.
    The Indian journal of medical research, 2017, Volume: 145, Issue:5

    Topics: Adult; Antiretroviral Therapy, Highly Active; Apolipoprotein C-III; Cholesterol Ester Transfer Prote

2017
Factors affecting high-density lipoprotein cholesterol in HIV-infected patients on nevirapine-based antiretroviral therapy.
    The Indian journal of medical research, 2017, Volume: 145, Issue:5

    Topics: Adult; Antiretroviral Therapy, Highly Active; Apolipoprotein C-III; Cholesterol Ester Transfer Prote

2017
HIV status and hearing loss among children between 6 and 12 years of age at a large urban health facility in south western Uganda.
    International journal of pediatric otorhinolaryngology, 2017, Volume: 101

    Topics: Anti-Retroviral Agents; Audiometry, Pure-Tone; Child; Cross-Sectional Studies; Female; Hearing Loss;

2017
HIV status and hearing loss among children between 6 and 12 years of age at a large urban health facility in south western Uganda.
    International journal of pediatric otorhinolaryngology, 2017, Volume: 101

    Topics: Anti-Retroviral Agents; Audiometry, Pure-Tone; Child; Cross-Sectional Studies; Female; Hearing Loss;

2017
Towards a universal second-line fixed-dose combination ART.
    The lancet. HIV, 2018, Volume: 5, Issue:1

    Topics: Anti-HIV Agents; HIV Infections; Humans; Nevirapine

2018
Towards a universal second-line fixed-dose combination ART.
    The lancet. HIV, 2018, Volume: 5, Issue:1

    Topics: Anti-HIV Agents; HIV Infections; Humans; Nevirapine

2018
HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    Journal of medical virology, 2018, Volume: 90, Issue:3

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induce

2018
HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    Journal of medical virology, 2018, Volume: 90, Issue:3

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induce

2018
Motives for change of first-line antiretroviral therapy regimens in an unselected cohort of HIV/AIDS patients at a major referral centre in South-west Cameroon.
    BMC research notes, 2017, Nov-28, Volume: 10, Issue:1

    Topics: Adult; Anti-HIV Agents; Cameroon; Cohort Studies; Cross-Sectional Studies; Drug Combinations; Drug S

2017
Motives for change of first-line antiretroviral therapy regimens in an unselected cohort of HIV/AIDS patients at a major referral centre in South-west Cameroon.
    BMC research notes, 2017, Nov-28, Volume: 10, Issue:1

    Topics: Adult; Anti-HIV Agents; Cameroon; Cohort Studies; Cross-Sectional Studies; Drug Combinations; Drug S

2017
Long-term viral suppression and immune recovery during first-line antiretroviral therapy: a study of an HIV-infected adult cohort in Hanoi, Vietnam.
    Journal of the International AIDS Society, 2017, Volume: 20, Issue:4

    Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studie

2017
Long-term viral suppression and immune recovery during first-line antiretroviral therapy: a study of an HIV-infected adult cohort in Hanoi, Vietnam.
    Journal of the International AIDS Society, 2017, Volume: 20, Issue:4

    Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studie

2017
A Bayesian Analysis of Prenatal Maternal Factors Predicting Nonadherence to Infant HIV Medication in South Africa.
    AIDS and behavior, 2018, Volume: 22, Issue:9

    Topics: Adolescent; Adult; Anti-HIV Agents; Bayes Theorem; Depression; Depression, Postpartum; Disclosure; F

2018
A Bayesian Analysis of Prenatal Maternal Factors Predicting Nonadherence to Infant HIV Medication in South Africa.
    AIDS and behavior, 2018, Volume: 22, Issue:9

    Topics: Adolescent; Adult; Anti-HIV Agents; Bayes Theorem; Depression; Depression, Postpartum; Disclosure; F

2018
Hypersensitivity to antiretroviral drugs.
    European annals of allergy and clinical immunology, 2018, Volume: 50, Issue:6

    Topics: Anti-HIV Agents; Drug Hypersensitivity; Emtricitabine; Female; HIV Infections; Humans; Male; Middle

2018
Hypersensitivity to antiretroviral drugs.
    European annals of allergy and clinical immunology, 2018, Volume: 50, Issue:6

    Topics: Anti-HIV Agents; Drug Hypersensitivity; Emtricitabine; Female; HIV Infections; Humans; Male; Middle

2018
A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria.
    African journal of medicine and medical sciences, 2016, Volume: 45, Issue:2

    Topics: Abdominal Pain; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active;

2016
A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria.
    African journal of medicine and medical sciences, 2016, Volume: 45, Issue:2

    Topics: Abdominal Pain; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active;

2016
Antiretroviral treatment Long-Term (ALT) cohort: a prospective cohort of 10 years of ART-experienced patients in Uganda.
    BMJ open, 2018, 02-21, Volume: 8, Issue:2

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cycloprop

2018
Antiretroviral treatment Long-Term (ALT) cohort: a prospective cohort of 10 years of ART-experienced patients in Uganda.
    BMJ open, 2018, 02-21, Volume: 8, Issue:2

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cycloprop

2018
Severe eye complications from toxic epidermal necrolysis following initiation of Nevirapine based HAART regimen in a child with HIV infection: a case from Cameroon.
    BMC pediatrics, 2018, 03-13, Volume: 18, Issue:1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blindness; Cameroon; Child, Preschool; HIV I

2018
Severe eye complications from toxic epidermal necrolysis following initiation of Nevirapine based HAART regimen in a child with HIV infection: a case from Cameroon.
    BMC pediatrics, 2018, 03-13, Volume: 18, Issue:1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blindness; Cameroon; Child, Preschool; HIV I

2018
Retention of children under 18 months testing HIV positive in care in Swaziland: a retrospective study.
    The Pan African medical journal, 2017, Volume: 28

    Topics: Anti-HIV Agents; Child Health Services; Cross-Sectional Studies; Eswatini; Female; HIV Infections; H

2017
Retention of children under 18 months testing HIV positive in care in Swaziland: a retrospective study.
    The Pan African medical journal, 2017, Volume: 28

    Topics: Anti-HIV Agents; Child Health Services; Cross-Sectional Studies; Eswatini; Female; HIV Infections; H

2017
Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
    AIDS research and human retroviruses, 2018, Volume: 34, Issue:8

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Botswana; Cycl

2018
Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
    AIDS research and human retroviruses, 2018, Volume: 34, Issue:8

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Botswana; Cycl

2018
A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine.
    The Journal of antimicrobial chemotherapy, 2018, 08-01, Volume: 73, Issue:8

    Topics: Adult; Alleles; Anti-HIV Agents; Case-Control Studies; Female; Gene Frequency; Genetic Predispositio

2018
A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine.
    The Journal of antimicrobial chemotherapy, 2018, 08-01, Volume: 73, Issue:8

    Topics: Adult; Alleles; Anti-HIV Agents; Case-Control Studies; Female; Gene Frequency; Genetic Predispositio

2018
Determinants of anti-retroviral regimen changes among HIV/AIDS patients of east and west Wollega zone health institutions, Oromia region, west Ethiopia: a cross-sectional study.
    BMC pharmacology & toxicology, 2018, 06-05, Volume: 19, Issue:1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Cros

2018
Determinants of anti-retroviral regimen changes among HIV/AIDS patients of east and west Wollega zone health institutions, Oromia region, west Ethiopia: a cross-sectional study.
    BMC pharmacology & toxicology, 2018, 06-05, Volume: 19, Issue:1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Cros

2018
"High" antiretroviral deintensification, a strategy to avoid drug interactions and unfavourable long-term effects of HAART.
    Infectious diseases (London, England), 2018, Volume: 50, Issue:10

    Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug

2018
"High" antiretroviral deintensification, a strategy to avoid drug interactions and unfavourable long-term effects of HAART.
    Infectious diseases (London, England), 2018, Volume: 50, Issue:10

    Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug

2018
Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study.
    Annals of internal medicine, 2018, 08-07, Volume: 169, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Depression; Female; HIV Infections; Hu

2018
Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study.
    Annals of internal medicine, 2018, 08-07, Volume: 169, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Depression; Female; HIV Infections; Hu

2018
Using dried blood spots to facilitate therapeutic drug monitoring of antiretroviral drugs in resource-poor regions.
    The Journal of antimicrobial chemotherapy, 2018, 10-01, Volume: 73, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Alkynes; Anti-Retroviral Agents; Benzoxazines; Biological Transport;

2018
Using dried blood spots to facilitate therapeutic drug monitoring of antiretroviral drugs in resource-poor regions.
    The Journal of antimicrobial chemotherapy, 2018, 10-01, Volume: 73, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Alkynes; Anti-Retroviral Agents; Benzoxazines; Biological Transport;

2018
Polymorphisms in TH1-TH2 cytokine and receptor genes associated with risk of vertical HIV transmission, in Mumbai, India.
    The journal of gene medicine, 2018, Volume: 20, Issue:10-11

    Topics: Anti-HIV Agents; Cohort Studies; Cytokines; Gene Frequency; Genetic Predisposition to Disease; Genot

2018
Polymorphisms in TH1-TH2 cytokine and receptor genes associated with risk of vertical HIV transmission, in Mumbai, India.
    The journal of gene medicine, 2018, Volume: 20, Issue:10-11

    Topics: Anti-HIV Agents; Cohort Studies; Cytokines; Gene Frequency; Genetic Predisposition to Disease; Genot

2018
Maternal age, infant age, feeding options, single/multiple pregnancy, type of twin sets and mother-to-child transmission of HIV.
    Journal of tropical pediatrics, 2019, 06-01, Volume: 65, Issue:3

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Cameroon; Female; HIV

2019
Maternal age, infant age, feeding options, single/multiple pregnancy, type of twin sets and mother-to-child transmission of HIV.
    Journal of tropical pediatrics, 2019, 06-01, Volume: 65, Issue:3

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Cameroon; Female; HIV

2019
Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda.
    BMC public health, 2018, Aug-22, Volume: 18, Issue:1

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Counseling; Female; Health Facilities; HIV Inf

2018
Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda.
    BMC public health, 2018, Aug-22, Volume: 18, Issue:1

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Counseling; Female; Health Facilities; HIV Inf

2018
Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy.
    AIDS research and human retroviruses, 2018, Volume: 34, Issue:11

    Topics: Adult; Anti-HIV Agents; Antimalarials; Cross-Sectional Studies; Drug Interactions; Female; Fetal Blo

2018
Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy.
    AIDS research and human retroviruses, 2018, Volume: 34, Issue:11

    Topics: Adult; Anti-HIV Agents; Antimalarials; Cross-Sectional Studies; Drug Interactions; Female; Fetal Blo

2018
Nevirapine Concentrations During the First Month of Life and Maternal Efavirenz Washout in High-Risk HIV-Exposed Infants Receiving Triple Antiretroviral Prophylaxis.
    The Pediatric infectious disease journal, 2019, Volume: 38, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chemoprevention; Cyclopropanes; Female; HIV Infections; Huma

2019
Nevirapine Concentrations During the First Month of Life and Maternal Efavirenz Washout in High-Risk HIV-Exposed Infants Receiving Triple Antiretroviral Prophylaxis.
    The Pediatric infectious disease journal, 2019, Volume: 38, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chemoprevention; Cyclopropanes; Female; HIV Infections; Huma

2019
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report.
    Annales de dermatologie et de venereologie, 2018, Volume: 145, Issue:12

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitu

2018
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report.
    Annales de dermatologie et de venereologie, 2018, Volume: 145, Issue:12

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitu

2018
Mother-baby dyads enrolled in PMTCT care in western Kenya: characteristics and implications for ART programmes.
    African journal of AIDS research : AJAR, 2018, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infant; Infectious Diseas

2018
Mother-baby dyads enrolled in PMTCT care in western Kenya: characteristics and implications for ART programmes.
    African journal of AIDS research : AJAR, 2018, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infant; Infectious Diseas

2018
Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
    Pharmacology research & perspectives, 2018, Volume: 6, Issue:5

    Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; An

2018
Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
    Pharmacology research & perspectives, 2018, Volume: 6, Issue:5

    Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; An

2018
Prevalence of CYP2D6*4 1934G/A polymorphism in Western Indian HIV patients.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2018, Volume: 126, Issue:11

    Topics: Adult; Alcohol Drinking; Alleles; Anti-HIV Agents; Biotransformation; Case-Control Studies; Cytochro

2018
Prevalence of CYP2D6*4 1934G/A polymorphism in Western Indian HIV patients.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2018, Volume: 126, Issue:11

    Topics: Adult; Alcohol Drinking; Alleles; Anti-HIV Agents; Biotransformation; Case-Control Studies; Cytochro

2018
Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure.
    Journal of the Pediatric Infectious Diseases Society, 2020, Feb-28, Volume: 9, Issue:1

    Topics: Adolescent; Anti-Retroviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Drug Resistanc

2020
Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure.
    Journal of the Pediatric Infectious Diseases Society, 2020, Feb-28, Volume: 9, Issue:1

    Topics: Adolescent; Anti-Retroviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Drug Resistanc

2020
Frequency of cross-resistance to rilpivirine and etravirine among HIV-1 subtype C infected individuals failing nevirapine/efavirenz based ART regimen.
    Infectious diseases (London, England), 2019, Volume: 51, Issue:1

    Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Nitriles; Pyridazin

2019
Frequency of cross-resistance to rilpivirine and etravirine among HIV-1 subtype C infected individuals failing nevirapine/efavirenz based ART regimen.
    Infectious diseases (London, England), 2019, Volume: 51, Issue:1

    Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Nitriles; Pyridazin

2019
Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.
    BMC infectious diseases, 2018, Nov-12, Volume: 18, Issue:1

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Drug Therapy

2018
Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.
    BMC infectious diseases, 2018, Nov-12, Volume: 18, Issue:1

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Drug Therapy

2018
Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study).
    Medecine et maladies infectieuses, 2019, Volume: 49, Issue:7

    Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Interactions; Drug Substitution;

2019
Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study).
    Medecine et maladies infectieuses, 2019, Volume: 49, Issue:7

    Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Interactions; Drug Substitution;

2019
Programmes for the prevention of mother-to-child HIV infection transmission have made progress in Yunnan Province, China, from 2006 to 2015: a cost effective and cost-benefit evaluation.
    BMC infectious diseases, 2019, Jan-17, Volume: 19, Issue:1

    Topics: Adult; China; Cost-Benefit Analysis; Delivery of Health Care; Female; Health Expenditures; HIV; HIV

2019
Programmes for the prevention of mother-to-child HIV infection transmission have made progress in Yunnan Province, China, from 2006 to 2015: a cost effective and cost-benefit evaluation.
    BMC infectious diseases, 2019, Jan-17, Volume: 19, Issue:1

    Topics: Adult; China; Cost-Benefit Analysis; Delivery of Health Care; Female; Health Expenditures; HIV; HIV

2019
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
    International journal of antimicrobial agents, 2019, Volume: 53, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Delavirdine;

2019
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
    International journal of antimicrobial agents, 2019, Volume: 53, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Delavirdine;

2019
Report: A case report on Nevirapine induced exfoliative dermatitis.
    Pakistan journal of pharmaceutical sciences, 2019, Volume: 32, Issue:1

    Topics: Adult; Anti-HIV Agents; Dermatitis, Exfoliative; Dermatologic Agents; Drug Eruptions; Drug Substitut

2019
Report: A case report on Nevirapine induced exfoliative dermatitis.
    Pakistan journal of pharmaceutical sciences, 2019, Volume: 32, Issue:1

    Topics: Adult; Anti-HIV Agents; Dermatitis, Exfoliative; Dermatologic Agents; Drug Eruptions; Drug Substitut

2019
Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
    BMC infectious diseases, 2019, Feb-26, Volume: 19, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cameroon; Cohort Studies; Cyclopropanes; Drug Therapy

2019
Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
    BMC infectious diseases, 2019, Feb-26, Volume: 19, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cameroon; Cohort Studies; Cyclopropanes; Drug Therapy

2019
Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection.
    The lancet. HIV, 2019, Volume: 6, Issue:3

    Topics: Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Substitution; Fem

2019
Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection.
    The lancet. HIV, 2019, Volume: 6, Issue:3

    Topics: Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Substitution; Fem

2019
Changes in Lipid Indices in HIV+ Cases on HAART.
    BioMed research international, 2019, Volume: 2019

    Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Dia

2019
Changes in Lipid Indices in HIV+ Cases on HAART.
    BioMed research international, 2019, Volume: 2019

    Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Dia

2019
Mucocutaneous manifestations of human immunodeficiency virus (HIV) infection in children in relation to the degree of immunosuppression.
    International journal of dermatology, 2019, Volume: 58, Issue:10

    Topics: Adolescent; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Drug Eruption

2019
Mucocutaneous manifestations of human immunodeficiency virus (HIV) infection in children in relation to the degree of immunosuppression.
    International journal of dermatology, 2019, Volume: 58, Issue:10

    Topics: Adolescent; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Drug Eruption

2019
Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy.
    Journal of pharmacological sciences, 2019, Volume: 139, Issue:4

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes

2019
Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy.
    Journal of pharmacological sciences, 2019, Volume: 139, Issue:4

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes

2019
Incidence, prevalence and associated factors of mother-to-child transmission of HIV, among children exposed to maternal HIV, in Belgaum district, Karnataka, India.
    BMC public health, 2019, Apr-06, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Age Factors; Anti-HIV Agents; Breast Feeding; Child, Preschool; Female; HIV; HIV

2019
Incidence, prevalence and associated factors of mother-to-child transmission of HIV, among children exposed to maternal HIV, in Belgaum district, Karnataka, India.
    BMC public health, 2019, Apr-06, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Age Factors; Anti-HIV Agents; Breast Feeding; Child, Preschool; Female; HIV; HIV

2019
Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management?
    Swiss medical weekly, 2019, Apr-22, Volume: 149

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV; HIV Infecti

2019
Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management?
    Swiss medical weekly, 2019, Apr-22, Volume: 149

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV; HIV Infecti

2019
Retention of HIV exposed infants in care at Arua regional referral hospital, Uganda: a retrospective cohort study.
    BMC public health, 2019, Apr-25, Volume: 19, Issue:1

    Topics: Adult; Anti-HIV Agents; Chi-Square Distribution; Female; HIV; HIV Infections; Humans; Infant, Newbor

2019
Retention of HIV exposed infants in care at Arua regional referral hospital, Uganda: a retrospective cohort study.
    BMC public health, 2019, Apr-25, Volume: 19, Issue:1

    Topics: Adult; Anti-HIV Agents; Chi-Square Distribution; Female; HIV; HIV Infections; Humans; Infant, Newbor

2019
Viral suppression rate among children tested for HIV viral load at the Amhara Public Health Institute, Bahir Dar, Ethiopia.
    BMC infectious diseases, 2019, May-14, Volume: 19, Issue:1

    Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Child, Preschool; Cross-Sectional

2019
Viral suppression rate among children tested for HIV viral load at the Amhara Public Health Institute, Bahir Dar, Ethiopia.
    BMC infectious diseases, 2019, May-14, Volume: 19, Issue:1

    Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Child, Preschool; Cross-Sectional

2019
HIV diagnostic challenges in breast-fed infants of mothers on antiretroviral therapy.
    AIDS (London, England), 2019, 09-01, Volume: 33, Issue:11

    Topics: Anti-HIV Agents; Breast Feeding; Early Diagnosis; Female; HIV Infections; HIV Seronegativity; Humans

2019
HIV diagnostic challenges in breast-fed infants of mothers on antiretroviral therapy.
    AIDS (London, England), 2019, 09-01, Volume: 33, Issue:11

    Topics: Anti-HIV Agents; Breast Feeding; Early Diagnosis; Female; HIV Infections; HIV Seronegativity; Humans

2019
Impact of the frequency of plasma viral load monitoring on treatment outcomes among children with perinatally acquired HIV.
    Journal of the International AIDS Society, 2019, Volume: 22, Issue:6

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Coh

2019
Impact of the frequency of plasma viral load monitoring on treatment outcomes among children with perinatally acquired HIV.
    Journal of the International AIDS Society, 2019, Volume: 22, Issue:6

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Coh

2019
Non-nucleoside reverse transcriptase inhibitor levels among HIV-exposed uninfected infants at the time of HIV PCR testing - findings from a tertiary healthcare facility in Pretoria, South Africa.
    Journal of the International AIDS Society, 2019, Volume: 22, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; Cohort Studies; Cyclopropanes; Female

2019
Non-nucleoside reverse transcriptase inhibitor levels among HIV-exposed uninfected infants at the time of HIV PCR testing - findings from a tertiary healthcare facility in Pretoria, South Africa.
    Journal of the International AIDS Society, 2019, Volume: 22, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; Cohort Studies; Cyclopropanes; Female

2019
Increasing body mass index or weight does not appear to influence the association between efavirenz-based antiretroviral therapy and implant effectiveness among HIV-positive women in western Kenya.
    Contraception, 2019, Volume: 100, Issue:4

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; Body Weight; Cohort Stud

2019
Increasing body mass index or weight does not appear to influence the association between efavirenz-based antiretroviral therapy and implant effectiveness among HIV-positive women in western Kenya.
    Contraception, 2019, Volume: 100, Issue:4

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; Body Weight; Cohort Stud

2019
Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda.
    The Journal of antimicrobial chemotherapy, 2019, 10-01, Volume: 74, Issue:10

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Seropositivity; HIV-1; H

2019
Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda.
    The Journal of antimicrobial chemotherapy, 2019, 10-01, Volume: 74, Issue:10

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Seropositivity; HIV-1; H

2019
A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda.
    AIDS (London, England), 2019, 11-01, Volume: 33, Issue:13

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Desogest

2019
A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda.
    AIDS (London, England), 2019, 11-01, Volume: 33, Issue:13

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Desogest

2019
Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants.
    The Pediatric infectious disease journal, 2019, Volume: 38, Issue:10

    Topics: Anti-Retroviral Agents; Chemoprevention; Drug Therapy, Combination; Drug-Related Side Effects and Ad

2019
Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants.
    The Pediatric infectious disease journal, 2019, Volume: 38, Issue:10

    Topics: Anti-Retroviral Agents; Chemoprevention; Drug Therapy, Combination; Drug-Related Side Effects and Ad

2019
Complications of long-term antiretroviral therapy in HIV-infected children.
    Archives of disease in childhood, 2013, Volume: 98, Issue:4

    Topics: Anti-HIV Agents; Body Composition; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Hu

2013
Complications of long-term antiretroviral therapy in HIV-infected children.
    Archives of disease in childhood, 2013, Volume: 98, Issue:4

    Topics: Anti-HIV Agents; Body Composition; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Hu

2013
Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
    Antiviral therapy, 2013, Volume: 18, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2013
Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
    Antiviral therapy, 2013, Volume: 18, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2013
ART and tuberculosis: the final nail in nevirapine's coffin?
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections

2013
ART and tuberculosis: the final nail in nevirapine's coffin?
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections

2013
[Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Medecine et maladies infectieuses, 2013, Volume: 43, Issue:3

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asthenia; Benzoxazi

2013
[Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Medecine et maladies infectieuses, 2013, Volume: 43, Issue:3

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asthenia; Benzoxazi

2013
Detection of drug bioactivation in vivo: mechanism of nevirapine-albumin conjugate formation in patients.
    Chemical research in toxicology, 2013, Apr-15, Volume: 26, Issue:4

    Topics: Adult; Aged; Anti-HIV Agents; Biotransformation; Cysteine; Glutathione S-Transferase pi; Histidine;

2013
Detection of drug bioactivation in vivo: mechanism of nevirapine-albumin conjugate formation in patients.
    Chemical research in toxicology, 2013, Apr-15, Volume: 26, Issue:4

    Topics: Adult; Aged; Anti-HIV Agents; Biotransformation; Cysteine; Glutathione S-Transferase pi; Histidine;

2013
Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, Malawi.
    Malawi medical journal : the journal of Medical Association of Malawi, 2011, Volume: 23, Issue:4

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Ambulatory Care Facilities; Anti-HIV Agents; Cross-S

2011
Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, Malawi.
    Malawi medical journal : the journal of Medical Association of Malawi, 2011, Volume: 23, Issue:4

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Ambulatory Care Facilities; Anti-HIV Agents; Cross-S

2011
Effect of highly active antiretroviral treatment (HAART) during pregnancy on pregnancy outcomes: experiences from a PMTCT program in western India.
    AIDS patient care and STDs, 2013, Volume: 27, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Fem

2013
Effect of highly active antiretroviral treatment (HAART) during pregnancy on pregnancy outcomes: experiences from a PMTCT program in western India.
    AIDS patient care and STDs, 2013, Volume: 27, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Fem

2013
HIV-1 drug resistance among newly HIV-1 infected individuals attending tertiary referral center in Chennai, India.
    Indian journal of medical sciences, 2011, Volume: 65, Issue:11

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Genotype

2011
HIV-1 drug resistance among newly HIV-1 infected individuals attending tertiary referral center in Chennai, India.
    Indian journal of medical sciences, 2011, Volume: 65, Issue:11

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Genotype

2011
Scaling up prevention of mother-to-child HIV transmission programs in sub-Saharan African countries: a multilevel assessment of site-, program- and country-level determinants of performance.
    BMC public health, 2013, Apr-01, Volume: 13

    Topics: Africa South of the Sahara; Anti-HIV Agents; Female; Follow-Up Studies; HIV Infections; Humans; Infe

2013
Scaling up prevention of mother-to-child HIV transmission programs in sub-Saharan African countries: a multilevel assessment of site-, program- and country-level determinants of performance.
    BMC public health, 2013, Apr-01, Volume: 13

    Topics: Africa South of the Sahara; Anti-HIV Agents; Female; Follow-Up Studies; HIV Infections; Humans; Infe

2013
Birth diagnosis of HIV infection in infants to reduce infant mortality and monitor for elimination of mother-to-child transmission.
    The Pediatric infectious disease journal, 2013, Volume: 32, Issue:10

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant; Infant Mortality; Infant, Newborn; I

2013
Birth diagnosis of HIV infection in infants to reduce infant mortality and monitor for elimination of mother-to-child transmission.
    The Pediatric infectious disease journal, 2013, Volume: 32, Issue:10

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant; Infant Mortality; Infant, Newborn; I

2013
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
    Lipids in health and disease, 2013, Apr-10, Volume: 12

    Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxa

2013
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
    Lipids in health and disease, 2013, Apr-10, Volume: 12

    Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxa

2013
Nevirapine-induced Stevens-Johnson syndrome following HIV postexposure prophylaxis.
    BMJ case reports, 2013, Apr-25, Volume: 2013

    Topics: Adult; Diagnosis, Differential; HIV Infections; Humans; Male; Nevirapine; Post-Exposure Prophylaxis;

2013
Nevirapine-induced Stevens-Johnson syndrome following HIV postexposure prophylaxis.
    BMJ case reports, 2013, Apr-25, Volume: 2013

    Topics: Adult; Diagnosis, Differential; HIV Infections; Humans; Male; Nevirapine; Post-Exposure Prophylaxis;

2013
Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children.
    JAMA, 2013, May-01, Volume: 309, Issue:17

    Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Botswana; Child; Child, Preschool; Cohort

2013
Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children.
    JAMA, 2013, May-01, Volume: 309, Issue:17

    Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Botswana; Child; Child, Preschool; Cohort

2013
Talk of HIV cure goes viral.
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child, Preschool; DNA, Viral; Drug Administratio

2013
Talk of HIV cure goes viral.
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child, Preschool; DNA, Viral; Drug Administratio

2013
Nevirapine and/or co-trimoxazole induced Stevens Johnson syndrome in HIV infected patient--a case report.
    Current drug safety, 2013, Volume: 8, Issue:1

    Topics: Anti-HIV Agents; Anti-Infective Agents; Fatal Outcome; HIV Infections; Humans; Male; Middle Aged; Ne

2013
Nevirapine and/or co-trimoxazole induced Stevens Johnson syndrome in HIV infected patient--a case report.
    Current drug safety, 2013, Volume: 8, Issue:1

    Topics: Anti-HIV Agents; Anti-Infective Agents; Fatal Outcome; HIV Infections; Humans; Male; Middle Aged; Ne

2013
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
    European journal of internal medicine, 2013, Volume: 24, Issue:6

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carba

2013
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
    European journal of internal medicine, 2013, Volume: 24, Issue:6

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carba

2013
Antiretroviral drugs in Africa: a public health versus a market approach.
    Journal of acquired immune deficiency syndromes (1999), 2013, Jun-01, Volume: 63, Issue:2

    Topics: Africa; Anti-HIV Agents; Drug Packaging; Health Resources; Health Services Accessibility; HIV Infect

2013
Antiretroviral drugs in Africa: a public health versus a market approach.
    Journal of acquired immune deficiency syndromes (1999), 2013, Jun-01, Volume: 63, Issue:2

    Topics: Africa; Anti-HIV Agents; Drug Packaging; Health Resources; Health Services Accessibility; HIV Infect

2013
A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women.
    Sexually transmitted diseases, 2013, Volume: 40, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiprotozoal Agents; Cohort Studies; Drug Therapy, Combination; Female; HIV

2013
A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women.
    Sexually transmitted diseases, 2013, Volume: 40, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiprotozoal Agents; Cohort Studies; Drug Therapy, Combination; Female; HIV

2013
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
    The Journal of infectious diseases, 2013, Jun-15, Volume: 207 Suppl 2

    Topics: Adenine; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Databases, Factual; Drug Resi

2013
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
    The Journal of infectious diseases, 2013, Jun-15, Volume: 207 Suppl 2

    Topics: Adenine; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Databases, Factual; Drug Resi

2013
Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand.
    The Southeast Asian journal of tropical medicine and public health, 2013, Volume: 44, Issue:2

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Hematologic Tests; HIV Infections; Humans; Imm

2013
Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand.
    The Southeast Asian journal of tropical medicine and public health, 2013, Volume: 44, Issue:2

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Hematologic Tests; HIV Infections; Humans; Imm

2013
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
    AIDS (London, England), 2013, Mar-13, Volume: 27, Issue:5

    Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studi

2013
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
    AIDS (London, England), 2013, Mar-13, Volume: 27, Issue:5

    Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studi

2013
Economic evaluation of 3-drug antiretroviral regimens for the prevention of mother-to-child HIV transmission in Thailand.
    Asia-Pacific journal of public health, 2015, Volume: 27, Issue:2

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cost-Benefit Analysis; Cyclopro

2015
Economic evaluation of 3-drug antiretroviral regimens for the prevention of mother-to-child HIV transmission in Thailand.
    Asia-Pacific journal of public health, 2015, Volume: 27, Issue:2

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cost-Benefit Analysis; Cyclopro

2015
Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.
    BMC infectious diseases, 2013, Jun-03, Volume: 13

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cross-Sectional Studies; C

2013
Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.
    BMC infectious diseases, 2013, Jun-03, Volume: 13

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cross-Sectional Studies; C

2013
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
    AIDS (London, England), 2013, Apr-24, Volume: 27, Issue:7

    Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug

2013
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
    AIDS (London, England), 2013, Apr-24, Volume: 27, Issue:7

    Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug

2013
Stevens-Johnson syndrome and HIV in children in Swaziland.
    The Pediatric infectious disease journal, 2013, Volume: 32, Issue:12

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; C

2013
Stevens-Johnson syndrome and HIV in children in Swaziland.
    The Pediatric infectious disease journal, 2013, Volume: 32, Issue:12

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; C

2013
Adherence to antiretroviral therapy among HIV infected children measured by caretaker report, medication return, and drug level in Dar Es Salaam, Tanzania.
    BMC pediatrics, 2013, Jun-15, Volume: 13

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Caregivers; CD4 Lymphocyte Count; Child; Child, Preschool;

2013
Adherence to antiretroviral therapy among HIV infected children measured by caretaker report, medication return, and drug level in Dar Es Salaam, Tanzania.
    BMC pediatrics, 2013, Jun-15, Volume: 13

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Caregivers; CD4 Lymphocyte Count; Child; Child, Preschool;

2013
HIV-positive nigerian adults harbor significantly higher serum lumefantrine levels than HIV-negative individuals seven days after treatment for Plasmodium falciparum infection.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:9

    Topics: Adult; Anti-HIV Agents; Antimalarials; Antiretroviral Therapy, Highly Active; Artemether, Lumefantri

2013
HIV-positive nigerian adults harbor significantly higher serum lumefantrine levels than HIV-negative individuals seven days after treatment for Plasmodium falciparum infection.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:9

    Topics: Adult; Anti-HIV Agents; Antimalarials; Antiretroviral Therapy, Highly Active; Artemether, Lumefantri

2013
Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study.
    European journal of clinical pharmacology, 2013, Volume: 69, Issue:11

    Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2B6; Female; Genotype; HI

2013
Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study.
    European journal of clinical pharmacology, 2013, Volume: 69, Issue:11

    Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2B6; Female; Genotype; HI

2013
Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:12

    Topics: Acute-Phase Proteins; Adenine; Adult; Anti-HIV Agents; Cross-Sectional Studies; Deoxycytidine; Emtri

2013
Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:12

    Topics: Acute-Phase Proteins; Adenine; Adult; Anti-HIV Agents; Cross-Sectional Studies; Deoxycytidine; Emtri

2013
Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service.
    Journal of acquired immune deficiency syndromes (1999), 2013, Nov-01, Volume: 64, Issue:3

    Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte

2013
Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service.
    Journal of acquired immune deficiency syndromes (1999), 2013, Nov-01, Volume: 64, Issue:3

    Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte

2013
Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
    The Pan African medical journal, 2013, Volume: 15

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Eswatini; Female; Foll

2013
Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
    The Pan African medical journal, 2013, Volume: 15

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Eswatini; Female; Foll

2013
Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen.
    Journal of medical virology, 2013, Volume: 85, Issue:11

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cross-Sectional Studies; Cyclopropane

2013
Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen.
    Journal of medical virology, 2013, Volume: 85, Issue:11

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cross-Sectional Studies; Cyclopropane

2013
Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopro

2013
Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopro

2013
The effect of antiretrovirals on Plasmodium falciparum liver stages.
    AIDS (London, England), 2013, Jun-19, Volume: 27, Issue:10

    Topics: HIV Infections; HIV Protease Inhibitors; Humans; In Vitro Techniques; Liver; Lopinavir; Malaria, Fal

2013
The effect of antiretrovirals on Plasmodium falciparum liver stages.
    AIDS (London, England), 2013, Jun-19, Volume: 27, Issue:10

    Topics: HIV Infections; HIV Protease Inhibitors; Humans; In Vitro Techniques; Liver; Lopinavir; Malaria, Fal

2013
Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis.
    Retrovirology, 2013, Aug-14, Volume: 10

    Topics: Anti-HIV Agents; Chemoprevention; Cluster Analysis; Drug Resistance, Viral; Female; Genotype; HIV In

2013
Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis.
    Retrovirology, 2013, Aug-14, Volume: 10

    Topics: Anti-HIV Agents; Chemoprevention; Cluster Analysis; Drug Resistance, Viral; Female; Genotype; HIV In

2013
Rash and hepatitis within days of starting a new antiretroviral regimen: nevirapine hypersensitivity, secondary syphilis or both?
    International journal of STD & AIDS, 2014, Volume: 25, Issue:3

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Diagnosis, Differential; Exanthema; Hepatitis; HIV Inf

2014
Rash and hepatitis within days of starting a new antiretroviral regimen: nevirapine hypersensitivity, secondary syphilis or both?
    International journal of STD & AIDS, 2014, Volume: 25, Issue:3

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Diagnosis, Differential; Exanthema; Hepatitis; HIV Inf

2014
Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007 - 2012.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2013, Volume: 103, Issue:5

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Female; HIV Infections; Humans; Logistic Models; Nevir

2013
Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007 - 2012.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2013, Volume: 103, Issue:5

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Female; HIV Infections; Humans; Logistic Models; Nevir

2013
HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Resistan

2013
HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Resistan

2013
Anemia and risk factors in HAART naïve and HAART experienced HIV positive persons in south west Ethiopia: a comparative study.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Adolescent; Adult; Anemia; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child

2013
Anemia and risk factors in HAART naïve and HAART experienced HIV positive persons in south west Ethiopia: a comparative study.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Adolescent; Adult; Anemia; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child

2013
Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?
    Pharmacogenetics and genomics, 2013, Volume: 23, Issue:11

    Topics: Adult; Aged; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfa

2013
Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?
    Pharmacogenetics and genomics, 2013, Volume: 23, Issue:11

    Topics: Adult; Aged; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfa

2013
High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Adolescent; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cross-Sectional Stu

2013
High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Adolescent; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cross-Sectional Stu

2013
Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:1

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lym

2014
Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:1

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lym

2014
Child cured of HIV: can this be repeated?
    Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:17

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Infant, Newb

2013
Child cured of HIV: can this be repeated?
    Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:17

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Infant, Newb

2013
Finding of nevirapine extended release tablet remnants in stools does not threaten the success of combination antiretroviral therapy.
    HIV medicine, 2014, Volume: 15, Issue:2

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Delayed-Action Preparations; Dr

2014
Finding of nevirapine extended release tablet remnants in stools does not threaten the success of combination antiretroviral therapy.
    HIV medicine, 2014, Volume: 15, Issue:2

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Delayed-Action Preparations; Dr

2014
Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response.
    Journal of medical virology, 2014, Volume: 86, Issue:6

    Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; En

2014
Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response.
    Journal of medical virology, 2014, Volume: 86, Issue:6

    Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; En

2014
Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Antiviral therapy, 2014, Volume: 19, Issue:1

    Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Combinations; Drug Substitution; F

2014
Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Antiviral therapy, 2014, Volume: 19, Issue:1

    Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Combinations; Drug Substitution; F

2014
[Evaluation of tolerance of zidovudine-lamivudine-nevirapine combination in HIV 1 patients in Fann Teaching Hospital in Dakar].
    Bulletin de la Societe de pathologie exotique (1990), 2013, Volume: 106, Issue:4

    Topics: Adult; Anti-HIV Agents; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female;

2013
[Evaluation of tolerance of zidovudine-lamivudine-nevirapine combination in HIV 1 patients in Fann Teaching Hospital in Dakar].
    Bulletin de la Societe de pathologie exotique (1990), 2013, Volume: 106, Issue:4

    Topics: Adult; Anti-HIV Agents; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female;

2013
Short communication: A low-cost method for analyzing nevirapine levels in hair as a marker of adherence in resource-limited settings.
    AIDS research and human retroviruses, 2014, Volume: 30, Issue:1

    Topics: Anti-HIV Agents; Chromatography, Thin Layer; Hair; HIV Infections; Humans; Medication Adherence; Nev

2014
Short communication: A low-cost method for analyzing nevirapine levels in hair as a marker of adherence in resource-limited settings.
    AIDS research and human retroviruses, 2014, Volume: 30, Issue:1

    Topics: Anti-HIV Agents; Chromatography, Thin Layer; Hair; HIV Infections; Humans; Medication Adherence; Nev

2014
HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants.
    The Journal of nutrition, 2014, Volume: 144, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Black People; Female; Growth Disorders; HIV; HIV Infections; HIV

2014
HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants.
    The Journal of nutrition, 2014, Volume: 144, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Black People; Female; Growth Disorders; HIV; HIV Infections; HIV

2014
Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:2

    Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Biotransformation; Black People; Cytochrome P

2014
Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:2

    Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Biotransformation; Black People; Cytochrome P

2014
HIV-1 drug-resistant minority variants: sweating the small stuff.
    The Journal of infectious diseases, 2014, Mar-01, Volume: 209, Issue:5

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Nevirapine

2014
HIV-1 drug-resistant minority variants: sweating the small stuff.
    The Journal of infectious diseases, 2014, Mar-01, Volume: 209, Issue:5

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Nevirapine

2014
Nevirapine concentrations in saliva measured by thin layer chromatography and self-reported adherence in patients on antiretroviral therapy at Kilimanjaro Christian Medical Centre, Tanzania.
    Therapeutic drug monitoring, 2014, Volume: 36, Issue:3

    Topics: Adolescent; Adult; Alcohol Drinking; Anti-HIV Agents; Body Mass Index; Chromatography, Thin Layer; C

2014
Nevirapine concentrations in saliva measured by thin layer chromatography and self-reported adherence in patients on antiretroviral therapy at Kilimanjaro Christian Medical Centre, Tanzania.
    Therapeutic drug monitoring, 2014, Volume: 36, Issue:3

    Topics: Adolescent; Adult; Alcohol Drinking; Anti-HIV Agents; Body Mass Index; Chromatography, Thin Layer; C

2014
Trends in clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Shanghai from 2006 to 2011.
    International journal of STD & AIDS, 2014, Volume: 25, Issue:7

    Topics: Adolescent; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Cou

2014
Trends in clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Shanghai from 2006 to 2011.
    International journal of STD & AIDS, 2014, Volume: 25, Issue:7

    Topics: Adolescent; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Cou

2014
The effect of efavirenz versus nevirapine-containing regimens in the HIV-CAUSAL Collaboration: reply to Llibre and Podzamczer and additional results.
    AIDS (London, England), 2013, Aug-24, Volume: 27, Issue:13

    Topics: Anti-HIV Agents; Benzoxazines; Hepatitis C; HIV Infections; Humans; Nevirapine; Reverse Transcriptas

2013
The effect of efavirenz versus nevirapine-containing regimens in the HIV-CAUSAL Collaboration: reply to Llibre and Podzamczer and additional results.
    AIDS (London, England), 2013, Aug-24, Volume: 27, Issue:13

    Topics: Anti-HIV Agents; Benzoxazines; Hepatitis C; HIV Infections; Humans; Nevirapine; Reverse Transcriptas

2013
Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies.
    AIDS (London, England), 2014, Mar-13, Volume: 28, Issue:5

    Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Contraceptive Agents, Female; Cycl

2014
Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies.
    AIDS (London, England), 2014, Mar-13, Volume: 28, Issue:5

    Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Contraceptive Agents, Female; Cycl

2014
Preliminary study of quinine pharmacokinetics in pregnant women with malaria-HIV co-infection.
    The American journal of tropical medicine and hygiene, 2014, Volume: 90, Issue:3

    Topics: Adult; Anti-HIV Agents; Antimalarials; Antiretroviral Therapy, Highly Active; Coinfection; Drug Inte

2014
Preliminary study of quinine pharmacokinetics in pregnant women with malaria-HIV co-infection.
    The American journal of tropical medicine and hygiene, 2014, Volume: 90, Issue:3

    Topics: Adult; Anti-HIV Agents; Antimalarials; Antiretroviral Therapy, Highly Active; Coinfection; Drug Inte

2014
Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:5

    Topics: Adolescent; Adult; Amodiaquine; Anti-Retroviral Agents; Antimalarials; Antiretroviral Therapy, Highl

2014
Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:5

    Topics: Adolescent; Adult; Amodiaquine; Anti-Retroviral Agents; Antimalarials; Antiretroviral Therapy, Highl

2014
Clinical profile and response to first-line ARV in HIV patients from Eastern UP and Bihar: a retrospective study.
    The Journal of the Association of Physicians of India, 2013, Volume: 61, Issue:4

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Coun

2013
Clinical profile and response to first-line ARV in HIV patients from Eastern UP and Bihar: a retrospective study.
    The Journal of the Association of Physicians of India, 2013, Volume: 61, Issue:4

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Coun

2013
Population pharmacokinetics of nevirapine in Thai HIV-infected patients.
    Antiviral therapy, 2014, Volume: 19, Issue:7

    Topics: Adolescent; Adult; Aged; Algorithms; Anti-HIV Agents; Datasets as Topic; Drug Monitoring; Female; HI

2014
Population pharmacokinetics of nevirapine in Thai HIV-infected patients.
    Antiviral therapy, 2014, Volume: 19, Issue:7

    Topics: Adolescent; Adult; Aged; Algorithms; Anti-HIV Agents; Datasets as Topic; Drug Monitoring; Female; HI

2014
Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.
    The Indian journal of medical research, 2013, Volume: 138, Issue:6

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genetic Association St

2013
Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.
    The Indian journal of medical research, 2013, Volume: 138, Issue:6

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genetic Association St

2013
Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cerebrospinal F

2014
Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cerebrospinal F

2014
Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cambodia; CD4 Lymphocyte Count; Coinfection; C

2014
Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cambodia; CD4 Lymphocyte Count; Coinfection; C

2014
Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:9

    Topics: Anti-HIV Agents; Drug Therapy, Combination; Epstein-Barr Virus Infections; HIV Infections; Humans; I

2014
Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:9

    Topics: Anti-HIV Agents; Drug Therapy, Combination; Epstein-Barr Virus Infections; HIV Infections; Humans; I

2014
Progress in the prevention of mother to child transmission of HIV in three regions of Tanzania: a retrospective analysis.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dried Blood Spot Testing; Female; HIV Infect

2014
Progress in the prevention of mother to child transmission of HIV in three regions of Tanzania: a retrospective analysis.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dried Blood Spot Testing; Female; HIV Infect

2014
Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxis in South Africa.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:10

    Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active

2014
Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxis in South Africa.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:10

    Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active

2014
Transmission of nevirapine-resistant HIV type 1 via breast milk to infants after single-dose nevirapine in Beira, Mozambique.
    The Journal of infectious diseases, 2014, Aug-15, Volume: 210, Issue:4

    Topics: Anti-HIV Agents; Breast Feeding; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infe

2014
Transmission of nevirapine-resistant HIV type 1 via breast milk to infants after single-dose nevirapine in Beira, Mozambique.
    The Journal of infectious diseases, 2014, Aug-15, Volume: 210, Issue:4

    Topics: Anti-HIV Agents; Breast Feeding; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infe

2014
Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women.
    Journal of acquired immune deficiency syndromes (1999), 2014, Jun-01, Volume: 66, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Desogestrel; Do

2014
Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women.
    Journal of acquired immune deficiency syndromes (1999), 2014, Jun-01, Volume: 66, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Desogestrel; Do

2014
Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces.
    Sexually transmitted infections, 2014, Volume: 90, Issue:7

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies;

2014
Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces.
    Sexually transmitted infections, 2014, Volume: 90, Issue:7

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies;

2014
Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya.
    Journal of acquired immune deficiency syndromes (1999), 2014, Jul-01, Volume: 66, Issue:3

    Topics: Adult; Aged; Anti-Retroviral Agents; Biomarkers; Chromatography, Thin Layer; Feasibility Studies; Fe

2014
Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya.
    Journal of acquired immune deficiency syndromes (1999), 2014, Jul-01, Volume: 66, Issue:3

    Topics: Adult; Aged; Anti-Retroviral Agents; Biomarkers; Chromatography, Thin Layer; Feasibility Studies; Fe

2014
Reduction of nevirapine-driven HIV mutations by carbamazepine is modulated by CYP3A activity.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:7

    Topics: Anti-HIV Agents; Carbamazepine; Chemoprevention; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Indu

2014
Reduction of nevirapine-driven HIV mutations by carbamazepine is modulated by CYP3A activity.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:7

    Topics: Anti-HIV Agents; Carbamazepine; Chemoprevention; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Indu

2014
The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV.
    Bulletin of the World Health Organization, 2014, Mar-01, Volume: 92, Issue:3

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Cohort Studies; Cost-

2014
The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV.
    Bulletin of the World Health Organization, 2014, Mar-01, Volume: 92, Issue:3

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Cohort Studies; Cost-

2014
The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.
    BMC infectious diseases, 2014, Apr-04, Volume: 14

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; Hepatitis B; He

2014
The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.
    BMC infectious diseases, 2014, Apr-04, Volume: 14

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; Hepatitis B; He

2014
Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study.
    Sexually transmitted infections, 2014, Volume: 90, Issue:4

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemo

2014
Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study.
    Sexually transmitted infections, 2014, Volume: 90, Issue:4

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemo

2014
HIV status, breastfeeding modality at 5 months and postpartum maternal weight changes over 24 months in rural South Africa.
    Tropical medicine & international health : TM & IH, 2014, Volume: 19, Issue:7

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Female; Follow-Up Studies; HIV Infections; Humans; Infant; I

2014
HIV status, breastfeeding modality at 5 months and postpartum maternal weight changes over 24 months in rural South Africa.
    Tropical medicine & international health : TM & IH, 2014, Volume: 19, Issue:7

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Female; Follow-Up Studies; HIV Infections; Humans; Infant; I

2014
Presence of HIV drug resistance in antiretroviral therapy-naive and -experienced patients from Papua New Guinea.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:8

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cy

2014
Presence of HIV drug resistance in antiretroviral therapy-naive and -experienced patients from Papua New Guinea.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:8

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cy

2014
Clinical manifestations and treatment outcomes in HIV-1-infected children receiving antiretroviral therapy in Karachi, Pakistan.
    Journal of infection in developing countries, 2014, Apr-15, Volume: 8, Issue:4

    Topics: Anti-HIV Agents; Body Height; Body Weight; CD4 Lymphocyte Count; Child, Preschool; Drug Resistance,

2014
Clinical manifestations and treatment outcomes in HIV-1-infected children receiving antiretroviral therapy in Karachi, Pakistan.
    Journal of infection in developing countries, 2014, Apr-15, Volume: 8, Issue:4

    Topics: Anti-HIV Agents; Body Height; Body Weight; CD4 Lymphocyte Count; Child, Preschool; Drug Resistance,

2014
Pharmacokinetics of nevirapine, stavudine and lamivudine in Indian HIV-infected children receiving generic fixed dose combinations.
    Indian pediatrics, 2014, Volume: 51, Issue:3

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Drugs, Generic; Femal

2014
Pharmacokinetics of nevirapine, stavudine and lamivudine in Indian HIV-infected children receiving generic fixed dose combinations.
    Indian pediatrics, 2014, Volume: 51, Issue:3

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Drugs, Generic; Femal

2014
Evaluating the benefits of incorporating traditional birth attendants in HIV prevention of mother to child transmission service delivery in Lilongwe, Malawi.
    African journal of reproductive health, 2014, Volume: 18, Issue:1

    Topics: Adult; Anti-HIV Agents; Feasibility Studies; Female; Focus Groups; HIV Infections; Humans; Infant, N

2014
Evaluating the benefits of incorporating traditional birth attendants in HIV prevention of mother to child transmission service delivery in Lilongwe, Malawi.
    African journal of reproductive health, 2014, Volume: 18, Issue:1

    Topics: Adult; Anti-HIV Agents; Feasibility Studies; Female; Focus Groups; HIV Infections; Humans; Infant, N

2014
Evaluation of polycaprolactone matrices for sustained vaginal delivery of nevirapine in the prevention of heterosexual HIV transmission.
    Journal of pharmaceutical sciences, 2014, Volume: 103, Issue:7

    Topics: Administration, Intravaginal; Anti-HIV Agents; Chromatography, High Pressure Liquid; Delayed-Action

2014
Evaluation of polycaprolactone matrices for sustained vaginal delivery of nevirapine in the prevention of heterosexual HIV transmission.
    Journal of pharmaceutical sciences, 2014, Volume: 103, Issue:7

    Topics: Administration, Intravaginal; Anti-HIV Agents; Chromatography, High Pressure Liquid; Delayed-Action

2014
Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.
    BMC infectious diseases, 2014, May-05, Volume: 14

    Topics: Alkynes; Benzoxazines; China; Cyclopropanes; Drug Resistance, Multiple, Viral; HIV Infections; HIV R

2014
Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.
    BMC infectious diseases, 2014, May-05, Volume: 14

    Topics: Alkynes; Benzoxazines; China; Cyclopropanes; Drug Resistance, Multiple, Viral; HIV Infections; HIV R

2014
Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.
    Malaria journal, 2014, May-30, Volume: 13

    Topics: Adult; Africa South of the Sahara; Aged; Alkynes; Anti-Retroviral Agents; Antimalarials; Artemether,

2014
Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.
    Malaria journal, 2014, May-30, Volume: 13

    Topics: Adult; Africa South of the Sahara; Aged; Alkynes; Anti-Retroviral Agents; Antimalarials; Artemether,

2014
Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2014, Volume: 88, Issue:2

    Topics: Adenine; Anti-HIV Agents; Drug Administration Routes; Drug Synergism; Drug Therapy, Combination; Fem

2014
Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2014, Volume: 88, Issue:2

    Topics: Adenine; Anti-HIV Agents; Drug Administration Routes; Drug Synergism; Drug Therapy, Combination; Fem

2014
Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:10

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Com

2014
Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:10

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Com

2014
HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity.
    AIDS (London, England), 2014, Aug-24, Volume: 28, Issue:13

    Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; Drug Hypersensitivity

2014
HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity.
    AIDS (London, England), 2014, Aug-24, Volume: 28, Issue:13

    Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; Drug Hypersensitivity

2014
Switching from efavirenz to nevirapine in children: 1-week dose escalation strategy.
    AIDS research and human retroviruses, 2014, Volume: 30, Issue:8

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Female; HIV Infections; Hu

2014
Switching from efavirenz to nevirapine in children: 1-week dose escalation strategy.
    AIDS research and human retroviruses, 2014, Volume: 30, Issue:8

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Female; HIV Infections; Hu

2014
Nevirapine concentrations in preterm and low birth weight HIV-exposed infants: implications for dosing recommendations.
    The Pediatric infectious disease journal, 2014, Volume: 33, Issue:12

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn;

2014
Nevirapine concentrations in preterm and low birth weight HIV-exposed infants: implications for dosing recommendations.
    The Pediatric infectious disease journal, 2014, Volume: 33, Issue:12

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn;

2014
Improved retention of patients starting antiretroviral treatment in Karonga District, northern Malawi, 2005-2012.
    Journal of acquired immune deficiency syndromes (1999), 2014, Sep-01, Volume: 67, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Hu

2014
Improved retention of patients starting antiretroviral treatment in Karonga District, northern Malawi, 2005-2012.
    Journal of acquired immune deficiency syndromes (1999), 2014, Sep-01, Volume: 67, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Hu

2014
HIV is detected in child thought to have been cured.
    BMJ (Clinical research ed.), 2014, Jul-14, Volume: 349

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Early Medical Intervention

2014
HIV is detected in child thought to have been cured.
    BMJ (Clinical research ed.), 2014, Jul-14, Volume: 349

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Early Medical Intervention

2014
Etravirine and rilpivirine-specific mutations selected by efavirenz and nevirapine exposure in patients infected with HIV-1 non-B subtypes.
    AIDS (London, England), 2014, Sep-24, Volume: 28, Issue:15

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genotype; HIV Infecti

2014
Etravirine and rilpivirine-specific mutations selected by efavirenz and nevirapine exposure in patients infected with HIV-1 non-B subtypes.
    AIDS (London, England), 2014, Sep-24, Volume: 28, Issue:15

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genotype; HIV Infecti

2014
Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Dec-01, Volume: 59, Issue:11

    Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus;

2014
Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Dec-01, Volume: 59, Issue:11

    Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus;

2014
Impact of adherence and anthropometric characteristics on nevirapine pharmacokinetics and exposure among HIV-infected Kenyan children.
    Journal of acquired immune deficiency syndromes (1999), 2014, Nov-01, Volume: 67, Issue:3

    Topics: Adolescent; Anthropometry; Anti-HIV Agents; Biological Availability; Body Size; Body Water; Child; C

2014
Impact of adherence and anthropometric characteristics on nevirapine pharmacokinetics and exposure among HIV-infected Kenyan children.
    Journal of acquired immune deficiency syndromes (1999), 2014, Nov-01, Volume: 67, Issue:3

    Topics: Adolescent; Anthropometry; Anti-HIV Agents; Biological Availability; Body Size; Body Water; Child; C

2014
CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:12

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Cohort Studies; Cytochrome P-450 CYP2B6; Drug Hypersen

2014
CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:12

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Cohort Studies; Cytochrome P-450 CYP2B6; Drug Hypersen

2014
Therapeutic drug monitoring of nevirapine in saliva in Uganda using high performance liquid chromatography and a low cost thin-layer chromatography technique.
    BMC infectious diseases, 2014, Sep-01, Volume: 14

    Topics: Adult; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Cohort Studies; Cross-Secti

2014
Therapeutic drug monitoring of nevirapine in saliva in Uganda using high performance liquid chromatography and a low cost thin-layer chromatography technique.
    BMC infectious diseases, 2014, Sep-01, Volume: 14

    Topics: Adult; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Cohort Studies; Cross-Secti

2014
Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asia; Dideoxynucleosides; Drug-Relate

2014
Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asia; Dideoxynucleosides; Drug-Relate

2014
Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Child; Child, Preschool; Drug Resistance, Viral; Drug Substitution; Drug Therapy, Combination; Femal

2014
Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Child; Child, Preschool; Drug Resistance, Viral; Drug Substitution; Drug Therapy, Combination; Femal

2014
Optimization of the oligonucleotide ligation assay for the detection of nevirapine resistance mutations in Zimbabwean Human Immunodeficiency Virus type-1 subtype C.
    Journal of virological methods, 2014, 12-15, Volume: 210

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Genotype; Genotyping Techniques; HIV Infections; HIV-1; Hum

2014
Optimization of the oligonucleotide ligation assay for the detection of nevirapine resistance mutations in Zimbabwean Human Immunodeficiency Virus type-1 subtype C.
    Journal of virological methods, 2014, 12-15, Volume: 210

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Genotype; Genotyping Techniques; HIV Infections; HIV-1; Hum

2014
Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzo

2015
Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzo

2015
Initiation of antiretroviral therapy in HIV-infected adults with skin complaints in northern Tanzania.
    International journal of dermatology, 2015, Volume: 54, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV; HIV Infections; Humans;

2015
Initiation of antiretroviral therapy in HIV-infected adults with skin complaints in northern Tanzania.
    International journal of dermatology, 2015, Volume: 54, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV; HIV Infections; Humans;

2015
Variable and suboptimal nevirapine levels in infants given single-dose nevirapine at birth without maternal prophylaxis.
    AIDS (London, England), 2014, Oct-23, Volume: 28, Issue:16

    Topics: Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Infant, Newborn; Nevirapine; Plasma

2014
Variable and suboptimal nevirapine levels in infants given single-dose nevirapine at birth without maternal prophylaxis.
    AIDS (London, England), 2014, Oct-23, Volume: 28, Issue:16

    Topics: Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Infant, Newborn; Nevirapine; Plasma

2014
Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2014, Volume: 29

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Exanthema; Female; Hepatitis C Antibodies; HIV In

2014
Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2014, Volume: 29

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Exanthema; Female; Hepatitis C Antibodies; HIV In

2014
Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India.
    African health sciences, 2014, Volume: 14, Issue:2

    Topics: Adolescent; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool;

2014
Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India.
    African health sciences, 2014, Volume: 14, Issue:2

    Topics: Adolescent; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool;

2014
The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.
    Journal of the International AIDS Society, 2014, Volume: 17

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Follow-Up Studies;

2014
The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.
    Journal of the International AIDS Society, 2014, Volume: 17

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Follow-Up Studies;

2014
Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study.
    BMC infectious diseases, 2014, Oct-30, Volume: 14

    Topics: Adult; Aged; Anti-Retroviral Agents; Asia; CD4 Lymphocyte Count; Cohort Studies; Drug Administration

2014
Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study.
    BMC infectious diseases, 2014, Oct-30, Volume: 14

    Topics: Adult; Aged; Anti-Retroviral Agents; Asia; CD4 Lymphocyte Count; Cohort Studies; Drug Administration

2014
Detecting virological failure in HIV-infected Tanzanian children.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2014, Jun-26, Volume: 104, Issue:10

    Topics: Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2014
Detecting virological failure in HIV-infected Tanzanian children.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2014, Jun-26, Volume: 104, Issue:10

    Topics: Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2014
Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi.
    British journal of clinical pharmacology, 2015, Volume: 79, Issue:5

    Topics: Adult; Anti-HIV Agents; Blood Stains; Burundi; Child; Cross-Sectional Studies; Drug Monitoring; Drug

2015
Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi.
    British journal of clinical pharmacology, 2015, Volume: 79, Issue:5

    Topics: Adult; Anti-HIV Agents; Blood Stains; Burundi; Child; Cross-Sectional Studies; Drug Monitoring; Drug

2015
Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint.
    AIDS (London, England), 2014, Oct-23, Volume: 28, Issue:16

    Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Drug Monitoring; HIV Infections; Humans; Lopinavir; Nevi

2014
Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint.
    AIDS (London, England), 2014, Oct-23, Volume: 28, Issue:16

    Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Drug Monitoring; HIV Infections; Humans; Lopinavir; Nevi

2014
HIV testing in pregnancy.
    Sexually transmitted infections, 2014, Volume: 90, Issue:8

    Topics: Adenine; Anti-HIV Agents; Benzoxazines; Female; HIV Infections; Humans; Infectious Disease Transmiss

2014
HIV testing in pregnancy.
    Sexually transmitted infections, 2014, Volume: 90, Issue:8

    Topics: Adenine; Anti-HIV Agents; Benzoxazines; Female; HIV Infections; Humans; Infectious Disease Transmiss

2014
Clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.
    The Southeast Asian journal of tropical medicine and public health, 2014, Volume: 45, Issue:5

    Topics: Adult; Age Factors; Alkynes; Ambulatory Care Facilities; Anti-Retroviral Agents; Benzoxazines; Cross

2014
Clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.
    The Southeast Asian journal of tropical medicine and public health, 2014, Volume: 45, Issue:5

    Topics: Adult; Age Factors; Alkynes; Ambulatory Care Facilities; Anti-Retroviral Agents; Benzoxazines; Cross

2014
Assessment of HIV antiretroviral therapy adherence by measuring drug concentrations in hair among children in rural Uganda.
    AIDS care, 2015, Volume: 27, Issue:3

    Topics: Anti-HIV Agents; Child; Child, Preschool; Female; Hair; HIV Infections; Humans; Longitudinal Studies

2015
Assessment of HIV antiretroviral therapy adherence by measuring drug concentrations in hair among children in rural Uganda.
    AIDS care, 2015, Volume: 27, Issue:3

    Topics: Anti-HIV Agents; Child; Child, Preschool; Female; Hair; HIV Infections; Humans; Longitudinal Studies

2015
[Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy].
    Enfermedades infecciosas y microbiologia clinica, 2016, Volume: 34, Issue:1

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cross-Sectional Studies; Female; HIV Infect

2016
[Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy].
    Enfermedades infecciosas y microbiologia clinica, 2016, Volume: 34, Issue:1

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cross-Sectional Studies; Female; HIV Infect

2016
Missing HIV prevention opportunities in South African children--a 7-year review.
    BMC public health, 2014, Dec-13, Volume: 14

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Child, Preschool; Female; Health Promotion; HIV Infection

2014
Missing HIV prevention opportunities in South African children--a 7-year review.
    BMC public health, 2014, Dec-13, Volume: 14

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Child, Preschool; Female; Health Promotion; HIV Infection

2014
Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs--modern Trojan horses to combat HIV.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2015, Volume: 89

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Antigens; Drug Carriers; HEK293 Cells; H

2015
Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs--modern Trojan horses to combat HIV.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2015, Volume: 89

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Antigens; Drug Carriers; HEK293 Cells; H

2015
Nevirapine-related adverse events among children switched from efavirenz to nevirapine as compared to children who were started on nevirapine-based antiretroviral therapy directly.
    AIDS care, 2015, Volume: 27, Issue:5

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes

2015
Nevirapine-related adverse events among children switched from efavirenz to nevirapine as compared to children who were started on nevirapine-based antiretroviral therapy directly.
    AIDS care, 2015, Volume: 27, Issue:5

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes

2015
Virological efficacy of a reduced dose of nevirapine in a small cohort of suppressed HIV-1-infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2015, Apr-01, Volume: 68, Issue:4

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies;

2015
Virological efficacy of a reduced dose of nevirapine in a small cohort of suppressed HIV-1-infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2015, Apr-01, Volume: 68, Issue:4

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies;

2015
Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine.
    Disease markers, 2014, Volume: 2014

    Topics: Alanine Transaminase; Anti-HIV Agents; Biomarkers; Blood Proteins; Chemical and Drug Induced Liver I

2014
Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine.
    Disease markers, 2014, Volume: 2014

    Topics: Alanine Transaminase; Anti-HIV Agents; Biomarkers; Blood Proteins; Chemical and Drug Induced Liver I

2014
Comprehensive evaluation of caregiver-reported antiretroviral therapy adherence for HIV-infected children.
    AIDS and behavior, 2015, Volume: 19, Issue:4

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Caregiver

2015
Comprehensive evaluation of caregiver-reported antiretroviral therapy adherence for HIV-infected children.
    AIDS and behavior, 2015, Volume: 19, Issue:4

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Caregiver

2015
[Recurrence of Stevens-Johnson syndrome following erroneous readministration of nevirapine].
    Annales de dermatologie et de venereologie, 2015, Volume: 142, Issue:5

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Medication Errors; Nevirapine; Recurrence; S

2015
[Recurrence of Stevens-Johnson syndrome following erroneous readministration of nevirapine].
    Annales de dermatologie et de venereologie, 2015, Volume: 142, Issue:5

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Medication Errors; Nevirapine; Recurrence; S

2015
Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2015, Volume: 21, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug R

2015
Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2015, Volume: 21, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug R

2015
The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.
    The Pediatric infectious disease journal, 2015, Volume: 34, Issue:3

    Topics: Adolescent; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Cyclopropane

2015
The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.
    The Pediatric infectious disease journal, 2015, Volume: 34, Issue:3

    Topics: Adolescent; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Cyclopropane

2015
A pharmacogenetics study in Mozambican patients treated with nevirapine: full resequencing of TRAF3IP2 gene shows a novel association with SJS/TEN susceptibility.
    International journal of molecular sciences, 2015, Mar-12, Volume: 16, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Adult; Alleles; Anti-HIV Agents; Black People; Exons; Genetic

2015
A pharmacogenetics study in Mozambican patients treated with nevirapine: full resequencing of TRAF3IP2 gene shows a novel association with SJS/TEN susceptibility.
    International journal of molecular sciences, 2015, Mar-12, Volume: 16, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Adult; Alleles; Anti-HIV Agents; Black People; Exons; Genetic

2015
Painless penile papule.
    The Journal of family practice, 2015, Volume: 64, Issue:3

    Topics: Adenine; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biops

2015
Painless penile papule.
    The Journal of family practice, 2015, Volume: 64, Issue:3

    Topics: Adenine; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biops

2015
Nevirapine, sodium concentration and HIV-1 RNA in breast milk and plasma among HIV-infected women receiving short-course antiretroviral prophylaxis.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV-1; Humans

2015
Nevirapine, sodium concentration and HIV-1 RNA in breast milk and plasma among HIV-infected women receiving short-course antiretroviral prophylaxis.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV-1; Humans

2015
Genetic Analyses of HIV-1 Strains Transmitted from Mother to Child in Northern Vietnam.
    AIDS research and human retroviruses, 2015, Volume: 31, Issue:8

    Topics: Anti-HIV Agents; Cluster Analysis; Drug Resistance, Viral; Female; Follow-Up Studies; Genetic Variat

2015
Genetic Analyses of HIV-1 Strains Transmitted from Mother to Child in Northern Vietnam.
    AIDS research and human retroviruses, 2015, Volume: 31, Issue:8

    Topics: Anti-HIV Agents; Cluster Analysis; Drug Resistance, Viral; Female; Follow-Up Studies; Genetic Variat

2015
CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa.
    International journal of epidemiology, 2015, Volume: 44, Issue:1

    Topics: Adult; Africa; Alkynes; Anti-HIV Agents; Asia; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dr

2015
CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa.
    International journal of epidemiology, 2015, Volume: 44, Issue:1

    Topics: Adult; Africa; Alkynes; Anti-HIV Agents; Asia; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dr

2015
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
    AIDS (London, England), 2015, Jun-19, Volume: 29, Issue:10

    Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Clinical Trials as

2015
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
    AIDS (London, England), 2015, Jun-19, Volume: 29, Issue:10

    Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Clinical Trials as

2015
[Analysis on HIV suppression effect after initiating antiretroviral treatment and related factors among AIDS patients in Henan province during 2008 and 2013].
    Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine], 2015, Volume: 49, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; H

2015
[Analysis on HIV suppression effect after initiating antiretroviral treatment and related factors among AIDS patients in Henan province during 2008 and 2013].
    Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine], 2015, Volume: 49, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; H

2015
Time trends of baseline demographics and clinical characteristics of HIV infected children enrolled in care and treatment service in Dar es Salaam, Tanzania.
    BMC infectious diseases, 2015, Mar-26, Volume: 15

    Topics: Adolescent; Age Distribution; Alkynes; Ambulatory Care Facilities; Anti-HIV Agents; Benzoxazines; CD

2015
Time trends of baseline demographics and clinical characteristics of HIV infected children enrolled in care and treatment service in Dar es Salaam, Tanzania.
    BMC infectious diseases, 2015, Mar-26, Volume: 15

    Topics: Adolescent; Age Distribution; Alkynes; Ambulatory Care Facilities; Anti-HIV Agents; Benzoxazines; CD

2015
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
    Malaria journal, 2015, Apr-25, Volume: 14

    Topics: Adult; Aged; Alkynes; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Cyclopropanes; Drug Inter

2015
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
    Malaria journal, 2015, Apr-25, Volume: 14

    Topics: Adult; Aged; Alkynes; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Cyclopropanes; Drug Inter

2015
Lack of evidence for the selection of E138 mutations by first-generation non-nucleoside reverse transcriptase inhibitors in patients infected with HIV-1 non-B subtypes.
    AIDS (London, England), 2015, May-15, Volume: 29, Issue:8

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcript

2015
Lack of evidence for the selection of E138 mutations by first-generation non-nucleoside reverse transcriptase inhibitors in patients infected with HIV-1 non-B subtypes.
    AIDS (London, England), 2015, May-15, Volume: 29, Issue:8

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcript

2015
Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Atherosclerosis; Benzoxazines; Biomarkers; Blood Pressure; C-Reacti

2015
Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Atherosclerosis; Benzoxazines; Biomarkers; Blood Pressure; C-Reacti

2015
A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
    Journal of medical virology, 2015, Volume: 87, Issue:10

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Deoxycytidine; Drug Administra

2015
A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
    Journal of medical virology, 2015, Volume: 87, Issue:10

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Deoxycytidine; Drug Administra

2015
Simultaneous And Extended Delivery Of Stavudine, Lamivudine And Nevirapine In Fixed Dose Combination Using Sandwiched Osmotic Tablets For Hiv Therapy.
    Current drug delivery, 2015, Volume: 12, Issue:5

    Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Carriers; Drug Delivery System

2015
Simultaneous And Extended Delivery Of Stavudine, Lamivudine And Nevirapine In Fixed Dose Combination Using Sandwiched Osmotic Tablets For Hiv Therapy.
    Current drug delivery, 2015, Volume: 12, Issue:5

    Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Carriers; Drug Delivery System

2015
Post-marketing experience with nevirapine extended release (XR) tablets: effectiveness and tolerability in a population-based cohort in British Columbia, Canada.
    Antiviral therapy, 2015, Volume: 20, Issue:7

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; British Columbia; Cohort Studies; Del

2015
Post-marketing experience with nevirapine extended release (XR) tablets: effectiveness and tolerability in a population-based cohort in British Columbia, Canada.
    Antiviral therapy, 2015, Volume: 20, Issue:7

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; British Columbia; Cohort Studies; Del

2015
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
    The pharmacogenomics journal, 2016, Volume: 16, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; ATP Binding Cassette Transporter,

2016
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
    The pharmacogenomics journal, 2016, Volume: 16, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; ATP Binding Cassette Transporter,

2016
Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi.
    Journal of the International AIDS Society, 2015, Volume: 18

    Topics: Adult; Cohort Studies; Female; HIV Infections; Humans; Lamivudine; Malawi; Male; Nevirapine; Retrosp

2015
Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi.
    Journal of the International AIDS Society, 2015, Volume: 18

    Topics: Adult; Cohort Studies; Female; HIV Infections; Humans; Lamivudine; Malawi; Male; Nevirapine; Retrosp

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma

2015
The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:8

    Topics: Anti-HIV Agents; Cell Line; China; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase

2015
The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:8

    Topics: Anti-HIV Agents; Cell Line; China; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase

2015
Performance of HIV Prevention of Mother-To-Child Transmission Programs in Sub-Saharan Africa: Longitudinal Assessment of 64 Nevirapine-Based Programs Implemented in 25 Countries, 2000-2011.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infection

2015
Performance of HIV Prevention of Mother-To-Child Transmission Programs in Sub-Saharan Africa: Longitudinal Assessment of 64 Nevirapine-Based Programs Implemented in 25 Countries, 2000-2011.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infection

2015
Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:10

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female;

2015
Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:10

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female;

2015
Lower Preprandial Insulin and Altered Fuel Use in HIV/Antiretroviral-Exposed Infants in Cameroon.
    The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:9

    Topics: Amino Acids, Branched-Chain; Anti-Retroviral Agents; Cameroon; Energy Metabolism; Female; HIV Infect

2015
Lower Preprandial Insulin and Altered Fuel Use in HIV/Antiretroviral-Exposed Infants in Cameroon.
    The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:9

    Topics: Amino Acids, Branched-Chain; Anti-Retroviral Agents; Cameroon; Energy Metabolism; Female; HIV Infect

2015
Missed Opportunities along the Prevention of Mother-to-Child Transmission Services Cascade in South Africa: Uptake, Determinants, and Attributable Risk (the SAPMTCTE).
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Adolescent; Adult; AIDS Serodiagnosis; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studie

2015
Missed Opportunities along the Prevention of Mother-to-Child Transmission Services Cascade in South Africa: Uptake, Determinants, and Attributable Risk (the SAPMTCTE).
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Adolescent; Adult; AIDS Serodiagnosis; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studie

2015
Development of Nevirapine Resistance in Children Exposed to the Prevention of Mother-to-Child HIV-1 Transmission Programme in Maputo, Mozambique.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Anti-HIV Agents; Cross-Sectional Studies; DNA Mutational Analysis; Drug Resistance, Viral; Female; G

2015
Development of Nevirapine Resistance in Children Exposed to the Prevention of Mother-to-Child HIV-1 Transmission Programme in Maputo, Mozambique.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Anti-HIV Agents; Cross-Sectional Studies; DNA Mutational Analysis; Drug Resistance, Viral; Female; G

2015
Frequent nevirapine resistance in infants infected by HIV-1 via breastfeeding while on nevirapine prophylaxis.
    AIDS (London, England), 2015, Oct-23, Volume: 29, Issue:16

    Topics: Anti-HIV Agents; Breast Feeding; Chemoprevention; Drug Resistance, Viral; Female; Genotype; HIV Infe

2015
Frequent nevirapine resistance in infants infected by HIV-1 via breastfeeding while on nevirapine prophylaxis.
    AIDS (London, England), 2015, Oct-23, Volume: 29, Issue:16

    Topics: Anti-HIV Agents; Breast Feeding; Chemoprevention; Drug Resistance, Viral; Female; Genotype; HIV Infe

2015
Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.
    AIDS (London, England), 2015, Aug-24, Volume: 29, Issue:13

    Topics: Anti-Retroviral Agents; Child, Preschool; Female; HIV Infections; Humans; Infant; Male; Nevirapine;

2015
Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.
    AIDS (London, England), 2015, Aug-24, Volume: 29, Issue:13

    Topics: Anti-Retroviral Agents; Child, Preschool; Female; HIV Infections; Humans; Infant; Male; Nevirapine;

2015
Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.
    BMC health services research, 2015, Jul-28, Volume: 15

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Depression; Fema

2015
Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.
    BMC health services research, 2015, Jul-28, Volume: 15

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Depression; Fema

2015
Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.
    HIV medicine, 2015, Volume: 16, Issue:10

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Di

2015
Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.
    HIV medicine, 2015, Volume: 16, Issue:10

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Di

2015
CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2015, Volume: 35

    Topics: Adolescent; Adult; Alkynes; Benzoxazines; Black People; Cameroon; Child; Child, Preschool; Cross-Sec

2015
CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2015, Volume: 35

    Topics: Adolescent; Adult; Alkynes; Benzoxazines; Black People; Cameroon; Child; Child, Preschool; Cross-Sec

2015
Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Anti-HIV Agents; Female; Fetus; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy Outcome; St

2015
Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Anti-HIV Agents; Female; Fetus; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy Outcome; St

2015
Manuscript title: Facilitators and barriers to cotrimoxazole prophylaxis among HIV exposed babies: a qualitative study from Harare, Zimbabwe.
    BMC public health, 2015, Aug-15, Volume: 15

    Topics: Adult; Cross-Sectional Studies; Drug Combinations; Female; HIV Infections; Humans; Infant; Nevirapin

2015
Manuscript title: Facilitators and barriers to cotrimoxazole prophylaxis among HIV exposed babies: a qualitative study from Harare, Zimbabwe.
    BMC public health, 2015, Aug-15, Volume: 15

    Topics: Adult; Cross-Sectional Studies; Drug Combinations; Female; HIV Infections; Humans; Infant; Nevirapin

2015
Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort.
    Current HIV research, 2016, Volume: 14, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2016
Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort.
    Current HIV research, 2016, Volume: 14, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2016
HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:12

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; DNA, Viral;

2015
HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:12

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; DNA, Viral;

2015
Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.
    Omics : a journal of integrative biology, 2015, Volume: 19, Issue:9

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Cytochrome P-450 CYP1A2; Cyto

2015
Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.
    Omics : a journal of integrative biology, 2015, Volume: 19, Issue:9

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Cytochrome P-450 CYP1A2; Cyto

2015
Notes on the road to perfection; use of nevirapine in combination antiretroviral therapy for children with perinatal nevirapine exposure.
    AIDS (London, England), 2015, Aug-24, Volume: 29, Issue:13

    Topics: Anti-Retroviral Agents; Female; HIV Infections; Humans; Male; Nevirapine; Viral Load

2015
Notes on the road to perfection; use of nevirapine in combination antiretroviral therapy for children with perinatal nevirapine exposure.
    AIDS (London, England), 2015, Aug-24, Volume: 29, Issue:13

    Topics: Anti-Retroviral Agents; Female; HIV Infections; Humans; Male; Nevirapine; Viral Load

2015
Raltegravir/nevirapine dual therapy at reduced doses as 'maintenance' treatment in virally suppressed HIV-infected patients.
    AIDS (London, England), 2015, Aug-24, Volume: 29, Issue:13

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV; HI

2015
Raltegravir/nevirapine dual therapy at reduced doses as 'maintenance' treatment in virally suppressed HIV-infected patients.
    AIDS (London, England), 2015, Aug-24, Volume: 29, Issue:13

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV; HI

2015
Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:12

    Topics: Adult; Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; Case-Control Studies; Coinfection;

2015
Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:12

    Topics: Adult; Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; Case-Control Studies; Coinfection;

2015
Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot study.
    Antiviral therapy, 2016, Volume: 21, Issue:3

    Topics: Adult; Anti-HIV Agents; Bone Density; Cohort Studies; Emtricitabine, Tenofovir Disoproxil Fumarate D

2016
Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot study.
    Antiviral therapy, 2016, Volume: 21, Issue:3

    Topics: Adult; Anti-HIV Agents; Bone Density; Cohort Studies; Emtricitabine, Tenofovir Disoproxil Fumarate D

2016
Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics.
    Current HIV research, 2016, Volume: 14, Issue:1

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy

2016
Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics.
    Current HIV research, 2016, Volume: 14, Issue:1

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy

2016
A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study".
    BMC public health, 2015, Sep-29, Volume: 15

    Topics: Adult; Cross-Sectional Studies; Disclosure; Fear; Female; HIV Infections; HIV-1; Humans; Mass Screen

2015
A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study".
    BMC public health, 2015, Sep-29, Volume: 15

    Topics: Adult; Cross-Sectional Studies; Disclosure; Fear; Female; HIV Infections; HIV-1; Humans; Mass Screen

2015
Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
    Tropical medicine & international health : TM & IH, 2015, Volume: 20, Issue:12

    Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antitubercular Agents; Cambodia; Drug Interactio

2015
Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
    Tropical medicine & international health : TM & IH, 2015, Volume: 20, Issue:12

    Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antitubercular Agents; Cambodia; Drug Interactio

2015
HAART, DOTS and renal disease of patients co-infected with HIV/AIDS and TB in the South West Region of Cameroon.
    BMC public health, 2015, Oct-09, Volume: 15

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antiretroviral Therapy, Highly Active; Cameroon; Co

2015
HAART, DOTS and renal disease of patients co-infected with HIV/AIDS and TB in the South West Region of Cameroon.
    BMC public health, 2015, Oct-09, Volume: 15

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antiretroviral Therapy, Highly Active; Cameroon; Co

2015
Longitudinal adherence to antiretroviral drugs for preventing mother-to-child transmission of HIV in Zambia.
    BMC pregnancy and childbirth, 2015, Oct-12, Volume: 15

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis

2015
Longitudinal adherence to antiretroviral drugs for preventing mother-to-child transmission of HIV in Zambia.
    BMC pregnancy and childbirth, 2015, Oct-12, Volume: 15

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis

2015
Tracing defaulters in HIV prevention of mother-to-child transmission programmes through community health workers: results from a rural setting in Zimbabwe.
    Journal of the International AIDS Society, 2015, Volume: 18

    Topics: Adult; Cohort Studies; Community Health Workers; Female; HIV Infections; Humans; Infant, Newborn; In

2015
Tracing defaulters in HIV prevention of mother-to-child transmission programmes through community health workers: results from a rural setting in Zimbabwe.
    Journal of the International AIDS Society, 2015, Volume: 18

    Topics: Adult; Cohort Studies; Community Health Workers; Female; HIV Infections; Humans; Infant, Newborn; In

2015
Presence of Tablet Remnants of Nevirapine Extended-Release in Stools and Its Impact on Virological Outcome in HIV-1-Infected Patients: A Prospective Cohort Study.
    PloS one, 2015, Volume: 10, Issue:10

    Topics: Adult; Anti-HIV Agents; Drug Liberation; Feces; Female; HIV Infections; HIV-1; Humans; Male; Middle

2015
Presence of Tablet Remnants of Nevirapine Extended-Release in Stools and Its Impact on Virological Outcome in HIV-1-Infected Patients: A Prospective Cohort Study.
    PloS one, 2015, Volume: 10, Issue:10

    Topics: Adult; Anti-HIV Agents; Drug Liberation; Feces; Female; HIV Infections; HIV-1; Humans; Male; Middle

2015
Outcome of Prevention of Parent-to-Child Transmission of HIV in an Urban Population in Southern India.
    Indian pediatrics, 2015, Volume: 52, Issue:9

    Topics: Adult; Anti-HIV Agents; Antibiotic Prophylaxis; CD4 Lymphocyte Count; HIV Infections; HIV-1; Humans;

2015
Outcome of Prevention of Parent-to-Child Transmission of HIV in an Urban Population in Southern India.
    Indian pediatrics, 2015, Volume: 52, Issue:9

    Topics: Adult; Anti-HIV Agents; Antibiotic Prophylaxis; CD4 Lymphocyte Count; HIV Infections; HIV-1; Humans;

2015
Antiretroviral Therapy for Nevirapine-Exposed Children With HIV Infection.
    JAMA, 2015, Nov-03, Volume: 314, Issue:17

    Topics: Anti-Retroviral Agents; Benzoxazines; Female; HIV Infections; Humans; Infectious Disease Transmissio

2015
Antiretroviral Therapy for Nevirapine-Exposed Children With HIV Infection.
    JAMA, 2015, Nov-03, Volume: 314, Issue:17

    Topics: Anti-Retroviral Agents; Benzoxazines; Female; HIV Infections; Humans; Infectious Disease Transmissio

2015
Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Feb-15, Volume: 62, Issue:4

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort S

2016
Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Feb-15, Volume: 62, Issue:4

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort S

2016
Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children.
    Infectious diseases (London, England), 2016, Volume: 48, Issue:4

    Topics: Adult; Anti-HIV Agents; Bacterial Capsules; Child, Preschool; Female; HIV Infections; Humans; Immuno

2016
Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children.
    Infectious diseases (London, England), 2016, Volume: 48, Issue:4

    Topics: Adult; Anti-HIV Agents; Bacterial Capsules; Child, Preschool; Female; HIV Infections; Humans; Immuno

2016
The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants.
    Journal of the International AIDS Society, 2015, Volume: 18, Issue:Suppl 6

    Topics: Female; HIV Infections; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature

2015
The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants.
    Journal of the International AIDS Society, 2015, Volume: 18, Issue:Suppl 6

    Topics: Female; HIV Infections; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature

2015
Clinical, Virologic, Immunologic Outcomes and Emerging HIV Drug Resistance Patterns in Children and Adolescents in Public ART Care in Zimbabwe.
    PloS one, 2015, Volume: 10, Issue:12

    Topics: Adolescent; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; C

2015
Clinical, Virologic, Immunologic Outcomes and Emerging HIV Drug Resistance Patterns in Children and Adolescents in Public ART Care in Zimbabwe.
    PloS one, 2015, Volume: 10, Issue:12

    Topics: Adolescent; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; C

2015
Supra-treatment threshold neonatal jaundice: Incidence in HIV-exposed compared to non-exposed neonates at Queen Elizabeth Central Hospital in Blantyre, Malawi.
    Malawi medical journal : the journal of Medical Association of Malawi, 2015, Volume: 27, Issue:3

    Topics: Anti-HIV Agents; Bilirubin; Breast Feeding; Comorbidity; Female; Gestational Age; HIV Infections; Hu

2015
Supra-treatment threshold neonatal jaundice: Incidence in HIV-exposed compared to non-exposed neonates at Queen Elizabeth Central Hospital in Blantyre, Malawi.
    Malawi medical journal : the journal of Medical Association of Malawi, 2015, Volume: 27, Issue:3

    Topics: Anti-HIV Agents; Bilirubin; Breast Feeding; Comorbidity; Female; Gestational Age; HIV Infections; Hu

2015
Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
    The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:4

    Topics: Adult; Antitubercular Agents; Diarylquinolines; Drug Combinations; Drug Interactions; Drug Monitorin

2016
Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
    The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:4

    Topics: Adult; Antitubercular Agents; Diarylquinolines; Drug Combinations; Drug Interactions; Drug Monitorin

2016
Nevirapine Plasma Concentrations in Human Immunodeficiency Virus-Exposed Neonates Receiving High-Dose Nevirapine Prophylaxis as Part of 3-Drug Regimen.
    Journal of the Pediatric Infectious Diseases Society, 2017, Mar-01, Volume: 6, Issue:1

    Topics: Adult; Anti-Retroviral Agents; Drug Therapy, Combination; False Positive Reactions; Female; HIV; HIV

2017
Nevirapine Plasma Concentrations in Human Immunodeficiency Virus-Exposed Neonates Receiving High-Dose Nevirapine Prophylaxis as Part of 3-Drug Regimen.
    Journal of the Pediatric Infectious Diseases Society, 2017, Mar-01, Volume: 6, Issue:1

    Topics: Adult; Anti-Retroviral Agents; Drug Therapy, Combination; False Positive Reactions; Female; HIV; HIV

2017
A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Adult; Antiretroviral Therapy, Highly Active; Female; Gene Frequency; Gene-Environment Interaction;

2016
A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Adult; Antiretroviral Therapy, Highly Active; Female; Gene Frequency; Gene-Environment Interaction;

2016
Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa.
    BMC pregnancy and childbirth, 2016, Feb-11, Volume: 16

    Topics: Adolescent; Adult; Anti-Retroviral Agents; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate D

2016
Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa.
    BMC pregnancy and childbirth, 2016, Feb-11, Volume: 16

    Topics: Adolescent; Adult; Anti-Retroviral Agents; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate D

2016
Prevention of perinatal transmission of zidovudine- and nevirapine-resistant HIV.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, Apr-01, Volume: 73, Issue:7

    Topics: Adolescent; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infectio

2016
Prevention of perinatal transmission of zidovudine- and nevirapine-resistant HIV.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, Apr-01, Volume: 73, Issue:7

    Topics: Adolescent; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infectio

2016
Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.
    AIDS research and human retroviruses, 2016, Volume: 32, Issue:8

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance

2016
Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.
    AIDS research and human retroviruses, 2016, Volume: 32, Issue:8

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance

2016
HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.
    PloS one, 2016, Volume: 11, Issue:4

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female;

2016
HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.
    PloS one, 2016, Volume: 11, Issue:4

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female;

2016
Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
    PloS one, 2016, Volume: 11, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Resistan

2016
Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
    PloS one, 2016, Volume: 11, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Resistan

2016
Providing Safe and Effective Preventative Antiretroviral Prophylaxis to HIV-exposed Newborns via a Novel Drug Delivery System in Tanzania.
    The Pediatric infectious disease journal, 2016, Volume: 35, Issue:9

    Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Dried Blood Spot Testing; Drug Delivery Systems; Female; HI

2016
Providing Safe and Effective Preventative Antiretroviral Prophylaxis to HIV-exposed Newborns via a Novel Drug Delivery System in Tanzania.
    The Pediatric infectious disease journal, 2016, Volume: 35, Issue:9

    Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Dried Blood Spot Testing; Drug Delivery Systems; Female; HI

2016
Assessment of non-standard HIV antiretroviral therapy regimens at Lighthouse Trust in Lilongwe, Malawi.
    Malawi medical journal : the journal of Medical Association of Malawi, 2016, Volume: 28, Issue:1

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Drug Therapy

2016
Assessment of non-standard HIV antiretroviral therapy regimens at Lighthouse Trust in Lilongwe, Malawi.
    Malawi medical journal : the journal of Medical Association of Malawi, 2016, Volume: 28, Issue:1

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Drug Therapy

2016
Antiretroviral Therapy in Children Less Than 24 Months of Age at Pediatric HIV Centers in Tanzania: 12-Month Clinical Outcomes and Survival.
    Journal of the International Association of Providers of AIDS Care, 2016, Volume: 15, Issue:5

    Topics: Anti-Retroviral Agents; Female; HIV Infections; Humans; Infant; Male; Nevirapine; Retrospective Stud

2016
Antiretroviral Therapy in Children Less Than 24 Months of Age at Pediatric HIV Centers in Tanzania: 12-Month Clinical Outcomes and Survival.
    Journal of the International Association of Providers of AIDS Care, 2016, Volume: 15, Issue:5

    Topics: Anti-Retroviral Agents; Female; HIV Infections; Humans; Infant; Male; Nevirapine; Retrospective Stud

2016
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
    Parasitology research, 2016, Volume: 115, Issue:10

    Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Co

2016
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
    Parasitology research, 2016, Volume: 115, Issue:10

    Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Co

2016
Nevirapine prophylaxis to prevent HIV-1 mother-to-child transmission: pharmacokinetic considerations in preterm infants.
    The new microbiologica, 2016, Volume: 39, Issue:4

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infant, Premature; Infectio

2016
Nevirapine prophylaxis to prevent HIV-1 mother-to-child transmission: pharmacokinetic considerations in preterm infants.
    The new microbiologica, 2016, Volume: 39, Issue:4

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infant, Premature; Infectio

2016
First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda.
    Journal of the International AIDS Society, 2016, Volume: 19, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Therapy, Combinat

2016
First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda.
    Journal of the International AIDS Society, 2016, Volume: 19, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Therapy, Combinat

2016
HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission.
    Journal of acquired immune deficiency syndromes (1999), 2016, Dec-01, Volume: 73, Issue:4

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infec

2016
HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission.
    Journal of acquired immune deficiency syndromes (1999), 2016, Dec-01, Volume: 73, Issue:4

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infec

2016
Effect of co-administration of Hypoxis hemerocallidea extract and antiretroviral therapy (HAART) on the histomorphology and seminal parameters in Sprague Dawley rats.
    Andrologia, 2017, Volume: 49, Issue:2

    Topics: Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Ascorbic Acid; Chemotherapy, Adjuva

2017
Effect of co-administration of Hypoxis hemerocallidea extract and antiretroviral therapy (HAART) on the histomorphology and seminal parameters in Sprague Dawley rats.
    Andrologia, 2017, Volume: 49, Issue:2

    Topics: Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Ascorbic Acid; Chemotherapy, Adjuva

2017
Morphine Increases Lamivudine- and Nevirapine-Induced Human Immunodeficiency Virus-1 Drug-Resistant Mutations In Vitro.
    Microbial drug resistance (Larchmont, N.Y.), 2017, Volume: 23, Issue:3

    Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Morph

2017
Morphine Increases Lamivudine- and Nevirapine-Induced Human Immunodeficiency Virus-1 Drug-Resistant Mutations In Vitro.
    Microbial drug resistance (Larchmont, N.Y.), 2017, Volume: 23, Issue:3

    Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Morph

2017
Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis.
    Pharmacoepidemiology and drug safety, 2016, Volume: 25, Issue:11

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Drug Eruptions; Drug Therapy, Combination; Female; HIV

2016
Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis.
    Pharmacoepidemiology and drug safety, 2016, Volume: 25, Issue:11

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Drug Eruptions; Drug Therapy, Combination; Female; HIV

2016
Maternal Influences on Access to and Use of Infant ARVs and HIV Health Services in Uganda.
    AIDS and behavior, 2017, Volume: 21, Issue:9

    Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Anti-Retroviral Agents; Cross-Sectional Studies;

2017
Maternal Influences on Access to and Use of Infant ARVs and HIV Health Services in Uganda.
    AIDS and behavior, 2017, Volume: 21, Issue:9

    Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Anti-Retroviral Agents; Cross-Sectional Studies;

2017
Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children.
    The Pediatric infectious disease journal, 2016, Volume: 35, Issue:12

    Topics: Child, Preschool; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavi

2016
Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children.
    The Pediatric infectious disease journal, 2016, Volume: 35, Issue:12

    Topics: Child, Preschool; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavi

2016
Early infant diagnosis of HIV infection using DNA-PCR at a referral center: an 8 years retrospective analysis.
    AIDS research and therapy, 2016, Volume: 13, Issue:1

    Topics: Anti-HIV Agents; DNA, Viral; Early Diagnosis; Ethiopia; Female; HIV; HIV Infections; Humans; Infant;

2016
Early infant diagnosis of HIV infection using DNA-PCR at a referral center: an 8 years retrospective analysis.
    AIDS research and therapy, 2016, Volume: 13, Issue:1

    Topics: Anti-HIV Agents; DNA, Viral; Early Diagnosis; Ethiopia; Female; HIV; HIV Infections; Humans; Infant;

2016
Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.
    Medicine, 2016, Volume: 95, Issue:37

    Topics: Adult; Dideoxynucleosides; Drug Therapy, Combination; Female; France; HIV Infections; Humans; Lamivu

2016
Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.
    Medicine, 2016, Volume: 95, Issue:37

    Topics: Adult; Dideoxynucleosides; Drug Therapy, Combination; Female; France; HIV Infections; Humans; Lamivu

2016
Adverse drug reactions associated with antiretroviral therapy in South Africa.
    African journal of AIDS research : AJAR, 2016, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dizziness; Exanthema; Fema

2016
Adverse drug reactions associated with antiretroviral therapy in South Africa.
    African journal of AIDS research : AJAR, 2016, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dizziness; Exanthema; Fema

2016
Timely antiretroviral prophylaxis during pregnancy effectively reduces HIV mother-to-child transmission in eight counties in China: a prospective study during 2004-2011.
    Scientific reports, 2016, 10-10, Volume: 6

    Topics: Adult; Anti-HIV Agents; China; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmissio

2016
Timely antiretroviral prophylaxis during pregnancy effectively reduces HIV mother-to-child transmission in eight counties in China: a prospective study during 2004-2011.
    Scientific reports, 2016, 10-10, Volume: 6

    Topics: Adult; Anti-HIV Agents; China; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmissio

2016
Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa.
    AIDS and behavior, 2017, Volume: 21, Issue:2

    Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Attitude to Health; Benzoxazines; Caregivers;

2017
Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa.
    AIDS and behavior, 2017, Volume: 21, Issue:2

    Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Attitude to Health; Benzoxazines; Caregivers;

2017
Virological failure reduced with HIV-serostatus disclosure, extra baseline weight and rising CD4 cells among HIV-positive adults in Northwestern Uganda.
    BMC infectious diseases, 2016, Oct-28, Volume: 16, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Weight; CD4-Positive T-Lymphocytes; Cohort Studi

2016
Virological failure reduced with HIV-serostatus disclosure, extra baseline weight and rising CD4 cells among HIV-positive adults in Northwestern Uganda.
    BMC infectious diseases, 2016, Oct-28, Volume: 16, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Weight; CD4-Positive T-Lymphocytes; Cohort Studi

2016
Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China.
    Scientific reports, 2016, 10-31, Volume: 6

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Aged, 80 and over; Antiretroviral Therapy, Highly A

2016
Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China.
    Scientific reports, 2016, 10-31, Volume: 6

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Aged, 80 and over; Antiretroviral Therapy, Highly A

2016
Development of a Qualitative Quantitative Polymerase Chain Reaction Test to Identify Patients Failing First-Line Therapy to Non-Nucleotide Reverse Transcriptase Inhibitor.
    AIDS research and human retroviruses, 2017, Volume: 33, Issue:4

    Topics: Alkynes; Benzoxazines; Costs and Cost Analysis; Cyclopropanes; Drug Monitoring; Drug Resistance, Vir

2017
Development of a Qualitative Quantitative Polymerase Chain Reaction Test to Identify Patients Failing First-Line Therapy to Non-Nucleotide Reverse Transcriptase Inhibitor.
    AIDS research and human retroviruses, 2017, Volume: 33, Issue:4

    Topics: Alkynes; Benzoxazines; Costs and Cost Analysis; Cyclopropanes; Drug Monitoring; Drug Resistance, Vir

2017
Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models.
    Scientific reports, 2016, 12-02, Volume: 6

    Topics: Alkynes; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; DNA, Viral; Genes, Reporter; Green

2016
Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models.
    Scientific reports, 2016, 12-02, Volume: 6

    Topics: Alkynes; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; DNA, Viral; Genes, Reporter; Green

2016
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:3

    Topics: Adult; Africa South of the Sahara; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyc

2017
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.
    The Lancet. Infectious diseases, 2017, Volume: 17, Issue:3

    Topics: Adult; Africa South of the Sahara; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyc

2017
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child.
    BMC infectious diseases, 2016, Dec-09, Volume: 16, Issue:1

    Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, N

2016
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child.
    BMC infectious diseases, 2016, Dec-09, Volume: 16, Issue:1

    Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, N

2016
Antiretrovirals causing severe pre-eclampsia.
    Pregnancy hypertension, 2016, Volume: 6, Issue:4

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Delivery, Obstetric; F

2016
Antiretrovirals causing severe pre-eclampsia.
    Pregnancy hypertension, 2016, Volume: 6, Issue:4

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Delivery, Obstetric; F

2016
Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
    International journal of antimicrobial agents, 2017, Volume: 49, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antitubercular Agents; Diarylquinolines

2017
Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
    International journal of antimicrobial agents, 2017, Volume: 49, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antitubercular Agents; Diarylquinolines

2017
Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets.
    AIDS (London, England), 2017, 04-24, Volume: 31, Issue:7

    Topics: Africa; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV Infections; Huma

2017
Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets.
    AIDS (London, England), 2017, 04-24, Volume: 31, Issue:7

    Topics: Africa; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV Infections; Huma

2017
Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.
    The Journal of antimicrobial chemotherapy, 2017, 04-01, Volume: 72, Issue:4

    Topics: Adult; Africa South of the Sahara; Aged; Anti-HIV Agents; Biomarkers; Black People; Case-Control Stu

2017
Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.
    The Journal of antimicrobial chemotherapy, 2017, 04-01, Volume: 72, Issue:4

    Topics: Adult; Africa South of the Sahara; Aged; Anti-HIV Agents; Biomarkers; Black People; Case-Control Stu

2017
Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals.
    Medicine, 2017, Volume: 96, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Comorbidity; Female; Heterosexuality;

2017
Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals.
    Medicine, 2017, Volume: 96, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Comorbidity; Female; Heterosexuality;

2017
Exploring CYP2B6 activity by measuring the presence ofnevirapine hydroxy metabolites in plasma.
    Turkish journal of medical sciences, 2016, Dec-20, Volume: 46, Issue:6

    Topics: Anti-HIV Agents; Cytochrome P-450 CYP2B6; HIV Infections; Humans; Nevirapine; Reverse Transcriptase

2016
Exploring CYP2B6 activity by measuring the presence ofnevirapine hydroxy metabolites in plasma.
    Turkish journal of medical sciences, 2016, Dec-20, Volume: 46, Issue:6

    Topics: Anti-HIV Agents; Cytochrome P-450 CYP2B6; HIV Infections; Humans; Nevirapine; Reverse Transcriptase

2016
Nevirapine Pharmacokinetics and Safety in Neonates Receiving Combination Antiretroviral Therapy for Prevention of Vertical HIV Transmission.
    Journal of acquired immune deficiency syndromes (1999), 2017, Apr-15, Volume: 74, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemoprevention; Female; HIV Infectio

2017
Nevirapine Pharmacokinetics and Safety in Neonates Receiving Combination Antiretroviral Therapy for Prevention of Vertical HIV Transmission.
    Journal of acquired immune deficiency syndromes (1999), 2017, Apr-15, Volume: 74, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemoprevention; Female; HIV Infectio

2017
Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.
    The Journal of antimicrobial chemotherapy, 2017, 05-01, Volume: 72, Issue:5

    Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymph

2017
Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.
    The Journal of antimicrobial chemotherapy, 2017, 05-01, Volume: 72, Issue:5

    Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymph

2017
In situ hybrid nano drug delivery system (IHN-DDS) of antiretroviral drug for simultaneous targeting to multiple viral reservoirs: An in vivo proof of concept.
    International journal of pharmaceutics, 2017, Apr-15, Volume: 521, Issue:1-2

    Topics: Animals; Anti-HIV Agents; Drug Delivery Systems; Female; HIV Infections; Nanoparticles; Nevirapine;

2017
In situ hybrid nano drug delivery system (IHN-DDS) of antiretroviral drug for simultaneous targeting to multiple viral reservoirs: An in vivo proof of concept.
    International journal of pharmaceutics, 2017, Apr-15, Volume: 521, Issue:1-2

    Topics: Animals; Anti-HIV Agents; Drug Delivery Systems; Female; HIV Infections; Nanoparticles; Nevirapine;

2017
Plasma nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure.
    PloS one, 2017, Volume: 12, Issue:2

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Child; Female; HIV Infections; HIV-1; Humans; Kenya; Male;

2017
Plasma nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure.
    PloS one, 2017, Volume: 12, Issue:2

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Child; Female; HIV Infections; HIV-1; Humans; Kenya; Male;

2017
Effect of
    AIDS research and therapy, 2017, Volume: 14

    Topics: Adult; Aged; Anti-HIV Agents; Chromatography, Liquid; Cross-Over Studies; Drug Interactions; Female;

2017
Effect of
    AIDS research and therapy, 2017, Volume: 14

    Topics: Adult; Aged; Anti-HIV Agents; Chromatography, Liquid; Cross-Over Studies; Drug Interactions; Female;

2017
Persistence of HIV drug resistance among South African children given nevirapine to prevent mother-to-child-transmission.
    AIDS (London, England), 2017, 05-15, Volume: 31, Issue:8

    Topics: Anti-HIV Agents; Child, Preschool; Drug Resistance, Viral; Female; Genotyping Techniques; HIV Infect

2017
Persistence of HIV drug resistance among South African children given nevirapine to prevent mother-to-child-transmission.
    AIDS (London, England), 2017, 05-15, Volume: 31, Issue:8

    Topics: Anti-HIV Agents; Child, Preschool; Drug Resistance, Viral; Female; Genotyping Techniques; HIV Infect

2017
Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes;

2008
Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes;

2008
Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:6

    Topics: Adult; Anti-HIV Agents; Cameroon; Child; Child, Preschool; Cohort Studies; Drug Resistance, Multiple

2008
Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:6

    Topics: Adult; Anti-HIV Agents; Cameroon; Child; Child, Preschool; Cohort Studies; Drug Resistance, Multiple

2008
Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon.
    Journal of acquired immune deficiency syndromes (1999), 2008, Jun-01, Volume: 48, Issue:2

    Topics: Adult; Anti-HIV Agents; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; Humans;

2008
Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon.
    Journal of acquired immune deficiency syndromes (1999), 2008, Jun-01, Volume: 48, Issue:2

    Topics: Adult; Anti-HIV Agents; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; Humans;

2008
Breast-feeding, antiretroviral prophylaxis, and HIV.
    The New England journal of medicine, 2008, Jul-10, Volume: 359, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV; HIV Infections; Humans; Infant; Infectious Disease Tra

2008
Breast-feeding, antiretroviral prophylaxis, and HIV.
    The New England journal of medicine, 2008, Jul-10, Volume: 359, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV; HIV Infections; Humans; Infant; Infectious Disease Tra

2008
[Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo].
    Bulletin de la Societe de pathologie exotique (1990), 2008, Volume: 101, Issue:2

    Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazin

2008
[Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo].
    Bulletin de la Societe de pathologie exotique (1990), 2008, Volume: 101, Issue:2

    Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazin

2008
Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia.
    HIV medicine, 2008, Volume: 9, Issue:7

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cambodia; Cycl

2008
Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia.
    HIV medicine, 2008, Volume: 9, Issue:7

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cambodia; Cycl

2008
Voluntary counselling and testing (VCT) uptake, nevirapine use and infant feeding options at the University of Nigeria Teaching Hospital.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2008, Volume: 28, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS Serodiagnosis; Ambulatory Care; Breast F

2008
Voluntary counselling and testing (VCT) uptake, nevirapine use and infant feeding options at the University of Nigeria Teaching Hospital.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2008, Volume: 28, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS Serodiagnosis; Ambulatory Care; Breast F

2008
Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission.
    The Journal of infectious diseases, 2008, Aug-15, Volume: 198, Issue:4

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infec

2008
Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission.
    The Journal of infectious diseases, 2008, Aug-15, Volume: 198, Issue:4

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infec

2008
Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 62, Issue:4

    Topics: Adult; Anti-HIV Agents; Chromatography, High Pressure Liquid; Female; HIV Infections; Humans; Male;

2008
Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 62, Issue:4

    Topics: Adult; Anti-HIV Agents; Chromatography, High Pressure Liquid; Female; HIV Infections; Humans; Male;

2008
Extra drugs and slower weaning lowers HIV risk for newborns.
    Nature medicine, 2008, Volume: 14, Issue:7

    Topics: Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; Case-Control Studies; Female; HIV Infec

2008
Extra drugs and slower weaning lowers HIV risk for newborns.
    Nature medicine, 2008, Volume: 14, Issue:7

    Topics: Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; Case-Control Studies; Female; HIV Infec

2008
HIV and obstetric complications and fetal outcomes in Vellore, India.
    Tropical doctor, 2008, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; HIV Seronegativity; Humans; India; Infan

2008
HIV and obstetric complications and fetal outcomes in Vellore, India.
    Tropical doctor, 2008, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; HIV Seronegativity; Humans; India; Infan

2008
Effect of haematological alterations on thalassaemia investigation in HIV-1-infected Thai patients receiving antiretroviral therapy.
    HIV medicine, 2008, Volume: 9, Issue:8

    Topics: Adult; Anti-Retroviral Agents; Biomarkers; Case-Control Studies; Erythrocyte Indices; Female; Hemogl

2008
Effect of haematological alterations on thalassaemia investigation in HIV-1-infected Thai patients receiving antiretroviral therapy.
    HIV medicine, 2008, Volume: 9, Issue:8

    Topics: Adult; Anti-Retroviral Agents; Biomarkers; Case-Control Studies; Erythrocyte Indices; Female; Hemogl

2008
Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
    HIV medicine, 2008, Volume: 9, Issue:8

    Topics: Adolescent; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Cou

2008
Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
    HIV medicine, 2008, Volume: 9, Issue:8

    Topics: Adolescent; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Cou

2008
Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 62, Issue:5

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1

2008
Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 62, Issue:5

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1

2008
Extended nevirapine prophylaxis to prevent HIV transmission.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Mul

2008
Extended nevirapine prophylaxis to prevent HIV transmission.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Mul

2008
SWEN--when authors disagree.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Anti-HIV Agents; Attitude of Health Personnel; Bias; HIV Infections; Humans; India; Infant; Infant,

2008
SWEN--when authors disagree.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Anti-HIV Agents; Attitude of Health Personnel; Bias; HIV Infections; Humans; India; Infant; Infant,

2008
Nevirapine to prevent HIV transmission via breastfeeding.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Anti-HIV Agents; Breast Feeding; HIV Infections; Humans; India; Infant; Infant, Newborn; Nevirapine;

2008
Nevirapine to prevent HIV transmission via breastfeeding.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Anti-HIV Agents; Breast Feeding; HIV Infections; Humans; India; Infant; Infant, Newborn; Nevirapine;

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
    Antiviral therapy, 2008, Volume: 13, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV-1;

2008
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
    Antiviral therapy, 2008, Volume: 13, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV-1;

2008
Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
    JAMA, 2008, Aug-06, Volume: 300, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzo

2008
Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
    JAMA, 2008, Aug-06, Volume: 300, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzo

2008
A review of the prevention of mother-to-child transmission programme of the Western Cape provincial government, 2003 - 2004.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2008, Volume: 98, Issue:6

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infectious Disease Transmissi

2008
A review of the prevention of mother-to-child transmission programme of the Western Cape provincial government, 2003 - 2004.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2008, Volume: 98, Issue:6

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infectious Disease Transmissi

2008
Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission.
    The Journal of infectious diseases, 2008, Oct-01, Volume: 198, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Infec

2008
Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission.
    The Journal of infectious diseases, 2008, Oct-01, Volume: 198, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Infec

2008
Hepatotoxicity in patients prescribed efavirenz or nevirapine.
    European journal of medical research, 2008, Jul-28, Volume: 13, Issue:7

    Topics: Adult; Alkynes; Benzoxazines; CD4-Positive T-Lymphocytes; Chemical and Drug Induced Liver Injury; Cy

2008
Hepatotoxicity in patients prescribed efavirenz or nevirapine.
    European journal of medical research, 2008, Jul-28, Volume: 13, Issue:7

    Topics: Adult; Alkynes; Benzoxazines; CD4-Positive T-Lymphocytes; Chemical and Drug Induced Liver Injury; Cy

2008
Preventing mother-to-child transmission of HIV in resource-limited settings: the Elizabeth Glaser Pediatric AIDS Foundation experience.
    American journal of public health, 2009, Volume: 99, Issue:4

    Topics: Anti-HIV Agents; Counseling; Developing Countries; Female; Foundations; Health Education; HIV Infect

2009
Preventing mother-to-child transmission of HIV in resource-limited settings: the Elizabeth Glaser Pediatric AIDS Foundation experience.
    American journal of public health, 2009, Volume: 99, Issue:4

    Topics: Anti-HIV Agents; Counseling; Developing Countries; Female; Foundations; Health Education; HIV Infect

2009
Serious toxicity associated with continuous nevirapine-based HAART in pregnancy.
    BJOG : an international journal of obstetrics and gynaecology, 2008, Volume: 115, Issue:10

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Multivariate

2008
Serious toxicity associated with continuous nevirapine-based HAART in pregnancy.
    BJOG : an international journal of obstetrics and gynaecology, 2008, Volume: 115, Issue:10

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Multivariate

2008
FDA notifications. FDA approves label change for nevirapine.
    AIDS alert, 2008, Volume: 23, Issue:8

    Topics: Adolescent; Child; Child, Preschool; Drug Approval; Drug Labeling; HIV Infections; Humans; Infant; I

2008
FDA notifications. FDA approves label change for nevirapine.
    AIDS alert, 2008, Volume: 23, Issue:8

    Topics: Adolescent; Child; Child, Preschool; Drug Approval; Drug Labeling; HIV Infections; Humans; Infant; I

2008
Fatal outcome of nevirapine-associated toxic epidermal necrolysis.
    International journal of STD & AIDS, 2008, Volume: 19, Issue:9

    Topics: Adult; Anti-HIV Agents; Fatal Outcome; HIV Infections; HIV-1; Humans; Male; Nevirapine; Stevens-John

2008
Fatal outcome of nevirapine-associated toxic epidermal necrolysis.
    International journal of STD & AIDS, 2008, Volume: 19, Issue:9

    Topics: Adult; Anti-HIV Agents; Fatal Outcome; HIV Infections; HIV-1; Humans; Male; Nevirapine; Stevens-John

2008
Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
    Therapeutic drug monitoring, 2008, Volume: 30, Issue:5

    Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Therapy, Combination;

2008
Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
    Therapeutic drug monitoring, 2008, Volume: 30, Issue:5

    Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Therapy, Combination;

2008
Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
    AIDS (London, England), 2008, Sep-12, Volume: 22, Issue:14

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire;

2008
Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
    AIDS (London, England), 2008, Sep-12, Volume: 22, Issue:14

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire;

2008
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
    Antiviral therapy, 2008, Volume: 13, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Black People; Body Weight; Cyc

2008
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
    Antiviral therapy, 2008, Volume: 13, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Black People; Body Weight; Cyc

2008
Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Oct-01, Volume: 47, Issue:7

    Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; H

2008
Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Oct-01, Volume: 47, Issue:7

    Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; H

2008
Analysis of nevirapine resistance mutations in cloned HIV type 1 variants from HIV-infected Ugandan infants using a single-step amplification-sequencing method (AmpliSeq).
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:9

    Topics: Amino Acid Substitution; Anti-HIV Agents; DNA Mutational Analysis; Drug Resistance, Viral; HIV Infec

2008
Analysis of nevirapine resistance mutations in cloned HIV type 1 variants from HIV-infected Ugandan infants using a single-step amplification-sequencing method (AmpliSeq).
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:9

    Topics: Amino Acid Substitution; Anti-HIV Agents; DNA Mutational Analysis; Drug Resistance, Viral; HIV Infec

2008
Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
    AIDS (London, England), 2008, Oct-18, Volume: 22, Issue:16

    Topics: Adult; Africa, Southern; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazin

2008
Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
    AIDS (London, England), 2008, Oct-18, Volume: 22, Issue:16

    Topics: Adult; Africa, Southern; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazin

2008
Human immunodeficiency virus-infected boy with Stevens-Johnson syndrome caused by nevirapine.
    The Pediatric infectious disease journal, 2008, Volume: 27, Issue:11

    Topics: Anti-HIV Agents; Child; HIV Infections; Humans; Male; Nevirapine; Stevens-Johnson Syndrome

2008
Human immunodeficiency virus-infected boy with Stevens-Johnson syndrome caused by nevirapine.
    The Pediatric infectious disease journal, 2008, Volume: 27, Issue:11

    Topics: Anti-HIV Agents; Child; HIV Infections; Humans; Male; Nevirapine; Stevens-Johnson Syndrome

2008
Clinical manifestations and antiretroviral management of HIV/AIDS patients with tuberculosis co-infection in Kramat 128 Hospital.
    Acta medica Indonesiana, 2008, Volume: 40, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV

2008
Clinical manifestations and antiretroviral management of HIV/AIDS patients with tuberculosis co-infection in Kramat 128 Hospital.
    Acta medica Indonesiana, 2008, Volume: 40, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV

2008
Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.
    BMC infectious diseases, 2008, Oct-14, Volume: 8

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2008
Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.
    BMC infectious diseases, 2008, Oct-14, Volume: 8

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2008
Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs.
    Current HIV research, 2008, Volume: 6, Issue:5

    Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Blood; Chromatography, High Pressure Liquid; Cohort Stu

2008
Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs.
    Current HIV research, 2008, Volume: 6, Issue:5

    Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Blood; Chromatography, High Pressure Liquid; Cohort Stu

2008
Therapeutic drug monitoring of nevirapine in resource-limited settings.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Nov-15, Volume: 47, Issue:10

    Topics: Adolescent; Adult; Africa; Aged; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; D

2008
Therapeutic drug monitoring of nevirapine in resource-limited settings.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Nov-15, Volume: 47, Issue:10

    Topics: Adolescent; Adult; Africa; Aged; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; D

2008
Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.
    BMC infectious diseases, 2008, Oct-22, Volume: 8

    Topics: Absorptiometry, Photon; Adipose Tissue; Adolescent; Antiretroviral Therapy, Highly Active; CD4 Lymph

2008
Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.
    BMC infectious diseases, 2008, Oct-22, Volume: 8

    Topics: Absorptiometry, Photon; Adipose Tissue; Adolescent; Antiretroviral Therapy, Highly Active; CD4 Lymph

2008
Antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
    The New England journal of medicine, 2008, Oct-23, Volume: 359, Issue:17

    Topics: Anti-Retroviral Agents; Breast Feeding; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Human

2008
Antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
    The New England journal of medicine, 2008, Oct-23, Volume: 359, Issue:17

    Topics: Anti-Retroviral Agents; Breast Feeding; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Human

2008
Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:1

    Topics: Adult; Chromatography, Liquid; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease T

2009
Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:1

    Topics: Adult; Chromatography, Liquid; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease T

2009
Infant feeding, HIV transmission and mortality at 18 months: the need for appropriate choices by mothers and prioritization within programmes.
    AIDS (London, England), 2008, Nov-12, Volume: 22, Issue:17

    Topics: Adolescent; Adult; AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Choice

2008
Infant feeding, HIV transmission and mortality at 18 months: the need for appropriate choices by mothers and prioritization within programmes.
    AIDS (London, England), 2008, Nov-12, Volume: 22, Issue:17

    Topics: Adolescent; Adult; AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Choice

2008
Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2008, Dec-15, Volume: 49, Issue:5

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV Infecti

2008
Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2008, Dec-15, Volume: 49, Issue:5

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV Infecti

2008
Transient antiretroviral therapy selecting for common HIV-1 mutations substantially accelerates the appearance of rare mutations.
    Theoretical biology & medical modelling, 2008, Nov-14, Volume: 5

    Topics: Antiviral Agents; Female; Genome; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Ve

2008
Transient antiretroviral therapy selecting for common HIV-1 mutations substantially accelerates the appearance of rare mutations.
    Theoretical biology & medical modelling, 2008, Nov-14, Volume: 5

    Topics: Antiviral Agents; Female; Genome; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Ve

2008
[Reliable effectiveness for years with good long-term tolerance: 10 years nevirapine--a summary].
    MMW Fortschritte der Medizin, 2008, Apr-28, Volume: 150 Spec No 1

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; Humans; Long-T

2008
[Reliable effectiveness for years with good long-term tolerance: 10 years nevirapine--a summary].
    MMW Fortschritte der Medizin, 2008, Apr-28, Volume: 150 Spec No 1

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; Humans; Long-T

2008
Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
    Antiviral therapy, 2008, Volume: 13, Issue:7

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; DNA, Viral; Drug Admini

2008
Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
    Antiviral therapy, 2008, Volume: 13, Issue:7

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; DNA, Viral; Drug Admini

2008
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jan-15, Volume: 48, Issue:2

    Topics: Adenine; Alkynes; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyc

2009
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jan-15, Volume: 48, Issue:2

    Topics: Adenine; Alkynes; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyc

2009
Prevalence of nevirapine-associated resistance mutations after single dose prophylactic treatment among antenatal clinic attendees in north rift Kenya.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:12

    Topics: Anti-HIV Agents; Chemoprevention; DNA, Viral; Drug Resistance, Viral; Female; HIV Infections; HIV Re

2008
Prevalence of nevirapine-associated resistance mutations after single dose prophylactic treatment among antenatal clinic attendees in north rift Kenya.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:12

    Topics: Anti-HIV Agents; Chemoprevention; DNA, Viral; Drug Resistance, Viral; Female; HIV Infections; HIV Re

2008
HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.
    Pharmacogenetics and genomics, 2009, Volume: 19, Issue:2

    Topics: Adult; Alleles; Anti-HIV Agents; Case-Control Studies; Exanthema; Female; Genotype; HIV Infections;

2009
HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.
    Pharmacogenetics and genomics, 2009, Volume: 19, Issue:2

    Topics: Adult; Alleles; Anti-HIV Agents; Case-Control Studies; Exanthema; Female; Genotype; HIV Infections;

2009
Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood; Breast Feeding; Cl

2009
Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood; Breast Feeding; Cl

2009
Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study.
    BMC infectious diseases, 2008, Dec-30, Volume: 8

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV; HIV Infections; Humans; I

2008
Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study.
    BMC infectious diseases, 2008, Dec-30, Volume: 8

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV; HIV Infections; Humans; I

2008
A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India.
    Journal of clinical pharmacy and therapeutics, 2009, Volume: 34, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2009
A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India.
    Journal of clinical pharmacy and therapeutics, 2009, Volume: 34, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2009
Determinants of nonadherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Rwanda.
    Journal of acquired immune deficiency syndromes (1999), 2009, Feb-01, Volume: 50, Issue:2

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Female; HIV Infections; HIV-1; Humans; Infant, Newborn

2009
Determinants of nonadherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Rwanda.
    Journal of acquired immune deficiency syndromes (1999), 2009, Feb-01, Volume: 50, Issue:2

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Female; HIV Infections; HIV-1; Humans; Infant, Newborn

2009
Single-dose nevirapine to prevent mother-to-child transmission of HIV type 1: balancing the benefits and risks.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Feb-15, Volume: 48, Issue:4

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infectious Disease Transmis

2009
Single-dose nevirapine to prevent mother-to-child transmission of HIV type 1: balancing the benefits and risks.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Feb-15, Volume: 48, Issue:4

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infectious Disease Transmis

2009
Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Feb-15, Volume: 48, Issue:4

    Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV

2009
Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Feb-15, Volume: 48, Issue:4

    Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV

2009
[Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital].
    Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 2008, Volume: 30, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Brazil; Female; HIV Infections; Hospitals, University; Humans; N

2008
[Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital].
    Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 2008, Volume: 30, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Brazil; Female; HIV Infections; Hospitals, University; Humans; N

2008
Prevention of mother-to-child HIV transmission using 3-drug combination antiretroviral treatment: observational cohort in clinical practice setting in India.
    Journal of acquired immune deficiency syndromes (1999), 2009, Feb-01, Volume: 50, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; HIV

2009
Prevention of mother-to-child HIV transmission using 3-drug combination antiretroviral treatment: observational cohort in clinical practice setting in India.
    Journal of acquired immune deficiency syndromes (1999), 2009, Feb-01, Volume: 50, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; HIV

2009
Comment on: High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:5

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Lamivudine;

2009
Comment on: High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:5

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Lamivudine;

2009
Estimating the lost benefits of antiretroviral drug use in South Africa.
    Journal of acquired immune deficiency syndromes (1999), 2008, Dec-01, Volume: 49, Issue:4

    Topics: Anti-Retroviral Agents; Cost of Illness; Health Care Costs; HIV Infections; Humans; Infectious Disea

2008
Estimating the lost benefits of antiretroviral drug use in South Africa.
    Journal of acquired immune deficiency syndromes (1999), 2008, Dec-01, Volume: 49, Issue:4

    Topics: Anti-Retroviral Agents; Cost of Illness; Health Care Costs; HIV Infections; Humans; Infectious Disea

2008
[Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/névirapine (Triomune). Study of 297 cases in Togo].
    Bulletin de la Societe de pathologie exotique (1990), 2008, Volume: 101, Issue:5

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Child; Child, Preschool; Drug Administration Schedule; Dru

2008
[Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/névirapine (Triomune). Study of 297 cases in Togo].
    Bulletin de la Societe de pathologie exotique (1990), 2008, Volume: 101, Issue:5

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Child; Child, Preschool; Drug Administration Schedule; Dru

2008
Does gender and nevirapine (NVP) influence abnormal liver functions in HIV disease?
    The Journal of infection, 2009, Volume: 58, Issue:3

    Topics: Adult; Female; Gender Identity; HIV Infections; Humans; Liver; Male; Nevirapine

2009
Does gender and nevirapine (NVP) influence abnormal liver functions in HIV disease?
    The Journal of infection, 2009, Volume: 58, Issue:3

    Topics: Adult; Female; Gender Identity; HIV Infections; Humans; Liver; Male; Nevirapine

2009
Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochr

2009
Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochr

2009
Switch to Viramune safe for some who can't tolerate Sustiva.
    Project Inform perspective, 2008, Issue:47

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Tran

2008
Switch to Viramune safe for some who can't tolerate Sustiva.
    Project Inform perspective, 2008, Issue:47

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Tran

2008
Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.
    HIV medicine, 2009, Volume: 10, Issue:5

    Topics: Adult; Aged; Alleles; Analysis of Variance; ATP Binding Cassette Transporter, Subfamily B; ATP Bindi

2009
Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.
    HIV medicine, 2009, Volume: 10, Issue:5

    Topics: Adult; Aged; Alleles; Analysis of Variance; ATP Binding Cassette Transporter, Subfamily B; ATP Bindi

2009
Which ART regimen is best after receipt of single-dose nevirapine?
    AIDS clinical care, 2009, Volume: 21, Issue:1

    Topics: Disease Transmission, Infectious; Female; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy C

2009
Which ART regimen is best after receipt of single-dose nevirapine?
    AIDS clinical care, 2009, Volume: 21, Issue:1

    Topics: Disease Transmission, Infectious; Female; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy C

2009
Cryptococcal meningoradiculitis: an atypical presentation after initiation of antiretroviral therapy.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2007, Volume: 90 Suppl 2

    Topics: Adult; Amphotericin B; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Retroviral Agents; Ceftriaxone;

2007
Cryptococcal meningoradiculitis: an atypical presentation after initiation of antiretroviral therapy.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2007, Volume: 90 Suppl 2

    Topics: Adult; Amphotericin B; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Retroviral Agents; Ceftriaxone;

2007
The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2008, Volume: 91 Suppl 2

    Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cost-Benefit Analys

2008
The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2008, Volume: 91 Suppl 2

    Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cost-Benefit Analys

2008
Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.
    International journal of STD & AIDS, 2009, Volume: 20, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Chi-Square Distribution; Cohort

2009
Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.
    International journal of STD & AIDS, 2009, Volume: 20, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Chi-Square Distribution; Cohort

2009
Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:5

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Ne

2009
Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:5

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Ne

2009
Higher placental anti-inflammatory IL-10 cytokine expression in HIV-1 infected women receiving longer zidovudine prophylaxis associated with nevirapine.
    Current HIV research, 2009, Volume: 7, Issue:2

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Interleukin-10; Nevirapine; Placenta;

2009
Higher placental anti-inflammatory IL-10 cytokine expression in HIV-1 infected women receiving longer zidovudine prophylaxis associated with nevirapine.
    Current HIV research, 2009, Volume: 7, Issue:2

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Interleukin-10; Nevirapine; Placenta;

2009
Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2009, Volume: 13, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; CD4 Lymphocyte Count; Comorbidity; Cyclopro

2009
Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2009, Volume: 13, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; CD4 Lymphocyte Count; Comorbidity; Cyclopro

2009
Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance.
    AIDS (London, England), 2009, Apr-27, Volume: 23, Issue:7

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV

2009
Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance.
    AIDS (London, England), 2009, Apr-27, Volume: 23, Issue:7

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV

2009
Prevention of mother-to-child transmission of HIV in a refugee camp setting in Tanzania.
    Global public health, 2008, Volume: 3, Issue:1

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV Seropositivity; Humans; Infant, Newborn; Infecti

2008
Prevention of mother-to-child transmission of HIV in a refugee camp setting in Tanzania.
    Global public health, 2008, Volume: 3, Issue:1

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV Seropositivity; Humans; Infant, Newborn; Infecti

2008
Proinflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir.
    Journal of acquired immune deficiency syndromes (1999), 2009, Apr-15, Volume: 50, Issue:5

    Topics: Adiponectin; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Adminis

2009
Proinflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir.
    Journal of acquired immune deficiency syndromes (1999), 2009, Apr-15, Volume: 50, Issue:5

    Topics: Adiponectin; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Adminis

2009
Generic combination approved.
    AIDS patient care and STDs, 2009, Volume: 23, Issue:3

    Topics: Anti-HIV Agents; Drug Approval; Drug Combinations; Drugs, Generic; HIV Infections; Humans; Lamivudin

2009
Generic combination approved.
    AIDS patient care and STDs, 2009, Volume: 23, Issue:3

    Topics: Anti-HIV Agents; Drug Approval; Drug Combinations; Drugs, Generic; HIV Infections; Humans; Lamivudin

2009
Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.
    The Southeast Asian journal of tropical medicine and public health, 2009, Volume: 40, Issue:1

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Demography; Drug Therapy, Combination; Drugs, Generic;

2009
Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.
    The Southeast Asian journal of tropical medicine and public health, 2009, Volume: 40, Issue:1

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Demography; Drug Therapy, Combination; Drugs, Generic;

2009
Establishment of drug-resistant HIV-1 in latent reservoirs.
    The Journal of infectious diseases, 2009, May-01, Volume: 199, Issue:9

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Breast Feeding; Developing Countries; Disease R

2009
Establishment of drug-resistant HIV-1 in latent reservoirs.
    The Journal of infectious diseases, 2009, May-01, Volume: 199, Issue:9

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Breast Feeding; Developing Countries; Disease R

2009
Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1.
    The Journal of infectious diseases, 2009, May-01, Volume: 199, Issue:9

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Reservoirs; Drug Resistance, Viral; Female; HIV Infec

2009
Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1.
    The Journal of infectious diseases, 2009, May-01, Volume: 199, Issue:9

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Reservoirs; Drug Resistance, Viral; Female; HIV Infec

2009
The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals.
    Journal of acquired immune deficiency syndromes (1999), 2009, Jun-01, Volume: 51, Issue:2

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes;

2009
The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals.
    Journal of acquired immune deficiency syndromes (1999), 2009, Jun-01, Volume: 51, Issue:2

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes;

2009
The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda.
    African health sciences, 2008, Volume: 8, Issue:1

    Topics: Anti-HIV Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Comorbidity; Female;

2008
The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda.
    African health sciences, 2008, Volume: 8, Issue:1

    Topics: Anti-HIV Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Comorbidity; Female;

2008
Arthritis as the presenting feature of HIV infection in a child.
    The Journal of infection, 2009, Volume: 58, Issue:5

    Topics: Ankle Joint; Anti-HIV Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Infectious; Child,

2009
Arthritis as the presenting feature of HIV infection in a child.
    The Journal of infection, 2009, Volume: 58, Issue:5

    Topics: Ankle Joint; Anti-HIV Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Infectious; Child,

2009
The obstetric face and challenge of HIV/AIDS.
    Clinical obstetrics and gynecology, 2009, Volume: 52, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Inf

2009
The obstetric face and challenge of HIV/AIDS.
    Clinical obstetrics and gynecology, 2009, Volume: 52, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Inf

2009
Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.
    Journal of acquired immune deficiency syndromes (1999), 2009, Apr-15, Volume: 50, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Cohort Studies; Cyclopropanes; Dose

2009
Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.
    Journal of acquired immune deficiency syndromes (1999), 2009, Apr-15, Volume: 50, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Cohort Studies; Cyclopropanes; Dose

2009
Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Mutation; Nevirapine

2009
Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Mutation; Nevirapine

2009
Efavirenz and nevirapine interactions with rifampicin: resolving the dilemmas?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Alkynes; Anti-Bacterial Agents; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV

2009
Efavirenz and nevirapine interactions with rifampicin: resolving the dilemmas?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Alkynes; Anti-Bacterial Agents; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV

2009
Reducing vertical HIV transmission in Kinshasa, Democratic Republic of Congo: trends in HIV prevalence and service delivery.
    AIDS care, 2009, Volume: 21, Issue:5

    Topics: Anti-HIV Agents; Delivery of Health Care; Democratic Republic of the Congo; Female; HIV Infections;

2009
Reducing vertical HIV transmission in Kinshasa, Democratic Republic of Congo: trends in HIV prevalence and service delivery.
    AIDS care, 2009, Volume: 21, Issue:5

    Topics: Anti-HIV Agents; Delivery of Health Care; Democratic Republic of the Congo; Female; HIV Infections;

2009
HIV patients presenting common adverse drug events caused by highly active antiretroviral therapy in Tanzania.
    Tanzania journal of health research, 2009, Volume: 11, Issue:1

    Topics: Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Drug Eruptions; HIV Infections; Huma

2009
HIV patients presenting common adverse drug events caused by highly active antiretroviral therapy in Tanzania.
    Tanzania journal of health research, 2009, Volume: 11, Issue:1

    Topics: Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Drug Eruptions; HIV Infections; Huma

2009
Long-term follow-up of nevirapine-treated patients in a single-centre cohort.
    HIV medicine, 2009, Volume: 10, Issue:8

    Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Aspartate Aminotransferases; CD4 Lymphocyte Cou

2009
Long-term follow-up of nevirapine-treated patients in a single-centre cohort.
    HIV medicine, 2009, Volume: 10, Issue:8

    Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Aspartate Aminotransferases; CD4 Lymphocyte Cou

2009
Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach.
    HIV medicine, 2009, Volume: 10, Issue:9

    Topics: Adult; Aged; Anti-HIV Agents; Biological Availability; Darunavir; Drug Therapy, Combination; Female;

2009
Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach.
    HIV medicine, 2009, Volume: 10, Issue:9

    Topics: Adult; Aged; Anti-HIV Agents; Biological Availability; Darunavir; Drug Therapy, Combination; Female;

2009
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.
    AIDS (London, England), 2009, Aug-24, Volume: 23, Issue:13

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Hypersensi

2009
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.
    AIDS (London, England), 2009, Aug-24, Volume: 23, Issue:13

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Hypersensi

2009
Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia.
    Journal of acquired immune deficiency syndromes (1999), 2009, Sep-01, Volume: 52, Issue:1

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Hu

2009
Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia.
    Journal of acquired immune deficiency syndromes (1999), 2009, Sep-01, Volume: 52, Issue:1

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Hu

2009
Acute intoxication with nevirapine in an HIV-1-infected patient: clinical and pharmacokinetic follow up.
    AIDS (London, England), 2009, Jun-19, Volume: 23, Issue:10

    Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Male; Nevirapine; Suicide, Attempted

2009
Acute intoxication with nevirapine in an HIV-1-infected patient: clinical and pharmacokinetic follow up.
    AIDS (London, England), 2009, Jun-19, Volume: 23, Issue:10

    Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Male; Nevirapine; Suicide, Attempted

2009
Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jul-15, Volume: 49, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Blood; Chemoprevention; Drug Resistance, Viral; HIV Infections;

2009
Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jul-15, Volume: 49, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Blood; Chemoprevention; Drug Resistance, Viral; HIV Infections;

2009
Prevention of human immunodeficiency virus mother-to-child transmission in Israel.
    International journal of STD & AIDS, 2009, Volume: 20, Issue:7

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Emigrants and Immigrants;

2009
Prevention of human immunodeficiency virus mother-to-child transmission in Israel.
    International journal of STD & AIDS, 2009, Volume: 20, Issue:7

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Emigrants and Immigrants;

2009
Report from the 16th Conference on Retroviruses and Opportunistic Infections. Lopinavir/r is superior to nevirapine in women who previously received single-dose nevirapine.
    Journal watch. AIDS clinical care, 2009, Volume: 21, Issue:4

    Topics: Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nevirapine; Pyrimidinones; Rever

2009
Report from the 16th Conference on Retroviruses and Opportunistic Infections. Lopinavir/r is superior to nevirapine in women who previously received single-dose nevirapine.
    Journal watch. AIDS clinical care, 2009, Volume: 21, Issue:4

    Topics: Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nevirapine; Pyrimidinones; Rever

2009
In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:7

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Administration Schedule; Drug

2009
In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:7

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Administration Schedule; Drug

2009
Evolving care of HIV-infected pregnant women in Jamaica--from nevirapine to HAART.
    The West Indian medical journal, 2008, Volume: 57, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; H

2008
Evolving care of HIV-infected pregnant women in Jamaica--from nevirapine to HAART.
    The West Indian medical journal, 2008, Volume: 57, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; H

2008
Adherence to antiretroviral drug therapy in children with HIV/AIDS in Jamaica.
    The West Indian medical journal, 2008, Volume: 57, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Anti-Retroviral Agents; Biomarkers;

2008
Adherence to antiretroviral drug therapy in children with HIV/AIDS in Jamaica.
    The West Indian medical journal, 2008, Volume: 57, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Anti-Retroviral Agents; Biomarkers;

2008
Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.
    AIDS (London, England), 2009, Nov-27, Volume: 23, Issue:18

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Female; HIV Infecti

2009
Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.
    AIDS (London, England), 2009, Nov-27, Volume: 23, Issue:18

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Female; HIV Infecti

2009
No influence of nevirapine on vitamin D deficiency in HIV-infected patients.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:8

    Topics: Anti-HIV Agents; HIV; HIV Infections; Humans; Longitudinal Studies; Nevirapine; Vitamin D Deficiency

2009
No influence of nevirapine on vitamin D deficiency in HIV-infected patients.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:8

    Topics: Anti-HIV Agents; HIV; HIV Infections; Humans; Longitudinal Studies; Nevirapine; Vitamin D Deficiency

2009
Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infants.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:7

    Topics: Age Factors; Drug Resistance, Viral; HIV; HIV Infections; Humans; Infant; Mutation; Nevirapine; Reag

2009
Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infants.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:7

    Topics: Age Factors; Drug Resistance, Viral; HIV; HIV Infections; Humans; Infant; Mutation; Nevirapine; Reag

2009
Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis.
    American journal of respiratory and critical care medicine, 2009, Oct-01, Volume: 180, Issue:7

    Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; CD4 Lym

2009
Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis.
    American journal of respiratory and critical care medicine, 2009, Oct-01, Volume: 180, Issue:7

    Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; CD4 Lym

2009
Effect of maternal HIV status on infant mortality: evidence from a 9-month follow-up of mothers and their infants in Zimbabwe.
    Journal of perinatology : official journal of the California Perinatal Association, 2010, Volume: 30, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; Drug Administration Schedule; Female; Foll

2010
Effect of maternal HIV status on infant mortality: evidence from a 9-month follow-up of mothers and their infants in Zimbabwe.
    Journal of perinatology : official journal of the California Perinatal Association, 2010, Volume: 30, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; Drug Administration Schedule; Female; Foll

2010
Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis.
    Journal of acquired immune deficiency syndromes (1999), 2009, Sep-01, Volume: 52, Issue:1

    Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; CD4 Lymphocyte Count; Female; Follow-Up Studies

2009
Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis.
    Journal of acquired immune deficiency syndromes (1999), 2009, Sep-01, Volume: 52, Issue:1

    Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; CD4 Lymphocyte Count; Female; Follow-Up Studies

2009
Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2010, Volume: 104, Issue:2

    Topics: Acidosis, Lactic; Adult; Age Factors; Anti-HIV Agents; Drug Therapy, Combination; Drugs, Generic; Ex

2010
Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2010, Volume: 104, Issue:2

    Topics: Acidosis, Lactic; Adult; Age Factors; Anti-HIV Agents; Drug Therapy, Combination; Drugs, Generic; Ex

2010
Mother-to-child HIV and HHV-8 transmission in neonates at Saint Camille Medical Centre in Burkina Faso.
    Pakistan journal of biological sciences : PJBS, 2009, Jun-15, Volume: 12, Issue:12

    Topics: Adult; Anti-HIV Agents; Burkina Faso; CD4 Lymphocyte Count; DNA, Viral; Female; Herpesviridae Infect

2009
Mother-to-child HIV and HHV-8 transmission in neonates at Saint Camille Medical Centre in Burkina Faso.
    Pakistan journal of biological sciences : PJBS, 2009, Jun-15, Volume: 12, Issue:12

    Topics: Adult; Anti-HIV Agents; Burkina Faso; CD4 Lymphocyte Count; DNA, Viral; Female; Herpesviridae Infect

2009
Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:10

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child, Preschool; Drug

2009
Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:10

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child, Preschool; Drug

2009
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
    Journal of acquired immune deficiency syndromes (1999), 2009, Volume: 52, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2009
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
    Journal of acquired immune deficiency syndromes (1999), 2009, Volume: 52, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2009
Single-dose nevirapine exposure affects T cell response and cytokine levels in HIV type 1-infected women.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:10

    Topics: Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Cytokines; Female; HIV Infections; Humans; Infa

2009
Single-dose nevirapine exposure affects T cell response and cytokine levels in HIV type 1-infected women.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:10

    Topics: Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Cytokines; Female; HIV Infections; Humans; Infa

2009
Modeling vertical transmission of HIV: imperfect vaccines can be of benefit.
    Vaccine, 2009, Nov-23, Volume: 27, Issue:50

    Topics: AIDS Vaccines; Anti-HIV Agents; Antibodies, Monoclonal; Breast Feeding; Child, Preschool; Female; HI

2009
Modeling vertical transmission of HIV: imperfect vaccines can be of benefit.
    Vaccine, 2009, Nov-23, Volume: 27, Issue:50

    Topics: AIDS Vaccines; Anti-HIV Agents; Antibodies, Monoclonal; Breast Feeding; Child, Preschool; Female; HI

2009
Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:6

    Topics: Administration, Oral; Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Combinations; Femal

2009
Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:6

    Topics: Administration, Oral; Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Combinations; Femal

2009
Reflections: neurology and the humanities: reflections for October.
    Neurology, 2009, Oct-13, Volume: 73, Issue:15

    Topics: Anti-HIV Agents; Anticonvulsants; Drug Combinations; Drug Interactions; Female; HIV Infections; Huma

2009
Reflections: neurology and the humanities: reflections for October.
    Neurology, 2009, Oct-13, Volume: 73, Issue:15

    Topics: Anti-HIV Agents; Anticonvulsants; Drug Combinations; Drug Interactions; Female; HIV Infections; Huma

2009
Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Nov-01, Volume: 49, Issue:9

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; HIV Infect

2009
Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Nov-01, Volume: 49, Issue:9

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; HIV Infect

2009
Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 53, Issue:1

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Developing Countries; Female; Gastroenteritis; HIV Infection

2010
Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 53, Issue:1

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Developing Countries; Female; Gastroenteritis; HIV Infection

2010
Antiretroviral strategies to prevent mother-to-child transmission of HIV: striking a balance between efficacy, feasibility, and resistance.
    PLoS medicine, 2009, Volume: 6, Issue:10

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV Infectio

2009
Antiretroviral strategies to prevent mother-to-child transmission of HIV: striking a balance between efficacy, feasibility, and resistance.
    PLoS medicine, 2009, Volume: 6, Issue:10

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV Infectio

2009
Substituting nevirapine for efavirenz: risk factors for toxicity in nonnaive patients in a resource-constrained setting.
    AIDS (London, England), 2009, Nov-13, Volume: 23, Issue:17

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Nevirapine; Risk Fac

2009
Substituting nevirapine for efavirenz: risk factors for toxicity in nonnaive patients in a resource-constrained setting.
    AIDS (London, England), 2009, Nov-13, Volume: 23, Issue:17

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Nevirapine; Risk Fac

2009
Plasma lipid profile in pregnant women with HIV receiving nevirapine.
    AIDS patient care and STDs, 2009, Volume: 23, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Cholesterol; Drug Therapy, Combination; Female; HIV Infections;

2009
Plasma lipid profile in pregnant women with HIV receiving nevirapine.
    AIDS patient care and STDs, 2009, Volume: 23, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Cholesterol; Drug Therapy, Combination; Female; HIV Infections;

2009
Improving the coverage of the PMTCT programme through a participatory quality improvement intervention in South Africa.
    BMC public health, 2009, Nov-05, Volume: 9

    Topics: Anti-HIV Agents; Continuity of Patient Care; Female; HIV Infections; Humans; Infant, Newborn; Infect

2009
Improving the coverage of the PMTCT programme through a participatory quality improvement intervention in South Africa.
    BMC public health, 2009, Nov-05, Volume: 9

    Topics: Anti-HIV Agents; Continuity of Patient Care; Female; HIV Infections; Humans; Infant, Newborn; Infect

2009
Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.
    AIDS (London, England), 2010, Jan-02, Volume: 24, Issue:1

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Inf

2010
Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.
    AIDS (London, England), 2010, Jan-02, Volume: 24, Issue:1

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Inf

2010
Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
    Antiviral therapy, 2009, Volume: 14, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Drug Hypersensitivity

2009
Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
    Antiviral therapy, 2009, Volume: 14, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Drug Hypersensitivity

2009
Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine.
    Current HIV research, 2009, Volume: 7, Issue:5

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Retrospective

2009
Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine.
    Current HIV research, 2009, Volume: 7, Issue:5

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Retrospective

2009
Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.
    AIDS (London, England), 2010, Jan-02, Volume: 24, Issue:1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Indu

2010
Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.
    AIDS (London, England), 2010, Jan-02, Volume: 24, Issue:1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Indu

2010
Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.
    Current HIV research, 2009, Volume: 7, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Atazanavir Sulfate; Birt

2009
Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.
    Current HIV research, 2009, Volume: 7, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Atazanavir Sulfate; Birt

2009
Response to antiretroviral therapy in HIV-infected Ugandan children exposed and not exposed to single-dose nevirapine at birth.
    Journal of acquired immune deficiency syndromes (1999), 2009, Volume: 52, Issue:5

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Cohort Studies

2009
Response to antiretroviral therapy in HIV-infected Ugandan children exposed and not exposed to single-dose nevirapine at birth.
    Journal of acquired immune deficiency syndromes (1999), 2009, Volume: 52, Issue:5

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Cohort Studies

2009
Dammarenolic acid, a secodammarane triterpenoid from Aglaia sp. shows potent anti-retroviral activity in vitro.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2010, Volume: 17, Issue:7

    Topics: Aglaia; Animals; Anti-Retroviral Agents; Cell Cycle; Cell Proliferation; Cytotoxins; Esters; Haplorh

2010
Dammarenolic acid, a secodammarane triterpenoid from Aglaia sp. shows potent anti-retroviral activity in vitro.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2010, Volume: 17, Issue:7

    Topics: Aglaia; Animals; Anti-Retroviral Agents; Cell Cycle; Cell Proliferation; Cytotoxins; Esters; Haplorh

2010
Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:2

    Topics: Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance,

2010
Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:2

    Topics: Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance,

2010
Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero.
    AIDS (London, England), 2010, Jan-28, Volume: 24, Issue:3

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infectious D

2010
Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero.
    AIDS (London, England), 2010, Jan-28, Volume: 24, Issue:3

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infectious D

2010
Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.
    Pharmacogenomics, 2010, Volume: 11, Issue:1

    Topics: Alleles; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily

2010
Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.
    Pharmacogenomics, 2010, Volume: 11, Issue:1

    Topics: Alleles; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily

2010
Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
    Antiviral therapy, 2009, Volume: 14, Issue:8

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Argentina; Child; Child, Prescho

2009
Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
    Antiviral therapy, 2009, Volume: 14, Issue:8

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Argentina; Child; Child, Prescho

2009
Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration.
    AIDS (London, England), 2010, Feb-20, Volume: 24, Issue:4

    Topics: Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Chromatography, Liquid; Drug Resistanc

2010
Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration.
    AIDS (London, England), 2010, Feb-20, Volume: 24, Issue:4

    Topics: Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Chromatography, Liquid; Drug Resistanc

2010
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
    Archives of internal medicine, 2010, Jan-11, Volume: 170, Issue:1

    Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate;

2010
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
    Archives of internal medicine, 2010, Jan-11, Volume: 170, Issue:1

    Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate;

2010
Decline in early life mortality in a high HIV prevalence rural area of South Africa: evidence of HIV prevention or treatment impact?
    AIDS (London, England), 2010, Feb-20, Volume: 24, Issue:4

    Topics: Adult; Anti-HIV Agents; Child, Preschool; Cohort Studies; Female; HIV Infections; Humans; Infant; In

2010
Decline in early life mortality in a high HIV prevalence rural area of South Africa: evidence of HIV prevention or treatment impact?
    AIDS (London, England), 2010, Feb-20, Volume: 24, Issue:4

    Topics: Adult; Anti-HIV Agents; Child, Preschool; Cohort Studies; Female; HIV Infections; Humans; Infant; In

2010
Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2010, Volume: 14, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Chemical and Drug Induced Liver Inj

2010
Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2010, Volume: 14, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Chemical and Drug Induced Liver Inj

2010
Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Chinese medical journal, 2009, Oct-20, Volume: 122, Issue:20

    Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Blotting, Western;

2009
Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Chinese medical journal, 2009, Oct-20, Volume: 122, Issue:20

    Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Blotting, Western;

2009
Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance.
    Proceedings of the National Academy of Sciences of the United States of America, 2010, Jan-26, Volume: 107, Issue:4

    Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HI

2010
Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance.
    Proceedings of the National Academy of Sciences of the United States of America, 2010, Jan-26, Volume: 107, Issue:4

    Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HI

2010
Determinants of adherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Gert Sibande district in South Africa.
    Acta paediatrica (Oslo, Norway : 1992), 2010, Volume: 99, Issue:5

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; Health Knowledge, Attitudes, Practice; HIV Infections; H

2010
Determinants of adherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Gert Sibande district in South Africa.
    Acta paediatrica (Oslo, Norway : 1992), 2010, Volume: 99, Issue:5

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; Health Knowledge, Attitudes, Practice; HIV Infections; H

2010
Another milestone in minimizing risks to mothers exposed to single-dose nevirapine for prevention of vertical transmission of HIV-1 to infants: what next?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Mar-15, Volume: 50, Issue:6

    Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant;

2010
Another milestone in minimizing risks to mothers exposed to single-dose nevirapine for prevention of vertical transmission of HIV-1 to infants: what next?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Mar-15, Volume: 50, Issue:6

    Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant;

2010
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Mar-15, Volume: 50, Issue:6

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Viral; Female; HIV Infect

2010
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Mar-15, Volume: 50, Issue:6

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Viral; Female; HIV Infect

2010
Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1.
    Current HIV research, 2010, Volume: 8, Issue:3

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Genot

2010
Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1.
    Current HIV research, 2010, Volume: 8, Issue:3

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Genot

2010
Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients.
    AIDS (London, England), 2010, Mar-13, Volume: 24, Issue:5

    Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HI

2010
Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients.
    AIDS (London, England), 2010, Mar-13, Volume: 24, Issue:5

    Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HI

2010
Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study.
    PLoS medicine, 2010, Feb-16, Volume: 7, Issue:2

    Topics: Adult; Cohort Studies; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Ke

2010
Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study.
    PLoS medicine, 2010, Feb-16, Volume: 7, Issue:2

    Topics: Adult; Cohort Studies; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Ke

2010
Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa.
    PloS one, 2010, Feb-17, Volume: 5, Issue:2

    Topics: Adult; Alanine Transaminase; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical a

2010
Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa.
    PloS one, 2010, Feb-17, Volume: 5, Issue:2

    Topics: Adult; Alanine Transaminase; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical a

2010
Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.
    Journal of clinical microbiology, 2010, Volume: 48, Issue:5

    Topics: Adult; Anti-HIV Agents; Chemoprevention; DNA Primers; DNA, Viral; Drug Resistance, Viral; Female; HI

2010
Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.
    Journal of clinical microbiology, 2010, Volume: 48, Issue:5

    Topics: Adult; Anti-HIV Agents; Chemoprevention; DNA Primers; DNA, Viral; Drug Resistance, Viral; Female; HI

2010
Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2010, Volume: 47, Issue:4

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Developing Countries; Female; HIV Inf

2010
Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2010, Volume: 47, Issue:4

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Developing Countries; Female; HIV Inf

2010
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
    BMC public health, 2010, Mar-01, Volume: 10

    Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Coho

2010
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
    BMC public health, 2010, Mar-01, Volume: 10

    Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Coho

2010
17th Conference on Retroviruses and Opportunistic Infections, 16-19 February, San Francisco, CA. Limits of success.
    Science (New York, N.Y.), 2010, Mar-05, Volume: 327, Issue:5970

    Topics: Anti-HIV Agents; Developing Countries; Female; HIV Infections; Humans; Infant; Infectious Disease Tr

2010
17th Conference on Retroviruses and Opportunistic Infections, 16-19 February, San Francisco, CA. Limits of success.
    Science (New York, N.Y.), 2010, Mar-05, Volume: 327, Issue:5970

    Topics: Anti-HIV Agents; Developing Countries; Female; HIV Infections; Humans; Infant; Infectious Disease Tr

2010
HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil.
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:3

    Topics: Alkynes; Benzoxazines; Brazil; Cohort Studies; Cyclopropanes; Darunavir; Drug Resistance, Multiple,

2010
HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil.
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:3

    Topics: Alkynes; Benzoxazines; Brazil; Cohort Studies; Cyclopropanes; Darunavir; Drug Resistance, Multiple,

2010
Epidemic Stevens-Johnson syndrome in HIV patients in Guinea-Bissau: a side effect of the drug-supply policy?
    AIDS (London, England), 2010, Mar-13, Volume: 24, Issue:5

    Topics: Adult; Anti-HIV Agents; Epidemics; Female; Guinea-Bissau; HIV Infections; Humans; Male; Nevirapine;

2010
Epidemic Stevens-Johnson syndrome in HIV patients in Guinea-Bissau: a side effect of the drug-supply policy?
    AIDS (London, England), 2010, Mar-13, Volume: 24, Issue:5

    Topics: Adult; Anti-HIV Agents; Epidemics; Female; Guinea-Bissau; HIV Infections; Humans; Male; Nevirapine;

2010
Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 54, Issue:4

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; CD4 Antigens; CD4 Lympho

2010
Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 54, Issue:4

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; CD4 Antigens; CD4 Lympho

2010
A Safe Motherhood project in Kenya: assessment of antenatal attendance, service provision and implications for PMTCT.
    Tropical medicine & international health : TM & IH, 2010, Volume: 15, Issue:5

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; Health Knowledge, Attitudes, Practice; HIV Infect

2010
A Safe Motherhood project in Kenya: assessment of antenatal attendance, service provision and implications for PMTCT.
    Tropical medicine & international health : TM & IH, 2010, Volume: 15, Issue:5

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; Health Knowledge, Attitudes, Practice; HIV Infect

2010
Couples' voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals: a prospective cohort study.
    Journal of the International AIDS Society, 2010, Mar-15, Volume: 13

    Topics: Adult; Cohort Studies; Counseling; Family Characteristics; Female; HIV Infections; Humans; Infectiou

2010
Couples' voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals: a prospective cohort study.
    Journal of the International AIDS Society, 2010, Mar-15, Volume: 13

    Topics: Adult; Cohort Studies; Counseling; Family Characteristics; Female; HIV Infections; Humans; Infectiou

2010
Rising mother-to-child HIV transmission in a resource-limited breastfeeding population.
    Tropical doctor, 2010, Volume: 40, Issue:2

    Topics: Adult; Breast Feeding; Cohort Studies; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Inf

2010
Rising mother-to-child HIV transmission in a resource-limited breastfeeding population.
    Tropical doctor, 2010, Volume: 40, Issue:2

    Topics: Adult; Breast Feeding; Cohort Studies; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Inf

2010
Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension.
    Pharmacotherapy, 2010, Volume: 30, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Arteries; Bosentan; Drug Interactions; Female; HIV Infections; H

2010
Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension.
    Pharmacotherapy, 2010, Volume: 30, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Arteries; Bosentan; Drug Interactions; Female; HIV Infections; H

2010
Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:3

    Topics: Botswana; Drug Resistance, Viral; Female; Gene Frequency; Genetic Variation; HIV Infections; HIV-1;

2010
Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:3

    Topics: Botswana; Drug Resistance, Viral; Female; Gene Frequency; Genetic Variation; HIV Infections; HIV-1;

2010
Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines.
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therap

2010
Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines.
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therap

2010
Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
    Intervirology, 2010, Volume: 53, Issue:4

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; China; Chole

2010
Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
    Intervirology, 2010, Volume: 53, Issue:4

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; China; Chole

2010
Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, May-15, Volume: 50, Issue:10

    Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Female; HIV Inf

2010
Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, May-15, Volume: 50, Issue:10

    Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Female; HIV Inf

2010
Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort.
    Antiviral research, 2010, Volume: 87, Issue:1

    Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resista

2010
Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort.
    Antiviral research, 2010, Volume: 87, Issue:1

    Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resista

2010
Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, May-15, Volume: 50, Issue:10

    Topics: Chemoprevention; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Inf

2010
Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, May-15, Volume: 50, Issue:10

    Topics: Chemoprevention; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Inf

2010
Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.
    Therapeutic drug monitoring, 2010, Volume: 32, Issue:3

    Topics: Anti-HIV Agents; Area Under Curve; Child; Confidence Intervals; Dosage Forms; Drug Therapy, Combinat

2010
Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.
    Therapeutic drug monitoring, 2010, Volume: 32, Issue:3

    Topics: Anti-HIV Agents; Area Under Curve; Child; Confidence Intervals; Dosage Forms; Drug Therapy, Combinat

2010
Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine.
    AIDS care, 2010, Volume: 22, Issue:1

    Topics: Adult; Aged; Alkynes; Anxiety; Benzoxazines; Cyclopropanes; Depression; Female; France; Health Statu

2010
Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine.
    AIDS care, 2010, Volume: 22, Issue:1

    Topics: Adult; Aged; Alkynes; Anxiety; Benzoxazines; Cyclopropanes; Depression; Female; France; Health Statu

2010
Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 54, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymphocyte

2010
Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 54, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymphocyte

2010
[Durability and tolerability of long-term nevirapine-based HAART].
    Le infezioni in medicina, 2010, Volume: 18, Issue:1

    Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Comorbidity; Dideoxynucleosides; Female; Hepatit

2010
[Durability and tolerability of long-term nevirapine-based HAART].
    Le infezioni in medicina, 2010, Volume: 18, Issue:1

    Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Comorbidity; Dideoxynucleosides; Female; Hepatit

2010
Non-adherence to the single dose nevirapine regimen for the prevention of mother-to-child transmission of HIV in Bindura town, Zimbabwe: a cross-sectional analytic study.
    BMC public health, 2010, Apr-28, Volume: 10

    Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Delivery, Obstetric; Educational Status; Female; He

2010
Non-adherence to the single dose nevirapine regimen for the prevention of mother-to-child transmission of HIV in Bindura town, Zimbabwe: a cross-sectional analytic study.
    BMC public health, 2010, Apr-28, Volume: 10

    Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Delivery, Obstetric; Educational Status; Female; He

2010
Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2010, Volume: 48, Issue:3

    Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Drug Re

2010
Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2010, Volume: 48, Issue:3

    Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Drug Re

2010
Pharmacokinetics of the treatment switch from efavirenz to nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Jun-01, Volume: 50, Issue:11

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV In

2010
Pharmacokinetics of the treatment switch from efavirenz to nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Jun-01, Volume: 50, Issue:11

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV In

2010
Testing and interval estimation for two-sample survival comparisons with small sample sizes and unequal censoring.
    Biostatistics (Oxford, England), 2010, Volume: 11, Issue:4

    Topics: Algorithms; Biostatistics; Breast Neoplasms; Clinical Trials as Topic; Computer Simulation; Confiden

2010
Testing and interval estimation for two-sample survival comparisons with small sample sizes and unequal censoring.
    Biostatistics (Oxford, England), 2010, Volume: 11, Issue:4

    Topics: Algorithms; Biostatistics; Breast Neoplasms; Clinical Trials as Topic; Computer Simulation; Confiden

2010
Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Nevirapine vs. boosted atazanavir--the ARTEN Study.
    Journal watch. AIDS clinical care, 2009, Volume: 21, Issue:10

    Topics: Atazanavir Sulfate; CD4 Lymphocyte Count; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapin

2009
Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Nevirapine vs. boosted atazanavir--the ARTEN Study.
    Journal watch. AIDS clinical care, 2009, Volume: 21, Issue:10

    Topics: Atazanavir Sulfate; CD4 Lymphocyte Count; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapin

2009
Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
    The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:7

    Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA Mutational Analy

2010
Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
    The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:7

    Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA Mutational Analy

2010
The benefit of supplementary feeding for wasted Malawian adults initiating ART.
    AIDS care, 2010, Volume: 22, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Retroviral Agents; Body Mass

2010
The benefit of supplementary feeding for wasted Malawian adults initiating ART.
    AIDS care, 2010, Volume: 22, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Retroviral Agents; Body Mass

2010
Report from the 17th Conference on Retroviruses and Opportunistic Infections. Randomized studies of once-daily darunavir and tenofovir/FTC + nevirapine.
    Journal watch. AIDS clinical care, 2010, Volume: 22, Issue:4

    Topics: Adenine; Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV In

2010
Report from the 17th Conference on Retroviruses and Opportunistic Infections. Randomized studies of once-daily darunavir and tenofovir/FTC + nevirapine.
    Journal watch. AIDS clinical care, 2010, Volume: 22, Issue:4

    Topics: Adenine; Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV In

2010
Peripartum nevirapine exposure and subsequent clinical outcomes among HIV-infected women receiving antiretroviral therapy for at least 12 months.
    Tropical medicine & international health : TM & IH, 2010, Volume: 15, Issue:7

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Epidemi

2010
Peripartum nevirapine exposure and subsequent clinical outcomes among HIV-infected women receiving antiretroviral therapy for at least 12 months.
    Tropical medicine & international health : TM & IH, 2010, Volume: 15, Issue:7

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Epidemi

2010
Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine.
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1

2010
Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine.
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1

2010
Predictors of treatment failure in Cambodian children with human immunodeficiency virus infection.
    The Pediatric infectious disease journal, 2010, Volume: 29, Issue:6

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cambodia; Child; Child, Preschoo

2010
Predictors of treatment failure in Cambodian children with human immunodeficiency virus infection.
    The Pediatric infectious disease journal, 2010, Volume: 29, Issue:6

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cambodia; Child; Child, Preschoo

2010
Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.
    The Pediatric infectious disease journal, 2010, Volume: 29, Issue:8

    Topics: Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Stud

2010
Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.
    The Pediatric infectious disease journal, 2010, Volume: 29, Issue:8

    Topics: Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Stud

2010
Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.
    Antiviral therapy, 2010, Volume: 15, Issue:3

    Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Sectional Studies;

2010
Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.
    Antiviral therapy, 2010, Volume: 15, Issue:3

    Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Sectional Studies;

2010
Reducing pediatric HIV infection: estimating mother-to-child transmission rates in a program setting in Zambia.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 54, Issue:4

    Topics: Antiretroviral Therapy, Highly Active; Breast Feeding; Child; DNA, Viral; Drug Therapy, Combination;

2010
Reducing pediatric HIV infection: estimating mother-to-child transmission rates in a program setting in Zambia.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 54, Issue:4

    Topics: Antiretroviral Therapy, Highly Active; Breast Feeding; Child; DNA, Viral; Drug Therapy, Combination;

2010
Long-term outcomes of HIV-infected patients with <95% rates of adherence to nonnucleoside reverse-transcriptase inhibitors.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Jul-01, Volume: 51, Issue:1

    Topics: Adolescent; Adult; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Ag

2010
Long-term outcomes of HIV-infected patients with <95% rates of adherence to nonnucleoside reverse-transcriptase inhibitors.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Jul-01, Volume: 51, Issue:1

    Topics: Adolescent; Adult; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Ag

2010
Prevention of mother-to-child transmission of HIV infection: views and perceptions about swallowing nevirapine in rural Lilongwe, Malawi.
    BMC public health, 2010, Jun-21, Volume: 10

    Topics: Administration, Oral; Adult; Aged; Anti-HIV Agents; Attitude to Health; Female; Focus Groups; Health

2010
Prevention of mother-to-child transmission of HIV infection: views and perceptions about swallowing nevirapine in rural Lilongwe, Malawi.
    BMC public health, 2010, Jun-21, Volume: 10

    Topics: Administration, Oral; Adult; Aged; Anti-HIV Agents; Attitude to Health; Female; Focus Groups; Health

2010
Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.
    BMC infectious diseases, 2010, Jun-24, Volume: 10

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur

2010
Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.
    BMC infectious diseases, 2010, Jun-24, Volume: 10

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur

2010
Virologic and immunologic outcomes in HIV-infected Cambodian children after 18 months of highly active antiretroviral therapy (HAART).
    The Southeast Asian journal of tropical medicine and public health, 2010, Volume: 41, Issue:1

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cambodia; CD4 Lymphocyte Count;

2010
Virologic and immunologic outcomes in HIV-infected Cambodian children after 18 months of highly active antiretroviral therapy (HAART).
    The Southeast Asian journal of tropical medicine and public health, 2010, Volume: 41, Issue:1

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cambodia; CD4 Lymphocyte Count;

2010
Switching from efavirenz to nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Aug-01, Volume: 51, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Time Fact

2010
Switching from efavirenz to nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Aug-01, Volume: 51, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Time Fact

2010
Extensive hypertrophic lichen planus in an HIV positive patient.
    Dermatology online journal, 2010, Jun-15, Volume: 16, Issue:6

    Topics: Adult; Anti-HIV Agents; Clobetasol; Drug Combinations; Hand Dermatoses; HIV Infections; Humans; Lami

2010
Extensive hypertrophic lichen planus in an HIV positive patient.
    Dermatology online journal, 2010, Jun-15, Volume: 16, Issue:6

    Topics: Adult; Anti-HIV Agents; Clobetasol; Drug Combinations; Hand Dermatoses; HIV Infections; Humans; Lami

2010
Theoretical studies on the molecular basis of HIV-1RT/NNRTIs interactions.
    Journal of enzyme inhibition and medicinal chemistry, 2011, Volume: 26, Issue:1

    Topics: Alkynes; Amino Acids; Benzoxazines; Binding Sites; Cyclopropanes; HIV Infections; HIV Reverse Transc

2011
Theoretical studies on the molecular basis of HIV-1RT/NNRTIs interactions.
    Journal of enzyme inhibition and medicinal chemistry, 2011, Volume: 26, Issue:1

    Topics: Alkynes; Amino Acids; Benzoxazines; Binding Sites; Cyclopropanes; HIV Infections; HIV Reverse Transc

2011
Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 54, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Combined Modality Therapy; HIV Infections; HIV-

2010
Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 54, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Combined Modality Therapy; HIV Infections; HIV-

2010
[Fate of children born to HIV positive mothers followed in the context of preventing mother-to-child transmission of HIV in Togo. Study of 1042 infants].
    Bulletin de la Societe de pathologie exotique (1990), 2010, Volume: 103, Issue:4

    Topics: Anti-HIV Agents; Breast Feeding; Delivery, Obstetric; Female; HIV Infections; HIV Seropositivity; Hu

2010
[Fate of children born to HIV positive mothers followed in the context of preventing mother-to-child transmission of HIV in Togo. Study of 1042 infants].
    Bulletin de la Societe de pathologie exotique (1990), 2010, Volume: 103, Issue:4

    Topics: Anti-HIV Agents; Breast Feeding; Delivery, Obstetric; Female; HIV Infections; HIV Seropositivity; Hu

2010
Vanishing bile duct syndrome in human immunodeficiency virus: nevirapine hepatotoxicity revisited.
    World journal of gastroenterology, 2010, Jul-14, Volume: 16, Issue:26

    Topics: Adult; Anti-HIV Agents; Bile Duct Diseases; Bile Ducts, Intrahepatic; Cholestasis, Intrahepatic; Fem

2010
Vanishing bile duct syndrome in human immunodeficiency virus: nevirapine hepatotoxicity revisited.
    World journal of gastroenterology, 2010, Jul-14, Volume: 16, Issue:26

    Topics: Adult; Anti-HIV Agents; Bile Duct Diseases; Bile Ducts, Intrahepatic; Cholestasis, Intrahepatic; Fem

2010
Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 55, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Longitudinal Studies; Nev

2010
Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 55, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Longitudinal Studies; Nev

2010
CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
    Therapeutic drug monitoring, 2010, Volume: 32, Issue:5

    Topics: Adult; Aged; Alkynes; Aryl Hydrocarbon Hydroxylases; Asian People; ATP Binding Cassette Transporter,

2010
CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
    Therapeutic drug monitoring, 2010, Volume: 32, Issue:5

    Topics: Adult; Aged; Alkynes; Aryl Hydrocarbon Hydroxylases; Asian People; ATP Binding Cassette Transporter,

2010
Impact of maternal HAART on the prevention of mother-to-child transmission of HIV: results of an 18-month follow-up study in Ouagadougou, Burkina Faso.
    AIDS care, 2010, Volume: 22, Issue:7

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Burkina Faso; Cohort Stud

2010
Impact of maternal HAART on the prevention of mother-to-child transmission of HIV: results of an 18-month follow-up study in Ouagadougou, Burkina Faso.
    AIDS care, 2010, Volume: 22, Issue:7

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Burkina Faso; Cohort Stud

2010
Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries.
    JAMA, 2010, Jul-21, Volume: 304, Issue:3

    Topics: Adult; Africa; Anti-HIV Agents; Cross-Sectional Studies; Female; Fetal Blood; HIV Infections; Humans

2010
Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries.
    JAMA, 2010, Jul-21, Volume: 304, Issue:3

    Topics: Adult; Africa; Anti-HIV Agents; Cross-Sectional Studies; Female; Fetal Blood; HIV Infections; Humans

2010
Nevirapine-induced stevens johnson-syndrome and fulminant hepatic failure requiring liver transplantation.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2010, Volume: 10, Issue:7

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Hemofiltration; HIV Infections; Huma

2010
Nevirapine-induced stevens johnson-syndrome and fulminant hepatic failure requiring liver transplantation.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2010, Volume: 10, Issue:7

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Hemofiltration; HIV Infections; Huma

2010
Evaluation of the safety of nevirapine therapy during pregnancy.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 54, Issue:5

    Topics: Adult; Anti-HIV Agents; Chemoprevention; Drug-Related Side Effects and Adverse Reactions; Female; HI

2010
Evaluation of the safety of nevirapine therapy during pregnancy.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 54, Issue:5

    Topics: Adult; Anti-HIV Agents; Chemoprevention; Drug-Related Side Effects and Adverse Reactions; Female; HI

2010
Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
    HIV medicine, 2010, Volume: 11, Issue:10

    Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; CD4 Lymphocyte Count; Chemical

2010
Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
    HIV medicine, 2010, Volume: 11, Issue:10

    Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; CD4 Lymphocyte Count; Chemical

2010
Operational evaluation of a service for prevention of mother-to-child transmission of HIV in rural Uganda: barriers to uptake of single-dose nevirapine and the role of birth reporting.
    Tropical medicine & international health : TM & IH, 2010, Volume: 15, Issue:10

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Infant, Newborn; Infectious

2010
Operational evaluation of a service for prevention of mother-to-child transmission of HIV in rural Uganda: barriers to uptake of single-dose nevirapine and the role of birth reporting.
    Tropical medicine & international health : TM & IH, 2010, Volume: 15, Issue:10

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Infant, Newborn; Infectious

2010
Estimating frequencies of minority nevirapine-resistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model.
    Journal of virology, 2010, Volume: 84, Issue:19

    Topics: Drug Resistance, Viral; Evolution, Molecular; Female; Genome, Viral; HIV Infections; HIV-1; Humans;

2010
Estimating frequencies of minority nevirapine-resistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model.
    Journal of virology, 2010, Volume: 84, Issue:19

    Topics: Drug Resistance, Viral; Evolution, Molecular; Female; Genome, Viral; HIV Infections; HIV-1; Humans;

2010
Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 54, Issue:5

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1;

2010
Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 54, Issue:5

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1;

2010
Antenatal HIV-1 RNA load and timing of mother to child transmission; a nested case-control study in a resource poor setting.
    Virology journal, 2010, Aug-02, Volume: 7

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Cohort Studies; Female; HIV Infections; HIV-1; Humans;

2010
Antenatal HIV-1 RNA load and timing of mother to child transmission; a nested case-control study in a resource poor setting.
    Virology journal, 2010, Aug-02, Volume: 7

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Cohort Studies; Female; HIV Infections; HIV-1; Humans;

2010
Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV-1: a study in Côte d'Ivoire.
    Journal of the International AIDS Society, 2010, Aug-02, Volume: 13

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire;

2010
Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV-1: a study in Côte d'Ivoire.
    Journal of the International AIDS Society, 2010, Aug-02, Volume: 13

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire;

2010
Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children.
    Journal of the International AIDS Society, 2010, Aug-06, Volume: 13

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Fem

2010
Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children.
    Journal of the International AIDS Society, 2010, Aug-06, Volume: 13

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Fem

2010
Recent FDA approvals and changes.
    AIDS patient care and STDs, 2010, Volume: 24, Issue:8

    Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Approval; Drug Combinations; Drugs, Generic; HIV Anti

2010
Recent FDA approvals and changes.
    AIDS patient care and STDs, 2010, Volume: 24, Issue:8

    Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Approval; Drug Combinations; Drugs, Generic; HIV Anti

2010
[Stevens-Johnson syndrome and toxic epidermal necrolysis in a teaching hospital in Lomé, Togo: retrospective study of 89 cases].
    Medecine tropicale : revue du Corps de sante colonial, 2010, Volume: 70, Issue:3

    Topics: Adult; Anti-HIV Agents; Anti-Infective Agents; Drug Therapy, Combination; Female; HIV Infections; Ho

2010
[Stevens-Johnson syndrome and toxic epidermal necrolysis in a teaching hospital in Lomé, Togo: retrospective study of 89 cases].
    Medecine tropicale : revue du Corps de sante colonial, 2010, Volume: 70, Issue:3

    Topics: Adult; Anti-HIV Agents; Anti-Infective Agents; Drug Therapy, Combination; Female; HIV Infections; Ho

2010
Protein adducts as prospective biomarkers of nevirapine toxicity.
    Chemical research in toxicology, 2010, Nov-15, Volume: 23, Issue:11

    Topics: Amino Acid Sequence; Anti-HIV Agents; Biomarkers; Chromatography, High Pressure Liquid; Hemoglobins;

2010
Protein adducts as prospective biomarkers of nevirapine toxicity.
    Chemical research in toxicology, 2010, Nov-15, Volume: 23, Issue:11

    Topics: Amino Acid Sequence; Anti-HIV Agents; Biomarkers; Chromatography, High Pressure Liquid; Hemoglobins;

2010
A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
    HIV medicine, 2011, Volume: 12, Issue:5

    Topics: Alkynes; Argentina; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Resistance; Drug

2011
A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
    HIV medicine, 2011, Volume: 12, Issue:5

    Topics: Alkynes; Argentina; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Resistance; Drug

2011
Outcomes and challenges of scaling up comprehensive PMTCT services in rural Swaziland, Southern Africa.
    AIDS care, 2010, Volume: 22, Issue:9

    Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Eswatini; Female; HIV Infections; Humans; Infant; Infant

2010
Outcomes and challenges of scaling up comprehensive PMTCT services in rural Swaziland, Southern Africa.
    AIDS care, 2010, Volume: 22, Issue:9

    Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Eswatini; Female; HIV Infections; Humans; Infant; Infant

2010
Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.
    PloS one, 2010, Sep-07, Volume: 5, Issue:9

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Follow-Up Studies; HIV Infecti

2010
Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.
    PloS one, 2010, Sep-07, Volume: 5, Issue:9

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Follow-Up Studies; HIV Infecti

2010
Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.
    Journal of acquired immune deficiency syndromes (1999), 2011, Jan-01, Volume: 56, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2011
Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.
    Journal of acquired immune deficiency syndromes (1999), 2011, Jan-01, Volume: 56, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2011
Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2010, Volume: 14, Issue:11

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antitubercular Agents; CD4 Lymphocyte Count; Confide

2010
Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2010, Volume: 14, Issue:11

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antitubercular Agents; CD4 Lymphocyte Count; Confide

2010
Extended antenatal antiretroviral use correlates with improved infant outcomes throughout the first year of life.
    AIDS (London, England), 2010, Nov-27, Volume: 24, Issue:18

    Topics: Adult; Breast Feeding; CD4 Lymphocyte Count; Cohort Studies; Drug Administration Schedule; Female; H

2010
Extended antenatal antiretroviral use correlates with improved infant outcomes throughout the first year of life.
    AIDS (London, England), 2010, Nov-27, Volume: 24, Issue:18

    Topics: Adult; Breast Feeding; CD4 Lymphocyte Count; Cohort Studies; Drug Administration Schedule; Female; H

2010
Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing.
    Journal of acquired immune deficiency syndromes (1999), 2010, Dec-15, Volume: 55, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV; HIV

2010
Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing.
    Journal of acquired immune deficiency syndromes (1999), 2010, Dec-15, Volume: 55, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV; HIV

2010
Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment.
    The Journal of infectious diseases, 2010, Nov-15, Volume: 202, Issue:10

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cervix Uteri; Disease Transmission, I

2010
Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment.
    The Journal of infectious diseases, 2010, Nov-15, Volume: 202, Issue:10

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cervix Uteri; Disease Transmission, I

2010
Recent FDA approvals and changes.
    AIDS patient care and STDs, 2010, Volume: 24, Issue:10

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Capsules; Clinical Trials as Topic; Drug Approval; Drug Combina

2010
Recent FDA approvals and changes.
    AIDS patient care and STDs, 2010, Volume: 24, Issue:10

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Capsules; Clinical Trials as Topic; Drug Approval; Drug Combina

2010
Acute porphyria precipitated by nevirapine.
    AIDS (London, England), 2010, Oct-23, Volume: 24, Issue:16

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Nevirapine; Porphyria, Acute Intermittent; P

2010
Acute porphyria precipitated by nevirapine.
    AIDS (London, England), 2010, Oct-23, Volume: 24, Issue:16

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Nevirapine; Porphyria, Acute Intermittent; P

2010
Preventing mother-to-child transmission of HIV—protecting this generation and the next.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Female; HIV Infections; Humans; Infectious Disease Transmis

2010
Preventing mother-to-child transmission of HIV—protecting this generation and the next.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Female; HIV Infections; Humans; Infectious Disease Transmis

2010
Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
    Antiviral therapy, 2010, Volume: 15, Issue:7

    Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV; HIV In

2010
Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
    Antiviral therapy, 2010, Volume: 15, Issue:7

    Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV; HIV In

2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
    The New England journal of medicine, 2010, 11-11, Volume: 363, Issue:20

    Topics: Anti-Retroviral Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infe

2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
    The New England journal of medicine, 2010, 11-11, Volume: 363, Issue:20

    Topics: Anti-Retroviral Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infe

2010
Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire.
    Journal of acquired immune deficiency syndromes (1999), 2011, Feb-01, Volume: 56, Issue:2

    Topics: Abortion, Induced; Abortion, Spontaneous; Adult; Africa, Western; Alkynes; Anti-HIV Agents; Benzoxaz

2011
Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire.
    Journal of acquired immune deficiency syndromes (1999), 2011, Feb-01, Volume: 56, Issue:2

    Topics: Abortion, Induced; Abortion, Spontaneous; Adult; Africa, Western; Alkynes; Anti-HIV Agents; Benzoxaz

2011
The impact of maternal highly active antiretroviral therapy and short-course combination antiretrovirals for prevention of mother-to-child transmission on early infant infection rates at the Mulago national referral hospital in Kampala, Uganda, January 20
    Journal of acquired immune deficiency syndromes (1999), 2011, Jan-01, Volume: 56, Issue:1

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Confidence Intervals; Female; HIV Inf

2011
The impact of maternal highly active antiretroviral therapy and short-course combination antiretrovirals for prevention of mother-to-child transmission on early infant infection rates at the Mulago national referral hospital in Kampala, Uganda, January 20
    Journal of acquired immune deficiency syndromes (1999), 2011, Jan-01, Volume: 56, Issue:1

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Confidence Intervals; Female; HIV Inf

2011
Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.
    Journal of acquired immune deficiency syndromes (1999), 2011, Mar-01, Volume: 56, Issue:3

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschoo

2011
Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.
    Journal of acquired immune deficiency syndromes (1999), 2011, Mar-01, Volume: 56, Issue:3

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschoo

2011
Comparing two service delivery models for the prevention of mother-to-child transmission (PMTCT) of HIV during transition from single-dose nevirapine to multi-drug antiretroviral regimens.
    BMC public health, 2010, Dec-06, Volume: 10

    Topics: Adolescent; Adult; Africa South of the Sahara; Anti-Retroviral Agents; CD4 Lymphocyte Count; Clinica

2010
Comparing two service delivery models for the prevention of mother-to-child transmission (PMTCT) of HIV during transition from single-dose nevirapine to multi-drug antiretroviral regimens.
    BMC public health, 2010, Dec-06, Volume: 10

    Topics: Adolescent; Adult; Africa South of the Sahara; Anti-Retroviral Agents; CD4 Lymphocyte Count; Clinica

2010
Easier said than done: World Health Organization recommendations for prevention of mother-to-child transmission of HIV-areas of concern.
    AIDS research and human retroviruses, 2011, Volume: 27, Issue:8

    Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte C

2011
Easier said than done: World Health Organization recommendations for prevention of mother-to-child transmission of HIV-areas of concern.
    AIDS research and human retroviruses, 2011, Volume: 27, Issue:8

    Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte C

2011
A combined sequence-structure approach for predicting resistance to the non-nucleoside HIV-1 reverse transcriptase inhibitor Nevirapine.
    Biophysical chemistry, 2011, Volume: 153, Issue:2-3

    Topics: Drug Resistance, Viral; Genetic Testing; Genetic Vectors; HIV Infections; HIV Reverse Transcriptase;

2011
A combined sequence-structure approach for predicting resistance to the non-nucleoside HIV-1 reverse transcriptase inhibitor Nevirapine.
    Biophysical chemistry, 2011, Volume: 153, Issue:2-3

    Topics: Drug Resistance, Viral; Genetic Testing; Genetic Vectors; HIV Infections; HIV Reverse Transcriptase;

2011
Emergence of drug resistant mutations after single dose nevirapine exposure in HIV-1 infected pregnant women in south India.
    The Indian journal of medical research, 2010, Volume: 132

    Topics: Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; India

2010
Emergence of drug resistant mutations after single dose nevirapine exposure in HIV-1 infected pregnant women in south India.
    The Indian journal of medical research, 2010, Volume: 132

    Topics: Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; India

2010
Antiretroviral treatment for HIV-infected infants exposed to nevirapine.
    JAMA, 2010, Dec-15, Volume: 304, Issue:23

    Topics: Anti-Retroviral Agents; Child; Drug Resistance, Viral; Endpoint Determination; HIV Infections; Human

2010
Antiretroviral treatment for HIV-infected infants exposed to nevirapine.
    JAMA, 2010, Dec-15, Volume: 304, Issue:23

    Topics: Anti-Retroviral Agents; Child; Drug Resistance, Viral; Endpoint Determination; HIV Infections; Human

2010
Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml.
    AIDS (London, England), 2011, Jan-28, Volume: 25, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2011
Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml.
    AIDS (London, England), 2011, Jan-28, Volume: 25, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2011
Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands.
    Therapeutic drug monitoring, 2011, Volume: 33, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Monitoring; Drug Ther

2011
Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands.
    Therapeutic drug monitoring, 2011, Volume: 33, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Monitoring; Drug Ther

2011
Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India.
    Journal of infection in developing countries, 2010, Nov-24, Volume: 4, Issue:11

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug-Related Side Effects an

2010
Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India.
    Journal of infection in developing countries, 2010, Nov-24, Volume: 4, Issue:11

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug-Related Side Effects an

2010
Automatic nevirapine concentration interpretation system using support vector regression.
    Computer methods and programs in biomedicine, 2011, Volume: 101, Issue:3

    Topics: Anti-HIV Agents; Artificial Intelligence; Drug Resistance, Viral; HIV Infections; Humans; Models, Th

2011
Automatic nevirapine concentration interpretation system using support vector regression.
    Computer methods and programs in biomedicine, 2011, Volume: 101, Issue:3

    Topics: Anti-HIV Agents; Artificial Intelligence; Drug Resistance, Viral; HIV Infections; Humans; Models, Th

2011
Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections.
    The Journal of infectious diseases, 2011, Mar-15, Volume: 203, Issue:6

    Topics: Anti-HIV Agents; Disease Transmission, Infectious; DNA Primers; Female; HIV Infections; HIV-1; Human

2011
Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections.
    The Journal of infectious diseases, 2011, Mar-15, Volume: 203, Issue:6

    Topics: Anti-HIV Agents; Disease Transmission, Infectious; DNA Primers; Female; HIV Infections; HIV-1; Human

2011
Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Feb-15, Volume: 52, Issue:4

    Topics: Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Resistance, Viral; Female; Genotype; H

2011
Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Feb-15, Volume: 52, Issue:4

    Topics: Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Resistance, Viral; Female; Genotype; H

2011
Clinical manifestations and outcome in HIV-infected young infants presenting with acute illness in Durban, South Africa.
    Annals of tropical paediatrics, 2011, Volume: 31, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmi

2011
Clinical manifestations and outcome in HIV-infected young infants presenting with acute illness in Durban, South Africa.
    Annals of tropical paediatrics, 2011, Volume: 31, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmi

2011
Perinatal tuberculosis: two unusual cases.
    Annals of tropical paediatrics, 2011, Volume: 31, Issue:1

    Topics: Anti-HIV Agents; Anti-Inflammatory Agents; Antimalarials; Drug Therapy, Combination; Endometritis; F

2011
Perinatal tuberculosis: two unusual cases.
    Annals of tropical paediatrics, 2011, Volume: 31, Issue:1

    Topics: Anti-HIV Agents; Anti-Inflammatory Agents; Antimalarials; Drug Therapy, Combination; Endometritis; F

2011
Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
    Pharmacotherapy, 2011, Volume: 31, Issue:2

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cli

2011
Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
    Pharmacotherapy, 2011, Volume: 31, Issue:2

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cli

2011
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.
    AIDS (London, England), 2011, Feb-20, Volume: 25, Issue:4

    Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Female; HIV Infections; Humans; Infant, Newborn; Infe

2011
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.
    AIDS (London, England), 2011, Feb-20, Volume: 25, Issue:4

    Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Female; HIV Infections; Humans; Infant, Newborn; Infe

2011
Minor drug-resistant HIV type-1 variants in breast milk and plasma of HIV type-1-infected Ugandan women after nevirapine single-dose prophylaxis.
    Antiviral therapy, 2011, Volume: 16, Issue:1

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; Genetic Variation; HIV Infec

2011
Minor drug-resistant HIV type-1 variants in breast milk and plasma of HIV type-1-infected Ugandan women after nevirapine single-dose prophylaxis.
    Antiviral therapy, 2011, Volume: 16, Issue:1

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; Genetic Variation; HIV Infec

2011
Multi-nucleoside reverse transcriptase inhibitor resistant HIV type-1 in a patient from Sierra Leone failing stavudine, lamivudine and nevirapine.
    Antiviral therapy, 2011, Volume: 16, Issue:1

    Topics: Adult; Drug Resistance, Multiple, Viral; Genetic Variation; HIV Infections; HIV Reverse Transcriptas

2011
Multi-nucleoside reverse transcriptase inhibitor resistant HIV type-1 in a patient from Sierra Leone failing stavudine, lamivudine and nevirapine.
    Antiviral therapy, 2011, Volume: 16, Issue:1

    Topics: Adult; Drug Resistance, Multiple, Viral; Genetic Variation; HIV Infections; HIV Reverse Transcriptas

2011
Study leads to revision in WHO guidelines for HIV women.
    AIDS policy & law, 2010, Volume: 26, Issue:1

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Practice Guid

2010
Study leads to revision in WHO guidelines for HIV women.
    AIDS policy & law, 2010, Volume: 26, Issue:1

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Practice Guid

2010
Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.
    AIDS research and human retroviruses, 2011, Volume: 27, Issue:9

    Topics: Amino Acid Substitution; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Resistance, Vir

2011
Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.
    AIDS research and human retroviruses, 2011, Volume: 27, Issue:9

    Topics: Amino Acid Substitution; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Resistance, Vir

2011
Effectiveness of a PMTCT programme in rural Western Kenya.
    AIDS care, 2011, Volume: 23, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Epidemiologic Methods; Fe

2011
Effectiveness of a PMTCT programme in rural Western Kenya.
    AIDS care, 2011, Volume: 23, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Epidemiologic Methods; Fe

2011
Efavirenz-based combination antiretroviral therapy after peripartum single-dose nevirapine.
    International journal of STD & AIDS, 2011, Volume: 22, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2011
Efavirenz-based combination antiretroviral therapy after peripartum single-dose nevirapine.
    International journal of STD & AIDS, 2011, Volume: 22, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2011
Factors associated with short-course antiretroviral prophylaxis (dual therapy) adherence for PMTCT in Nkangala district, South Africa.
    Acta paediatrica (Oslo, Norway : 1992), 2011, Volume: 100, Issue:9

    Topics: Anti-HIV Agents; Chi-Square Distribution; Depression, Postpartum; Directive Counseling; Female; Heal

2011
Factors associated with short-course antiretroviral prophylaxis (dual therapy) adherence for PMTCT in Nkangala district, South Africa.
    Acta paediatrica (Oslo, Norway : 1992), 2011, Volume: 100, Issue:9

    Topics: Anti-HIV Agents; Chi-Square Distribution; Depression, Postpartum; Directive Counseling; Female; Heal

2011
Cumulative exposure to cell-free HIV in breast milk, rather than feeding pattern per se, identifies postnatally infected infants.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Mar-15, Volume: 52, Issue:6

    Topics: Adult; Anthropometry; Anti-HIV Agents; Case-Control Studies; Chemoprevention; Feeding Behavior; Fema

2011
Cumulative exposure to cell-free HIV in breast milk, rather than feeding pattern per se, identifies postnatally infected infants.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Mar-15, Volume: 52, Issue:6

    Topics: Adult; Anthropometry; Anti-HIV Agents; Case-Control Studies; Chemoprevention; Feeding Behavior; Fema

2011
Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:4

    Topics: Amino Acid Substitution; Anti-HIV Agents; Brazil; Drug Resistance, Viral; HIV Infections; HIV Revers

2011
Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:4

    Topics: Amino Acid Substitution; Anti-HIV Agents; Brazil; Drug Resistance, Viral; HIV Infections; HIV Revers

2011
Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:6

    Topics: Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases;

2011
Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:6

    Topics: Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases;

2011
Self-reported adherence to HAART in South-Eastern Nigeria is related to patients' use of pill box.
    SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance, 2010, Volume: 7, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Algorithms; Anti-HIV Agents; Antiretrov

2010
Self-reported adherence to HAART in South-Eastern Nigeria is related to patients' use of pill box.
    SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance, 2010, Volume: 7, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Algorithms; Anti-HIV Agents; Antiretrov

2010
Do nevirapine and efavirenz affect vitamin D homeostasis similarly?
    AIDS (London, England), 2011, Mar-27, Volume: 25, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Vitamin D

2011
Do nevirapine and efavirenz affect vitamin D homeostasis similarly?
    AIDS (London, England), 2011, Mar-27, Volume: 25, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Vitamin D

2011
Short communication: high prevalence of drug resistance in HIV type 1-infected children born in Honduras and Belize 2001 to 2004.
    AIDS research and human retroviruses, 2011, Volume: 27, Issue:10

    Topics: Anti-HIV Agents; Base Sequence; Belize; Cohort Studies; Drug Resistance, Multiple, Viral; Female; HI

2011
Short communication: high prevalence of drug resistance in HIV type 1-infected children born in Honduras and Belize 2001 to 2004.
    AIDS research and human retroviruses, 2011, Volume: 27, Issue:10

    Topics: Anti-HIV Agents; Base Sequence; Belize; Cohort Studies; Drug Resistance, Multiple, Viral; Female; HI

2011
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Body Wei

2011
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Body Wei

2011
[Immune reconstitution inflammatory syndrome and HIV leprosy co-infection].
    Medecine et maladies infectieuses, 2011, Volume: 41, Issue:7

    Topics: Adrenal Cortex Hormones; Adult; Anti-HIV Agents; Dapsone; Diagnostic Errors; Female; HIV Infections;

2011
[Immune reconstitution inflammatory syndrome and HIV leprosy co-infection].
    Medecine et maladies infectieuses, 2011, Volume: 41, Issue:7

    Topics: Adrenal Cortex Hormones; Adult; Anti-HIV Agents; Dapsone; Diagnostic Errors; Female; HIV Infections;

2011
Trial in youngest group points to HIV treatment overhaul.
    Nature medicine, 2011, Volume: 17, Issue:4

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; HIV Protease Inhibitors; Humans;

2011
Trial in youngest group points to HIV treatment overhaul.
    Nature medicine, 2011, Volume: 17, Issue:4

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; HIV Protease Inhibitors; Humans;

2011
Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis.
    AIDS (London, England), 2011, Apr-24, Volume: 25, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; In

2011
Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis.
    AIDS (London, England), 2011, Apr-24, Volume: 25, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; In

2011
Resistance, resistance, go away: persistence of nevirapine-resistant HIV mutations in HIV-infected infants.
    AIDS (London, England), 2011, Apr-24, Volume: 25, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; Humans; Infant; Infectious Disease Transmis

2011
Resistance, resistance, go away: persistence of nevirapine-resistant HIV mutations in HIV-infected infants.
    AIDS (London, England), 2011, Apr-24, Volume: 25, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; Humans; Infant; Infectious Disease Transmis

2011
"They call our children "Nevirapine babies?" ": A qualitative study about exclusive breastfeeding among HIV positive mothers in Malawi.
    African journal of reproductive health, 2010, Volume: 14, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Family; Female; Health Knowledge, Attitudes, Pra

2010
"They call our children "Nevirapine babies?" ": A qualitative study about exclusive breastfeeding among HIV positive mothers in Malawi.
    African journal of reproductive health, 2010, Volume: 14, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Family; Female; Health Knowledge, Attitudes, Pra

2010
Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition.
    BMC infectious diseases, 2011, Apr-19, Volume: 11

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Follow-Up Studies; Health Status; HIV Infectio

2011
Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition.
    BMC infectious diseases, 2011, Apr-19, Volume: 11

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Follow-Up Studies; Health Status; HIV Infectio

2011
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.
    AIDS (London, England), 2011, Jun-19, Volume: 25, Issue:10

    Topics: Adolescent; Adult; Asian People; Black People; CD4-Positive T-Lymphocytes; Female; Genetic Variation

2011
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.
    AIDS (London, England), 2011, Jun-19, Volume: 25, Issue:10

    Topics: Adolescent; Adult; Asian People; Black People; CD4-Positive T-Lymphocytes; Female; Genetic Variation

2011
Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
    International journal of STD & AIDS, 2011, Volume: 22, Issue:4

    Topics: Adenine; Adult; Anti-HIV Agents; Australia; Deoxycytidine; Drug Administration Schedule; Emtricitabi

2011
Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
    International journal of STD & AIDS, 2011, Volume: 22, Issue:4

    Topics: Adenine; Adult; Anti-HIV Agents; Australia; Deoxycytidine; Drug Administration Schedule; Emtricitabi

2011
[Mass screening for hypothyroidism in a cohort of HIV infected patients in a Bogotá hospital, Colombia].
    Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia, 2011, Volume: 28, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Col

2011
[Mass screening for hypothyroidism in a cohort of HIV infected patients in a Bogotá hospital, Colombia].
    Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia, 2011, Volume: 28, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Col

2011
Improving retention in the early infant diagnosis of HIV program in rural Mozambique by better service integration.
    Journal of acquired immune deficiency syndromes (1999), 2011, Sep-01, Volume: 58, Issue:1

    Topics: Adult; Anti-HIV Agents; Delivery of Health Care; Drug Therapy, Combination; Female; HIV Infections;

2011
Improving retention in the early infant diagnosis of HIV program in rural Mozambique by better service integration.
    Journal of acquired immune deficiency syndromes (1999), 2011, Sep-01, Volume: 58, Issue:1

    Topics: Adult; Anti-HIV Agents; Delivery of Health Care; Drug Therapy, Combination; Female; HIV Infections;

2011
Serum Nevirapine and Efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy.
    Indian pediatrics, 2011, Volume: 48, Issue:12

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropa

2011
Serum Nevirapine and Efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy.
    Indian pediatrics, 2011, Volume: 48, Issue:12

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropa

2011
Targeted maximum likelihood estimation of effect modification parameters in survival analysis.
    The international journal of biostatistics, 2011, Mar-30, Volume: 7, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Female; HIV

2011
Targeted maximum likelihood estimation of effect modification parameters in survival analysis.
    The international journal of biostatistics, 2011, Mar-30, Volume: 7, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Female; HIV

2011
Discontinuation rate of nevirapine-based highly active antiretroviral therapy.
    AIDS research and human retroviruses, 2012, Volume: 28, Issue:1

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Induced Liver

2012
Discontinuation rate of nevirapine-based highly active antiretroviral therapy.
    AIDS research and human retroviruses, 2012, Volume: 28, Issue:1

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Induced Liver

2012
Reduced HIV transmission at subsequent pregnancy in a resource-poor setting.
    Tropical doctor, 2011, Volume: 41, Issue:3

    Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Female; HIV Infections; HIV-1; Humans; Infant, Newb

2011
Reduced HIV transmission at subsequent pregnancy in a resource-poor setting.
    Tropical doctor, 2011, Volume: 41, Issue:3

    Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Female; HIV Infections; HIV-1; Humans; Infant, Newb

2011
HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.
    AIDS (London, England), 2011, Jul-31, Volume: 25, Issue:12

    Topics: Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Human

2011
HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.
    AIDS (London, England), 2011, Jul-31, Volume: 25, Issue:12

    Topics: Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Human

2011
WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers.
    PloS one, 2011, Volume: 6, Issue:6

    Topics: Anti-HIV Agents; Breast Feeding; Child; Female; HIV Infections; Humans; Infant, Newborn; Infectious

2011
WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers.
    PloS one, 2011, Volume: 6, Issue:6

    Topics: Anti-HIV Agents; Breast Feeding; Child; Female; HIV Infections; Humans; Infant, Newborn; Infectious

2011
Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis.
    PloS one, 2011, Volume: 6, Issue:5

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Nevirapine; U

2011
Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis.
    PloS one, 2011, Volume: 6, Issue:5

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Nevirapine; U

2011
Evaluation of saliva as an alternative matrix for monitoring plasma Zidovudine, Lamivudine and nevirapine concentrations in Rwanda.
    Current HIV research, 2011, Volume: 9, Issue:4

    Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Drug Monitoring; Feasibility Studies; Female; HIV I

2011
Evaluation of saliva as an alternative matrix for monitoring plasma Zidovudine, Lamivudine and nevirapine concentrations in Rwanda.
    Current HIV research, 2011, Volume: 9, Issue:4

    Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Drug Monitoring; Feasibility Studies; Female; HIV I

2011
Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes.
    AIDS (London, England), 2011, Aug-24, Volume: 25, Issue:13

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Lo

2011
Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes.
    AIDS (London, England), 2011, Aug-24, Volume: 25, Issue:13

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Lo

2011
Pregnancy outcome among HIV positive women receiving antenatal HAART versus untreated maternal HIV infection.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2011, Volume: 21, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Cesarean Section; Chi-Sq

2011
Pregnancy outcome among HIV positive women receiving antenatal HAART versus untreated maternal HIV infection.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2011, Volume: 21, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Cesarean Section; Chi-Sq

2011
Rilpivirine: a step forward in tailored HIV treatment.
    Lancet (London, England), 2011, Jul-16, Volume: 378, Issue:9787

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes;

2011
Rilpivirine: a step forward in tailored HIV treatment.
    Lancet (London, England), 2011, Jul-16, Volume: 378, Issue:9787

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes;

2011
Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach.
    Lancet (London, England), 2011, Jul-16, Volume: 378, Issue:9787

    Topics: Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Administration Schedule; Drug The

2011
Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach.
    Lancet (London, England), 2011, Jul-16, Volume: 378, Issue:9787

    Topics: Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Administration Schedule; Drug The

2011
Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.
    Journal of acquired immune deficiency syndromes (1999), 2011, Nov-01, Volume: 58, Issue:3

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV; HIV Inf

2011
Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.
    Journal of acquired immune deficiency syndromes (1999), 2011, Nov-01, Volume: 58, Issue:3

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV; HIV Inf

2011
Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Volume: 53, Issue:4

    Topics: Anti-HIV Agents; Chromosomes, Human, Pair 6; Drug Eruptions; Genetic Predisposition to Disease; Geno

2011
Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Volume: 53, Issue:4

    Topics: Anti-HIV Agents; Chromosomes, Human, Pair 6; Drug Eruptions; Genetic Predisposition to Disease; Geno

2011
Effects of cessation of breastfeeding in HIV-1-exposed, uninfected children in Malawi.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Volume: 53, Issue:4

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Infectious Disease T

2011
Effects of cessation of breastfeeding in HIV-1-exposed, uninfected children in Malawi.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Volume: 53, Issue:4

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Infectious Disease T

2011
Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
    Journal of virology, 2011, Volume: 85, Issue:20

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HI

2011
Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
    Journal of virology, 2011, Volume: 85, Issue:20

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HI

2011
Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    Journal of medical virology, 2011, Volume: 83, Issue:10

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cross-Sectional Studies; Cyclop

2011
Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    Journal of medical virology, 2011, Volume: 83, Issue:10

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cross-Sectional Studies; Cyclop

2011
A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
    The Journal of infectious diseases, 2011, Sep-01, Volume: 204, Issue:5

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infection

2011
A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
    The Journal of infectious diseases, 2011, Sep-01, Volume: 204, Issue:5

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infection

2011
Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry.
    Analytical and bioanalytical chemistry, 2011, Volume: 401, Issue:6

    Topics: Anti-HIV Agents; Chromatography, Liquid; Cohort Studies; Hair; HIV Infections; Humans; Nevirapine; R

2011
Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry.
    Analytical and bioanalytical chemistry, 2011, Volume: 401, Issue:6

    Topics: Anti-HIV Agents; Chromatography, Liquid; Cohort Studies; Hair; HIV Infections; Humans; Nevirapine; R

2011
The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.
    HIV medicine, 2012, Volume: 13, Issue:1

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA Mutational Analysis; Drug Re

2012
The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.
    HIV medicine, 2012, Volume: 13, Issue:1

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA Mutational Analysis; Drug Re

2012
Nevirapine for the prevention of mother-to-child transmission of HIV: a nation-wide coverage survey in Côte d'Ivoire.
    Journal of acquired immune deficiency syndromes (1999), 2011, Jul-01, Volume: 57 Suppl 1

    Topics: Adult; Cote d'Ivoire; Disease Transmission, Infectious; Female; HIV Infections; Humans; Multivariate

2011
Nevirapine for the prevention of mother-to-child transmission of HIV: a nation-wide coverage survey in Côte d'Ivoire.
    Journal of acquired immune deficiency syndromes (1999), 2011, Jul-01, Volume: 57 Suppl 1

    Topics: Adult; Cote d'Ivoire; Disease Transmission, Infectious; Female; HIV Infections; Humans; Multivariate

2011
Prevalence of etravirine-associated mutations in clinical samples with genotypic resistance to nevirapine and efavirenz in Brazilian clinics.
    Journal of acquired immune deficiency syndromes (1999), 2011, Volume: 57 Suppl 3

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cyclopropanes

2011
Prevalence of etravirine-associated mutations in clinical samples with genotypic resistance to nevirapine and efavirenz in Brazilian clinics.
    Journal of acquired immune deficiency syndromes (1999), 2011, Volume: 57 Suppl 3

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cyclopropanes

2011
HIV Therapy Simulator: a graphical user interface for comparing the effectiveness of novel therapy regimens.
    Bioinformatics (Oxford, England), 2011, Nov-01, Volume: 27, Issue:21

    Topics: Anti-HIV Agents; Computer Graphics; Computer Simulation; HIV Infections; Humans; Models, Biological;

2011
HIV Therapy Simulator: a graphical user interface for comparing the effectiveness of novel therapy regimens.
    Bioinformatics (Oxford, England), 2011, Nov-01, Volume: 27, Issue:21

    Topics: Anti-HIV Agents; Computer Graphics; Computer Simulation; HIV Infections; Humans; Models, Biological;

2011
Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
    Clinical drug investigation, 2011, Nov-01, Volume: 31, Issue:11

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Body Fat Dist

2011
Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
    Clinical drug investigation, 2011, Nov-01, Volume: 31, Issue:11

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Body Fat Dist

2011
Virologic suppression in nevirapine-exposed HIV-infected infants initiating antiretroviral therapy in rural Uganda.
    Journal of tropical pediatrics, 2012, Volume: 58, Issue:3

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child, Preschool; Fema

2012
Virologic suppression in nevirapine-exposed HIV-infected infants initiating antiretroviral therapy in rural Uganda.
    Journal of tropical pediatrics, 2012, Volume: 58, Issue:3

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child, Preschool; Fema

2012
Should sponsors and DSMBs share interim results across trials?
    Journal of acquired immune deficiency syndromes (1999), 2011, Dec-15, Volume: 58, Issue:5

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Confidentiali

2011
Should sponsors and DSMBs share interim results across trials?
    Journal of acquired immune deficiency syndromes (1999), 2011, Dec-15, Volume: 58, Issue:5

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Confidentiali

2011
Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:12

    Topics: Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Female; HIV Infections; HIV-1; Humans; Infant,

2011
Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:12

    Topics: Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Female; HIV Infections; HIV-1; Humans; Infant,

2011
Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009.
    Journal of the International AIDS Society, 2011, Sep-28, Volume: 14

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross-Sectional

2011
Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009.
    Journal of the International AIDS Society, 2011, Sep-28, Volume: 14

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross-Sectional

2011
Synthesis and oxidation of 2-hydroxynevirapine, a metabolite of the HIV reverse transcriptase inhibitor nevirapine.
    Organic & biomolecular chemistry, 2011, Oct-26, Volume: 9, Issue:22

    Topics: Anti-HIV Agents; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Revers

2011
Synthesis and oxidation of 2-hydroxynevirapine, a metabolite of the HIV reverse transcriptase inhibitor nevirapine.
    Organic & biomolecular chemistry, 2011, Oct-26, Volume: 9, Issue:22

    Topics: Anti-HIV Agents; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Revers

2011
Efficacy and safety of nevirapine + Kivexa (abacavir/lamivudine) as a simplification strategy for HIV patients with undetectable viral load.
    Journal of acquired immune deficiency syndromes (1999), 2011, Nov-01, Volume: 58, Issue:3

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynu

2011
Efficacy and safety of nevirapine + Kivexa (abacavir/lamivudine) as a simplification strategy for HIV patients with undetectable viral load.
    Journal of acquired immune deficiency syndromes (1999), 2011, Nov-01, Volume: 58, Issue:3

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynu

2011
Impact of internal standard addition on dried blood spot analysis in bioanalytical method development.
    Bioanalysis, 2011, Volume: 3, Issue:20

    Topics: Anti-HIV Agents; Dried Blood Spot Testing; HIV Infections; Humans; Isotope Labeling; Nevirapine; Spe

2011
Impact of internal standard addition on dried blood spot analysis in bioanalytical method development.
    Bioanalysis, 2011, Volume: 3, Issue:20

    Topics: Anti-HIV Agents; Dried Blood Spot Testing; HIV Infections; Humans; Isotope Labeling; Nevirapine; Spe

2011
HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India.
    The International journal of risk & safety in medicine, 2011, Volume: 23, Issue:3

    Topics: Alkynes; Anemia; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Live

2011
HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India.
    The International journal of risk & safety in medicine, 2011, Volume: 23, Issue:3

    Topics: Alkynes; Anemia; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Live

2011
Resistance data in the ARTEN trial.
    Antiviral therapy, 2011, Volume: 16, Issue:7

    Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Female; HIV Infections; Humans; Male; Nevirapine; Oligopept

2011
Resistance data in the ARTEN trial.
    Antiviral therapy, 2011, Volume: 16, Issue:7

    Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Female; HIV Infections; Humans; Male; Nevirapine; Oligopept

2011
F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:1

    Topics: Amino Acid Motifs; Anti-HIV Agents; Binding Sites; Cells, Cultured; Drug Resistance, Viral; Drug Syn

2012
F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:1

    Topics: Amino Acid Motifs; Anti-HIV Agents; Binding Sites; Cells, Cultured; Drug Resistance, Viral; Drug Syn

2012
HIV and pregnancy: maternal and neonatal evolution.
    Medicina, 2011, Volume: 71, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Argentina; Female; Follow-Up Studies;

2011
HIV and pregnancy: maternal and neonatal evolution.
    Medicina, 2011, Volume: 71, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Argentina; Female; Follow-Up Studies;

2011
Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection.
    PloS one, 2011, Volume: 6, Issue:10

    Topics: Adult; Asian People; CD4 Lymphocyte Count; China; Clinical Trials as Topic; Demography; Female; Hepa

2011
Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection.
    PloS one, 2011, Volume: 6, Issue:10

    Topics: Adult; Asian People; CD4 Lymphocyte Count; China; Clinical Trials as Topic; Demography; Female; Hepa

2011
Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.
    Journal of acquired immune deficiency syndromes (1999), 2012, Feb-01, Volume: 59, Issue:2

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cli

2012
Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.
    Journal of acquired immune deficiency syndromes (1999), 2012, Feb-01, Volume: 59, Issue:2

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cli

2012
Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.
    Pharmacogenomics, 2012, Volume: 13, Issue:1

    Topics: Adult; Africa South of the Sahara; Alleles; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydr

2012
Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.
    Pharmacogenomics, 2012, Volume: 13, Issue:1

    Topics: Adult; Africa South of the Sahara; Alleles; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydr

2012
Nevirapine-based regimens in routine clinical settings: results from a large Italian cohort of HIV-1 infected adults.
    Current drug safety, 2011, Volume: 6, Issue:3

    Topics: Adult; Age Factors; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol; Cohort Studies; Databa

2011
Nevirapine-based regimens in routine clinical settings: results from a large Italian cohort of HIV-1 infected adults.
    Current drug safety, 2011, Volume: 6, Issue:3

    Topics: Adult; Age Factors; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol; Cohort Studies; Databa

2011
Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes.
    AIDS (London, England), 2012, Jan-02, Volume: 26, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; N

2012
Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes.
    AIDS (London, England), 2012, Jan-02, Volume: 26, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; N

2012
Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
    PloS one, 2011, Volume: 6, Issue:11

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bayes Theorem; Benzoxazines;

2011
Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
    PloS one, 2011, Volume: 6, Issue:11

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bayes Theorem; Benzoxazines;

2011
Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation.
    The Pediatric infectious disease journal, 2012, Volume: 31, Issue:4

    Topics: Administration, Oral; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Child; Child, Presch

2012
Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation.
    The Pediatric infectious disease journal, 2012, Volume: 31, Issue:4

    Topics: Administration, Oral; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Child; Child, Presch

2012
Nevirapine extended-release for the treatment of HIV-1 infection.
    Expert review of anti-infective therapy, 2012, Volume: 10, Issue:1

    Topics: Anti-HIV Agents; Delayed-Action Preparations; Drug Administration Schedule; HIV Infections; HIV-1; H

2012
Nevirapine extended-release for the treatment of HIV-1 infection.
    Expert review of anti-infective therapy, 2012, Volume: 10, Issue:1

    Topics: Anti-HIV Agents; Delayed-Action Preparations; Drug Administration Schedule; HIV Infections; HIV-1; H

2012
Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic.
    Antiviral therapy, 2011, Volume: 16, Issue:8

    Topics: Anti-HIV Agents; Central African Republic; Child; Child, Preschool; DNA Fingerprinting; DNA Mutation

2011
Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic.
    Antiviral therapy, 2011, Volume: 16, Issue:8

    Topics: Anti-HIV Agents; Central African Republic; Child; Child, Preschool; DNA Fingerprinting; DNA Mutation

2011
Malaria therapy in HIV: drug interactions between nevirapine and quinine.
    International journal of STD & AIDS, 2011, Volume: 22, Issue:12

    Topics: Anti-HIV Agents; Antimalarials; Atovaquone; Drug Combinations; Drug Interactions; HIV Infections; Hu

2011
Malaria therapy in HIV: drug interactions between nevirapine and quinine.
    International journal of STD & AIDS, 2011, Volume: 22, Issue:12

    Topics: Anti-HIV Agents; Antimalarials; Atovaquone; Drug Combinations; Drug Interactions; HIV Infections; Hu

2011
Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2012, Volume: 116, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis

2012
Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2012, Volume: 116, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis

2012
Kinetics of nevirapine and its impact on HIV-1 RNA levels in maternal plasma and breast milk over time after perinatal single-dose nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2012, Aug-15, Volume: 60, Issue:5

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious D

2012
Kinetics of nevirapine and its impact on HIV-1 RNA levels in maternal plasma and breast milk over time after perinatal single-dose nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2012, Aug-15, Volume: 60, Issue:5

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious D

2012
Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
    The Journal of infection, 2012, Volume: 64, Issue:4

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cohort Studies; Coinfection; Drug Th

2012
Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
    The Journal of infection, 2012, Volume: 64, Issue:4

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cohort Studies; Coinfection; Drug Th

2012
Treatment challenges in co-infected HIV and TB children.
    Indian pediatrics, 2011, Volume: 48, Issue:12

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Nevirap

2011
Treatment challenges in co-infected HIV and TB children.
    Indian pediatrics, 2011, Volume: 48, Issue:12

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Nevirap

2011
Predictors of attrition among children born in a PMTCT programme in Zimbabwe followed up over 5 years.
    Journal of tropical pediatrics, 2012, Volume: 58, Issue:5

    Topics: Adult; Anti-HIV Agents; Child; Child, Preschool; Female; Follow-Up Studies; Forecasting; HIV Infecti

2012
Predictors of attrition among children born in a PMTCT programme in Zimbabwe followed up over 5 years.
    Journal of tropical pediatrics, 2012, Volume: 58, Issue:5

    Topics: Adult; Anti-HIV Agents; Child; Child, Preschool; Female; Follow-Up Studies; Forecasting; HIV Infecti

2012
Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
    Antiviral therapy, 2012, Volume: 17, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combina

2012
Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
    Antiviral therapy, 2012, Volume: 17, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combina

2012
Effectiveness of fixed-dose combination stavudine, lamivudine and nevirapine (GPO-VIR) for treatment of naïve HIV patients in Thailand: a 3-year follow-up.
    The Southeast Asian journal of tropical medicine and public health, 2011, Volume: 42, Issue:6

    Topics: Adult; Analysis of Variance; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; HIV I

2011
Effectiveness of fixed-dose combination stavudine, lamivudine and nevirapine (GPO-VIR) for treatment of naïve HIV patients in Thailand: a 3-year follow-up.
    The Southeast Asian journal of tropical medicine and public health, 2011, Volume: 42, Issue:6

    Topics: Adult; Analysis of Variance; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; HIV I

2011
Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.
    British journal of clinical pharmacology, 2012, Volume: 74, Issue:3

    Topics: Adult; Aged; Anti-HIV Agents; Biological Availability; Drug Interactions; Female; Food-Drug Interact

2012
Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.
    British journal of clinical pharmacology, 2012, Volume: 74, Issue:3

    Topics: Adult; Aged; Anti-HIV Agents; Biological Availability; Drug Interactions; Female; Food-Drug Interact

2012
Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:5

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Blood Chemical Analysis; Cyclopropanes; Desicca

2012
Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:5

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Blood Chemical Analysis; Cyclopropanes; Desicca

2012
Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:5

    Topics: Acyclovir; Anti-HIV Agents; Cell Line; Drug Resistance, Viral; Drug Synergism; HIV Fusion Inhibitors

2012
Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:5

    Topics: Acyclovir; Anti-HIV Agents; Cell Line; Drug Resistance, Viral; Drug Synergism; HIV Fusion Inhibitors

2012
Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
    Therapeutic drug monitoring, 2012, Volume: 34, Issue:2

    Topics: Adult; Alkynes; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hy

2012
Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
    Therapeutic drug monitoring, 2012, Volume: 34, Issue:2

    Topics: Adult; Alkynes; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hy

2012
Recombination between variants from genital tract and plasma: evolution of multidrug-resistant HIV type 1.
    AIDS research and human retroviruses, 2012, Volume: 28, Issue:12

    Topics: Adult; Anti-HIV Agents; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Lamivudine; Molecu

2012
Recombination between variants from genital tract and plasma: evolution of multidrug-resistant HIV type 1.
    AIDS research and human retroviruses, 2012, Volume: 28, Issue:12

    Topics: Adult; Anti-HIV Agents; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Lamivudine; Molecu

2012
Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
    BMC clinical pharmacology, 2012, Feb-27, Volume: 12

    Topics: Adenine; Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cycloprop

2012
Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
    BMC clinical pharmacology, 2012, Feb-27, Volume: 12

    Topics: Adenine; Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cycloprop

2012
Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission.
    PloS one, 2012, Volume: 7, Issue:2

    Topics: Adult; Alleles; Anti-Retroviral Agents; Drug Resistance, Viral; Female; Genetic Variation; HIV Infec

2012
Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission.
    PloS one, 2012, Volume: 7, Issue:2

    Topics: Adult; Alleles; Anti-Retroviral Agents; Drug Resistance, Viral; Female; Genetic Variation; HIV Infec

2012
Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment.
    Journal of acquired immune deficiency syndromes (1999), 2012, Jul-01, Volume: 60, Issue:3

    Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; D

2012
Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment.
    Journal of acquired immune deficiency syndromes (1999), 2012, Jul-01, Volume: 60, Issue:3

    Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; D

2012
Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.
    AIDS (London, England), 2012, Mar-13, Volume: 26, Issue:5

    Topics: Abnormalities, Drug-Induced; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Computer Simulation; Cot

2012
Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.
    AIDS (London, England), 2012, Mar-13, Volume: 26, Issue:5

    Topics: Abnormalities, Drug-Induced; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Computer Simulation; Cot

2012
Safety and effectiveness of efavirenz versus nevirapine-based regimens in resource-limited settings: evidence, clinical practice and modelling projections.
    AIDS (London, England), 2012, Mar-13, Volume: 26, Issue:5

    Topics: Abnormalities, Drug-Induced; Alkynes; Anti-HIV Agents; Benzoxazines; Computer Simulation; Cyclopropa

2012
Safety and effectiveness of efavirenz versus nevirapine-based regimens in resource-limited settings: evidence, clinical practice and modelling projections.
    AIDS (London, England), 2012, Mar-13, Volume: 26, Issue:5

    Topics: Abnormalities, Drug-Induced; Alkynes; Anti-HIV Agents; Benzoxazines; Computer Simulation; Cyclopropa

2012
Hemodiafiltration with online regeneration of ultrafiltrate for severe nevirapine intoxication in a HIV-infected patient.
    AIDS (London, England), 2012, Mar-13, Volume: 26, Issue:5

    Topics: Adult; Anti-HIV Agents; Hemodiafiltration; HIV Infections; Humans; Nevirapine; Stevens-Johnson Syndr

2012
Hemodiafiltration with online regeneration of ultrafiltrate for severe nevirapine intoxication in a HIV-infected patient.
    AIDS (London, England), 2012, Mar-13, Volume: 26, Issue:5

    Topics: Adult; Anti-HIV Agents; Hemodiafiltration; HIV Infections; Humans; Nevirapine; Stevens-Johnson Syndr

2012
Transplacental passage of nevirapine, nelfinavir and lopinavir.
    The Netherlands journal of medicine, 2012, Volume: 70, Issue:2

    Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Female; Fetal Blood; HIV Infections; Humans;

2012
Transplacental passage of nevirapine, nelfinavir and lopinavir.
    The Netherlands journal of medicine, 2012, Volume: 70, Issue:2

    Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Female; Fetal Blood; HIV Infections; Humans;

2012
Nevirapine-based therapy after suppression: can we switch?
    The Lancet. Infectious diseases, 2012, Volume: 12, Issue:7

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Nevirapin

2012
Nevirapine-based therapy after suppression: can we switch?
    The Lancet. Infectious diseases, 2012, Volume: 12, Issue:7

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Nevirapin

2012
Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine.
    The Journal of infectious diseases, 2012, Jun-15, Volume: 205, Issue:12

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Human

2012
Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine.
    The Journal of infectious diseases, 2012, Jun-15, Volume: 205, Issue:12

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Human

2012
Susceptibility to etravirine of HIV type 1 subtype C isolates from nevirapine/efavirenz-experienced patients: comparative interpretation of ANRS and STANFORD algorithms.
    AIDS research and human retroviruses, 2012, Volume: 28, Issue:12

    Topics: Alkynes; Amino Acid Sequence; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA, Viral; Drug Resista

2012
Susceptibility to etravirine of HIV type 1 subtype C isolates from nevirapine/efavirenz-experienced patients: comparative interpretation of ANRS and STANFORD algorithms.
    AIDS research and human retroviruses, 2012, Volume: 28, Issue:12

    Topics: Alkynes; Amino Acid Sequence; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA, Viral; Drug Resista

2012
Policy. 3 steps can drastically reduce mother-to-child transmission.
    AIDS policy & law, 2012, Volume: 27, Issue:4

    Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi

2012
Policy. 3 steps can drastically reduce mother-to-child transmission.
    AIDS policy & law, 2012, Volume: 27, Issue:4

    Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi

2012
Lignosulfonic acid exhibits broadly anti-HIV-1 activity--potential as a microbicide candidate for the prevention of HIV-1 sexual transmission.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Anti-HIV Agents; Anti-Infective Agents; Antibodies, Monoclonal; Antibodies, Viral; Antibody Specific

2012
Lignosulfonic acid exhibits broadly anti-HIV-1 activity--potential as a microbicide candidate for the prevention of HIV-1 sexual transmission.
    PloS one, 2012, Volume: 7, Issue:4

    Topics: Anti-HIV Agents; Anti-Infective Agents; Antibodies, Monoclonal; Antibodies, Viral; Antibody Specific

2012
Nevirapine prophylaxis during breastfeeding.
    Lancet (London, England), 2012, May-12, Volume: 379, Issue:9828

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmiss

2012
Nevirapine prophylaxis during breastfeeding.
    Lancet (London, England), 2012, May-12, Volume: 379, Issue:9828

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmiss

2012
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:8

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cloning, Molecular; Cyclopropanes; Drug Resistance, Multiple

2012
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:8

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cloning, Molecular; Cyclopropanes; Drug Resistance, Multiple

2012
Use of service data to inform pediatric HIV-free survival following prevention of mother-to-child transmission programs in rural Malawi.
    BMC public health, 2012, Jun-06, Volume: 12

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Disease-Free Survival; Female; Follow-Up Studies; Health Ser

2012
Use of service data to inform pediatric HIV-free survival following prevention of mother-to-child transmission programs in rural Malawi.
    BMC public health, 2012, Jun-06, Volume: 12

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Disease-Free Survival; Female; Follow-Up Studies; Health Ser

2012
Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.
    British journal of clinical pharmacology, 2012, Volume: 74, Issue:1

    Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B

2012
Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.
    British journal of clinical pharmacology, 2012, Volume: 74, Issue:1

    Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B

2012
Standing genetic variation and the evolution of drug resistance in HIV.
    PLoS computational biology, 2012, Volume: 8, Issue:6

    Topics: Anti-HIV Agents; Computational Biology; Computer Simulation; Drug Resistance, Viral; Evolution, Mole

2012
Standing genetic variation and the evolution of drug resistance in HIV.
    PLoS computational biology, 2012, Volume: 8, Issue:6

    Topics: Anti-HIV Agents; Computational Biology; Computer Simulation; Drug Resistance, Viral; Evolution, Mole

2012
N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2012, Oct-01, Volume: 61, Issue:2

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Synergism; HIV Infections; HIV Reverse Transcriptase;

2012
N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2012, Oct-01, Volume: 61, Issue:2

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Synergism; HIV Infections; HIV Reverse Transcriptase;

2012
Influence of rifampicin on nevirapine plasma concentration in HIV-TB coinfected patients.
    Acta medica Indonesiana, 2012, Volume: 44, Issue:2

    Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Coinfection; Cross-Sectional Studies; Female; H

2012
Influence of rifampicin on nevirapine plasma concentration in HIV-TB coinfected patients.
    Acta medica Indonesiana, 2012, Volume: 44, Issue:2

    Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Coinfection; Cross-Sectional Studies; Female; H

2012
Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission.
    The Pediatric infectious disease journal, 2012, Volume: 31, Issue:11

    Topics: Adult; Aging, Premature; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Eruptions; Fe

2012
Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission.
    The Pediatric infectious disease journal, 2012, Volume: 31, Issue:11

    Topics: Adult; Aging, Premature; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Eruptions; Fe

2012
HIV-1 mother-to-child transmission, post-test counselling, and antiretroviral prophylaxis in Northern Viet Nam: a prospective observational study.
    Scandinavian journal of infectious diseases, 2012, Volume: 44, Issue:11

    Topics: Anti-Retroviral Agents; Antibiotic Prophylaxis; Counseling; Delivery, Obstetric; Drug Resistance, Vi

2012
HIV-1 mother-to-child transmission, post-test counselling, and antiretroviral prophylaxis in Northern Viet Nam: a prospective observational study.
    Scandinavian journal of infectious diseases, 2012, Volume: 44, Issue:11

    Topics: Anti-Retroviral Agents; Antibiotic Prophylaxis; Counseling; Delivery, Obstetric; Drug Resistance, Vi

2012
Nevirapine- and efavirenz-associated hepatotoxicity under programmatic conditions in Kenya and Mozambique.
    International journal of STD & AIDS, 2012, Volume: 23, Issue:6

    Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver

2012
Nevirapine- and efavirenz-associated hepatotoxicity under programmatic conditions in Kenya and Mozambique.
    International journal of STD & AIDS, 2012, Volume: 23, Issue:6

    Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver

2012
Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activity.
    Journal of acquired immune deficiency syndromes (1999), 2012, Nov-01, Volume: 61, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Binding Sites; Cyclopropanes; Deoxycytidine; Drug Resistance

2012
Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activity.
    Journal of acquired immune deficiency syndromes (1999), 2012, Nov-01, Volume: 61, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Binding Sites; Cyclopropanes; Deoxycytidine; Drug Resistance

2012
Dosage optimization of treatments using population pharmacokinetic modeling and simulation.
    Chimia, 2012, Volume: 66, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Cohort S

2012
Dosage optimization of treatments using population pharmacokinetic modeling and simulation.
    Chimia, 2012, Volume: 66, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Cohort S

2012
Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:10

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Administration Schedule; Female; HIV Infe

2012
Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:10

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Administration Schedule; Female; HIV Infe

2012
[Goal: a long-term successful HIV therapy. Nevirapine as sustained-release tablet offers good prospects].
    MMW Fortschritte der Medizin, 2012, May-16, Volume: 154 Suppl 1

    Topics: Anti-HIV Agents; Cardiovascular Diseases; Delayed-Action Preparations; Dose-Response Relationship, D

2012
[Goal: a long-term successful HIV therapy. Nevirapine as sustained-release tablet offers good prospects].
    MMW Fortschritte der Medizin, 2012, May-16, Volume: 154 Suppl 1

    Topics: Anti-HIV Agents; Cardiovascular Diseases; Delayed-Action Preparations; Dose-Response Relationship, D

2012
Identification of drug resistant mutations in HIV-1 CRF07_BC variants selected by nevirapine in vitro.
    PloS one, 2012, Volume: 7, Issue:9

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; China; Computational Biology; Drug Resistance, Viral

2012
Identification of drug resistant mutations in HIV-1 CRF07_BC variants selected by nevirapine in vitro.
    PloS one, 2012, Volume: 7, Issue:9

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; China; Computational Biology; Drug Resistance, Viral

2012
Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
    HIV medicine, 2013, Volume: 14, Issue:3

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4

2013
Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
    HIV medicine, 2013, Volume: 14, Issue:3

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4

2013
Editorial commentary: turning the tide on HIV in women and children: preventing breast-milk HIV transmission while increasing maternal life expectancy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:1

    Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Female; HIV Infections; HIV-1; Humans; Infectious Disease T

2013
Editorial commentary: turning the tide on HIV in women and children: preventing breast-milk HIV transmission while increasing maternal life expectancy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:1

    Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Female; HIV Infections; HIV-1; Humans; Infectious Disease T

2013
Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.
    Viruses, 2012, Volume: 4, Issue:8

    Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Nevira

2012
Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.
    Viruses, 2012, Volume: 4, Issue:8

    Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Nevira

2012
Effect of efavirenz versus nevirapine in antiretroviral-naive individuals in the HIV-CAUSAL Collaboration Cohort.
    AIDS (London, England), 2012, Oct-23, Volume: 26, Issue:16

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Dose-Respo

2012
Effect of efavirenz versus nevirapine in antiretroviral-naive individuals in the HIV-CAUSAL Collaboration Cohort.
    AIDS (London, England), 2012, Oct-23, Volume: 26, Issue:16

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Dose-Respo

2012
Long term outcomes of nevirapine containing antiretroviral therapy at a center in Thailand.
    The Southeast Asian journal of tropical medicine and public health, 2012, Volume: 43, Issue:4

    Topics: Adult; Age Factors; Anti-HIV Agents; Body Mass Index; CD4 Lymphocyte Count; Female; HIV Infections;

2012
Long term outcomes of nevirapine containing antiretroviral therapy at a center in Thailand.
    The Southeast Asian journal of tropical medicine and public health, 2012, Volume: 43, Issue:4

    Topics: Adult; Age Factors; Anti-HIV Agents; Body Mass Index; CD4 Lymphocyte Count; Female; HIV Infections;

2012
Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.
    Pharmacogenetics and genomics, 2012, Volume: 22, Issue:12

    Topics: Adult; Anti-HIV Agents; Asian People; Cohort Studies; Female; Genetic Variation; Genotype; HIV Infec

2012
Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.
    Pharmacogenetics and genomics, 2012, Volume: 22, Issue:12

    Topics: Adult; Anti-HIV Agents; Asian People; Cohort Studies; Female; Genetic Variation; Genotype; HIV Infec

2012
Influence of intragenic CCL3 haplotypes and CCL3L copy number in HIV-1 infection in a sub-Saharan African population.
    Genes and immunity, 2013, Volume: 14, Issue:1

    Topics: Africa South of the Sahara; Anti-HIV Agents; CD4 Antigens; Chemokine CCL3; Female; Gene Dosage; Gene

2013
Influence of intragenic CCL3 haplotypes and CCL3L copy number in HIV-1 infection in a sub-Saharan African population.
    Genes and immunity, 2013, Volume: 14, Issue:1

    Topics: Africa South of the Sahara; Anti-HIV Agents; CD4 Antigens; Chemokine CCL3; Female; Gene Dosage; Gene

2013
The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems.
    Therapeutic drug monitoring, 2013, Volume: 35, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; C

2013
The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems.
    Therapeutic drug monitoring, 2013, Volume: 35, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; C

2013
Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.
    Journal of acquired immune deficiency syndromes (1999), 2013, Feb-01, Volume: 62, Issue:2

    Topics: Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induce

2013
Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.
    Journal of acquired immune deficiency syndromes (1999), 2013, Feb-01, Volume: 62, Issue:2

    Topics: Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induce

2013
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.
    The Journal of infectious diseases, 2013, Mar-15, Volume: 207, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Gene D

2013
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.
    The Journal of infectious diseases, 2013, Mar-15, Volume: 207, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Gene D

2013
Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program.
    Journal of infection in developing countries, 2012, Nov-26, Volume: 6, Issue:11

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Databases, Factual; Drug-Related Side Effects and Ad

2012
Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program.
    Journal of infection in developing countries, 2012, Nov-26, Volume: 6, Issue:11

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Databases, Factual; Drug-Related Side Effects and Ad

2012
Evaluation of nevirapine dosing recommendations in HIV-infected children.
    British journal of clinical pharmacology, 2013, Volume: 76, Issue:1

    Topics: Adolescent; Age Factors; Anti-HIV Agents; Child; Child, Preschool; Dose-Response Relationship, Drug;

2013
Evaluation of nevirapine dosing recommendations in HIV-infected children.
    British journal of clinical pharmacology, 2013, Volume: 76, Issue:1

    Topics: Adolescent; Age Factors; Anti-HIV Agents; Child; Child, Preschool; Dose-Response Relationship, Drug;

2013
Long-term clinical and immunologic outcomes of HIV-infected women with and without previous exposure to nevirapine.
    Tropical medicine & international health : TM & IH, 2013, Volume: 18, Issue:3

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; Follow-

2013
Long-term clinical and immunologic outcomes of HIV-infected women with and without previous exposure to nevirapine.
    Tropical medicine & international health : TM & IH, 2013, Volume: 18, Issue:3

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; Follow-

2013
Risk adapted transmission prophylaxis to prevent vertical HIV-1 transmission: effectiveness and safety of an abbreviated regimen of postnatal oral zidovudine.
    BMC pregnancy and childbirth, 2013, Jan-24, Volume: 13

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HI

2013
Risk adapted transmission prophylaxis to prevent vertical HIV-1 transmission: effectiveness and safety of an abbreviated regimen of postnatal oral zidovudine.
    BMC pregnancy and childbirth, 2013, Jan-24, Volume: 13

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HI

2013
Infant feeding and transmission of human immunodeficiency virus in the United States.
    Pediatrics, 2013, Volume: 131, Issue:2

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Cooperative Behavior; Developin

2013
Infant feeding and transmission of human immunodeficiency virus in the United States.
    Pediatrics, 2013, Volume: 131, Issue:2

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Cooperative Behavior; Developin

2013
Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:9

    Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; Drug Hypersensitivity; Female; Gene Freque

2013
Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:9

    Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; Drug Hypersensitivity; Female; Gene Freque

2013
The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children.
    African health sciences, 2012, Volume: 12, Issue:3

    Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; CD4 Lymphocyte

2012
The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children.
    African health sciences, 2012, Volume: 12, Issue:3

    Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; CD4 Lymphocyte

2012
Nevirapine bioactivation and covalent binding in the skin.
    Chemical research in toxicology, 2013, Mar-18, Volume: 26, Issue:3

    Topics: Animals; Exanthema; Female; HIV Infections; Humans; Liver; Mice; Mice, Inbred BALB C; Mice, Inbred C

2013
Nevirapine bioactivation and covalent binding in the skin.
    Chemical research in toxicology, 2013, Mar-18, Volume: 26, Issue:3

    Topics: Animals; Exanthema; Female; HIV Infections; Humans; Liver; Mice; Mice, Inbred BALB C; Mice, Inbred C

2013
Performance evaluation of PPTCT (Prevention of parent to child transmission of HIV) programme: an experience from West Bengal.
    The Indian journal of medical research, 2012, Volume: 136, Issue:6

    Topics: Adult; Female; Focus Groups; HIV Infections; Humans; India; Infant; Infectious Disease Transmission,

2012
Performance evaluation of PPTCT (Prevention of parent to child transmission of HIV) programme: an experience from West Bengal.
    The Indian journal of medical research, 2012, Volume: 136, Issue:6

    Topics: Adult; Female; Focus Groups; HIV Infections; Humans; India; Infant; Infectious Disease Transmission,

2012
Nevirapine inhibits the anti-HIV activity of CD8+ cells.
    Journal of acquired immune deficiency syndromes (1999), 2013, Jun-01, Volume: 63, Issue:2

    Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Coculture

2013
Nevirapine inhibits the anti-HIV activity of CD8+ cells.
    Journal of acquired immune deficiency syndromes (1999), 2013, Jun-01, Volume: 63, Issue:2

    Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Coculture

2013
Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen.
    Annals of internal medicine, 2002, Jul-16, Volume: 137, Issue:2

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; HIV Infections; Humans; Nevirapine; Occupat

2002
Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen.
    Annals of internal medicine, 2002, Jul-16, Volume: 137, Issue:2

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; HIV Infections; Humans; Nevirapine; Occupat

2002
Side effects. Severe nevirapine rash found more likely in women than men.
    TreatmentUpdate, 2001,Winter, Volume: 12, Issue:8

    Topics: Drug Hypersensitivity; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhib

2001
Side effects. Severe nevirapine rash found more likely in women than men.
    TreatmentUpdate, 2001,Winter, Volume: 12, Issue:8

    Topics: Drug Hypersensitivity; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhib

2001
NNRTIs compared in switch group.
    AIDS patient care and STDs, 2002, Volume: 16, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Oxazines;

2002
NNRTIs compared in switch group.
    AIDS patient care and STDs, 2002, Volume: 16, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Oxazines;

2002
South Africans win MTCT court case.
    WORLD (Oakland, Calif. : 1993), 2002, Issue:129

    Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi

2002
South Africans win MTCT court case.
    WORLD (Oakland, Calif. : 1993), 2002, Issue:129

    Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi

2002
South Africa shifts position on antiretroviral drugs.
    The Lancet. Infectious diseases, 2002, Volume: 2, Issue:6

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infant, Newborn; Infectious Disease

2002
South Africa shifts position on antiretroviral drugs.
    The Lancet. Infectious diseases, 2002, Volume: 2, Issue:6

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infant, Newborn; Infectious Disease

2002
An interim plan to reduce mother-to-child HIV infection in South Africa.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2002, Volume: 92, Issue:6

    Topics: Anti-HIV Agents; Breast Feeding; Chemoprevention; Female; Health Promotion; HIV Infections; Humans;

2002
An interim plan to reduce mother-to-child HIV infection in South Africa.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2002, Volume: 92, Issue:6

    Topics: Anti-HIV Agents; Breast Feeding; Chemoprevention; Female; Health Promotion; HIV Infections; Humans;

2002
Court ruling orders South Africa to provide nevirapine.
    The Lancet. Infectious diseases, 2002, Volume: 2, Issue:8

    Topics: Adult; Child; Female; HIV Infections; Hospitals; Humans; Nevirapine; Reverse Transcriptase Inhibitor

2002
Court ruling orders South Africa to provide nevirapine.
    The Lancet. Infectious diseases, 2002, Volume: 2, Issue:8

    Topics: Adult; Child; Female; HIV Infections; Hospitals; Humans; Nevirapine; Reverse Transcriptase Inhibitor

2002
Extent and importance of cross-resistance to efavirenz after nevirapine failure.
    AIDS research and human retroviruses, 2002, Jul-20, Volume: 18, Issue:11

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infection

2002
Extent and importance of cross-resistance to efavirenz after nevirapine failure.
    AIDS research and human retroviruses, 2002, Jul-20, Volume: 18, Issue:11

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infection

2002
Nevirapine (Viramune) strengthens warning on liver, skin toxicities.
    AIDS treatment news, 2000, Nov-17, Issue:355

    Topics: Drug Labeling; HIV Infections; Humans; Liver; Liver Function Tests; Nevirapine; Reverse Transcriptas

2000
Nevirapine (Viramune) strengthens warning on liver, skin toxicities.
    AIDS treatment news, 2000, Nov-17, Issue:355

    Topics: Drug Labeling; HIV Infections; Humans; Liver; Liver Function Tests; Nevirapine; Reverse Transcriptas

2000
Nevirapine, prednisone and rash.
    Project Inform perspective, 2000, Issue:31

    Topics: Diphenhydramine; Exanthema; HIV Infections; Humans; Nevirapine; Prednisone

2000
Nevirapine, prednisone and rash.
    Project Inform perspective, 2000, Issue:31

    Topics: Diphenhydramine; Exanthema; HIV Infections; Humans; Nevirapine; Prednisone

2000
Nevirapine warning on post-exposure prophylaxis.
    AIDS treatment news, 2001, Jan-12, Issue:358

    Topics: Centers for Disease Control and Prevention, U.S.; Female; HIV Infections; Humans; Infectious Disease

2001
Nevirapine warning on post-exposure prophylaxis.
    AIDS treatment news, 2001, Jan-12, Issue:358

    Topics: Centers for Disease Control and Prevention, U.S.; Female; HIV Infections; Humans; Infectious Disease

2001
Nevirapine reduces perinatal HIV transmission.
    The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 1999, Volume: 11, Issue:5

    Topics: Disease Transmission, Infectious; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibito

1999
Nevirapine reduces perinatal HIV transmission.
    The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 1999, Volume: 11, Issue:5

    Topics: Disease Transmission, Infectious; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibito

1999
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.
    AIDS research and human retroviruses, 2002, Aug-10, Volume: 18, Issue:12

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Mut

2002
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.
    AIDS research and human retroviruses, 2002, Aug-10, Volume: 18, Issue:12

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Mut

2002
Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors?
    AIDS (London, England), 2002, Sep-06, Volume: 16, Issue:13

    Topics: Adult; Anti-HIV Agents; Dreams; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Male; Midd

2002
Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors?
    AIDS (London, England), 2002, Sep-06, Volume: 16, Issue:13

    Topics: Adult; Anti-HIV Agents; Dreams; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Male; Midd

2002
Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals.
    Pharmacological research, 2002, Volume: 46, Issue:3

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Bilirubin; Female; Hepati

2002
Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals.
    Pharmacological research, 2002, Volume: 46, Issue:3

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Bilirubin; Female; Hepati

2002
Antiretroviral treatment in developing countries.
    The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 2002, Volume: 14, Issue:5

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Developing Countries; Fe

2002
Antiretroviral treatment in developing countries.
    The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 2002, Volume: 14, Issue:5

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Developing Countries; Fe

2002
WHO takes major steps to make HIV treatment accessible.
    Journal of advanced nursing, 2002, Volume: 39, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Developing Countries; Drug Therapy, Combination

2002
WHO takes major steps to make HIV treatment accessible.
    Journal of advanced nursing, 2002, Volume: 39, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Developing Countries; Drug Therapy, Combination

2002
WHO and UNAIDS continue to support use of nevirapine for prevention of mother-to-child HIV transmission.
    Journal of advanced nursing, 2002, Volume: 39, Issue:6

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2002
WHO and UNAIDS continue to support use of nevirapine for prevention of mother-to-child HIV transmission.
    Journal of advanced nursing, 2002, Volume: 39, Issue:6

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2002
Regression of HIV parotid swellings after antiviral therapy: case reports with computed tomographic scan evidence.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2002, Volume: 94, Issue:4

    Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD8-Positive T-Lymphocytes; HIV Infec

2002
Regression of HIV parotid swellings after antiviral therapy: case reports with computed tomographic scan evidence.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2002, Volume: 94, Issue:4

    Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD8-Positive T-Lymphocytes; HIV Infec

2002
A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Nov-15, Volume: 35, Issue:10

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Cholesterol; Cohort Studies; Female; France; HIV Infec

2002
A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Nov-15, Volume: 35, Issue:10

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Cholesterol; Cohort Studies; Female; France; HIV Infec

2002
Two drugs reduce transmission.
    AIDS patient care and STDs, 2002, Volume: 16, Issue:9

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2002
Two drugs reduce transmission.
    AIDS patient care and STDs, 2002, Volume: 16, Issue:9

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2002
Underpowered clinical trials of antiretroviral treatment.
    JAMA, 2002, Nov-06, Volume: 288, Issue:17

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; HIV Infections; HI

2002
Underpowered clinical trials of antiretroviral treatment.
    JAMA, 2002, Nov-06, Volume: 288, Issue:17

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; HIV Infections; HI

2002
Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012).
    Journal of acquired immune deficiency syndromes (1999), 2002, Nov-01, Volume: 31, Issue:3

    Topics: Cohort Studies; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmis

2002
Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012).
    Journal of acquired immune deficiency syndromes (1999), 2002, Nov-01, Volume: 31, Issue:3

    Topics: Cohort Studies; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmis

2002
Nevirapine patient assistance program: model for better administration?
    AIDS treatment news, 2002, Nov-22, Issue:385

    Topics: Drug Industry; Eligibility Determination; HIV Infections; Humans; Medicaid; Medical Assistance; Mode

2002
Nevirapine patient assistance program: model for better administration?
    AIDS treatment news, 2002, Nov-22, Issue:385

    Topics: Drug Industry; Eligibility Determination; HIV Infections; Humans; Medicaid; Medical Assistance; Mode

2002
Hope emerges for controlling perinatal HIV transmission.
    Positive living (Los Angeles, Calif.), 1999, Volume: 8, Issue:7

    Topics: Developing Countries; Drug Costs; Female; HIV Infections; Humans; Infant, Newborn; Infectious Diseas

1999
Hope emerges for controlling perinatal HIV transmission.
    Positive living (Los Angeles, Calif.), 1999, Volume: 8, Issue:7

    Topics: Developing Countries; Drug Costs; Female; HIV Infections; Humans; Infant, Newborn; Infectious Diseas

1999
Mass treatment with nevirapine to prevent mother-to-child transmission of HIV/AIDS in sub-Saharan African countries.
    The journal of obstetrics and gynaecology research, 2002, Volume: 28, Issue:6

    Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Counseling; Female; HIV Infections; Humans; Infa

2002
Mass treatment with nevirapine to prevent mother-to-child transmission of HIV/AIDS in sub-Saharan African countries.
    The journal of obstetrics and gynaecology research, 2002, Volume: 28, Issue:6

    Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Counseling; Female; HIV Infections; Humans; Infa

2002
Nevirapine all set to succeed in Gauteng.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2002, Volume: 92, Issue:12

    Topics: Anti-HIV Agents; Counseling; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tra

2002
Nevirapine all set to succeed in Gauteng.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2002, Volume: 92, Issue:12

    Topics: Anti-HIV Agents; Counseling; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tra

2002
The right to health and the nevirapine case in South Africa.
    The New England journal of medicine, 2003, Feb-20, Volume: 348, Issue:8

    Topics: Anti-HIV Agents; Child Advocacy; Female; Health Care Costs; Health Policy; Health Services Accessibi

2003
The right to health and the nevirapine case in South Africa.
    The New England journal of medicine, 2003, Feb-20, Volume: 348, Issue:8

    Topics: Anti-HIV Agents; Child Advocacy; Female; Health Care Costs; Health Policy; Health Services Accessibi

2003
Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis.
    AIDS (London, England), 2003, Mar-07, Volume: 17, Issue:4

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Therapy, Combination; Female; Follow-Up Studies;

2003
Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis.
    AIDS (London, England), 2003, Mar-07, Volume: 17, Issue:4

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Therapy, Combination; Female; Follow-Up Studies;

2003
Preventing HIV transmission.
    Lancet (London, England), 2003, Mar-08, Volume: 361, Issue:9360

    Topics: Anti-HIV Agents; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Nevi

2003
Preventing HIV transmission.
    Lancet (London, England), 2003, Mar-08, Volume: 361, Issue:9360

    Topics: Anti-HIV Agents; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Nevi

2003
Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.
    AIDS research and human retroviruses, 2003, Volume: 19, Issue:3

    Topics: Alanine Transaminase; Anti-HIV Agents; Antibodies, Viral; Antiretroviral Therapy, Highly Active; Che

2003
Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.
    AIDS research and human retroviruses, 2003, Volume: 19, Issue:3

    Topics: Alanine Transaminase; Anti-HIV Agents; Antibodies, Viral; Antiretroviral Therapy, Highly Active; Che

2003
Nevirapine levels may predict toxicity.
    TreatmentUpdate, 2002, Volume: 14, Issue:2

    Topics: Hepatitis C; HIV Infections; Humans; Liver Function Tests; Nevirapine; Reverse Transcriptase Inhibit

2002
Nevirapine levels may predict toxicity.
    TreatmentUpdate, 2002, Volume: 14, Issue:2

    Topics: Hepatitis C; HIV Infections; Humans; Liver Function Tests; Nevirapine; Reverse Transcriptase Inhibit

2002
Comparing liver toxicity between efavirenz and nevirapine.
    TreatmentUpdate, 2002, Volume: 14, Issue:2

    Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Humans; Male; Ne

2002
Comparing liver toxicity between efavirenz and nevirapine.
    TreatmentUpdate, 2002, Volume: 14, Issue:2

    Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Humans; Male; Ne

2002
Negligence. Liver transplant patient too late to sue Viramune maker.
    AIDS policy & law, 2003, Mar-28, Volume: 18, Issue:6

    Topics: Drug Combinations; Drug Industry; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivud

2003
Negligence. Liver transplant patient too late to sue Viramune maker.
    AIDS policy & law, 2003, Mar-28, Volume: 18, Issue:6

    Topics: Drug Combinations; Drug Industry; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivud

2003
Report from the Tenth Retrovirus Conference. Comparing efavirenz and nevirapine: the 2NN study.
    AIDS clinical care, 2003, Volume: 15, Issue:4

    Topics: Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; HIV Infections; Humans; Nevirapine;

2003
Report from the Tenth Retrovirus Conference. Comparing efavirenz and nevirapine: the 2NN study.
    AIDS clinical care, 2003, Volume: 15, Issue:4

    Topics: Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; HIV Infections; Humans; Nevirapine;

2003
Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Antiviral therapy, 2003, Volume: 8, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count;

2003
Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Antiviral therapy, 2003, Volume: 8, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count;

2003
A saga in international HIV policy modeling: preventing mother-to-child HIV transmission.
    Journal of policy analysis and management : [the journal of the Association for Public Policy Analysis and Management], 2002,Summer, Volume: 21, Issue:3

    Topics: Africa; Antiretroviral Therapy, Highly Active; Female; Fetus; Health Policy; HIV Infections; Humans;

2002
A saga in international HIV policy modeling: preventing mother-to-child HIV transmission.
    Journal of policy analysis and management : [the journal of the Association for Public Policy Analysis and Management], 2002,Summer, Volume: 21, Issue:3

    Topics: Africa; Antiretroviral Therapy, Highly Active; Female; Fetus; Health Policy; HIV Infections; Humans;

2002
Preventing mother-to-infant transmission of HIV in the developing world.
    The AIDS reader, 1999, Volume: 9, Issue:7

    Topics: Anti-HIV Agents; Developing Countries; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infe

1999
Preventing mother-to-infant transmission of HIV in the developing world.
    The AIDS reader, 1999, Volume: 9, Issue:7

    Topics: Anti-HIV Agents; Developing Countries; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infe

1999
More good news on reducing the incidence of maternal-fetal transmission of HIV and simplifying HAART.
    The AIDS reader, 1999, Volume: 9, Issue:7

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Developing Countri

1999
More good news on reducing the incidence of maternal-fetal transmission of HIV and simplifying HAART.
    The AIDS reader, 1999, Volume: 9, Issue:7

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Developing Countri

1999
Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus.
    Obstetrics and gynecology, 2003, Volume: 101, Issue:5 Pt 2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur

2003
Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus.
    Obstetrics and gynecology, 2003, Volume: 101, Issue:5 Pt 2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur

2003
Resistant HIV in breast milk.
    AIDS patient care and STDs, 2003, Volume: 17, Issue:4

    Topics: Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Milk, Human; Nevirapine; Pregnancy

2003
Resistant HIV in breast milk.
    AIDS patient care and STDs, 2003, Volume: 17, Issue:4

    Topics: Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Milk, Human; Nevirapine; Pregnancy

2003
'Buffalo-hump' dermatitis: a hat trick of antiretroviral side-effects.
    Contact dermatitis, 2003, Volume: 48, Issue:3

    Topics: Anti-HIV Agents; Dermatitis, Irritant; Diagnosis, Differential; Drug Eruptions; HIV Infections; Huma

2003
'Buffalo-hump' dermatitis: a hat trick of antiretroviral side-effects.
    Contact dermatitis, 2003, Volume: 48, Issue:3

    Topics: Anti-HIV Agents; Dermatitis, Irritant; Diagnosis, Differential; Drug Eruptions; HIV Infections; Huma

2003
Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.
    Therapeutic drug monitoring, 2003, Volume: 25, Issue:3

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Chromatography, High Pressure Liquid; Female; HIV Infectio

2003
Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.
    Therapeutic drug monitoring, 2003, Volume: 25, Issue:3

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Chromatography, High Pressure Liquid; Female; HIV Infectio

2003
PMTCT court order: Manana in contempt?
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2003, Volume: 93, Issue:3

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Jurispru

2003
PMTCT court order: Manana in contempt?
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2003, Volume: 93, Issue:3

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Jurispru

2003
[Decrease of HIV-1 virus load by nevirapin/efavirenz].
    Deutsche medizinische Wochenschrift (1946), 2003, May-09, Volume: 128, Issue:19

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Ox

2003
[Decrease of HIV-1 virus load by nevirapin/efavirenz].
    Deutsche medizinische Wochenschrift (1946), 2003, May-09, Volume: 128, Issue:19

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Ox

2003
Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs.
    Journal of clinical microbiology, 2003, Volume: 41, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Administration Sch

2003
Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs.
    Journal of clinical microbiology, 2003, Volume: 41, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Administration Sch

2003
Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population.
    Clinical pharmacokinetics, 2003, Volume: 42, Issue:6

    Topics: Adult; Cohort Studies; Female; HIV Infections; HIV-1; Homosexuality; Humans; Male; Nevirapine; Rever

2003
Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population.
    Clinical pharmacokinetics, 2003, Volume: 42, Issue:6

    Topics: Adult; Cohort Studies; Female; HIV Infections; HIV-1; Homosexuality; Humans; Male; Nevirapine; Rever

2003
Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia.
    AIDS (London, England), 2003, Jun-13, Volume: 17, Issue:9

    Topics: Antiviral Agents; Cost-Benefit Analysis; Counseling; Developing Countries; Drug Costs; Female; HIV I

2003
Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia.
    AIDS (London, England), 2003, Jun-13, Volume: 17, Issue:9

    Topics: Antiviral Agents; Cost-Benefit Analysis; Counseling; Developing Countries; Drug Costs; Female; HIV I

2003
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.
    AIDS (London, England), 2003, Jun-13, Volume: 17, Issue:9

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resis

2003
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.
    AIDS (London, England), 2003, Jun-13, Volume: 17, Issue:9

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resis

2003
Mother-to-child HIV transmission in resource poor settings: how to improve coverage?
    AIDS (London, England), 2003, May-23, Volume: 17, Issue:8

    Topics: Anti-HIV Agents; Counseling; Developing Countries; Female; HIV Infections; Humans; Infant, Newborn;

2003
Mother-to-child HIV transmission in resource poor settings: how to improve coverage?
    AIDS (London, England), 2003, May-23, Volume: 17, Issue:8

    Topics: Anti-HIV Agents; Counseling; Developing Countries; Female; HIV Infections; Humans; Infant, Newborn;

2003
"All-in-One Assay", a direct phenotypic anti-human immunodeficiency virus type 1 drug resistance assay for three-drug combination therapies that takes into consideration in vivo drug concentrations.
    Journal of virological methods, 2003, Volume: 111, Issue:1

    Topics: Anti-HIV Agents; CD4 Antigens; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; He

2003
"All-in-One Assay", a direct phenotypic anti-human immunodeficiency virus type 1 drug resistance assay for three-drug combination therapies that takes into consideration in vivo drug concentrations.
    Journal of virological methods, 2003, Volume: 111, Issue:1

    Topics: Anti-HIV Agents; CD4 Antigens; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; He

2003
Nevirapine: an option for preventing as well as treating paediatric HIV infection.
    African health sciences, 2001, Volume: 1, Issue:1

    Topics: Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease

2001
Nevirapine: an option for preventing as well as treating paediatric HIV infection.
    African health sciences, 2001, Volume: 1, Issue:1

    Topics: Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease

2001
Nevirapine-based fixed-dose combination ARVs.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 2003, Volume: 17, Issue:5

    Topics: Dose-Response Relationship, Drug; Drug Eruptions; Drug Therapy, Combination; HIV Infections; Humans;

2003
Nevirapine-based fixed-dose combination ARVs.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 2003, Volume: 17, Issue:5

    Topics: Dose-Response Relationship, Drug; Drug Eruptions; Drug Therapy, Combination; HIV Infections; Humans;

2003
Nevirapine use in HIV-1-infected children.
    AIDS (London, England), 2003, Jul-25, Volume: 17, Issue:11

    Topics: Adolescent; Anti-HIV Agents; Body Height; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Secti

2003
Nevirapine use in HIV-1-infected children.
    AIDS (London, England), 2003, Jul-25, Volume: 17, Issue:11

    Topics: Adolescent; Anti-HIV Agents; Body Height; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Secti

2003
Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine.
    AIDS (London, England), 2003, Jul-25, Volume: 17, Issue:11

    Topics: Adult; Developing Countries; Drug Resistance, Viral; Female; Gene Frequency; HIV Infections; HIV-1;

2003
Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine.
    AIDS (London, England), 2003, Jul-25, Volume: 17, Issue:11

    Topics: Adult; Developing Countries; Drug Resistance, Viral; Female; Gene Frequency; HIV Infections; HIV-1;

2003
Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2003, Jul-25, Volume: 792, Issue:2

    Topics: Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; HIV Infections; HIV-1; H

2003
Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2003, Jul-25, Volume: 792, Issue:2

    Topics: Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; HIV Infections; HIV-1; H

2003
Scaling the frontier--should traditional birth attendants also be used to provide nevirapine for PMTCT in Uganda?
    African health sciences, 2003, Volume: 3, Issue:2

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infectious Disease Transmission, Ver

2003
Scaling the frontier--should traditional birth attendants also be used to provide nevirapine for PMTCT in Uganda?
    African health sciences, 2003, Volume: 3, Issue:2

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infectious Disease Transmission, Ver

2003
Cost-effectiveness of strategies to reduce mother-to-child HIV transmission in Mexico, a low-prevalence setting.
    Health policy and planning, 2003, Volume: 18, Issue:3

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Cesarean Section; Cost of Illness; Cost-Benefit

2003
Cost-effectiveness of strategies to reduce mother-to-child HIV transmission in Mexico, a low-prevalence setting.
    Health policy and planning, 2003, Volume: 18, Issue:3

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Cesarean Section; Cost of Illness; Cost-Benefit

2003
Incidence and risk factors for nevirapine-associated rash.
    European journal of clinical pharmacology, 2003, Volume: 59, Issue:5-6

    Topics: Adult; Ambulatory Care; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination

2003
Incidence and risk factors for nevirapine-associated rash.
    European journal of clinical pharmacology, 2003, Volume: 59, Issue:5-6

    Topics: Adult; Ambulatory Care; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination

2003
South African government threatens to ban nevirapine. Move would take away option for treating vertical HIV transmission.
    Lancet (London, England), 2003, Aug-09, Volume: 362, Issue:9382

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Disease Outbreaks; Dr

2003
South African government threatens to ban nevirapine. Move would take away option for treating vertical HIV transmission.
    Lancet (London, England), 2003, Aug-09, Volume: 362, Issue:9382

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Disease Outbreaks; Dr

2003
[Antiviral agents for reduction of mother-to-child transmission of HIV infection].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2003, Aug-14, Volume: 123, Issue:15

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Evidence-Based Medicine; Female; HIV Infecti

2003
[Antiviral agents for reduction of mother-to-child transmission of HIV infection].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2003, Aug-14, Volume: 123, Issue:15

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Evidence-Based Medicine; Female; HIV Infecti

2003
[Exanthema simulating measles without measles virus? Allergic reaction to a non-nucleoside reverse transcriptase inhibitor in an HIV infected boy treated with HAART].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2003, Volume: 54, Issue:8

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Eruptions; Exanthema;

2003
[Exanthema simulating measles without measles virus? Allergic reaction to a non-nucleoside reverse transcriptase inhibitor in an HIV infected boy treated with HAART].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2003, Volume: 54, Issue:8

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Eruptions; Exanthema;

2003
Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1.
    Lancet (London, England), 2003, Aug-23, Volume: 362, Issue:9384

    Topics: Anti-HIV Agents; Antibodies, Viral; Child; Developed Countries; Female; Fetal Blood; HIV Infections;

2003
Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1.
    Lancet (London, England), 2003, Aug-23, Volume: 362, Issue:9384

    Topics: Anti-HIV Agents; Antibodies, Viral; Child; Developed Countries; Female; Fetal Blood; HIV Infections;

2003
Long-term findings of HIVNET 012: the next steps.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Anti-HIV Agents; Clinical Protocols; Disease Outbreaks; Disease-Free Survival; Drug Administration S

2003
Long-term findings of HIVNET 012: the next steps.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Anti-HIV Agents; Clinical Protocols; Disease Outbreaks; Disease-Free Survival; Drug Administration S

2003
Thailand's do-it-yourself therapy.
    Science (New York, N.Y.), 2003, Sep-19, Volume: 301, Issue:5640

    Topics: Anti-HIV Agents; Drug Combinations; Drug Compounding; Drug Costs; Drug Industry; Drugs, Generic; HIV

2003
Thailand's do-it-yourself therapy.
    Science (New York, N.Y.), 2003, Sep-19, Volume: 301, Issue:5640

    Topics: Anti-HIV Agents; Drug Combinations; Drug Compounding; Drug Costs; Drug Industry; Drugs, Generic; HIV

2003
Decision analysis to guide choice of interventions to reduce mother-to-child transmission of HIV.
    AIDS (London, England), 2003, Sep-26, Volume: 17, Issue:14

    Topics: Anti-Retroviral Agents; Breast Feeding; Child, Preschool; Decision Support Techniques; Decision Tree

2003
Decision analysis to guide choice of interventions to reduce mother-to-child transmission of HIV.
    AIDS (London, England), 2003, Sep-26, Volume: 17, Issue:14

    Topics: Anti-Retroviral Agents; Breast Feeding; Child, Preschool; Decision Support Techniques; Decision Tree

2003
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
    AIDS (London, England), 2003, Oct-17, Volume: 17, Issue:15

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclop

2003
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
    AIDS (London, England), 2003, Oct-17, Volume: 17, Issue:15

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclop

2003
Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment.
    AIDS (London, England), 2003, Oct-17, Volume: 17, Issue:15

    Topics: Acute Disease; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Drug Therapy, Combination; Female; He

2003
Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment.
    AIDS (London, England), 2003, Oct-17, Volume: 17, Issue:15

    Topics: Acute Disease; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Drug Therapy, Combination; Female; He

2003
The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India.
    AIDS (London, England), 2003, Oct-17, Volume: 17, Issue:15

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies;

2003
The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India.
    AIDS (London, England), 2003, Oct-17, Volume: 17, Issue:15

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies;

2003
Pharmacokinetic drug interactions with nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Drug Interactions; Herbal Medicine; HIV Infections; HIV Protease Inhibitors; Humans; Methadone; Nevi

2003
Pharmacokinetic drug interactions with nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Drug Interactions; Herbal Medicine; HIV Infections; HIV Protease Inhibitors; Humans; Methadone; Nevi

2003
A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Alanine Transaminase; Aspartate Aminotransferases; Clinical Trials as Topic; Cohort Studies; HIV Inf

2003
A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Alanine Transaminase; Aspartate Aminotransferases; Clinical Trials as Topic; Cohort Studies; HIV Inf

2003
Defining the toxicity profile of nevirapine and other antiretroviral drugs.
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Exanthema; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors

2003
Defining the toxicity profile of nevirapine and other antiretroviral drugs.
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Exanthema; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors

2003
Efficacy and durability of nevirapine in antiretroviral drug näive patients.
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse Tra

2003
Efficacy and durability of nevirapine in antiretroviral drug näive patients.
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse Tra

2003
Sex differences in nevirapine disposition in HIV-infected patients.
    AIDS (London, England), 2003, Nov-07, Volume: 17, Issue:16

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhibitors;

2003
Sex differences in nevirapine disposition in HIV-infected patients.
    AIDS (London, England), 2003, Nov-07, Volume: 17, Issue:16

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhibitors;

2003
The relationship between prevention of mother to child transmission of HIV and stakeholder decision making in Uganda: implications for health policy.
    Health policy (Amsterdam, Netherlands), 2003, Volume: 66, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Attitude to Health; Cost-Benefit Analysis; E

2003
The relationship between prevention of mother to child transmission of HIV and stakeholder decision making in Uganda: implications for health policy.
    Health policy (Amsterdam, Netherlands), 2003, Volume: 66, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Attitude to Health; Cost-Benefit Analysis; E

2003
CD4 cell count response to nonnucleoside reverse transcriptase inhibitor- or protease inhibitor-based highly active antiretroviral therapy in an observational cohort study.
    Journal of acquired immune deficiency syndromes (1999), 2003, Nov-01, Volume: 34, Issue:3

    Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Stud

2003
CD4 cell count response to nonnucleoside reverse transcriptase inhibitor- or protease inhibitor-based highly active antiretroviral therapy in an observational cohort study.
    Journal of acquired immune deficiency syndromes (1999), 2003, Nov-01, Volume: 34, Issue:3

    Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Stud

2003
Does prior short-course nevirapine reduce the effectiveness of subsequent combination treatment with efavirenz?
    Journal of acquired immune deficiency syndromes (1999), 2003, Nov-01, Volume: 34, Issue:3

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cycloprop

2003
Does prior short-course nevirapine reduce the effectiveness of subsequent combination treatment with efavirenz?
    Journal of acquired immune deficiency syndromes (1999), 2003, Nov-01, Volume: 34, Issue:3

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cycloprop

2003
Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
    International journal of STD & AIDS, 2003, Volume: 14, Issue:11

    Topics: Adult; Alanine Transaminase; Alcoholism; Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug I

2003
Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
    International journal of STD & AIDS, 2003, Volume: 14, Issue:11

    Topics: Adult; Alanine Transaminase; Alcoholism; Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug I

2003
Resolution of HCV infection in a HIV-infected patient under HAART after several hepatitis flare-ups.
    European journal of medical research, 2003, Nov-12, Volume: 8, Issue:11

    Topics: Acute Disease; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis C, Chronic;

2003
Resolution of HCV infection in a HIV-infected patient under HAART after several hepatitis flare-ups.
    European journal of medical research, 2003, Nov-12, Volume: 8, Issue:11

    Topics: Acute Disease; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis C, Chronic;

2003
[A short-term trial of Didanosine, stavudine, and nevirapine combination therapy for human immunodeficiency virus infection].
    Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University, 2003, Volume: 28, Issue:4

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Drug Thera

2003
[A short-term trial of Didanosine, stavudine, and nevirapine combination therapy for human immunodeficiency virus infection].
    Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University, 2003, Volume: 28, Issue:4

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Drug Thera

2003
Preventing mother-to-child HIV transmission in a developing country: the Dominican Republic experience.
    Journal of acquired immune deficiency syndromes (1999), 2003, Dec-15, Volume: 34, Issue:5

    Topics: Bottle Feeding; Delivery, Obstetric; Developing Countries; Dominican Republic; Female; HIV Infection

2003
Preventing mother-to-child HIV transmission in a developing country: the Dominican Republic experience.
    Journal of acquired immune deficiency syndromes (1999), 2003, Dec-15, Volume: 34, Issue:5

    Topics: Bottle Feeding; Delivery, Obstetric; Developing Countries; Dominican Republic; Female; HIV Infection

2003
Nevirapine reduced mother-to-child transmission better than AZT--at 70 times less the cost.
    AIDS treatment news, 2003, Sep-12, Issue:394

    Topics: Drug Costs; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertic

2003
Nevirapine reduced mother-to-child transmission better than AZT--at 70 times less the cost.
    AIDS treatment news, 2003, Sep-12, Issue:394

    Topics: Drug Costs; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertic

2003
Substitution for protease inhibitors in HIV therapy.
    The New England journal of medicine, 2003, Dec-18, Volume: 349, Issue:25

    Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapine; O

2003
Substitution for protease inhibitors in HIV therapy.
    The New England journal of medicine, 2003, Dec-18, Volume: 349, Issue:25

    Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapine; O

2003
Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
    AIDS (London, England), 2003, Dec-05, Volume: 17, Issue:18

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2003
Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
    AIDS (London, England), 2003, Dec-05, Volume: 17, Issue:18

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2003
Sensitive enzyme immunoassay for measuring plasma and intracellular nevirapine levels in human immunodeficiency virus-infected patients.
    Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:1

    Topics: Adult; Animals; Anti-HIV Agents; Cells, Cultured; Female; HIV Infections; Humans; Immunoenzyme Techn

2004
Sensitive enzyme immunoassay for measuring plasma and intracellular nevirapine levels in human immunodeficiency virus-infected patients.
    Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:1

    Topics: Adult; Animals; Anti-HIV Agents; Cells, Cultured; Female; HIV Infections; Humans; Immunoenzyme Techn

2004
Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
    Journal of the National Medical Association, 2003, Volume: 95, Issue:12

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count;

2003
Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
    Journal of the National Medical Association, 2003, Volume: 95, Issue:12

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count;

2003
Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs.
    The Journal of biological chemistry, 2004, Feb-20, Volume: 279, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Adenosine Triphosphate; Allosteric Site; Anti-HIV Agents; Bindin

2004
Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs.
    The Journal of biological chemistry, 2004, Feb-20, Volume: 279, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Adenosine Triphosphate; Allosteric Site; Anti-HIV Agents; Bindin

2004
Detection of nevirapine in plasma using thin-layer chromatography.
    Journal of acquired immune deficiency syndromes (1999), 2004, Feb-01, Volume: 35, Issue:2

    Topics: Anti-HIV Agents; Chromatography, Thin Layer; HIV Infections; Humans; Nevirapine; Reproducibility of

2004
Detection of nevirapine in plasma using thin-layer chromatography.
    Journal of acquired immune deficiency syndromes (1999), 2004, Feb-01, Volume: 35, Issue:2

    Topics: Anti-HIV Agents; Chromatography, Thin Layer; HIV Infections; Humans; Nevirapine; Reproducibility of

2004
HIVNET 012 and Petra.
    Lancet (London, England), 2004, Jan-17, Volume: 363, Issue:9404

    Topics: Anti-HIV Agents; Counseling; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant, Newbo

2004
HIVNET 012 and Petra.
    Lancet (London, England), 2004, Jan-17, Volume: 363, Issue:9404

    Topics: Anti-HIV Agents; Counseling; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant, Newbo

2004
HIVNET 012 and Petra.
    Lancet (London, England), 2004, Jan-17, Volume: 363, Issue:9404

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; I

2004
HIVNET 012 and Petra.
    Lancet (London, England), 2004, Jan-17, Volume: 363, Issue:9404

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; I

2004
HIVNET 012 and Petra.
    Lancet (London, England), 2004, Jan-17, Volume: 363, Issue:9404

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Follow-Up Studies; Genetic Variation; HIV Infection

2004
HIVNET 012 and Petra.
    Lancet (London, England), 2004, Jan-17, Volume: 363, Issue:9404

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Follow-Up Studies; Genetic Variation; HIV Infection

2004
HIVNET 012 and Petra.
    Lancet (London, England), 2004, Jan-17, Volume: 363, Issue:9404

    Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newborn;

2004
HIVNET 012 and Petra.
    Lancet (London, England), 2004, Jan-17, Volume: 363, Issue:9404

    Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newborn;

2004
Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.
    Bioorganic & medicinal chemistry letters, 2004, Feb-09, Volume: 14, Issue:3

    Topics: Animals; Anti-HIV Agents; Azepines; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptas

2004
Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.
    Bioorganic & medicinal chemistry letters, 2004, Feb-09, Volume: 14, Issue:3

    Topics: Animals; Anti-HIV Agents; Azepines; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptas

2004
Nurses in Zambia gain access to antiretroviral treatment.
    International nursing review, 2004, Volume: 51, Issue:1

    Topics: Anti-HIV Agents; Female; Health Policy; Health Services Accessibility; HIV Infections; Humans; Mater

2004
Nurses in Zambia gain access to antiretroviral treatment.
    International nursing review, 2004, Volume: 51, Issue:1

    Topics: Anti-HIV Agents; Female; Health Policy; Health Services Accessibility; HIV Infections; Humans; Mater

2004
Preventing mother-to-child transmission: landmark decision by South African court.
    Canadian HIV/AIDS policy & law review, 2002, Volume: 6, Issue:3

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr

2002
Preventing mother-to-child transmission: landmark decision by South African court.
    Canadian HIV/AIDS policy & law review, 2002, Volume: 6, Issue:3

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr

2002
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Access to health care services as a justiciable socio-economic right under the South African constitution.
    Medical law international, 2003, Volume: 6, Issue:1

    Topics: Civil Rights; Female; Health Services Accessibility; HIV Infections; Humans; Infant, Newborn; Infect

2003
Access to health care services as a justiciable socio-economic right under the South African constitution.
    Medical law international, 2003, Volume: 6, Issue:1

    Topics: Civil Rights; Female; Health Services Accessibility; HIV Infections; Humans; Infant, Newborn; Infect

2003
Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Mar-01, Volume: 38 Suppl 2

    Topics: Adult; Chemical and Drug Induced Liver Injury; Female; HIV Infections; Humans; Liver; Liver Diseases

2004
Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Mar-01, Volume: 38 Suppl 2

    Topics: Adult; Chemical and Drug Induced Liver Injury; Female; HIV Infections; Humans; Liver; Liver Diseases

2004
[A "once daily" drug that with proven effectiveness. Efavirenz has successful outcome also in direct comparisons].
    MMW Fortschritte der Medizin, 2003, Apr-28, Volume: 145 Spec No 1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Admini

2003
[A "once daily" drug that with proven effectiveness. Efavirenz has successful outcome also in direct comparisons].
    MMW Fortschritte der Medizin, 2003, Apr-28, Volume: 145 Spec No 1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Admini

2003
Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.
    HIV medicine, 2004, Volume: 5, Issue:2

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Coho

2004
Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.
    HIV medicine, 2004, Volume: 5, Issue:2

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Coho

2004
Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.
    HIV medicine, 2004, Volume: 5, Issue:2

    Topics: Adolescent; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Coun

2004
Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.
    HIV medicine, 2004, Volume: 5, Issue:2

    Topics: Adolescent; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Coun

2004
[Assessment of nevirapine liver toxicity in patients with HIV and HVC coinfection].
    Medicina clinica, 2004, Mar-06, Volume: 122, Issue:8

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; Hepatitis C, Chronic; HIV In

2004
[Assessment of nevirapine liver toxicity in patients with HIV and HVC coinfection].
    Medicina clinica, 2004, Mar-06, Volume: 122, Issue:8

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; Hepatitis C, Chronic; HIV In

2004
Mitochondrial effects of antiretroviral therapies in asymptomatic patients.
    Antiviral therapy, 2004, Volume: 9, Issue:1

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Base Sequence; Cross-Sectional Studi

2004
Mitochondrial effects of antiretroviral therapies in asymptomatic patients.
    Antiviral therapy, 2004, Volume: 9, Issue:1

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Base Sequence; Cross-Sectional Studi

2004
Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C.
    AIDS (London, England), 2004, Apr-09, Volume: 18, Issue:6

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genetic Variation; HIV

2004
Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C.
    AIDS (London, England), 2004, Apr-09, Volume: 18, Issue:6

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genetic Variation; HIV

2004
Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings.
    AIDS (London, England), 2004, Apr-09, Volume: 18, Issue:6

    Topics: Adult; Anti-HIV Agents; Developing Countries; Directly Observed Therapy; Female; HIV Infections; Hum

2004
Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings.
    AIDS (London, England), 2004, Apr-09, Volume: 18, Issue:6

    Topics: Adult; Anti-HIV Agents; Developing Countries; Directly Observed Therapy; Female; HIV Infections; Hum

2004
Newly identified human retrovirus receptor; new ways to prevent viral infections.
    The AIDS reader, 2004, Volume: 14, Issue:3

    Topics: Chemoprevention; HIV Infections; HIV-1; Human T-lymphotropic virus 1; Human T-lymphotropic virus 2;

2004
Newly identified human retrovirus receptor; new ways to prevent viral infections.
    The AIDS reader, 2004, Volume: 14, Issue:3

    Topics: Chemoprevention; HIV Infections; HIV-1; Human T-lymphotropic virus 1; Human T-lymphotropic virus 2;

2004
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
    AIDS (London, England), 2004, Mar-26, Volume: 18, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Disease Prog

2004
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
    AIDS (London, England), 2004, Mar-26, Volume: 18, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Disease Prog

2004
Safe substitution for efavirenz.
    AIDS patient care and STDs, 2004, Volume: 18, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; HIV Infectio

2004
Safe substitution for efavirenz.
    AIDS patient care and STDs, 2004, Volume: 18, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; HIV Infectio

2004
Antiretroviral therapy for previously untreated HIV-1-infected adults: 2NN, or just one?
    Lancet (London, England), 2004, Apr-17, Volume: 363, Issue:9417

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HI

2004
Antiretroviral therapy for previously untreated HIV-1-infected adults: 2NN, or just one?
    Lancet (London, England), 2004, Apr-17, Volume: 363, Issue:9417

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HI

2004
Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.
    Journal of acquired immune deficiency syndromes (1999), 2004, Apr-01, Volume: 35, Issue:4

    Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Drug Interactions; Femal

2004
Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.
    Journal of acquired immune deficiency syndromes (1999), 2004, Apr-01, Volume: 35, Issue:4

    Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Drug Interactions; Femal

2004
Mother-to-child transmission. How will AZT and nevirapine use for MTCT affect future treatment? Two studies provide clues.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 2004,Winter, Volume: 16, Issue:2

    Topics: CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmissi

2004
Mother-to-child transmission. How will AZT and nevirapine use for MTCT affect future treatment? Two studies provide clues.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 2004,Winter, Volume: 16, Issue:2

    Topics: CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmissi

2004
WHO hopes 3-by-5 plan will reverse Africa's HIV/AIDS epidemic.
    Bulletin of the World Health Organization, 2004, Volume: 82, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adult; Africa; Anti-HIV Agents; Child; Developing Countries; Dis

2004
WHO hopes 3-by-5 plan will reverse Africa's HIV/AIDS epidemic.
    Bulletin of the World Health Organization, 2004, Volume: 82, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adult; Africa; Anti-HIV Agents; Child; Developing Countries; Dis

2004
HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda.
    AIDS research and human retroviruses, 2004, Volume: 20, Issue:3

    Topics: Drug Resistance, Viral; Female; Genes, pol; HIV Infections; HIV Protease; HIV Reverse Transcriptase;

2004
HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda.
    AIDS research and human retroviruses, 2004, Volume: 20, Issue:3

    Topics: Drug Resistance, Viral; Female; Genes, pol; HIV Infections; HIV Protease; HIV Reverse Transcriptase;

2004
Nevirapine precautions published.
    AIDS treatment news, 2004, Feb-27, Issue:398

    Topics: CD4 Lymphocyte Count; HIV Infections; Humans; Liver; Nevirapine; Practice Guidelines as Topic; Rever

2004
Nevirapine precautions published.
    AIDS treatment news, 2004, Feb-27, Issue:398

    Topics: CD4 Lymphocyte Count; HIV Infections; Humans; Liver; Nevirapine; Practice Guidelines as Topic; Rever

2004
New nevirapine label underscores the risk for hepatotoxicity in key populations.
    AIDS clinical care, 2004, Volume: 16, Issue:3

    Topics: CD4 Lymphocyte Count; Drug Labeling; Female; HIV Infections; Humans; Liver; Male; Nevirapine; Revers

2004
New nevirapine label underscores the risk for hepatotoxicity in key populations.
    AIDS clinical care, 2004, Volume: 16, Issue:3

    Topics: CD4 Lymphocyte Count; Drug Labeling; Female; HIV Infections; Humans; Liver; Male; Nevirapine; Revers

2004
Retrovirus conferees discuss new strategies.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004, Apr-01, Volume: 61, Issue:7

    Topics: Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant, Newborn;

2004
Retrovirus conferees discuss new strategies.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004, Apr-01, Volume: 61, Issue:7

    Topics: Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant, Newborn;

2004
Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, May-01, Volume: 38, Issue:9

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopro

2004
Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, May-01, Volume: 38, Issue:9

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopro

2004
Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance.
    HIV medicine, 2004, Volume: 5, Issue:3

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Indu

2004
Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance.
    HIV medicine, 2004, Volume: 5, Issue:3

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Indu

2004
PMTCT from research to reality--results from a routine service.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:4

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease

2004
PMTCT from research to reality--results from a routine service.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:4

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease

2004
Nevirapine warning.
    AIDS patient care and STDs, 2004, Volume: 18, Issue:4

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; HIV Infections; Humans; Nevirapine;

2004
Nevirapine warning.
    AIDS patient care and STDs, 2004, Volume: 18, Issue:4

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; HIV Infections; Humans; Nevirapine;

2004
Nevirapine may promote resistance.
    AIDS patient care and STDs, 2004, Volume: 18, Issue:4

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infectious Disease Transmis

2004
Nevirapine may promote resistance.
    AIDS patient care and STDs, 2004, Volume: 18, Issue:4

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infectious Disease Transmis

2004
No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.
    European journal of clinical pharmacology, 2004, Volume: 60, Issue:5

    Topics: Anti-HIV Agents; Aspartate Aminotransferases; Bayes Theorem; Female; Half-Life; HIV Infections; HIV-

2004
No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.
    European journal of clinical pharmacology, 2004, Volume: 60, Issue:5

    Topics: Anti-HIV Agents; Aspartate Aminotransferases; Bayes Theorem; Female; Half-Life; HIV Infections; HIV-

2004
Immune status and uptake of antiretroviral interventions to prevent mother-to-child transmission of HIV-1 in Africa.
    Journal of acquired immune deficiency syndromes (1999), 2004, Jun-01, Volume: 36, Issue:2

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Female; HIV Infections; HIV-1; Humans;

2004
Immune status and uptake of antiretroviral interventions to prevent mother-to-child transmission of HIV-1 in Africa.
    Journal of acquired immune deficiency syndromes (1999), 2004, Jun-01, Volume: 36, Issue:2

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Female; HIV Infections; HIV-1; Humans;

2004
[Antiretroviral therapy of acute HIV-infection].
    Terapevticheskii arkhiv, 2004, Volume: 76, Issue:4

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; Female; HIV Infect

2004
[Antiretroviral therapy of acute HIV-infection].
    Terapevticheskii arkhiv, 2004, Volume: 76, Issue:4

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; Female; HIV Infect

2004
Prevention of mother-to-child transmission of HIV at Maiduguri, Nigeria.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2004, Volume: 24, Issue:3

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease

2004
Prevention of mother-to-child transmission of HIV at Maiduguri, Nigeria.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2004, Volume: 24, Issue:3

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease

2004
Risk of archived resistance after intrapartum nevirapine.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:5

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; Humans;

2004
Risk of archived resistance after intrapartum nevirapine.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:5

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; Humans;

2004
Nevirapine-induced resistance is a problem.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:5

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; Humans;

2004
Nevirapine-induced resistance is a problem.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:5

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; Humans;

2004
Acceptability and utilisation of voluntary HIV testing and nevirapine to reduce mother-to-child transmission of HIV-1 integrated into routine clinical care.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:5

    Topics: Anti-HIV Agents; Diagnostic Tests, Routine; Female; HIV Infections; HIV-1; Humans; Infant Welfare; I

2004
Acceptability and utilisation of voluntary HIV testing and nevirapine to reduce mother-to-child transmission of HIV-1 integrated into routine clinical care.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:5

    Topics: Anti-HIV Agents; Diagnostic Tests, Routine; Female; HIV Infections; HIV-1; Humans; Infant Welfare; I

2004
Implementing a rural programme of prevention of mother-to-child transmission of HIV in Zimbabwe: first 18 months of experience.
    Tropical medicine & international health : TM & IH, 2004, Volume: 9, Issue:7

    Topics: Adolescent; Adult; Anti-HIV Agents; Attitude to Health; Female; HIV Infections; Humans; Infectious D

2004
Implementing a rural programme of prevention of mother-to-child transmission of HIV in Zimbabwe: first 18 months of experience.
    Tropical medicine & international health : TM & IH, 2004, Volume: 9, Issue:7

    Topics: Adolescent; Adult; Anti-HIV Agents; Attitude to Health; Female; HIV Infections; Humans; Infectious D

2004
HIV/AIDS news: comparable anti-HIV antiviral efficacy of Viramune and Efavirenz--the Lancet publishes first large-scale comparison study.
    Infection, 2004, Volume: 32, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HI

2004
HIV/AIDS news: comparable anti-HIV antiviral efficacy of Viramune and Efavirenz--the Lancet publishes first large-scale comparison study.
    Infection, 2004, Volume: 32, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HI

2004
Antiretroviral agents--how best to protect infants from HIV and save their mothers from AIDS.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Developing Countries; Drug Resistance

2004
Antiretroviral agents--how best to protect infants from HIV and save their mothers from AIDS.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Developing Countries; Drug Resistance

2004
Health minister ignites row over drugs for HIV mothers.
    Nature, 2004, Jul-22, Volume: 430, Issue:6998

    Topics: Congresses as Topic; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Infant, Newborn; I

2004
Health minister ignites row over drugs for HIV mothers.
    Nature, 2004, Jul-22, Volume: 430, Issue:6998

    Topics: Congresses as Topic; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Infant, Newborn; I

2004
Some design issues in trials of microbicides for the prevention of HIV infection.
    The Journal of infectious diseases, 2004, Aug-15, Volume: 190, Issue:4

    Topics: Anti-HIV Agents; Anti-Infective Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase I

2004
Some design issues in trials of microbicides for the prevention of HIV infection.
    The Journal of infectious diseases, 2004, Aug-15, Volume: 190, Issue:4

    Topics: Anti-HIV Agents; Anti-Infective Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase I

2004
Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries.
    AIDS (London, England), 2004, Aug-20, Volume: 18, Issue:12

    Topics: Adult; Anti-HIV Agents; Botswana; Cost-Benefit Analysis; Cote d'Ivoire; Female; HIV Infections; Huma

2004
Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries.
    AIDS (London, England), 2004, Aug-20, Volume: 18, Issue:12

    Topics: Adult; Anti-HIV Agents; Botswana; Cost-Benefit Analysis; Cote d'Ivoire; Female; HIV Infections; Huma

2004
Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less.
    AIDS (London, England), 2004, Aug-20, Volume: 18, Issue:12

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV Infections; Humans

2004
Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less.
    AIDS (London, England), 2004, Aug-20, Volume: 18, Issue:12

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV Infections; Humans

2004
South Africa rejects use of AIDS drug for women.
    The New York times on the Web, 2004, Jul-14

    Topics: Acquired Immunodeficiency Syndrome; Female; Health Policy; HIV Infections; Humans; Infectious Diseas

2004
South Africa rejects use of AIDS drug for women.
    The New York times on the Web, 2004, Jul-14

    Topics: Acquired Immunodeficiency Syndrome; Female; Health Policy; HIV Infections; Humans; Infectious Diseas

2004
Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors.
    European journal of clinical investigation, 2004, Volume: 34, Issue:8

    Topics: Adiponectin; Adult; Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans;

2004
Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors.
    European journal of clinical investigation, 2004, Volume: 34, Issue:8

    Topics: Adiponectin; Adult; Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans;

2004
The relationship between nevirapine plasma concentrations and abnormal liver function tests.
    AIDS research and human retroviruses, 2004, Volume: 20, Issue:7

    Topics: Alanine Transaminase; Anti-HIV Agents; Cross-Sectional Studies; Ethnicity; Female; gamma-Glutamyltra

2004
The relationship between nevirapine plasma concentrations and abnormal liver function tests.
    AIDS research and human retroviruses, 2004, Volume: 20, Issue:7

    Topics: Alanine Transaminase; Anti-HIV Agents; Cross-Sectional Studies; Ethnicity; Female; gamma-Glutamyltra

2004
Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.
    AIDS (London, England), 2004, Sep-03, Volume: 18, Issue:13

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes;

2004
Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.
    AIDS (London, England), 2004, Sep-03, Volume: 18, Issue:13

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes;

2004
Low efficacy of nevirapine (HIVNET012) in preventing perinatal HIV-1 transmission in a real-life situation.
    AIDS (London, England), 2004, Sep-03, Volume: 18, Issue:13

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Nevirapine; Pregnancy; Pregnancy Complicatio

2004
Low efficacy of nevirapine (HIVNET012) in preventing perinatal HIV-1 transmission in a real-life situation.
    AIDS (London, England), 2004, Sep-03, Volume: 18, Issue:13

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Nevirapine; Pregnancy; Pregnancy Complicatio

2004
Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients.
    Virology, 2004, Oct-01, Volume: 327, Issue:2

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hu

2004
Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients.
    Virology, 2004, Oct-01, Volume: 327, Issue:2

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hu

2004
Mutations correlated to NVP concentrations.
    AIDS patient care and STDs, 2004, Volume: 18, Issue:8

    Topics: Drug Resistance, Viral; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis

2004
Mutations correlated to NVP concentrations.
    AIDS patient care and STDs, 2004, Volume: 18, Issue:8

    Topics: Drug Resistance, Viral; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis

2004
[Favorable new data for nevirapine. Antiretroviral effect confirmed--and also lipid profile].
    MMW Fortschritte der Medizin, 2004, Apr-26, Volume: 146 Spec No 1

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol, HDL; Clinical Trials as Topic; HIV Infections; H

2004
[Favorable new data for nevirapine. Antiretroviral effect confirmed--and also lipid profile].
    MMW Fortschritte der Medizin, 2004, Apr-26, Volume: 146 Spec No 1

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol, HDL; Clinical Trials as Topic; HIV Infections; H

2004
[CROI--presentation of new study results. In a comparison of NNRTI nevirapine is equally effective].
    MMW Fortschritte der Medizin, 2004, Apr-26, Volume: 146 Spec No 1

    Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; HIV Infections

2004
[CROI--presentation of new study results. In a comparison of NNRTI nevirapine is equally effective].
    MMW Fortschritte der Medizin, 2004, Apr-26, Volume: 146 Spec No 1

    Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; HIV Infections

2004
Infant HIV infection: acceptability of preventive strategies in central Tanzania.
    AIDS education and prevention : official publication of the International Society for AIDS Education, 2004, Volume: 16, Issue:5

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Community Health Services; Female; Focus Groups; Health Educ

2004
Infant HIV infection: acceptability of preventive strategies in central Tanzania.
    AIDS education and prevention : official publication of the International Society for AIDS Education, 2004, Volume: 16, Issue:5

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Community Health Services; Female; Focus Groups; Health Educ

2004
Decreased likelihood [correction of likelyhood] of infants contracting HIV when taking nevirapine.
    Expert review of anti-infective therapy, 2003, Volume: 1, Issue:3

    Topics: Female; HIV Infections; Humans; Infant; Infant, Newborn; Nevirapine; Pregnancy

2003
Decreased likelihood [correction of likelyhood] of infants contracting HIV when taking nevirapine.
    Expert review of anti-infective therapy, 2003, Volume: 1, Issue:3

    Topics: Female; HIV Infections; Humans; Infant; Infant, Newborn; Nevirapine; Pregnancy

2003
Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.
    Japanese journal of infectious diseases, 2004, Volume: 57, Issue:5

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; HIV Infections; Humans; Leuk

2004
Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.
    Japanese journal of infectious diseases, 2004, Volume: 57, Issue:5

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; HIV Infections; Humans; Leuk

2004
Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2004, Volume: 87, Issue:7

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Middle

2004
Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2004, Volume: 87, Issue:7

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Middle

2004
Nevirapine plus zidovudine to prevent mother-to-child transmission of HIV.
    The New England journal of medicine, 2004, Nov-04, Volume: 351, Issue:19

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2004
Nevirapine plus zidovudine to prevent mother-to-child transmission of HIV.
    The New England journal of medicine, 2004, Nov-04, Volume: 351, Issue:19

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2004
Nevirapine plus zidovudine to prevent mother-to-child transmission of HIV.
    The New England journal of medicine, 2004, Nov-04, Volume: 351, Issue:19

    Topics: Anti-Retroviral Agents; DNA, Viral; Female; HIV; HIV Infections; Humans; Infant, Newborn; Infectious

2004
Nevirapine plus zidovudine to prevent mother-to-child transmission of HIV.
    The New England journal of medicine, 2004, Nov-04, Volume: 351, Issue:19

    Topics: Anti-Retroviral Agents; DNA, Viral; Female; HIV; HIV Infections; Humans; Infant, Newborn; Infectious

2004
The efficacy-effectiveness gap in PMTCT.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:10

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease

2004
The efficacy-effectiveness gap in PMTCT.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:10

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease

2004
Meeting report from the XV International AIDS Conference. Perinatal transmission.
    AIDS clinical care, 2004, Volume: 16, Issue:9

    Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi

2004
Meeting report from the XV International AIDS Conference. Perinatal transmission.
    AIDS clinical care, 2004, Volume: 16, Issue:9

    Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi

2004
[Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].
    Nederlands tijdschrift voor geneeskunde, 2004, Oct-09, Volume: 148, Issue:41

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; F

2004
[Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].
    Nederlands tijdschrift voor geneeskunde, 2004, Oct-09, Volume: 148, Issue:41

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; F

2004
Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission.
    Journal of acquired immune deficiency syndromes (1999), 2004, Dec-15, Volume: 37, Issue:5

    Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Condoms; Contact Tracing; Counseling; Fa

2004
Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission.
    Journal of acquired immune deficiency syndromes (1999), 2004, Dec-15, Volume: 37, Issue:5

    Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Condoms; Contact Tracing; Counseling; Fa

2004
Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations.
    AIDS (London, England), 2004, Oct-21, Volume: 18, Issue:15

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1

2004
Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations.
    AIDS (London, England), 2004, Oct-21, Volume: 18, Issue:15

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1

2004
Reduction of materno-fetal transmission of HIV by improved delivery techniques combined with nevirapine treatment in women attending two family planning clinics in Yaounde, Cameroon.
    International journal of STD & AIDS, 2004, Volume: 15, Issue:12

    Topics: Adolescent; Adult; Anti-HIV Agents; Cameroon; Delivery, Obstetric; Family Planning Services; Female;

2004
Reduction of materno-fetal transmission of HIV by improved delivery techniques combined with nevirapine treatment in women attending two family planning clinics in Yaounde, Cameroon.
    International journal of STD & AIDS, 2004, Volume: 15, Issue:12

    Topics: Adolescent; Adult; Anti-HIV Agents; Cameroon; Delivery, Obstetric; Family Planning Services; Female;

2004
Tolerance of a short course of nevirapine, associated with 2 nucleoside analogues, in postexposure prophylaxis of HIV.
    Journal of acquired immune deficiency syndromes (1999), 2004, Dec-01, Volume: 37, Issue:4

    Topics: Alanine Transaminase; Anti-HIV Agents; Drug Evaluation; Drug Therapy, Combination; History, 21st Cen

2004
Tolerance of a short course of nevirapine, associated with 2 nucleoside analogues, in postexposure prophylaxis of HIV.
    Journal of acquired immune deficiency syndromes (1999), 2004, Dec-01, Volume: 37, Issue:4

    Topics: Alanine Transaminase; Anti-HIV Agents; Drug Evaluation; Drug Therapy, Combination; History, 21st Cen

2004
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Jan-01, Volume: 40, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideox

2005
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Jan-01, Volume: 40, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideox

2005
Warning on two specific 3-drug regimens: Viread + Didanosine + either Sustiva or Viramune.
    AIDS treatment news, 2004, Oct-29, Issue:406

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combinatio

2004
Warning on two specific 3-drug regimens: Viread + Didanosine + either Sustiva or Viramune.
    AIDS treatment news, 2004, Oct-29, Issue:406

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combinatio

2004
HIV transmission. Allegations raise fears of backlash against AIDS prevention strategy.
    Science (New York, N.Y.), 2004, Dec-24, Volume: 306, Issue:5705

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant; Infant, Newborn;

2004
HIV transmission. Allegations raise fears of backlash against AIDS prevention strategy.
    Science (New York, N.Y.), 2004, Dec-24, Volume: 306, Issue:5705

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant; Infant, Newborn;

2004
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
    AIDS (London, England), 2005, Jan-03, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther

2005
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
    AIDS (London, England), 2005, Jan-03, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther

2005
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
    AIDS (London, England), 2005, Jan-03, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther

2005
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
    AIDS (London, England), 2005, Jan-03, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther

2005
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
    AIDS (London, England), 2005, Jan-03, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther

2005
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
    AIDS (London, England), 2005, Jan-03, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther

2005
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
    AIDS (London, England), 2005, Jan-03, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther

2005
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
    AIDS (London, England), 2005, Jan-03, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther

2005
US AIDS chief altered report on nevirapine safety risks.
    Nature medicine, 2005, Volume: 11, Issue:1

    Topics: Anti-HIV Agents; Government Publications as Topic; HIV Infections; Humans; National Institutes of He

2005
US AIDS chief altered report on nevirapine safety risks.
    Nature medicine, 2005, Volume: 11, Issue:1

    Topics: Anti-HIV Agents; Government Publications as Topic; HIV Infections; Humans; National Institutes of He

2005
Articles criticising nevirapine trial may endanger babies' lives.
    BMJ (Clinical research ed.), 2005, Jan-08, Volume: 330, Issue:7482

    Topics: Anti-HIV Agents; Controlled Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newbor

2005
Articles criticising nevirapine trial may endanger babies' lives.
    BMJ (Clinical research ed.), 2005, Jan-08, Volume: 330, Issue:7482

    Topics: Anti-HIV Agents; Controlled Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newbor

2005
In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
    The new microbiologica, 2004, Volume: 27, Issue:2 Suppl 1

    Topics: Alkynes; Amino Acid Substitution; Base Sequence; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes;

2004
In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
    The new microbiologica, 2004, Volume: 27, Issue:2 Suppl 1

    Topics: Alkynes; Amino Acid Substitution; Base Sequence; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes;

2004
Drug reaction. Rev. Jackson calls study 'crime against humanity'.
    AIDS policy & law, 2004, Dec-31, Volume: 20, Issue:1

    Topics: Black or African American; Ethics; HIV Infections; Humans; Nevirapine; Politics; Reverse Transcripta

2004
Drug reaction. Rev. Jackson calls study 'crime against humanity'.
    AIDS policy & law, 2004, Dec-31, Volume: 20, Issue:1

    Topics: Black or African American; Ethics; HIV Infections; Humans; Nevirapine; Politics; Reverse Transcripta

2004
Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine.
    AIDS (London, England), 2005, Jan-28, Volume: 19, Issue:2

    Topics: Adenine; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; D

2005
Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine.
    AIDS (London, England), 2005, Jan-28, Volume: 19, Issue:2

    Topics: Adenine; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; D

2005
Inhibitory drug levels found in breast milk.
    AIDS patient care and STDs, 2004, Volume: 18, Issue:12

    Topics: Anti-Retroviral Agents; Female; HIV Infections; Humans; Infant; Lamivudine; Milk, Human; Nevirapine;

2004
Inhibitory drug levels found in breast milk.
    AIDS patient care and STDs, 2004, Volume: 18, Issue:12

    Topics: Anti-Retroviral Agents; Female; HIV Infections; Humans; Infant; Lamivudine; Milk, Human; Nevirapine;

2004
An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2005, Feb-01, Volume: 38, Issue:2

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Glucose; Cross-Sectional Studies

2005
An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2005, Feb-01, Volume: 38, Issue:2

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Glucose; Cross-Sectional Studies

2005
HIV seroprevalence, uptake of interventions to reduce mother-to-child transmission and birth outcomes in greater Kingston, Jamaica.
    The West Indian medical journal, 2004, Volume: 53, Issue:5

    Topics: Adolescent; Adult; Female; HIV Infections; HIV Seropositivity; HIV Seroprevalence; Humans; Infectiou

2004
HIV seroprevalence, uptake of interventions to reduce mother-to-child transmission and birth outcomes in greater Kingston, Jamaica.
    The West Indian medical journal, 2004, Volume: 53, Issue:5

    Topics: Adolescent; Adult; Female; HIV Infections; HIV Seropositivity; HIV Seroprevalence; Humans; Infectiou

2004
Uptake of interventions, outcomes and challenges in caring for HIV-exposed infants in Kingston, Jamaica.
    The West Indian medical journal, 2004, Volume: 53, Issue:5

    Topics: Antibiotic Prophylaxis; Female; HIV Infections; Humans; Infant; Infant Care; Infant, Newborn; Infect

2004
Uptake of interventions, outcomes and challenges in caring for HIV-exposed infants in Kingston, Jamaica.
    The West Indian medical journal, 2004, Volume: 53, Issue:5

    Topics: Antibiotic Prophylaxis; Female; HIV Infections; Humans; Infant; Infant Care; Infant, Newborn; Infect

2004
Nevirapine-associated rash in a Jamaican child with HIV/AIDS.
    The West Indian medical journal, 2004, Volume: 53, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Exanthema; HIV Infections; Humans; Infant; Jama

2004
Nevirapine-associated rash in a Jamaican child with HIV/AIDS.
    The West Indian medical journal, 2004, Volume: 53, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Exanthema; HIV Infections; Humans; Infant; Jama

2004
Zidovudine monotherapy and the prevention of mother-to-child HIV-1 transmission.
    The Lancet. Infectious diseases, 2005, Volume: 5, Issue:2

    Topics: Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis

2005
Zidovudine monotherapy and the prevention of mother-to-child HIV-1 transmission.
    The Lancet. Infectious diseases, 2005, Volume: 5, Issue:2

    Topics: Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis

2005
Recent advances in prevention of mother to child (PMTCT) of HIV.
    African health sciences, 2004, Volume: 4, Issue:3

    Topics: Africa; Anti-HIV Agents; Breast Feeding; Disease Outbreaks; Female; HIV Infections; Humans; Infant,

2004
Recent advances in prevention of mother to child (PMTCT) of HIV.
    African health sciences, 2004, Volume: 4, Issue:3

    Topics: Africa; Anti-HIV Agents; Breast Feeding; Disease Outbreaks; Female; HIV Infections; Humans; Infant,

2004
Effectiveness of nevirapine and zidovudine in a pilot program for the prevention of mother-to-child transmission of HIV-1 in Uganda.
    African health sciences, 2004, Volume: 4, Issue:3

    Topics: Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Disease Outbreaks; Female; HIV Infections;

2004
Effectiveness of nevirapine and zidovudine in a pilot program for the prevention of mother-to-child transmission of HIV-1 in Uganda.
    African health sciences, 2004, Volume: 4, Issue:3

    Topics: Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Disease Outbreaks; Female; HIV Infections;

2004
Controversy around nevirapine trials continues.
    The Lancet. Infectious diseases, 2005, Volume: 5, Issue:2

    Topics: Anti-HIV Agents; Clinical Trials as Topic; HIV Infections; Humans; Nevirapine

2005
Controversy around nevirapine trials continues.
    The Lancet. Infectious diseases, 2005, Volume: 5, Issue:2

    Topics: Anti-HIV Agents; Clinical Trials as Topic; HIV Infections; Humans; Nevirapine

2005
Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Feb-15, Volume: 40, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and D

2005
Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Feb-15, Volume: 40, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and D

2005
Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:4

    Topics: Adult; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; H

2005
Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:4

    Topics: Adult; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; H

2005
Top stories of 2004. Perinatal transmission interventions: the benefits come with resistance.
    AIDS clinical care, 2005, Volume: 17, Issue:1

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr

2005
Top stories of 2004. Perinatal transmission interventions: the benefits come with resistance.
    AIDS clinical care, 2005, Volume: 17, Issue:1

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr

2005
Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission.
    AIDS (London, England), 2005, Feb-18, Volume: 19, Issue:3

    Topics: Adult; Anti-HIV Agents; Cote d'Ivoire; Developing Countries; Drug Therapy, Combination; Female; HIV

2005
Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission.
    AIDS (London, England), 2005, Feb-18, Volume: 19, Issue:3

    Topics: Adult; Anti-HIV Agents; Cote d'Ivoire; Developing Countries; Drug Therapy, Combination; Female; HIV

2005
Reports on nevirapine threaten public health.
    Nature medicine, 2005, Volume: 11, Issue:3

    Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Female; Government Publications as Topic; HIV Infe

2005
Reports on nevirapine threaten public health.
    Nature medicine, 2005, Volume: 11, Issue:3

    Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Female; Government Publications as Topic; HIV Infe

2005
HIV drug remains unproven without placebo trial.
    Nature, 2005, Mar-10, Volume: 434, Issue:7030

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi

2005
HIV drug remains unproven without placebo trial.
    Nature, 2005, Mar-10, Volume: 434, Issue:7030

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi

2005
Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine.
    The Journal of infection, 2005, Volume: 50, Issue:3

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Chronic Disease; HIV Infections; Hum

2005
Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine.
    The Journal of infection, 2005, Volume: 50, Issue:3

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Chronic Disease; HIV Infections; Hum

2005
FDA advisory on nevirapine.
    AIDS treatment news, 2005, Jan-28, Issue:409

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Nevirapine; Pregnan

2005
FDA advisory on nevirapine.
    AIDS treatment news, 2005, Jan-28, Issue:409

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Nevirapine; Pregnan

2005
Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding.
    Journal of acquired immune deficiency syndromes (1999), 2005, Apr-15, Volume: 38, Issue:5

    Topics: Anti-HIV Agents; Breast Feeding; Costs and Cost Analysis; Female; HIV Infections; HIV Seroprevalence

2005
Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding.
    Journal of acquired immune deficiency syndromes (1999), 2005, Apr-15, Volume: 38, Issue:5

    Topics: Anti-HIV Agents; Breast Feeding; Costs and Cost Analysis; Female; HIV Infections; HIV Seroprevalence

2005
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
    Therapeutic drug monitoring, 2005, Volume: 27, Issue:2

    Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopro

2005
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
    Therapeutic drug monitoring, 2005, Volume: 27, Issue:2

    Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopro

2005
Should nevirapine be used to prevent mother-to-child transmission of HIV among women of unknown serostatus?
    Bulletin of the World Health Organization, 2005, Volume: 83, Issue:3

    Topics: Anti-HIV Agents; Female; Health Status; HIV Infections; HIV Seropositivity; Humans; Infectious Disea

2005
Should nevirapine be used to prevent mother-to-child transmission of HIV among women of unknown serostatus?
    Bulletin of the World Health Organization, 2005, Volume: 83, Issue:3

    Topics: Anti-HIV Agents; Female; Health Status; HIV Infections; HIV Seropositivity; Humans; Infectious Disea

2005
Routine provision of nevirapine to women of unknown serostatus: at best a temporary solution to prevent MTCT.
    Bulletin of the World Health Organization, 2005, Volume: 83, Issue:3

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infe

2005
Routine provision of nevirapine to women of unknown serostatus: at best a temporary solution to prevent MTCT.
    Bulletin of the World Health Organization, 2005, Volume: 83, Issue:3

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infe

2005
Women in couples antenatal HIV counseling and testing are not more likely to report adverse social events.
    AIDS (London, England), 2005, Mar-24, Volume: 19, Issue:6

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Cohort Studies; Counseling; Disclosure; Divorce; Domestic Vi

2005
Women in couples antenatal HIV counseling and testing are not more likely to report adverse social events.
    AIDS (London, England), 2005, Mar-24, Volume: 19, Issue:6

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Cohort Studies; Counseling; Disclosure; Divorce; Domestic Vi

2005
[Toxic epidermal necrolysis associated with abacavir].
    Enfermedades infecciosas y microbiologia clinica, 2005, Volume: 23, Issue:4

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; HIV I

2005
[Toxic epidermal necrolysis associated with abacavir].
    Enfermedades infecciosas y microbiologia clinica, 2005, Volume: 23, Issue:4

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; HIV I

2005
The non-nukes. Sustiva. Viramune. The two major players.
    Positively aware : the monthly journal of the Test Positive Aware Network, 2005,Winter, Volume: Spec No

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Hu

2005
The non-nukes. Sustiva. Viramune. The two major players.
    Positively aware : the monthly journal of the Test Positive Aware Network, 2005,Winter, Volume: Spec No

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Hu

2005
Practical guidelines to interpret plasma concentrations of antiretroviral drugs.
    Clinical pharmacokinetics, 2005, Volume: 44, Issue:4

    Topics: Anti-HIV Agents; Drug Monitoring; HIV Infections; Humans; Nevirapine; Practice Guidelines as Topic;

2005
Practical guidelines to interpret plasma concentrations of antiretroviral drugs.
    Clinical pharmacokinetics, 2005, Volume: 44, Issue:4

    Topics: Anti-HIV Agents; Drug Monitoring; HIV Infections; Humans; Nevirapine; Practice Guidelines as Topic;

2005
Study gives backing to HIV drug for mothers.
    Nature, 2005, Apr-14, Volume: 434, Issue:7035

    Topics: Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transm

2005
Study gives backing to HIV drug for mothers.
    Nature, 2005, Apr-14, Volume: 434, Issue:7035

    Topics: Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transm

2005
AIDS research. IOM panel clears HIV prevention study.
    Science (New York, N.Y.), 2005, Apr-15, Volume: 308, Issue:5720

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectio

2005
AIDS research. IOM panel clears HIV prevention study.
    Science (New York, N.Y.), 2005, Apr-15, Volume: 308, Issue:5720

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectio

2005
Nevirapine-related death draws attention.
    AIDS patient care and STDs, 2005, Volume: 19, Issue:3

    Topics: Clinical Trials as Topic; Fatal Outcome; Female; HIV Infections; Humans; Liver Failure; National Ins

2005
Nevirapine-related death draws attention.
    AIDS patient care and STDs, 2005, Volume: 19, Issue:3

    Topics: Clinical Trials as Topic; Fatal Outcome; Female; HIV Infections; Humans; Liver Failure; National Ins

2005
Resistance with short-course nevirapine.
    AIDS patient care and STDs, 2005, Volume: 19, Issue:3

    Topics: Clinical Trials as Topic; Drug Resistance, Viral; Female; HIV Infections; Humans; Nevirapine; Pregna

2005
Resistance with short-course nevirapine.
    AIDS patient care and STDs, 2005, Volume: 19, Issue:3

    Topics: Clinical Trials as Topic; Drug Resistance, Viral; Female; HIV Infections; Humans; Nevirapine; Pregna

2005
Averting drug resistance while preventing MTCT.
    The AIDS reader, 2005, Volume: 15, Issue:4

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; Human

2005
Averting drug resistance while preventing MTCT.
    The AIDS reader, 2005, Volume: 15, Issue:4

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; Human

2005
Maternal self-medication and provision of nevirapine to newborns by women in Rakai, Uganda.
    Journal of acquired immune deficiency syndromes (1999), 2005, May-01, Volume: 39, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2005
Maternal self-medication and provision of nevirapine to newborns by women in Rakai, Uganda.
    Journal of acquired immune deficiency syndromes (1999), 2005, May-01, Volume: 39, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2005
A drug is effective if better than a harmless control.
    Nature, 2005, Apr-28, Volume: 434, Issue:7037

    Topics: Controlled Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Dis

2005
A drug is effective if better than a harmless control.
    Nature, 2005, Apr-28, Volume: 434, Issue:7037

    Topics: Controlled Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Dis

2005
Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.
    Tropical medicine & international health : TM & IH, 2005, Volume: 10, Issue:5

    Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Drug Therapy, Com

2005
Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.
    Tropical medicine & international health : TM & IH, 2005, Volume: 10, Issue:5

    Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Drug Therapy, Com

2005
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.
    Pharmacogenetics and genomics, 2005, Volume: 15, Issue:1

    Topics: Adult; Alkynes; Alleles; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes

2005
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.
    Pharmacogenetics and genomics, 2005, Volume: 15, Issue:1

    Topics: Adult; Alkynes; Alleles; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes

2005
Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors.
    Antiviral therapy, 2005, Volume: 10, Issue:2

    Topics: Alkynes; Benzoxazines; Cell Line; Codon; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-

2005
Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors.
    Antiviral therapy, 2005, Volume: 10, Issue:2

    Topics: Alkynes; Benzoxazines; Cell Line; Codon; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-

2005
Nelfinavir and nevirapine side effects during pregnancy.
    AIDS (London, England), 2005, May-20, Volume: 19, Issue:8

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymp

2005
Nelfinavir and nevirapine side effects during pregnancy.
    AIDS (London, England), 2005, May-20, Volume: 19, Issue:8

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymp

2005
Reducing HIV vertical transmission scrutinized.
    JAMA, 2005, May-04, Volume: 293, Issue:17

    Topics: Anti-HIV Agents; Developing Countries; Drug Resistance, Viral; Female; HIV Infections; Humans; Infan

2005
Reducing HIV vertical transmission scrutinized.
    JAMA, 2005, May-04, Volume: 293, Issue:17

    Topics: Anti-HIV Agents; Developing Countries; Drug Resistance, Viral; Female; HIV Infections; Humans; Infan

2005
Nevirapine misinformation: will it kill?
    IAPAC monthly, 2004, Volume: 10, Issue:12

    Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi

2004
Nevirapine misinformation: will it kill?
    IAPAC monthly, 2004, Volume: 10, Issue:12

    Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi

2004
IOM: nevirapine study is reliable.
    AIDS treatment news, 2005, Mar-25, Issue:411

    Topics: Clinical Trials as Topic; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, V

2005
IOM: nevirapine study is reliable.
    AIDS treatment news, 2005, Mar-25, Issue:411

    Topics: Clinical Trials as Topic; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, V

2005
No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel.
    Anti-cancer drugs, 2005, Volume: 16, Issue:6

    Topics: Adult; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Cytochrome P-450 CYP3A; Cytochrome P-450

2005
No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel.
    Anti-cancer drugs, 2005, Volume: 16, Issue:6

    Topics: Adult; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Cytochrome P-450 CYP3A; Cytochrome P-450

2005
Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Jul-01, Volume: 41, Issue:1

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymph

2005
Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Jul-01, Volume: 41, Issue:1

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymph

2005
Single-dose nevirapine and drug resistance: the more you look, the more you find.
    The Journal of infectious diseases, 2005, Jul-01, Volume: 192, Issue:1

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; Human

2005
Single-dose nevirapine and drug resistance: the more you look, the more you find.
    The Journal of infectious diseases, 2005, Jul-01, Volume: 192, Issue:1

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; Human

2005
Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.
    The Journal of infectious diseases, 2005, Jul-01, Volume: 192, Issue:1

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1

2005
Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.
    The Journal of infectious diseases, 2005, Jul-01, Volume: 192, Issue:1

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1

2005
Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.
    The Journal of infectious diseases, 2005, 07-01, Volume: 192, Issue:1

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV Infecti

2005
Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.
    The Journal of infectious diseases, 2005, 07-01, Volume: 192, Issue:1

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV Infecti

2005
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.
    The Journal of infectious diseases, 2005, Jul-01, Volume: 192, Issue:1

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV

2005
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.
    The Journal of infectious diseases, 2005, Jul-01, Volume: 192, Issue:1

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV

2005
Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine.
    AIDS research and human retroviruses, 2005, Volume: 21, Issue:4

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Protea

2005
Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine.
    AIDS research and human retroviruses, 2005, Volume: 21, Issue:4

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Protea

2005
[Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
    Zhonghua yi xue za zhi, 2005, Mar-23, Volume: 85, Issue:11

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2005
[Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
    Zhonghua yi xue za zhi, 2005, Mar-23, Volume: 85, Issue:11

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2005
HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen.
    AIDS (London, England), 2005, Jul-01, Volume: 19, Issue:10

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HI

2005
HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen.
    AIDS (London, England), 2005, Jul-01, Volume: 19, Issue:10

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HI

2005
Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations.
    AIDS research and human retroviruses, 2005, Volume: 21, Issue:6

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Chemical and Drug Induced

2005
Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations.
    AIDS research and human retroviruses, 2005, Volume: 21, Issue:6

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Chemical and Drug Induced

2005
Nevirapine absorbed well despite chronic diarrhea.
    AIDS research and human retroviruses, 2005, Volume: 21, Issue:6

    Topics: Adult; Anti-HIV Agents; Chronic Disease; Diarrhea; HIV Infections; HIV-1; Humans; Intestinal Absorpt

2005
Nevirapine absorbed well despite chronic diarrhea.
    AIDS research and human retroviruses, 2005, Volume: 21, Issue:6

    Topics: Adult; Anti-HIV Agents; Chronic Disease; Diarrhea; HIV Infections; HIV-1; Humans; Intestinal Absorpt

2005
Appropriate use of nevirapine for long-term therapy.
    The Journal of infectious diseases, 2005, Aug-01, Volume: 192, Issue:3

    Topics: CD4 Lymphocyte Count; HIV Infections; HIV-1; Humans; Liver; Nevirapine; Reverse Transcriptase Inhibi

2005
Appropriate use of nevirapine for long-term therapy.
    The Journal of infectious diseases, 2005, Aug-01, Volume: 192, Issue:3

    Topics: CD4 Lymphocyte Count; HIV Infections; HIV-1; Humans; Liver; Nevirapine; Reverse Transcriptase Inhibi

2005
Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies.
    Journal of acquired immune deficiency syndromes (1999), 2005, Aug-01, Volume: 39, Issue:4

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; N

2005
Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies.
    Journal of acquired immune deficiency syndromes (1999), 2005, Aug-01, Volume: 39, Issue:4

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; N

2005
Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.
    Antiviral therapy, 1999, Volume: 4 Suppl 3

    Topics: Acute Disease; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Enzyme

1999
Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.
    Antiviral therapy, 1999, Volume: 4 Suppl 3

    Topics: Acute Disease; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Enzyme

1999
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Antiviral therapy, 2005, Volume: 10, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Chemical and Drug In

2005
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Antiviral therapy, 2005, Volume: 10, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Chemical and Drug In

2005
Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012.
    Journal of acquired immune deficiency syndromes (1999), 2005, Aug-15, Volume: 39, Issue:5

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Female; Genotype; HIV Infections; HIV-1; Humans; Infectious D

2005
Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012.
    Journal of acquired immune deficiency syndromes (1999), 2005, Aug-15, Volume: 39, Issue:5

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Female; Genotype; HIV Infections; HIV-1; Humans; Infectious D

2005
TDM: therapeutic drug measuring or therapeutic drug monitoring?
    Therapeutic drug monitoring, 2005, Volume: 27, Issue:4

    Topics: Anti-Retroviral Agents; Carbamazepine; Drug Interactions; Drug Monitoring; Drug Resistance, Viral; H

2005
TDM: therapeutic drug measuring or therapeutic drug monitoring?
    Therapeutic drug monitoring, 2005, Volume: 27, Issue:4

    Topics: Anti-Retroviral Agents; Carbamazepine; Drug Interactions; Drug Monitoring; Drug Resistance, Viral; H

2005
Determination of nevirapine and efavirenz in plasma using GC/MS in selected ion monitoring mode.
    Therapeutic drug monitoring, 2005, Volume: 27, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Calibration; Cyclopro

2005
Determination of nevirapine and efavirenz in plasma using GC/MS in selected ion monitoring mode.
    Therapeutic drug monitoring, 2005, Volume: 27, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Calibration; Cyclopro

2005
Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia.
    AIDS (London, England), 2005, Aug-12, Volume: 19, Issue:12

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; Fetal Blood; HIV Infections; Humans; Infant, Newb

2005
Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia.
    AIDS (London, England), 2005, Aug-12, Volume: 19, Issue:12

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; Fetal Blood; HIV Infections; Humans; Infant, Newb

2005
Roundtable. Revisiting the role of single-dose nevirapine for preventing perinatal HIV transmission.
    AIDS clinical care, 2005, Volume: 17, Issue:7

    Topics: Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tr

2005
Roundtable. Revisiting the role of single-dose nevirapine for preventing perinatal HIV transmission.
    AIDS clinical care, 2005, Volume: 17, Issue:7

    Topics: Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tr

2005
Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
    BMC infectious diseases, 2005, Aug-24, Volume: 5

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Acti

2005
Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
    BMC infectious diseases, 2005, Aug-24, Volume: 5

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Acti

2005
Attitudes to voluntary counselling and testing prior to the offer of Nevirapine to prevent vertical transmission of HIV in northern Tanzania.
    AIDS care, 2005, Volume: 17, Issue:7

    Topics: Adolescent; Adult; Anti-HIV Agents; Attitude to Health; Counseling; Female; Focus Groups; HIV Infect

2005
Attitudes to voluntary counselling and testing prior to the offer of Nevirapine to prevent vertical transmission of HIV in northern Tanzania.
    AIDS care, 2005, Volume: 17, Issue:7

    Topics: Adolescent; Adult; Anti-HIV Agents; Attitude to Health; Counseling; Female; Focus Groups; HIV Infect

2005
Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012.
    Journal of acquired immune deficiency syndromes (1999), 2005, Sep-01, Volume: 40, Issue:1

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Genes, pol; HIV Infections; HIV-1; Humans; Molecula

2005
Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012.
    Journal of acquired immune deficiency syndromes (1999), 2005, Sep-01, Volume: 40, Issue:1

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Genes, pol; HIV Infections; HIV-1; Humans; Molecula

2005
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting.
    Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:9

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Mal

2005
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting.
    Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:9

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Mal

2005
Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.
    AIDS (London, England), 2005, Sep-23, Volume: 19, Issue:14

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cross-S

2005
Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.
    AIDS (London, England), 2005, Sep-23, Volume: 19, Issue:14

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cross-S

2005
Antiretroviral therapy in HIV-1 infected children.
    Indian pediatrics, 2005, Volume: 42, Issue:8

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymph

2005
Antiretroviral therapy in HIV-1 infected children.
    Indian pediatrics, 2005, Volume: 42, Issue:8

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymph

2005
Addressing the paediatric HIV epidemic: a perspective from the Western Cape Region of South Africa.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, Volume: 100, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Disease Outbreaks; Female; HIV Infections; Humans; Infant

2006
Addressing the paediatric HIV epidemic: a perspective from the Western Cape Region of South Africa.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, Volume: 100, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Disease Outbreaks; Female; HIV Infections; Humans; Infant

2006
Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa.
    Bulletin of the World Health Organization, 2005, Volume: 83, Issue:7

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Female; HIV Infections; Humans; Inf

2005
Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa.
    Bulletin of the World Health Organization, 2005, Volume: 83, Issue:7

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Female; HIV Infections; Humans; Inf

2005
Nevirapine concentration in cervicovaginal and oropharyngeal secretions after single-dose administration to the mother.
    Antiviral therapy, 2005, Volume: 10, Issue:6

    Topics: Anti-HIV Agents; Cervix Uteri; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Di

2005
Nevirapine concentration in cervicovaginal and oropharyngeal secretions after single-dose administration to the mother.
    Antiviral therapy, 2005, Volume: 10, Issue:6

    Topics: Anti-HIV Agents; Cervix Uteri; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Di

2005
Preventing mother-to-child transmission of HIV in Western Kenya: operational issues.
    Journal of acquired immune deficiency syndromes (1999), 2005, Nov-01, Volume: 40, Issue:3

    Topics: Anti-HIV Agents; Counseling; Developing Countries; Female; HIV Infections; Hospitals, General; Hospi

2005
Preventing mother-to-child transmission of HIV in Western Kenya: operational issues.
    Journal of acquired immune deficiency syndromes (1999), 2005, Nov-01, Volume: 40, Issue:3

    Topics: Anti-HIV Agents; Counseling; Developing Countries; Female; HIV Infections; Hospitals, General; Hospi

2005
Third-trimester maternal toxicity with nevirapine use in pregnancy.
    Obstetrics and gynecology, 2005, Volume: 106, Issue:5 Pt 1

    Topics: Adolescent; Adult; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Nevirapine; Pregnanc

2005
Third-trimester maternal toxicity with nevirapine use in pregnancy.
    Obstetrics and gynecology, 2005, Volume: 106, Issue:5 Pt 1

    Topics: Adolescent; Adult; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Nevirapine; Pregnanc

2005
Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    HIV medicine, 2005, Volume: 6, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2005
Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    HIV medicine, 2005, Volume: 6, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2005
Meeting notes from the 3rd IAS Conference. Treating TB and HIV concurrently.
    AIDS clinical care, 2005, Volume: 17, Issue:10

    Topics: Brazil; Congresses as Topic; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Rifampin

2005
Meeting notes from the 3rd IAS Conference. Treating TB and HIV concurrently.
    AIDS clinical care, 2005, Volume: 17, Issue:10

    Topics: Brazil; Congresses as Topic; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Rifampin

2005
Integrating prevention of mother-to-child HIV transmission into routine antenatal care: the key to program expansion in Cameroon.
    Journal of acquired immune deficiency syndromes (1999), 2005, Dec-01, Volume: 40, Issue:4

    Topics: Adolescent; Adult; Age Factors; Anti-HIV Agents; Cameroon; Counseling; Female; HIV Infections; Human

2005
Integrating prevention of mother-to-child HIV transmission into routine antenatal care: the key to program expansion in Cameroon.
    Journal of acquired immune deficiency syndromes (1999), 2005, Dec-01, Volume: 40, Issue:4

    Topics: Adolescent; Adult; Age Factors; Anti-HIV Agents; Cameroon; Counseling; Female; HIV Infections; Human

2005
HIV-1 drug resistance in Thailand: before and after National Access to Antiretroviral Program.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2005, Volume: 34, Issue:4

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Genes, pol; Government Programs; Health Surveys; HIV

2005
HIV-1 drug resistance in Thailand: before and after National Access to Antiretroviral Program.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2005, Volume: 34, Issue:4

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Genes, pol; Government Programs; Health Surveys; HIV

2005
Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2006, Jan-01, Volume: 41, Issue:1

    Topics: Adenine; Administration, Oral; Alkynes; Benzoxazines; Cyclopropanes; Drug Administration Schedule; D

2006
Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2006, Jan-01, Volume: 41, Issue:1

    Topics: Adenine; Administration, Oral; Alkynes; Benzoxazines; Cyclopropanes; Drug Administration Schedule; D

2006
Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India.
    Journal of acquired immune deficiency syndromes (1999), 2006, Jan-01, Volume: 41, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; C

2006
Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India.
    Journal of acquired immune deficiency syndromes (1999), 2006, Jan-01, Volume: 41, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; C

2006
[Detection of HIV infection in pregnant women by rapid testing: a successful strategy to reduce its vertical transmission].
    Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia, 2005, Volume: 22, Issue:4

    Topics: Adolescent; Adult; Anti-HIV Agents; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Female; HI

2005
[Detection of HIV infection in pregnant women by rapid testing: a successful strategy to reduce its vertical transmission].
    Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia, 2005, Volume: 22, Issue:4

    Topics: Adolescent; Adult; Anti-HIV Agents; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Female; HI

2005
Antiretroviral treatment in the Northern Cape.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2005, Volume: 95, Issue:11

    Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Presc

2005
Antiretroviral treatment in the Northern Cape.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2005, Volume: 95, Issue:11

    Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Presc

2005
Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.
    AIDS research and human retroviruses, 2005, Volume: 21, Issue:12

    Topics: Adult; Anti-HIV Agents; Chemoprevention; Cote d'Ivoire; DNA, Viral; Drug Resistance, Viral; Female;

2005
Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.
    AIDS research and human retroviruses, 2005, Volume: 21, Issue:12

    Topics: Adult; Anti-HIV Agents; Chemoprevention; Cote d'Ivoire; DNA, Viral; Drug Resistance, Viral; Female;

2005
[Reliability: nevirapine. Highly effective + favorable influence on lipid profile].
    MMW Fortschritte der Medizin, 2005, Apr-25, Volume: 147 Spec No 1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; HIV Infections; H

2005
[Reliability: nevirapine. Highly effective + favorable influence on lipid profile].
    MMW Fortschritte der Medizin, 2005, Apr-25, Volume: 147 Spec No 1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; HIV Infections; H

2005
[Efavirenz--comprehensive status of studies].
    MMW Fortschritte der Medizin, 2005, Apr-25, Volume: 147 Spec No 1

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug R

2005
[Efavirenz--comprehensive status of studies].
    MMW Fortschritte der Medizin, 2005, Apr-25, Volume: 147 Spec No 1

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug R

2005
Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
    American journal of obstetrics and gynecology, 2006, Volume: 194, Issue:1

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholestasis; Cohort Studies; Female; Hepatitis B; Hepa

2006
Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
    American journal of obstetrics and gynecology, 2006, Volume: 194, Issue:1

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholestasis; Cohort Studies; Female; Hepatitis B; Hepa

2006
HIV-1 reverse transcriptase gene 103K/N and 184M/V combinations in tandem: detection and quantification of HIV-1 populations in the CD45RO+ T-cell compartment by a double-ARMS real-time PCR assay.
    Journal of acquired immune deficiency syndromes (1999), 2006, Feb-01, Volume: 41, Issue:2

    Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies;

2006
HIV-1 reverse transcriptase gene 103K/N and 184M/V combinations in tandem: detection and quantification of HIV-1 populations in the CD45RO+ T-cell compartment by a double-ARMS real-time PCR assay.
    Journal of acquired immune deficiency syndromes (1999), 2006, Feb-01, Volume: 41, Issue:2

    Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies;

2006
Nevirapine-related adverse events in a patient receiving a fixed-drug combination pill.
    Journal of the National Medical Association, 2005, Volume: 97, Issue:12

    Topics: Adult; Anti-HIV Agents; Drug Combinations; Exanthema; Female; HIV Infections; Humans; Nevirapine; Re

2005
Nevirapine-related adverse events in a patient receiving a fixed-drug combination pill.
    Journal of the National Medical Association, 2005, Volume: 97, Issue:12

    Topics: Adult; Anti-HIV Agents; Drug Combinations; Exanthema; Female; HIV Infections; Humans; Nevirapine; Re

2005
HIV and pregnancy at the 12 CROI.
    The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 2005, Volume: 17, Issue:2

    Topics: AIDS Serodiagnosis; Diabetes, Gestational; Drug Resistance, Viral; Female; HIV Infections; HIV Prote

2005
HIV and pregnancy at the 12 CROI.
    The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 2005, Volume: 17, Issue:2

    Topics: AIDS Serodiagnosis; Diabetes, Gestational; Drug Resistance, Viral; Female; HIV Infections; HIV Prote

2005
Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1.
    The Journal of infectious diseases, 2006, Feb-15, Volume: 193, Issue:4

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2006
Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1.
    The Journal of infectious diseases, 2006, Feb-15, Volume: 193, Issue:4

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2006
Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire.
    The Journal of infectious diseases, 2006, Feb-15, Volume: 193, Issue:4

    Topics: Cote d'Ivoire; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hum

2006
Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire.
    The Journal of infectious diseases, 2006, Feb-15, Volume: 193, Issue:4

    Topics: Cote d'Ivoire; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hum

2006
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.
    Antiviral therapy, 2005, Volume: 10, Issue:8

    Topics: Anti-Infective Agents; Antibiotics, Antitubercular; Female; HIV Infections; Humans; Male; Middle Age

2005
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.
    Antiviral therapy, 2005, Volume: 10, Issue:8

    Topics: Anti-Infective Agents; Antibiotics, Antitubercular; Female; HIV Infections; Humans; Male; Middle Age

2005
[Cutaneous drug-reactions to nevirapine: study of risk factors in 101 HIV-infected patients].
    Annales de dermatologie et de venereologie, 2005, Volume: 132, Issue:12 Pt 1

    Topics: Adult; Antiretroviral Therapy, Highly Active; Drug Eruptions; Female; HIV Infections; Humans; Male;

2005
[Cutaneous drug-reactions to nevirapine: study of risk factors in 101 HIV-infected patients].
    Annales de dermatologie et de venereologie, 2005, Volume: 132, Issue:12 Pt 1

    Topics: Adult; Antiretroviral Therapy, Highly Active; Drug Eruptions; Female; HIV Infections; Humans; Male;

2005
Concerns regarding a randomized trial of two postexposure prophylaxis regimens.
    AIDS (London, England), 2006, Feb-28, Volume: 20, Issue:4

    Topics: Anti-HIV Agents; Bottle Feeding; Breast Feeding; HIV Infections; Humans; Infant; Infectious Disease

2006
Concerns regarding a randomized trial of two postexposure prophylaxis regimens.
    AIDS (London, England), 2006, Feb-28, Volume: 20, Issue:4

    Topics: Anti-HIV Agents; Bottle Feeding; Breast Feeding; HIV Infections; Humans; Infant; Infectious Disease

2006
The value of contraception to prevent perinatal HIV transmission.
    Sexually transmitted diseases, 2006, Volume: 33, Issue:6

    Topics: Adolescent; Adult; Africa South of the Sahara; Anti-HIV Agents; Contraception; Cost-Benefit Analysis

2006
The value of contraception to prevent perinatal HIV transmission.
    Sexually transmitted diseases, 2006, Volume: 33, Issue:6

    Topics: Adolescent; Adult; Africa South of the Sahara; Anti-HIV Agents; Contraception; Cost-Benefit Analysis

2006
Transmission of human immunodeficiency virus type 1 nevirapine resistance mutation K103N from a treatment-naive mother to her child.
    The Pediatric infectious disease journal, 2006, Volume: 25, Issue:3

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Fatal Outcome; Female; HIV Infections; HIV-1; Humans; Infan

2006
Transmission of human immunodeficiency virus type 1 nevirapine resistance mutation K103N from a treatment-naive mother to her child.
    The Pediatric infectious disease journal, 2006, Volume: 25, Issue:3

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Fatal Outcome; Female; HIV Infections; HIV-1; Humans; Infan

2006
The controversies of nevirapine for preventing mother-to-child HIV transmission.
    AIDS (London, England), 2006, Jan-09, Volume: 20, Issue:2

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2006
The controversies of nevirapine for preventing mother-to-child HIV transmission.
    AIDS (London, England), 2006, Jan-09, Volume: 20, Issue:2

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2006
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
    AIDS research and human retroviruses, 2006, Volume: 22, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Cyclopropanes; Female; HIV Infectio

2006
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
    AIDS research and human retroviruses, 2006, Volume: 22, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Cyclopropanes; Female; HIV Infectio

2006
Unrecognized near-fatal hyperlactatemia in an HIV-infected infant exposed to nucleoside reverse transcriptase inhibitors.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2007, Volume: 11, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Lactates; Lamivudine; Male; Mitoch

2007
Unrecognized near-fatal hyperlactatemia in an HIV-infected infant exposed to nucleoside reverse transcriptase inhibitors.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2007, Volume: 11, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Lactates; Lamivudine; Male; Mitoch

2007
Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.
    AIDS (London, England), 2006, Apr-24, Volume: 20, Issue:7

    Topics: Anti-HIV Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Female; Gene Freq

2006
Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.
    AIDS (London, England), 2006, Apr-24, Volume: 20, Issue:7

    Topics: Anti-HIV Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Female; Gene Freq

2006
This is no time to stop use of nevarapine to prevent mother-to-child transmission of HIV.
    AIDS (London, England), 2006, Apr-24, Volume: 20, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant, Newborn; Infectious

2006
This is no time to stop use of nevarapine to prevent mother-to-child transmission of HIV.
    AIDS (London, England), 2006, Apr-24, Volume: 20, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant, Newborn; Infectious

2006
Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients.
    AIDS research and human retroviruses, 2006, Volume: 22, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chi-Square Distribution; Cholesterol, HDL; Clinical Tr

2006
Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients.
    AIDS research and human retroviruses, 2006, Volume: 22, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chi-Square Distribution; Cholesterol, HDL; Clinical Tr

2006
Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy.
    HIV medicine, 2006, Volume: 7, Issue:4

    Topics: Adolescent; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Chemical and Drug

2006
Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy.
    HIV medicine, 2006, Volume: 7, Issue:4

    Topics: Adolescent; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Chemical and Drug

2006
Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:1

    Topics: Administration, Oral; Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Drug Administration Sched

2006
Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:1

    Topics: Administration, Oral; Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Drug Administration Sched

2006
Cost-effectiveness of HIV rescreening during late pregnancy to prevent mother-to-child HIV transmission in South Africa and other resource-limited settings.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:2

    Topics: Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Female; HIV Infection

2006
Cost-effectiveness of HIV rescreening during late pregnancy to prevent mother-to-child HIV transmission in South Africa and other resource-limited settings.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:2

    Topics: Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Female; HIV Infection

2006
Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.
    Proceedings of the National Academy of Sciences of the United States of America, 2006, May-02, Volume: 103, Issue:18

    Topics: Adult; Alleles; Anti-HIV Agents; Child; Drug Resistance, Microbial; Female; Genotype; HIV Infections

2006
Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.
    Proceedings of the National Academy of Sciences of the United States of America, 2006, May-02, Volume: 103, Issue:18

    Topics: Adult; Alleles; Anti-HIV Agents; Child; Drug Resistance, Microbial; Female; Genotype; HIV Infections

2006
Prevention of mother-to-child transmission of HIV in Cameroon: experiences from the University Teaching Hospital in Yaounde (Cameroon).
    Zentralblatt fur Gynakologie, 2006, Volume: 128, Issue:2

    Topics: Administration, Oral; Anti-HIV Agents; Cameroon; Developing Countries; Female; Follow-Up Studies; HI

2006
Prevention of mother-to-child transmission of HIV in Cameroon: experiences from the University Teaching Hospital in Yaounde (Cameroon).
    Zentralblatt fur Gynakologie, 2006, Volume: 128, Issue:2

    Topics: Administration, Oral; Anti-HIV Agents; Cameroon; Developing Countries; Female; Follow-Up Studies; HI

2006
Severe liver disease associated with prolonged exposure to antiretroviral drugs.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Ascites; Budd-Chiari Syndrome; Case-C

2006
Severe liver disease associated with prolonged exposure to antiretroviral drugs.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Ascites; Budd-Chiari Syndrome; Case-C

2006
Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
    AIDS (London, England), 2006, May-12, Volume: 20, Issue:8

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Developing Coun

2006
Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
    AIDS (London, England), 2006, May-12, Volume: 20, Issue:8

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Developing Coun

2006
Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Jun-15, Volume: 42, Issue:12

    Topics: Adult; Anti-HIV Agents; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Fem

2006
Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Jun-15, Volume: 42, Issue:12

    Topics: Adult; Anti-HIV Agents; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Fem

2006
HIV denialists ignore large gap in the study they cite.
    Nature, 2006, May-25, Volume: 441, Issue:7092

    Topics: Clinical Trials as Topic; Denial, Psychological; Female; History, 20th Century; HIV Infections; HIV

2006
HIV denialists ignore large gap in the study they cite.
    Nature, 2006, May-25, Volume: 441, Issue:7092

    Topics: Clinical Trials as Topic; Denial, Psychological; Female; History, 20th Century; HIV Infections; HIV

2006
Routine intrapartum HIV counseling and testing for prevention of mother-to-child transmission of HIV in a rural Ugandan hospital.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:2

    Topics: Anti-HIV Agents; Counseling; Feasibility Studies; Female; HIV Infections; HIV Seropositivity; Humans

2006
Routine intrapartum HIV counseling and testing for prevention of mother-to-child transmission of HIV in a rural Ugandan hospital.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:2

    Topics: Anti-HIV Agents; Counseling; Feasibility Studies; Female; HIV Infections; HIV Seropositivity; Humans

2006
Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:2

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Revers

2006
Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:2

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Revers

2006
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
    European journal of clinical pharmacology, 2006, Volume: 62, Issue:7

    Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cy

2006
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
    European journal of clinical pharmacology, 2006, Volume: 62, Issue:7

    Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cy

2006
Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D.
    Journal of acquired immune deficiency syndromes (1999), 2006, Aug-15, Volume: 42, Issue:5

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections;

2006
Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D.
    Journal of acquired immune deficiency syndromes (1999), 2006, Aug-15, Volume: 42, Issue:5

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections;

2006
Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Jul-15, Volume: 43, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Drug Interacti

2006
Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Jul-15, Volume: 43, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Drug Interacti

2006
Urine nevirapine as a predictor of antiretroviral adherence.
    The Indian journal of medical research, 2006, Volume: 123, Issue:4

    Topics: Adult; Anti-HIV Agents; Drug Monitoring; Female; Half-Life; HIV Infections; Humans; Male; Middle Age

2006
Urine nevirapine as a predictor of antiretroviral adherence.
    The Indian journal of medical research, 2006, Volume: 123, Issue:4

    Topics: Adult; Anti-HIV Agents; Drug Monitoring; Female; Half-Life; HIV Infections; Humans; Male; Middle Age

2006
Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D.
    Journal of acquired immune deficiency syndromes (1999), 2006, Aug-01, Volume: 42, Issue:4

    Topics: Black People; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vert

2006
Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D.
    Journal of acquired immune deficiency syndromes (1999), 2006, Aug-01, Volume: 42, Issue:4

    Topics: Black People; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vert

2006
In vivo effects of HIV-1 exposure in the presence and absence of single-dose nevirapine on cellular plasma activation markers of infants born to HIV-1-seropositive mothers.
    Journal of acquired immune deficiency syndromes (1999), 2006, Aug-15, Volume: 42, Issue:5

    Topics: Adult; Anti-HIV Agents; beta 2-Microglobulin; Biomarkers; Blood Chemical Analysis; Female; Fetal Blo

2006
In vivo effects of HIV-1 exposure in the presence and absence of single-dose nevirapine on cellular plasma activation markers of infants born to HIV-1-seropositive mothers.
    Journal of acquired immune deficiency syndromes (1999), 2006, Aug-15, Volume: 42, Issue:5

    Topics: Adult; Anti-HIV Agents; beta 2-Microglobulin; Biomarkers; Blood Chemical Analysis; Female; Fetal Blo

2006
Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.
    British journal of clinical pharmacology, 2006, Volume: 62, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breath Tests; Cohort Studies; Cytochr

2006
Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.
    British journal of clinical pharmacology, 2006, Volume: 62, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breath Tests; Cohort Studies; Cytochr

2006
HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.
    AIDS (London, England), 2006, Aug-01, Volume: 20, Issue:12

    Topics: Adolescent; Adult; Drug Hypersensitivity; Female; Gene Frequency; Haplotypes; Hepatitis C; Histocomp

2006
HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.
    AIDS (London, England), 2006, Aug-01, Volume: 20, Issue:12

    Topics: Adolescent; Adult; Drug Hypersensitivity; Female; Gene Frequency; Haplotypes; Hepatitis C; Histocomp

2006
Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles.
    AIDS patient care and STDs, 2006, Volume: 20, Issue:8

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Dyslipidemias; Female; HIV Infections; Humans; Lipids;

2006
Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles.
    AIDS patient care and STDs, 2006, Volume: 20, Issue:8

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Dyslipidemias; Female; HIV Infections; Humans; Lipids;

2006
Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine.
    HIV medicine, 2006, Volume: 7, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol; Cyclopropanes; Drug Therapy, Combination; HIV I

2006
Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine.
    HIV medicine, 2006, Volume: 7, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol; Cyclopropanes; Drug Therapy, Combination; HIV I

2006
Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash.
    HIV medicine, 2006, Volume: 7, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Exanthema; Female; HIV

2006
Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash.
    HIV medicine, 2006, Volume: 7, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Exanthema; Female; HIV

2006
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Sep-15, Volume: 43, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Case-Control Studies;

2006
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Sep-15, Volume: 43, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Case-Control Studies;

2006
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Sep-15, Volume: 43, Issue:6

    Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Chemical and Drug Induc

2006
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Sep-15, Volume: 43, Issue:6

    Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Chemical and Drug Induc

2006
Outcome of different nevirapine administration strategies in preventing mother-to-child transmission (PMTCT) programs in Tanzania and Uganda.
    MedGenMed : Medscape general medicine, 2006, Apr-12, Volume: 8, Issue:2

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; N

2006
Outcome of different nevirapine administration strategies in preventing mother-to-child transmission (PMTCT) programs in Tanzania and Uganda.
    MedGenMed : Medscape general medicine, 2006, Apr-12, Volume: 8, Issue:2

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; N

2006
Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.
    AIDS (London, England), 2006, Aug-22, Volume: 20, Issue:13

    Topics: Amniotic Fluid; Antiretroviral Therapy, Highly Active; Drug Combinations; Drug Interactions; Female;

2006
Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.
    AIDS (London, England), 2006, Aug-22, Volume: 20, Issue:13

    Topics: Amniotic Fluid; Antiretroviral Therapy, Highly Active; Drug Combinations; Drug Interactions; Female;

2006
Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women.
    HIV medicine, 2006, Volume: 7, Issue:5

    Topics: Adult; Antiretroviral Therapy, Highly Active; Black People; CD4 Lymphocyte Count; Cohort Studies; Fe

2006
Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women.
    HIV medicine, 2006, Volume: 7, Issue:5

    Topics: Adult; Antiretroviral Therapy, Highly Active; Black People; CD4 Lymphocyte Count; Cohort Studies; Fe

2006
Rapid HIV testing and counselling in labour in a northern Nigerian setting.
    African journal of reproductive health, 2006, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Counseling; Cross-Sectional Studies; Female; HIV Infections; HIV

2006
Rapid HIV testing and counselling in labour in a northern Nigerian setting.
    African journal of reproductive health, 2006, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Counseling; Cross-Sectional Studies; Female; HIV Infections; HIV

2006
Stability of nevirapine suspension in prefilled oral syringes used for reduction of mother-to-child HIV transmission.
    Journal of acquired immune deficiency syndromes (1999), 2006, Nov-01, Volume: 43, Issue:3

    Topics: Administration, Oral; Anti-HIV Agents; Drug Packaging; Drug Stability; Drug Storage; Female; HIV Inf

2006
Stability of nevirapine suspension in prefilled oral syringes used for reduction of mother-to-child HIV transmission.
    Journal of acquired immune deficiency syndromes (1999), 2006, Nov-01, Volume: 43, Issue:3

    Topics: Administration, Oral; Anti-HIV Agents; Drug Packaging; Drug Stability; Drug Storage; Female; HIV Inf

2006
Implementation of single-dose nevirapine for prevention of MTCT of HIV--lessons from Cape Town.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2006, Volume: 96, Issue:8

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Guideline Adherence; Health Planning; HIV Inf

2006
Implementation of single-dose nevirapine for prevention of MTCT of HIV--lessons from Cape Town.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2006, Volume: 96, Issue:8

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Guideline Adherence; Health Planning; HIV Inf

2006
Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    AIDS (London, England), 2006, Oct-24, Volume: 20, Issue:16

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2006
Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    AIDS (London, England), 2006, Oct-24, Volume: 20, Issue:16

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2006
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.
    British journal of clinical pharmacology, 2006, Volume: 62, Issue:5

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Pregnancy; Pr

2006
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.
    British journal of clinical pharmacology, 2006, Volume: 62, Issue:5

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Pregnancy; Pr

2006
Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl.
    AIDS (London, England), 2006, Nov-14, Volume: 20, Issue:17

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count;

2006
Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl.
    AIDS (London, England), 2006, Nov-14, Volume: 20, Issue:17

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count;

2006
Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2007, Feb-01, Volume: 44, Issue:2

    Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV; HIV Infections

2007
Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2007, Feb-01, Volume: 44, Issue:2

    Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV; HIV Infections

2007
Liver transplantation for fulminant hepatitis related to nevirapine therapy.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2006, Volume: 12, Issue:12

    Topics: Adult; Anti-HIV Agents; Female; Hepatitis; HIV Infections; HIV-1; Humans; Liver Failure, Acute; Live

2006
Liver transplantation for fulminant hepatitis related to nevirapine therapy.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2006, Volume: 12, Issue:12

    Topics: Adult; Anti-HIV Agents; Female; Hepatitis; HIV Infections; HIV-1; Humans; Liver Failure, Acute; Live

2006
Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jan-01, Volume: 44, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Administratio

2007
Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jan-01, Volume: 44, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Administratio

2007
Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jan-01, Volume: 44, Issue:1

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combinati

2007
Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jan-01, Volume: 44, Issue:1

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combinati

2007
The ethics of placebo-controlled studies on perinatal HIV transmission and its treatment in the developing world.
    Penn bioethics journal, 2006,Spring, Volume: 2, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; Control Groups; Controlled Clinical Trials as Topic; Developing Cou

2006
The ethics of placebo-controlled studies on perinatal HIV transmission and its treatment in the developing world.
    Penn bioethics journal, 2006,Spring, Volume: 2, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; Control Groups; Controlled Clinical Trials as Topic; Developing Cou

2006
Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jan-15, Volume: 44, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Body Weight; CD4 Ly

2007
Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jan-15, Volume: 44, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Body Weight; CD4 Ly

2007
HLA-Cw8 primarily associated with hypersensitivity to nevirapine.
    AIDS (London, England), 2007, Jan-11, Volume: 21, Issue:2

    Topics: Adult; Anti-HIV Agents; Drug Hypersensitivity; Female; Genetic Predisposition to Disease; HIV Infect

2007
HLA-Cw8 primarily associated with hypersensitivity to nevirapine.
    AIDS (London, England), 2007, Jan-11, Volume: 21, Issue:2

    Topics: Adult; Anti-HIV Agents; Drug Hypersensitivity; Female; Genetic Predisposition to Disease; HIV Infect

2007
Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Feb-01, Volume: 44, Issue:3

    Topics: Adult; Cohort Studies; Developing Countries; Drug Resistance, Multiple, Viral; Drug Therapy, Combina

2007
Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Feb-01, Volume: 44, Issue:3

    Topics: Adult; Cohort Studies; Developing Countries; Drug Resistance, Multiple, Viral; Drug Therapy, Combina

2007
Drug resistance after failure of initial antiretroviral therapy in resource-limited countries.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Feb-01, Volume: 44, Issue:3

    Topics: Developing Countries; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; H

2007
Drug resistance after failure of initial antiretroviral therapy in resource-limited countries.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Feb-01, Volume: 44, Issue:3

    Topics: Developing Countries; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; H

2007
Estimation of the rate of mother to child transmission of HIV in Nigeria.
    African journal of medicine and medical sciences, 2006, Volume: 35, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Female; HIV Infecti

2006
Estimation of the rate of mother to child transmission of HIV in Nigeria.
    African journal of medicine and medical sciences, 2006, Volume: 35, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Female; HIV Infecti

2006
Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort.
    The Journal of antimicrobial chemotherapy, 2007, Volume: 59, Issue:3

    Topics: Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Administration Schedule; Female;

2007
Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort.
    The Journal of antimicrobial chemotherapy, 2007, Volume: 59, Issue:3

    Topics: Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Administration Schedule; Female;

2007
A model of directional selection applied to the evolution of drug resistance in HIV-1.
    Molecular biology and evolution, 2007, Volume: 24, Issue:4

    Topics: Anti-HIV Agents; Codon; Computer Simulation; Drug Resistance, Viral; Evolution, Molecular; Female; G

2007
A model of directional selection applied to the evolution of drug resistance in HIV-1.
    Molecular biology and evolution, 2007, Volume: 24, Issue:4

    Topics: Anti-HIV Agents; Codon; Computer Simulation; Drug Resistance, Viral; Evolution, Molecular; Female; G

2007
Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
    Journal of acquired immune deficiency syndromes (1999), 2007, Apr-01, Volume: 44, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, H

2007
Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
    Journal of acquired immune deficiency syndromes (1999), 2007, Apr-01, Volume: 44, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, H

2007
Survival in women exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV: a stochastic model.
    The Journal of infectious diseases, 2007, Mar-15, Volume: 195, Issue:6

    Topics: Africa South of the Sahara; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infect

2007
Survival in women exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV: a stochastic model.
    The Journal of infectious diseases, 2007, Mar-15, Volume: 195, Issue:6

    Topics: Africa South of the Sahara; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infect

2007
Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database.
    HIV medicine, 2007, Volume: 8, Issue:1

    Topics: Adult; Anti-HIV Agents; Asia; Australia; Drug Therapy, Combination; Female; HIV Infections; Humans;

2007
Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database.
    HIV medicine, 2007, Volume: 8, Issue:1

    Topics: Adult; Anti-HIV Agents; Asia; Australia; Drug Therapy, Combination; Female; HIV Infections; Humans;

2007
The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience.
    Nigerian journal of clinical practice, 2006, Volume: 9, Issue:2

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymp

2006
The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience.
    Nigerian journal of clinical practice, 2006, Volume: 9, Issue:2

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymp

2006
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.
    The Journal of infectious diseases, 2007, Apr-01, Volume: 195, Issue:7

    Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Monitoring; F

2007
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.
    The Journal of infectious diseases, 2007, Apr-01, Volume: 195, Issue:7

    Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Monitoring; F

2007
Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort.
    The Journal of the Association of Physicians of India, 2006, Volume: 54

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Ther

2006
Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort.
    The Journal of the Association of Physicians of India, 2006, Volume: 54

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Ther

2006
Nevirapine-induced fulminant hepatitis.
    The Journal of the Association of Physicians of India, 2006, Volume: 54

    Topics: Adult; Anti-Retroviral Agents; Fatal Outcome; HIV Infections; Humans; Liver Failure, Acute; Male; Ne

2006
Nevirapine-induced fulminant hepatitis.
    The Journal of the Association of Physicians of India, 2006, Volume: 54

    Topics: Adult; Anti-Retroviral Agents; Fatal Outcome; HIV Infections; Humans; Liver Failure, Acute; Male; Ne

2006
Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.
    HIV medicine, 2007, Volume: 8, Issue:2

    Topics: Adult; Aryl Hydrocarbon Hydroxylases; Cohort Studies; Cytochrome P-450 CYP2B6; Female; Genotype; HIV

2007
Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.
    HIV medicine, 2007, Volume: 8, Issue:2

    Topics: Adult; Aryl Hydrocarbon Hydroxylases; Cohort Studies; Cytochrome P-450 CYP2B6; Female; Genotype; HIV

2007
Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
    BMC infectious diseases, 2007, Mar-12, Volume: 7

    Topics: Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dru

2007
Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
    BMC infectious diseases, 2007, Mar-12, Volume: 7

    Topics: Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dru

2007
Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2007, Volume: 90, Issue:2

    Topics: Adult; Anti-Retroviral Agents; Drug Combinations; Drugs, Generic; Female; HIV Infections; Humans; La

2007
Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2007, Volume: 90, Issue:2

    Topics: Adult; Anti-Retroviral Agents; Drug Combinations; Drugs, Generic; Female; HIV Infections; Humans; La

2007
[Vitiligo in a black patient associated with HIV infection and repigmentation under antiretroviral therapy].
    Annales de dermatologie et de venereologie, 2007, Volume: 134, Issue:3 Pt 1

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lamivudine; Nevirapine; Treatment Outcome; V

2007
[Vitiligo in a black patient associated with HIV infection and repigmentation under antiretroviral therapy].
    Annales de dermatologie et de venereologie, 2007, Volume: 134, Issue:3 Pt 1

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lamivudine; Nevirapine; Treatment Outcome; V

2007
Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.
    AIDS (London, England), 2007, Mar-30, Volume: 21, Issue:6

    Topics: Adult; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male;

2007
Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.
    AIDS (London, England), 2007, Mar-30, Volume: 21, Issue:6

    Topics: Adult; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male;

2007
Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine.
    AIDS (London, England), 2007, May-11, Volume: 21, Issue:8

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Administra

2007
Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine.
    AIDS (London, England), 2007, May-11, Volume: 21, Issue:8

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Administra

2007
Expanded services for the prevention of mother-to-child HIV transmission: field acceptability of a pilot program in Lusaka, Zambia.
    Journal of acquired immune deficiency syndromes (1999), 2007, May-01, Volume: 45, Issue:1

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cities; Drug Therapy, Combination; Female; HIV Infections; Hu

2007
Expanded services for the prevention of mother-to-child HIV transmission: field acceptability of a pilot program in Lusaka, Zambia.
    Journal of acquired immune deficiency syndromes (1999), 2007, May-01, Volume: 45, Issue:1

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cities; Drug Therapy, Combination; Female; HIV Infections; Hu

2007
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
    Journal of acquired immune deficiency syndromes (1999), 2007, May-01, Volume: 45, Issue:1

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black

2007
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
    Journal of acquired immune deficiency syndromes (1999), 2007, May-01, Volume: 45, Issue:1

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black

2007
Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.
    European journal of clinical pharmacology, 2007, Volume: 63, Issue:7

    Topics: Adult; Analgesics, Opioid; Analysis of Variance; Anti-HIV Agents; Area Under Curve; Drug Interaction

2007
Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.
    European journal of clinical pharmacology, 2007, Volume: 63, Issue:7

    Topics: Adult; Analgesics, Opioid; Analysis of Variance; Anti-HIV Agents; Area Under Curve; Drug Interaction

2007
Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia.
    Antiviral therapy, 2007, Volume: 12, Issue:2

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Drug Combinations; Dr

2007
Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia.
    Antiviral therapy, 2007, Volume: 12, Issue:2

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Drug Combinations; Dr

2007
Home deliveries: implications for adherence to nevirapine in a PMTCT programme in rural Malawi.
    AIDS care, 2007, Volume: 19, Issue:5

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Delivery, Obstetric; Female; HIV Infections; Home Childbi

2007
Home deliveries: implications for adherence to nevirapine in a PMTCT programme in rural Malawi.
    AIDS care, 2007, Volume: 19, Issue:5

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Delivery, Obstetric; Female; HIV Infections; Home Childbi

2007
Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jun-15, Volume: 44, Issue:12

    Topics: Adolescent; Adult; Africa, Western; Antiretroviral Therapy, Highly Active; Europe; Female; HIV Infec

2007
Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jun-15, Volume: 44, Issue:12

    Topics: Adolescent; Adult; Africa, Western; Antiretroviral Therapy, Highly Active; Europe; Female; HIV Infec

2007
Delaying maternal NVP-based ART more effective.
    IAPAC monthly, 2007, Volume: 13, Issue:1

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr

2007
Delaying maternal NVP-based ART more effective.
    IAPAC monthly, 2007, Volume: 13, Issue:1

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr

2007
Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity.
    International journal of STD & AIDS, 2007, Volume: 18, Issue:5

    Topics: Adolescent; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyt

2007
Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity.
    International journal of STD & AIDS, 2007, Volume: 18, Issue:5

    Topics: Adolescent; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyt

2007
Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:5

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Feasibility Studies; Fema

2007
Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:5

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Feasibility Studies; Fema

2007
Antiretroviral therapy in children: Indian experience.
    Indian pediatrics, 2007, Volume: 44, Issue:5

    Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Drug Therapy

2007
Antiretroviral therapy in children: Indian experience.
    Indian pediatrics, 2007, Volume: 44, Issue:5

    Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Drug Therapy

2007
Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in kampala, Uganda.
    Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 2007, Volume: 6, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV Infections; Humans

2007
Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in kampala, Uganda.
    Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 2007, Volume: 6, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV Infections; Humans

2007
Safety of HIV-1 Perinatal Transmission Prophylaxis With Zidovudine and Nevirapine in Rural South India.
    Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 2007, Volume: 6, Issue:2

    Topics: Anti-HIV Agents; Cohort Studies; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmiss

2007
Safety of HIV-1 Perinatal Transmission Prophylaxis With Zidovudine and Nevirapine in Rural South India.
    Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 2007, Volume: 6, Issue:2

    Topics: Anti-HIV Agents; Cohort Studies; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmiss

2007
Dynamics of 103K/N and 184M/V HIV-1 drug resistant populations: relative comparison in plasma virus RNA versus CD45RO+T cell proviral DNA.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2007, Volume: 39, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Drug Ther

2007
Dynamics of 103K/N and 184M/V HIV-1 drug resistant populations: relative comparison in plasma virus RNA versus CD45RO+T cell proviral DNA.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2007, Volume: 39, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Drug Ther

2007
Surveillance of mother-to-child transmission prevention programmes at immunization clinics: the case for universal screening.
    AIDS (London, England), 2007, Jun-19, Volume: 21, Issue:10

    Topics: Adolescent; Adult; Ambulatory Care Facilities; Anti-HIV Agents; Drug Administration Schedule; Female

2007
Surveillance of mother-to-child transmission prevention programmes at immunization clinics: the case for universal screening.
    AIDS (London, England), 2007, Jun-19, Volume: 21, Issue:10

    Topics: Adolescent; Adult; Ambulatory Care Facilities; Anti-HIV Agents; Drug Administration Schedule; Female

2007
Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
    HIV medicine, 2007, Volume: 8, Issue:5

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; British Columbia; CD4 Lymphocyte Count; Coho

2007
Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
    HIV medicine, 2007, Volume: 8, Issue:5

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; British Columbia; CD4 Lymphocyte Count; Coho

2007
Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies.
    Journal of clinical microbiology, 2007, Volume: 45, Issue:8

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Hum

2007
Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies.
    Journal of clinical microbiology, 2007, Volume: 45, Issue:8

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Hum

2007
Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect?
    AIDS (London, England), 2007, Jul-11, Volume: 21, Issue:11

    Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur

2007
Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect?
    AIDS (London, England), 2007, Jul-11, Volume: 21, Issue:11

    Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur

2007
Safety issues about nevirapine administration in HIV-infected pregnant women.
    Journal of acquired immune deficiency syndromes (1999), 2007, Jul-01, Volume: 45, Issue:3

    Topics: Adult; Anti-HIV Agents; Bilirubin; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Con

2007
Safety issues about nevirapine administration in HIV-infected pregnant women.
    Journal of acquired immune deficiency syndromes (1999), 2007, Jul-01, Volume: 45, Issue:3

    Topics: Adult; Anti-HIV Agents; Bilirubin; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Con

2007
Most common prescribing error in postexposure prophylaxis of HIV/AIDS.
    The Journal of the Association of Physicians of India, 2007, Volume: 55

    Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Therapy, Combination; Female; HIV Infections; Humans; I

2007
Most common prescribing error in postexposure prophylaxis of HIV/AIDS.
    The Journal of the Association of Physicians of India, 2007, Volume: 55

    Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Therapy, Combination; Female; HIV Infections; Humans; I

2007
Persistence of nevirapine in breast milk after discontinuation of treatment.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Aug-01, Volume: 45, Issue:3

    Topics: Anti-HIV Agents; Female; Functional Laterality; HIV Infections; Humans; Milk, Human; Nevirapine; Pre

2007
Persistence of nevirapine in breast milk after discontinuation of treatment.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Aug-01, Volume: 45, Issue:3

    Topics: Anti-HIV Agents; Female; Functional Laterality; HIV Infections; Humans; Milk, Human; Nevirapine; Pre

2007
Effect of exposure to clinic-based health education interventions on behavioural intention to prevent mother-to-child transmission of HIV infection.
    SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance, 2006, Volume: 3, Issue:1

    Topics: Adolescent; Adult; Catchment Area, Health; Condoms; Cross-Sectional Studies; Female; Health Behavior

2006
Effect of exposure to clinic-based health education interventions on behavioural intention to prevent mother-to-child transmission of HIV infection.
    SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance, 2006, Volume: 3, Issue:1

    Topics: Adolescent; Adult; Catchment Area, Health; Condoms; Cross-Sectional Studies; Female; Health Behavior

2006
Uncomplicated outcome after an accidental overdose of nevirapine in a newborn.
    European journal of pediatrics, 2008, Volume: 167, Issue:6

    Topics: Anti-HIV Agents; Drug Overdose; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, New

2008
Uncomplicated outcome after an accidental overdose of nevirapine in a newborn.
    European journal of pediatrics, 2008, Volume: 167, Issue:6

    Topics: Anti-HIV Agents; Drug Overdose; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, New

2008
Immunochromatographic strip test for rapid detection of nevirapine in plasma samples from human immunodeficiency virus-infected patients.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9

    Topics: Adult; Anti-HIV Agents; Chromatography; Chromatography, High Pressure Liquid; Drug Monitoring; Femal

2007
Immunochromatographic strip test for rapid detection of nevirapine in plasma samples from human immunodeficiency virus-infected patients.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:9

    Topics: Adult; Anti-HIV Agents; Chromatography; Chromatography, High Pressure Liquid; Drug Monitoring; Femal

2007
Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
    Archives of virology, 2007, Volume: 152, Issue:10

    Topics: Adult; Amino Acid Sequence; China; Cohort Studies; Consensus Sequence; Databases, Factual; Drug Resi

2007
Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
    Archives of virology, 2007, Volume: 152, Issue:10

    Topics: Adult; Amino Acid Sequence; China; Cohort Studies; Consensus Sequence; Databases, Factual; Drug Resi

2007
Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
    AIDS (London, England), 2007, Jul-31, Volume: 21, Issue:12

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dru

2007
Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
    AIDS (London, England), 2007, Jul-31, Volume: 21, Issue:12

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dru

2007
HIV variants of low frequency may have a big impact.
    The AIDS reader, 2007, Volume: 17, Issue:6

    Topics: Animals; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Nevirapine; Reverse Transcri

2007
HIV variants of low frequency may have a big impact.
    The AIDS reader, 2007, Volume: 17, Issue:6

    Topics: Animals; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Nevirapine; Reverse Transcri

2007
[Efficacy and tolerance of non nucleosidic reverse transcriptase inhibitors containing tritherapy in HIV-1 infection].
    Dakar medical, 2005, Volume: 50, Issue:3

    Topics: Adolescent; Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Drug Combinations; Female; HIV Infect

2005
[Efficacy and tolerance of non nucleosidic reverse transcriptase inhibitors containing tritherapy in HIV-1 infection].
    Dakar medical, 2005, Volume: 50, Issue:3

    Topics: Adolescent; Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Drug Combinations; Female; HIV Infect

2005
Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Aug-15, Volume: 45, Issue:4

    Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lactic Acid; Lamivudine; M

2007
Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Aug-15, Volume: 45, Issue:4

    Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lactic Acid; Lamivudine; M

2007
Operational effectiveness of single-dose nevirapine in preventing mother-to-child transmission of HIV.
    Bulletin of the World Health Organization, 2007, Volume: 85, Issue:6

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Female; Health Services Accessibility; HIV Inf

2007
Operational effectiveness of single-dose nevirapine in preventing mother-to-child transmission of HIV.
    Bulletin of the World Health Organization, 2007, Volume: 85, Issue:6

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Female; Health Services Accessibility; HIV Inf

2007
Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
    HIV medicine, 2007, Volume: 8, Issue:6

    Topics: Antiretroviral Therapy, Highly Active; Drug Eruptions; Female; HIV Infections; Humans; Infectious Di

2007
Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
    HIV medicine, 2007, Volume: 8, Issue:6

    Topics: Antiretroviral Therapy, Highly Active; Drug Eruptions; Female; HIV Infections; Humans; Infectious Di

2007
Development of a highly efficient extraction technique and specific multiplex assay for measuring antiretroviral drug concentrations in breast milk.
    Therapeutic drug monitoring, 2007, Volume: 29, Issue:4

    Topics: Chromatography, High Pressure Liquid; Female; HIV Infections; Humans; Infectious Disease Transmissio

2007
Development of a highly efficient extraction technique and specific multiplex assay for measuring antiretroviral drug concentrations in breast milk.
    Therapeutic drug monitoring, 2007, Volume: 29, Issue:4

    Topics: Chromatography, High Pressure Liquid; Female; HIV Infections; Humans; Infectious Disease Transmissio

2007
Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
    Antiviral therapy, 2007, Volume: 12, Issue:4

    Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Drug Administr

2007
Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
    Antiviral therapy, 2007, Volume: 12, Issue:4

    Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Drug Administr

2007
African infants' CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine.
    AIDS (London, England), 2007, Aug-20, Volume: 21, Issue:13

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Chemok

2007
African infants' CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine.
    AIDS (London, England), 2007, Aug-20, Volume: 21, Issue:13

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Chemok

2007
Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification.
    AIDS (London, England), 2007, Aug-20, Volume: 21, Issue:13

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; Hum

2007
Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification.
    AIDS (London, England), 2007, Aug-20, Volume: 21, Issue:13

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; Hum

2007
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.
    Journal of acquired immune deficiency syndromes (1999), 2007, Oct-01, Volume: 46, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Developing Countr

2007
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.
    Journal of acquired immune deficiency syndromes (1999), 2007, Oct-01, Volume: 46, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Developing Countr

2007
Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
    PLoS medicine, 2007, Volume: 4, Issue:8

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Cohort

2007
Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
    PLoS medicine, 2007, Volume: 4, Issue:8

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Cohort

2007
Diffuse interstitial pulmonary opacities induced by nevirapine.
    AIDS (London, England), 2007, Sep-12, Volume: 21, Issue:14

    Topics: Antiretroviral Therapy, Highly Active; HIV Infections; HIV-1; Humans; Lung Diseases, Interstitial; M

2007
Diffuse interstitial pulmonary opacities induced by nevirapine.
    AIDS (London, England), 2007, Sep-12, Volume: 21, Issue:14

    Topics: Antiretroviral Therapy, Highly Active; HIV Infections; HIV-1; Humans; Lung Diseases, Interstitial; M

2007
Widespread vitiligo after erythroderma caused by nevirapine in a patient with AIDS.
    Acta dermato-venereologica, 2007, Volume: 87, Issue:5

    Topics: Adult; Dermatitis, Exfoliative; Facial Dermatoses; HIV Infections; Humans; Male; Nevirapine; Reverse

2007
Widespread vitiligo after erythroderma caused by nevirapine in a patient with AIDS.
    Acta dermato-venereologica, 2007, Volume: 87, Issue:5

    Topics: Adult; Dermatitis, Exfoliative; Facial Dermatoses; HIV Infections; Humans; Male; Nevirapine; Reverse

2007
Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:8

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; M

2007
Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:8

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; M

2007
Human immunodeficiency virus infection in a child presenting as herpes zoster ophthalmicus.
    Journal of the Indian Medical Association, 2007, Volume: 105, Issue:4

    Topics: Acyclovir; Child; Eye Diseases; Herpes Zoster Ophthalmicus; HIV Infections; Humans; Lamivudine; Male

2007
Human immunodeficiency virus infection in a child presenting as herpes zoster ophthalmicus.
    Journal of the Indian Medical Association, 2007, Volume: 105, Issue:4

    Topics: Acyclovir; Child; Eye Diseases; Herpes Zoster Ophthalmicus; HIV Infections; Humans; Lamivudine; Male

2007
Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
    Pediatrics, 2007, Volume: 120, Issue:4

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Weight; CD4 Lymphocyte Coun

2007
Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
    Pediatrics, 2007, Volume: 120, Issue:4

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Weight; CD4 Lymphocyte Coun

2007
Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine.
    AIDS (London, England), 2007, Oct-01, Volume: 21, Issue:15

    Topics: Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infectious Disease

2007
Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine.
    AIDS (London, England), 2007, Oct-01, Volume: 21, Issue:15

    Topics: Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infectious Disease

2007
Effect of anticoagulants on plasma nevirapine and efavirenz concentrations.
    Therapeutic drug monitoring, 2007, Volume: 29, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Anticoagulants; Benzoxazines; Cyclopropanes; Drug Monitoring; Edeti

2007
Effect of anticoagulants on plasma nevirapine and efavirenz concentrations.
    Therapeutic drug monitoring, 2007, Volume: 29, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Anticoagulants; Benzoxazines; Cyclopropanes; Drug Monitoring; Edeti

2007
Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting.
    AIDS patient care and STDs, 2007, Volume: 21, Issue:10

    Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination;

2007
Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting.
    AIDS patient care and STDs, 2007, Volume: 21, Issue:10

    Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination;

2007
Regression of a cervical spinal mass following highly active antiretroviral therapy (HAART) in child with advanced human immunodeficiency virus (HIV) disease.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2007, Volume: 90, Issue:9

    Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cervical Vertebrae; Child; Disease Pr

2007
Regression of a cervical spinal mass following highly active antiretroviral therapy (HAART) in child with advanced human immunodeficiency virus (HIV) disease.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2007, Volume: 90, Issue:9

    Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cervical Vertebrae; Child; Disease Pr

2007
[Treatment of children born of AIDS mothers in Tsevie hospital regional center, Togo].
    Bulletin de la Societe de pathologie exotique (1990), 2007, Volume: 100, Issue:4

    Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Breast Feeding; Child Health Services; Femal

2007
[Treatment of children born of AIDS mothers in Tsevie hospital regional center, Togo].
    Bulletin de la Societe de pathologie exotique (1990), 2007, Volume: 100, Issue:4

    Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Breast Feeding; Child Health Services; Femal

2007
Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection.
    The Pediatric infectious disease journal, 2007, Volume: 26, Issue:11

    Topics: Anti-HIV Agents; Child; Drug Hypersensitivity; Eosinophilia; Exanthema; Female; HIV Infections; HIV-

2007
Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection.
    The Pediatric infectious disease journal, 2007, Volume: 26, Issue:11

    Topics: Anti-HIV Agents; Child; Drug Hypersensitivity; Eosinophilia; Exanthema; Female; HIV Infections; HIV-

2007
Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine.
    Lancet (London, England), 2007, Nov-17, Volume: 370, Issue:9600

    Topics: Anti-HIV Agents; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; I

2007
Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine.
    Lancet (London, England), 2007, Nov-17, Volume: 370, Issue:9600

    Topics: Anti-HIV Agents; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; I

2007
Dandy-Walker variant in an infant prenatally exposed to antiretroviral medication.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2007, Volume: 97, Issue:10

    Topics: Adult; Anti-Retroviral Agents; Dandy-Walker Syndrome; Female; Heart Ventricles; HIV Infections; Huma

2007
Dandy-Walker variant in an infant prenatally exposed to antiretroviral medication.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2007, Volume: 97, Issue:10

    Topics: Adult; Anti-Retroviral Agents; Dandy-Walker Syndrome; Female; Heart Ventricles; HIV Infections; Huma

2007
Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL.
    International journal of STD & AIDS, 2007, Volume: 18, Issue:11

    Topics: Adult; CD4 Lymphocyte Count; Cohort Studies; Exanthema; Female; HIV Infections; Humans; Incidence; M

2007
Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL.
    International journal of STD & AIDS, 2007, Volume: 18, Issue:11

    Topics: Adult; CD4 Lymphocyte Count; Cohort Studies; Exanthema; Female; HIV Infections; Humans; Incidence; M

2007
Once-daily dosing of nevirapine in HAART.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 61, Issue:1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; HIV Infections

2008
Once-daily dosing of nevirapine in HAART.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 61, Issue:1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; HIV Infections

2008
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
    Drug safety, 2007, Volume: 30, Issue:12

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; CD4 Lymphocyte Count; Che

2007
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
    Drug safety, 2007, Volume: 30, Issue:12

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; CD4 Lymphocyte Count; Che

2007
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
    PLoS medicine, 2007, Volume: 4, Issue:12

    Topics: Cell Line; Drug Resistance, Multiple, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HI

2007
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
    PLoS medicine, 2007, Volume: 4, Issue:12

    Topics: Cell Line; Drug Resistance, Multiple, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HI

2007
Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing.
    PLoS medicine, 2007, Volume: 4, Issue:12

    Topics: Drug Resistance, Multiple, Viral; Genetic Testing; Genotype; HIV Infections; HIV Reverse Transcripta

2007
Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing.
    PLoS medicine, 2007, Volume: 4, Issue:12

    Topics: Drug Resistance, Multiple, Viral; Genetic Testing; Genotype; HIV Infections; HIV Reverse Transcripta

2007
Triple antiretroviral therapy improves psoriasis associated with human immunodeficiency virus infection: a clinico-therapeutic experience.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2008, Volume: 22, Issue:8

    Topics: Adult; Anti-HIV Agents; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Psoriasis; Stavudine

2008
Triple antiretroviral therapy improves psoriasis associated with human immunodeficiency virus infection: a clinico-therapeutic experience.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2008, Volume: 22, Issue:8

    Topics: Adult; Anti-HIV Agents; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Psoriasis; Stavudine

2008
Prevention of parent-to-child transmission of HIV: an experience in rural population.
    Indian journal of medical microbiology, 2007, Volume: 25, Issue:4

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2007
Prevention of parent-to-child transmission of HIV: an experience in rural population.
    Indian journal of medical microbiology, 2007, Volume: 25, Issue:4

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2007
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
    AIDS (London, England), 2007, Oct-18, Volume: 21, Issue:16

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette

2007
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
    AIDS (London, England), 2007, Oct-18, Volume: 21, Issue:16

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette

2007
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
    AIDS (London, England), 2007, Oct-18, Volume: 21, Issue:16

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette

2007
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
    AIDS (London, England), 2007, Oct-18, Volume: 21, Issue:16

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette

2007
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
    AIDS (London, England), 2007, Oct-18, Volume: 21, Issue:16

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette

2007
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
    AIDS (London, England), 2007, Oct-18, Volume: 21, Issue:16

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette

2007
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
    AIDS (London, England), 2007, Oct-18, Volume: 21, Issue:16

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette

2007
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
    AIDS (London, England), 2007, Oct-18, Volume: 21, Issue:16

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette

2007
HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen.
    AIDS (London, England), 2007, Nov-12, Volume: 21, Issue:17

    Topics: Adult; Developing Countries; Drug Combinations; Drug Resistance, Multiple, Viral; Drugs, Generic; Fe

2007
HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen.
    AIDS (London, England), 2007, Nov-12, Volume: 21, Issue:17

    Topics: Adult; Developing Countries; Drug Combinations; Drug Resistance, Multiple, Viral; Drugs, Generic; Fe

2007
Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 61, Issue:2

    Topics: Adult; Antitubercular Agents; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections;

2008
Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 61, Issue:2

    Topics: Adult; Antitubercular Agents; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections;

2008
Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
    AIDS patient care and STDs, 2007, Volume: 21, Issue:12

    Topics: Adult; Antiretroviral Therapy, Highly Active; Female; Hepatitis C; HIV Infections; HIV Protease Inhi

2007
Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
    AIDS patient care and STDs, 2007, Volume: 21, Issue:12

    Topics: Adult; Antiretroviral Therapy, Highly Active; Female; Hepatitis C; HIV Infections; HIV Protease Inhi

2007
An efficient tool for surveying CRF01_AE HIV type 1 resistance in Thailand to combined stavudine-lamivudine-nevirapine treatment: mutagenically separated PCR targeting M184I/V.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:12

    Topics: Anti-HIV Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV-1;

2007
An efficient tool for surveying CRF01_AE HIV type 1 resistance in Thailand to combined stavudine-lamivudine-nevirapine treatment: mutagenically separated PCR targeting M184I/V.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:12

    Topics: Anti-HIV Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV-1;

2007
Reverse transcriptase mutations in Cambodian CRF01_AE isolates after antiretroviral prophylaxis against HIV Type 1 perinatal transmission.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:12

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cambodia; Female; HIV Infections; HIV Revers

2007
Reverse transcriptase mutations in Cambodian CRF01_AE isolates after antiretroviral prophylaxis against HIV Type 1 perinatal transmission.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:12

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cambodia; Female; HIV Infections; HIV Revers

2007
Characterization of HIV type 1 reverse transcriptase mutations in infants infected by mothers who received peripartum nevirapine prophylaxis in Jos, Nigeria.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:12

    Topics: Amino Acid Sequence; Anti-HIV Agents; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Huma

2007
Characterization of HIV type 1 reverse transcriptase mutations in infants infected by mothers who received peripartum nevirapine prophylaxis in Jos, Nigeria.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:12

    Topics: Amino Acid Sequence; Anti-HIV Agents; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Huma

2007
Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda.
    Journal of acquired immune deficiency syndromes (1999), 2007, Nov-01, Volume: 46, Issue:3

    Topics: Anti-HIV Agents; Cohort Studies; DNA, Viral; Female; Follow-Up Studies; HIV; HIV Infections; Humans;

2007
Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda.
    Journal of acquired immune deficiency syndromes (1999), 2007, Nov-01, Volume: 46, Issue:3

    Topics: Anti-HIV Agents; Cohort Studies; DNA, Viral; Female; Follow-Up Studies; HIV; HIV Infections; Humans;

2007
Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Jan-01, Volume: 46, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Disease Progr

2008
Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Jan-01, Volume: 46, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Disease Progr

2008
Extensive hypopigmentation after starting antiretroviral treatment in an human immunodeficiency virus (HIV)-seropositive African woman.
    International journal of dermatology, 2008, Volume: 47, Issue:1

    Topics: Adult; Anti-HIV Agents; Anti-Infective Agents; Female; HIV Infections; Humans; Hypopigmentation; Lam

2008
Extensive hypopigmentation after starting antiretroviral treatment in an human immunodeficiency virus (HIV)-seropositive African woman.
    International journal of dermatology, 2008, Volume: 47, Issue:1

    Topics: Adult; Anti-HIV Agents; Anti-Infective Agents; Female; HIV Infections; Humans; Hypopigmentation; Lam

2008
Oral adverse effects due to the use of Nevirapine.
    The journal of contemporary dental practice, 2008, Jan-01, Volume: 9, Issue:1

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Burning Mouth Syndrome; CD4 Lymphocyt

2008
Oral adverse effects due to the use of Nevirapine.
    The journal of contemporary dental practice, 2008, Jan-01, Volume: 9, Issue:1

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Burning Mouth Syndrome; CD4 Lymphocyt

2008
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    AIDS (London, England), 2008, Jan-30, Volume: 22, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Resistance, Viral

2008
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    AIDS (London, England), 2008, Jan-30, Volume: 22, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Resistance, Viral

2008
Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity.
    AIDS (London, England), 2008, Jan-30, Volume: 22, Issue:3

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Hypersensitivity; Hepatitis C, Chronic; HIV Infe

2008
Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity.
    AIDS (London, England), 2008, Jan-30, Volume: 22, Issue:3

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Hypersensitivity; Hepatitis C, Chronic; HIV Infe

2008
Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Feb-15, Volume: 46, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Drug Resistance, Viral; Female; HIV Inf

2008
Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Feb-15, Volume: 46, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Drug Resistance, Viral; Female; HIV Inf

2008
Risk of side effects associated with the use of nevirapine in treatment-naïve patients, with respect to gender and CD4 cell count.
    HIV medicine, 2008, Volume: 9, Issue:1

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Exanthema; Female; HI

2008
Risk of side effects associated with the use of nevirapine in treatment-naïve patients, with respect to gender and CD4 cell count.
    HIV medicine, 2008, Volume: 9, Issue:1

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Exanthema; Female; HI

2008
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.
    HIV medicine, 2008, Volume: 9, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2008
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.
    HIV medicine, 2008, Volume: 9, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte

2008
Nevirapine-associated toxicity in Niger.
    HIV medicine, 2008, Volume: 9, Issue:1

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Epidemiologic Methods; Exanthema; Fe

2008
Nevirapine-associated toxicity in Niger.
    HIV medicine, 2008, Volume: 9, Issue:1

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Epidemiologic Methods; Exanthema; Fe

2008
Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
    Journal of virology, 2008, Volume: 82, Issue:7

    Topics: Amino Acid Substitution; Animals; Cell Line; Drug Resistance, Viral; HIV Infections; HIV Reverse Tra

2008
Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
    Journal of virology, 2008, Volume: 82, Issue:7

    Topics: Amino Acid Substitution; Animals; Cell Line; Drug Resistance, Viral; HIV Infections; HIV Reverse Tra

2008
Steady-State Pharmacokinetics of Nevirapine in HIV-1 Infected Adults in India.
    Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 2007, Volume: 6, Issue:4

    Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; India; Nevirapine

2007
Steady-State Pharmacokinetics of Nevirapine in HIV-1 Infected Adults in India.
    Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 2007, Volume: 6, Issue:4

    Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; India; Nevirapine

2007
Outputs, cost and efficiency of public sector centres for prevention of mother to child transmission of HIV in Andhra Pradesh, India.
    BMC health services research, 2008, Jan-31, Volume: 8

    Topics: Abortion, Induced; AIDS Serodiagnosis; Anti-HIV Agents; Costs and Cost Analysis; Counseling; Deliver

2008
Outputs, cost and efficiency of public sector centres for prevention of mother to child transmission of HIV in Andhra Pradesh, India.
    BMC health services research, 2008, Jan-31, Volume: 8

    Topics: Abortion, Induced; AIDS Serodiagnosis; Anti-HIV Agents; Costs and Cost Analysis; Counseling; Deliver

2008
Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Antiviral therapy, 2007, Volume: 12, Issue:8

    Topics: Adolescent; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; C

2007
Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Antiviral therapy, 2007, Volume: 12, Issue:8

    Topics: Adolescent; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; C

2007
A grave delay for South Africa's mothers and infants.
    Lancet (London, England), 2008, Feb-02, Volume: 371, Issue:9610

    Topics: Female; Health Policy; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine

2008
A grave delay for South Africa's mothers and infants.
    Lancet (London, England), 2008, Feb-02, Volume: 371, Issue:9610

    Topics: Female; Health Policy; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine

2008
Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
    Fundamental & clinical pharmacology, 2008, Volume: 22, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Bayes Theorem; Benzoxazines; Carbamates; Cyclopropanes; Drug Therap

2008
Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
    Fundamental & clinical pharmacology, 2008, Volume: 22, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Bayes Theorem; Benzoxazines; Carbamates; Cyclopropanes; Drug Therap

2008
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 61, Issue:4

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alkynes; Aryl Hydrocarbon Hydroxylases; Benzoxazines; B

2008
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
    The Journal of antimicrobial chemotherapy, 2008, Volume: 61, Issue:4

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alkynes; Aryl Hydrocarbon Hydroxylases; Benzoxazines; B

2008
A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:2

    Topics: Amino Acid Substitution; Anti-HIV Agents; Cluster Analysis; DNA, Viral; Drug Resistance, Viral; Gene

2008
A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:2

    Topics: Amino Acid Substitution; Anti-HIV Agents; Cluster Analysis; DNA, Viral; Drug Resistance, Viral; Gene

2008
18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission.
    PloS one, 2008, Feb-20, Volume: 3, Issue:2

    Topics: Africa; Anti-HIV Agents; Breast Feeding; Drug Therapy, Combination; Female; HIV Infections; Humans;

2008
18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission.
    PloS one, 2008, Feb-20, Volume: 3, Issue:2

    Topics: Africa; Anti-HIV Agents; Breast Feeding; Drug Therapy, Combination; Female; HIV Infections; Humans;

2008
Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings.
    Current HIV research, 2008, Volume: 6, Issue:1

    Topics: Adult; Body Weight; Case-Control Studies; CD4 Lymphocyte Count; Developing Countries; Drug Hypersens

2008
Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings.
    Current HIV research, 2008, Volume: 6, Issue:1

    Topics: Adult; Body Weight; Case-Control Studies; CD4 Lymphocyte Count; Developing Countries; Drug Hypersens

2008
Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C.
    Journal of virological methods, 2008, Volume: 149, Issue:1

    Topics: Alleles; Anti-HIV Agents; Binding Sites; Botswana; DNA Primers; Drug Resistance, Viral; Female; HIV

2008
Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C.
    Journal of virological methods, 2008, Volume: 149, Issue:1

    Topics: Alleles; Anti-HIV Agents; Binding Sites; Botswana; DNA Primers; Drug Resistance, Viral; Female; HIV

2008
HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz.
    AIDS (London, England), 2008, Feb-19, Volume: 22, Issue:4

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Eruptions; Female; HIV Infe

2008
HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz.
    AIDS (London, England), 2008, Feb-19, Volume: 22, Issue:4

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Eruptions; Female; HIV Infe

2008
Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply.
    AIDS (London, England), 2008, Feb-19, Volume: 22, Issue:4

    Topics: Anti-HIV Agents; Drug Hypersensitivity; Hepatitis C, Chronic; HIV Infections; Humans; Nevirapine

2008
Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply.
    AIDS (London, England), 2008, Feb-19, Volume: 22, Issue:4

    Topics: Anti-HIV Agents; Drug Hypersensitivity; Hepatitis C, Chronic; HIV Infections; Humans; Nevirapine

2008
Response to Birbeck et al.
    Epilepsia, 2008, Volume: 49, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Africa South of the Sahara; Anti-Retroviral Agents; Anticonvulsa

2008
Response to Birbeck et al.
    Epilepsia, 2008, Volume: 49, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Africa South of the Sahara; Anti-Retroviral Agents; Anticonvulsa

2008
From PMTCT to a more comprehensive AIDS response for women: a much-needed shift.
    Developing world bioethics, 2008, Volume: 8, Issue:1

    Topics: Abortion, Induced; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Developing Countries;

2008
From PMTCT to a more comprehensive AIDS response for women: a much-needed shift.
    Developing world bioethics, 2008, Volume: 8, Issue:1

    Topics: Abortion, Induced; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Developing Countries;

2008
Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2008, Volume: 41, Issue:4

    Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Femal

2008
Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2008, Volume: 41, Issue:4

    Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Femal

2008
Estimating vertically acquired HIV infections and the impact of the prevention of mother-to-child transmission program in Zimbabwe: insights from decision analysis models.
    Journal of acquired immune deficiency syndromes (1999), 2008, May-01, Volume: 48, Issue:1

    Topics: Decision Support Techniques; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tra

2008
Estimating vertically acquired HIV infections and the impact of the prevention of mother-to-child transmission program in Zimbabwe: insights from decision analysis models.
    Journal of acquired immune deficiency syndromes (1999), 2008, May-01, Volume: 48, Issue:1

    Topics: Decision Support Techniques; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tra

2008
Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2007, Volume: 11, Issue:6

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Drug Eruptions

2007
Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2007, Volume: 11, Issue:6

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Drug Eruptions

2007
Incidence of nevirapine-associated hepatitis in an antenatal clinic.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2008, Volume: 98, Issue:2

    Topics: Adult; Alanine Transaminase; Ambulatory Care Facilities; Chemical and Drug Induced Liver Injury; Fem

2008
Incidence of nevirapine-associated hepatitis in an antenatal clinic.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2008, Volume: 98, Issue:2

    Topics: Adult; Alanine Transaminase; Ambulatory Care Facilities; Chemical and Drug Induced Liver Injury; Fem

2008
Association of antiretroviral therapy with fibrinogen levels in HIV-infection.
    AIDS (London, England), 2008, Mar-30, Volume: 22, Issue:6

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Case-Co

2008
Association of antiretroviral therapy with fibrinogen levels in HIV-infection.
    AIDS (London, England), 2008, Mar-30, Volume: 22, Issue:6

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Case-Co

2008
Feasibility of prevention of perinatal HIV infection by nevirapine in rural areas of the northeast Democratic Republic of Congo, 2002-2004.
    Journal of medical virology, 2008, Volume: 80, Issue:5

    Topics: Chemoprevention; Democratic Republic of the Congo; Female; HIV Infections; Humans; Infant, Newborn;

2008
Feasibility of prevention of perinatal HIV infection by nevirapine in rural areas of the northeast Democratic Republic of Congo, 2002-2004.
    Journal of medical virology, 2008, Volume: 80, Issue:5

    Topics: Chemoprevention; Democratic Republic of the Congo; Female; HIV Infections; Humans; Infant, Newborn;

2008
Syncope as a probable side effect to combination antiretroviral therapy initiated during primary HIV-1 infection.
    Sexual health, 2008, Volume: 5, Issue:1

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine

2008
Syncope as a probable side effect to combination antiretroviral therapy initiated during primary HIV-1 infection.
    Sexual health, 2008, Volume: 5, Issue:1

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine

2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy;

2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy;

2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy;

2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy;

2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy;

2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy;

2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy;

2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy;

2008
Steady-state nevirapine plasma concentrations are influenced by pregnancy.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Africa; Case-Control Studies; Female; HIV Infections; HIV-1; Humans; Infectious Disease Trans

2008
Steady-state nevirapine plasma concentrations are influenced by pregnancy.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Africa; Case-Control Studies; Female; HIV Infections; HIV-1; Humans; Infectious Disease Trans

2008
Comparison of LigAmp and an ASPCR assay for detection and quantification of K103N-containing HIV variants.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:4

    Topics: Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; Genes, pol; Genetic Variation; HIV I

2008
Comparison of LigAmp and an ASPCR assay for detection and quantification of K103N-containing HIV variants.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:4

    Topics: Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; Genes, pol; Genetic Variation; HIV I

2008
Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
    Antiviral therapy, 2008, Volume: 13, Issue:1

    Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Multiple, Viral;

2008
Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
    Antiviral therapy, 2008, Volume: 13, Issue:1

    Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Multiple, Viral;

2008
Characteristics of pregnancy with human immuno-deficiency virus (HIV) and perinatal transmission in Nakornping Hospital.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2008, Volume: 91, Issue:2

    Topics: Adolescent; Adult; Anti-Retroviral Agents; Female; HIV Infections; Humans; Incidence; Infant, Newbor

2008
Characteristics of pregnancy with human immuno-deficiency virus (HIV) and perinatal transmission in Nakornping Hospital.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2008, Volume: 91, Issue:2

    Topics: Adolescent; Adult; Anti-Retroviral Agents; Female; HIV Infections; Humans; Incidence; Infant, Newbor

2008
Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2008, Volume: 91, Issue:2

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Anti-Retroviral Agents; Aspartate Aminotransferases; C

2008
Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2008, Volume: 91, Issue:2

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Anti-Retroviral Agents; Aspartate Aminotransferases; C

2008
Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    HIV medicine, 2008, Volume: 9, Issue:5

    Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Antitubercular Agents; Benzoxazines; CD4 Lymp

2008
Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    HIV medicine, 2008, Volume: 9, Issue:5

    Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Antitubercular Agents; Benzoxazines; CD4 Lymp

2008
Self-reported adherence to single dose nevirapine in the prevention of mother to child transmission of HIV at Kitale District Hospital.
    East African medical journal, 2007, Volume: 84, Issue:12

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Child Welfare; Cross-Sectional Studies; Female; Health Su

2007
Self-reported adherence to single dose nevirapine in the prevention of mother to child transmission of HIV at Kitale District Hospital.
    East African medical journal, 2007, Volume: 84, Issue:12

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Child Welfare; Cross-Sectional Studies; Female; Health Su

2007
FDA notifications. Tentative approval granted of generic nevirapine.
    AIDS alert, 2007, Volume: 22, Issue:9

    Topics: Drug Approval; Drugs, Generic; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors;

2007
FDA notifications. Tentative approval granted of generic nevirapine.
    AIDS alert, 2007, Volume: 22, Issue:9

    Topics: Drug Approval; Drugs, Generic; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors;

2007
Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.
    AIDS patient care and STDs, 2008, Volume: 22, Issue:4

    Topics: Adult; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemica

2008
Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.
    AIDS patient care and STDs, 2008, Volume: 22, Issue:4

    Topics: Adult; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemica

2008
Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants.
    AIDS (London, England), 2008, Apr-23, Volume: 22, Issue:7

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'I

2008
Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants.
    AIDS (London, England), 2008, Apr-23, Volume: 22, Issue:7

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'I

2008
Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa.
    Journal of medical virology, 2008, Volume: 80, Issue:6

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H

2008
Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa.
    Journal of medical virology, 2008, Volume: 80, Issue:6

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H

2008
[Polyneuropathies in patients treated with HAART in Bobo-Dioulasso hospital, Burkina Faso].
    Bulletin de la Societe de pathologie exotique (1990), 2008, Volume: 101, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Burkina Faso;

2008
[Polyneuropathies in patients treated with HAART in Bobo-Dioulasso hospital, Burkina Faso].
    Bulletin de la Societe de pathologie exotique (1990), 2008, Volume: 101, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Burkina Faso;

2008
Human immunodeficiency virus-infected boy with Stevens-Johnson syndrome caused by nevirapine.
    The Pediatric infectious disease journal, 2008, Volume: 27, Issue:6

    Topics: Child; HIV Infections; Humans; Male; Nevirapine; Stevens-Johnson Syndrome

2008
Human immunodeficiency virus-infected boy with Stevens-Johnson syndrome caused by nevirapine.
    The Pediatric infectious disease journal, 2008, Volume: 27, Issue:6

    Topics: Child; HIV Infections; Humans; Male; Nevirapine; Stevens-Johnson Syndrome

2008
Update on HIV transmission and pathogenesis.
    Lancet (London, England), 1995, Nov-11, Volume: 346, Issue:8985

    Topics: Animals; Antiviral Agents; CD4-Positive T-Lymphocytes; Disease Models, Animal; Genes, env; HIV; HIV

1995
Update on HIV transmission and pathogenesis.
    Lancet (London, England), 1995, Nov-11, Volume: 346, Issue:8985

    Topics: Animals; Antiviral Agents; CD4-Positive T-Lymphocytes; Disease Models, Animal; Genes, env; HIV; HIV

1995
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.
    Journal of virology, 1994, Volume: 68, Issue:3

    Topics: Antiviral Agents; Base Sequence; CD4-Positive T-Lymphocytes; Drug Resistance, Microbial; Drug Therap

1994
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.
    Journal of virology, 1994, Volume: 68, Issue:3

    Topics: Antiviral Agents; Base Sequence; CD4-Positive T-Lymphocytes; Drug Resistance, Microbial; Drug Therap

1994
High turnover of HIV in blood revealed by new studies.
    Science (New York, N.Y.), 1995, Jan-13, Volume: 267, Issue:5195

    Topics: Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; HIV; HIV Infections; HIV Proteas

1995
High turnover of HIV in blood revealed by new studies.
    Science (New York, N.Y.), 1995, Jan-13, Volume: 267, Issue:5195

    Topics: Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; HIV; HIV Infections; HIV Proteas

1995
Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.
    The Journal of infectious diseases, 1994, Volume: 169, Issue:6

    Topics: Adolescent; Adult; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Core

1994
Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.
    The Journal of infectious diseases, 1994, Volume: 169, Issue:6

    Topics: Adolescent; Adult; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Core

1994
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.
    Antimicrobial agents and chemotherapy, 1993, Volume: 37, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Female; Half-Life; HIV Infections; HIV-

1993
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.
    Antimicrobial agents and chemotherapy, 1993, Volume: 37, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Female; Half-Life; HIV Infections; HIV-

1993
Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo.
    Journal of virology, 1996, Volume: 70, Issue:1

    Topics: Base Sequence; Cohort Studies; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Kinetics;

1996
Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo.
    Journal of virology, 1996, Volume: 70, Issue:1

    Topics: Base Sequence; Cohort Studies; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Kinetics;

1996
Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains.
    AIDS research and human retroviruses, 1996, Apr-10, Volume: 12, Issue:6

    Topics: Antiviral Agents; Cell Line, Transformed; Cytotoxicity, Immunologic; Drug Resistance, Microbial; Dru

1996
Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains.
    AIDS research and human retroviruses, 1996, Apr-10, Volume: 12, Issue:6

    Topics: Antiviral Agents; Cell Line, Transformed; Cytotoxicity, Immunologic; Drug Resistance, Microbial; Dru

1996
New HIV drugs cast in supporting roles.
    JAMA, 1996, Aug-28, Volume: 276, Issue:8

    Topics: Antiviral Agents; HIV; HIV Infections; Humans; Nevirapine; Pyridines; Reverse Transcriptase Inhibito

1996
New HIV drugs cast in supporting roles.
    JAMA, 1996, Aug-28, Volume: 276, Issue:8

    Topics: Antiviral Agents; HIV; HIV Infections; Humans; Nevirapine; Pyridines; Reverse Transcriptase Inhibito

1996
Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus.
    The Journal of pediatrics, 1996, Volume: 129, Issue:3

    Topics: Antiviral Agents; Biopsy; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; DNA, Viral; Dru

1996
Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus.
    The Journal of pediatrics, 1996, Volume: 129, Issue:3

    Topics: Antiviral Agents; Biopsy; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; DNA, Viral; Dru

1996
Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds.
    Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:3

    Topics: Animals; Antiviral Agents; Didanosine; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Fetal Tissue T

1996
Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds.
    Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:3

    Topics: Animals; Antiviral Agents; Didanosine; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Fetal Tissue T

1996
FDA approval of nevirapine for HIV.
    American family physician, 1996, Volume: 54, Issue:5

    Topics: Anti-HIV Agents; Drug Approval; HIV Infections; Humans; Nevirapine; Pyridines; United States; United

1996
FDA approval of nevirapine for HIV.
    American family physician, 1996, Volume: 54, Issue:5

    Topics: Anti-HIV Agents; Drug Approval; HIV Infections; Humans; Nevirapine; Pyridines; United States; United

1996
Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients.
    Journal of virology, 1996, Volume: 70, Issue:11

    Topics: Clinical Trials as Topic; Double-Blind Method; Drug Resistance, Microbial; HeLa Cells; HIV; HIV Infe

1996
Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients.
    Journal of virology, 1996, Volume: 70, Issue:11

    Topics: Clinical Trials as Topic; Double-Blind Method; Drug Resistance, Microbial; HeLa Cells; HIV; HIV Infe

1996
[Nevirapine: a new principle of action against HIV].
    Deutsche medizinische Wochenschrift (1946), 1996, Dec-06, Volume: 121, Issue:49

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Do

1996
[Nevirapine: a new principle of action against HIV].
    Deutsche medizinische Wochenschrift (1946), 1996, Dec-06, Volume: 121, Issue:49

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Do

1996
Triple therapy reduces HIV virus to undetected levels.
    Australian family physician, 1996, Volume: 25, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Pyridines; Reverse

1996
Triple therapy reduces HIV virus to undetected levels.
    Australian family physician, 1996, Volume: 25, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Pyridines; Reverse

1996
More new drugs for HIV and associated infections.
    The Medical letter on drugs and therapeutics, 1997, Feb-14, Volume: 39, Issue:994

    Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Bacterial Agents; Antiviral Agents; Cido

1997
More new drugs for HIV and associated infections.
    The Medical letter on drugs and therapeutics, 1997, Feb-14, Volume: 39, Issue:994

    Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Bacterial Agents; Antiviral Agents; Cido

1997
Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations.
    Journal of theoretical biology, 1997, Jan-21, Volume: 184, Issue:2

    Topics: Antiviral Agents; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Models, Biological; Mut

1997
Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations.
    Journal of theoretical biology, 1997, Jan-21, Volume: 184, Issue:2

    Topics: Antiviral Agents; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Models, Biological; Mut

1997
Viramune, new antiretroviral agent, crosses the blood-brain barrier.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:5

    Topics: Anti-HIV Agents; Blood-Brain Barrier; HIV Infections; Humans; Nevirapine; Pyridines

1997
Viramune, new antiretroviral agent, crosses the blood-brain barrier.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:5

    Topics: Anti-HIV Agents; Blood-Brain Barrier; HIV Infections; Humans; Nevirapine; Pyridines

1997
Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase.
    Nature medicine, 1997, Volume: 3, Issue:6

    Topics: Animals; Anti-HIV Agents; DNA, Viral; HIV Antibodies; HIV Infections; HIV-1; Leukocytes, Mononuclear

1997
Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase.
    Nature medicine, 1997, Volume: 3, Issue:6

    Topics: Animals; Anti-HIV Agents; DNA, Viral; HIV Antibodies; HIV Infections; HIV-1; Leukocytes, Mononuclear

1997
Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group.
    The Journal of infectious diseases, 1997, Volume: 175, Issue:6

    Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Codon; DNA Mutational Analysis; Drug Resistance,

1997
Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group.
    The Journal of infectious diseases, 1997, Volume: 175, Issue:6

    Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Codon; DNA Mutational Analysis; Drug Resistance,

1997
Cure or control of HIV/AIDS?
    Medical hypotheses, 1997, Volume: 48, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Th

1997
Cure or control of HIV/AIDS?
    Medical hypotheses, 1997, Volume: 48, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Th

1997
Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment.
    AIDS (London, England), 1997, Volume: 11, Issue:11

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Indinavi

1997
Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment.
    AIDS (London, England), 1997, Volume: 11, Issue:11

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Indinavi

1997
Drugs for HIV infection.
    The Medical letter on drugs and therapeutics, 1997, Dec-12, Volume: 39, Issue:1015

    Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Inte

1997
Drugs for HIV infection.
    The Medical letter on drugs and therapeutics, 1997, Dec-12, Volume: 39, Issue:1015

    Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Inte

1997
Confusion of nelfinavir and nevirapine.
    The New England journal of medicine, 1998, Feb-05, Volume: 338, Issue:6

    Topics: Anti-HIV Agents; Drug Labeling; Female; HIV Infections; Humans; Medication Errors; Nelfinavir; Nevir

1998
Confusion of nelfinavir and nevirapine.
    The New England journal of medicine, 1998, Feb-05, Volume: 338, Issue:6

    Topics: Anti-HIV Agents; Drug Labeling; Female; HIV Infections; Humans; Medication Errors; Nelfinavir; Nevir

1998
Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.
    AIDS research and human retroviruses, 1998, Jan-20, Volume: 14, Issue:2

    Topics: Anti-HIV Agents; Cell Line, Transformed; Cells, Cultured; Didanosine; Foscarnet; HIV Infections; HIV

1998
Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.
    AIDS research and human retroviruses, 1998, Jan-20, Volume: 14, Issue:2

    Topics: Anti-HIV Agents; Cell Line, Transformed; Cells, Cultured; Didanosine; Foscarnet; HIV Infections; HIV

1998
Nevirapine-associated Stevens-Johnson syndrome.
    Lancet (London, England), 1998, Feb-21, Volume: 351, Issue:9102

    Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Male; Nevirapine; Reverse Transcriptase Inhib

1998
Nevirapine-associated Stevens-Johnson syndrome.
    Lancet (London, England), 1998, Feb-21, Volume: 351, Issue:9102

    Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Male; Nevirapine; Reverse Transcriptase Inhib

1998
Induction-maintenance antiretroviral therapy: proof of concept.
    AIDS (London, England), 1998, May-07, Volume: 12, Issue:7

    Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; N

1998
Induction-maintenance antiretroviral therapy: proof of concept.
    AIDS (London, England), 1998, May-07, Volume: 12, Issue:7

    Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; N

1998
Researchers report sustained suppression of HIV with nevirapine--didanosine--zidovudine.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1998, Jun-01, Volume: 55, Issue:11

    Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse

1998
Researchers report sustained suppression of HIV with nevirapine--didanosine--zidovudine.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1998, Jun-01, Volume: 55, Issue:11

    Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse

1998
Nevirapine-induced hepatitis treated with corticosteroids?
    AIDS (London, England), 1998, Jun-18, Volume: 12, Issue:9

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; Glucocorticoids; HIV Infecti

1998
Nevirapine-induced hepatitis treated with corticosteroids?
    AIDS (London, England), 1998, Jun-18, Volume: 12, Issue:9

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; Glucocorticoids; HIV Infecti

1998
The pharmacokinetics of combination therapy with nelfinavir plus nevirapine.
    AIDS (London, England), 1998, Jul-09, Volume: 12, Issue:10

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Drug Therapy, Combination; Female; HIV Infections; Humans;

1998
The pharmacokinetics of combination therapy with nelfinavir plus nevirapine.
    AIDS (London, England), 1998, Jul-09, Volume: 12, Issue:10

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Drug Therapy, Combination; Female; HIV Infections; Humans;

1998
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.
    AIDS (London, England), 1998, Jul-30, Volume: 12, Issue:11

    Topics: Adult; Anti-HIV Agents; Data Interpretation, Statistical; Dideoxynucleosides; Drug Therapy, Combinat

1998
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.
    AIDS (London, England), 1998, Jul-30, Volume: 12, Issue:11

    Topics: Adult; Anti-HIV Agents; Data Interpretation, Statistical; Dideoxynucleosides; Drug Therapy, Combinat

1998
Rebound of plasma HIV viral load following prolonged suppression with combination therapy.
    AIDS (London, England), 1998, Jul-30, Volume: 12, Issue:11

    Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Male; Nevirap

1998
Rebound of plasma HIV viral load following prolonged suppression with combination therapy.
    AIDS (London, England), 1998, Jul-30, Volume: 12, Issue:11

    Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Male; Nevirap

1998
HIV drug now approved for use with protease inhibitors.
    The Nurse practitioner, 1998, Volume: 23, Issue:10

    Topics: Anti-HIV Agents; Drug Approval; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors;

1998
HIV drug now approved for use with protease inhibitors.
    The Nurse practitioner, 1998, Volume: 23, Issue:10

    Topics: Anti-HIV Agents; Drug Approval; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors;

1998
High incidence of nevirapine-associated rash in HIV-infected Chinese.
    AIDS (London, England), 1998, Oct-22, Volume: 12, Issue:15

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; China; Didanosine; Drug Eruptions; Drug Therapy, Combination;

1998
High incidence of nevirapine-associated rash in HIV-infected Chinese.
    AIDS (London, England), 1998, Oct-22, Volume: 12, Issue:15

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; China; Didanosine; Drug Eruptions; Drug Therapy, Combination;

1998
DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1998, Volume: 27, Issue:5

    Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Hypersensitivity; Drug Therapy, Combination; Eosinophil

1998
DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1998, Volume: 27, Issue:5

    Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Hypersensitivity; Drug Therapy, Combination; Eosinophil

1998
Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent.
    AIDS (London, England), 1998, Nov-12, Volume: 12, Issue:16

    Topics: Analysis of Variance; Anti-HIV Agents; Data Interpretation, Statistical; Didanosine; HIV Infections;

1998
Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent.
    AIDS (London, England), 1998, Nov-12, Volume: 12, Issue:16

    Topics: Analysis of Variance; Anti-HIV Agents; Data Interpretation, Statistical; Didanosine; HIV Infections;

1998
HIV-1 peripheral neuropathy and combination antiretroviral therapy.
    Lancet (London, England), 1998, Dec-12, Volume: 352, Issue:9144

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir;

1998
HIV-1 peripheral neuropathy and combination antiretroviral therapy.
    Lancet (London, England), 1998, Dec-12, Volume: 352, Issue:9144

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir;

1998
Lest we forget: neuropsychiatry and the new generation anti-HIV drugs.
    AIDS (London, England), 1998, Dec-24, Volume: 12, Issue:18

    Topics: Anti-HIV Agents; Antipsychotic Agents; Blood-Brain Barrier; Central Nervous System; Cytochrome P-450

1998
Lest we forget: neuropsychiatry and the new generation anti-HIV drugs.
    AIDS (London, England), 1998, Dec-24, Volume: 12, Issue:18

    Topics: Anti-HIV Agents; Antipsychotic Agents; Blood-Brain Barrier; Central Nervous System; Cytochrome P-450

1998
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
    JAMA, 1999, Jan-13, Volume: 281, Issue:2

    Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Randomiz

1999
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
    JAMA, 1999, Jan-13, Volume: 281, Issue:2

    Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Randomiz

1999
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
    JAMA, 1999, Jan-13, Volume: 281, Issue:2

    Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Randomiz

1999
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
    JAMA, 1999, Jan-13, Volume: 281, Issue:2

    Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Randomiz

1999
[Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors].
    Nederlands tijdschrift voor geneeskunde, 1998, Dec-26, Volume: 142, Issue:52

    Topics: Adult; Cardiovascular Diseases; CD4 Lymphocyte Count; Diabetes Mellitus, Type 2; Drug Therapy, Combi

1998
[Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors].
    Nederlands tijdschrift voor geneeskunde, 1998, Dec-26, Volume: 142, Issue:52

    Topics: Adult; Cardiovascular Diseases; CD4 Lymphocyte Count; Diabetes Mellitus, Type 2; Drug Therapy, Combi

1998
Incidence of rash and discontinuation of nevirapine using two different escalating initial doses.
    AIDS (London, England), 1999, Mar-11, Volume: 13, Issue:4

    Topics: Anti-HIV Agents; Exanthema; HIV Infections; HIV-1; Humans; Incidence; Nevirapine; Reverse Transcript

1999
Incidence of rash and discontinuation of nevirapine using two different escalating initial doses.
    AIDS (London, England), 1999, Mar-11, Volume: 13, Issue:4

    Topics: Anti-HIV Agents; Exanthema; HIV Infections; HIV-1; Humans; Incidence; Nevirapine; Reverse Transcript

1999
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.
    AIDS (London, England), 1999, Feb-04, Volume: 13, Issue:2

    Topics: Adult; Aging; Anti-HIV Agents; Didanosine; Follow-Up Studies; HIV Infections; HIV-1; Humans; Immunol

1999
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.
    AIDS (London, England), 1999, Feb-04, Volume: 13, Issue:2

    Topics: Adult; Aging; Anti-HIV Agents; Didanosine; Follow-Up Studies; HIV Infections; HIV-1; Humans; Immunol

1999
Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.
    AIDS (London, England), 1999, Jan-14, Volume: 13, Issue:1

    Topics: Adult; Amino Acids; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Microbial; Genotype; HIV I

1999
Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.
    AIDS (London, England), 1999, Jan-14, Volume: 13, Issue:1

    Topics: Adult; Amino Acids; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Microbial; Genotype; HIV I

1999
Methadone withdrawal when starting an antiretroviral regimen including nevirapine.
    Pharmacotherapy, 1999, Volume: 19, Issue:4

    Topics: Adult; Anti-HIV Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; E

1999
Methadone withdrawal when starting an antiretroviral regimen including nevirapine.
    Pharmacotherapy, 1999, Volume: 19, Issue:4

    Topics: Adult; Anti-HIV Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; E

1999
Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.
    AIDS (London, England), 1999, May-07, Volume: 13, Issue:7

    Topics: Adipose Tissue; Adult; Anthropometry; Blood Glucose; CD4 Lymphocyte Count; Cholesterol; Female; HIV

1999
Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.
    AIDS (London, England), 1999, May-07, Volume: 13, Issue:7

    Topics: Adipose Tissue; Adult; Anthropometry; Blood Glucose; CD4 Lymphocyte Count; Cholesterol; Female; HIV

1999
Lipodystrophy associated with nevirapine-containing antiretroviral therapies.
    AIDS (London, England), 1999, May-07, Volume: 13, Issue:7

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Lipodystrophy; Ma

1999
Lipodystrophy associated with nevirapine-containing antiretroviral therapies.
    AIDS (London, England), 1999, May-07, Volume: 13, Issue:7

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Lipodystrophy; Ma

1999
HIV-1 infected patients with toxic epidermal necrolysis: an occupational risk for healthcare workers.
    Lancet (London, England), 1999, May-29, Volume: 353, Issue:9167

    Topics: Aged; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Patient-to-Pr

1999
HIV-1 infected patients with toxic epidermal necrolysis: an occupational risk for healthcare workers.
    Lancet (London, England), 1999, May-29, Volume: 353, Issue:9167

    Topics: Aged; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Patient-to-Pr

1999
Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.
    AIDS (London, England), 1999, May-28, Volume: 13, Issue:8

    Topics: Adult; Anti-HIV Agents; Drug Interactions; Female; HIV Infections; Humans; Male; Methadone; Middle A

1999
Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.
    AIDS (London, England), 1999, May-28, Volume: 13, Issue:8

    Topics: Adult; Anti-HIV Agents; Drug Interactions; Female; HIV Infections; Humans; Male; Methadone; Middle A

1999
Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.
    AIDS (London, England), 1999, May-28, Volume: 13, Issue:8

    Topics: Adult; Anti-HIV Agents; Drug Interactions; HIV Infections; Humans; Methadone; Narcotics; Nevirapine;

1999
Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.
    AIDS (London, England), 1999, May-28, Volume: 13, Issue:8

    Topics: Adult; Anti-HIV Agents; Drug Interactions; HIV Infections; Humans; Methadone; Narcotics; Nevirapine;

1999
Changing cost of English HIV service provision 1996-1997. NPMS Steering Group. National Prospective Monitoring System.
    International journal of STD & AIDS, 1999, Volume: 10, Issue:6

    Topics: Adult; Anti-HIV Agents; Didanosine; Drug Costs; Drug Therapy, Combination; HIV Infections; HIV Prote

1999
Changing cost of English HIV service provision 1996-1997. NPMS Steering Group. National Prospective Monitoring System.
    International journal of STD & AIDS, 1999, Volume: 10, Issue:6

    Topics: Adult; Anti-HIV Agents; Didanosine; Drug Costs; Drug Therapy, Combination; HIV Infections; HIV Prote

1999
Kaposi's sarcoma regression following treatment with a triple antiretroviral regimen containing nevirapine.
    International journal of STD & AIDS, 1999, Volume: 10, Issue:6

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Male; Nevirapine; Reverse

1999
Kaposi's sarcoma regression following treatment with a triple antiretroviral regimen containing nevirapine.
    International journal of STD & AIDS, 1999, Volume: 10, Issue:6

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Male; Nevirapine; Reverse

1999
Drug could slash rate of perinatal HIV.
    Nature, 1999, Jul-22, Volume: 400, Issue:6742

    Topics: Anti-HIV Agents; Drug Costs; Drug Therapy, Combination; HIV Infections; Humans; Infant, Newborn; Inf

1999
Drug could slash rate of perinatal HIV.
    Nature, 1999, Jul-22, Volume: 400, Issue:6742

    Topics: Anti-HIV Agents; Drug Costs; Drug Therapy, Combination; HIV Infections; Humans; Infant, Newborn; Inf

1999
Low-cost drug cuts perinatal HIV-transmission rate.
    Lancet (London, England), 1999, Jul-24, Volume: 354, Issue:9175

    Topics: Anti-HIV Agents; Drug Costs; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tra

1999
Low-cost drug cuts perinatal HIV-transmission rate.
    Lancet (London, England), 1999, Jul-24, Volume: 354, Issue:9175

    Topics: Anti-HIV Agents; Drug Costs; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tra

1999
Substituting nevirapine for protease inhibitors because of intolerance.
    AIDS (London, England), 1999, Jul-30, Volume: 13, Issue:11

    Topics: Adult; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ma

1999
Substituting nevirapine for protease inhibitors because of intolerance.
    AIDS (London, England), 1999, Jul-30, Volume: 13, Issue:11

    Topics: Adult; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ma

1999
Nevirapine-induced cutaneous hypersensitivity reactions and successful tolerance induction.
    The Journal of allergy and clinical immunology, 1999, Volume: 104, Issue:2 Pt 1

    Topics: Adult; Drug Tolerance; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhib

1999
Nevirapine-induced cutaneous hypersensitivity reactions and successful tolerance induction.
    The Journal of allergy and clinical immunology, 1999, Volume: 104, Issue:2 Pt 1

    Topics: Adult; Drug Tolerance; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhib

1999
Severe hepatic failure related to nevirapine treatment.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1999, Volume: 29, Issue:2

    Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Liver Failure; Male; Middle Aged; Nevirapine; Revers

1999
Severe hepatic failure related to nevirapine treatment.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1999, Volume: 29, Issue:2

    Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Liver Failure; Male; Middle Aged; Nevirapine; Revers

1999
Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma.
    AIDS research and human retroviruses, 1999, Sep-01, Volume: 15, Issue:13

    Topics: Anti-HIV Agents; Codon; Drug Resistance, Microbial; HIV Infections; HIV Reverse Transcriptase; HIV-1

1999
Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma.
    AIDS research and human retroviruses, 1999, Sep-01, Volume: 15, Issue:13

    Topics: Anti-HIV Agents; Codon; Drug Resistance, Microbial; HIV Infections; HIV Reverse Transcriptase; HIV-1

1999
Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
    Lancet (London, England), 1999, Sep-04, Volume: 354, Issue:9181

    Topics: Africa South of the Sahara; Anti-HIV Agents; Cost-Benefit Analysis; Drug Administration Schedule; Fe

1999
Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
    Lancet (London, England), 1999, Sep-04, Volume: 354, Issue:9181

    Topics: Africa South of the Sahara; Anti-HIV Agents; Cost-Benefit Analysis; Drug Administration Schedule; Fe

1999
Call to buy nevirapine for developing countries.
    Nature medicine, 1999, Volume: 5, Issue:10

    Topics: Africa; Congresses as Topic; Developing Countries; Female; HIV Infections; Humans; India; Infectious

1999
Call to buy nevirapine for developing countries.
    Nature medicine, 1999, Volume: 5, Issue:10

    Topics: Africa; Congresses as Topic; Developing Countries; Female; HIV Infections; Humans; India; Infectious

1999
Perinatal HIV prevention.
    JAMA, 1999, Aug-18, Volume: 282, Issue:7

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

1999
Perinatal HIV prevention.
    JAMA, 1999, Aug-18, Volume: 282, Issue:7

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

1999
AIDS drug trials in Thailand and Uganda.
    Nature medicine, 1999, Volume: 5, Issue:11

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectio

1999
AIDS drug trials in Thailand and Uganda.
    Nature medicine, 1999, Volume: 5, Issue:11

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectio

1999
Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual.
    AIDS (London, England), 1999, Oct-22, Volume: 13, Issue:15

    Topics: Administration, Oral; Anti-HIV Agents; Drug Therapy, Combination; HIV Envelope Protein gp41; HIV Inf

1999
Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual.
    AIDS (London, England), 1999, Oct-22, Volume: 13, Issue:15

    Topics: Administration, Oral; Anti-HIV Agents; Drug Therapy, Combination; HIV Envelope Protein gp41; HIV Inf

1999
Prednisolone does not prevent the occurrence of nevirapine-induced rashes.
    AIDS (London, England), 1999, Nov-12, Volume: 13, Issue:16

    Topics: Anti-HIV Agents; Anti-Inflammatory Agents; Drug Eruptions; HIV Infections; Humans; Nevirapine; Predn

1999
Prednisolone does not prevent the occurrence of nevirapine-induced rashes.
    AIDS (London, England), 1999, Nov-12, Volume: 13, Issue:16

    Topics: Anti-HIV Agents; Anti-Inflammatory Agents; Drug Eruptions; HIV Infections; Humans; Nevirapine; Predn

1999
HIVNET nevirapine trials.
    Lancet (London, England), 1999, Nov-20, Volume: 354, Issue:9192

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Infant, Newbor

1999
HIVNET nevirapine trials.
    Lancet (London, England), 1999, Nov-20, Volume: 354, Issue:9192

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Infant, Newbor

1999
HIVNET nevirapine trials.
    Lancet (London, England), 1999, Nov-20, Volume: 354, Issue:9192

    Topics: Anti-HIV Agents; Cost-Benefit Analysis; Counseling; Developing Countries; Female; HIV Infections; HI

1999
HIVNET nevirapine trials.
    Lancet (London, England), 1999, Nov-20, Volume: 354, Issue:9192

    Topics: Anti-HIV Agents; Cost-Benefit Analysis; Counseling; Developing Countries; Female; HIV Infections; HI

1999
HIVNET nevirapine trials.
    Lancet (London, England), 1999, Nov-20, Volume: 354, Issue:9192

    Topics: Anti-HIV Agents; Counseling; Ethics, Medical; Female; HIV Infections; HIV-1; Humans; Infectious Dise

1999
HIVNET nevirapine trials.
    Lancet (London, England), 1999, Nov-20, Volume: 354, Issue:9192

    Topics: Anti-HIV Agents; Counseling; Ethics, Medical; Female; HIV Infections; HIV-1; Humans; Infectious Dise

1999
AZT--the saga continues.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1999, Volume: 89, Issue:12

    Topics: Adolescent; Adult; Child; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission,

1999
AZT--the saga continues.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1999, Volume: 89, Issue:12

    Topics: Adolescent; Adult; Child; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission,

1999
[Pharma-clinics. The drug of the month. Nevirapine. Viramune].
    Revue medicale de Liege, 1999, Volume: 54, Issue:12

    Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Nevirapine; Viral Load

1999
[Pharma-clinics. The drug of the month. Nevirapine. Viramune].
    Revue medicale de Liege, 1999, Volume: 54, Issue:12

    Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Nevirapine; Viral Load

1999
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
    AIDS (London, England), 2000, Jan-28, Volume: 14, Issue:2

    Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Delavirdine; Drug Resistance, Microbial

2000
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
    AIDS (London, England), 2000, Jan-28, Volume: 14, Issue:2

    Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Delavirdine; Drug Resistance, Microbial

2000
Are nelfinavir-containing regimens effective as second-line triple therapy?
    AIDS (London, England), 2000, Jan-07, Volume: 14, Issue:1

    Topics: Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Human

2000
Are nelfinavir-containing regimens effective as second-line triple therapy?
    AIDS (London, England), 2000, Jan-07, Volume: 14, Issue:1

    Topics: Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Human

2000
[Nevirapine induces abstinence symptoms in patients on a methadone maintenance program with HIV infection].
    Revista clinica espanola, 2000, Volume: 200, Issue:1

    Topics: Adult; Analysis of Variance; Anti-HIV Agents; Chronic Disease; Drug Interactions; Drug Therapy, Comb

2000
[Nevirapine induces abstinence symptoms in patients on a methadone maintenance program with HIV infection].
    Revista clinica espanola, 2000, Volume: 200, Issue:1

    Topics: Adult; Analysis of Variance; Anti-HIV Agents; Chronic Disease; Drug Interactions; Drug Therapy, Comb

2000
Stopping vertical transmission of HIV: global strategies.
    AIDS patient care and STDs, 1999, Volume: 13, Issue:11

    Topics: Anti-HIV Agents; Breast Feeding; Drug Costs; Global Health; Health Priorities; HIV Infections; Human

1999
Stopping vertical transmission of HIV: global strategies.
    AIDS patient care and STDs, 1999, Volume: 13, Issue:11

    Topics: Anti-HIV Agents; Breast Feeding; Drug Costs; Global Health; Health Priorities; HIV Infections; Human

1999
South Africa to tighten control on drug trials after five death.
    BMJ (Clinical research ed.), 2000, Apr-15, Volume: 320, Issue:7241

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Death, Sudden; Deoxycytidine; Drug Combinations; Emtricit

2000
South Africa to tighten control on drug trials after five death.
    BMJ (Clinical research ed.), 2000, Apr-15, Volume: 320, Issue:7241

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Death, Sudden; Deoxycytidine; Drug Combinations; Emtricit

2000
The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome.
    International journal of STD & AIDS, 2000, Volume: 11, Issue:4

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease

2000
The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome.
    International journal of STD & AIDS, 2000, Volume: 11, Issue:4

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease

2000
Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal dialysis.
    The Journal of antimicrobial chemotherapy, 2000, Volume: 45, Issue:5

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Kidney Failure, Chronic; Nelfinavir;

2000
Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal dialysis.
    The Journal of antimicrobial chemotherapy, 2000, Volume: 45, Issue:5

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Kidney Failure, Chronic; Nelfinavir;

2000
Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy.
    International journal of STD & AIDS, 2000, Volume: 11, Issue:5

    Topics: Anti-HIV Agents; Biopsy; Chemical and Drug Induced Liver Injury; HIV Infections; Humans; Liver; Male

2000
Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy.
    International journal of STD & AIDS, 2000, Volume: 11, Issue:5

    Topics: Anti-HIV Agents; Biopsy; Chemical and Drug Induced Liver Injury; HIV Infections; Humans; Liver; Male

2000
Antiretroviral drug removal by haemodialysis.
    AIDS (London, England), 2000, May-05, Volume: 14, Issue:7

    Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Kidney Failure, Chronic; Nevirap

2000
Antiretroviral drug removal by haemodialysis.
    AIDS (London, England), 2000, May-05, Volume: 14, Issue:7

    Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Kidney Failure, Chronic; Nevirap

2000
Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000, Volume: 30 Suppl 2

    Topics: Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV Pr

2000
Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000, Volume: 30 Suppl 2

    Topics: Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV Pr

2000
Can early failure with nevirapine be rescued with efavirenz?
    Journal of acquired immune deficiency syndromes (1999), 2000, May-01, Volume: 24, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans;

2000
Can early failure with nevirapine be rescued with efavirenz?
    Journal of acquired immune deficiency syndromes (1999), 2000, May-01, Volume: 24, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans;

2000
[Effectiveness also in general practice conditions. Just as good in routine practice as in studies].
    MMW Fortschritte der Medizin, 2000, Volume: 142, Issue:3 Suppl

    Topics: Ambulatory Care; Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infection

2000
[Effectiveness also in general practice conditions. Just as good in routine practice as in studies].
    MMW Fortschritte der Medizin, 2000, Volume: 142, Issue:3 Suppl

    Topics: Ambulatory Care; Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infection

2000
The mother of all HIV challenges.
    Science (New York, N.Y.), 2000, Jun-23, Volume: 288, Issue:5474

    Topics: Africa South of the Sahara; AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Clinical Trials as

2000
The mother of all HIV challenges.
    Science (New York, N.Y.), 2000, Jun-23, Volume: 288, Issue:5474

    Topics: Africa South of the Sahara; AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Clinical Trials as

2000
Pharmacological implications of lengthened in-utero exposure to nevirapine.
    Lancet (London, England), 2000, Jun-17, Volume: 355, Issue:9221

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Fetal Blood; Half-Life; HIV Infections; HIV-1

2000
Pharmacological implications of lengthened in-utero exposure to nevirapine.
    Lancet (London, England), 2000, Jun-17, Volume: 355, Issue:9221

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Fetal Blood; Half-Life; HIV Infections; HIV-1

2000
Nevirapine: new preparation. In second-line triple-drug anti-HIV regimens.
    Prescrire international, 1998, Volume: 7, Issue:37

    Topics: Clinical Trials as Topic; Drug Combinations; Drug Interactions; HIV Infections; Humans; Nevirapine;

1998
Nevirapine: new preparation. In second-line triple-drug anti-HIV regimens.
    Prescrire international, 1998, Volume: 7, Issue:37

    Topics: Clinical Trials as Topic; Drug Combinations; Drug Interactions; HIV Infections; Humans; Nevirapine;

1998
Methadone withdrawal symptoms with nevirapine and efavirenz.
    The Annals of pharmacotherapy, 2000, Volume: 34, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; Hum

2000
Methadone withdrawal symptoms with nevirapine and efavirenz.
    The Annals of pharmacotherapy, 2000, Volume: 34, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; Hum

2000
Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use.
    AIDS (London, England), 2000, Jul-07, Volume: 14, Issue:10

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV Prote

2000
Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use.
    AIDS (London, England), 2000, Jul-07, Volume: 14, Issue:10

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV Prote

2000
South African government continues policy of inactivity.
    Nature medicine, 2000, Volume: 6, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Female; HIV Infections; Humans; Maternal-Fetal

2000
South African government continues policy of inactivity.
    Nature medicine, 2000, Volume: 6, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Female; HIV Infections; Humans; Maternal-Fetal

2000
Lactic acidosis associated with nucleoside analog therapy in an HIV-positive patient.
    AIDS patient care and STDs, 2000, Volume: 14, Issue:7

    Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Diagnosis, Differen

2000
Lactic acidosis associated with nucleoside analog therapy in an HIV-positive patient.
    AIDS patient care and STDs, 2000, Volume: 14, Issue:7

    Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Diagnosis, Differen

2000
Europe warned of side effects.
    AIDS patient care and STDs, 2000, Volume: 14, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Drug Eruptions; Europe; HIV Infections; Humans; Liver Failur

2000
Europe warned of side effects.
    AIDS patient care and STDs, 2000, Volume: 14, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Drug Eruptions; Europe; HIV Infections; Humans; Liver Failur

2000
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Antiviral chemistry & chemotherapy, 2000, Volume: 11, Issue:4

    Topics: Anti-HIV Agents; Cells, Cultured; Deoxycytidine; Didanosine; Drug Combinations; Drug Resistance, Mic

2000
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Antiviral chemistry & chemotherapy, 2000, Volume: 11, Issue:4

    Topics: Anti-HIV Agents; Cells, Cultured; Deoxycytidine; Didanosine; Drug Combinations; Drug Resistance, Mic

2000
Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.
    AIDS (London, England), 2000, Jul-28, Volume: 14, Issue:11

    Topics: Anti-HIV Agents; Drug Resistance, Microbial; Female; HIV Infections; HIV Reverse Transcriptase; HIV-

2000
Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.
    AIDS (London, England), 2000, Jul-28, Volume: 14, Issue:11

    Topics: Anti-HIV Agents; Drug Resistance, Microbial; Female; HIV Infections; HIV Reverse Transcriptase; HIV-

2000
Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study.
    AIDS (London, England), 2000, Jul-28, Volume: 14, Issue:11

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; Human

2000
Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study.
    AIDS (London, England), 2000, Jul-28, Volume: 14, Issue:11

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; Human

2000
Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?
    AIDS (London, England), 2000, Jul-28, Volume: 14, Issue:11

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Eruptions; Exanthema; HIV Infections; Hu

2000
Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?
    AIDS (London, England), 2000, Jul-28, Volume: 14, Issue:11

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Eruptions; Exanthema; HIV Infections; Hu

2000
AZT blues.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2000, Volume: 90, Issue:7

    Topics: Anti-HIV Agents; Counseling; Female; Foster Home Care; HIV Infections; HIV-1; Humans; Infant, Newbor

2000
AZT blues.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2000, Volume: 90, Issue:7

    Topics: Anti-HIV Agents; Counseling; Female; Foster Home Care; HIV Infections; HIV-1; Humans; Infant, Newbor

2000
Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography.
    Journal of chromatography. B, Biomedical sciences and applications, 2000, Jul-07, Volume: 744, Issue:1

    Topics: Adult; Chromatography, High Pressure Liquid; Drug Stability; Female; HIV Infections; HIV Reverse Tra

2000
Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography.
    Journal of chromatography. B, Biomedical sciences and applications, 2000, Jul-07, Volume: 744, Issue:1

    Topics: Adult; Chromatography, High Pressure Liquid; Drug Stability; Female; HIV Infections; HIV Reverse Tra

2000
Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.
    AIDS (London, England), 2000, Sep-08, Volume: 14, Issue:13

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV-1; Humans; Lamivu

2000
Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.
    AIDS (London, England), 2000, Sep-08, Volume: 14, Issue:13

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV-1; Humans; Lamivu

2000
Prevention of mother-child HIV transmission: progress and problems.
    Prescrire international, 2000, Volume: 9, Issue:47

    Topics: Africa; Antiviral Agents; Breast Feeding; Cesarean Section; Clinical Trials as Topic; Cohort Studies

2000
Prevention of mother-child HIV transmission: progress and problems.
    Prescrire international, 2000, Volume: 9, Issue:47

    Topics: Africa; Antiviral Agents; Breast Feeding; Cesarean Section; Clinical Trials as Topic; Cohort Studies

2000
Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy.
    Journal of acquired immune deficiency syndromes (1999), 2000, Aug-01, Volume: 24, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Arteriosclerosis; Benzoxazines; Cholesterol; Cyclopropanes; Drug Th

2000
Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy.
    Journal of acquired immune deficiency syndromes (1999), 2000, Aug-01, Volume: 24, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Arteriosclerosis; Benzoxazines; Cholesterol; Cyclopropanes; Drug Th

2000
Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa.
    Journal of acquired immune deficiency syndromes (1999), 2000, Aug-01, Volume: 24, Issue:4

    Topics: Africa South of the Sahara; AIDS Serodiagnosis; Anti-HIV Agents; Cost-Benefit Analysis; Decision Sup

2000
Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa.
    Journal of acquired immune deficiency syndromes (1999), 2000, Aug-01, Volume: 24, Issue:4

    Topics: Africa South of the Sahara; AIDS Serodiagnosis; Anti-HIV Agents; Cost-Benefit Analysis; Decision Sup

2000
The tolerability of efavirenz after nevirapine-related adverse events.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000, Volume: 31, Issue:3

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Anxiety Disorders; Benzoxazines; Cyclopropanes; Female; HIV;

2000
The tolerability of efavirenz after nevirapine-related adverse events.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000, Volume: 31, Issue:3

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Anxiety Disorders; Benzoxazines; Cyclopropanes; Female; HIV;

2000
Nevirapine plus didanosine: once or twice daily combination?
    Journal of acquired immune deficiency syndromes (1999), 2000, Sep-01, Volume: 25, Issue:1

    Topics: Administration, Oral; Adult; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy

2000
Nevirapine plus didanosine: once or twice daily combination?
    Journal of acquired immune deficiency syndromes (1999), 2000, Sep-01, Volume: 25, Issue:1

    Topics: Administration, Oral; Adult; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy

2000
Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.
    Antiviral therapy, 2000, Volume: 5, Issue:3

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; DNA, Viral; Drug Resistance, Microbial; D

2000
Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.
    Antiviral therapy, 2000, Volume: 5, Issue:3

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; DNA, Viral; Drug Resistance, Microbial; D

2000
No turning back now.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2000, Volume: 90, Issue:9

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmis

2000
No turning back now.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2000, Volume: 90, Issue:9

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmis

2000
Nevirapine for HIV prevention after rape.
    Lancet (London, England), 2000, Aug-26, Volume: 356, Issue:9231

    Topics: Africa; Anti-HIV Agents; Female; HIV Infections; Humans; Nevirapine; Rape

2000
Nevirapine for HIV prevention after rape.
    Lancet (London, England), 2000, Aug-26, Volume: 356, Issue:9231

    Topics: Africa; Anti-HIV Agents; Female; HIV Infections; Humans; Nevirapine; Rape

2000
[Genotypic resistance to antiretroviral drugs in patients with therapeutic failure to highly active antiretroviral therapy].
    Medicina clinica, 2000, Oct-07, Volume: 115, Issue:11

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Microbial; End

2000
[Genotypic resistance to antiretroviral drugs in patients with therapeutic failure to highly active antiretroviral therapy].
    Medicina clinica, 2000, Oct-07, Volume: 115, Issue:11

    Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Microbial; End

2000
Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers.
    JAMA, 2000, Dec-06, Volume: 284, Issue:21

    Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Therapy, Combination; Female; HIV Infections; Humans; I

2000
Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers.
    JAMA, 2000, Dec-06, Volume: 284, Issue:21

    Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Therapy, Combination; Female; HIV Infections; Humans; I

2000
Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers.
    JAMA, 2000, Dec-06, Volume: 284, Issue:21

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Female; H

2000
Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers.
    JAMA, 2000, Dec-06, Volume: 284, Issue:21

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Female; H

2000
Human immunodeficiency virus type-1: mother-to-child transmission. Meeting of World Federation of Scientists in Erice, Italy, August 2000. Joint report of AIDS/Infectious Diseases PMP and Mother and Child PMP.
    Acta paediatrica (Oslo, Norway : 1992), 2000, Volume: 89, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Africa South of the Sahara; Age Factors; Anti-HIV Agents; Breast

2000
Human immunodeficiency virus type-1: mother-to-child transmission. Meeting of World Federation of Scientists in Erice, Italy, August 2000. Joint report of AIDS/Infectious Diseases PMP and Mother and Child PMP.
    Acta paediatrica (Oslo, Norway : 1992), 2000, Volume: 89, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Africa South of the Sahara; Age Factors; Anti-HIV Agents; Breast

2000
Sex differences in nevirapine rash.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Volume: 32, Issue:1

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Eruptions; Exanthema; Female; HIV Infections; Humans; M

2001
Sex differences in nevirapine rash.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Volume: 32, Issue:1

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Eruptions; Exanthema; Female; HIV Infections; Humans; M

2001
A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics.
    Proceedings of the National Academy of Sciences of the United States of America, 2001, Jan-02, Volume: 98, Issue:1

    Topics: Antiviral Agents; Base Sequence; Cross-Sectional Studies; DNA Probes; Drug Resistance, Microbial; Ev

2001
A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics.
    Proceedings of the National Academy of Sciences of the United States of America, 2001, Jan-02, Volume: 98, Issue:1

    Topics: Antiviral Agents; Base Sequence; Cross-Sectional Studies; DNA Probes; Drug Resistance, Microbial; Ev

2001
Authorities fiddle while HIV burns in South Africa.
    Lancet (London, England), 2000, Dec-02, Volume: 356, Issue:9245

    Topics: Anti-HIV Agents; Communicable Disease Control; HIV Infections; Humans; Nevirapine; South Africa

2000
Authorities fiddle while HIV burns in South Africa.
    Lancet (London, England), 2000, Dec-02, Volume: 356, Issue:9245

    Topics: Anti-HIV Agents; Communicable Disease Control; HIV Infections; Humans; Nevirapine; South Africa

2000
Future directions.
    Annals of the New York Academy of Sciences, 2000, Volume: 918

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Counseling; Fem

2000
Future directions.
    Annals of the New York Academy of Sciences, 2000, Volume: 918

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Counseling; Fem

2000
Antiretroviral pharmacology in pregnant women and their newborns.
    Annals of the New York Academy of Sciences, 2000, Volume: 918

    Topics: Administration, Oral; Anti-HIV Agents; Delivery, Obstetric; Female; HIV Infections; Humans; Infant;

2000
Antiretroviral pharmacology in pregnant women and their newborns.
    Annals of the New York Academy of Sciences, 2000, Volume: 918

    Topics: Administration, Oral; Anti-HIV Agents; Delivery, Obstetric; Female; HIV Infections; Humans; Infant;

2000
Incomplete genotypic resistance to nonnucleoside reverse transcriptase inhibitors in patients treated with nevirapine: a potential interest in clinical practice.
    Journal of acquired immune deficiency syndromes (1999), 2000, Dec-15, Volume: 25, Issue:5

    Topics: Adult; Cross-Sectional Studies; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genot

2000
Incomplete genotypic resistance to nonnucleoside reverse transcriptase inhibitors in patients treated with nevirapine: a potential interest in clinical practice.
    Journal of acquired immune deficiency syndromes (1999), 2000, Dec-15, Volume: 25, Issue:5

    Topics: Adult; Cross-Sectional Studies; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genot

2000
Experience with nevirapine in previously treated HIV-1-infected individuals.
    Antiviral therapy, 2000, Volume: 5, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; HIV

2000
Experience with nevirapine in previously treated HIV-1-infected individuals.
    Antiviral therapy, 2000, Volume: 5, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; HIV

2000
Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine.
    Journal of the American Academy of Dermatology, 2001, Volume: 44, Issue:2 Suppl

    Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Prognosis; Ris

2001
Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine.
    Journal of the American Academy of Dermatology, 2001, Volume: 44, Issue:2 Suppl

    Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Prognosis; Ris

2001
Nevirapine and postexposure prophylaxis for human immunodeficiency virus.
    JAMA, 2001, Feb-21, Volume: 285, Issue:7

    Topics: Anti-HIV Agents; Health Personnel; HIV Infections; Humans; Nevirapine; Occupational Exposure

2001
Nevirapine and postexposure prophylaxis for human immunodeficiency virus.
    JAMA, 2001, Feb-21, Volume: 285, Issue:7

    Topics: Anti-HIV Agents; Health Personnel; HIV Infections; Humans; Nevirapine; Occupational Exposure

2001
Switch study of nevirapine.
    AIDS patient care and STDs, 2000, Volume: 14, Issue:12

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol; Drug Resistance, Microbial; HIV

2000
Switch study of nevirapine.
    AIDS patient care and STDs, 2000, Volume: 14, Issue:12

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol; Drug Resistance, Microbial; HIV

2000
[Exanthema in a patient infected with the human immunodeficiency virus after starting antiretroviral treatment].
    Revista clinica espanola, 2000, Volume: 200, Issue:11

    Topics: Adult; Anti-HIV Agents; Didanosine; Drug Eruptions; HIV Infections; Humans; Male; Nevirapine; Revers

2000
[Exanthema in a patient infected with the human immunodeficiency virus after starting antiretroviral treatment].
    Revista clinica espanola, 2000, Volume: 200, Issue:11

    Topics: Adult; Anti-HIV Agents; Didanosine; Drug Eruptions; HIV Infections; Humans; Male; Nevirapine; Revers

2000
Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.
    MMWR. Morbidity and mortality weekly report, 2001, Jan-05, Volume: 49, Issue:51-52

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Eruptions; Female; HIV Infectio

2001
Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.
    MMWR. Morbidity and mortality weekly report, 2001, Jan-05, Volume: 49, Issue:51-52

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Eruptions; Female; HIV Infectio

2001
Pharmacokinetic of nevirapine in haemodialysis.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16, Issue:1

    Topics: Adult; Anti-HIV Agents; HIV Infections; Humans; Kidney Failure, Chronic; Male; Middle Aged; Nevirapi

2001
Pharmacokinetic of nevirapine in haemodialysis.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16, Issue:1

    Topics: Adult; Anti-HIV Agents; HIV Infections; Humans; Kidney Failure, Chronic; Male; Middle Aged; Nevirapi

2001
Need for increased dose of warfarin in HIV patients taking nevirapine.
    AIDS (London, England), 2001, Jan-26, Volume: 15, Issue:2

    Topics: Adult; Anti-HIV Agents; Anticoagulants; Dose-Response Relationship, Drug; HIV Infections; Humans; Ma

2001
Need for increased dose of warfarin in HIV patients taking nevirapine.
    AIDS (London, England), 2001, Jan-26, Volume: 15, Issue:2

    Topics: Adult; Anti-HIV Agents; Anticoagulants; Dose-Response Relationship, Drug; HIV Infections; Humans; Ma

2001
Leukocytopenia due to zidovudine- and nevirapine-containing regimens in elderly patients with HIV infection.
    Japanese journal of infectious diseases, 2000, Volume: 53, Issue:6

    Topics: Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Therapy, Combination;

2000
Leukocytopenia due to zidovudine- and nevirapine-containing regimens in elderly patients with HIV infection.
    Japanese journal of infectious diseases, 2000, Volume: 53, Issue:6

    Topics: Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Therapy, Combination;

2000
Further views by the Erice working group on mother-to-child transmission of HIV type 1.
    Acta paediatrica (Oslo, Norway : 1992), 2001, Volume: 90, Issue:1

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease T

2001
Further views by the Erice working group on mother-to-child transmission of HIV type 1.
    Acta paediatrica (Oslo, Norway : 1992), 2001, Volume: 90, Issue:1

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease T

2001
Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1.
    Lancet (London, England), 2001, Mar-03, Volume: 357, Issue:9257

    Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine;

2001
Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1.
    Lancet (London, England), 2001, Mar-03, Volume: 357, Issue:9257

    Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine;

2001
Galactorrhoea, hyperprolactinaemia, and protease inhibitors.
    Lancet (London, England), 2001, Feb-10, Volume: 357, Issue:9254

    Topics: Adult; Drug Therapy, Combination; Female; Galactorrhea; HIV Infections; HIV Protease Inhibitors; HIV

2001
Galactorrhoea, hyperprolactinaemia, and protease inhibitors.
    Lancet (London, England), 2001, Feb-10, Volume: 357, Issue:9254

    Topics: Adult; Drug Therapy, Combination; Female; Galactorrhea; HIV Infections; HIV Protease Inhibitors; HIV

2001
Drug interaction between St John's wort and nevirapine.
    AIDS (London, England), 2001, Feb-16, Volume: 15, Issue:3

    Topics: Adult; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; HIV Infections; Humans; Hyperi

2001
Drug interaction between St John's wort and nevirapine.
    AIDS (London, England), 2001, Feb-16, Volume: 15, Issue:3

    Topics: Adult; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; HIV Infections; Humans; Hyperi

2001
Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure.
    Antiviral therapy, 1996, Volume: 1, Issue:1

    Topics: Codon; Cysteine; Drug Resistance, Microbial; Follow-Up Studies; HIV Infections; HIV-1; Humans; Mutat

1996
Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure.
    Antiviral therapy, 1996, Volume: 1, Issue:1

    Topics: Codon; Cysteine; Drug Resistance, Microbial; Follow-Up Studies; HIV Infections; HIV-1; Humans; Mutat

1996
[Cutaneous adverse events related to simultaneous nevirapine treatment and pneumococcal vaccination in HIV-infected patients].
    Medicina clinica, 2001, Mar-31, Volume: 116, Issue:12

    Topics: Adult; Drug Eruptions; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Pneumococcal Vaccines;

2001
[Cutaneous adverse events related to simultaneous nevirapine treatment and pneumococcal vaccination in HIV-infected patients].
    Medicina clinica, 2001, Mar-31, Volume: 116, Issue:12

    Topics: Adult; Drug Eruptions; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Pneumococcal Vaccines;

2001
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Journal of virology, 2001, Volume: 75, Issue:11

    Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cells, Cultured; Clinical Trials, P

2001
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Journal of virology, 2001, Volume: 75, Issue:11

    Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cells, Cultured; Clinical Trials, P

2001
Triple therapy in previously untreated patients reduces viral load below limit of detection.
    AIDS patient care and STDs, 1996, Volume: 10, Issue:5

    Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; P

1996
Triple therapy in previously untreated patients reduces viral load below limit of detection.
    AIDS patient care and STDs, 1996, Volume: 10, Issue:5

    Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; P

1996
Viramune Expanded Access Program begins.
    AIDS patient care and STDs, 1996, Volume: 10, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drugs, Investigational; Female; HIV Infections;

1996
Viramune Expanded Access Program begins.
    AIDS patient care and STDs, 1996, Volume: 10, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drugs, Investigational; Female; HIV Infections;

1996
Two studies suggest nevirapine benefit for children.
    AIDS patient care and STDs, 1997, Volume: 11, Issue:3

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Female; HIV Infect

1997
Two studies suggest nevirapine benefit for children.
    AIDS patient care and STDs, 1997, Volume: 11, Issue:3

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Female; HIV Infect

1997
Viramune triple therapy shows suppression of HIV after 1 year, 7 months.
    AIDS patient care and STDs, 1997, Volume: 11, Issue:6

    Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Zidovudi

1997
Viramune triple therapy shows suppression of HIV after 1 year, 7 months.
    AIDS patient care and STDs, 1997, Volume: 11, Issue:6

    Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Zidovudi

1997
Data on nevirapine combinations released.
    AIDS patient care and STDs, 1998, Volume: 12, Issue:4

    Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinav

1998
Data on nevirapine combinations released.
    AIDS patient care and STDs, 1998, Volume: 12, Issue:4

    Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinav

1998
Recruitment underway for oral contraceptive trial.
    AIDS patient care and STDs, 1998, Volume: 12, Issue:5

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Contraceptives, Oral, Combined; Drug Combinations; Drug I

1998
Recruitment underway for oral contraceptive trial.
    AIDS patient care and STDs, 1998, Volume: 12, Issue:5

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Contraceptives, Oral, Combined; Drug Combinations; Drug I

1998
Protease inhibitor-sparing regimen suppresses HIV.
    AIDS patient care and STDs, 1998, Volume: 12, Issue:12

    Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse

1998
Protease inhibitor-sparing regimen suppresses HIV.
    AIDS patient care and STDs, 1998, Volume: 12, Issue:12

    Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse

1998
New information on HIV rapid turnover--what does it mean?
    AIDS treatment news, 1995, Jan-20, Issue:No 215

    Topics: Antiviral Agents; CD4 Lymphocyte Count; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indina

1995
New information on HIV rapid turnover--what does it mean?
    AIDS treatment news, 1995, Jan-20, Issue:No 215

    Topics: Antiviral Agents; CD4 Lymphocyte Count; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indina

1995
Nevirapine triple combo results released.
    Common factor (Stoughton, Mass.), 1995, Issue:no 10

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combinat

1995
Nevirapine triple combo results released.
    Common factor (Stoughton, Mass.), 1995, Issue:no 10

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combinat

1995
New combo trial/same old style.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:4

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Protocols; Drug Therapy, Combination; HIV Infection

1995
New combo trial/same old style.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:4

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Protocols; Drug Therapy, Combination; HIV Infection

1995
Nevirapine: ethical dilemmas and care for HIV-infected mothers.
    Focus (San Francisco, Calif.), 1995, Volume: 10, Issue:7

    Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Counseling; Ethics, Medical; F

1995
Nevirapine: ethical dilemmas and care for HIV-infected mothers.
    Focus (San Francisco, Calif.), 1995, Volume: 10, Issue:7

    Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Counseling; Ethics, Medical; F

1995
Non-nucleoside reverse transcriptase inhibitors.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1996

    Topics: Acetamides; Acetophenones; Antiviral Agents; Delavirdine; Drug Approval; Drug Resistance, Microbial;

1996
Non-nucleoside reverse transcriptase inhibitors.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1996

    Topics: Acetamides; Acetophenones; Antiviral Agents; Delavirdine; Drug Approval; Drug Resistance, Microbial;

1996
Nevirapine recommended for approval.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1996

    Topics: Antiviral Agents; Drug Approval; HIV Infections; Humans; Nevirapine; Pyridines; United States; Unite

1996
Nevirapine recommended for approval.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1996

    Topics: Antiviral Agents; Drug Approval; HIV Infections; Humans; Nevirapine; Pyridines; United States; Unite

1996
FDA approves first new class of HIV drugs. Food and Drug Administration.
    AIDS alert, 1996, Volume: 11, Issue:8

    Topics: Antiviral Agents; Drug Approval; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibi

1996
FDA approves first new class of HIV drugs. Food and Drug Administration.
    AIDS alert, 1996, Volume: 11, Issue:8

    Topics: Antiviral Agents; Drug Approval; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibi

1996
Nevirapine and delavirdine plus protease inhibitors.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1996, Volume: 10, Issue:4

    Topics: Delavirdine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indoles; Ne

1996
Nevirapine and delavirdine plus protease inhibitors.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1996, Volume: 10, Issue:4

    Topics: Delavirdine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indoles; Ne

1996
Nevirapine: new drug, new class, new questions.
    Journal of the International Association of Physicians in AIDS Care, 1996, Volume: 2, Issue:7

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Approval; Drug Therapy, Combi

1996
Nevirapine: new drug, new class, new questions.
    Journal of the International Association of Physicians in AIDS Care, 1996, Volume: 2, Issue:7

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Approval; Drug Therapy, Combi

1996
New York ADAP to cover new AIDS drugs plus viral load testing.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1996, Volume: 10, Issue:9

    Topics: Acquired Immunodeficiency Syndrome; Antibiotics, Antineoplastic; Antiviral Agents; Cytomegalovirus I

1996
New York ADAP to cover new AIDS drugs plus viral load testing.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1996, Volume: 10, Issue:9

    Topics: Acquired Immunodeficiency Syndrome; Antibiotics, Antineoplastic; Antiviral Agents; Cytomegalovirus I

1996
Nevirapine--first of a new class of drugs.
    PI perspective, 1996, Issue:No 19

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV; HIV

1996
Nevirapine--first of a new class of drugs.
    PI perspective, 1996, Issue:No 19

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV; HIV

1996
Nevirapine approved by FDA. Food and Drug Administration.
    NIAID AIDS agenda, 1996

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Approval; Drug Th

1996
Nevirapine approved by FDA. Food and Drug Administration.
    NIAID AIDS agenda, 1996

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Approval; Drug Th

1996
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
    NIAID AIDS agenda, 1997

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as To

1997
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
    NIAID AIDS agenda, 1997

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as To

1997
Scientific basis for PEP rests in animal trials.
    AIDS alert, 1997, Volume: 12, Issue:9

    Topics: Adenine; Animals; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Health Personne

1997
Scientific basis for PEP rests in animal trials.
    AIDS alert, 1997, Volume: 12, Issue:9

    Topics: Adenine; Animals; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Health Personne

1997
Update on nevirapine: quest for a niche.
    Journal of the International Association of Physicians in AIDS Care, 1997, Volume: 3, Issue:9

    Topics: Adult; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Dru

1997
Update on nevirapine: quest for a niche.
    Journal of the International Association of Physicians in AIDS Care, 1997, Volume: 3, Issue:9

    Topics: Adult; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Dru

1997
Pregnant women eligible for single-dose nevirapine study.
    AIDS treatment news, 1997, Oct-03, Issue:No 280

    Topics: Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transm

1997
Pregnant women eligible for single-dose nevirapine study.
    AIDS treatment news, 1997, Oct-03, Issue:No 280

    Topics: Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transm

1997
Perinatal HIV down as treatment increases.
    AIDS alert, 1997, Volume: 12, Issue:11

    Topics: Adult; Clinical Trials as Topic; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant,

1997
Perinatal HIV down as treatment increases.
    AIDS alert, 1997, Volume: 12, Issue:11

    Topics: Adult; Clinical Trials as Topic; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant,

1997
Preventing HIV infection in infants in developing countries: NIAID's role. National Institute of Allergy and Infectious Diseases.
    NIAID AIDS agenda, 1997

    Topics: Anti-HIV Agents; Child; Child, Preschool; Clinical Trials as Topic; Developing Countries; Ethiopia;

1997
Preventing HIV infection in infants in developing countries: NIAID's role. National Institute of Allergy and Infectious Diseases.
    NIAID AIDS agenda, 1997

    Topics: Anti-HIV Agents; Child; Child, Preschool; Clinical Trials as Topic; Developing Countries; Ethiopia;

1997
Pediatric HIV clinical trials in the United States.
    NIAID AIDS agenda, 1997

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy, Combin

1997
Pediatric HIV clinical trials in the United States.
    NIAID AIDS agenda, 1997

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy, Combin

1997
HIV in the brain: an interview with Dr. Michael Wool, UCLA researcher.
    Positive Directions news : a support and information network of people with HIV/AIDS, their families, friends and providers, 1998, Volume: 10, Issue:1

    Topics: AIDS Dementia Complex; Anti-HIV Agents; Blood-Brain Barrier; Brain; Drug Therapy, Combination; Drugs

1998
HIV in the brain: an interview with Dr. Michael Wool, UCLA researcher.
    Positive Directions news : a support and information network of people with HIV/AIDS, their families, friends and providers, 1998, Volume: 10, Issue:1

    Topics: AIDS Dementia Complex; Anti-HIV Agents; Blood-Brain Barrier; Brain; Drug Therapy, Combination; Drugs

1998
Oral contraceptive/nevirapine interaction trial, New York and San Francisco.
    AIDS treatment news, 1998, Mar-06, Issue:No 290

    Topics: Clinical Trials as Topic; Contraceptives, Oral; Drug Interactions; Female; HIV Infections; Nevirapin

1998
Oral contraceptive/nevirapine interaction trial, New York and San Francisco.
    AIDS treatment news, 1998, Mar-06, Issue:No 290

    Topics: Clinical Trials as Topic; Contraceptives, Oral; Drug Interactions; Female; HIV Infections; Nevirapin

1998
Thai study success affects ongoing placebo trials.
    AIDS alert, 1998, Volume: 13, Issue:4

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectio

1998
Thai study success affects ongoing placebo trials.
    AIDS alert, 1998, Volume: 13, Issue:4

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectio

1998
Late breaking news: two additional DHHS guidelines changes. Department of Health and Human Services.
    The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 1998, Volume: 10, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Delavirdine; HIV Infections; Humans; Nevirapine; Reverse Transcr

1998
Late breaking news: two additional DHHS guidelines changes. Department of Health and Human Services.
    The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 1998, Volume: 10, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Delavirdine; HIV Infections; Humans; Nevirapine; Reverse Transcr

1998
NNRTIs: a neglected class.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1998, Volume: 12, Issue:9

    Topics: Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Delavirdine; Drug Resistance, Microb

1998
NNRTIs: a neglected class.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1998, Volume: 12, Issue:9

    Topics: Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Delavirdine; Drug Resistance, Microb

1998
Salvage therapy studies.
    Project Inform perspective, 1998, Issue:25

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Dideoxynucleosides; Drug Resistance

1998
Salvage therapy studies.
    Project Inform perspective, 1998, Issue:25

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Dideoxynucleosides; Drug Resistance

1998
Nevirapine receives green light from Health Protection Branch.
    TreatmentUpdate, 1998, Volume: 10, Issue:8

    Topics: Canada; Drug Approval; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors

1998
Nevirapine receives green light from Health Protection Branch.
    TreatmentUpdate, 1998, Volume: 10, Issue:8

    Topics: Canada; Drug Approval; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors

1998
Viral load--how low is best?
    TreatmentUpdate, 1998, Volume: 10, Issue:10

    Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse

1998
Viral load--how low is best?
    TreatmentUpdate, 1998, Volume: 10, Issue:10

    Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse

1998
Unequal care sustains vertical transmission rate.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1999, Volume: 13, Issue:2

    Topics: Anti-HIV Agents; Cesarean Section; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans;

1999
Unequal care sustains vertical transmission rate.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1999, Volume: 13, Issue:2

    Topics: Anti-HIV Agents; Cesarean Section; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans;

1999
FDA news. Food and Drug Administration.
    Research initiative, treatment action : RITA, 1999, Volume: 5, Issue:1

    Topics: Antineoplastic Agents; Child; Dermatologic Agents; Drug Approval; HIV Infections; Humans; Nevirapine

1999
FDA news. Food and Drug Administration.
    Research initiative, treatment action : RITA, 1999, Volume: 5, Issue:1

    Topics: Antineoplastic Agents; Child; Dermatologic Agents; Drug Approval; HIV Infections; Humans; Nevirapine

1999
Methadone and anti-HIV drugs.
    The Body positive, 1999, Volume: 12, Issue:5

    Topics: Alkynes; Analgesics, Opioid; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV In

1999
Methadone and anti-HIV drugs.
    The Body positive, 1999, Volume: 12, Issue:5

    Topics: Alkynes; Analgesics, Opioid; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV In

1999
Switching drugs for lipodystophy.
    The Body positive, 1999, Volume: 12, Issue:5

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol; Cyclopropanes; Drug Administration Schedule; HI

1999
Switching drugs for lipodystophy.
    The Body positive, 1999, Volume: 12, Issue:5

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol; Cyclopropanes; Drug Administration Schedule; HI

1999
Strategy update: protease-sparing regimens.
    Project Inform perspective, 1998, Issue:26

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Drug Therapy, Combination; HIV Infections; HIV Pr

1998
Strategy update: protease-sparing regimens.
    Project Inform perspective, 1998, Issue:26

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Drug Therapy, Combination; HIV Infections; HIV Pr

1998
Nevirapine in children.
    Project Inform perspective, 1998, Issue:26

    Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; HIV Infections; Humans; Infant;

1998
Nevirapine in children.
    Project Inform perspective, 1998, Issue:26

    Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; HIV Infections; Humans; Infant;

1998
Antivirals update.
    Project Inform perspective, 1998, Issue:26

    Topics: Anti-HIV Agents; Carbamates; Delavirdine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Thera

1998
Antivirals update.
    Project Inform perspective, 1998, Issue:26

    Topics: Anti-HIV Agents; Carbamates; Delavirdine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Thera

1998
Single-dose Nevirapine during pregnancy.
    AIDS clinical care, 1999, Volume: 11, Issue:10

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmis

1999
Single-dose Nevirapine during pregnancy.
    AIDS clinical care, 1999, Volume: 11, Issue:10

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmis

1999
Prevention of perinatal HIV infection: cause for optimism.
    AIDS clinical care, 1999, Volume: 11, Issue:12

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Cesarean Section; Clinical Trials as Topic; Drug Therapy, Combi

1999
Prevention of perinatal HIV infection: cause for optimism.
    AIDS clinical care, 1999, Volume: 11, Issue:12

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Cesarean Section; Clinical Trials as Topic; Drug Therapy, Combi

1999
Gender difference in Nevirapine-associated rash.
    Project Inform perspective, 1999, Issue:27

    Topics: Anti-HIV Agents; Drug Hypersensitivity; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Tr

1999
Gender difference in Nevirapine-associated rash.
    Project Inform perspective, 1999, Issue:27

    Topics: Anti-HIV Agents; Drug Hypersensitivity; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Tr

1999
Transfer therapy--Nevirapine for protease problems?
    TreatmentUpdate, 1999, Jun-01, Volume: 11, Issue:4

    Topics: Adipose Tissue; Anthropometry; Blood Glucose; CD4 Lymphocyte Count; Cholesterol; Drug Therapy, Combi

1999
Transfer therapy--Nevirapine for protease problems?
    TreatmentUpdate, 1999, Jun-01, Volume: 11, Issue:4

    Topics: Adipose Tissue; Anthropometry; Blood Glucose; CD4 Lymphocyte Count; Cholesterol; Drug Therapy, Combi

1999
Perinatal transmission.
    AIDS policy & law, 1999, Sep-17, Volume: 14, Issue:17

    Topics: Anti-HIV Agents; Developing Countries; Female; Foundations; HIV Infections; Humans; Infant, Newborn;

1999
Perinatal transmission.
    AIDS policy & law, 1999, Sep-17, Volume: 14, Issue:17

    Topics: Anti-HIV Agents; Developing Countries; Female; Foundations; HIV Infections; Humans; Infant, Newborn;

1999
Hope for Africa's next generation.
    WORLD (Oakland, Calif. : 1993), 1999, Issue:No 100

    Topics: Administration, Oral; Clinical Trials as Topic; Drug Administration Schedule; Female; HIV Infections

1999
Hope for Africa's next generation.
    WORLD (Oakland, Calif. : 1993), 1999, Issue:No 100

    Topics: Administration, Oral; Clinical Trials as Topic; Drug Administration Schedule; Female; HIV Infections

1999
Study offers hope for Africa's next generation.
    WORLD (Oakland, Calif. : 1993), 1999, Issue:No 101

    Topics: Administration, Oral; Anti-HIV Agents; Breast Feeding; Clinical Trials as Topic; Drug Administration

1999
Study offers hope for Africa's next generation.
    WORLD (Oakland, Calif. : 1993), 1999, Issue:No 101

    Topics: Administration, Oral; Anti-HIV Agents; Breast Feeding; Clinical Trials as Topic; Drug Administration

1999
Can a $4 drug stop vertical HIV transmission?
    AIDS alert, 1999, Volume: 14, Issue:11

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Health Services Accessibility; HIV Infections

1999
Can a $4 drug stop vertical HIV transmission?
    AIDS alert, 1999, Volume: 14, Issue:11

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Health Services Accessibility; HIV Infections

1999
Perinatal transmission.
    AIDS policy & law, 1999, Aug-06, Volume: 14, Issue:14

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infe

1999
Perinatal transmission.
    AIDS policy & law, 1999, Aug-06, Volume: 14, Issue:14

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infe

1999
Desensitization to Nevirapine.
    TreatmentUpdate, 1999, Nov-01, Volume: 11, Issue:8

    Topics: Anti-HIV Agents; Desensitization, Immunologic; Drug Hypersensitivity; HIV Infections; Humans; Nevira

1999
Desensitization to Nevirapine.
    TreatmentUpdate, 1999, Nov-01, Volume: 11, Issue:8

    Topics: Anti-HIV Agents; Desensitization, Immunologic; Drug Hypersensitivity; HIV Infections; Humans; Nevira

1999
HIV transmission.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1999, Volume: 12, Issue:4

    Topics: Condylomata Acuminata; Gonorrhea; HIV Infections; Homosexuality, Male; Humans; Male; Nevirapine; New

1999
HIV transmission.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1999, Volume: 12, Issue:4

    Topics: Condylomata Acuminata; Gonorrhea; HIV Infections; Homosexuality, Male; Humans; Male; Nevirapine; New

1999
Global strategies for the prevention of HIV transmission from mothers to infants: the second conference.
    Journal of the International Association of Physicians in AIDS Care, 1999, Volume: 5, Issue:12

    Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Clinical Trials as Topic; Congresses as Topic; De

1999
Global strategies for the prevention of HIV transmission from mothers to infants: the second conference.
    Journal of the International Association of Physicians in AIDS Care, 1999, Volume: 5, Issue:12

    Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Clinical Trials as Topic; Congresses as Topic; De

1999
Simpler regimens for preventing mother-to-child HIV transmission.
    Project Inform perspective, 1999, Issue:28

    Topics: Delivery, Obstetric; Developing Countries; Drug Administration Schedule; Female; HIV Infections; Hum

1999
Simpler regimens for preventing mother-to-child HIV transmission.
    Project Inform perspective, 1999, Issue:28

    Topics: Delivery, Obstetric; Developing Countries; Drug Administration Schedule; Female; HIV Infections; Hum

1999
[Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
    MMW Fortschritte der Medizin, 2001, Apr-02, Volume: 143 Suppl 1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; HIV; HIV Infections

2001
[Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
    MMW Fortschritte der Medizin, 2001, Apr-02, Volume: 143 Suppl 1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; HIV; HIV Infections

2001
[Highly active antiretroviral therapy with nevirapine. Therapy compliance determines success].
    MMW Fortschritte der Medizin, 2001, Apr-02, Volume: 143 Suppl 1

    Topics: Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Nevirapine; Patient Compliance; Treat

2001
[Highly active antiretroviral therapy with nevirapine. Therapy compliance determines success].
    MMW Fortschritte der Medizin, 2001, Apr-02, Volume: 143 Suppl 1

    Topics: Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Nevirapine; Patient Compliance; Treat

2001
Jaundice and hepatocellular damage associated with nevirapine therapy.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:5

    Topics: Adult; Chemical and Drug Induced Liver Injury; HIV Infections; Humans; Jaundice; Male; Middle Aged;

2001
Jaundice and hepatocellular damage associated with nevirapine therapy.
    The American journal of gastroenterology, 2001, Volume: 96, Issue:5

    Topics: Adult; Chemical and Drug Induced Liver Injury; HIV Infections; Humans; Jaundice; Male; Middle Aged;

2001
An in vivo model for HIV resistance development.
    AIDS research and human retroviruses, 2001, May-01, Volume: 17, Issue:7

    Topics: Animals; Chimera; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance; HIV Inf

2001
An in vivo model for HIV resistance development.
    AIDS research and human retroviruses, 2001, May-01, Volume: 17, Issue:7

    Topics: Animals; Chimera; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance; HIV Inf

2001
Preventing mother-to-child transmission of HIV in developing countries: recent developments and ethical implications.
    Reproductive health matters, 2000, Volume: 8, Issue:15

    Topics: Anti-HIV Agents; Developing Countries; Ethics, Medical; Female; HIV Infections; Humans; Infant, Newb

2000
Preventing mother-to-child transmission of HIV in developing countries: recent developments and ethical implications.
    Reproductive health matters, 2000, Volume: 8, Issue:15

    Topics: Anti-HIV Agents; Developing Countries; Ethics, Medical; Female; HIV Infections; Humans; Infant, Newb

2000
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
    AIDS (London, England), 2001, Jul-06, Volume: 15, Issue:10

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; HIV

2001
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
    AIDS (London, England), 2001, Jul-06, Volume: 15, Issue:10

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; HIV

2001
Rwanda to receive cheaper anti-HIV drugs for chronic treatment and free viramune to prevent viral transmission from mother to child.
    SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging, 2001, Volume: 56, Issue:4

    Topics: Anti-HIV Agents; Chronic Disease; Developing Countries; Drug Costs; Drug Industry; Female; HIV Infec

2001
Rwanda to receive cheaper anti-HIV drugs for chronic treatment and free viramune to prevent viral transmission from mother to child.
    SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging, 2001, Volume: 56, Issue:4

    Topics: Anti-HIV Agents; Chronic Disease; Developing Countries; Drug Costs; Drug Industry; Female; HIV Infec

2001
Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy.
    Scandinavian journal of infectious diseases, 2001, Volume: 33, Issue:6

    Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Hypersensitivity; Eosinophilia; Exanthema; HIV Infectio

2001
Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy.
    Scandinavian journal of infectious diseases, 2001, Volume: 33, Issue:6

    Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Hypersensitivity; Eosinophilia; Exanthema; HIV Infectio

2001
Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.
    Journal of acquired immune deficiency syndromes (1999), 2001, Aug-01, Volume: 27, Issue:4

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies;

2001
Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.
    Journal of acquired immune deficiency syndromes (1999), 2001, Aug-01, Volume: 27, Issue:4

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies;

2001
New drug regimen helps prevent HIV infection in infants.
    Health care financing review, 1999,Fall, Volume: 21, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

1999
New drug regimen helps prevent HIV infection in infants.
    Health care financing review, 1999,Fall, Volume: 21, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

1999
In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
    Antiviral therapy, 2001, Volume: 6, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; Drug Synergism; D

2001
In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
    Antiviral therapy, 2001, Volume: 6, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; Drug Synergism; D

2001
Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy.
    AIDS (London, England), 2001, Aug-17, Volume: 15, Issue:12

    Topics: Adult; Anti-Allergic Agents; Anti-HIV Agents; Drug Therapy, Combination; Exanthema; Female; HIV Infe

2001
Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy.
    AIDS (London, England), 2001, Aug-17, Volume: 15, Issue:12

    Topics: Adult; Anti-Allergic Agents; Anti-HIV Agents; Drug Therapy, Combination; Exanthema; Female; HIV Infe

2001
Adverse effects of nevirapine.
    Lancet (London, England), 2001, Aug-11, Volume: 358, Issue:9280

    Topics: Anti-HIV Agents; Health Personnel; HIV Infections; Humans; Infectious Disease Transmission, Patient-

2001
Adverse effects of nevirapine.
    Lancet (London, England), 2001, Aug-11, Volume: 358, Issue:9280

    Topics: Anti-HIV Agents; Health Personnel; HIV Infections; Humans; Infectious Disease Transmission, Patient-

2001
Adverse effects of nevirapine.
    Lancet (London, England), 2001, Aug-11, Volume: 358, Issue:9280

    Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; Health Personnel; HIV Infections; Humans; Infect

2001
Adverse effects of nevirapine.
    Lancet (London, England), 2001, Aug-11, Volume: 358, Issue:9280

    Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; Health Personnel; HIV Infections; Humans; Infect

2001
Taking HIV to court.
    Lancet (London, England), 2001, Sep-01, Volume: 358, Issue:9283

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2001
Taking HIV to court.
    Lancet (London, England), 2001, Sep-01, Volume: 358, Issue:9283

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2001
Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine.
    AIDS research and human retroviruses, 2001, Sep-01, Volume: 17, Issue:13

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hu

2001
Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine.
    AIDS research and human retroviruses, 2001, Sep-01, Volume: 17, Issue:13

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hu

2001
Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Nov-01, Volume: 33, Issue:9

    Topics: Adult; Analgesics, Opioid; Anti-HIV Agents; Drug Antagonism; Female; HIV Infections; HIV-1; Humans;

2001
Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Nov-01, Volume: 33, Issue:9

    Topics: Adult; Analgesics, Opioid; Anti-HIV Agents; Drug Antagonism; Female; HIV Infections; HIV-1; Humans;

2001
St. John's wort found to lower nevirapine levels.
    TreatmentUpdate, 2001,Spring, Volume: 12, Issue:11

    Topics: Anti-HIV Agents; Drug Interactions; HIV Infections; Humans; Hypericum; Nevirapine; Phytotherapy; Pla

2001
St. John's wort found to lower nevirapine levels.
    TreatmentUpdate, 2001,Spring, Volume: 12, Issue:11

    Topics: Anti-HIV Agents; Drug Interactions; HIV Infections; Humans; Hypericum; Nevirapine; Phytotherapy; Pla

2001
Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
    AIDS (London, England), 2001, Sep-28, Volume: 15, Issue:14

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Drug Eruptions; Female; HIV Infections; Humans; Male;

2001
Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
    AIDS (London, England), 2001, Sep-28, Volume: 15, Issue:14

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Drug Eruptions; Female; HIV Infections; Humans; Male;

2001
To test or not to test--ethical dilemmas and practical realities in the use of co-trimoxazole and nevirapine in HIV-infected adults.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2001, Volume: 91, Issue:8

    Topics: Adult; AIDS Serodiagnosis; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Developing Countr

2001
To test or not to test--ethical dilemmas and practical realities in the use of co-trimoxazole and nevirapine in HIV-infected adults.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2001, Volume: 91, Issue:8

    Topics: Adult; AIDS Serodiagnosis; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Developing Countr

2001
Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Journal of medical virology, 2001, Volume: 65, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Resist

2001
Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Journal of medical virology, 2001, Volume: 65, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Resist

2001
Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.
    AIDS (London, England), 2001, Nov-23, Volume: 15, Issue:17

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Furans; HI

2001
Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.
    AIDS (London, England), 2001, Nov-23, Volume: 15, Issue:17

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Furans; HI

2001
South Africa's stance on nevirapine on trial.
    Lancet (London, England), 2001, Nov-03, Volume: 358, Issue:9292

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infant; Infant, Newborn; Infectious

2001
South Africa's stance on nevirapine on trial.
    Lancet (London, England), 2001, Nov-03, Volume: 358, Issue:9292

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infant; Infant, Newborn; Infectious

2001
Nevirapine (Viramune).
    Research initiative, treatment action : RITA, 2000, Volume: 6, Issue:1

    Topics: Drug Resistance, Microbial; HIV; HIV Infections; Humans; Nevirapine; Practice Guidelines as Topic; R

2000
Nevirapine (Viramune).
    Research initiative, treatment action : RITA, 2000, Volume: 6, Issue:1

    Topics: Drug Resistance, Microbial; HIV; HIV Infections; Humans; Nevirapine; Practice Guidelines as Topic; R

2000
Zambian women's attitudes toward mass nevirapine therapy to prevent perinatal transmission of HIV.
    Lancet (London, England), 2001, Nov-10, Volume: 358, Issue:9293

    Topics: Anti-HIV Agents; Attitude to Health; Female; HIV Infections; Humans; Infectious Disease Transmission

2001
Zambian women's attitudes toward mass nevirapine therapy to prevent perinatal transmission of HIV.
    Lancet (London, England), 2001, Nov-10, Volume: 358, Issue:9293

    Topics: Anti-HIV Agents; Attitude to Health; Female; HIV Infections; Humans; Infectious Disease Transmission

2001
Drugs for HIV infection.
    The Medical letter on drugs and therapeutics, 2001, Nov-26, Volume: 43, Issue:1119

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dose-Response Relationship, Drug; HIV

2001
Drugs for HIV infection.
    The Medical letter on drugs and therapeutics, 2001, Nov-26, Volume: 43, Issue:1119

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dose-Response Relationship, Drug; HIV

2001
A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users.
    HIV medicine, 2000, Volume: 1, Issue:3

    Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Administration Schedule; Drug Therapy,

2000
A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users.
    HIV medicine, 2000, Volume: 1, Issue:3

    Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Administration Schedule; Drug Therapy,

2000
Experience of nevirapine use in a London cohort of HIV-infected pregnant women.
    HIV medicine, 2001, Volume: 2, Issue:2

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; HIV-1; Humans;

2001
Experience of nevirapine use in a London cohort of HIV-infected pregnant women.
    HIV medicine, 2001, Volume: 2, Issue:2

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; HIV-1; Humans;

2001
Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis.
    Journal of acquired immune deficiency syndromes (1999), 2001, Dec-15, Volume: 28, Issue:5

    Topics: Anti-HIV Agents; Antibiotics, Antitubercular; Chromatography, High Pressure Liquid; Drug Interaction

2001
Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis.
    Journal of acquired immune deficiency syndromes (1999), 2001, Dec-15, Volume: 28, Issue:5

    Topics: Anti-HIV Agents; Antibiotics, Antitubercular; Chromatography, High Pressure Liquid; Drug Interaction

2001
Severe ototoxicity in a health care worker who received postexposure prophylaxis with stavudine, lamivudine, and nevirapine after occupational exposure to HIV.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Feb-01, Volume: 34, Issue:3

    Topics: Adult; Anti-HIV Agents; Chemoprevention; Female; Health Personnel; Hearing Disorders; HIV Infections

2002
Severe ototoxicity in a health care worker who received postexposure prophylaxis with stavudine, lamivudine, and nevirapine after occupational exposure to HIV.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Feb-01, Volume: 34, Issue:3

    Topics: Adult; Anti-HIV Agents; Chemoprevention; Female; Health Personnel; Hearing Disorders; HIV Infections

2002
I want to see them grow up.
    WORLD (Oakland, Calif. : 1993), 2001, Issue:127

    Topics: Anecdotes as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission

2001
I want to see them grow up.
    WORLD (Oakland, Calif. : 1993), 2001, Issue:127

    Topics: Anecdotes as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission

2001
The faces of AIDS in Uganda: Mulago Hospital.
    WORLD (Oakland, Calif. : 1993), 2001, Issue:127

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Nevirapine; Pregnan

2001
The faces of AIDS in Uganda: Mulago Hospital.
    WORLD (Oakland, Calif. : 1993), 2001, Issue:127

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Nevirapine; Pregnan

2001
South Africa: activists, physicians sue government to prevent maternal transmission, ask international support.
    AIDS treatment news, 2001, Nov-23, Issue:374

    Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Internat

2001
South Africa: activists, physicians sue government to prevent maternal transmission, ask international support.
    AIDS treatment news, 2001, Nov-23, Issue:374

    Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Internat

2001
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Hepatology (Baltimore, Md.), 2002, Volume: 35, Issue:1

    Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspart

2002
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Hepatology (Baltimore, Md.), 2002, Volume: 35, Issue:1

    Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspart

2002
Optimal treatment of nevirapine-associated hepatotoxicity remains uncertain.
    The AIDS reader, 2001, Volume: 11, Issue:11

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur

2001
Optimal treatment of nevirapine-associated hepatotoxicity remains uncertain.
    The AIDS reader, 2001, Volume: 11, Issue:11

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur

2001
Development of resistance mutations to nevirapine as part of triple-drug therapy in children.
    Pharmacotherapy, 2002, Volume: 22, Issue:1

    Topics: Adolescent; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Drug Resistance, Viral;

2002
Development of resistance mutations to nevirapine as part of triple-drug therapy in children.
    Pharmacotherapy, 2002, Volume: 22, Issue:1

    Topics: Adolescent; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Drug Resistance, Viral;

2002
Resuppression of virus load after interruption in treatment with nevirapine and 2 nucleoside reverse-transcriptase inhibitors.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Feb-15, Volume: 34, Issue:4

    Topics: Antiretroviral Therapy, Highly Active; HIV Infections; HIV-1; Humans; Nevirapine; Retrospective Stud

2002
Resuppression of virus load after interruption in treatment with nevirapine and 2 nucleoside reverse-transcriptase inhibitors.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Feb-15, Volume: 34, Issue:4

    Topics: Antiretroviral Therapy, Highly Active; HIV Infections; HIV-1; Humans; Nevirapine; Retrospective Stud

2002
Liver toxicity caused by nevirapine.
    AIDS (London, England), 2002, Jan-25, Volume: 16, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis C, Chronic; HIV Infections; Humans

2002
Liver toxicity caused by nevirapine.
    AIDS (London, England), 2002, Jan-25, Volume: 16, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis C, Chronic; HIV Infections; Humans

2002
Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures--Worldwide, '97-'00.
    HIV clinician, 2001,Spring, Volume: 13, Issue:2

    Topics: HIV Infections; Humans; Nevirapine; Occupational Exposure; Practice Guidelines as Topic; Reverse Tra

2001
Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures--Worldwide, '97-'00.
    HIV clinician, 2001,Spring, Volume: 13, Issue:2

    Topics: HIV Infections; Humans; Nevirapine; Occupational Exposure; Practice Guidelines as Topic; Reverse Tra

2001
Primary HIV-1 drug resistance in Abidjan (Côte d'Ivoire): a genotypic and phenotypic study.
    AIDS (London, England), 2002, Feb-15, Volume: 16, Issue:3

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Cote d'Ivoire; Drug Resistance, Viral; Female; Genotype; HIV

2002
Primary HIV-1 drug resistance in Abidjan (Côte d'Ivoire): a genotypic and phenotypic study.
    AIDS (London, England), 2002, Feb-15, Volume: 16, Issue:3

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Cote d'Ivoire; Drug Resistance, Viral; Female; Genotype; HIV

2002
S Africa state offers HIV drug to pregnant women.
    Lancet (London, England), 2002, Feb-02, Volume: 359, Issue:9304

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2002
S Africa state offers HIV drug to pregnant women.
    Lancet (London, England), 2002, Feb-02, Volume: 359, Issue:9304

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2002
South African government procrastinates over policy on HIV drug.
    Lancet (London, England), 2002, Feb-09, Volume: 359, Issue:9305

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infant, Newborn; Infectious Disease

2002
South African government procrastinates over policy on HIV drug.
    Lancet (London, England), 2002, Feb-09, Volume: 359, Issue:9305

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infant, Newborn; Infectious Disease

2002
Rapid determination of nevirapine in human plasma by gas chromatography.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002, Feb-05, Volume: 767, Issue:1

    Topics: Chromatography, Gas; HIV Infections; Humans; Nevirapine; Reproducibility of Results; Reverse Transcr

2002
Rapid determination of nevirapine in human plasma by gas chromatography.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002, Feb-05, Volume: 767, Issue:1

    Topics: Chromatography, Gas; HIV Infections; Humans; Nevirapine; Reproducibility of Results; Reverse Transcr

2002
South African President hints at expansion of HIV-drug pilot programmes.
    Lancet (London, England), 2002, Feb-16, Volume: 359, Issue:9306

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi

2002
South African President hints at expansion of HIV-drug pilot programmes.
    Lancet (London, England), 2002, Feb-16, Volume: 359, Issue:9306

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi

2002
Effect of nevirapine toxicity on choice of perinatal HIV prevention strategies.
    American journal of public health, 2002, Volume: 92, Issue:3

    Topics: Anti-HIV Agents; Cohort Studies; Decision Support Techniques; Female; Fetal Death; HIV Infections; H

2002
Effect of nevirapine toxicity on choice of perinatal HIV prevention strategies.
    American journal of public health, 2002, Volume: 92, Issue:3

    Topics: Anti-HIV Agents; Cohort Studies; Decision Support Techniques; Female; Fetal Death; HIV Infections; H

2002
Nevirapine + efavirenz based salvage therapy in heavily pretreated HIV infected patients.
    Sexually transmitted infections, 2002, Volume: 78, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; HIV Infections; Humans; Ne

2002
Nevirapine + efavirenz based salvage therapy in heavily pretreated HIV infected patients.
    Sexually transmitted infections, 2002, Volume: 78, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; HIV Infections; Humans; Ne

2002
Confusion over Mandela's "support" of ANC HIV policy.
    Lancet (London, England), 2002, Mar-09, Volume: 359, Issue:9309

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infectious Disease Transmission, Ver

2002
Confusion over Mandela's "support" of ANC HIV policy.
    Lancet (London, England), 2002, Mar-09, Volume: 359, Issue:9309

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infectious Disease Transmission, Ver

2002
A South African perspective on 2001.
    Science (New York, N.Y.), 2002, Mar-15, Volume: 295, Issue:5562

    Topics: Anti-HIV Agents; Drug Industry; Female; HIV Infections; Humans; Infant; Infectious Disease Transmiss

2002
A South African perspective on 2001.
    Science (New York, N.Y.), 2002, Mar-15, Volume: 295, Issue:5562

    Topics: Anti-HIV Agents; Drug Industry; Female; HIV Infections; Humans; Infant; Infectious Disease Transmiss

2002
Stage of the epidemic and viral phenotype should influence recommendations regarding mother-to-child transmission of HIV-1.
    The Lancet. Infectious diseases, 2002, Volume: 2, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; Disease Outbreaks; Female; HIV Infections; HIV-1; Humans; Infant; I

2002
Stage of the epidemic and viral phenotype should influence recommendations regarding mother-to-child transmission of HIV-1.
    The Lancet. Infectious diseases, 2002, Volume: 2, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; Disease Outbreaks; Female; HIV Infections; HIV-1; Humans; Infant; I

2002
South African judge reaffirms judgement to expand access to AIDS drug.
    Lancet (London, England), 2002, Mar-16, Volume: 359, Issue:9310

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV Seropositivity; Humans; Infectious Disease Transmission

2002
South African judge reaffirms judgement to expand access to AIDS drug.
    Lancet (London, England), 2002, Mar-16, Volume: 359, Issue:9310

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV Seropositivity; Humans; Infectious Disease Transmission

2002
Feasibility of antenatal and late HIV testing in pregnant women in Phnom Penh Cambodia: the PERIKAM/ANRS1205 study.
    AIDS (London, England), 2002, Apr-12, Volume: 16, Issue:6

    Topics: AIDS Serodiagnosis; Cambodia; Counseling; Feasibility Studies; Female; HIV Infections; HIV Seropreva

2002
Feasibility of antenatal and late HIV testing in pregnant women in Phnom Penh Cambodia: the PERIKAM/ANRS1205 study.
    AIDS (London, England), 2002, Apr-12, Volume: 16, Issue:6

    Topics: AIDS Serodiagnosis; Cambodia; Counseling; Feasibility Studies; Female; HIV Infections; HIV Seropreva

2002
HIV drug under review as firm withdraws FDA application.
    BMJ (Clinical research ed.), 2002, Apr-06, Volume: 324, Issue:7341

    Topics: Anti-HIV Agents; Drug Approval; HIV Infections; Humans; Infectious Disease Transmission, Vertical; N

2002
HIV drug under review as firm withdraws FDA application.
    BMJ (Clinical research ed.), 2002, Apr-06, Volume: 324, Issue:7341

    Topics: Anti-HIV Agents; Drug Approval; HIV Infections; Humans; Infectious Disease Transmission, Vertical; N

2002
Vertical HIV transmission in South Africa: translating research into policy and practice.
    Lancet (London, England), 2002, Mar-23, Volume: 359, Issue:9311

    Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Female; HIV Infections; Humans; Infant; Infan

2002
Vertical HIV transmission in South Africa: translating research into policy and practice.
    Lancet (London, England), 2002, Mar-23, Volume: 359, Issue:9311

    Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Female; HIV Infections; Humans; Infant; Infan

2002
Enough time wasted in South Africa.
    The Lancet. Infectious diseases, 2002, Volume: 2, Issue:4

    Topics: Anti-HIV Agents; Female; Government Programs; HIV Infections; Humans; Legislation, Drug; Nevirapine;

2002
Enough time wasted in South Africa.
    The Lancet. Infectious diseases, 2002, Volume: 2, Issue:4

    Topics: Anti-HIV Agents; Female; Government Programs; HIV Infections; Humans; Legislation, Drug; Nevirapine;

2002
South African court again tells government to increase access to AIDS drug.
    Lancet (London, England), 2002, Mar-30, Volume: 359, Issue:9312

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; HIV Seropositivity; Humans; Infant, Newborn;

2002
South African court again tells government to increase access to AIDS drug.
    Lancet (London, England), 2002, Mar-30, Volume: 359, Issue:9312

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; HIV Seropositivity; Humans; Infant, Newborn;

2002
South African nevirapine policy faces growing pressure.
    The Lancet. Infectious diseases, 2002, Volume: 2, Issue:3

    Topics: Anti-HIV Agents; Female; Government Programs; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnan

2002
South African nevirapine policy faces growing pressure.
    The Lancet. Infectious diseases, 2002, Volume: 2, Issue:3

    Topics: Anti-HIV Agents; Female; Government Programs; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnan

2002
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy.
    Journal of clinical laboratory analysis, 2002, Volume: 16, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Multip

2002
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy.
    Journal of clinical laboratory analysis, 2002, Volume: 16, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Multip

2002
Mothers, orphans, and prevention of paediatric AIDS.
    Lancet (London, England), 2002, Apr-06, Volume: 359, Issue:9313

    Topics: Anti-HIV Agents; Female; Foster Home Care; HIV Infections; Humans; Infant, Newborn; Infectious Disea

2002
Mothers, orphans, and prevention of paediatric AIDS.
    Lancet (London, England), 2002, Apr-06, Volume: 359, Issue:9313

    Topics: Anti-HIV Agents; Female; Foster Home Care; HIV Infections; Humans; Infant, Newborn; Infectious Disea

2002
Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy.
    AIDS (London, England), 2002, Mar-29, Volume: 16, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Follow-Up Studies

2002
Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy.
    AIDS (London, England), 2002, Mar-29, Volume: 16, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Follow-Up Studies

2002
South African leader relents in storm over HIV drugs for women.
    Nature, 2002, Apr-25, Volume: 416, Issue:6883

    Topics: Anti-HIV Agents; Female; Government; HIV Infections; Humans; Infectious Disease Transmission, Vertic

2002
South African leader relents in storm over HIV drugs for women.
    Nature, 2002, Apr-25, Volume: 416, Issue:6883

    Topics: Anti-HIV Agents; Female; Government; HIV Infections; Humans; Infectious Disease Transmission, Vertic

2002
Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression.
    The Journal of infectious diseases, 2002, May-01, Volume: 185, Issue:9

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infe

2002
Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression.
    The Journal of infectious diseases, 2002, May-01, Volume: 185, Issue:9

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infe

2002
Stevens-Johnson syndrome in HIV patients treated with nevirapine: two case reports.
    AIDS (London, England), 2002, May-24, Volume: 16, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Hepatitis C, Chronic; HIV Infections; Hu

2002
Stevens-Johnson syndrome in HIV patients treated with nevirapine: two case reports.
    AIDS (London, England), 2002, May-24, Volume: 16, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Hepatitis C, Chronic; HIV Infections; Hu

2002
FDA application withdrawn to market Viramune for new use.
    AIDS policy & law, 2002, Apr-12, Volume: 17, Issue:7

    Topics: Drug Approval; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine

2002
FDA application withdrawn to market Viramune for new use.
    AIDS policy & law, 2002, Apr-12, Volume: 17, Issue:7

    Topics: Drug Approval; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine

2002
Let nevirapine do what it does best.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 2002, Volume: 16, Issue:3

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr

2002
Let nevirapine do what it does best.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 2002, Volume: 16, Issue:3

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr

2002
Thailand markets low-cost, 3-in-1 antiretroviral medication.
    AIDS policy & law, 2002, Apr-26, Volume: 17, Issue:8

    Topics: Drug Combinations; Drug Costs; HIV Infections; Humans; Lamivudine; Nevirapine; Reverse Transcriptase

2002
Thailand markets low-cost, 3-in-1 antiretroviral medication.
    AIDS policy & law, 2002, Apr-26, Volume: 17, Issue:8

    Topics: Drug Combinations; Drug Costs; HIV Infections; Humans; Lamivudine; Nevirapine; Reverse Transcriptase

2002
High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
    Therapeutic drug monitoring, 2002, Volume: 24, Issue:3

    Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitor

2002
High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
    Therapeutic drug monitoring, 2002, Volume: 24, Issue:3

    Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitor

2002
Paying to waste lives: the affordability of reducing mother-to-child transmission of HIV in South Africa.
    Journal of health economics, 2002, Volume: 21, Issue:3

    Topics: Adult; Anti-HIV Agents; Child Welfare; Child, Preschool; Cost of Illness; Cost-Benefit Analysis; Fem

2002
Paying to waste lives: the affordability of reducing mother-to-child transmission of HIV in South Africa.
    Journal of health economics, 2002, Volume: 21, Issue:3

    Topics: Adult; Anti-HIV Agents; Child Welfare; Child, Preschool; Cost of Illness; Cost-Benefit Analysis; Fem

2002
Judasa, HPCSA and CMSA take up cudgels.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2002, Volume: 92, Issue:3

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Nevirapine; Patient Advocacy; Pregnancy; Pregnancy

2002
Judasa, HPCSA and CMSA take up cudgels.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2002, Volume: 92, Issue:3

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Nevirapine; Patient Advocacy; Pregnancy; Pregnancy

2002
[Hepatotoxicity with antiretroviral therapy. The liver is affected as well].
    MMW Fortschritte der Medizin, 2002, Apr-09, Volume: 144 Suppl 1

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical

2002
[Hepatotoxicity with antiretroviral therapy. The liver is affected as well].
    MMW Fortschritte der Medizin, 2002, Apr-09, Volume: 144 Suppl 1

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical

2002
[Delayed virus suppression has its price. Heart and liver are no longer secondary theaters].
    MMW Fortschritte der Medizin, 2002, Apr-09, Volume: 144 Suppl 1

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical

2002
[Delayed virus suppression has its price. Heart and liver are no longer secondary theaters].
    MMW Fortschritte der Medizin, 2002, Apr-09, Volume: 144 Suppl 1

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical

2002
Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002, Jul-05, Volume: 774, Issue:1

    Topics: Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Delavirdine; HIV Infecti

2002
Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002, Jul-05, Volume: 774, Issue:1

    Topics: Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Delavirdine; HIV Infecti

2002
PMTCT--who decides on the right to life?
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2002, Volume: 92, Issue:4

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Male; Nevirapine; Practice

2002
PMTCT--who decides on the right to life?
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2002, Volume: 92, Issue:4

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Male; Nevirapine; Practice

2002
Policy watch. Good news, bad news.
    The AIDS reader, 2002, Volume: 12, Issue:4

    Topics: Anti-HIV Agents; Bioterrorism; Budgets; Female; Health Policy; HIV Infections; Humans; Infant, Newbo

2002
Policy watch. Good news, bad news.
    The AIDS reader, 2002, Volume: 12, Issue:4

    Topics: Anti-HIV Agents; Bioterrorism; Budgets; Female; Health Policy; HIV Infections; Humans; Infant, Newbo

2002
Nevirapine-associated toxicity.
    The AIDS reader, 2002, Volume: 12, Issue:4

    Topics: Anti-HIV Agents; Exanthema; HIV Infections; Humans; Liver Diseases; Nevirapine

2002
Nevirapine-associated toxicity.
    The AIDS reader, 2002, Volume: 12, Issue:4

    Topics: Anti-HIV Agents; Exanthema; HIV Infections; Humans; Liver Diseases; Nevirapine

2002
Court orders South Africa to treat pregnant HIV-positive women with nevirapine.
    Bulletin of the World Health Organization, 2002, Volume: 80, Issue:4

    Topics: Female; Health Services Accessibility; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy Comp

2002
Court orders South Africa to treat pregnant HIV-positive women with nevirapine.
    Bulletin of the World Health Organization, 2002, Volume: 80, Issue:4

    Topics: Female; Health Services Accessibility; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy Comp

2002
HIV does cause AIDS but it's hard to prescribe the drugs, says South Africa's ANC.
    Bulletin of the World Health Organization, 2002, Volume: 80, Issue:5

    Topics: Female; Health Services Accessibility; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy Comp

2002
HIV does cause AIDS but it's hard to prescribe the drugs, says South Africa's ANC.
    Bulletin of the World Health Organization, 2002, Volume: 80, Issue:5

    Topics: Female; Health Services Accessibility; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy Comp

2002
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
    The Journal of infectious diseases, 2002, Jul-01, Volume: 186, Issue:1

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Dr

2002
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
    The Journal of infectious diseases, 2002, Jul-01, Volume: 186, Issue:1

    Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Dr

2002